PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Oates, GD; Stenning, SP; Hardcastle, JD; McAdam, WAF; Greaney, MG; Gunn, A; Pearson, JB; Davis, PW; Kenefick, J; Postlethwaite, JC; Bartolo, D; Williamson, RCN; Stoddard, CJ; deCastella, HC; Dean, ACB; Thomson, JWW; Bardsley, D; Wilkins, JL; Motson, R; Foster, GE; Kane, JF; Lee, MJR; HollAllen, RTJ; Hale, JE; Davies, GC; Macleod, IB; Lallemand, RC; AlexanderWilliams, J; Dorricott, NJ; Keighley, MRB; Berger, PL; Goldring, JR; Miller, DF; Morran, CG; Richards, JR; Thomson, WO; Madigan, MR; Kettlewell, MGW; Mortensen, NJ; Greatrex, GH; MacIntyre, IMC; Blake, JRS; Doran, J; Clague, MB; Cuschieri, A; Preece, PE; Smith, JAR; ThorntonHolmes, J; Downing, R; Fielding, JRF; Temple, JG; Slaney, G; Jones, RB; Lewis, AAM; Johnson, AGR; Randall, DH; Stuart, AE; Pollock, AV; Giles, GR; Boulos, PB; Abernethy, BC; HamerHodges, DW; Saunders, JH; Small, WP; Smith, AN; Flew, TJ; Gough, AL; Craven, JL; Hall, R				Oates, GD; Stenning, SP; Hardcastle, JD; McAdam, WAF; Greaney, MG; Gunn, A; Pearson, JB; Davis, PW; Kenefick, J; Postlethwaite, JC; Bartolo, D; Williamson, RCN; Stoddard, CJ; deCastella, HC; Dean, ACB; Thomson, JWW; Bardsley, D; Wilkins, JL; Motson, R; Foster, GE; Kane, JF; Lee, MJR; HollAllen, RTJ; Hale, JE; Davies, GC; Macleod, IB; Lallemand, RC; AlexanderWilliams, J; Dorricott, NJ; Keighley, MRB; Berger, PL; Goldring, JR; Miller, DF; Morran, CG; Richards, JR; Thomson, WO; Madigan, MR; Kettlewell, MGW; Mortensen, NJ; Greatrex, GH; MacIntyre, IMC; Blake, JRS; Doran, J; Clague, MB; Cuschieri, A; Preece, PE; Smith, JAR; ThorntonHolmes, J; Downing, R; Fielding, JRF; Temple, JG; Slaney, G; Jones, RB; Lewis, AAM; Johnson, AGR; Randall, DH; Stuart, AE; Pollock, AV; Giles, GR; Boulos, PB; Abernethy, BC; HamerHodges, DW; Saunders, JH; Small, WP; Smith, AN; Flew, TJ; Gough, AL; Craven, JL; Hall, R			Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer	LANCET			English	Article							PREOPERATIVE IRRADIATION; ADENOCARCINOMA; CARCINOMAS	Background Survival rates after surgery for rectal cancer remain at about 40% at 5 years from diagnosis, The aim of this study was to find out whether local recurrence rate could be reduced and survival increased by a moderately high dose of preoperative radiotherapy in patients with locally advanced, but otherwise operable, carcinoma of the rectum. Methods We carried out a prospective randomised trial of surgery alone (n=140) versus surgery preceded by 40 Gy radiotherapy (n=139) given in 20 fractions of 2 Gy over 4 weeks. The patients, from 20 regional centres throughout the UK, were enrolled between 1981 and 1989, and followed up for a minimum of 5 years or to death. Findings 217 patients died, 114 of 140 allocated surgery alone and 103 of 139 allocated preoperative radiotherapy: median survival limes were 24 months and 31 months, respectively. The hazard ratio for overall survival was 0.79 (95% CI 0.60-1.04, p=0.10). At 5 years' follow-up 65 patients allocated surgery alone and 50 who received preoperative radiotherapy bad local recurrence (hazard ratio 0.68 [0.47-0.98], p=0.04); the corresponding numbers of patients with distant recurrence were 67 and 49 (hazard ratio 0.66 [0.46-0.95], p=0.02). There was a significant benefit of radiotherapy on disease-free survival (hazard ratio 0.76 [0.58-1.0], p=0.05). There was no increase in postoperative or late complications in the radiotherapy group, Interpretation Our results provide further evidence that preoperative radiotherapy can reduce the rate of local recurrence of rectal cancer in patients with locally advanced disease. However, survival results are still equivocal, and so we must await the results of a metaanalysis of all radiotherapy trials from which precise and definitive results, particularly for survival, may be obtained.	GEN HOSP,BIRMINGHAM B4 6NH,W MIDLANDS,ENGLAND; MRC,CANC TRIALS OFF,CAMBRIDGE,ENGLAND; AIREDALE DIST GEN HOSP,KEIGHLEY,W YORKSHIRE,ENGLAND; ARROWE PK HOSP,LIVERPOOL,MERSEYSIDE,ENGLAND; ASHINGTON HOSP,ASHINGTON,NORTHD,ENGLAND; BARKING HOSP,BARKING,ENGLAND; BARNET GEN HOSP,BARNET,ENGLAND; BRISTOL ROYAL INFIRM & GEN HOSP,BRISTOL,AVON,ENGLAND; BROAD GREEN HOSP,LIVERPOOL,MERSEYSIDE,ENGLAND; BURTON ON TRENT DIST GEN HOSP,BURTON TRENT,STAFFS,ENGLAND; CHALMERS HOSP,EDINBURGH,MIDLOTHIAN,SCOTLAND; CHESTERFIELD ROYAL HOSP,CHESTERFIELD,DERBY,ENGLAND; CITY HOSP NOTTINGHAM,NOTTINGHAM,ENGLAND; COLCHESTER GEN HOSP,COLCHESTER,ESSEX,ENGLAND; COUNTESS CHESTER HOSP,CHESTER,CHESHIRE,ENGLAND; DUDLEY RD GEN HOSP,BIRMINGHAM,W MIDLANDS,ENGLAND; E BIRMINGHAM DIST GEN HOSP,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND; E SURREY HOSP,REDHILL,SURREY,ENGLAND; ROYAL EDINBURGH INFIRM,EDINBURGH,MIDLOTHIAN,SCOTLAND; FRIMLEY PK HOSP,CAMBERLEY,SURREY,ENGLAND; GEN HOSP BIRMINGHAM,BIRMINGHAM,W MIDLANDS,ENGLAND; GOOD HOPE HOSP,SUTTON COLDFIELD,W MIDLANDS,ENGLAND; HIARMYRES HOSP,E KILBRIDE,LANARK,SCOTLAND; JOHN RADCLIFFE HOSP,OXFORD OX3 9DU,ENGLAND; KINGS MILL HOSP,SUTTON ASHFIELD,NOTTS,ENGLAND; LEITH HOSP,EDINBURGH,MIDLOTHIAN,SCOTLAND; MANSFIELD HOSP,MANSFIELD,NOTTS,ENGLAND; NEWCASTLE GEN HOSP,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND; NINEWELLS HOSP,DUNDEE DD1 9SY,SCOTLAND; NO GEN HOSP,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND; PETERBOROUGH DIST GEN HOSP,PETERBOROUGH,CAMBS,ENGLAND; QUEEN ELIZABETH HOSP,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; ROTHERHAM DIST HOSP,ROTHERHAM,S YORKSHIRE,ENGLAND; ROYAL FREE HOSP,LONDON NW3 2QG,ENGLAND; ROYAL HALLAMSHIRE HOSP,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND; RUSH GREEN HOSP,ROMFORD,ESSEX,ENGLAND; SCARBOROUGH GEN HOSP,SCARBOROUGH,ENGLAND; ST JAMES UNIV HOSP,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND; UNIV NOTTINGHAM HOSP,NOTTINGHAM NG7 2UH,ENGLAND; VICTORIA HOSP,EDINBURGH,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; WESTON SUPER MARE GEN,BRISTOL,AVON,ENGLAND; YORK DIST GEN HOSP,YORK,N YORKSHIRE,ENGLAND	Bristol Royal Infirmary; Nottingham University Hospital NHS Trust; Nottingham City Hospital; East Surrey Hospital; Royal Infirmary of Edinburgh; Heart of England NHS Foundation Trust; Good Hope Hospital; University of Oxford; Newcastle General Hospital; University of Dundee; Northern General Hospital; University of Birmingham; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Sheffield; Saint James's University Hospital; University of Nottingham; University of Edinburgh			Cuschieri, Alfred/O-4092-2019	Cuschieri, Alfred/0000-0003-0764-5947				CEDERMARK B, 1994, P AN M AM SOC CLIN, V14, P198; CUMMINGS BJ, 1992, CANCER-AM CANCER SOC, V70, P1372, DOI 10.1002/1097-0142(19920901)70:3+<1372::AID-CNCR2820701527>3.0.CO;2-A; DOSORETZ DE, 1983, CANCER, V52, P814, DOI 10.1002/1097-0142(19830901)52:5<814::AID-CNCR2820520511>3.0.CO;2-1; EMAMI B, 1982, INT J RADIAT ONCOL, V8, P1295, DOI 10.1016/0360-3016(82)90578-8; FRYKHOLM GJ, 1993, DIS COLON RECTUM, V36, P564, DOI 10.1007/BF02049863; GERARD A, 1988, ANN SURG, V208, P606, DOI 10.1097/00000658-198811000-00011; GLIMELIUS B, 1982, ACTA RADIOL ONCOL, V21, P373, DOI 10.3109/02841868209134315; JAMES RD, 1985, BRIT J SURG, V72, P279, DOI 10.1002/bjs.1800720410; *MRC WORK PART, 1984, BRIT J SURG, V71, P21; PAHLMAN L, 1990, ANN SURG, V211, P187, DOI 10.1097/00000658-199002000-00011; RIDER WD, 1977, CAN J SURG, V20, P335; ROSWIT B, 1975, CANCER, V35, P1597, DOI 10.1002/1097-0142(197506)35:6<1597::AID-CNCR2820350618>3.0.CO;2-S; *STOCKH RECT CANC, 1988, ANN SURG, V208, P606; *SWED RECT CANC TR, 1993, BRIT J SURG, V80, P1333	14	286	295	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1605	1610						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8961989				2022-12-28	WOS:A1996VX87600008
J	Clever, L; Colaianni, LA; Davidoff, F; Horton, R; Kassirer, JP; Angell, M; Lundberg, GD; Glass, R; Nylenna, M; Robinson, RG; Smith, R; Squires, BP; VanDerWeyden, M				Clever, L; Colaianni, LA; Davidoff, F; Horton, R; Kassirer, JP; Angell, M; Lundberg, GD; Glass, R; Nylenna, M; Robinson, RG; Smith, R; Squires, BP; VanDerWeyden, M			Uniform requirements for manuscripts submitted to biomedical journals	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									ANNALS INTERNAL MED,PHILADELPHIA,PA; JOURNAL AMER MED ASSOC,SAN FRANCISCO,CA; BRITISH MED JOURNAL,LONDON,ENGLAND; CANADIAN MED ASSOC JOURNAL,OTTAWA,ON,CANADA; MED JOURNAL AUSTRALIA,SYDNEY,NSW,AUSTRALIA; LANCET,LONDON,ENGLAND	American Medical Association									0	145	152	1	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1997	336	4					309	315						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE632	8995096				2022-12-28	WOS:A1997WE63200032
J	Rao, AM; Richter, E; Bandow, S; Chase, B; Eklund, PC; Williams, KA; Fang, S; Subbaswamy, KR; Menon, M; Thess, A; Smalley, RE; Dresselhaus, G; Dresselhaus, MS				Rao, AM; Richter, E; Bandow, S; Chase, B; Eklund, PC; Williams, KA; Fang, S; Subbaswamy, KR; Menon, M; Thess, A; Smalley, RE; Dresselhaus, G; Dresselhaus, MS			Diameter-selective Raman scattering from vibrational modes in carbon nanotubes	SCIENCE			English	Article							SPECTROSCOPY	Single wall carbon nanotubes (SWNTs) that are found as close-packed arrays in crystalline ropes have been studied by using Raman scattering techniques with laser excitation wavelengths in the range from 514.5 to 1320 nanometers. Numerous Raman peaks were observed and identified with vibrational modes of armchair symmetry (n, n) SWNTs. The Raman spectra are in good agreement with lattice dynamics calculations based on C-C force constants used to fit the two-dimensional, experimental phonon dispersion of a single graphene sheet. Calculated intensities from a nonresonant, bond polarizability model optimized for sp(2) carbon are also in qualitative agreement with the Raman data, although a resonant Raman scattering process is also taking place. This resonance results from the one-dimensional quantum confinement of the electrons in the nanotube.	UNIV KENTUCKY,DEPT PHYS & ASTRON,LEXINGTON,KY 40506; UNIV KENTUCKY,CTR APPL ENERGY RES,LEXINGTON,KY 40506; INST MOL SCI,INSTRUMENT CTR,OKAZAKI,AICHI 444,JAPAN; DUPONT CO INC,EXPT STN,WILMINGTON,DE 19880; UNIV KENTUCKY,CTR COMPUTAT SCI,LEXINGTON,KY 40506; RICE UNIV,DEPT CHEM,HOUSTON,TX 77005; MIT,FRANCIS BITTER NATL MAGNET LAB,CAMBRIDGE,MA 02139; MIT,DEPT PHYS,CAMBRIDGE,MA 02139; MIT,DEPT ELECT ENGN & COMP SCI,CAMBRIDGE,MA 02139	University of Kentucky; University of Kentucky; National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); DuPont; University of Kentucky; Rice University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)								BETHUNE DS, 1993, NATURE, V363, P605, DOI 10.1038/363605a0; CHANDRABHAS N, 1994, PRAMANA-J PHYS, V42, P375, DOI 10.1007/BF02847554; COWLEY JM, PREPRINT; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; EKLUND PC, 1995, CARBON, V33, P959, DOI 10.1016/0008-6223(95)00035-C; Hayes W., 1978, LIGHT SCATTERING CRY; HIURA H, 1993, CHEM PHYS LETT, V202, P509, DOI 10.1016/0009-2614(93)90040-8; HOLDEN JM, 1994, CHEM PHYS LETT, V220, P186, DOI 10.1016/0009-2614(94)00154-5; IIJIMA S, 1993, NATURE, V363, P603, DOI 10.1038/363603a0; JISHI RA, 1993, CHEM PHYS LETT, V209, P77, DOI 10.1016/0009-2614(93)87205-H; KASTNER J, 1994, CHEM PHYS LETT, V221, P53, DOI 10.1016/0009-2614(94)87015-2; LEE YS, COMMUNICATION; Menon M, 1996, J CHEM PHYS, V104, P5875, DOI 10.1063/1.471319; RICHTER E, UNPUB; SMALLEY RE, UNPUB; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; VENKATARAMAN L, 1993, TEHSIS MIT; XU CH, 1992, J PHYS-CONDENS MAT, V4, P6047, DOI 10.1088/0953-8984/4/28/006; [No title captured]	19	1976	2034	6	594	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					187	191		10.1126/science.275.5297.187	http://dx.doi.org/10.1126/science.275.5297.187			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985007				2022-12-28	WOS:A1997WC02200030
J	Crespo, P; Schuebel, KE; Ostrom, AA; Gutkind, JS; Bustelo, XR				Crespo, P; Schuebel, KE; Ostrom, AA; Gutkind, JS; Bustelo, XR			Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product	NATURE			English	Article							TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; RAS TRANSFORMATION; SIGNALING PATHWAY; SH2 DOMAIN; B-CELLS; T-CELL; RHO	THE oncogenic protein Vav(1,2) harbours a complex array of structural motifs, including leucine-rich, Dbl-homology, pleckstrin-homology, zinc-finger, SH2 and SH3 domains, Upon stimulation by antigens or mitogens, Vav becomes phosphorylated on key tyrosine residues(3-5) and associates with other signalling proteins, including the mitogen receptors(3,4) Zap-70 (ref. 6). Vap-1 (ref. 5) and Slp-76 (ref. 7). Disruption of the vav locus by homologous recombination causes severe defects in signalling by primary antigen receptors, leading to abnormal lymphocyte proliferation and lymphopenia(8,9). Despite the importance of Vav cell signalling, the function of this protein remains unknown, Here we show that tyrosine-phosphorylated Vav, but not the non-phosphorylated protein, catalyses GDP/GTP exchange on Rac-1, a protein implicated in cell proliferation and cytoskeletal organization(10,11), causing this GTPase to switch from its inactive to its active state, Transfection experiments also show that phosphorylation of Vav on tyrosine residues leads to nucleotide exchange on Rac-1 in vivo and stimulates c-Jun kinase, a downstream element in the signalling pathway involving this GTPase, Our results have identified a function for Vav and define a mechanism in which engaged membrane receptors activate its signalling pathway.	SUNY STONY BROOK,SCH MED,DEPT PATHOL,STONY BROOK,NY 11794; SUNY STONY BROOK,UNIV HOSP,STONY BROOK,NY 11794; NIDR,MOL SIGNALLING UNIT,CELLULAR DEV & ONCOL LAB,NIH,BETHESDA,MD 20892; UNIV CANTABRIA,FAC MED,DEPT MOL BIOL,SANTANDER 39011,CANTABRIA,SPAIN	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Universidad de Cantabria			Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010; Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Crespo, Piero/M-3273-2014	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Gutkind, J. Silvio/0000-0002-5150-4482; Crespo, Piero/0000-0003-2825-7783				BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SPANA C, 1993, PROTEIN EXPRES PURIF, V4, P390, DOI 10.1006/prep.1993.1051; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; WU J, 1995, MOL CELL BIOL, V15, P4337; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77	24	660	666	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1997	385	6612					169	172		10.1038/385169a0	http://dx.doi.org/10.1038/385169a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WB728	8990121				2022-12-28	WOS:A1997WB72800057
J	Stoute, JA; Slaoui, M; Heppner, DG; Momin, P; Kester, KE; Desmons, P; Wellde, BT; Garcon, N; Krzych, U; Marchand, M; Ballou, WR; Cohen, JD				Stoute, JA; Slaoui, M; Heppner, DG; Momin, P; Kester, KE; Desmons, P; Wellde, BT; Garcon, N; Krzych, U; Marchand, M; Ballou, WR; Cohen, JD			A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							B SURFACE-ANTIGEN; SPOROZOITE VACCINE; IMMUNOGENICITY; SAFETY; ANTIBODIES; EFFICACY; RESPONSES; IMMUNITY; ASSOCIATION; EPITOPE	Background The candidate vaccines against malaria are poorly immunogenic and thus have been ineffective in preventing infection. We developed a vaccine based on the circumsporozoite protein of Plasmodium falciparum that incorporates adjuvants selected to enhance the immune response. Methods The antigen consists of a hybrid in which the circumsporozoite protein fused to hepatitis B surface antigen (HBsAg) is expressed together with unfused HBsAg. We evaluated three formulations of this antigen in an unblinded trial in 46 subjects who had never been exposed to malaria. Results Two of the vaccine formulations were highly immunogenic. Four subjects had adverse systemic reactions that may have resulted from the intensity of the immune response after the second dose, which led us to reduce the third dose. Twenty-two vaccinated subjects and six unimmunized controls under went a challenge consisting of bites from mosquitoes infected with P. falciparum. Malaria developed in all six control subjects, seven of eight subjects who received vaccine 1, and five of seven subjects who received vaccine 2. In contrast, only one of seven subjects who received vaccine 3 became infected (relative risk of infection, 0.14; 95 percent confidence interval, 0.02 to 0.88; P<0.005). Conclusions A recombinant vaccine based on fusion of the circumsporozoite protein and HBsAg plus a potent adjuvant can protect against experimental challenge with P. falciparum sporozoites. After additional studies of protective immunity and the vaccination schedule, field trials are indicated for this new vaccine against P. falciparum malaria. (C) 1997, Massachusetts Medical Society.	WALTER REED ARMY INST RES, DEPT IMMUNOL, WASHINGTON, DC 20307 USA; SMITHKLINE BEECHAM BIOL, RIXENSART, BELGIUM	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); GlaxoSmithKline			Kester, Kent/AAF-8235-2020; Kester, Kent/A-2114-2011	Kester, Kent/0000-0002-5056-0802; Kester, Kent/0000-0002-5056-0802				AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8; BALLOU WR, 1989, ADV EXP MED BIOL, V251, P295; BALLOU WR, 1985, SCIENCE, V228, P996, DOI 10.1126/science.2988126; BALLOU WR, 1987, LANCET, V1, P1277; BALLOU WR, 1991, VACCINES IMMUNOTHERA, P378; BLUMTIROUVANZIAM U, 1995, J IMMUNOL, V154, P3922; BROWN AE, 1994, VACCINE, V12, P102, DOI 10.1016/0264-410X(94)90046-9; CHULAY JD, 1986, AM J TROP MED HYG, V35, P66, DOI 10.4269/ajtmh.1986.35.66; DiRosa F, 1996, J EXP MED, V183, P2153, DOI 10.1084/jem.183.5.2153; EGAN JE, 1993, AM J TROP MED HYG, V49, P166, DOI 10.4269/ajtmh.1993.49.166; GLENN GM, 1995, IMMUNOL LETT, V47, P73, DOI 10.1016/0165-2478(95)00069-H; GORDON DM, 1995, J INFECT DIS, V171, P1576, DOI 10.1093/infdis/171.6.1576; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HOFFMAN SL, 1994, AM J TROP MED HYG, V51, P603, DOI 10.4269/ajtmh.1994.51.603; HOFFMAN SL, 1987, SCIENCE, V237, P639, DOI 10.1126/science.3299709; HOLLINGDALE MR, 1984, J IMMUNOL, V132, P909; HOLLINGER FB, 1986, J INFECT DIS, V153, P156, DOI 10.1093/infdis/153.1.156; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MORENO A, 1993, J IMMUNOL, V151, P489; NARDIN EH, 1982, J EXP MED, V156, P20, DOI 10.1084/jem.156.1.20; NARDIN EH, 1993, ANNU REV IMMUNOL, V11, P687, DOI 10.1146/annurev.iy.11.040193.003351; NUSSENZWEIG V, 1989, ADV IMMUNOL, V45, P283, DOI 10.1016/S0065-2776(08)60695-1; RIECKMANN KH, 1974, T ROY SOC TROP MED H, V68, P258, DOI 10.1016/0035-9203(74)90129-1; RUTGERS T, 1988, BIO-TECHNOL, V6, P1065, DOI 10.1038/nbt0988-1065; SCHELLER LF, 1995, P NATL ACAD SCI USA, V92, P4066, DOI 10.1073/pnas.92.9.4066; SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0; SHERWOOD JA, 1991, T ROY SOC TROP MED H, V85, P336, DOI 10.1016/0035-9203(91)90281-3; SINIGAGLIA F, 1988, NATURE, V336, P778, DOI 10.1038/336778a0; Sinnis Photini, 1996, P15; VREDEN SGS, 1991, AM J TROP MED HYG, V45, P533, DOI 10.4269/ajtmh.1991.45.533; *WHO, 1995, B WORLD HEALTH ORGAN, V12, P64; WIRTZ RA, 1987, EXP PARASITOL, V63, P166, DOI 10.1016/0014-4894(87)90158-5	33	694	764	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1997	336	2					86	91		10.1056/NEJM199701093360202	http://dx.doi.org/10.1056/NEJM199701093360202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC481	8988885				2022-12-28	WOS:A1997WC48100002
J	Soumeral, SB; McLaughlin, TJ; Spiegelman, D; Hertzmark, E; Thibault, G; Goldman, L				Soumeral, SB; McLaughlin, TJ; Spiegelman, D; Hertzmark, E; Thibault, G; Goldman, L			Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	19th Annual Meeting of the Society-of-General-Internal-Medicine	MAY 02-04, 1996	WASHINGTON, D.C.	Soc Gen Internal Med			CORONARY HEART-DISEASE; CLINICAL-TRIALS; CLAIMS DATA; THERAPY; MEDICAID; MORTALITY; MASSACHUSETTS; SERVICES; QUALITY; DRUGS	Objectives-To study determinants and adverse outcomes (mortality and rehospitalization) of beta-blocker underuse in elderly patients with myocardial infarction; and whether the relative risks (RRs) of survival associated with beta-blocker use were comparable to those reported in the large randomized controlled trials (RCTs). Setting.-New Jersey Medicare population. Design.-Retrospective cohort design using linked Medicare and drug claims data from 1987 to 1992. Patients.-Statewide cohort of 5332 elderly 30-day acute myocardial infarction (AMI) survivors with prescription drug coverage, of whom 3737 were eligible for beta-blockers. Main Outcome Measures.-beta-Blocker and calcium channel blocker use in the first 90 days after discharge and mortality rates and cardiac hospital readmissions over the 2-year period after discharge, controlling for sociodemographic and baseline risk variables. Results.-Only 21% of eligible patients received beta-blocker therapy; this rate remained unchanged from 1987 to 1991. Patients were almost 3 times more likely to receive a new prescription for a calcium channel blocker than for a new beta-blocker after their AMIs. Advanced age and calcium channel blocker use predicted underuse of beta-blockers. Controlling for other predictors of survival, the mortality rate among beta-blocker recipients was 43% less than that for nonrecipients (RR=0.57; 95% confidence interval [CI], 0.47-0.69). Effects on mortality were substantial in all age strata (65-74 years, 75-84 years, and greater than or equal to 85 years) and consistent with the results for elderly subgroups of 2 large RCTs, beta-Blocker recipients were rehospitalized 22% less often than nonrecipients (RR=0.78; 95% CI, 0.67-0.90). Use of a calcium channel blocker instead of a beta-blocker was associated with a doubled risk of death (RR=1.98; 95% CI, 1.44-2.72), not because calcium channel blockers had a demonstrable adverse effect, but because they were substitutes for beta-blockers. Conclusions.-beta-Blockers are underused in elderly AMI survivors, leading to measurable adverse outcomes. These data suggest that the survival benefits of beta-blockade after an AMI may extend to eligible patients older than 75 years, a group that has been excluded from RCTs.	HARVARD PILGRIM HLTH CTR, BOSTON, MA 02215 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA USA	Harvard Pilgrim Health Care; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of California System; University of California San Francisco	Soumeral, SB (corresponding author), HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, 126 BROOKLINE AVE, SUITE 200, BOSTON, MA 02215 USA.				AHRQ HHS [R01 HSO7631, R01 HSO6341] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; BRAND DA, 1995, J AM COLL CARDIOL, V26, P1432, DOI 10.1016/0735-1097(95)00362-2; BURRIS JF, 1993, ARCH INTERN MED, V153, P2085, DOI 10.1001/archinte.153.18.2085; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; DAHLOF C, 1991, CIRCULATION, V84, P108; ECCLES M, 1991, BMJ-BRIT MED J, V302, P91, DOI 10.1136/bmj.302.6768.91; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; EPSTEIN AM, 1992, JAMA-J AM MED ASSOC, V268, P2530; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GOLDMAN L, 1988, NEW ENGL J MED, V319, P152, DOI 10.1056/NEJM198807213190306; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; HARRELL FE, 1988, P 12 ANN SAS US GROU, P1107; HARRELL FE, 1987, P 11 ANN SAS US GROU, P823; HORWITZ RI, 1990, AM J MED, V89, P630, DOI 10.1016/0002-9343(90)90182-D; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; JANSEN RWMM, 1994, DRUG AGING, V4, P175, DOI 10.2165/00002512-199404030-00001; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KENNEDY HL, 1994, AM J CARDIOL, V74, P674, DOI 10.1016/0002-9149(94)90308-5; KENNEDY HL, 1995, J AM COLL CARDIOL, V26, P547, DOI 10.1016/0735-1097(95)80035-F; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; Lohr K N, 1990, Int J Technol Assess Health Care, V6, P263; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; McLaughlin TJ, 1996, ARCH INTERN MED, V156, P799, DOI 10.1001/archinte.156.7.799; PASHOS CL, 1994, J AM COLL CARDIOL, V23, P1023, DOI 10.1016/0735-1097(94)90585-1; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; RAY WA, 1990, ARCH INTERN MED, V150, P2109, DOI 10.1001/archinte.150.10.2109; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; ROOS LL, 1989, STRENGTHS WEAKNESS H; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SIAL SH, 1994, J GEN INTERN MED, V9, P599, DOI 10.1007/BF02600301; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; Temple R, 1990, Int J Technol Assess Health Care, V6, P211; Wennberg J E, 1984, Health Manage Q, P6, DOI 10.1377/hlthaff.3.2.6; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255	44	416	422	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1997	277	2					115	121		10.1001/jama.277.2.115	http://dx.doi.org/10.1001/jama.277.2.115			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WA650	8990335				2022-12-28	WOS:A1997WA65000030
J	Churchill, D; Perry, IJ; Beevers, DG				Churchill, D; Perry, IJ; Beevers, DG			Ambulatory blood pressure in pregnancy and fetal growth	LANCET			English	Article							HYPERTENSION; WEIGHT; RATIO; LIFE	Background Retarded growth in utero has been linked with high blood pressure and other risk factors for cardiovascular disease in adult life. However, the influence on fetal growth of the maternal blood pressure during pregnancy is not well defined. In a prospective study, we examined the relation between maternal ambulatory blood pressure during pregnancy and indices of fetal growth. Methods We studied 209 healthy nulliparous pregnant women referred to an inner-city district general hospital (86% of 244 consecutively referred women who met the study criteria). 24 h ambulatory blood-pressure recordings were obtained in early (median 18 weeks [IQR 17-18]) mid (28 weeks [28]), and late (36 weeks [36]) gestation. Eight infants delivered before 32 weeks' gestation were excluded from the analysis. Findings A 5 mm Hg (1 SD) increase in mean 24 h diastolic blood pressure at 28 weeks' gestation was associated with a 68 g (95% CI 3-132) decrease in birthweight; a similar change in diastolic pressure at 36 weeks' gestation was associated with a 76 g (24-129) decrease in birthweight. These associations were independent of potential confounders (maternal age, height, weight, cigarette smoking, alcohol intake, ethnic origin, pregnancy hypertension syndromes, and preterm birth). Maternal mean 24 h diastolic blood pressure at 28 weeks' gestation was also inversely associated with the infant's ponderal index at birth in multivariate analysis (p=0.06). Higher maternal ambulatory blood pressure at 28 weeks' and 36 weeks' gestation also predicted lower head circumference, although these associations were dependent on birthweight. Associations between ambulatory systolic blood pressure and indices of fetal growth were weak and inconsistent and ambulatory blood pressure at 18 weeks' gestation did not predict fetal growth. Interpretation There is a continuous inverse association between fetal growth and maternal blood pressure, throughout the range seen in normal pregnancy. Maternal blood pressure may be an important confounding factor in the reported associations between fetal growth retardation and adult hypertension and cardiovascular disease.	GOOD HOPE HOSP NHS TRUST, DEPT OBSTET & GYNAECOL, SUTTON COLDFIELD, W MIDLANDS, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT PRIMARY CARE & POPULAT SCI, LONDON, ENGLAND; CITY HOSP, DEPT MED, BIRMINGHAM, W MIDLANDS, ENGLAND	Heart of England NHS Foundation Trust; Good Hope Hospital; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Birmingham				Perry, Ivan/0000-0002-4965-9792				Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Barker DJP, 1992, FETAL INFANT ORIGINS; BARTLEY M, 1994, BMJ-BRIT MED J, V309, P1475, DOI 10.1136/bmj.309.6967.1475; Churchill D, 1996, OBSTET GYNECOL, V88, P455, DOI 10.1016/0029-7844(96)00192-5; COLLEY NV, 1991, BRIT J OBSTET GYNAEC, V98, P524, DOI 10.1111/j.1471-0528.1991.tb10363.x; DAVEY DA, 1988, AM J OBSTET GYNECOL, V158, P892, DOI 10.1016/0002-9378(88)90090-7; Davies AM., 1983, OBSTETRICAL EPIDEMIO, P167; FERRY IJ, 1994, BRIT MED BULL, V50, P246, DOI 10.1093/oxfordjournals.bmb.a072890; FISHER KA, 1981, MEDICINE, V60, P267, DOI 10.1097/00005792-198107000-00002; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; MACGILLIVRAY I, 1969, CLIN SCI, V37, P395; Misra DP, 1996, PAEDIATR PERINAT EP, V10, P244, DOI 10.1111/j.1365-3016.1996.tb00048.x; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PERRY IJ, 1991, BRIT J OBSTET GYNAEC, V98, P241, DOI 10.1111/j.1471-0528.1991.tb13386.x; PERRY IJ, 1995, BMJ-BRIT MED J, V310, P436, DOI 10.1136/bmj.310.6977.436; Shennan A, 1996, LANCET, V347, P139, DOI 10.1016/S0140-6736(96)90338-4; SHENNAN AH, 1993, BRIT J OBSTET GYNAEC, V100, P904, DOI 10.1111/j.1471-0528.1993.tb15104.x; WARD R, 1990, HYPERTENSION PATHOPH, P81; ZINNER SH, 1985, HYPERTENSION, V7, P411, DOI 10.1161/01.HYP.7.3_Pt_1.411	21	109	111	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 4	1997	349	9044					7	10		10.1016/S0140-6736(96)06297-6	http://dx.doi.org/10.1016/S0140-6736(96)06297-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988114				2022-12-28	WOS:A1997WA72500008
J	Songyang, Z; Fanning, AS; Fu, C; Xu, J; Marfatia, SM; Chishti, AH; Crompton, A; Chan, AC; Anderson, JM; Cantley, LC				Songyang, Z; Fanning, AS; Fu, C; Xu, J; Marfatia, SM; Chishti, AH; Crompton, A; Chan, AC; Anderson, JM; Cantley, LC			Recognition of unique carboxyl-terminal motifs by distinct PDZ domains	SCIENCE			English	Article							TUMOR-SUPPRESSOR PROTEIN; SEPTATE JUNCTIONS; GENE; BINDING; CLONING; TIGHT; ZO-1; IDENTIFICATION; PEPTIDES; ENCODES	The oriented peptide library technique was used to investigate the peptide-binding specificities of nine PDZ domains. Each PDZ domain selected peptides with hydrophobic residues at the carboxyl terminus. Individual PDZ domains selected unique optimal motifs defined primarily by the carboxyl terminal three to seven residues of the peptides. One family of PDZ domains, including those of the Discs Large protein, selected peptides with the consensus motif Glu-(Ser/Thr)-Xxx-(Val/Ile) (where Xxx represents any ami no acid) at the carboxyl terminus. in contrast, another ami ly of PDZ domains, including those of LIN-2, p55, and Tiam-1, selected peptides with hydrophobic or aromatic side chains at the carboxyl terminal three residues. On the basis of crystal structures of the PSD-95-3 PDZ domain, the specificities observed with the peptide library can be rationalized.	BETH ISRAEL HOSP, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; YALE UNIV, SCH MED, DEPT INTERNAL MED, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06520 USA; WASHINGTON UNIV, SCH MED,DEPT PATHOL & MED,CTR IMMUNOL, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; TUFTS UNIV, ST ELIZABETHS MED CTR, DEPT BIOMED RES, TUMOR CELL BIOL LAB, BOSTON, MA 02135 USA; ONYX PHARMACEUT, RICHMOND, CA 94806 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Yale University; Yale University; Howard Hughes Medical Institute; Washington University (WUSTL); St. Elizabeth's Medical Center; Tufts University			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NCI NIH HHS [CA66263] Funding Source: Medline; NIDDK NIH HHS [DK34989] Funding Source: Medline; NIGMS NIH HHS [R01 GM056203] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRECHER A, UNPUB; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hata Y, 1996, J NEUROSCI, V16, P2488; Hoskins R, 1996, DEVELOPMENT, V122, P97; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; KIRN E, 1995, NATURE, V378, P85; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LIPINSKA B, 1990, J BACTERIOL, V172, P1791, DOI 10.1128/jb.172.4.1791-1797.1990; MARFATIA SM, IN PRESS J BIOL CHEM; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; PRASAD R, 1993, CANCER RES, V53, P5624; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SHESTAKOV SV, 1994, J BIOL CHEM, V269, P19354; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; SONGYANG Z, UNPUB; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	29	1181	1217	0	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 3	1997	275	5296					73	77		10.1126/science.275.5296.73	http://dx.doi.org/10.1126/science.275.5296.73			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974395				2022-12-28	WOS:A1997WA90300051
J	Austrup, F; Vestweber, D; Borges, E; Lohning, M; Brauer, R; Herz, U; Renz, H; Hallmann, R; Scheffold, A; Radbruch, A; Hamann, A				Austrup, F; Vestweber, D; Borges, E; Lohning, M; Brauer, R; Herz, U; Renz, H; Hallmann, R; Scheffold, A; Radbruch, A; Hamann, A			P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues	NATURE			English	Article							HOMING RECEPTOR; MYELOID CELLS; IN-VIVO; EXPRESSION; ANTIGEN; LYMPHOCYTES; TH1	WHEN activated, T helper cells differentiate into one of two subsets, Th1 and Th2, characterized by distinct profiles of cytokine production. Th1 cells activate pro-inflammatory effector mechanisms involved in protection and autoimmunity, whereas Th2 cells induce humoral and allergic responses and downregulate local inflammation(1,2). Apart from differences in the repertoire of cytokines, no phenotypic attributes are established that distinguish the two subsets. Here we show that Th1 cells, but not Th2 cells, are able to bind to P-selectin and E-selectin. Moreover, only Th1 cells can efficiently enter inflamed sites in Th1-dominated models, such as sensitized skin or arthritic joints, but not in a Th2-dominated allergic response, Immigration of Th1 cells into inflamed skin can be blocked by antibodies against P- and E-selectin, These results provide evidence for adhesion mechanisms to distinguish between the two T helper subsets and mediate their differential trafficking, They indicate that selective recruitment is an additional level of regulation for both effector function profile and character of a local immune response.	UNIV HAMBURG, KRANKENHAUS EPPENDORF, MED KLIN, IMMUNOL ABT, D-20246 HAMBURG, GERMANY; UNIV MUNSTER, INST ZELLBIOL, D-48149 MUNSTER, GERMANY; UNIV COLOGNE, INST GENET, D-50931 COLOGNE, GERMANY; FRIEDRICH SCHILLER UNIV KLINIKUM, INST PATHOL, D-07740 JENA, GERMANY; HUMBOLDT UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, INST KLIN CHEM & BIOCHEM, D-13353 BERLIN, GERMANY; UNIV ERLANGEN NURNBERG, INST EXPT MED & BINDEGEWEBSFORSCH, D-91054 ERLANGEN, GERMANY	University of Hamburg; University of Munster; University of Cologne; Friedrich Schiller University of Jena; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Erlangen Nuremberg			Scheffold, Alexander/S-2090-2016; Löhning, Max/AAL-2967-2021	Scheffold, Alexander/0000-0002-0626-343X; Löhning, Max/0000-0001-6382-7281; Radbruch, Andreas/0000-0001-5753-0000; Vestweber, Dietmar/0000-0002-3517-732X				ASSENMACHER M, 1994, EUR J IMMUNOL, V24, P1097, DOI 10.1002/eji.1830240513; Assenmacher M, 1996, EUR J IMMUNOL, V26, P263, DOI 10.1002/eji.1830260141; AUSTRUP F, 1995, EUR J IMMUNOL, V25, P1487, DOI 10.1002/eji.1830250602; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; BRAUER R, 1993, AGENTS ACTIONS, V38, pC95, DOI 10.1007/BF01991149; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; HALLMANN R, 1995, J RHEUAMTOL S101, V24, P107; HAMANN A, 1994, J IMMUNOL, V152, P3282; HAMANN A, 1993, ADHESION LEUCOCYTE H, P109; HAMANN A, 1996, IMMUNOLOGY METHODS M, P1333; LABOW MA, 1994, IMMUNITY, V1, P709, DOI 10.1016/1074-7613(94)90041-8; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Smith M E, 1980, Monogr Allergy, V16, P203; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; SWAIN SL, 1994, IMMUNITY, V1, P543, DOI 10.1016/1074-7613(94)90044-2	22	653	670	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 2	1997	385	6611					81	83		10.1038/385081a0	http://dx.doi.org/10.1038/385081a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985251				2022-12-28	WOS:A1997WA73100054
J	Bate, K; Colman, PG				Bate, K; Colman, PG			Diabetes - New pieces in the puzzle of diabetes	LANCET			English	Article											Bate, K (corresponding author), ROYAL MELBOURNE HOSP,DEPT DIABET & ENDOCRINOL,GRATTEN ST,PARKVILLE,VIC 3050,AUSTRALIA.							Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Hawkes CJ, 1996, DIABETES, V45, P1187, DOI 10.2337/diabetes.45.9.1187; JensenUrstad KJ, 1996, DIABETES, V45, P1253, DOI 10.2337/diabetes.45.9.1253; Maffei M, 1996, DIABETES, V45, P679, DOI 10.2337/diabetes.45.5.679; Rabinovitch A, 1996, J CLIN ENDOCR METAB, V81, P3197, DOI 10.1210/jc.81.9.3197	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348			2			SII4	SII4						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973482				2022-12-28	WOS:A1996WA46300004
J	Horton, R				Horton, R			The Wakley Prize	LANCET			English	Editorial Material																			0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1676	1676		10.1016/S0140-6736(05)65819-9	http://dx.doi.org/10.1016/S0140-6736(05)65819-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973427				2022-12-28	WOS:A1996VZ76600007
J	John, LCH				John, LCH			''Phlebomania Hancocksia'': Prevalence of a previously undescribed psychomotor disturbance	BRITISH MEDICAL JOURNAL			English	Article							INHIBITION; HEPARIN				John, LCH (corresponding author), ST BARTHOLOMEWS HOSP,DEPT CARDIOTHORAC SURG,LONDON EC1A 7BE,ENGLAND.							JOHN LCH, 1993, ANN THORAC SURG, V56, P899, DOI 10.1016/0003-4975(93)90352-I; JOHN LCH, 1993, J THORAC CARDIOV SUR, V105, P816; JOHN LCH, 1993, ANN THORAC SURG, V55, P1175, DOI 10.1016/0003-4975(93)90029-H	3	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1620	1620		10.1136/bmj.313.7072.1620	http://dx.doi.org/10.1136/bmj.313.7072.1620			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991011	Green Published			2022-12-28	WOS:A1996VZ81100043
J	Verhulst, J; Onghena, P				Verhulst, J; Onghena, P			Circaseptennial rhythm in ear growth	BRITISH MEDICAL JOURNAL			English	Article													Onghena, Patrick/M-6649-2017	Onghena, Patrick/0000-0002-3986-8312				FULLER WA, 1996, INTRO STATISTICAL TI; Heathcote JA, 1995, BRIT MED J, V311, P1668, DOI 10.1136/bmj.311.7021.1668; *SAS I, 1989, STAT AN SYST VERS 6; Verhulst J, 1996, PSYCHOL REP, V78, P19, DOI 10.2466/pr0.1996.78.1.19; VERHULST J, IN PRESS ANN HUM BIO	5	6	6	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1597	1598		10.1136/bmj.313.7072.1597	http://dx.doi.org/10.1136/bmj.313.7072.1597			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991002	Green Published			2022-12-28	WOS:A1996VZ81100025
J	Morgentaler, A; Bruning, CO; DeWolf, WC				Morgentaler, A; Bruning, CO; DeWolf, WC			Occult prostate cancer in men with low serum testosterone levels	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIGITAL RECTAL EXAMINATION; SCREENING-TEST; ANTIGEN; ADENOCARCINOMA; ULTRASONOGRAPHY; DIAGNOSIS; CARCINOMA; DENSITY	Objective.-To determine the prevalence of occult prostate cancer in men with low serum total testosterone or free testosterone levels. Design.-Retrospective analysis of a consecutive series of men. Setting.-Academic teaching hospital. Patients.-Seventy-seven men with low total testosterone or free testosterone levels, with normal results of digital rectal examination and prostate-specific antigen (PSA) levels of 4.0 ng/mL or less. The mean age was 58 years. Interventions.-Sextant prostate needle biopsies with ultrasound guidance. Main Outcome Measures.-Results of prostate needle biopsies, transrectal ultrasound, prostate volume, PSA level, PSA density, total and free testosterone levels. Results.-Prostate cancer was identified in 14% (11/77) of the entire group and in 10 men (29%) aged 60 years or older. The median age for men with cancer was 64 years. Histologic examination showed Gleason scores of 6 or 7 for all cancers. No significant differences were noted between the cancer and benign groups with regard to PSA level, PSA density, prostate volume, total testosterone level, or free testosterone level. Conclusions.-A high prevalence of biopsy-detectable prostate cancer was identified in men with low total or free testosterone levels despite normal PSA levels and results of digital rectal examination. These data suggest that (1) digital rectal examination and PSA levels are insensitive indicators of prostate cancer in men with low total or free testosterone levels, and (2) PSA levels may be altered by naturally occurring reductions in serum androgen levels.			Morgentaler, A (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV UROL,330 BROOKLINE AVE,BOSTON,MA 02215, USA.							BEHRE HM, 1994, CLIN ENDOCRINOL, V40, P341; BILLIS A, 1986, UROLOGY, V28, P324, DOI 10.1016/0090-4295(86)90019-1; BRAWER MK, 1995, PROSTATE, V27, P1, DOI 10.1002/pros.2990270102; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; ELLIS WJ, 1994, J UROLOGY, V152, P1520, DOI 10.1016/S0022-5347(17)32460-6; ENGLISH HF, 1986, CANCER RES, V46, P839; Gleason DF, 1977, UROLOGIC PATHOLOGY P; GUESS HA, 1993, UROL CLIN N AM, V20, P627; HAMMERER P, 1992, J UROLOGY, V147, P833, DOI 10.1016/S0022-5347(17)37399-8; JACKSON JA, 1989, ARCH INTERN MED, V149, P2365, DOI 10.1001/archinte.149.10.2365; LABRIE F, 1992, J UROLOGY, V147, P846, DOI 10.1016/S0022-5347(17)37402-5; MESHREF AW, 1995, UROLOGY, V45, P972, DOI 10.1016/S0090-4295(99)80117-4; MONATH JR, 1995, UROLOGY, V46, P58, DOI 10.1016/S0090-4295(99)80159-9; MONDA JM, 1995, UROLOGY, V46, P62, DOI 10.1016/S0090-4295(99)80160-5; RUDMAN D, 1994, J AM GERIATR SOC, V42, P522, DOI 10.1111/j.1532-5415.1994.tb04975.x; SEAMAN E, 1993, UROL CLIN N AM, V20, P653; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STAMEY TA, 1989, J UROLOGY, V141, P1088, DOI 10.1016/S0022-5347(17)41177-3; STONE NN, 1994, UROLOGY, V44, P18, DOI 10.1016/S0090-4295(94)80239-4; TENOVER JS, 1992, J CLIN ENDOCR METAB, V75, P1092, DOI 10.1210/jc.75.4.1092; TENOVER JS, 1994, ENDOCRIN METAB CLIN, V23, P877, DOI 10.1016/S0889-8529(18)30073-2; UZZO RG, 1995, UROLOGY, V46, P831, DOI 10.1016/S0090-4295(99)80353-7; VALLANCIEN G, 1991, J UROLOGY, V146, P1308, DOI 10.1016/S0022-5347(17)38076-X	24	195	201	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1996	276	23					1904	1906		10.1001/jama.276.23.1904	http://dx.doi.org/10.1001/jama.276.23.1904			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX522	8968017				2022-12-28	WOS:A1996VX52200039
J	Ramirez, JA; Ahkee, S; Summersgill, JT; Ganzel, BL; Ogden, LL; Quinn, TC; Gaydos, CA; Bobo, LL; Hammerschlag, MR; Roblin, PM; LeBar, W; Grayston, JT; Campbell, LA; Patton, DL; Dean, D; Schachter, J				Ramirez, JA; Ahkee, S; Summersgill, JT; Ganzel, BL; Ogden, LL; Quinn, TC; Gaydos, CA; Bobo, LL; Hammerschlag, MR; Roblin, PM; LeBar, W; Grayston, JT; Campbell, LA; Patton, DL; Dean, D; Schachter, J			Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis	ANNALS OF INTERNAL MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; TWAR; IDENTIFICATION; ASSOCIATION; TRACHOMATIS; INFECTION; DISEASE; LESIONS; GENE	Background: Atherosclerosis is pathologically similar to a chronic inflammatory response, Recent reports have suggested that Chlamydia pneumoniae may play a role in the pathogenesis of atherosclerosis. Objective: To determine, by using various detection methods, whether C. pneumoniae is present in the coronary arteries of patients with coronary atherosclerosis. Design: Multicenter investigation. Setting: The Jewish Hospital Heart and Lung Institute in Louisville, Kentucky, and several laboratories. Patients: 12 patients seeking heart transplantation. Measurements: Culture for C. pneumoniae was done in HEp-2 cell monolayers. Other methods of detection included polymerase chain reaction (PCR) assay, immunocytochemistry, transmission electron microscopy, and in situ hybridization. Results: Chlamydia pneumoniae was cultured from atherosclerotic plaques in one patient with severe coronary artery disease. The organism was found in the atheromas of this patient by PCR assay, immunocytochemistry, electron microscopy, and in situ hybridization. In addition, at least one testing method showed C. pneumoniae in coronary artery tissue in six of nine additional patients with coronary atherosclerosis. Conclusions: This study provides direct evidence of the presence of viable C. pneumoniae in atheromatous lesions, A chronic inflammatory response caused by a persistent infection of the coronary arteries may explain the link between C. pneumoniae and atherosclerosis.	JEWISH HOSP, LOUISVILLE, KY USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD USA; SUNY BROOKLYN, BROOKLYN, NY USA; PROVIDENCE HOSP, CITAT CLIN LABS, SOUTHFIELD, MI 48037 USA; UNIV WASHINGTON, SEATTLE, WA 98195 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA	Johns Hopkins University; State University of New York (SUNY) System; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco	Ramirez, JA (corresponding author), UNIV LOUISVILLE, DIV INFECT DIS, MDR BLDG, ROOM 622, 511 S FLOYD ST, LOUISVILLE, KY 40292 USA.		Gaydos, Charlotte A./E-9937-2010; Quinn, Thomas/A-2494-2010	Ramirez, Julio/0000-0001-7801-5374				CAMPBELL LA, 1992, J CLIN MICROBIOL, V30, P434, DOI 10.1128/JCM.30.2.434-439.1992; CAMPBELL LA, 1995, J INFECT DIS, V172, P585, DOI 10.1093/infdis/172.2.585; COLIGAN JE, 1992, CURRENT PROTOCOLS IM; DEAN D, 1995, J INFECT DIS, V172, P1013, DOI 10.1093/infdis/172.4.1013; DEAN D, 1995, CLIN INFECT DIS, V20, P1179, DOI 10.1093/clinids/20.5.1179; GAYDOS CA, 1992, J CLIN MICROBIOL, V30, P796, DOI 10.1128/JCM.30.4.796-800.1992; GAYDOS CA, 1993, CLIN INFECT DIS, V17, P718, DOI 10.1093/clinids/17.4.718; GAYDOS CA, 1992, INFECT IMMUN, V60, P5319, DOI 10.1128/IAI.60.12.5319-5323.1992; Gaydos CA, 1996, INFECT IMMUN, V64, P1614, DOI 10.1128/IAI.64.5.1614-1620.1996; HAMMERSCHLAG MR, 1992, CLIN INFECT DIS, V14, P178, DOI 10.1093/clinids/14.1.178; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; KUO CC, 1993, ARTERIOSCLER THROMB, V13, P1501, DOI 10.1161/01.ATV.13.10.1501; KUO CC, 1995, P NATL ACAD SCI USA, V92, P6911, DOI 10.1073/pnas.92.15.6911; KUO CC, 1995, CLIN MICROBIOL REV, V8, P451, DOI 10.1128/CMR.8.4.451; ROBLIN PM, 1992, J CLIN MICROBIOL, V30, P1968, DOI 10.1128/JCM.30.8.1968-1971.1992; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; THOM DH, 1992, JAMA-J AM MED ASSOC, V268, P68, DOI 10.1001/jama.268.1.68; WANG SP, 1979, J CLIN MICROBIOL, V10, P259, DOI 10.1128/JCM.10.2.259-261.1979; Weiss SM, 1996, J INFECT DIS, V173, P957, DOI 10.1093/infdis/173.4.957	20	386	407	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1996	125	12					979	982		10.7326/0003-4819-125-12-199612150-00008	http://dx.doi.org/10.7326/0003-4819-125-12-199612150-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX768	8967709				2022-12-28	WOS:A1996VX76800009
J	Palmieri, G; Lastoria, S; Colao, A; Vergara, E; Varrella, P; Biondi, E; Selleri, C; Catalano, L; Lombardi, G; Bianco, AR; Salvatore, M				Palmieri, G; Lastoria, S; Colao, A; Vergara, E; Varrella, P; Biondi, E; Selleri, C; Catalano, L; Lombardi, G; Bianco, AR; Salvatore, M			Successful treatment of a patient with a thymoma and pure red-cell aplasia with octreotide and prednisone	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOMATOSTATIN; SUBCLASSIFICATION; CHEMOTHERAPY; APOPTOSIS; FEATURES; IMMUNE; GAMMA		UNIV NAPLES FEDERICO II,DEPT MOL & CLIN ONCOL & ENDOCRINOL,SCH MED,NAPLES,ITALY; UNIV NAPLES FEDERICO II,DEPT HEMATOL,SCH MED,NAPLES,ITALY; NATL CANC INST G PASCALE,DEPT NUCL MED,NAPLES,ITALY	University of Naples Federico II; University of Naples Federico II; IRCCS Fondazione Pascale			Lastoria, Secondo/J-9607-2018; selleri, Carmine/AAL-4595-2020	Lastoria, Secondo/0000-0002-6649-9903; 				Casadevall N, 1996, NEW ENGL J MED, V334, P630, DOI 10.1056/NEJM199603073341004; DESEVILLA E, 1975, CANCER, V36, P1154, DOI 10.1002/1097-0142(197509)36:3<1154::AID-CNCR2820360349>3.0.CO;2-9; DESSYPRIS EN, 1991, SEMIN HEMATOL, V28, P275; GOLDEL N, 1989, CANCER, V63, P1493, DOI 10.1002/1097-0142(19890415)63:8<1493::AID-CNCR2820630807>3.0.CO;2-C; HU E, 1986, CANCER, V57, P1101, DOI 10.1002/1097-0142(19860315)57:6<1101::AID-CNCR2820570606>3.0.CO;2-A; KRANTZ SB, 1974, NEW ENGL J MED, V291, P345; KRUMAN II, 1991, J CELL PHYSIOL, V148, P267, DOI 10.1002/jcp.1041480212; LAMBERTS SWJ, 1991, ENDOCR REV, V12, P450, DOI 10.1210/edrv-12-4-450; Lamberts SWJ, 1996, NEW ENGL J MED, V334, P246, DOI 10.1056/NEJM199601253340408; LASTORIA S, 1994, PROCEEDINGS OF THE XVI INTERNATIONAL CANCER CONGRESS - FREE PAPERS AND POSTERS, TOMES 1-4, P685; MASAOKA A, 1989, CANCER, V64, P1872, DOI 10.1002/1097-0142(19891101)64:9<1872::AID-CNCR2820640920>3.0.CO;2-0; PARK HS, 1994, CANCER-AM CANCER SOC, V73, P2491, DOI 10.1002/1097-0142(19940515)73:10<2491::AID-CNCR2820731007>3.0.CO;2-6; POLLACK A, 1992, INT J RADIAT ONCOL, V23, P1037, DOI 10.1016/0360-3016(92)90911-Z; QUINTANILLAMARTINEZ L, 1993, HUM PATHOL, V24, P958, DOI 10.1016/0046-8177(93)90109-T; QUINTANILLAMARTINEZ L, 1994, CANCER-AM CANCER SOC, V74, P606, DOI 10.1002/1097-0142(19940715)74:2<606::AID-CNCR2820740212>3.0.CO;2-T; REICHLIN S, 1993, NEW ENGL J MED, V329, P1246; REUBI JC, 1993, BLOOD, V82, P2143; ROLAND AS, 1964, AM J MED SCI, V247, P719, DOI 10.1097/00000441-196406000-00013; SELLERI C, 1995, J CELL PHYSIOL, V165, P538, DOI 10.1002/jcp.1041650312; SOUADJIAN JV, 1974, ARCH INTERN MED, V134, P374, DOI 10.1001/archinte.134.2.374; STEWART BW, 1994, JNCI-J NATL CANCER I, V86, P1286, DOI 10.1093/jnci/86.17.1286; VANHAGEN PM, 1994, EUR J CLIN INVEST, V24, P91; VERLEY JM, 1985, CANCER, V55, P1074, DOI 10.1002/1097-0142(19850301)55:5<1074::AID-CNCR2820550524>3.0.CO;2-T	23	74	76	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1997	336	4					263	265		10.1056/NEJM199701233360405	http://dx.doi.org/10.1056/NEJM199701233360405			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE632	8995089				2022-12-28	WOS:A1997WE63200005
J	Weinstein, JN; Myers, TG; OConnor, PM; Friend, SH; Fornace, AJ; Kohn, KW; Fojo, T; Bates, SE; Rubinstein, LV; Anderson, NL; Buolamwini, JK; vanOsdol, WW; Monks, AP; Scudiero, DA; Sausville, EA; Zaharevitz, DW; Bunow, B; Viswanadhan, VN; Johnson, GS; Wittes, RE; Paull, KD				Weinstein, JN; Myers, TG; OConnor, PM; Friend, SH; Fornace, AJ; Kohn, KW; Fojo, T; Bates, SE; Rubinstein, LV; Anderson, NL; Buolamwini, JK; vanOsdol, WW; Monks, AP; Scudiero, DA; Sausville, EA; Zaharevitz, DW; Bunow, B; Viswanadhan, VN; Johnson, GS; Wittes, RE; Paull, KD			An information-intensive approach to the molecular pharmacology of cancer	SCIENCE			English	Article							TUMOR-CELL-LINES; ANTICANCER DRUG SCREEN; DIFFERENTIAL CYTOTOXICITY DATA; TOPOISOMERASE-II; DISCOVERY SCREEN; SUPPRESSOR GENE; INSTITUTE; P53; TUBULIN; AGENTS	Since 1990, the National Cancer institute (NCI) has screened more than 60,000 compounds against a panel of 60 human cancer cell lines, The 50-percent growth-inhibitory concentration (GI(50)) for any single cell line is simply an index of cytotoxicity or cytostasis, but the patterns of 60 such GI(50) values encode unexpectedly rich, detailed information on mechanisms of drug action and drug resistance. Each compound's pattern is like a fingerprint, essentially unique among the many billions of distinguishable possibilities. These activity patterns are being used in conjunction with molecular structural features of the tested agents to explore the NCI's database of more than 460,000 compounds, and they are providing insight into potential target molecules and modulators of activity in the 60 cell lines, For example, the information is being used to search for candidate anticancer drugs that are not dependent on intact p53 suppressor gene function for their activity. It remains to be seen how effective this information-intensive strategy will be at generating new clinically active agents.	FRED HUTCHINSON CANC RES CTR, NCI, SEATTLE, WA 98105 USA; NCI, DIV CLIN SCI, MED BRANCH, NIH, BETHESDA, MD 20892 USA; NCI, DIV CANC TREATMENT DIAGNOSIS & CTR, CANC THERAPY EVALUAT PROGRAM,BIOMETR RES BRANCH, NIH, BETHESDA, MD 20892 USA; LARGE SCALE BIOL, ROCKVILLE, MD 20850 USA; NCI, FREDERICK CANC RES & DEV CTR, SAIC, FREDERICK, MD 21701 USA; NCI, DEV THERAPEUT PROGRAM, DCTDC, NIH, BETHESDA, MD 20892 USA; NCI, INFORMAT TECHNOL BRANCH,DEV THERAPEUT PROGRAM, DCTDC,NIH, BETHESDA, MD 20892 USA; NCI, GRANTS & CONTRACTS OPERAT BRANCH, DEV THERAPEUT PROGRAM,DCTDC,NIH, BETHESDA, MD 20892 USA; NCI, OFF DIRECTOR, DCTDC, NIH, BETHESDA, MD 20892 USA	Fred Hutchinson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Weinstein, JN (corresponding author), NCI, DIV BASIC SCI,MOL PHARMACOL LAB,NIH,BLDG 37, ROOM 5C-25, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.		Bates, Susan/AFP-9514-2022; Fornace, Albert J/A-7407-2008; LAIRD, PETER W/G-8683-2012	Fornace, Albert J/0000-0001-9695-085X; LAIRD, PETER W/0000-0001-9117-3641; Myers, Timothy Gene/0000-0002-7059-5906; Weinstein, John/0000-0001-9401-6908; Rubinstein, Lawrence/0000-0002-9720-9737				ALVAREZ M, 1995, J CLIN INVEST, V95, P2205, DOI 10.1172/JCI117910; BAI R, 1991, J BIOL CHEM, V266, P15882; BATES SE, 1995, J CANCER RES CLIN, V121, P495, DOI 10.1007/BF01197759; Boyd M. R., 1989, CANCER PRINCIPLES PR, V3, P1; BOYD MR, 1995, DRUG DEVELOP RES, V34, P91, DOI 10.1002/ddr.430340203; BOYD MR, 1992, DEV ONCOL, V68, P11; BUOLAMWINI JK, UNPUB; CHABNER BA, 1994, CANC TREATMENT UPDAT, P10; CHIN KV, 1993, ADV CANCER RES, V60, P157; CLEAVELAND ES, 1995, BIOCHEM PHARMACOL, V49, P947, DOI 10.1016/0006-2952(95)00009-O; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GREVER MR, 1992, SEMIN ONCOL, V19, P622; GUPTA M, 1995, MOL PHARMACOL, V48, P658; Hamel E, 1996, BIOCHEM PHARMACOL, V51, P53, DOI 10.1016/0006-2952(95)02156-6; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Izquierdo MA, 1996, INT J CANCER, V65, P230; JAYARAM HN, 1992, BIOCHEM BIOPH RES CO, V186, P1600, DOI 10.1016/S0006-291X(05)81591-8; Koo HM, 1996, CANCER RES, V56, P5211; KOUTSOUKOS AD, 1994, STAT MED, V13, P719, DOI 10.1002/sim.4780130532; KUO SC, 1993, J MED CHEM, V36, P1146, DOI 10.1021/jm00061a005; LEE JS, 1994, MOL PHARMACOL, V46, P627; LETEURTRE F, 1995, BIOCHEM PHARMACOL, V49, P1283, DOI 10.1016/0006-2952(95)00047-4; LETEURTRE F, 1994, J NATL CANCER I, V86, P1239, DOI 10.1093/jnci/86.16.1239; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARSONI S, 1987, CANCER TREAT REP, V71, P71; MILNE GWA, 1994, J CHEM INF COMP SCI, V34, P1219, DOI 10.1021/ci00021a032; MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757; Myers T. G., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P299; Myers T. G., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P305; MYERS TG, IN PRESS ELECTROPHOR; OCONNOR PW, UNPUB; PAULL KD, 1992, CANCER RES, V52, P3892; PAULL KD, 1989, J NATL CANCER I, V81, P1088, DOI 10.1093/jnci/81.14.1088; PAULL KD, 1993, CANC CHEMOTHERAPEUTI, P1574; PENDYALA L, 1993, CANCER RES, V53, P5970; Scala S., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P325; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; SOLARY E, 1993, BIOCHEM PHARMACOL, V45, P2449, DOI 10.1016/0006-2952(93)90226-M; STINSON SF, 1992, ANTICANCER RES, V12, P1035; VANOSDOL WW, 1994, J NATL CANCER I, V86, P1853, DOI 10.1093/jnci/86.24.1853; WANG SM, 1994, J MED CHEM, V37, P4479, DOI 10.1021/jm00052a007; WEINSTEIN JN, 1994, STEM CELLS, V12, P13, DOI 10.1002/stem.5530120106; WEINSTEIN JN, 1992, SCIENCE, V258, P447, DOI 10.1126/science.1411538; Wilkins MR, 1996, BIOTECHNOL GENET ENG, V13, P19, DOI 10.1080/02648725.1996.10647923; WOSIKOWSKI K, UNPUB; WU L, 1992, CANCER RES, V52, P3029; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	53	989	1038	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 17	1997	275	5298					343	349		10.1126/science.275.5298.343	http://dx.doi.org/10.1126/science.275.5298.343			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994024				2022-12-28	WOS:A1997WC87300035
J	Husain, M; Shapiro, K; Martin, J; Kennard, C				Husain, M; Shapiro, K; Martin, J; Kennard, C			Abnormal temporal dynamics of visual attention in spatial neglect patients	NATURE			English	Article							UNILATERAL NEGLECT; COVERT ATTENTION; LESIONS; BLINK	WHEN rye identify a visual object such as a word or letter, sur ability to detect a second object is impaired if it appears within 400 ms of the first(1-5). This phenomenon has been termed the attentional blink or dwell time and is a measure of our ability Lo allocate attention over time (temporal attention), Patients with unilateral visual neglect are unaware of people or objects contralateral to their lesion(6,7). They are considered to have It disorder of attending to a particular location in space (spatial attention)(6-11). Here we examined the non-spatial temporal dynamics of attention in patients, using a protocol for assessing the attentional blink. Neglect patients with right parietal, frontal or basal ganglia strokes had an abnormally severe and protracted attentional blink. When they identified a letter, their awareness of a subsequent letter was significantly diminished for a length of time that was three times as long as fur individuals without neglect, Our results demonstrate far the first time that visual neglect is a disorder of directing attention in time, as well as space.	UNIV WALES,SCH PSYCHOL,BANGOR LL57 2DG,GWYNEDD,WALES	Bangor University	Husain, M (corresponding author), CHARING CROSS HOSP,CHARING CROSS & WESTMINSTER MED SCH,DEPT CLIN NEUROSCI,LONDON W6 8RF,ENGLAND.		Shapiro, Kimron/AAC-9685-2019; Husain, Masud/C-2074-2008	Shapiro, Kimron/0000-0002-0419-1460; Husain, Masud/0000-0002-6850-9255	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BATINT R, 1907, ORVOSI HETILAP, P209; BROADBENT DE, 1987, PERCEPT PSYCHOPHYS, V42, P105, DOI 10.3758/BF03210498; CORBETTA M, 1995, SCIENCE, V270, P802, DOI 10.1126/science.270.5237.802; Damasio H, 1989, ANAL NEUROPSYCHOLOGY; DUNCAN J, 1989, PSYCHOL REV, V96, P433, DOI 10.1037/0033-295X.96.3.433; DUNCAN J, 1994, NATURE, V369, P313, DOI 10.1038/369313a0; FRIEDMANHILL SR, 1995, SCIENCE, V269, P853, DOI 10.1126/science.7638604; FULLERTON KJ, 1988, Q J MED, V66, P147; HEILMAN KM, 1994, LOCALIZATION NEUROIM, P495; HUMPHREYS GW, 1994, NATURE, V372, P357, DOI 10.1038/372357a0; Husain M, 1996, J NEUROL, V243, P652, DOI 10.1007/BF00878662; HUSAIN M, 1988, ARCH NEUROL-CHICAGO, V45, P89, DOI 10.1001/archneur.1988.00520250095029; JACKSON S, IN PRESS CURR OPIN N; Kinsbourne M, 1970, Trans Am Neurol Assoc, V95, P143; Kinsbourne M., 1987, NEUROPHYSIOLOGICAL N, P69, DOI [10.1016/0028-3932(88)90103-0, DOI 10.1016/0028-3932(88)90103-0]; Mesulam M-M, 1985, PRINCIPLES BEHAV NEU; MORROW LA, 1988, PSYCHOBIOLOGY, V16, P261; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1987, NEUROPSYCHOLOGIA, V25, P135, DOI 10.1016/0028-3932(87)90049-2; RAYMOND JE, 1992, J EXP PSYCHOL HUMAN, V18, P849, DOI 10.1037/0096-1523.18.3.849; Richer F, 1996, NEUROPSYCHOLOGIA, V34, P509, DOI 10.1016/0028-3932(95)00132-8; RIDDOCH MJ, 1983, NEUROPSYCHOLOGIA, V21, P589, DOI 10.1016/0028-3932(83)90056-8; ROBERTSON IH, 1993, UNILATERAL NEGLECT C; Shapiro Kimron L., 1994, P151; SHAPIRO KL, 1994, J EXP PSYCHOL HUMAN, V20, P357, DOI 10.1037/0096-1523.20.2.357; STONE SP, 1993, J NEUROL NEUROSUR PS, V56, P463, DOI 10.1136/jnnp.56.5.463; Treisman A, 1996, CURR OPIN NEUROBIOL, V6, P171, DOI 10.1016/S0959-4388(96)80070-5; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; VALLAR G, 1986, NEUROPSYCHOLOGIA, V24, P609, DOI 10.1016/0028-3932(86)90001-1	29	301	306	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1997	385	6612					154	156		10.1038/385154a0	http://dx.doi.org/10.1038/385154a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WB728	8990117				2022-12-28	WOS:A1997WB72800053
J	Wolfe, SA; Zhou, P; Dotsch, V; Chen, L; You, A; Ho, SN; Crabtree, GR; Wagner, G; Verdine, GL				Wolfe, SA; Zhou, P; Dotsch, V; Chen, L; You, A; Ho, SN; Crabtree, GR; Wagner, G; Verdine, GL			Unusual Rel-like architecture in the DNA-binding domain of the transcription factor NFATc	NATURE			English	Article							NF-KAPPA-B; FAMILY; SPECIFICITY; ELEMENTS; HOMOLOGY; SUBUNIT; MEMBER	TRANSCRIPTION factors of the NFAT family regulate the production of effector proteins that coordinate the immune response(1). The immunosuppressive drugs FK506 and cyclosporin A (CsA) act by blocking a Ca2+-mediated signalling pathway leading to NFAT. Although FK506 and CsA have enabled human organs to Re transplanted routinely, the toxic side-effects of these drugs limit their usage. This toxicity might be absent in antagonists that target NFAT directly. As a first step in the structure-based search for NFAT antagonists, we now report the identification and solution structure of a 20K domain of NFATc (NFATc-DBD) that is both necessary and sufficient to bind DNA and activate transcription cooperatively. Although the overall fold of the NFATc DNA-hinding domain is related to that of NF-kappa B p50 (refs 2, 3), the two proteins use significantly different strategies for DNA recognition. On the basis of these results, we present a model for the cooperative complex formed between NFAT and the mitogenic transcription factor AP-1 on the interleukin-2 enhancer.	HARVARD UNIV,DEPT CHEM & CHEM BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115; STANFORD UNIV,HOWARD HUGHES MED INST,SCH MED,STANFORD,CA 94305	Harvard University; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Stanford University			chen, Lin/A-3392-2008; Zhou, Pei/O-6704-2019; Doetsch, Volker/D-5697-2011	chen, Lin/0000-0003-4798-6199; Zhou, Pei/0000-0002-7823-3416; Dotsch, Volker/0000-0001-5720-212X				BLACKWELL TK, 1994, SCIENCE, V266, P621, DOI 10.1126/science.7939715; CHEN L, 1995, CURR BIOL, V5, P882, DOI 10.1016/S0960-9822(95)00178-3; CHEN L, 1994, THESIS HARVARD U; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LIU J, 1994, P NATL ACAD SCI USA, V91, P908, DOI 10.1073/pnas.91.3.908; MASCARENAS JL, 1993, J AM CHEM SOC, V115, P373, DOI 10.1021/ja00054a068; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Min CH, 1996, J AM CHEM SOC, V118, P6116, DOI 10.1021/ja953658z; MULLER CW, 1995, NATURE, V373, P301; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PENG JW, 1992, J MAGN RESON, V98, P308, DOI 10.1016/0022-2364(92)90135-T; Peterson BR, 1996, P NATL ACAD SCI USA, V93, P13671, DOI 10.1073/pnas.93.24.13671; SHORTLE D, 1994, J MAGN RESON SER B, V105, P88, DOI 10.1006/jmrb.1994.1106; STAN DB, 1991, CELL, V67, P1231; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; WOLFE SA, 1996, THESIS HARVARD U; [No title captured]	30	88	93	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1997	385	6612					172	176		10.1038/385172a0	http://dx.doi.org/10.1038/385172a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WB728	8990122				2022-12-28	WOS:A1997WB72800058
J	Fischbach, W; Tacke, W; Greiner, A; MullerHermelink, HK				Fischbach, W; Tacke, W; Greiner, A; MullerHermelink, HK			Regression of immunoproliferative smell intestinal disease after eradication of Helicobacter pylori	LANCET			English	Article							LYMPHOID-TISSUE TYPE; GASTRIC LYMPHOMA; INFECTION		UNIV WURZBURG,INST PATHOL,D-97070 WURZBURG,GERMANY	University of Wurzburg	Fischbach, W (corresponding author), UNIV WURZBURG,AKAD LEHRKRANKENHAUS,KLINIKUM ASCHAFFENBURG,DEPT MED 2,D-63739 ASCHAFFENBURG,GERMANY.							Alkan S, 1996, LANCET, V348, P268, DOI 10.1016/S0140-6736(05)65578-X; BAYERDORFFER E, 1995, LANCET, V345, P1591, DOI 10.1016/S0140-6736(95)90113-2; ROGGERO E, 1995, ANN INTERN MED, V122, P767, DOI 10.7326/0003-4819-122-10-199505150-00006; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F	4	82	82	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					31	32		10.1016/S0140-6736(05)62165-4	http://dx.doi.org/10.1016/S0140-6736(05)62165-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988128				2022-12-28	WOS:A1997WA72500022
J	Bradley, D; Ratcliffe, O; Vincent, C; Carpenter, R; Coen, E				Bradley, D; Ratcliffe, O; Vincent, C; Carpenter, R; Coen, E			Inflorescence commitment and architecture in Arabidopsis	SCIENCE			English	Article							FLOWER DEVELOPMENT; MERISTEM; INITIATION; PROTEIN; PLANTS; GENES	Flowering plants exhibit one of two types of inflorescence architecture: indeterminate, in which the inflorescence grows indefinitely, or determinate, in which a terminal flower is produced. The indeterminate condition is thought to have evolved from the determinate many times, independently. In two mutants in distantly related species, terminal flower 1 in Arabidopsis and centroradialis in Antirrhinum, inflorescences that are normally indeterminate are converted to a determinate architecture, The Antirrhinum gene CENTRORADIALIS (CEN) and the Arabidopsis gene TERMINAL FLOWER 1 (TFL1) were shown to be homologous, which suggests that a common mechanism underlies indeterminacy in these plants. However, unlike CEN, TFL1 is also expressed during the vegetative phase, where it delays the commitment to inflorescence development and thus affects the timing of the formation of the inflorescence meristem as well as its identity.	JOHN INNES CTR PLANT SCI RES,DEPT GENET,NORWICH NR4 7UH,NORFOLK,ENGLAND; JOHN INNES CTR PLANT SCI RES,SAINSBURY LAB,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; Bradley D, 1996, NATURE, V379, P791, DOI 10.1038/379791a0; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; BUCQUOY S, 1994, EUR J BIOCHEM, V225, P1203, DOI 10.1111/j.1432-1033.1994.1203b.x; COEN ES, 1991, ANNU REV PLANT PHYS, V42, P241, DOI 10.1146/annurev.pp.42.060191.001325; COEN ES, 1994, DEVELOPMENT, P107; FOBERT PR, 1994, EMBO J, V13, P616, DOI 10.1002/j.1460-2075.1994.tb06299.x; GRANDY DK, 1990, MOL ENDOCRINOL, V4, P1370, DOI 10.1210/mend-4-9-1370; KUCKUCK H, 1930, Z IND ABST VER, V56, P51; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Rickett H. W., 1944, BOT REV, V10, P187, DOI 10.1007/BF02861094; Schmidt Randy L, COMMUNICATION; SCHULTZ EA, 1993, DEVELOPMENT, V119, P745; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; Simon R., 2016, COMMUNICATION; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; Stebbins G.L., 1974, FLOWERING PLANTS EVO, DOI 10.4159/harvard.9780674864856; STUBBE H, 1966, GENETIK ZYTOLOGIE AN; WEBERTING F, 1989, MORPHOLOGY FLOWERS I; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0; WHITELAM GC, 1993, PLANT CELL, V5, P757, DOI 10.1105/tpc.5.7.757; WILLIAMS MH, 1988, PROTOPLASMA, V147, P77, DOI 10.1007/BF01403879	24	635	693	6	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					80	83		10.1126/science.275.5296.80	http://dx.doi.org/10.1126/science.275.5296.80			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974397				2022-12-28	WOS:A1997WA90300053
J	Fabian, AC				Fabian, AC			A possible intracluster origin for the excess soft X-ray component in some clusters	SCIENCE			English	Article							COOLING FLOWS; GALAXIES	The soft x-ray spectra of the Virgo and Coma clusters cannot be modeled by emission from the well-known hot intracluster medium attenuated by photoelectric absorption along the line of sight in our galaxy. If the excess soft emission is due to thermal emission in the clusters from gas at about 1 million kelvin, then the gas should be rapidly cooling. The high rate of cooling poses problems for the origin of the gas and its sink. A model in which the component is due to turbulent mixing layers around clouds scattered throughout the intracluster medium may explain the excess emission. The gas in the mixing layer is reheated after cooling, so that the total mass remains relatively small.			Fabian, AC (corresponding author), UNIV CAMBRIDGE,INST ASTRON,MADINGLEY RD,CAMBRIDGE CB3 0HA,ENGLAND.							Begelman M. C., 1990, MNRAS, V244, P26; Bowyer S, 1996, SCIENCE, V274, P1338, DOI 10.1126/science.274.5291.1338; COWIE LL, 1983, ASTROPHYS J, V272, P29, DOI 10.1086/161259; CRAWFORD CS, 1992, MON NOT R ASTRON SOC, V259, P265, DOI 10.1093/mnras/259.2.265; Dixon WV, 1996, ASTROPHYS J, V469, pL77, DOI 10.1086/310271; Fabian AC, 1996, SCIENCE, V271, P1244, DOI 10.1126/science.271.5253.1244; FABIAN AC, 1994, ANNU REV ASTRON ASTR, V32, P277, DOI 10.1146/annurev.aa.32.090194.001425; FERGUSON HC, 1993, MON NOT R ASTRON SOC, V263, P343, DOI 10.1093/mnras/263.2.343; Lieu R, 1996, SCIENCE, V274, P1335, DOI 10.1126/science.274.5291.1335; Lieu R, 1996, ASTROPHYS J, V458, pL5, DOI 10.1086/309908; SLAVIN JD, 1993, ASTROPHYS J, V407, P83, DOI 10.1086/172494; SPARKS WB, 1993, ASTROPHYS J, V413, P531, DOI 10.1086/173022	12	20	20	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					48	49		10.1126/science.275.5296.48	http://dx.doi.org/10.1126/science.275.5296.48			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974385				2022-12-28	WOS:A1997WA90300041
J	Abernethy, W; Sekijima, JH				Abernethy, W; Sekijima, JH			Aortoenteric fistula	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Abernethy, W (corresponding author), VET AFFAIRS MED CTR,SEATTLE,WA 98108, USA.								0	5	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1997	336	1					27	27		10.1056/NEJM199701023360105	http://dx.doi.org/10.1056/NEJM199701023360105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA496	8970937				2022-12-28	WOS:A1997WA49600005
J	Batchelor, AM; Garthwaite, J				Batchelor, AM; Garthwaite, J			Frequency detection and temporally dispersed synaptic signal association through a metabotropic glutamate receptor pathway	NATURE			English	Article							CEREBELLAR PURKINJE-CELLS; LONG-TERM DEPRESSION; PROTEIN-KINASE-C; CALCIUM TRANSIENTS; CLIMBING FIBER; ACTIVATION; INVITRO; SLICES; INDUCTION; DENDRITES	IN the classical view, a central neuron integrates incoming synaptic information by simple algebraic summation of the resultant bioelectrical signals that coincide in time, The voltage dependence of the NMDA (N-methyl-D-aspartate) type of ionotropic glutamate receptor endows neurons with an additional tool that allows one synaptic input to influence another, providing again, that the two are active simultaneously(1). Here we identify a new mechanism by which non-coincident signals generated by different synaptic inputs are integrated, The device serves to regulate neuronal excitation through G-protein-coupled, metabotropic glutamate receptors (mGluRs)(2) in a powerful and specific manner. We show that, in cerebellar Purkinje cells, a single activation of the climbing-fibre input markedly potentiates mGluR-mediated excitation at parallel-fibre synapses(3). The potentiation results; from a transient rise in cytosolic Ca2+ which is 'memorized' in such a way that it promotes excitation through mGluRs for about two minutes. A Ca2+-transient is also effective if imposed up to two seconds after parallel-fibre stimulation. By allowing temporally and spatially dispersed synaptic signals to be assimilated, this mechanism adds a new element to the computational power of central neurons.	UCL, CRUCIFORM PROJECT, LONDON W1P 9LN, ENGLAND	University of London; University College London			Batchelor, Andrew/C-1174-2008	Batchelor, Andrew/0000-0002-5984-7842				ABE T, 1992, J BIOL CHEM, V267, P13361; ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; BATCHELOR AM, 1994, NEUROSCIENCE, V63, P911, DOI 10.1016/0306-4522(94)90558-4; BATCHELOR AM, 1993, NEUROPHARMACOLOGY, V32, P11, DOI 10.1016/0028-3908(93)90124-L; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; Eccles J.C., 1967, CEREBELLUM NEURONAL, DOI [10.1016/0013-4694(69)90099-6, DOI 10.1016/0013-4694(69)90099-6]; EILERS J, 1995, NATURE, V373, P155, DOI 10.1038/373155a0; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; Garthwaite J, 1996, J NEUROSCI METH, V64, P189, DOI 10.1016/0165-0270(95)00133-6; HUANG KP, 1989, TRENDS NEUROSCI, V12, P425, DOI 10.1016/0166-2236(89)90091-X; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P171, DOI 10.1113/jphysiol.1980.sp013357; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; MARSH SJ, 1995, NEURON, V15, P729, DOI 10.1016/0896-6273(95)90160-4; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MERRILL EG, 1978, J PHYSIOL-LONDON, V284, P127, DOI 10.1113/jphysiol.1978.sp012531; MIYAKAWA H, 1992, J NEUROPHYSIOL, V68, P1178, DOI 10.1152/jn.1992.68.4.1178; ROSS WN, 1987, J PHYSIOL-LONDON, V389, P319, DOI 10.1113/jphysiol.1987.sp016659; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; STAUB C, 1992, EUR J NEUROSCI, V4, P832, DOI 10.1111/j.1460-9568.1992.tb00193.x; SUGIMORI M, 1990, P NATL ACAD SCI USA, V87, P5084, DOI 10.1073/pnas.87.13.5084; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W	25	159	159	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 2	1997	385	6611					74	77		10.1038/385074a0	http://dx.doi.org/10.1038/385074a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985249				2022-12-28	WOS:A1997WA73100052
J	Monks, CRF; Kupfer, H; Tamir, I; Barlow, A; Kupfer, A				Monks, CRF; Kupfer, H; Tamir, I; Barlow, A; Kupfer, A			Selective modulation of protein kinase C-theta during T-cell activation	NATURE			English	Article							SIGNAL-TRANSDUCTION; B-CELLS; RECEPTOR; MEMBER; FAMILY	EVERY cell contains many families of protein kinases, and may express several structurally related yet genetically distinct kinases of each family. The activity of the serine/threonine protein kinase C (PKC) enzymes(1-2) has long been implicated in T-cell activation(3), but it is not known which members of the PKC family regulate the T-cell response to foreign antigens. The activation of T cells by antigen-presenting cells (APCs) is spatially restricted to their site of contact, where receptors on the T cells engage their counter-receptors on the APCs(4,5). We used this localized engagement to identify, at the single-cell level, intracellular proteins involved in the activation process. By digital immunofluorescence microscopy, we localized six isoforms of PKC in antigen-specific T-cell clones activated by APCs. Surprisingly, only PKC-theta translocated to the site of cell contact. Accordingly, in vitro kinase activity assays of PkC immunoprecipitates from the conjugates of T cells and APCs showed a selective increase in the activity of PKC-theta, indicating that the translocated enzyme is active. Several modes of partial T-cell activation that failed to cause PKC-theta translocation also failed to cause T-cell proliferation, further suggesting the involvement of PKC-theta in T-cell activation.	NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,DENVER,CO 80262; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Howard Hughes Medical Institute; Yale University								BAIER G, 1993, J BIOL CHEM, V268, P4997; BALER G, 1994, EUR J BIOCHEM, V225, P195; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; CHERWINSKI HM, 1992, J IMMUNOL, V148, P2996; HARWELL L, 1980, J EXP MED, V152, P893, DOI 10.1084/jem.152.4.893; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; KUPFER A, 1990, J MOL CELL IMMUNOL, V4, P317; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; KUPFER A, 1989, J EXP MED, V170, P1697, DOI 10.1084/jem.170.5.1697; KUPFER H, 1994, J EXP MED, V179, P1507, DOI 10.1084/jem.179.5.1507; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; PODACK ER, 1991, ANNU REV CELL BIOL, V7, P479, DOI 10.1146/annurev.cellbio.7.1.479; ROBLESFLORES M, 1993, BIOCHEM J, V296, P467, DOI 10.1042/bj2960467; ROJO JM, 1989, EUR J IMMUNOL, V19, P2061, DOI 10.1002/eji.1830191114; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAMADA K, 1995, BIOCHEM J, V308, P177, DOI 10.1042/bj3080177; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673; YOON ST, 1994, IMMUNITY, V1, P563	20	470	482	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1997	385	6611					83	86		10.1038/385083a0	http://dx.doi.org/10.1038/385083a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985252				2022-12-28	WOS:A1997WA73100055
J	MaciasSilva, M; Abdollah, S; Hoodless, PA; Pirone, R; Attisano, L; Wrana, JL				MaciasSilva, M; Abdollah, S; Hoodless, PA; Pirone, R; Attisano, L; Wrana, JL			MADR2 is a substrate of the TGF beta receptor and its phosphorylation is required for nuclear accumulation and signaling	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; MUTATION; COMPLEX; PROTEIN	MAD-related (MADR) proteins are essential intracellular components of TGF beta signaling pathways and are regulated by phosphorylation. Here, we demonstrate that MADR2 and not the related protein DPC4 transiently interacts with the TGF beta receptor and is directly phosphorylated by the complex on C-terminal serines. Interaction of MADR2 with receptors and phosphorylation requires activation of receptor I by receptor II and is mediated by the receptor I kinase. Mutation of the phosphorylation sites generates a dominant negative MADR2 that blocks TGF beta-dependent transcriptional responses, stably associates with receptors, and fails to accumulate in the nucleus in response to TGF beta signaling. Thus, transient association and phosphorylation of MADR2 by the TGF beta receptor is necessary for nuclear accumulation and initiation of signaling.	HOSP SICK CHILDREN, DIV GASTROENTEROL, PROGRAM DEV BIOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DEPT MED GENET & MICROBIOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DEPT ANAT & CELL BIOL, TORONTO, ON M5G 1X8, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Wrana, Jeffrey/F-8857-2013	Macias-Silva, Marina/0000-0002-3972-0983; Hoodless, Pamela/0000-0003-1371-0725				Attisano L, 1996, MOL CELL BIOL, V16, P1066; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Massague J, 1996, CANCER SURV, V27, P41; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SMITH DB, 1994, CURRENT PROTOCOL S28, V2; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Ventura F, 1996, J BIOL CHEM, V271, P13931, DOI 10.1074/jbc.271.24.13931; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRANA JL, 1996, IN PRESS TRENDS GENE; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	35	636	668	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 27	1996	87	7					1215	1224		10.1016/S0092-8674(00)81817-6	http://dx.doi.org/10.1016/S0092-8674(00)81817-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980228	Bronze			2022-12-28	WOS:A1996WA54100010
J	Espinel, CH				Espinel, CH			Chou Ch'en's street character: Facial deformity in the art of the Ming Dynasty	LANCET			English	Editorial Material							MEMORIAL		GEORGETOWN UNIV,SCH MED,ARLINGTON,VA 22205; METROPOLITAN WASHINGTON,BLOOD PRESSURE CTR,WASHINGTON,DC	Georgetown University								*BIBLE, EXODUS, V4; *BIBLE, EXODUS, V6; BIEN SM, 1967, LANCET, V2, P1152; CAHILL J, 1972, CHINESE PAINTING, P137; CHOU C, 1978, BEGGARS STREET CHARA, P159; ESPINEL CH, 1994, LANCET, V344, P1750, DOI 10.1016/S0140-6736(94)92891-6; Espinel CH, 1995, LANCET, V346, P1684, DOI 10.1016/S0140-6736(95)92846-4; FONG WC, 1996, POSSESSING PAST, P369; FRASER FC, 1980, AM J HUM GENET, V32, P796; Giles L., 1976, ANALECTS CONFUCIUS; GORLIN RJ, 1990, SYNDROMES HEAD NECK, P693; GRABB WC, 1971, CLEFT LIP PALATE, P1; Johnston M C, 1975, Clin Plast Surg, V2, P195; KHOO BC, 1966, PLAST RECONSTR SURG, V38, P89; LAWTON T, 1973, CHINESES FIGURE PAIN; LEE SE, 1980, 8 DYNASTIES CHINESE, P2; LEGGE J, 1861, CHINESE CLASSICS, V1, P221; Moore K.L., 1988, DEV HUMAN; MUSGRAVE RH, 1977, RECONSTRUCTIVE PLAST, P1930; NISWANDER JD, 1975, SOC BIOL, V22, P203, DOI 10.1080/19485565.1975.9988168; PLACIDI K, 1989, SOCIAL REALISM 16 CE; ROWLY G, 1959, PRINCIPLES CHINESE P; SHPRINTZEN RJ, 1985, AM J MED GENET, V20, P585, DOI 10.1002/ajmg.1320200404; SIGGSTEDT M, 1982, MUSEUM FAR E ANTIQUI, V54, P1; SULIK KK, 1985, SCANNING ELECTRON MI, V4, P1735; TOLOROVA M, 1987, SCAND J PLAST RECONS, V21, P19; WALLACE AF, 1990, BRIT J PLAST SURG, V43, P713, DOI 10.1016/0007-1226(90)90197-8	27	3	3	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1714	1716		10.1016/S0140-6736(96)10054-4	http://dx.doi.org/10.1016/S0140-6736(96)10054-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	VZ766	8973439	hybrid			2022-12-28	WOS:A1996VZ76600020
J	Morrison, D; Smith, RP				Morrison, D; Smith, RP			Respiratory medicine - A breath of fresh air?	LANCET			English	Article									FRENCHAY HOSP, DEPT MED, BRISTOL BS16 1LE, AVON, ENGLAND		Morrison, D (corresponding author), FALKIRK & DIST ROYAL INFIRM, DEPT MED, FALKIRK FK1 5QE, SCOTLAND.							Bascom R, 1996, AM J RESP CRIT CARE, V153, P3, DOI 10.1164/ajrccm.153.1.8542133; Condos R, 1996, LANCET, V347, P1082, DOI 10.1016/S0140-6736(96)90281-0; George CFP, 1996, AM J RESP CRIT CARE, V154, P175, DOI 10.1164/ajrccm.154.1.8680676; Gibson GJ, 1996, THORAX, V51, P238, DOI 10.1136/thx.51.3.238; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	1996	348			2			SII23	SII23						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973501				2022-12-28	WOS:A1996WA46300023
J	Schieppati, A; Remuzzi, G				Schieppati, A; Remuzzi, G			Nephrology - The year of the pores	LANCET			English	Article									MARIO NEGRI INST PHARMACOL RES, I-24125 BERGAMO, ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Schieppati, A (corresponding author), OSPED RIUNITI BERGAMO, DIV NEPHROL & DIALYSIS, I-24100 BERGAMO, ITALY.		Remuzzi, Giuseppe/V-9766-2017	Remuzzi, Giuseppe/0000-0002-6194-3446				Bai LQ, 1996, J BIOL CHEM, V271, P5171; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; Knoers N V, 1996, Curr Opin Nephrol Hypertens, V5, P353, DOI 10.1097/00041552-199607000-00011; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Ward CJ, 1996, P NATL ACAD SCI USA, V93, P1524, DOI 10.1073/pnas.93.4.1524	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	1996	348			2			SII13	SII13						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973491				2022-12-28	WOS:A1996WA46300013
J	Tesfaye, S; Watt, J; Benbow, SJ; Pang, KA; Miles, J; MacFarlane, IA				Tesfaye, S; Watt, J; Benbow, SJ; Pang, KA; Miles, J; MacFarlane, IA			Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy	LANCET			English	Article							BLOOD-FLOW; INTRACTABLE PAIN; EXPERIENCE	Background Conventional treatment for painful peripheral diabetic neuropathy is largely symptomatic and often ineffective, with unacceptable side-effects. We tested electrical spinal-cord stimulation for the management of chronic neuropathic pain, Methods Ten diabetic patients who did not respond to conventional treatment (mean age 51 [SD 9.3] years, six with type II diabetes, mean duration of diabetes 12 [6.3] years, mean duration of neuropathy 5 [2.1] years) were studied. The electrode was implanted in the thoracic/lumbar epidural space. Immediate neuropathic pain relief was assessed by visual analogue scale (VAS) after connecting the electrode, in a random order, to a percutaneous electrical stimulator or to a placebo stimulator, Exercise tolerance was assessed on a treadmill. Findings Eight subjects had statistically significant pain relief with the electrical stimulator (p<0.02) and were therefore converted to a permanent system, Statisically significant relief of both background and peak neuropathic pain was achieved at 3 months (n=7, p=0.016), at 6 months (n=7, p=0.03), and at the end of the study (14 months, n=7, background pain p=0.06, peak pain p=0.03). One patient died 2 months after the start of the study of unrelated cause while continuing to benefit from treatment and another patient ceased to benefit at 4 months. McGill pain questionnaire scores with the stimulator turned off did not change significantly from baseline scores, indicating that the severity of the underlying pain was unaltered. However, with the stimulator turned on, there was a statistically significant (p<0.05) improvement in all four components of the score, by the end of the study. At the end of the study, six patients continued to gain significant pain relief and used the stimulator as the sole treatment for their neuropathic pain. For example, median background and peak pain scores at the end of study, were, respectively, 77 and 81 with the stimulator off and 23 and 20 with the stimulator on. Exercise tolerance significantly improved at 3 months (n=7, median % increase 85 [IQR, 62-360], p=0.015) and at 6 months (n=6, 163 [61-425], p=0.0007). Electrophysiological tests, vibration perception-threshold, and glycaemic control were unchanged. Interpretation Electrical spinal-cord stimulation offers a new and effective way of relieving chronic diabetic neuropathic pain and improves exercise tolerance. The technique should be considered in patients with neuropathic pain who do not respond to conventional treatment.	WALTON DIABET CTR,LIVERPOOL,MERSEYSIDE,ENGLAND; WALTON HOSP,DEPT NEUROPHYSIOL,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND; PAIN RES INST,LIVERPOOL,MERSEYSIDE,ENGLAND	Walton Centre; University of Liverpool				Tesfaye, Solomon/0000-0003-1190-1472				BENBOW SJ, 1994, DIABETIC MED, V11, P17, DOI 10.1111/j.1464-5491.1994.tb00223.x; BOULTON AJM, 1982, DIABETES CARE, V5, P386, DOI 10.2337/diacare.5.4.386; CAMERON NE, 1993, DIABETIC MED, V10, P593, DOI 10.1111/j.1464-5491.1993.tb00131.x; CHAN A W, 1990, Pain Clinic, V3, P147; CHAN AW, 1988, J NEUROL NEUROSUR PS, V51, P688, DOI 10.1136/jnnp.51.5.688; *DIAB CONTR COMPL, 1993, NEW ENGL J MED, V329, P977, DOI DOI 10.1056/NEJM199309303291401; DYCK PJ, 1988, MUSCLE NERVE, V11, P21, DOI 10.1002/mus.880110106; JACOBS MJHM, 1988, ANN SURG, V207, P179, DOI 10.1097/00000658-198802000-00011; Long D M, 1975, Surg Neurol, V4, P134; LONG DM, 1981, APPL NEUROPHYSIOL, V44, P207; *MCG PAIN QUEST, 1975, PAIN, V1, P277; NAUGHTON J, 1964, AM J CARDIOL, V14, P837, DOI 10.1016/0002-9149(64)90011-6; NORTH RB, 1993, NEUROSURGERY, V32, P384, DOI 10.1227/00006123-199303000-00008; RAY CD, 1988, LUMBAR SPINE SURG IN; SIMPSON BA, 1991, J NEUROL NEUROSUR PS, V54, P196, DOI 10.1136/jnnp.54.3.196; SIMPSON BA, 1994, PAIN REV, V1, P1999; TESFAYE S, 1993, DIABETOLOGIA, V36, P1266, DOI 10.1007/BF00400804; Tesfaye S, 1996, DIABETOLOGIA, V39, P1377, DOI 10.1007/s001250050586; TESFAYE S, 1994, DIABETES NUTR METAB, V7, P375; TESFAYE S, 1994, DIABETOLOGIA, V37, P847, DOI 10.1007/BF00400938; TESFAYE S, 1992, DIABETOLOGIA, V35, P155, DOI 10.1007/BF00402548; WATKINS ES, 1993, BRIT MED J, V307, P462, DOI 10.1136/bmj.307.6902.462; WATKINS PJ, 1984, BRIT MED J, V288, P168, DOI 10.1136/bmj.288.6412.168; 1985, LANCET, V1, P83	24	177	183	1	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1698	1701		10.1016/S0140-6736(96)02467-1	http://dx.doi.org/10.1016/S0140-6736(96)02467-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973433				2022-12-28	WOS:A1996VZ76600013
J	Fontana, PE; Gabutti, L; Piffaretti, JC; Marone, C				Fontana, PE; Gabutti, L; Piffaretti, JC; Marone, C			Antibiotic treatment for giant-cell arteritis?	LANCET			English	Article							LYME		OSPED SAN GIOVANNI BELLINZONA,DEPT INTERNAL MED,CH-6500 BELLINZONA,SWITZERLAND; IST BATTERIOSIEROL CANTONALE,LUGANO,SWITZERLAND	Regional Hospital of Bellinzona & Valleys, San Giovanni								COYLE PK, 1993, RHEUM DIS CLIN N AM, V4, P993; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DELPLA PA, 1993, REV NEUROL PARIS, V6, P411; HALPREIN JJ, 1995, AM J MED S4A, V98, P52; VARTIOVAARA I, 1995, LANCET, V345, P842, DOI 10.1016/S0140-6736(95)92970-3	5	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1630	1630		10.1016/S0140-6736(96)07504-6	http://dx.doi.org/10.1016/S0140-6736(96)07504-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8961995				2022-12-28	WOS:A1996VX87600014
J	Blane, D; Hart, CL; Smith, GD; Gillis, CR; Hole, DJ; Hawthorne, VM				Blane, D; Hart, CL; Smith, GD; Gillis, CR; Hole, DJ; Hawthorne, VM			Association of cardiovascular disease risk factors with socioeconomic position during childhood and during adulthood	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; BRITISH CIVIL-SERVANTS; BIRTH COHORT; MORTALITY; MEN; PREDICTORS; SCOTLAND; FINLAND; WEIGHT; HEALTH	Objective-To investigate strength of associations between risk factors for cardiovascular disease and socioeconomic position during childhood and adulthood. Design-Cross sectional analysis of status of cardiovascular risk factors and past and present social circumstances. Subjects-5645 male participants in the west of Scotland collaborative study, a workplace screening study. Main outcome measures-Strength of association between each risk factor for cardiovascular disease (diastolic blood pressure, serum cholesterol concentration, level of recreational physical exercise, cigarette smoking, body mass index, and FEV(1) score (forced expiratory volume in one second as percentage of expected value) and social class during childhood (based on father's main occupation) and adulthood (based on own occupation at time of screening). Results-All the measured risk factors were significantly associated with both father's and own social class (P<0.05), apart from exercise and smoking (nut significantly associated with father's social class) and body mass index (not significantly associated with own social class). For all risk factors except body mass index, the regression coefficient of own social class was larger than the regression coefficient of father's social class. The difference between the coefficients was significant for serum cholesterol concentration, cigarette smoking, body mass index, and FEV(1) score (all P<0.001). Conclusions-Subjects) status for behavioural risk factors (exercise and smoking) was associated primarily with current socioeconomic, circumstances, while status for physiological risk factors (serum cholesterol, blood pressure, body mass index, and FEV(1)) was associated to varying extents with both past and present socioeconomic circumstances.	UNIV GLASGOW, DEPT PUBL HLTH, GLASGOW, LANARK, SCOTLAND; UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL BS8 2PR, AVON, ENGLAND; RUCHILL HOSP, W SCOTLAND CANC SURVEILLANCE UNIT, GLASGOW, LANARK, SCOTLAND; UNIV MICHIGAN, DEPT EPIDEMIOL, ANN ARBOR, MI 48109 USA	University of Glasgow; University of Bristol; University of Glasgow; University of Michigan System; University of Michigan	Blane, D (corresponding author), CHARING CROSS & WESTMINSTER MED SCH, ACAD DEPT PSYCHIAT, LONDON W6 8RP, ENGLAND.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				Armitage P., 1971, STAT METHODS MED RES, V1; ARNESEN E, 1985, J EPIDEMIOL COMMUN H, V39, P210, DOI 10.1136/jech.39.3.210; Barker DJP, 1992, FETAL INFANT ORIGINS; BARTLEY M, 1994, BMJ-BRIT MED J, V309, P1475, DOI 10.1136/bmj.309.6967.1475; BRADDON FFM, 1986, BMJ-BRIT MED J, V293, P299, DOI 10.1136/bmj.293.6542.299; Brunner E, 1996, LANCET, V347, P1008, DOI 10.1016/S0140-6736(96)90147-6; BURR ML, 1980, J EPIDEMIOL COMMUN H, V34, P93, DOI 10.1136/jech.34.2.93; EBIKRYSTON KL, 1989, INT J EPIDEMIOL, V18, P84, DOI 10.1093/ije/18.1.84; Erikson R., 1993, CONSTANT FLUX; FORSDAHL A, 1978, J EPIDEMIOL COMMUN H, V32, P34, DOI 10.1136/jech.32.1.34; FOX AJ, 1976, BRIT J PREVENTATIVE, V9, P180; Glass D.V., 1954, SOCIAL MOBILITY BRIT; GLIKSMAN MD, 1995, J EPIDEMIOL COMMUN H, V49, P10, DOI 10.1136/jech.49.1.10; Goldthorpe J., 1980, SOCIAL MOBILITY CLAS; HAWTHORNE VM, 1978, J EPIDEMIOL COMMUN H, V32, P260, DOI 10.1136/jech.32.4.260; HAWTHORNE VM, 1995, SCOT MED J, V40, P102, DOI 10.1177/003693309504000402; Hole DJ, 1996, BRIT MED J, V313, P711; KAPLAN GA, 1990, BRIT MED J, V301, P1121, DOI 10.1136/bmj.301.6761.1121; LEON DA, 1995, J EPIDEMIOL COMMUN H, V49, P5, DOI 10.1136/jech.49.1.5; LYNCH JW, 1994, LANCET, V343, P524, DOI 10.1016/S0140-6736(94)91468-0; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; Marshall G., 1988, SOCIAL CLASS MODERN; NOTKOLA V, 1985, SOC SCI MED, V21, P517, DOI 10.1016/0277-9536(85)90035-8; NOTKOLA V, 1985, COMMENTATIONES SCIEN, V29, P15; *OFF POP CENS SURV, 1966, CLASS OCC 1966; PARKER DJP, 1992, J EPIDEMIOL COMMUN H, V46, P8, DOI 10.1136/jech.46.1.8; PAYNE G, 1987, MOBILITY CHANGE MODE; POWER C, 1988, INT J OBESITY, V12, P445; REID I, 1989, SOCIAL CLASS DIFFERE; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; WADSWORTH MEJ, 1985, BRIT MED J, V291, P1534, DOI 10.1136/bmj.291.6508.1534; WOODWARD M, 1992, PREV MED, V21, P136, DOI 10.1016/0091-7435(92)90013-8	33	269	270	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 7	1996	313	7070					1434	1438		10.1136/bmj.313.7070.1434	http://dx.doi.org/10.1136/bmj.313.7070.1434			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX612	8973230	Green Published			2022-12-28	WOS:A1996VX61200026
J	vanderWal, G; van der Maas, PJ; Bosma, JM; OnwuteakaPhilipsen, BD; Willems, DL; Haverkate, I; Kostense, PJ				vanderWal, G; van der Maas, PJ; Bosma, JM; OnwuteakaPhilipsen, BD; Willems, DL; Haverkate, I; Kostense, PJ			Evaluation of the notification procedure for physician-assisted death in the Netherlands	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EUTHANASIA	Background In the Netherlands, a notification procedure for physician-assisted death has been in use since 1991. it requires doctors to report each case to the coroner, who in turn notifies the public prosecutor. Ultimately, the Assembly of Prosecutors General decides whether to prosecute. Although physician-assisted death remains technically illegal, doctors are extremely unlikely to be prosecuted if they comply with the requirements for accepted practice. In 1995, the ministers of health and justice commissioned an evaluation to determine the adequacy of the notification procedure. Methods A random sample of 405 physicians were interviewed. We also interviewed 147 physicians who had reported cases of physician-assisted death and 116 coroners, and we reviewed 353 judicial files of reported cases. In addition, we interviewed 48 public prosecutors and reviewed the minutes of the Assembly of Prosecutors General for 1991 to 1995 and all published court decisions from 1981 through 1995. Results in 1995, about 41 percent of all cases of euthanasia and physician-assisted suicide were reported. There were no major differences between reported and unreported cases in terms of the patients' characteristics, clinical conditions, or reasons for the action. Most patients had cancer and were described as suffering ''unbearably'' and ''hopelessly.'' Of the 6324 cases reported during the period from 1991 through 1995, only 13 involved prosecution of the physician. The majority of respondents in the groups interviewed thought that all cases of physician-asssisted death should be reviewed, although most doctors thought the review should be performed by other doctors, and there was substantial concern about the burden associated with the reporting procedure. Conclusions Substantial progress in the oversight of physician-assisted death has been achieved in the Netherlands. The reporting procedure could be more streamlined and less threatening. (C)1996, Massachusetts Medical Society.	VRIJE UNIV AMSTERDAM, INST RES EXTRAMURAL MED, NL-1081 BT AMSTERDAM, NETHERLANDS; VRIJE UNIV AMSTERDAM, DEPT GEN PRACTICE NURSING HOME & SOCIAL MED, NL-1081 BT AMSTERDAM, NETHERLANDS; VRIJE UNIV AMSTERDAM, DEPT EPIDEMIOL & BIOSTAT, NL-1081 BT AMSTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, ROTTERDAM, NETHERLANDS	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Erasmus University Rotterdam								ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; ANNAS GJ, 1990, JAMA-J AM MED ASSOC, V263, P858, DOI 10.1001/jama.263.6.858; Gardner M, 1989, BRIT MED J; Haverkate I, 1996, JAMA-J AM MED ASSOC, V275, P435, DOI 10.1001/jama.275.6.435; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; van der Maas PJ, 1995, JAMA-J AM MED ASSOC, V273, P1411, DOI 10.1001/jama.273.18.1411; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; VANDERMAAS PJ, 1992, HLTH POLICY, V22; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346	10	160	160	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1996	335	22					1706	1711						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV936	8965876				2022-12-28	WOS:A1996VV93600035
J	Stubbe, J				Stubbe, J			Natural products - One of nature's macromolecular machines demystified	SCIENCE			English	Editorial Material							LANTIBIOTICS; ANTIBIOTICS				Stubbe, J (corresponding author), MIT,DEPT CHEM,CAMBRIDGE,MA 02139, USA.							BAYER A, 1995, EUR J BIOCHEM, V234, P414, DOI 10.1111/j.1432-1033.1995.414_b.x; HUTCHINSON CR, 1995, ANNU REV MICROBIOL, V49, P201; JUNG G, 1991, ANGEW CHEM INT EDIT, V30, P1051, DOI 10.1002/anie.199110513; KLEINKAUF H, 1995, ANTON LEEUW INT J G, V67, P229, DOI 10.1007/BF00873687; KOLTER R, 1992, ANNU REV MICROBIOL, V46, P141, DOI 10.1146/annurev.mi.46.100192.001041; Li YM, 1996, SCIENCE, V274, P1188, DOI 10.1126/science.274.5290.1188; SAHL HG, 1995, EUR J BIOCHEM, V230, P827, DOI 10.1111/j.1432-1033.1995.tb20627.x; STACHELHAUS T, 1995, FEMS MICROBIOL LETT, V125, P3, DOI 10.1111/j.1574-6968.1995.tb07328.x	8	1	1	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1152	1153		10.1126/science.274.5290.1152	http://dx.doi.org/10.1126/science.274.5290.1152			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8966589				2022-12-28	WOS:A1996VT33500041
J	Murray, CJL; Lopez, AD				Murray, CJL; Lopez, AD			Evidence-based health policy - Lessons from the global burden of disease study	SCIENCE			English	Article							DISABILITY; TRANSITION; COUNTRIES		WHO,CH-1211 GENEVA,SWITZERLAND	World Health Organization	Murray, CJL (corresponding author), HARVARD UNIV,SCH PUBL HLTH,BURDEN DIS UNIT,9 BOW ST,CAMBRIDGE,MA 02138, USA.		Lopez, Alan/AAA-2734-2022; Lopez, Alan D/F-1487-2010	Lopez, Alan D/0000-0001-5818-6512				Feachem RGA, 1992, HLTH ADULTS DEV WORL; Frenk J., 1989, Health Policy and Planning, V4, P29, DOI 10.1093/heapol/4.1.29; Jamison D.T., 1993, DIS CONTROL PRIORITI; Murray C. J. L., 1996, GLOBAL BURDEN DIS, VII; Murray C.J.L., 1996, GLOBAL BURDEN DIS CO, P295; Murray C. J. L., 1996, GLOBAL BURDEN DIS; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P447; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P495; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P429; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P481; MURRAY CJL, 1996, GLOBAL BURDEN DIS, V1; MURRAY CJL, 1990, B INT UNION TUBERC, V65, P2; MURRAY CJL, 1996, GLOBAL BURDEN DIS, V1, P22; MURRAY CJL, 1996, GLOBAL BURDEN DIS, V1, P325; NORD E, 1992, SOC SCI MED, V41, P1429; OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375; RICHARDSON J, 1994, SOC SCI MED, V39, P7, DOI 10.1016/0277-9536(94)90162-7; Weinstein M C, 1990, Int J Technol Assess Health Care, V6, P93; 1993, 1993 WORLD DEV	20	1396	1475	7	148	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					740	743		10.1126/science.274.5288.740	http://dx.doi.org/10.1126/science.274.5288.740			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8966556				2022-12-28	WOS:A1996VQ14500029
J	Nulman, I; Rovet, J; Stewart, DE; Wolpin, J; Gardner, HA; Theis, JGW; Kulin, N; Koren, G				Nulman, I; Rovet, J; Stewart, DE; Wolpin, J; Gardner, HA; Theis, JGW; Kulin, N; Koren, G			Neurodevelopment of children exposed in utero to antidepressant drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREGNANCY; FLUOXETINE; IMIPRAMINE; DEPRESSION; THERAPY	Background Many women of reproductive age have depression, necessitating therapy with either a tricyclic antidepressant drug or a drug, such as fluoxetine, that inhibits the reuptake of serotonin. Whether these drugs affect fetal neurodevelopment is not known. Methods We studied the children of 80 mothers who had received a tricyclic antidepressant drug during pregnancy, 55 children whose mothers had received fluoxetine during pregnancy, and 84 children whose mothers had not been exposed during pregnancy to any agent known to affect the fetus adversely. The children's global IQ and language development were assessed between 16 and 86 months of postnatal age by age-appropriate Bayley Scales of Infant Development or the McCarthy Scales of Children's Abilities (for IQ) and the Reynell Developmental Language Scales. Results The mean (+/-SD) global 10 scores were 118+/-17 in the children of mothers who received a tricyclic antidepressant drug, 117+/-17 in those whose mothers received fluoxetine, and 115+/-14 in those in the control group. The language scores were similar in all three groups. The results were similar in children exposed to a tricyclic antidepressant drug or fluoxetine during the first trimester and those exposed throughout pregnancy. There were also no significant differences in temperament, mood, arousability, activity level, distractibility, or behavior problems in the three groups of children. Conclusions In utero exposure to either tricyclic antidepressant drugs or fluoxetine does not affect global 10, language development, or behavioral development in preschool children. (C) 1997, Massachusetis Medical Society.	HOSP SICK CHILDREN,DIV CLIN PHARMACOL,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,MOTHERISK PROGRAM,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,DEPT PEDIAT,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,DEPT PSYCHOL,TORONTO,ON M5G 1X8,CANADA; TORONTO HOSP,WOMENS HLTH PROGRAM,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,TORONTO,ON,CANADA; OSHAWA GEN HOSP,OSHAWA,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto			Theis, Jochen Goar Walther/AAB-5884-2020; Stewart, Donna Eileen E/J-2844-2016	Stewart, Donna Eileen E/0000-0002-8157-7746				ACHENBACH TM, 1991, MANUAL CHILD BEHAVIO; Bayley N, 1993, BAYLEY SCALES INFANT; BORYS DJ, 1992, AM J EMERG MED, V10, P115, DOI 10.1016/0735-6757(92)90041-U; Chambers CD, 1996, NEW ENGL J MED, V335, P1010, DOI 10.1056/NEJM199610033351402; COHEN LS, 1989, PSYCHOSOMATICS, V30, P25, DOI 10.1016/S0033-3182(89)72314-8; CROMBIE DL, 1972, BRIT MED J, V1, P745, DOI 10.1136/bmj.1.5802.745; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; Fullard W., 1978, TODDLER TEMPERAMENT; Goodman S H, 1992, Prog Exp Pers Psychopathol Res, V15, P47; Gram L, 1994, NEW ENGL J MED, V332, P343; GRAM LF, 1994, NEW ENGL J MED, V331, P1354; Hollingshead A.B., 1975, 4 FACTOR INDEX SOCIA; Hudson WW, 1982, CLIN MEASUREMENT PAC; IDANPAAN.J, 1973, LANCET, V2, P282; KESSLER RC, 1993, J AFFECT DISORDERS, V29, P85, DOI 10.1016/0165-0327(93)90026-G; KOREN G, 1989, AM J OBSTET GYNECOL, V160, P1190, DOI 10.1016/0002-9378(89)90186-5; KOREN G, 1994, MATERNAL FETAL TOXIC; KUENSSBERG EV, 1972, BMJ-BRIT MED J, V2, P292, DOI 10.1136/bmj.2.5808.292-b; McCarthy D, 1972, MCCARTHY SCALES CHIL; MCDEVITT SC, 1978, J CHILD PSYCHOL PSYC, V19, P245, DOI 10.1111/j.1469-7610.1978.tb00467.x; MISRI S, 1991, INT J PSYCHIAT MED, V21, P157, DOI 10.2190/JDTX-BYC3-K3VP-LWAH; MORRISON HL, 1983, CHILDREN DEPRESSED P; Nulman I, 1996, TERATOLOGY, V53, P304; PANDE AC, 1993, INT CLIN PSYCHOPHARM, V8, P267, DOI 10.1097/00004850-199300840-00010; PASTUSZAK A, 1993, JAMA-J AM MED ASSOC, V269, P2246, DOI 10.1001/jama.269.17.2246; POTTER WZ, 1991, NEW ENGL J MED, V325, P633; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; REYNELL J, 1985, REYNELL DEV LANGUAGE; Shepard TH, 1986, CATALOG TERATOGENIC; SIM M, 1972, BRIT MED J, V2, P45, DOI 10.1136/bmj.2.5804.45; VORHEES CV, 1994, FUND APPL TOXICOL, V23, P194, DOI 10.1006/faat.1994.1098; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; Weissman MM, 1991, PSYCHIAT DISORDERS A, P53; 1972, LANCET, V1, P838	34	399	404	0	23	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1997	336	4					258	262		10.1056/NEJM199701233360404	http://dx.doi.org/10.1056/NEJM199701233360404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WE632	8995088	Bronze			2022-12-28	WOS:A1997WE63200004
J	Dimond, JP; Palazzo, MGA				Dimond, JP; Palazzo, MGA			An unconscious man with asthma and a fixed, dilated pupil	LANCET			English	Article									CHARING CROSS HOSP,INTENS CARE UNIT,LONDON W6 8RF,ENGLAND	Imperial College London								FORESTNER JE, 1980, ANESTHESIOLOGY, V52, P438, DOI 10.1097/00000542-198005000-00013; GAUSSORGUES P, 1987, Annales Francaises d'Anesthesie et de Reanimation, V6, P38, DOI 10.1016/S0750-7658(87)80008-4; NUNN JF, 1987, APPL RESP PHYSL, P462; PRIELIPP RC, 1994, CAN J ANAESTH, V41, P140, DOI 10.1007/BF03009808; TUOCHY PG, 1989, NZ MED J, V102, P386	5	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					98	98		10.1016/S0140-6736(96)10507-9	http://dx.doi.org/10.1016/S0140-6736(96)10507-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996423				2022-12-28	WOS:A1997WB80000014
J	McCarton, CM; BrooksGunn, J; Wallace, IF; Bauer, CR; Bennett, FC; Bernbaum, JC; Broyles, S; Casey, PH; McCormick, MC; Scott, DT; Tyson, J; Tonascia, J; Meinert, CL				McCarton, CM; BrooksGunn, J; Wallace, IF; Bauer, CR; Bennett, FC; Bernbaum, JC; Broyles, S; Casey, PH; McCormick, MC; Scott, DT; Tyson, J; Tonascia, J; Meinert, CL			Results at age 8 years of early intervention for low-birth-weight premature infants - The infant health and development program	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SCHOOL AGE; FOLLOW-UP; CHILDREN; CARE; METAANALYSIS; ACHIEVEMENT; RETENTION; FAILURE; TRIAL; RISK	Objective.-To reevaluate at age 8 years children who had participated during the first 3 years of life in a randomized clinical trial of special services for low-birthweight (LBW) premature infants. Design.-Follow-up of a randomized controlled trial of premature infants (less than or equal to 37 weeks' gestation), stratified by 2 LBW groups (lighter [less than or equal to 2000 g] and heavier [2001-2500 g]) and divided into intervention (n=377) and follow-up only (n=608) groups. Setting.-Eight sites serving diverse populations. Participants.-At age 8 years, 874 children were assessed: 336 in the intervention group and 538 in the follow-up only group. Intervention.-The 3-year intervention consisted of home visits (birth to 3 years), child development center services (ages 1 to 3 years), and parent group meetings (ages 1 to 3 years). Primary Outcome Measures.-Cognitive functioning (Weschler Intelligence Scale for Children-III; Peabody Picture Vocabulary Test-Revised); academic achievement (Woodcock-Johnson Tests of Achievement-Revised); and parental reports of school performance, behavior (Child Behavior Checklist), and health (Child General Health Survey). Results.-At age 8 years, in the entire cohort and in the lighter LBW stratum, the intervention and follow-up only groups were similar on all primary outcome measures, Differences favoring the intervention group were found within the heavier LBW group: full-scale IQ score (4.4 points higher, P=.007), verbal IQ score (4.2 points higher, P=.01), performance IQ score (3.9 points higher, P=.02), mathematics achievement score (4.8 points higher, P=.04), and receptive vocabulary score (6.7 points higher, P=.001). On a physical functioning subscale, the whole intervention group received less favorable ratings, while the lighter LBW in intervention group had lower maternal ratings assessing social limitations caused by behavior. Conclusion.-Although at age 8 years there were modest intervention-related differences in the cognitive and academic skills of heavier LBW premature children, attenuation of the large favorable effects seen at 3 years was observed in both the heavier and lighter LBW groups, This indicates a need-to develop additional intervention strategies for LBW premature children that can provide sustained benefits.	COLUMBIA UNIV, TEACHERS COLL, CTR CHILDREN & FAMILIES, NEW YORK, NY 10027 USA; RES TRIANGLE INST, RES TRIANGLE PK, NC 27709 USA; UNIV MIAMI, SCH MED, DEPT PEDIAT, MIAMI, FL USA; UNIV WASHINGTON, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV PENN, CHILDRENS HOSP PHILADELPHIA, PHILADELPHIA, PA 19104 USA; UNIV ARKANSAS MED SCI HOSP, DEPT PEDIAT, LITTLE ROCK, AR USA; CHILDRENS HOSP, DEPT MATERNAL & CHILD HLTH, BOSTON, MA 02115 USA; UNIV TEXAS, SW MED CTR, DEPT PEDIAT, DALLAS, TX USA; JOHNS HOPKINS UNIV, DEPT BIOSTAT & EPIDEMIOL, BALTIMORE, MD USA	Columbia University; Columbia University Teachers College; Research Triangle Institute; University of Miami; University of Washington; University of Washington Seattle; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Arkansas System; University of Arkansas Medical Sciences; Harvard University; Boston Children's Hospital; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Johns Hopkins University	McCarton, CM (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, ROSE F KENNEDY CTR, ROOM 820, 1410 PELHAM PKWY S, BRONX, NY 10461 USA.			Wallace, Ina/0000-0002-0194-4041; McCormmick, Marie/0000-0002-3938-1707	NICHD NIH HHS [5R01 HD 27344] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027344] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACHENBACH TM, 1988, MANUAL CHILD BEHAVIO; AYLWARD GP, 1989, J PEDIATR-US, V115, P515, DOI 10.1016/S0022-3476(89)80273-2; Barnett WS, 1995, FUTURE CHILD, V5, P25, DOI 10.2307/1602366; Beery KE, 1989, MANUAL DEV TEST VISU; BENNETT FC, 1987, EFFECTIVENESS EARLY, P79; BROOKSGUNN J, 1994, JAMA-J AM MED ASSOC, V272, P1257, DOI 10.1001/jama.272.16.1257; BROOKSGUNN J, 1992, PEDIATRICS, V89, P1209; BROWN L, 1990, MANUAL BEHAV RATING; BUKA SL, 1992, PSYCHOL DEV LOW BIRT, V6, P187; BYRD RS, 1994, PEDIATRICS, V93, P481; Caldwell B., 1987, PRINCIPAL, V66, P10; Consortium for Longitudinal Studies, 1983, TWIG IS BENT LAST EF; CONSTANTINE WL, 1993, J DEV BEHAV PEDIATR, V14, P1; Dunn L.M., 1981, MANUAL PEABODY PICTU; ELLIOTT CD, 1990, MANUAL DIFFERENTIAL; ESCOBAR GJ, 1991, ARCH DIS CHILD, V66, P204, DOI 10.1136/adc.66.2.204; FEWELL RR, IN PRESS INFANT HLTH; GROSS RT, 1990, JAMA-J AM MED ASSOC, V263, P3035; HACK M, 1992, J DEV BEHAV PEDIATR, V13, P412; HORACEK HJ, 1987, J AM ACAD CHILD PSY, V26, P758, DOI 10.1097/00004583-198709000-00024; KLEBANOV PK, 1994, PEDIATRICS, V94, P700; KLEBANOV PK, 1994, J DEV BEHAV PEDIATR, V15, P248, DOI 10.1097/00004703-199408000-00005; KLEIN NK, 1989, J DEV BEHAV PEDIATR, V10, P32; KRAEMER HC, 1990, J CLIN EPIDEMIOL, V43, P1157, DOI 10.1016/0895-4356(90)90017-J; LANDGRAF JM, 1993, 10 ANN M ASS HLTH SE; LEE VE, 1990, CHILD DEV, V61, P495, DOI 10.1111/j.1467-8624.1990.tb02795.x; MCCARTON C, IN PRESS INFANT HLTH; MCCARTON CM, 1995, SEMIN PERINATOL, V19, P330, DOI 10.1016/S0146-0005(05)80049-7; McCormick MC, 1996, PEDIATRICS, V97, P18; MCCORMICK MC, 1989, JAMA-J AM MED ASSOC, V261, P1767, DOI 10.1001/jama.261.12.1767; MCCORMICK MC, 1992, JAMA-J AM MED ASSOC, V267, P2204, DOI 10.1001/jama.267.16.2204; MCCORMICK MC, 1991, JAMA-J AM MED ASSOC, V265, P2212, DOI 10.1001/jama.265.17.2212; MCCORMICK MC, 1993, J PEDIATR-US, V123, P527, DOI 10.1016/S0022-3476(05)80945-X; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; MCKEY R, 1985, IMPACT HEAD START CH; RAMEY CT, 1992, PEDIATRICS, V89, P454; RAMEY CT, 1991, CHILDREN POVERTY CHI; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; SCOTT DT, 1989, PEDIATR RES, V25, pA263; SEARLE SR, 1980, AM STAT, V34, P216, DOI 10.2307/2684063; Sheslow D, 1990, MANUAL WIDE RANGE AS; SOSTEK A, 1992, PSYCHOL DEV LOW BIRT, V6, P259; WABER DP, 1985, J CLIN EXP NEUROPSYC, V7, P264, DOI 10.1080/01688638508401259; WASIK BH, 1990, CHILD DEV, V61, P1682; Wechsler D., 1991, WISC 3 WECHSLER INTE; WEIKART DP, 1978, HIGH SCOPE ED RES FD, P3; Woodcock RW, 1990, MANUAL WOODCOCK JOHN	47	250	253	1	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1997	277	2					126	132		10.1001/jama.277.2.126	http://dx.doi.org/10.1001/jama.277.2.126			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WA650	8990337				2022-12-28	WOS:A1997WA65000032
J	Ichijo, H; Nishida, E; Irie, K; tenDijke, P; Saitoh, M; Moriguchi, T; Takagi, M; Matsumoto, K; Miyazono, K; Gotoh, Y				Ichijo, H; Nishida, E; Irie, K; tenDijke, P; Saitoh, M; Moriguchi, T; Takagi, M; Matsumoto, K; Miyazono, K; Gotoh, Y			Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways	SCIENCE			English	Article							PROTEIN-KINASE CASCADES; C-JUN; TRANSDUCTION PATHWAYS; STRESS; PHOSPHORYLATION; CLONING; CDNA; THREONINE; BETA; RECEPTORS	Mitogen-activated protein (MAP) kinase cascades are activated in response to various extracellular stimuli, including growth factors and environmental stresses. A MAP kinase kinase kinase (MAPKKK), termed ASK1, was identified that activated two different subgroups of MAP kinase kinases (MAPKK), SEK1 (or MKK4) and MKK3/MAPKK6 (or MKK6), which in turn activated stress-activated protein kinase (SAPK, also known as JNK; c-Jun amino-terminal kinase) and p38 subgroups of MAP kinases, respectively. Overexpression of ASK1 induced apoptotic cell death, and ASK1 was activated in cells treated with tumor necrosis factor-alpha (TNF-alpha), Moreover, TNF-alpha-induced apoptosis was inhibited by a catalytically inactive form of ASK1. ASK1 may be a key element in the mechanism of stress- and cytokine-induced apoptosis.	KYOTO UNIV,INST VIRUS RES,DEPT GENET & MOL BIOL,SAKYO KU,KYOTO 60601,JAPAN; NAGOYA UNIV,FAC SCI,DEPT MOL BIOL,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; BIOMED CTR,LUDWIG INST CANC RES,S-75124 UPPSALA,SWEDEN; TOKYO MED & DENT UNIV,DEPT ORAL PATHOL,BUNKYO KU,TOKYO 113,JAPAN	Kyoto University; Nagoya University; Ludwig Institute for Cancer Research; Tokyo Medical & Dental University (TMDU)	Ichijo, H (corresponding author), JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOSHIMA KU,1-37-1 KAMI IKEBUKURO,TOKYO 170,JAPAN.		Dijke, Peter ten/AAG-4660-2021; Moriguchi, Tetsuo/D-7061-2012	Dijke, Peter ten/0000-0002-7234-342X; Moriguchi, Tetsuo/0000-0002-9598-4991; Ichijo, Hidenori/0000-0002-5005-6438				Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1994, ONCOGENE, V9, P1891; GOTOH Y, UNPUB; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAN JH, 1995, BBA-MOL CELL RES, V1265, P224, DOI 10.1016/0167-4889(95)00002-A; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; ICHIJO H, 1993, J BIOL CHEM, V268, P14505; ICHIJO H, UNPUB; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PONCZ M, 1987, BLOOD, V69, P219; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saitoh M, 1996, J BIOL CHEM, V271, P2769, DOI 10.1074/jbc.271.5.2769; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SELINS KS, 1987, J IMMUNOL, V139, P3199; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798	43	1950	2042	6	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					90	94		10.1126/science.275.5296.90	http://dx.doi.org/10.1126/science.275.5296.90			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974401				2022-12-28	WOS:A1997WA90300057
J	Clever, LH; Colaianni, LA; Davidoff, F; Glas, R; Horton, R; Lundberg, G; Nylenna, M; Robinson, RG; Smith, R; Squires, BP; Utiger, R; VanderWeyden, M; Woolf, P				Clever, LH; Colaianni, LA; Davidoff, F; Glas, R; Horton, R; Lundberg, G; Nylenna, M; Robinson, RG; Smith, R; Squires, BP; Utiger, R; VanderWeyden, M; Woolf, P			Uniform requirements for manuscripts submitted to biomedical journals	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									ANNALS INTERNAL MED, PHILADELPHIA, PA USA; PRINCETON UNIV, PRINCETON, NJ 08544 USA	Princeton University									0	169	179	2	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1997	126	1					36	47		10.7326/0003-4819-126-1-199701010-00006	http://dx.doi.org/10.7326/0003-4819-126-1-199701010-00006			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA165	8992922				2022-12-28	WOS:A1997WA16500006
J	Vikkula, M; Boon, LM; Carraway, KL; Calvert, JT; Diamonti, AJ; Goumnerov, B; Pasyk, KA; Marchuk, DA; Warman, ML; Cantley, LC; Mulliken, JB; Olsen, BR				Vikkula, M; Boon, LM; Carraway, KL; Calvert, JT; Diamonti, AJ; Goumnerov, B; Pasyk, KA; Marchuk, DA; Warman, ML; Cantley, LC; Mulliken, JB; Olsen, BR			Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2	CELL			English	Article							SMOOTH-MUSCLE CELLS; GROWTH-FACTOR-BETA; VENOUS MALFORMATIONS; ENDOTHELIAL-CELLS; MOUSE EMBRYO; GENE; EXPRESSION; PROTEIN; VASCULOGENESIS; ANGIOGENESIS	Venous malformations (VMs), the most common errors of vascular morphogenesis in humans, are composed of dilated, serpiginous channels. The walls of the channels have a variable thickness of smooth muscle; some mural regions lack smooth muscle altogether. A missense mutation resulting in an arginine-to-tryptophan substitution at position 849 in the kinase domain of the receptor tyrosine kinase TIE2 segregates with dominantly inherited VM in two unrelated families. Using proteins expressed in insect cells, we demonstrate that the mutation results in increased activity of TIE2. We conclude that an activating mutation in TlE2 causes inherited VMs in the two families and that the TIE2 signaling pathway is critical for endothelial cell-smooth muscle cell communication in venous morphogenesis.	HARVARD UNIV,SCH DENT MED,HARVARD FORSYTH DEPT ORAL BIOL,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV PLAST SURG,BOSTON,MA 02115; DUKE UNIV,MED CTR,DEPT GENET,DURHAM,NC 27710; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115; UNIV MICHIGAN,INST GERONTOL,ANN ARBOR,MI 48109; HARVARD UNIV,BETH ISRAEL DEACONESS HOSP,SCH MED,DEPT CELL BIOL,DIV SIGNAL TRANSDUCT,BOSTON,MA 02115	Harvard University; Harvard School of Dental Medicine; Harvard University; Boston Children's Hospital; Harvard Medical School; Duke University; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Michigan System; University of Michigan; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Vikkula, M (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.		Boon, Laurence/HCI-3629-2022; Cantley, Lewis C/D-1800-2014; Vikkula, Miikka/Q-1038-2018	Cantley, Lewis C/0000-0002-1298-7653; Vikkula, Miikka/0000-0002-6236-338X; Marchuk, Douglas/0000-0002-3110-6671	NHLBI NIH HHS [HL33014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN KE, 1994, J VASC SURG, V19, P577, DOI 10.1016/S0741-5214(94)70029-X; ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; BELLUS GA, 1995, AM J HUM GENET, V56, P368; BETSHOLTZ C, 1993, BIOL PLATELET DERIVE, P11; BONIN LR, 1994, AM J PHYSIOL-HEART C, V267, pH1698, DOI 10.1152/ajpheart.1994.267.5.H1698; BOON LM, 1994, HUM MOL GENET, V3, P1583, DOI 10.1093/hmg/3.9.1583; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAMORE PA, 1993, GROWTH FACTORS, V8, P61, DOI 10.3109/08977199309029135; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; DUMONT DJ, 1994, GENOMICS, V23, P512, DOI 10.1006/geno.1994.1536; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; FILLINGER MF, 1993, J VASC SURG, V17, P1058, DOI 10.1016/0741-5214(93)90676-D; GALLIONE CJ, 1995, J MED GENET, V32, P197, DOI 10.1136/jmg.32.3.197; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; GROTENDORST GR, 1982, J CELL PHYSIOL, V113, P261, DOI 10.1002/jcp.1041130213; GUY PM, 1992, J BIOL CHEM, V267, P13851; HOLMGREN L, 1991, DEVELOPMENT, V113, P749; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KIRBY ML, 1995, CIRC RES, V77, P211, DOI 10.1161/01.RES.77.2.211; Kraling BM, 1996, AM J PATHOL, V148, P1181; Levanat S, 1996, NAT GENET, V12, P85, DOI 10.1038/ng0196-85; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MERWIN JR, 1991, AM J PATHOL, V138, P37; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; MULLIKEN JB, 1988, HEMANGIOMAS MALFORMA; NAKAMURA H, 1988, AM J ANAT, V181, P406, DOI 10.1002/aja.1001810409; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; Powell RJ, 1996, J VASC SURG, V24, P51, DOI 10.1016/S0741-5214(96)70144-1; Powell RJ, 1996, ANN VASC SURG, V10, P4, DOI 10.1007/BF02002334; RISAU W, 1988, DEVELOPMENT, V102, P471; RISAU W, 1988, DEV BIOL, V125, P441, DOI 10.1016/0012-1606(88)90225-4; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; SHINBROT E, 1994, DEV DYNAM, V199, P169, DOI 10.1002/aja.1001990302; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; TAKAHASHI K, 1994, J CLIN INVEST, V93, P2357, DOI 10.1172/JCI117241; Webster MK, 1996, MOL CELL BIOL, V16, P4081; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128	45	530	555	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1181	1190		10.1016/S0092-8674(00)81814-0	http://dx.doi.org/10.1016/S0092-8674(00)81814-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980225	Bronze			2022-12-28	WOS:A1996WA54100007
J	Kent, AP; Dornan, JC				Kent, AP; Dornan, JC			Obstetrics - Judgment day in utero	LANCET			English	Article									QUEENS UNIV BELFAST, ROYAL MATERN HOSP, DEPT FETAL MED, BELFAST, ANTRIM, NORTH IRELAND	Queens University Belfast	Kent, AP (corresponding author), UNIV CAPE TOWN, GROOTE SCHUUR HOSP, DEPT OBSTET, ZA-7925 CAPE TOWN, SOUTH AFRICA.							Hepper P. G., 1996, FETAL MATERNAL MED R, V8, P109, DOI [10.1017/S0965539500001534, DOI 10.1017/S0965539500001534]; Lilford RJ, 1996, J ROY SOC MED, V89, P130, DOI 10.1177/014107689608900304; RODECK C, 1995, PRENATAL DIAG, V15, P933, DOI 10.1002/pd.1970151008; Snijders RJM, 1996, ULTRASOUND OBST GYN, V7, P216, DOI 10.1046/j.1469-0705.1996.07030216.x; Wald NJ, 1996, BRIT J OBSTET GYNAEC, V103, P407, DOI 10.1111/j.1471-0528.1996.tb09765.x	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	1996	348			2			SII16	SII16						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973494				2022-12-28	WOS:A1996WA46300016
J	Orton, P; Jones, M				Orton, P; Jones, M			Primary care - Primary care: Who leads?	LANCET			English	Article											Orton, P (corresponding author), MATCHING PARSONAGE FARM, NEWMANS END, MATCHING CM17 0QX, ESSEX, ENGLAND.							*GEN MED SERV COMM, 1996, DEF COR SERV GEN PRA; GRAY DP, 1996, C AC ORG GEN PRACT; Greenhalgh T, 1996, BRIT MED J, V313, P957; *HM STAT OFF, 1996, CHOIC OPP; McWhinney IR, 1996, BRIT J GEN PRACT, V46, P433	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	1996	348			2			SII20	SII20						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973498				2022-12-28	WOS:A1996WA46300020
J	Nichol, KL				Nichol, KL			Booster doses of influenza vaccine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PLACEBO-CONTROLLED TRIAL; ELDERLY PERSONS; COST-EFFECTIVENESS; ANTIBODY-RESPONSE; ADVERSE REACTIONS; EFFICACY; ADULTS; PEOPLE				Nichol, KL (corresponding author), UNIV MINNESOTA, SCH MED, VA MED CTR, DEPT MED, MINNEAPOLIS, MN 55455 USA.							[Anonymous], 1996, MMWR Recomm Rep, V45, P1; CATE TR, 1983, REV INFECT DIS, V5, P737; COUCH RB, 1983, ANNU REV MICROBIOL, V37, P529, DOI 10.1146/annurev.mi.37.100183.002525; FEDSON DS, 1993, JAMA-J AM MED ASSOC, V270, P1956, DOI 10.1001/jama.270.16.1956; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; FOY HM, 1973, JAMA-J AM MED ASSOC, V226, P758, DOI 10.1001/jama.226.7.758; GOVAERT TME, 1993, BMJ-BRIT MED J, V307, P988, DOI 10.1136/bmj.307.6910.988; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; GROSS PA, 1987, J CLIN MICROBIOL, V25, P1763, DOI 10.1128/JCM.25.9.1763-1765.1987; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; LO W, 1993, EUR J CLIN MICROBIOL, V12, P778, DOI 10.1007/BF02098469; MARGOLIS KL, 1990, JAMA-J AM MED ASSOC, V264, P1139, DOI 10.1001/jama.264.9.1139; MULLOOLY JP, 1994, ANN INTERN MED, V121, P947, DOI 10.7326/0003-4819-121-12-199412150-00008; NICHOL KL, 1995, NEW ENGL J MED, V333, P889, DOI 10.1056/NEJM199510053331401; Nichol KL, 1996, ARCH INTERN MED, V156, P1546, DOI 10.1001/archinte.156.14.1546; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; RASTOGI S, 1995, CLIN DIAGN LAB IMMUN, V2, P120, DOI 10.1128/CDLI.2.1.120-121.1995	17	4	5	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1996	276	23					1857	1857		10.1001/jama.1996.03540230007002	http://dx.doi.org/10.1001/jama.1996.03540230007002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX522	8967994				2022-12-28	WOS:A1996VX52200001
J	Buckley, LM; Leib, ES; Cartularo, KS; Vacek, PM; Cooper, SM				Buckley, LM; Leib, ES; Cartularo, KS; Vacek, PM; Cooper, SM			Calcium and vitamin D-3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						prednisone; bone density; arthritis, rheumatoid; calcium carbonate; cholecalciferol	GLUCOCORTICOID-INDUCED OSTEOPENIA; STEROID-INDUCED OSTEOPOROSIS; POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; SALMON-CALCITONIN; MINERAL DENSITY; 25-HYDROXYVITAMIN-D; 1,25-DIHYDROXYVITAMIN-D; TRANSPLANTATION; ABSORPTION	Background: Therapy with low-dose corticosteroids is commonly used to treat allergic and autoimmune diseases. Long-term use of corticosteroids can lead to loss of bone mineral density and higher risk for vertebral fractures. Calcium and vitamin D-3 supplementation is rational therapy for minimizing bone loss, but little evidence for its effectiveness exists. Objective: To assess 1) the effects of supplemental calcium and vitamin D-3 on bone mineral density of patients with rheumatoid arthritis and 2) the relation between the effects of this supplementation and corticosteroid use. Design: 2-year randomized, double-blind, placebo controlled trial. Setting: University outpatient-care facility. Patients: 96 patients with rheumatoid arthritis, 65 of whom were receiving treatment with corticosteroids (mean dosage, 5.6 mg/d). Intervention: Calcium carbonate (1000 mg/d) and vitamin D-3 (500 IU/d) or placebo. Measurements: Bone mineral densities of the lumbar spine and femur were determined annually. Results: Patients receiving prednisone therapy who were given placebo lost bone mineral density in the lumbar spine and trochanter at a rate of 2.0% and 0.9% per year, respectively. Patients receiving prednisone therapy who were given calcium and vitamin D-3 gained bone mineral density in the lumbar spine and trochanter at a rate of 0.72% (P = 0.005) and 0.85% (P = 0.024) per year, respectively. In patients receiving prednisone therapy, bone mineral densities of the femoral neck and the Ward triangle did not increase significantly with calcium and vitamin D-3. Calcium and vitamin D-3 did not improve bone mineral density at any site in patients who were not receiving corticosteroids. Conclusion: Calcium and vitamin D-3 prevented loss of bone mineral density in the lumbar spine and trochanter in patients with rheumatoid arthritis who were treated with low-dose corticosteroids.	UNIV VERMONT, COLL MED, BURLINGTON, VT 05405 USA	University of Vermont	Buckley, LM (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, 1200 EAST BROAD ST, POB 980102, RICHMOND, VA 23298 USA.							Adachi JD, 1996, J RHEUMATOL, V23, P995; ADACHI JD, 1994, J RHEUMATOL, V21, P1922; ALOIA JF, 1984, CALCIFIED TISSUE INT, V36, P327, DOI 10.1007/BF02405338; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BUCKLEY LM, 1995, J RHEUMATOL, V22, P1055; BUTLER RC, 1991, BRIT J RHEUMATOL, V30, P86; CANALIS E, 1983, ENDOCRINOLOGY, V112, P931, DOI 10.1210/endo-112-3-931; CHESNUT CH, 1992, NEW ENGL J MED, V326, P406, DOI 10.1056/NEJM199202063260609; CHYUN YS, 1984, ENDOCRINOLOGY, V114, P477, DOI 10.1210/endo-114-2-477; CLEGG D O, 1983, Arthritis and Rheumatism, V26, pS47; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; DYKMAN TR, 1984, ARTHRITIS RHEUM, V27, P1336, DOI 10.1002/art.1780271203; GARTON MJ, 1993, ARTHRITIS RHEUM, V36, P222, DOI 10.1002/art.1780360213; HAHN T J, 1976, Seminars in Arthritis and Rheumatism, V6, P165, DOI 10.1016/0049-0172(76)90020-2; HAHN TJ, 1981, J CLIN ENDOCR METAB, V52, P111, DOI 10.1210/jcem-52-1-111; HAHN TJ, 1979, J CLIN INVEST, V64, P655, DOI 10.1172/JCI109506; HAHN TJ, 1977, J LAB CLIN MED, V90, P399; HALL GM, 1994, ARTHRITIS RHEUM, V37, P1499, DOI 10.1002/art.1780371014; HALL GM, 1993, ARTHRITIS RHEUM, V36, P1510, DOI 10.1002/art.1780361105; Healey JH, 1996, CALCIFIED TISSUE INT, V58, P73, DOI 10.1007/s002239900014; JULIAN BA, 1991, NEW ENGL J MED, V325, P544, DOI 10.1056/NEJM199108223250804; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KIMBERG DV, 1971, J CLIN INVEST, V50, P1309, DOI 10.1172/JCI106610; KLEIN RG, 1977, J CLIN INVEST, V60, P253, DOI 10.1172/JCI108762; KUKREJA SC, 1976, P SOC EXP BIOL MED, V152, P358; LAAN RFJM, 1993, ANN INTERN MED, V119, P963, DOI 10.7326/0003-4819-119-10-199311150-00001; LARNACH TA, 1992, CALCIFIED TISSUE INT, V51, P255, DOI 10.1007/BF00334484; LEE AH, 1994, AM J MED, V96, P35, DOI 10.1016/0002-9343(94)90113-9; LINDHOLM TS, 1977, CLIN ENDOCRINOL, V7, pS183, DOI 10.1111/j.1365-2265.1977.tb03380.x; LUKERT BP, 1992, J BONE MINER RES, V7, P1063; LUKERT BP, 1976, ARCH INTERN MED, V136, P1249, DOI 10.1001/archinte.136.11.1249; MACADAMS MR, 1986, ANN INTERN MED, V104, P648, DOI 10.7326/0003-4819-104-5-648; MEUNIER PJ, 1993, NEW ENGL J MED, V328, P1781, DOI 10.1056/NEJM199306173282411; MEYS E, 1994, AM J MED, V97, P445, DOI 10.1016/0002-9343(94)90324-7; MONTEMURRO L, 1991, CALCIFIED TISSUE INT, V49, P71, DOI 10.1007/BF02565124; Ramey D R, 1992, Arthritis Care Res, V5, P119, DOI 10.1002/art.1790050303; REID IR, 1992, J BONE MINER RES, V7, P1221; REID IR, 1993, NEW ENGL J MED, V328, P460, DOI 10.1056/NEJM199302183280702; REID IR, 1986, AM J CLIN NUTR, V44, P287, DOI 10.1093/ajcn/44.2.287; RICKERS H, 1984, CALCIFIED TISSUE INT, V36, P269, DOI 10.1007/BF02405329; RINGE JD, 1987, EUR J CLIN PHARMACOL, V33, P35, DOI 10.1007/BF00610377; SAMBROOK P, 1993, NEW ENGL J MED, V328, P1747, DOI 10.1056/NEJM199306173282404; SAMBROOK PN, 1986, ANN RHEUM DIS, V45, P950, DOI 10.1136/ard.45.11.950; SAMBROOK PN, 1988, ARTHRITIS RHEUM, V31, P973, DOI 10.1002/art.1780310805; SEEMAN E, 1980, J CLIN INVEST, V66, P664, DOI 10.1172/JCI109902; SILVERMAN SL, 1992, BONE, V13, pS27, DOI 10.1016/8756-3282(92)90193-Z; SILVERMAN SL, 1993, ARTHRITIS RHEUM-US, V36, pS122; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; STRUYS A, 1995, AM J MED, V99, P235, DOI 10.1016/S0002-9343(99)80154-5; VERSTRAETEN A, 1986, ANN RHEUM DIS, V45, P852, DOI 10.1136/ard.45.10.852; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; ZERWEKH JE, 1984, ARTHRITIS RHEUM, V27, P1050, DOI 10.1002/art.1780270913	52	246	257	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1996	125	12					961	+		10.7326/0003-4819-125-12-199612150-00004	http://dx.doi.org/10.7326/0003-4819-125-12-199612150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX768	8967706				2022-12-28	WOS:A1996VX76800006
J	Houbiers, JGA; vandeWatering, LMG; vandeVelde, CHJ; Brand, A				Houbiers, JGA; vandeWatering, LMG; vandeVelde, CHJ; Brand, A			Postoperative injection after colorectal surgery	LANCET			English	Letter							COAT-DEPLETED BLOOD; CANCER		UNIV LEIDEN HOSP,BLOOD BANK,NL-2300 RC LEIDEN,NETHERLANDS; UNIV LEIDEN HOSP,DEPT SURG,NL-2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	Houbiers, JGA (corresponding author), UNIV LEIDEN HOSP,DEPT IMMUNOHAEMATOL,POB 9600,NL-2300 RC LEIDEN,NETHERLANDS.							HEIS MM, 1994, LANCET, V344, P1430; HOUBIERS JGA, 1994, LANCET, V344, P573, DOI 10.1016/S0140-6736(94)91965-8; HOUBIERS JGA, 1994, LANCET, V344, P1430; HOUBIERS JGA, IN PRESS TRANSFUSION; JENSEN LS, 1994, LANCET, V344, P1429	5	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1665	1666		10.1016/S0140-6736(05)65738-8	http://dx.doi.org/10.1016/S0140-6736(05)65738-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8962018				2022-12-28	WOS:A1996VX87600067
J	McMaster, P				McMaster, P			More radical surgical excision for hepatocellular cancer?	LANCET			English	Article											McMaster, P (corresponding author), UNIV HOSP,LIVER & HEPATOBILIARY UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.							Grellier L, 1996, LANCET, V348, P1212, DOI 10.1016/S0140-6736(96)04444-3; ROMANI F, 1994, J AM COLL SURGEONS, V178, P379; WU HC, 1996, SURGERY, V120, P34; Yamamoto J, 1996, BRIT J SURG, V83, P1219	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1601	1602		10.1016/S0140-6736(05)65689-9	http://dx.doi.org/10.1016/S0140-6736(05)65689-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8961985				2022-12-28	WOS:A1996VX87600004
J	Son, H; Hawkins, RD; Martin, K; Kiebler, M; Huang, PL; Fishman, MC; Kandel, ER				Son, H; Hawkins, RD; Martin, K; Kiebler, M; Huang, PL; Fishman, MC; Kandel, ER			Long-term potentiation is reduced in mice that are doubly mutant in endothelial and neuronal nitric oxide synthase	CELL			English	Article							PLATELET-ACTIVATING-FACTOR; HIPPOCAMPAL PYRAMIDAL CELLS; RAT HIPPOCAMPUS; SYNAPTIC TRANSMISSION; RETROGRADE MESSENGER; INHIBITORS; ENHANCEMENT; SYNAPSES; SLICES; CA1	Nitric oxide (NO) has been implicated in hippocampal long-term potentiation (LTP), but LTP is normal in mice with a targeted mutation in the neuronal form of NO synthase (nNOS(-)). LTP was also normal in mice with a targeted mutation in endothelial NOS (eNOS(-)), but LTP in stratum radiatum of CA1 was significantly reduced in doubly mutant mice (nNOS(-)/eNOS(-)). By contrast, LTP in stratum oriens was normal in the doubly mutant mice. These results provide the first genetic evidence that NOS is involved in LTP in stratum radiatum and suggest that the neuronal and endothelial forms can compensate for each other in mice with a single mutation. They further suggest that there is also a NOS-independent component of LTP in stratum radiatum and that LTP in stratum oriens is largely NOS independent.	COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032; MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,CHARLESTOWN,MA 02129; HARVARD UNIV,SCH MED,CHARLESTOWN,MA 02129	Columbia University; Harvard University; Massachusetts General Hospital; Harvard University	Son, H (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032, USA.			Kiebler, Michael/0000-0002-8850-6297	NIMH NIH HHS [MH50733] Funding Source: Medline; NINDS NIH HHS [NS33335, NS10828] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH050733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS010828, R01NS033335, P50NS010828] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAI A, 1994, HIPPOCAMPUS, V4, P1, DOI 10.1002/hipo.450040103; ARAI A, 1992, EUR J NEUROSCI, V4, P411, DOI 10.1111/j.1460-9568.1992.tb00890.x; BANNERMAN DM, 1994, J NEUROSCI, V14, P7415; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BOULTON CL, 1995, NEUROSCIENCE, V69, P699, DOI 10.1016/0306-4522(95)00349-N; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CHETKOVICH DM, 1993, NEUROREPORT, V4, P919, DOI 10.1097/00001756-199307000-00020; CLARK GD, 1992, NEURON, V9, P1211, DOI 10.1016/0896-6273(92)90078-R; CUMMINGS JA, 1994, NEUROSCI LETT, V176, P110, DOI 10.1016/0304-3940(94)90883-4; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; Doyle C, 1996, J NEUROSCI, V16, P418; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRIBKOFF VK, 1992, J NEUROPHYSIOL, V68, P639, DOI 10.1152/jn.1992.68.2.639; Haley J. E., 1995, Society for Neuroscience Abstracts, V21, P1809; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HALEY JE, 1993, NEUROSCI LETT, V160, P85, DOI 10.1016/0304-3940(93)90919-C; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; ISHIZUKA N, 1990, J COMP NEUROL, V295, P580, DOI 10.1002/cne.902950407; IZUMI Y, 1993, NEUROREPORT, V4, P1131; KAIBARA T, 1993, J NEUROSCI, V13, P2391, DOI 10.1523/JNEUROSCI.13-06-02391.1993; Kantor D. B., 1996, Society for Neuroscience Abstracts, V22, P1511; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LUMRAGAN JT, 1993, NEUROSCIENCE, V57, P973, DOI 10.1016/0306-4522(93)90042-E; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; OUARDOUZ M, 1995, J NEUROPHYSIOL, V73, P810, DOI 10.1152/jn.1995.73.2.810; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; WENDLAND B, 1994, P NATL ACAD SCI USA, V91, P2151, DOI 10.1073/pnas.91.6.2151; WIERASZKO A, 1993, NEURON, V10, P553, DOI 10.1016/0896-6273(93)90342-O; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; WILLIAMS JH, 1993, NEURON, V11, P877, DOI 10.1016/0896-6273(93)90117-A; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	41	363	377	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1015	1023		10.1016/S0092-8674(00)81796-1	http://dx.doi.org/10.1016/S0092-8674(00)81796-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978606	hybrid			2022-12-28	WOS:A1996VY44700007
J	Schneider, C; Hartl, FU				Schneider, C; Hartl, FU			Cell biology - Hats off to the tricorn protease	SCIENCE			English	Editorial Material							CRYSTAL-STRUCTURE		MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	Schneider, C (corresponding author), MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021, USA.		Hartl, F. Ulrich/Y-8206-2019					Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Tamura T, 1996, SCIENCE, V274, P1385, DOI 10.1126/science.274.5291.1385; TAMURA T, IN PRESS FEBS LETT	5	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1323	1324		10.1126/science.274.5291.1323	http://dx.doi.org/10.1126/science.274.5291.1323			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8966603				2022-12-28	WOS:A1996VU95400035
J	Jones, AH				Jones, AH			Literature and medicine: An evolving canon	LANCET			English	Editorial Material											Jones, AH (corresponding author), UNIV TEXAS, MED BRANCH, INST MED HUMANITIES, ASHBEL SMITH BLDG SUITE 2-210, 301 UNIV BLVD, GALVESTON, TX 77555 USA.							AULL F, 1995, ONLINE DATABASE LIT; Bakhtin M.M, 1981, DIALOGIC IMAGINATION; Bell Barbara Currier., 1984, LIT MED, V3, P143; *BIBLE, JOB; Camus, PLAGUE; CHARON R, 1995, ANN INTERN MED, V122, P599, DOI 10.7326/0003-4819-122-8-199504150-00008; Charon R., 1994, MATTER PRINCIPLES FE, P260; COLES R, 1984, DOCTOR STORIES, pR7; ELIOT G, MIDDLEMARCH; GARCIAMARQUEZ, LOVE TIME CHOLERA; HUNTER KM, 1995, ACAD MED, V70, P787, DOI 10.1097/00001888-199509000-00014; HUNTER KM, 1991, THESIS PRINCETON U P; Jones AH, 1996, J MED PHILOS, V21, P267; JONES AH, 1987, NEOHELICON, V14, P383, DOI 10.1007/BF02094701; JONES AH, 1990, ST COMPAR L, V22, P11; KAFKA F, METAMORPHOSIS; KING NMP, 1992, LIT MED, V11, P185; MANN T, DEATH IN VENICE AND; MANN T, MAGIC MOUNTAIN; McLellan MF, 1996, LANCET, V348, P109, DOI 10.1016/S0140-6736(96)03521-0; McLellan MF, 1996, LANCET, V348, P1014, DOI 10.1016/S0140-6736(96)07316-3; SELZER R, 1982, LETT YOUNG DOCTOR; SOPHOCLES, PHILOCTETES; TERRY JS, 1988, LIT MED, V7, P1, DOI 10.1353/lm.2011.0155; TOLSTOY, DEATH I ILYICH; Trautmann J, 1982, LIT MED ANNOTATED BI; Trautmann J., 1982, LIT MED, V1, P1, DOI [10.1353/lm.2011.0206, DOI 10.1353/LM.2011.0206]; Trautmann J., 1978, ROLE HUMANITIES MED, P32; WILLIAMS WC, 1984, DOCTOR STORIES, P56; WILLIAMS WC, 1963, SELECTED POEMS; Williams William Carlos., 1963, PATERSON; Woodcock J, 1992, J Med Humanit, V13, P157, DOI 10.1007/BF01127374	32	10	10	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 16	1996	348	9038					1360	1362		10.1016/S0140-6736(96)09219-7	http://dx.doi.org/10.1016/S0140-6736(96)09219-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	VT332	8965587				2022-12-28	WOS:A1996VT33200015
J	Brett, MT; Goldman, CR				Brett, MT; Goldman, CR			Consumer versus resource control in freshwater pelagic food webs	SCIENCE			English	Article							COMMUNITY STRUCTURE; PHYTOPLANKTON COMMUNITY; TROPHIC INTERACTIONS; POPULATION-DYNAMICS; PLANKTIVOROUS FISH; LAKE TAHOE; BOTTOM-UP; TOP-DOWN; ZOOPLANKTON; PRODUCTIVITY	Models predict that food-web structure is regulated by both consumers and resources, and the strength of this control is dependent on trophic position and food-web length. To test these hypotheses, a meta-analysis was conducted of 11 fish (consumer)-by-nutrient (resource) factorial plankton community experiments, As predicted, zooplankton biomass was under strong consumer control but was weakly stimulated by nutrient additions; phytoplankton biomass was under strong resource control with moderate control by fish. However, the phytoplankton and zooplankton responses to nutrient additions did not follow theoretical predictions based on the number of trophic levels in the food web.			Brett, MT (corresponding author), UNIV CALIF DAVIS,DIV ENVIRONM SCI,DAVIS,CA 95616, USA.		Brett, Michael T/A-2066-2010; Bond, Alexander L/A-3786-2010					BEAUCHAMP DA, 1994, GREAT BASIN NAT, V54, P130; Beauchamp David A., 1992, North American Journal of Fisheries Management, V12, P442, DOI 10.1577/1548-8675(1992)012<0442:LTSILT>2.3.CO;2; Brett MT, 1996, P NATL ACAD SCI USA, V93, P7723, DOI 10.1073/pnas.93.15.7723; BRETT MT, IN PRESS FRESHWATER; CARPENTER SR, 1985, BIOSCIENCE, V35, P634, DOI 10.2307/1309989; CARPENTER SR, 1992, LIMNOL OCEANOGR, V37, P208, DOI 10.4319/lo.1992.37.1.0208; DAY RW, 1989, ECOL MONOGR, V59, P433, DOI 10.2307/1943075; DEMELO R, 1992, LIMNOL OCEANOGR, V37, P192, DOI 10.4319/lo.1992.37.1.0192; DRENNER RW, 1990, HYDROBIOLOGIA, V208, P161, DOI 10.1007/BF00007782; ELLIOTT ET, 1983, OIKOS, V41, P7, DOI 10.2307/3544340; FAAFENG BA, 1990, HYDROBIOLOGIA, V200, P119, DOI 10.1007/BF02530333; GLIWICZ ZM, 1990, ECOLOGY, V71, P691, DOI 10.2307/1940323; GOLDMAN CR, 1979, LIMNOL OCEANOGR, V24, P289, DOI 10.4319/lo.1979.24.2.0289; HAIRSTON NG, 1960, AM NAT, V94, P421, DOI 10.1086/282146; HAIRSTON NG, 1993, AM NAT, V142, P379, DOI 10.1086/285546; HUNTER MD, 1992, ECOLOGY, V73, P724; KERFOOT WC, 1989, TRENDS ECOL EVOL, V4, P167, DOI 10.1016/0169-5347(89)90121-3; LAMPERT W, 1987, NEW ZEAL J MAR FRESH, V21, P483, DOI 10.1080/00288330.1987.9516244; LAMPERT W, 1981, INT REV GES HYDROBIO, V66, P285, DOI 10.1002/iroh.19810660302; LAMPERT W, 1986, LIMNOL OCEANOGR, V31, P478, DOI 10.4319/lo.1986.31.3.0478; LARSON GL, 1996, LAKE RESERVOIR MANAG, V12; LEIBOLD MA, 1989, AM NAT, V134, P922, DOI 10.1086/285022; LEIBOLD MA, 1992, NATURE, V360, P341, DOI 10.1038/360341a0; Lindeman RL, 1942, ECOLOGY, V23, P399, DOI 10.2307/1930126; LYNCH M, 1979, LIMNOL OCEANOGR, V24, P253, DOI 10.4319/lo.1979.24.2.0253; LYNCH M, 1981, LIMNOL OCEANOGR, V26, P86, DOI 10.4319/lo.1981.26.1.0086; MARKOSOVA R, 1993, HYDROBIOLOGIA, V264, P85, DOI 10.1007/BF00014096; MCCAULLY E, 1984, SECONDARY PRODUCTIVI, P228; MCQUEEN DJ, 1986, CAN J FISH AQUAT SCI, V43, P1571, DOI 10.1139/f86-195; MCQUEEN DJ, 1992, ARCH HYDROBIOL, V125, P1; MITTELBACH GG, 1989, SIZE STRUCTURED POPU, V4, P167; MORIN PJ, 1995, ANNU REV ECOL SYST, V26, P505, DOI 10.1146/annurev.es.26.110195.002445; MULLERNAVARRA D, 1995, ARCH HYDROBIOL, V132, P297; OKSANEN L, 1981, AM NAT, V118, P240, DOI 10.1086/283817; PAULY D, 1995, NATURE, V374, P255, DOI 10.1038/374255a0; Persson Lennart, 1996, P396; POLIS GA, 1994, AUST J ECOL, V19, P121; PORTER KG, 1973, NATURE, V244, P179, DOI 10.1038/244179a0; Potvin Catherine, 1993, P46; POWER ME, 1992, ECOLOGY, V73, P733, DOI 10.2307/1940153; Proulx M, 1996, ECOLOGY, V77, P1556, DOI 10.2307/2265551; QIN JG, 1995, J FRESHWATER ECOL, V10, P385, DOI 10.1080/02705060.1995.9663461; RICHERSO.P, 1970, P NATL ACAD SCI USA, V67, P1710, DOI 10.1073/pnas.67.4.1710; SOMMER U, 1986, ARCH HYDROBIOL, V106, P433; STRONG DR, 1992, ECOLOGY, V73, P747, DOI 10.2307/1940154; VANNI MJ, 1987, ECOLOGY, V68, P624, DOI 10.2307/1938467; VOLLENWEIDER R A, 1975, Schweizerische Zeitschrift fuer Hydrologie, V37, P53, DOI 10.1007/BF02505178; WOOTTON JT, 1993, P NATL ACAD SCI USA, V90, P1384, DOI 10.1073/pnas.90.4.1384	48	212	218	4	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					384	386		10.1126/science.275.5298.384	http://dx.doi.org/10.1126/science.275.5298.384			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994034				2022-12-28	WOS:A1997WC87300045
J	Davin, LB; Wang, HB; Crowell, AL; Bedgar, DL; Martin, DM; Sarkanen, S; Lewis, NG				Davin, LB; Wang, HB; Crowell, AL; Bedgar, DL; Martin, DM; Sarkanen, S; Lewis, NG			Stereoselective bimolecular phenoxy radical coupling by an auxiliary (dirigent) protein without an active center	SCIENCE			English	Article							CONIFERYL ALCOHOL OXIDASE; LIGNIFICATION; LIGNIN; (+)-PINORESINOL; MONOLIGNOLS; LACCASES	The regio- and stereospecificity of bimolecular phenoxy radical coupling reactions, of especial importance in lignin and lignan biosynthesis, are clearly controlled in some manner in vivo; yet in vitro coupling by oxidases, such as laccases, only produce racemic products. In other words, laccases, peroxidases, and comparable oxidases ave unable to control regio- or stereospecificity by themselves and thus some other agent must exist. A 78-kilodalton protein has been isolated that, in the presence of an oxidase or one electron oxidant, effects stereoselective bimolecular phenoxy radical coupling in vitro. Itself lacking a catalytically active (oxidative) center, its mechanism of action is presumed to involve capture of E-coniferyl alcohol-derived free-radical intermediates, with consequent stereoselective coupling to give (+)-pinoresinol.	WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99164; UNIV MINNESOTA,DEPT WOOD & PAPER SCI,KAUFERT LAB,ST PAUL,MN 55108	Washington State University; University of Minnesota System; University of Minnesota Twin Cities				Davin, Laurence/0000-0002-3248-6485; Lewis, Norman/0000-0001-5742-032X				Ayres D. C., 1990, LIGNANS, P12; BAO W, 1993, SCIENCE, V260, P672, DOI 10.1126/science.260.5108.672; BERNARDS MA, 1995, J BIOL CHEM, V270, P7382, DOI 10.1074/jbc.270.13.7382; BRUICE TC, 1980, ACCOUNTS CHEM RES, V13, P256, DOI 10.1021/ar50152a002; BULOCK JD, 1962, J CHEM SOC, P2085, DOI 10.1039/jr9620002085; CAMERON DW, 1967, ORGANIC SUBSTANCES N, V1, P203; Davin L.B., 1995, AN ACAD BRAS CIEN S3, V67, P363; DAVIN LB, 1992, PHYTOCHEMISTRY, V31, P3869, DOI 10.1016/S0031-9422(00)97544-7; DEYAMA T, 1983, CHEM PHARM BULL, V31, P2993; ERDTMAN H, 1939, SVENSK PAPPERSTIDN, V42, P115; FREUDENBERG K, 1958, CHEM BER-RECL, V91, P581, DOI 10.1002/cber.19580910317; FREUDENBERG K, 1959, NATURE, V183, P1152, DOI 10.1038/1831152a0; FREUDENBERG K, 1965, SCIENCE, V148, P595, DOI 10.1126/science.148.3670.595; Gottlieb O. R., 1989, NATURAL PRODUCTS WOO, P439; HARKIN JM, 1973, SCIENCE, V180, P296, DOI 10.1126/science.180.4083.296; HIGUCHI T, 1957, PHYSIOL PLANTARUM, V10, P356, DOI 10.1111/j.1399-3054.1957.tb06958.x; IQBAL J, 1994, CHEM REV, V94, P519, DOI 10.1021/cr00026a008; KOBLITZ H, 1964, NATURE, V204, P199, DOI 10.1038/204199a0; LEWIS NG, 1994, ACS SYM SER, V562, P202; Marmaras VJ, 1996, ARCH INSECT BIOCHEM, V31, P119, DOI 10.1002/(SICI)1520-6327(1996)31:2&lt;119::AID-ARCH1&gt;3.0.CO;2-V; MASON HS, 1955, J AM CHEM SOC, V77, P491, DOI 10.1021/ja01607a087; MIESSNER M, 1991, HELV CHIM ACTA, V74, P1205, DOI 10.1002/hlca.19910740607; NOSE M, 1995, PHYTOCHEMISTRY, V39, P71, DOI 10.1016/0031-9422(95)95268-Y; PARE PW, 1994, TETRAHEDRON LETT, V35, P4731, DOI 10.1016/S0040-4039(00)76953-X; RAGAN MA, 1984, PHYTOCHEMISTRY, V23, P2029, DOI 10.1016/S0031-9422(00)84964-X; SAVIDGE R, 1992, PHYTOCHEMISTRY, V31, P2959, DOI 10.1016/0031-9422(92)83427-Z; STERJIADES R, 1992, PLANT PHYSIOL, V99, P1162, DOI 10.1104/pp.99.3.1162; STERJIADES R, 1993, PLANTA, V190, P75, DOI 10.1007/BF00195678; UDAGAMARANDENIYA P, 1994, ELECTROPHORESIS, V15, P1072, DOI 10.1002/elps.11501501160; USAITIS A, 1994, POLYMER, V35, P4896	30	517	537	7	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					362	366		10.1126/science.275.5298.362	http://dx.doi.org/10.1126/science.275.5298.362			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994027				2022-12-28	WOS:A1997WC87300038
J	Barloon, TJ; Noyes, R				Barloon, TJ; Noyes, R			Charles Darwin and panic disorder	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ANXIETY	Charles Darwin (1809-1882) suffered from a chronic illness that, throughout much of his adult life, impaired his functioning and severely limited his activities. The writings of this famous scientist as well as biographical materials indicate that he probably suffered from an anxiety disorder. His symptoms, when considered individually, suggest a variety of conditions, but taken together they point toward panic disorder with agoraphobia. This diagnosis brings coherence to Darwin's activities and explains his secluded lifestyle, including difficulty in speaking before groups and meeting with colleagues.	UNIV IOWA,COLL MED,DEPT RADIOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PSYCHIAT,IOWA CITY,IA 52242	University of Iowa; University of Iowa								ADLER S, 1959, NATURE, V184, P1102, DOI 10.1038/1841102a0; ALVAREZ WC, 1959, NEW ENGL J MED, V261, P1109, DOI 10.1056/NEJM195911262612205; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P393; ANDREASON NC, 1995, INTRO TXB PSYCHIAT; BACON GW, 1883, LIFE C DARWIN, P9; Beard George Miller, 1881, AM NERVOUSNESS ITS C; BOWLBY J, 1965, BRIT MED J, V875, P999; Bowlby J., 1990, CHARLES DARWIN NEW L; Browne Janet, 1995, C DARWIN VOYAGING, V1; BURKHARDT F, 1989, CORRES C DARWIN, V5, P83; BURKHARDT F, 1985, CORRES C DARWIN, V1, P15; BURKHARDT F, 1986, CORRES C DARWIN, V2, P47; BURKHARDT F, 1988, CORRES C DARWIN, V4, P147; Burkhardt F., 1985, CORRES C DARWIN; Burkhardt F, 1994, CORRES C DARWIN, V9, P69; BURKHARDT F, 1988, CORRES C DARWIN, V4, P234; CLOUSE RE, 1988, PSYCHIAT CLIN N AM, V11, P399; COLP R, 1979, BE INVALID ILLNESS C, P38; COLP R, 1977, BE INVALID ILLNESS C, P83; Colp Ralph., 1977, BE INVALID ILLNESS C; DACOSTA JM, 1871, WINS, V61, P14; DARWIN, 1865, COMMUNICATION   0520; DARWIN, 1887, NATION          1117, P339; Darwin and Barlow, 1958, AUTOBIOGRAPHY C DARW; DARWIN C, 1848, COMMUNICATION    JUL; DARWIN C, 1863, COMMUNICATION   0623; DARWIN C, 1848, COMMUNICATION   0527; DARWIN C, 1837, COMMUNICATION   0920; DARWIN C, 1849, COMMUNICATION    MAR; DARWIN C, 1872, COMMUNICATION   1029; DARWIN C, 1837, COMMUNICATION   1014; DARWIN C, 1839, COMMUNICATION   1024; DARWIN C, 1849, COMMUNICATION   1012; DARWIN C, 1837, COMMUNICATION    MAR; DARWIN C, 1852, COMMUNICATION   0307; DARWIN C, 1863, COMMUNICATION   1110; DARWIN C, 1825, COMMUNICATION   1205; DARWIN C, 1878, COMMUNICATION   0302; DARWIN C, 1861, COMMUNICATION   0526; DARWIN C, 1848, COMMUNICATION   0324; DARWIN CR, 1882, TIMES           0421; DARWIN CR, 1982, LANCET          0429, P714; DARWIN E, 1825, COMMUNICATION   0224; DARWIN F, 1919, LIFE LETT C DARWIN; Desmond Adrian., 1991, DARWIN LIFE TORMENTE; FARAVELLI C, 1989, AM J PSYCHIAT, V146, P622; FLINT AJ, 1994, AM J PSYCHIAT, V151, P640; FYER AJ, 1995, COMPREHENSIVE TXB PS; GRUBER HE, 1974, DARWIN MAN PSYCHOL S, P272; Hubble D, 1943, LANCET, V1, P129; Johnston WW, 1901, AM ANTHROPOL, V3, P139, DOI 10.1525/aa.1901.3.1.02a00090; KAPLAN PW, 1995, PRINCIPLES AMBULATOR, P1178; KATON W, 1984, AM J MED, V77, P101, DOI 10.1016/0002-9343(84)90443-1; KEITH A, 1955, DARWIN REVALUED, P214; KOHN L A, 1963, Bull Hist Med, V37, P239; LANE, 1882, COMMUNICATION   1022; NIPARKO JK, 1995, PRINCIPLES AMBULATOR, P1403; RATHUS JH, 1995, PANIC DISORDER CLIN, P15; SHEAR MK, 1994, ARCH GEN PSYCHIAT, V51, P395; SIMPSON GG, 1958, SCI AM, V119, P117; SMITH BF, 1988, CORRES C DARWIN, V4, P227; STARCEVIC V, 1992, J AFFECT DISORDERS, V24, P73, DOI 10.1016/0165-0327(92)90021-W; STRACHEY J, 1962, STANDARD EDITION, V3; Winslow JH, 1971, DARWINS VICTORIAN MA; WOODRUFF AW, 1968, B NEW YORK ACAD MED, V44, P661	65	17	18	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1997	277	2					138	141						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WA650	8990339				2022-12-28	WOS:A1997WA65000034
J	Horton, R				Horton, R			Pardonable revisions and protocol reviews	LANCET			English	Editorial Material																		Horton R, 1996, LANCET, V348, P1255, DOI 10.1016/S0140-6736(05)65751-0	1	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					6	6		10.1016/S0140-6736(05)62158-7	http://dx.doi.org/10.1016/S0140-6736(05)62158-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988113				2022-12-28	WOS:A1997WA72500007
J	deNooij, JC; Letendre, MA; Hariharan, IK				deNooij, JC; Letendre, MA; Hariharan, IK			A cyclin-dependent kinase inhibitor, dacapo, is necessary for timely exit from the cell cycle during Drosophila embryogenesis	CELL			English	Article							S-PHASE; NERVOUS-SYSTEM; GENE; MELANOGASTER; EXPRESSION; EMBRYOS; CLONING; DOMAIN; EYE; P57(KIP2)	In a screen for genes that interact with the Rap1 GTPase, we have identified a Drosophila gene, dacapo (dap), which is a member of the p21/p27 family of cdk inhibitors. Unlike mammalian cdk inhibitors studied to dale, dap is essential for normal embryonic development. Dacapo inhibits cyclin-cdk activity in vitro. Overexpressing dap during eye development interferes with cell cycle progression and interacts genetically with the retinoblastoma homolog (Rbf) and cyclin E. dap expression in embryos parallels the exit of cells from the cell cycle. dap mutant embryos delay the normal cell cycle exit during development; many cells complete an additional cycle and subsequently become quiescent. Thus, dap functions during embryogenesis to achieve a precisely timed exit from the cell cycle.			deNooij, JC (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,BLDG 149,13TH ST,CHARLESTOWN,MA 02129, USA.							BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAMPOSORTEGA JA, 1993, DEV DROSOPHILA MELAN, P149; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DENOOIJ JC, 1995, SCIENCE, V270, P983, DOI 10.1126/science.270.5238.983; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FOE VE, 1989, DEVELOPMENT, V107, P1; Foe Victoria E., 1993, P149; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HARTENSTEIN V, 1987, ROUX ARCH DEV BIOL, V196, P473, DOI 10.1007/BF00399871; HAY BA, 1994, DEVELOPMENT, V120, P2121; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEHNER CF, 1991, COLD SH Q B, V56, P465; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; Murray A, 1993, CELL CYCLE INTRO; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; OBRIEN MA, 1994, GENETICS, V137, P121; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PATEL NH, 1994, DROSOPHILA MELANOGAS, P445; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PROKOP A, 1991, DEVELOPMENT, V111, P79; RICHARDSON H, 1995, DEVELOPMENT, V121, P3371; RICHARDSON HE, 1993, DEVELOPMENT, V119, P673; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; Sambrook J., 2002, MOL CLONING LAB MANU; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Williamson A, 1996, ANNU REV CELL DEV BI, V12, P365, DOI 10.1146/annurev.cellbio.12.1.365; XU T, 1993, DEVELOPMENT, V117, P1223; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	47	280	281	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1237	1247		10.1016/S0092-8674(00)81819-X	http://dx.doi.org/10.1016/S0092-8674(00)81819-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980230	Bronze			2022-12-28	WOS:A1996WA54100012
J	Finkel, E				Finkel, E			Surgery moves into the third dimension	LANCET			English	News Item																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1726	1726		10.1016/S0140-6736(05)65837-0	http://dx.doi.org/10.1016/S0140-6736(05)65837-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8992175				2022-12-28	WOS:A1996VZ76600029
J	Smith, GD; Egger, M				Smith, GD; Egger, M			Understanding it all - Health, meta-theories, and mortality trends - Commentary	BRITISH MEDICAL JOURNAL			English	Article							SOVIET		UNIV BERN,DEPT SOCIAL & PREVENT MED,BERN,SWITZERLAND	University of Bern	Smith, GD (corresponding author), UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL BS8 2PR,AVON,ENGLAND.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Egger, Matthias/0000-0001-7462-5132				ANDERSON BA, 1989, POPUL DEV REV, V15, P471, DOI 10.2307/1972443; Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1986, LANCET, V1, P1077; BARKER DJP, 1989, NATURE, V338, P371, DOI 10.1038/338371a0; Bobak M, 1996, BRIT MED J, V312, P421; Chenet L, 1996, J PUBLIC HEALTH MED, V18, P329, DOI 10.1093/oxfordjournals.pubmed.a024514; Clark A, 1996, J OCCUP ORGAN PSYCH, V69, P57, DOI 10.1111/j.2044-8325.1996.tb00600.x; CLARK AE, 1994, ECON J, V104, P648, DOI 10.2307/2234639; DINKEL RH, 1985, POP STUD-J DEMOG, V39, P87, DOI 10.1080/0032472031000141296; Floud R, 1990, HEIGHT HLTH HIST; JUDGE K, 1994, BRIT MED J, V309, P1454, DOI 10.1136/bmj.309.6967.1454; KUNITZ SJ, 1994, HLTH SOCIAL CHANGE I; Kunitz Stephen J., 1994, DIS SOCIAL DIVERSITY; PETO R, 1994, BRIT MED J, V309, P937, DOI 10.1136/bmj.309.6959.937; PETO R, 1993, CHOLESTEROL LOWERING; ROBINSON RJ, 1992, BMJ-BRIT MED J, V304, P789, DOI 10.1136/bmj.304.6830.789; WATSON P, 1995, SOC SCI MED, V41, P923, DOI 10.1016/0277-9536(94)00405-I; WILKINSON R, 1996, UNHEALTHY SOC AFFICT; WOODS R, 1995, CONTINUITY CHANGE, V10, P105, DOI 10.1017/S0268416000002514; *WORLD BANK, 1996, PLAN MARKET WORLD DE	20	42	43	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1584	1585		10.1136/bmj.313.7072.1584	http://dx.doi.org/10.1136/bmj.313.7072.1584			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VZ811	8990993	Green Published			2022-12-28	WOS:A1996VZ81100014
J	Studer, M; Lumsden, A; ArizaMcNaughton, L; Bradley, A; Krumlauf, R				Studer, M; Lumsden, A; ArizaMcNaughton, L; Bradley, A; Krumlauf, R			Altered segmental identity and abnormal migration of motor neurons in mice lacking Hoxb-1	NATURE			English	Article							ZINC-FINGER GENE; MOUSE HINDBRAIN; CRABP-I; EXPRESSION; HOXA-1; TRANSFORMATION; EMBRYOGENESIS; ORGANIZATION; TRANSCRIPTS; PATTERNS	SEGMENTATION of the vertebrate hindbrain into rhombomeres is important for the anterior-posterior arrangement of cranial motor nuclei and efferent nerves'. Underlying this reiterated organization, Hox genes display segmentally restricted domains of expression(2-4), such as expression of Hoxb-1 (refs 5, 6) in rhombomere 4 (r4). Here we report that absence of Hoxb-1 leads to changes in r4 identity. In mutant mouse embryos, molecular markers indicate that patterning of r4 is initiated properly but not maintained. Cellular analysis by DiI tracing reveals that the r4-specific facial branchiomotor (FBM) and contralateral vestibuloacoustic efferent (CVA) neurons are incorrectly specified. In wild-type mice CVA neurons migrate from r4 into the contralateral side(7), and we found in lineage analysis that FBM neurons migrate from r4 into r5. In mutants, motor neurons differentiate but the CVA and FBM neurons fail to migrate into their proper positions. Instead, they form a motor nucleus which migrates atypically, and there is a subsequent loss of the facial motor nerve. These results demonstrate that, as a part of its role in maintaining rhombomere identity, Hoxb-1 is involved in controlling migratory properties of motor neurons in the hindbrain.	NATL INST MED RES,MRC,DIV DEV NEUROBIOL,LONDON NW7 1AA,ENGLAND; UNITED MED & DENT SCH,GUYS HOSP,DEPT DEV NEUROBIOL,LONDON SE1 9RT,ENGLAND; BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030	MRC National Institute for Medical Research; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Baylor College of Medicine; Howard Hughes Medical Institute			Krumlauf, Robb/AAH-5012-2019; Lumsden, Andrew/C-5146-2009; Studer, Michele/P-4580-2016	Krumlauf, Robb/0000-0001-9102-7927; Studer, Michele/0000-0001-7105-2957; Bradley, Allan/0000-0002-2349-8839				ALEXANDRE D, 1996, DEVELOPMENT, V122, P723; Altman J., 1982, DEV CRANIAL NERVE GA; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; FRASCH M, 1995, DEVELOPMENT, V121, P957; HUME CR, 1993, DEVELOPMENT, V119, P1147; HUNT P, 1991, NATURE, V353, P891; Irving C, 1996, DEV BIOL, V173, P26, DOI 10.1006/dbio.1996.0004; Itasaki N, 1996, NEURON, V16, P487, DOI 10.1016/S0896-6273(00)80069-0; KEYNES R, 1994, ANNU REV NEUROSCI, V17, P109, DOI 10.1146/annurev.ne.17.030194.000545; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MADEN M, 1992, MECH DEVELOP, V37, P13, DOI 10.1016/0925-4773(92)90011-8; MARK M, 1993, DEVELOPMENT, V119, P219; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MCKAY I, IN PRESS MOL CELL NE; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; NIETO MA, 1992, DEVELOPMENT, V116, P1137; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; RAMIREZSOLIS R, 1993, GUIDE TECHNIQUES MOU, P885; RUBERTE E, 1992, DEVELOPMENT, V115, P973; RUIZ JC, 1994, MECH DEVELOP, V46, P87; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SIMON H, 1993, NEURON, V11, P209, DOI 10.1016/0896-6273(93)90179-U; STUDER M, 1994, SCIENCE, V265, P1728, DOI 10.1126/science.7916164; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; ZHANG MB, 1994, DEVELOPMENT, V120, P2431	34	336	337	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 19	1996	384	6610					630	634		10.1038/384630a0	http://dx.doi.org/10.1038/384630a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VZ296	8967950				2022-12-28	WOS:A1996VZ29600030
J	Langenberg, M; Hellemons, BSP; vanRee, JW; Vermeer, F; Lodder, J; Schouten, HA; Knottnerus, JA				Langenberg, M; Hellemons, BSP; vanRee, JW; Vermeer, F; Lodder, J; Schouten, HA; Knottnerus, JA			Atrial fibrillation in elderly patients: Prevalence and comorbidity in general practice	BRITISH MEDICAL JOURNAL			English	Article									UNIV MAASTRICHT,DEPT METHODOL & STAT,NL-6200 MD MAASTRICHT,NETHERLANDS; ACAD HOSP MAASTRICHT,DEPT CARDIOL,MAASTRICHT,NETHERLANDS; ACAD HOSP MAASTRICHT,DEPT NEUROL,MAASTRICHT,NETHERLANDS	Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC)	Langenberg, M (corresponding author), UNIV MAASTRICHT,DEPT GEN PRACTICE,POB 616,NL-6200 MD MAASTRICHT,NETHERLANDS.		Knottnerus, Andre/F-4866-2013; Knottnerus, Johannes A/A-3829-2009					*ATR FIBR INV, 1994, ARCH INTERN MED, V154, P1449; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; Lip GYH, 1996, BRIT MED J, V312, P175; METSEMAKERS JFM, 1992, BRIT J GEN PRACT, V42, P102; *STROK ED OFF, 1994, STROKE, V25, P1318	5	58	58	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1996	313	7071					1534	1534		10.1136/bmj.313.7071.1534	http://dx.doi.org/10.1136/bmj.313.7071.1534			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY691	8978233	Green Published			2022-12-28	WOS:A1996VY69100027
J	Engelman, DM				Engelman, DM			Crossing the hydrophobic barrier: Insertion of membrane proteins	SCIENCE			English	Editorial Material							LIPID BILAYER				Engelman, DM (corresponding author), YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,POB 6666,NEW HAVEN,CT 06520, USA.							Bhakdi S, 1996, ARCH MICROBIOL, V165, P73, DOI 10.1007/s002030050300; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; SURREY T, 1992, P NATL ACAD SCI USA, V89, P7457, DOI 10.1073/pnas.89.16.7457; WALKER B, 1995, CHEM BIOL, V2, P99, DOI 10.1016/1074-5521(95)90282-1; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242	12	38	38	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1850	1851		10.1126/science.274.5294.1850	http://dx.doi.org/10.1126/science.274.5294.1850			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8984645				2022-12-28	WOS:A1996VY20000026
J	Serafini, T; Colamarino, SA; Leonardo, ED; Wang, H; Beddington, R; Skarnes, WC; TessierLavigne, M				Serafini, T; Colamarino, SA; Leonardo, ED; Wang, H; Beddington, R; Skarnes, WC; TessierLavigne, M			Netrin-1 is required for commissural axon guidance in the developing vertebrate nervous system	CELL			English	Article							FLOOR PLATE; MOUSE EMBRYO; SONIC-HEDGEHOG; SPINAL-CORD; RAT EMBRYO; C-ELEGANS; EXPRESSION; NEURONS; CELL; CHEMOATTRACTANT	During nervous system development, spinal commissural axons project toward floor plate cells and trochlear motor axons extend away from these cells. Netrin-1, a diffusible protein made by floor plate cells, can attract spinal commissural axons and repel trochlear axons in vitro, but its role in vivo is unknown. Netrin-1 deficient mice exhibit defects in spinal commissural axon projections that are consistent with netrin-1 guiding these axons. Defects in several forebrain commissures are also observed, suggesting additional guidance roles for netrin-1. Trochlear axon projections are largely normal, predicting the existence of additional cues for these axons, and evidence is provided for a distinct trochlear axon chemorepellent produced by floor plate cells. These results establish netrin-1 as a guidance cue that likely collaborates with other diffusible cues to guide axons in vivo.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM CELL & DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143; NATL INST MED RES,LAB MAMMALIAN DEV,LONDON NW7 1AA,ENGLAND; UNIV EDINBURGH,BIOTECHNOL & BIOL SCI RES COUNCIL,CTR GENOME RES,EDINBURGH EH3 3JQ,MIDLOTHIAN,SCOTLAND	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; MRC National Institute for Medical Research; University of Edinburgh			Leonardo, Eduardo/AAH-1525-2020	Leonardo, Eduardo/0000-0001-7426-0217				ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BOURRAT F, 1990, J COMP NEUROL, V294, P1, DOI 10.1002/cne.902940102; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; COLAMARINO SA, 1995, ANNU REV NEUROSCI, V18, P497, DOI 10.1146/annurev.ne.18.030195.002433; Culotti JG, 1996, CURR OPIN NEUROBIOL, V6, P81, DOI 10.1016/S0959-4388(96)80012-2; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; EBENS A, 1996, IN PRESS NEURON; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FRITZSCH B, 1995, J NEUROBIOL, V27, P457, DOI 10.1002/neu.480270403; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDGECOCK EM, 1990, NEURON, V2, P61; Hu HY, 1996, NEURON, V16, P933, DOI 10.1016/S0896-6273(00)80116-6; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; PLACZEK M, 1990, DEVELOPMENT, V110, P19; Probst M, 1901, ARCH PSYCHIAT NERVEN, V34, P709, DOI 10.1007/BF02680175; SASAKI H, 1993, DEVELOPMENT, V118, P47; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SHIRASAKI R, 1995, NEURON, V14, P961, DOI 10.1016/0896-6273(95)90334-8; SHIRASAKI R, IN PRESS NEURON; SILVER J, 1993, J COMP NEUROL, V328, P415, DOI 10.1002/cne.903280308; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TESSIERLAVIGNE M, 1996, IN PRESS SCIENCE; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; WENTWORTH LE, 1984, J COMP NEUROL, V222, P96, DOI 10.1002/cne.902220109	31	1022	1044	1	40	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1001	1014		10.1016/S0092-8674(00)81795-X	http://dx.doi.org/10.1016/S0092-8674(00)81795-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978605	Bronze			2022-12-28	WOS:A1996VY44700006
J	Heath, JR; Saykally, RJ				Heath, JR; Saykally, RJ			Astrochemistry - Space carbon: Neutral pathways?	SCIENCE			English	Editorial Material							MOLECULES; IRC+10216		UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	Heath, JR (corresponding author), UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90095 USA.			SAYKALLY, RICHARD/0000-0001-8942-3656				AVERY LW, 1976, ASTROPHYS J, V205, pL173, DOI 10.1086/182117; BERNATH PF, 1989, SCIENCE, V244, P562, DOI 10.1126/science.244.4904.562; BIEGING JH, 1993, ASTRON J, V105, P576, DOI 10.1086/116455; BUHL D, 1970, NATURE, V228, P267, DOI 10.1038/228267a0; DAYAL A, 1995, ASTROPHYS J, V439, P996, DOI 10.1086/175237; FRENKLACH M, 1987, NASA C PUBL, V3061; GREEN S, 1974, ASTROPHYS J, V193, pL89, DOI 10.1086/181639; HAIDER N, 1992, Z PHYS CHEM, V176, P133, DOI 10.1524/zpch.1992.176.Part_2.133; HEATH JR, 1992, ACS SYM SER, V481, P1; HERBST E, 1973, ASTROPHYS J, V185, P505, DOI 10.1086/152436; Kaiser RI, 1996, SCIENCE, V274, P1508, DOI 10.1126/science.274.5292.1508; LIAO Q, 1995, ASTROPHYS J, V444, P694, DOI 10.1086/175642; RANK DM, 1971, SCIENCE, V174, P1083, DOI 10.1126/science.174.4014.1083; SCHUTTE WA, 1993, ASTROPHYS J, V415, P397, DOI 10.1086/173173; SIMS IR, 1995, ANNU REV PHYS CHEM, V46, P109, DOI 10.1146/annurev.pc.46.100195.000545; VANORDEN A, 1994, P 1994 KUYP AIRB AST, P53; WOODS RC, 1975, PHYS REV LETT, V35, P1269, DOI 10.1103/PhysRevLett.35.1269	17	5	5	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1996	274	5292					1480	1481		10.1126/science.274.5292.1480	http://dx.doi.org/10.1126/science.274.5292.1480			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8966618				2022-12-28	WOS:A1996VV77500031
J	Levin, SA; Grenfell, B; Hastings, A; Perelson, AS				Levin, SA; Grenfell, B; Hastings, A; Perelson, AS			Mathematical and computational challenges in population biology and ecosystems science	SCIENCE			English	Review							CENTER B-CELLS; HIV-INFECTION; MEASLES DYNAMICS; IMMUNE-RESPONSE; FOREST GROWTH; MODEL; CHAOS; DIVERSITY; SELECTION; AIDS	Mathematical and computational approaches provide powerful tools in the study of problems in population biology and ecosystems science. The subject has a rich history intertwined with the development oi statistics and dynamical systems theory, but recent analytical advances, coupled with the enhanced potential of high-speed computation, have opened up new vistas and presented new challenges. Key challenges involve ways to deal with the collective dynamics of heterogeneous ensembles oi individuals, and to scale from small spatial regions to large ones. The central issues-understanding how detail at one scale makes its signature felt at other scales, and how to relate phenomena across scales-cut across scientific disciplines and go to the heart of algorithmic development of approaches to high-speed computation. Examples are given from ecology, genetics, epidemiology, and immunology.	UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE CB2 3EJ, ENGLAND; UNIV CALIF DAVIS, INST THEORET DYNAM, DIV ENVIRONM STUDIES, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, CTR POPULAT BIOL, DAVIS, CA 95616 USA; LOS ALAMOS NATL LAB, LOS ALAMOS, NM 87545 USA	University of Cambridge; University of California System; University of California Davis; University of California System; University of California Davis; United States Department of Energy (DOE); Los Alamos National Laboratory	Levin, SA (corresponding author), PRINCETON UNIV, DEPT ECOL & EVOLUT BIOL, PRINCETON, NJ 08544 USA.		Perelson, Alan S/Z-1959-2019; Hastings, Alan/A-7423-2008; Hastings, Alan/O-6864-2019; Levin, Simon A/J-1218-2014	Perelson, Alan S/0000-0002-2455-0002; Hastings, Alan/0000-0002-0717-8026; Levin, Simon A/0000-0002-8216-5639	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028433, R37AI028433] Funding Source: NIH RePORTER; NCRR NIH HHS [RR06555] Funding Source: Medline; NIAID NIH HHS [AI28433] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUR Z, 1991, P ROY SOC B-BIOL SCI, V245, P147, DOI 10.1098/rspb.1991.0101; ANDERSON R M, 1991; Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; Anderson RM, 1996, LANCET, V348, P1010, DOI 10.1016/S0140-6736(96)07100-0; ANDERSON RM, 1989, CELL TO CELL SIGNALLING : FROM EXPERIMENTS TO THEORETICAL MODELS, P335; ANDERSON RM, 1989, PARASITOLOGY, V99, pS59, DOI 10.1017/S0031182000083426; Andreasen V, 1996, Z ANGEW MATH MECH, V76, P421; ANDREASEN V, IN PRESS J MATH BIOL; Austin DJ, 1996, PARASITOLOGY, V113, P157, DOI 10.1017/S0031182000066403; AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Baird SJE, 1995, EVOLUTION, V49, P1038, DOI [10.2307/2410429, 10.1111/j.1558-5646.1995.tb04431.x]; BANZHAF W, 1995, LECT NOTES COMPUTER, V899; Barenblatt G.I., 1994, SCALING PHENOMENA FL; BARTLETT MS, 1960, J R STAT SOC SER A-G, V123, P37, DOI 10.2307/2343186; BARTLETT MS, 1957, J R STAT SOC SER A-G, V120, P48, DOI 10.2307/2342553; Barton NH, 1996, PHILOS T R SOC B, V351, P785, DOI 10.1098/rstb.1996.0073; BECKER NG, 1995, MATH BIOSCI, V129, P189, DOI 10.1016/0025-5564(94)00061-4; BECKER NG, 1995, MATH BIOSCI, V127, P207, DOI 10.1016/0025-5564(94)00055-5; Bergman A, 1995, THEOR POPUL BIOL, V48, P251, DOI 10.1006/tpbi.1995.1029; BLANCHARD P, 1990, MATH MODELLING RANDO; BLOOM BR, 1992, NATURE, V358, P538, DOI 10.1038/358538b0; BOBASHEV GV, IN PRESS MATH BIOSCI; BOLKER B, 1995, PHILOS T R SOC B, V348, P309, DOI 10.1098/rstb.1995.0070; BOLKER B, 1993, IMA J MATH APPL MED, V10, P83; Bolker BM, 1996, P NATL ACAD SCI USA, V93, P12648, DOI 10.1073/pnas.93.22.12648; BOLKER BM, 1995, GLOB CHANGE BIOL, V1, P373, DOI 10.1111/j.1365-2486.1995.tb00035.x; BOLKER BM, 1993, P ROY SOC B-BIOL SCI, V251, P75, DOI 10.1098/rspb.1993.0011; BOTKIN DB, 1972, J ECOL, V60, P849, DOI 10.2307/2258570; BOTKIN DB, 1972, IBM J RES DEV, V16, P101, DOI 10.1147/rd.162.0101; BOYD R, 1987, NATURE, V327, P58, DOI 10.1038/327058a0; BRASS A, 1994, J THEOR BIOL, V166, P189, DOI 10.1006/jtbi.1994.1017; BREMERMANN HJ, 1995, J ACQ IMMUN DEF SYND, V9, P459; BURGER R, 1989, EVOLUTION, V43, P1748, DOI [10.2307/2409390, 10.1111/j.1558-5646.1989.tb02624.x]; CANEIRO J, 1995, INT IMMUNOL, V7, P1265; Celada F, 1996, EUR J IMMUNOL, V26, P1350, DOI 10.1002/eji.1830260626; Cliff A, 1993, MEASLES HIST GEOGRAP, P1840; CLIFF AD, 1992, STAT MED, V11, P1409, DOI 10.1002/sim.4780111102; Cliff AD, 1988, ATLAS DIS DISTRIBUTI; Cohen Mitchell L., 1994, Trends in Microbiology, V2, P422, DOI 10.1016/0966-842X(94)90623-8; DEBOER RJ, 1994, P NATL ACAD SCI USA, V91, P544, DOI 10.1073/pnas.91.2.544; DEBOER RJ, 1994, J THEOR BIOL, V169, P375, DOI 10.1006/jtbi.1994.1160; DeBoer RJ, 1996, P ROY SOC B-BIOL SCI, V263, P899, DOI 10.1098/rspb.1996.0133; DEBOER RJ, 1991, J THEOR BIOL, V149, P381, DOI 10.1016/S0022-5193(05)80313-3; deJong MD, 1996, P NATL ACAD SCI USA, V93, P5501, DOI 10.1073/pnas.93.11.5501; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DEUTSCHMAN D, SORTIE SIMULATIONS; DEUTSCHMAN DH, 1996, THESIS CORNELL U; Dietz K, 1993, Stat Methods Med Res, V2, P23, DOI 10.1177/096228029300200103; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DUGATKIN LA, 1991, AM NAT, V138, P687, DOI 10.1086/285243; DURRETT R, IN PRESS J THEOR BIO; DYTHAM C, 1995, EVOL ECOL, V9, P508, DOI 10.1007/BF01237832; ELINER S, 1993, CHAOS REAL DATA ANAL; ESSUNGER P, 1994, J THEOR BIOL, V170, P367, DOI 10.1006/jtbi.1994.1199; FELDMAN MW, 1991, GENETICS, V129, P297; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FERGUSON NM, IN PRESS SPATIAL ECO; FERGUSON NM, IN PRESS MATH BIOSCI; FINE PEM, 1983, INT J EPIDEMIOL, V12, P332, DOI 10.1093/ije/12.3.332; FISHMAN MA, 1994, J THEOR BIOL, V170, P25, DOI 10.1006/jtbi.1994.1166; FISHMAN MA, 1993, J THEOR BIOL, V160, P311, DOI 10.1006/jtbi.1993.1021; FLIERL G, UNPUB; FOX GA, 1992, GENETICS, V132, P277; FROST SDW, 1994, AIDS, V8, P323, DOI 10.1097/00002030-199403000-00005; FROST SDW, 1994, J ACQ IMMUN DEF SYND, V7, P236; GAVRILETS S, 1995, P ROY SOC B-BIOL SCI, V261, P233, DOI 10.1098/rspb.1995.0142; GAVRILETS S, 1995, GENET RES, V65, P63, DOI 10.1017/S0016672300033012; GHANI AC, IN PRESS SEX TRANSM; GILLIGAN CA, 1985, PHYTOPATHOLOGY, V75, P61, DOI 10.1094/Phyto-75-61; Gleick J., 1988, CHAOS MAKING NEW SCI; Grenfell B. T., 1995, P362, DOI 10.1017/CBO9780511629396.014; Grenfell B T, 1995, Stat Methods Med Res, V4, P160, DOI 10.1177/096228029500400205; Grenfell B. T., 1995, ECOLOGY INFECT DIS N; Grenfell BT, 1995, PARASITOLOGY, V111, pS135, DOI 10.1017/S0031182000075867; GRENFELL BT, 1995, P ROY SOC B-BIOL SCI, V259, P97, DOI 10.1098/rspb.1995.0015; GRENFELL BT, 1992, J ROY STAT SOC B MET, V54, P383; GRENFELL BT, 1994, PHILOS T R SOC A, V348, P515, DOI 10.1098/rsta.1994.0108; GRENFELL BT, 1994, FORECASTING CHAOS, P321; GRENFELL BT, IN PRESS CHAOS REAL; GRUNBAUM D, IN PRESS EVOL ECOL; Gueron S, 1996, J THEOR BIOL, V182, P85, DOI 10.1006/jtbi.1996.0144; GUERON S, 1993, J THEOR BIOL, V165, P541, DOI 10.1006/jtbi.1993.1206; Gupta S, 1996, NAT MED, V2, P437, DOI 10.1038/nm0496-437; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; HAN SH, 1995, J EXP MED, V182, P1635, DOI 10.1084/jem.182.6.1635; HARVEY PH, 1994, EVOLUTION, V48, P523, DOI 10.1111/j.1558-5646.1994.tb01341.x; HASTINGS A, 1989, LECTURES MATH LIFE S, V20, P27; HILTS PJ, 1996, NY TIMES        0910, pC1; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Holland J. H., 1992, ADAPTATION NATURAL A; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; HUSTON MA, 1991, TREE PHYSIOL, V9, P293, DOI 10.1093/treephys/9.1-2.293; JACOB J, 1993, J EXP MED, V178, P1293, DOI 10.1084/jem.178.4.1293; KAUFFMAN S, 1987, J THEOR BIOL, V128, P11, DOI 10.1016/S0022-5193(87)80029-2; KAUFFMAN SA, 1990, PHYSICA D, V42, P135, DOI 10.1016/0167-2789(90)90071-V; Keeling MJ, 1997, SCIENCE, V275, P65, DOI 10.1126/science.275.5296.65; KEELING MJ, UNPUB; KEPLER TB, 1995, P NATL ACAD SCI USA, V92, P8219, DOI 10.1073/pnas.92.18.8219; KEPLER TB, 1993, IMMUNOL TODAY, V14, P412, DOI 10.1016/0167-5699(93)90145-B; KINZIG AP, UNPUB; Kirschner D, 1996, B MATH BIOL, V58, P367, DOI 10.1007/BF02458312; Kirschner D., 1996, NOTICES AM MATH SOC, V43, P191; KIRSCHNER DE, 1995, MATH POPULATION DYNA, P295; KLENERMAN P, IN PRESS P NATL ACAD; KLOPFER E, UNPUB; KOLLMAN P, 1996, MODELING BIOL SYSTEM; Koza JR, 1992, GENETIC PROGRAMMING; Kretzschmar M, 1996, MATH BIOSCI, V133, P165, DOI 10.1016/0025-5564(95)00093-3; LAM NP, IN PRESS HEPATOLOGY; LANDE R, 1994, EVOLUTION, V48, P1460, DOI [10.2307/2410240, 10.1111/j.1558-5646.1994.tb02188.x]; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LANGTON CG, 1989, SANTA FE I STUDIES S, V12; Levin S., 1992, MATH BIOL INTERFACE; Levin S.A., 1983, COEVOLUTION, P21; Levin S.A., 1983, LECT NOTES BIOMATH, V52, P328, DOI DOI 10.1007/978-3-642-87893-0_41; LEVIN SA, IN PRESS SPATIAL ECO; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Lively C. M., 1995, P421, DOI 10.1017/CBO9780511629396.017; Lloyd AL, 1996, J THEOR BIOL, V179, P1, DOI 10.1006/jtbi.1996.0042; LUBCHENCO J, 1991, ECOLOGY, V72, P371, DOI 10.2307/2937183; Ma S. K., 2000, MODERN THEORY CRITIC; May R.M., 1983, P186; MAY RM, 1974, SCIENCE, V186, P645, DOI 10.1126/science.186.4164.645; Maynard Smith J., 1982, pi; McLean Angela R., 1993, Trends in Microbiology, V1, P9, DOI 10.1016/0966-842X(93)90018-M; MCLEAN AR, 1995, REV MED VIROL, V5, P141, DOI 10.1002/rmv.1980050304; MCLEAN AR, 1992, J THEOR BIOL, V155, P69, DOI 10.1016/S0022-5193(05)80549-1; MCLEAN AR, 1992, AIDS, V6, P71, DOI 10.1097/00002030-199201000-00009; MERRILL SJ, 1994, ROCKY MT J MATH, V24, P213; Miller JH, 1996, J ECON BEHAV ORGAN, V29, P87, DOI 10.1016/0167-2681(95)00052-6; Mittler JE, 1996, J ACQ IMMUN DEF SYND, V12, P233, DOI 10.1097/00042560-199607000-00003; Mollison D., 1995, P384, DOI 10.1017/CBO9780511629396.015; Morel BF, 1996, B MATH BIOL, V58, P569, DOI 10.1016/0092-8240(95)00363-0; MORRIS M, 1994, AM J EPIDEMIOL, V140, P217, DOI 10.1093/oxfordjournals.aje.a117241; MUHTENBEIN H, 1995, LECT NOTES COMPUTER, V899, P142; MURRAY JD, 1990, BIOMATHEMATICS, V19; NAGYLAKI T, 1992, BIOMATHEMATICS, V21; NEE S, 1994, PHILOS T ROY SOC B, V344, P77, DOI 10.1098/rstb.1994.0054; NOWAK MA, 1990, AIDS, V4, P1095, DOI 10.1097/00002030-199011000-00007; NOWAK MA, 1995, J THEOR BIOL, V175, P325, DOI 10.1006/jtbi.1995.0146; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; Nowak MA, 1996, SCIENCE, V272, P74, DOI 10.1126/science.272.5258.74; NOWAK MA, 1992, NATURE, V359, P826, DOI 10.1038/359826a0; Nowak MA, 1996, P NATL ACAD SCI USA, V93, P4398, DOI 10.1073/pnas.93.9.4398; Nowak MA, 1996, SCIENCE, V274, P1008, DOI 10.1126/science.274.5289.1008; NOWAK MA, 1994, P NATL ACAD SCI USA, V91, P4877, DOI 10.1073/pnas.91.11.4877; NOWAK MA, IN PRESS J THEOR BIO; OLSEN LF, 1990, SCIENCE, V249, P499, DOI 10.1126/science.2382131; PACALA SW, 1993, CAN J FOREST RES, V23, P1980, DOI 10.1139/x93-249; Pacala SW, 1995, OIKOS, V74, P357, DOI 10.2307/3545980; PACALA SW, IN PRESS SPATIAL ECO; PEASE CM, 1987, THEOR POPUL BIOL, V31, P422, DOI 10.1016/0040-5809(87)90014-1; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PERELSON AS, 1993, MATH BIOSCI, V114, P81, DOI 10.1016/0025-5564(93)90043-A; PERELSON AS, UNPUB; Perelson S., 1989, LECT NOTES BIOMATHEM, P350, DOI [10.1007/978-3-642-93454-4_17, DOI 10.1007/978-3-642-93454-4_17]; RAY T., 1992, ARTIF LIFE, P371, DOI DOI 10.1016/S0040-4039(01)97473-8; Rechenberg I., 1994, EVOLUTIONSSTRATEGIE; Reynolds C.W., 1987, ACM SIGGRAPH COMPUTE, V21, P25, DOI DOI 10.1145/37402.37406; Rhodes CJ, 1996, NATURE, V381, P600, DOI 10.1038/381600a0; Richman DD, 1996, ADV EXP MED BIOL, V394, P383; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; ROBINSON WP, 1991, GENETICS, V129, P931; ROBINSON WP, 1991, GENETICS, V129, P925; Roughgarden J, 1989, PERSPECTIVES ECOLOGI; SAGA T, 1995, P NATL ACAD SCI USA, V92, P8999, DOI 10.1073/pnas.92.19.8999; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SCHENZLE D, 1994, STAT MED, V13, P2067, DOI 10.1002/sim.4780131916; Schenzle D, 1984, IMA J Math Appl Med Biol, V1, P169; SEIDEN PE, 1992, J THEOR BIOL, V158, P329, DOI 10.1016/S0022-5193(05)80737-4; SHUGART H H, 1992, P313, DOI 10.1017/CBO9780511565489.015; SHUGART HH, 1992, ANNU REV ECOL SYST, V23, P15; SHUGART HH, 1977, J ENVIRON MANAGE, V5, P161; STILIANAKIS NI, 1994, MATH BIOSCI, V121, P235, DOI 10.1016/0025-5564(94)90072-8; STILIANAKIS NI, IN PRESS J VIROL; TAYLOR LR, 1961, NATURE, V189, P732, DOI 10.1038/189732a0; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; TURELLI M, 1994, GENETICS, V138, P913; Urban Dean L., 1992, V11, P249; VANES HHG, 1993, CLIN INVEST MED, V16, P285; Wagner GP, 1996, EVOLUTION, V50, P967, DOI [10.2307/2410639, 10.1111/j.1558-5646.1996.tb02339.x]; Walker WL, 1996, B MATH BIOL, V58, P1047; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WILSON KG, 1983, REV MOD PHYS, V55, P583, DOI 10.1103/RevModPhys.55.583; Wolinsky SM, 1996, SCIENCE, V274, P1010, DOI 10.1126/science.274.5289.1010; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0	189	286	297	0	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 17	1997	275	5298					334	343		10.1126/science.275.5298.334	http://dx.doi.org/10.1126/science.275.5298.334			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994023				2022-12-28	WOS:A1997WC87300034
J	Campeau, L; Knatterud, GLMK; Domanski, M; Hunninghake, DB; White, CW; Geller, NL; Rosenberg, Y; Herd, A; Cocanougher, MK; Dunn, K; Farmer, J; Foreyt, J; Gregory, K; Insull, W; Jackson, M; Kleiman, N; Lewis, R; Lloyd, C; Maresh, K; Matthew, C; Minor, S; Roberts, R; Salmon, A; Shackelford, P; Stewart, R; Thompson, M; Young, J; Guinn, A; Harris, G; Heibig, J; Levy, VV; Forrester, J; Hickey, A; Buchbinder, N; Davidson, R; Drury, K; Eber, L; Eigler, N; Geft, I; Goldberg, S; Grodan, P; Hendel, J; Higgins, S; Hodgson, T; Hughes, L; Karlsberg, R; Katz, J; Lepor, N; Litvak, F; Luptak, Y; Madera, G; Marcus, H; Mondkar, A; Neidorf, B; Neumann, M; Nivatpumin, T; Rabinowitz, Y; Raymond, M; Reader, A; Rurycz, V; Schapira, J; Schlanger, J; Silverberg, R; Smith, A; Tabak, S; Valovis, R; Gray, R; Hoogwerf, B; Stewart, W; Baervedt, G; BottSilverman, C; Breen, C; Buckner, P; Cabral, J; Cressman, M; Fonseca, C; Foster, J; Foster, R; Gutman, F; Harris, L; Heupler, F; Hobbs, R; Huang, S; Kalenak, J; Kassem, M; Kosmorsky, G; Kramer, J; Kurzawa, C; Langston, R; Lincoff, M; Lindberg, J; Lowder, C; McCafferty, F; McKeown, D; Meisler, D; Mendlovic, D; Meyers, S; Moore, J; Nousek, J; Raymond, R; Rincon, G; Robin, J; Rockwood, E; Sheldon, W; Simpfendorfer, C; Walsh, H; Waness, A; Wright, K; Yanak, F; Goulet, C; Bedard, H; Bois, M; Bujold, S; Cote, G; Davignon, J; deBelder, M; Ducharme, AM; Doucet, S; Dumas, J; Dydra, I; Foucher, S; Crepeau, J; Gosselin, G; Groulx, D; Joyal, M; Juneau, M; Lesperance, J; Levesque, C; Levesque, J; Marcil, M; Olivier, M; Pasternac, A; Poitras, AM; Poitras, D; Quevillon, A; Rioux, C; Robitaille, D; Sisouphone, K; Solymoss, C; Hunninghake, D; Christianson, B; DiAngelis, N; Gardner, K; Helgren, R; Iacarella, C; Knobloch, W; Lau, L; Laxson, D; Leon, A; London, E; Manion, R; McDonald, K; McGinn, A; Mianulli, M; Robinson, J; Turner, G; Wang, Y; White, C; Wilson, R; Zimmer, S; Gobel, F; Anderson, P; Baumgard, C; Christensen, J; Fulco, A; Hanson, K; Johnson, C; Larson, B; Madison, J; McCormack, P; Ostrov, C; Pecha, R; Pederson, W; Pier, T; Randall, M; Rodman, W; Roeller, S; Scott, K; Sher, N; Speilman, J; Thompson, R; Zupfer, S; Goldenberg, I; Healy, B; Knatterud, G; Terrin, M; Canner, M; Fick, S; Forman, S; Hanson, D; Howard, J; Huang, AL; Karabelas, S; LoPresti, F; Mercer, W; Ra, K; Randall, A; Schactman, M; Schleigh, B; Snider, R; Mirenzi, E; Fisher, M; Fox, NL; Czajkowski, S; Geller, N; Probstfield, J; Shumaker, S; Wittes, J; Yusuf, S; Zucker, D; Cartland, J; Das, G; Meyer, S; Powers, T; Ringdal, D; Rosza, Z; Shaheen, B; Sirek, M; Stone, C; Snider, J; Vanyi, J; Alaupovic, P; Fesmire, J; Walenga, J; Bermes, E; Hoppensteadt, D; Pifarre, R; Carleton, R; Bailey, K; Brody, B; Cairns, J; Furberg, C; Fuster, V; Grondin, C; Jenkins, D; LaRosa, J; Meier, P				Campeau, L; Knatterud, GLMK; Domanski, M; Hunninghake, DB; White, CW; Geller, NL; Rosenberg, Y; Herd, A; Cocanougher, MK; Dunn, K; Farmer, J; Foreyt, J; Gregory, K; Insull, W; Jackson, M; Kleiman, N; Lewis, R; Lloyd, C; Maresh, K; Matthew, C; Minor, S; Roberts, R; Salmon, A; Shackelford, P; Stewart, R; Thompson, M; Young, J; Guinn, A; Harris, G; Heibig, J; Levy, VV; Forrester, J; Hickey, A; Buchbinder, N; Davidson, R; Drury, K; Eber, L; Eigler, N; Geft, I; Goldberg, S; Grodan, P; Hendel, J; Higgins, S; Hodgson, T; Hughes, L; Karlsberg, R; Katz, J; Lepor, N; Litvak, F; Luptak, Y; Madera, G; Marcus, H; Mondkar, A; Neidorf, B; Neumann, M; Nivatpumin, T; Rabinowitz, Y; Raymond, M; Reader, A; Rurycz, V; Schapira, J; Schlanger, J; Silverberg, R; Smith, A; Tabak, S; Valovis, R; Gray, R; Hoogwerf, B; Stewart, W; Baervedt, G; BottSilverman, C; Breen, C; Buckner, P; Cabral, J; Cressman, M; Fonseca, C; Foster, J; Foster, R; Gutman, F; Harris, L; Heupler, F; Hobbs, R; Huang, S; Kalenak, J; Kassem, M; Kosmorsky, G; Kramer, J; Kurzawa, C; Langston, R; Lincoff, M; Lindberg, J; Lowder, C; McCafferty, F; McKeown, D; Meisler, D; Mendlovic, D; Meyers, S; Moore, J; Nousek, J; Raymond, R; Rincon, G; Robin, J; Rockwood, E; Sheldon, W; Simpfendorfer, C; Walsh, H; Waness, A; Wright, K; Yanak, F; Goulet, C; Bedard, H; Bois, M; Bujold, S; Cote, G; Davignon, J; deBelder, M; Ducharme, AM; Doucet, S; Dumas, J; Dydra, I; Foucher, S; Crepeau, J; Gosselin, G; Groulx, D; Joyal, M; Juneau, M; Lesperance, J; Levesque, C; Levesque, J; Marcil, M; Olivier, M; Pasternac, A; Poitras, AM; Poitras, D; Quevillon, A; Rioux, C; Robitaille, D; Sisouphone, K; Solymoss, C; Hunninghake, D; Christianson, B; DiAngelis, N; Gardner, K; Helgren, R; Iacarella, C; Knobloch, W; Lau, L; Laxson, D; Leon, A; London, E; Manion, R; McDonald, K; McGinn, A; Mianulli, M; Robinson, J; Turner, G; Wang, Y; White, C; Wilson, R; Zimmer, S; Gobel, F; Anderson, P; Baumgard, C; Christensen, J; Fulco, A; Hanson, K; Johnson, C; Larson, B; Madison, J; McCormack, P; Ostrov, C; Pecha, R; Pederson, W; Pier, T; Randall, M; Rodman, W; Roeller, S; Scott, K; Sher, N; Speilman, J; Thompson, R; Zupfer, S; Goldenberg, I; Healy, B; Knatterud, G; Terrin, M; Canner, M; Fick, S; Forman, S; Hanson, D; Howard, J; Huang, AL; Karabelas, S; LoPresti, F; Mercer, W; Ra, K; Randall, A; Schactman, M; Schleigh, B; Snider, R; Mirenzi, E; Fisher, M; Fox, NL; Czajkowski, S; Geller, N; Probstfield, J; Shumaker, S; Wittes, J; Yusuf, S; Zucker, D; Cartland, J; Das, G; Meyer, S; Powers, T; Ringdal, D; Rosza, Z; Shaheen, B; Sirek, M; Stone, C; Snider, J; Vanyi, J; Alaupovic, P; Fesmire, J; Walenga, J; Bermes, E; Hoppensteadt, D; Pifarre, R; Carleton, R; Bailey, K; Brody, B; Cairns, J; Furberg, C; Fuster, V; Grondin, C; Jenkins, D; LaRosa, J; Meier, P			The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ATHEROSCLEROSIS-REGRESSION; QUANTITATIVE ARTERIOGRAPHY; SERUM-CHOLESTEROL; HEART-DISEASE; RISK-FACTORS; SURGERY; THERAPY; MEN; PROGRESSION; HYPERCHOLESTEROLEMIA	Background Obstructive changes often occur in aortocoronary saphenous-vein bypass grafts because of atherosclerosis and thrombosis. We studied whether aggressive lowering of low-density lipoprotein (LDL) cholesterol levels or low-dose anticoagulation would delay the progression of atherosclerosis in grafts. Methods We studied 1351 patients who had undergone bypass surgery 1 to 11 years before base line and who had an LDL cholesterol level between 130 and 175 mg per deciliter and at least one patent vein graft as seen on angiography. We used a two-by-two factorial design to assign patients to aggressive or moderate treatment to lower LDL cholesterol levels (with lovastatin and, if needed, cholestyramine) and to treatment with warfarin or placebo. Angiography was repeated an average of 4.3 years after base line. The primary angiographic outcome was the mean percentage per patient of grafts with a decrease of 0.6 mm or more in lumen diameter. Results As measured annually during the study period, the mean LDL cholesterol level of patients who received aggressive treatment ranged from 93 to 97 mg per deciliter; with moderate treatment, the range was from 132 to 136 mg per deciliter (P<0.001). The mean international normalized ratio was 1.4 in the warfarin group and 1.1 in the placebo group (P<0.001). The mean percentage of grafts with progression of atherosclerosis was 27 percent for patients whose LDL cholesterol level was lowered with aggressive treatment and 39 percent for those who received moderate treatment (P<0.001). There was no significant difference in angiographic outcome between the warfarin and placebo groups. The rate of revascularization over four years was 29 percent lower in the group whose LDL cholesterol level was lowered aggressively than in the group receiving moderate treatment (6.5 percent vs. 9.2 percent, P=0.03). Conclusions Aggressive lowering of LDL cholesterol levels to below 100 mg per deciliter reduced the progression of atherosclerosis in grafts. Low-dose warfarin did not reduce the progression of atherosclerosis. (C) 1997, Massachusetts Medical Society.	BAYLOR COLL MED, METHODIST HOSP, HOUSTON, TX 77030 USA; BAYLOR COLL MED, VET AFFAIRS MED CTR, HOUSTON, TX 77030 USA; CEDARS SINAI MED CTR, LOS ANGELES, CA 90048 USA; CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA; MONTREAL HEART INST, MONTREAL, PQ, CANADA; UNIV MINNESOTA, MINNEAPOLIS HEART INST, MINNEAPOLIS, MN 55455 USA; NHLBI, BETHESDA, MD 20892 USA; UNIV MINNESOTA, ANGIOGRAM READING CTR, MINNEAPOLIS, MN 55455 USA; OKLAHOMA MED RES FDN, APOLIPOPROT CORE LAB, OKLAHOMA CITY, OK 73104 USA; LOYOLA UNIV, HEMATOL CORE LAB, NEW ORLEANS, LA 70118 USA	Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cedars Sinai Medical Center; Cleveland Clinic Foundation; Universite de Montreal; Minneapolis Heart Institute Foundation; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Minnesota System; University of Minnesota Twin Cities; Oklahoma Medical Research Foundation	Campeau, L (corresponding author), MARYLAND MED RES INST, POST CABG COORDINATING CTR, 600 WYNDHURST AVE, BALTIMORE, MD 21210 USA.		Fuster, Valentin/H-4319-2015; Cairns, John/AAI-8744-2021; Lepor, Norman/AAP-2488-2021	Fuster, Valentin/0000-0002-9043-9986; 				BARBORIAK JJ, 1976, ANN THORAC SURG, V21, P524, DOI 10.1016/S0003-4975(10)63922-7; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CAMPEAU L, 1984, NEW ENGL J MED, V311, P1329, DOI 10.1056/NEJM198411223112101; CAMPEAU L, 1983, CIRCULATION, V68, P1; CAMPEAU L, 1996, LIPID LOWERING THERA, V180, P203; CANNER PL, IN PRESS CONTROL CLI; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COX DR, 1972, J R STAT SOC B, V34, P187; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; KALBFLEISCH JD, 1980, STAT ANAL FAILURE TI, P83; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LESPERANCE J, 1994, ATHEROSCLEROSIS, V109, P298; LIE JT, 1977, AM J CARDIOL, V40, P906, DOI 10.1016/0002-9149(77)90041-8; *MAAS INV, 1994, LANCET, V344, P762; MARTIN MJ, 1986, LANCET, V2, P933; *NAT CHOL ED PROGR, 1994, CIRCULATION, V89, P1329; NEITZEL GF, 1986, ARTERIOSCLEROSIS, V6, P594, DOI 10.1161/01.ATV.6.6.594; OLIVER MF, 1994, LANCET, V344, P633; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; PALAC RT, 1982, CIRCULATION, V66, P40; PITT B, 1995, J AM COLL CARDIOL, V26, P1133, DOI 10.1016/0735-1097(95)00301-0; POLLER L, 1987, BRIT MED J, V295, P1309, DOI 10.1136/bmj.295.6609.1309; REIBER JHC, 1985, CIRCULATION, V71, P280, DOI 10.1161/01.CIR.71.2.280; REIBER JHC, 1993, DEV CARDIOVASC MED, V137, P75; SOLYMOSS BC, 1988, CIRCULATION, V78, P140; Syvanne M, 1994, Int J Card Imaging, V10, P243, DOI 10.1007/BF01137715; TURPIE AGG, 1988, LANCET, V1, P1242; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X	35	812	825	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1997	336	3					153	162						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC266	8992351				2022-12-28	WOS:A1997WC26600001
J	Magee, JC; Johnston, D				Magee, JC; Johnston, D			A synaptically controlled, associative signal for Hebbian plasticity in hippocampal neurons	SCIENCE			English	Article							LONG-TERM POTENTIATION; DEPOLARIZING CURRENT PULSES; PYRAMIDAL CELL DENDRITES; CA2+ CHANNELS; CALCIUM; CA1; ACTIVATION; SYNAPSES; SPINES; INFLUX	The role of back-propagating dendritic action potentials in the induction of long-term potentiation (LTP) was investigated in CA1 neurons by means of dendritic patch recordings and simultaneous calcium imaging. Pairing of subthreshold excitatory postsynaptic potentials (EPSPs) with back-propagating action potentials resulted in an amplification of dendritic action potentials and evoked calcium influx near the site of synaptic input. This pairing also induced a robust LTP, which was reduced when EPSPs were paired with non-back-propagating action potentials or when stimuli were unpaired. Action potentials thus provide a synaptically controlled, associative signal to the dendrites for Hebbian modifications of synaptic strength.			Magee, JC (corresponding author), BAYLOR COLL MED,DIV NEUROSCI,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NIMH NIH HHS [MH44754] Funding Source: Medline; NINDS NIH HHS [NS11535, NS09482] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH044754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011535, P50NS011535] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREASEN M, 1995, J PHYSIOL-LONDON, V483, P421, DOI 10.1113/jphysiol.1995.sp020595; BLISS T V P, 1988, P3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1995, SCIENCE, V269, P1730, DOI 10.1126/science.7569903; BROWN TH, 1990, ANNU REV NEUROSCI, V13, P475, DOI 10.1146/annurev.ne.13.030190.002355; CALLAWAY JC, 1995, J NEUROPHYSIOL, V74, P1395, DOI 10.1152/jn.1995.74.4.1395; Christie BR, 1996, LEARN MEMORY, V3, P160, DOI 10.1101/lm.3.2-3.160; CHRISTIE BR, 1995, J NEUROPHYSIOL, V73, P2553, DOI 10.1152/jn.1995.73.6.2553; Colbert CM, 1996, J NEUROSCI, V16, P6676; Denk W, 1996, CURR OPIN NEUROBIOL, V6, P372, DOI 10.1016/S0959-4388(96)80122-X; GUSTAFSSON B, 1987, J NEUROSCI, V7, P774; HEBB DO, 1949, ORG BEHAVIOR; Hoffman Dax, 1996, Society for Neuroscience Abstracts, V22, P793; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; JAFFE DB, 1994, J NEUROBIOL, V25, P220, DOI 10.1002/neu.480250303; JAFFE DB, 1992, NATURE, V357, P244, DOI 10.1038/357244a0; JOHNSTON D, 1992, ANNU REV PHYSIOL, V54, P489; Johnston D, 1996, ANNU REV NEUROSCI, V19, P165, DOI 10.1146/annurev.ne.19.030196.001121; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; KOCH C, 1982, PHILOS T R SOC B, V298, P227, DOI 10.1098/rstb.1982.0084; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; LASSERROSS N, 1991, J NEUROSCI METH, V36, P253, DOI 10.1016/0165-0270(91)90051-Z; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MAGEE JC, 1995, J PHYSIOL-LONDON, V487, P67, DOI 10.1113/jphysiol.1995.sp020862; MAGEE JC, 1995, J NEUROPHYSIOL, V74, P1335, DOI 10.1152/jn.1995.74.3.1335; Magee JC, 1996, J NEUROPHYSIOL, V76, P3460, DOI 10.1152/jn.1996.76.5.3460; MAGEE JC, 1995, SCIENCE, V268, P301, DOI 10.1126/science.7716525; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MILLS LR, 1994, J NEUROSCI, V14, P6815; MONTAGUE PR, 1994, LEARN MEMORY, V1, P1; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; REGEHR WG, 1992, J NEUROSCI, V12, P4202; SCHARFMAN HE, 1985, BRAIN RES, V331, P267, DOI 10.1016/0006-8993(85)91552-5; SCHWINDT PC, 1995, J NEUROPHYSIOL, V74, P2220, DOI 10.1152/jn.1995.74.5.2220; SEJNOWSKI TJ, 1989, NEURAL MODELS PLASTI, P105; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; STUART G, 1995, NEURON, V15, P1065, DOI 10.1016/0896-6273(95)90095-0; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; TEYLER TJ, 1994, HIPPOCAMPUS, V4, P623, DOI 10.1002/hipo.450040602; Tsubokawa H, 1996, J NEUROPHYSIOL, V76, P2896, DOI 10.1152/jn.1996.76.5.2896; TURNER RW, 1991, J NEUROSCI, V11, P2270; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0; ZADOR A, 1990, P NATL ACAD SCI USA, V87, P6718, DOI 10.1073/pnas.87.17.6718	49	945	965	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					209	213		10.1126/science.275.5297.209	http://dx.doi.org/10.1126/science.275.5297.209			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985013				2022-12-28	WOS:A1997WC02200037
J	Natoli, G; Costanzo, A; Ianni, A; Templeton, DJ; Woodgett, JR; Balsano, C; Levrero, M				Natoli, G; Costanzo, A; Ianni, A; Templeton, DJ; Woodgett, JR; Balsano, C; Levrero, M			Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; PROGRAMMED CELL-DEATH; NF-KAPPA-B; C-JUN; PROTEIN-KINASE; TRANSCRIPTION FACTOR; CYTOPLASMIC DOMAIN; INTERACTS; FAMILY; CD40	Interaction oi the p55 tumor necrosis factor receptor 1 (TNF-R1)-associated signal transducer TRADD with FADD signals apoptosis, whereas the TNF receptor-associated factor 2 protein (TRAF2) is required for activation of the nuclear transcription factor nuclear factor kappa B. TNF-induced activation of the stress-activated protein kinase (SAPK) was shown to occur through a noncytotoxic TRAF2-dependent pathway. TRAF2 was both sufficient and necessary for activation of SAPK by TNF-R1; conversely, expression of a dominant-negative FADD mutant, which blocks apoptosis, did not interfere with SAPK activation. Therefore, SAPK activation occurs through a pathway that is not required for TNF-R1-induced apoptosis.	POLICLIN UMBERTO 1,IST CLIN MED 1,I-00161 ROME,ITALY; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106; PRINCESS MARGARET HOSP,ONTARIO CANC INST,TORONTO,ON M5G 2M9,CANADA; UNIV AQUILA,DEPT MED INTERNA,I-67100 LAQUILA,ITALY	Sapienza University Rome; University Hospital Sapienza Rome; Case Western Reserve University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of L'Aquila	Natoli, G (corresponding author), POLICLIN UMBERTO 1,FDN ANDREA CESALPINO,VIALE POLICLIN 155,I-00161 ROME,ITALY.		Woodgett, Jim/F-1087-2010; Natoli, gioacchino/J-2100-2018; Costanzo, Antonio/D-3896-2012; Templeton, Dennis J/F-7695-2011; Natoli, gioacchino/ABB-8679-2020; Costanzo, Antonio/GZG-2433-2022; Balsano, Clara/AAK-9870-2020; Levrero, Massimo/G-5680-2016	Woodgett, Jim/0000-0003-3731-5797; Costanzo, Antonio/0000-0001-9697-2557; Balsano, Clara/0000-0002-9615-7031; Natoli, Gioacchino/0000-0003-0711-2411; Levrero, Massimo/0000-0002-4978-0875				ADLER V, 1992, J BIOL CHEM, V267, P17001; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Baker SJ, 1996, ONCOGENE, V12, P1; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERBERICH I, 1996, EMBO J, V14, P5338; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; NATOLI G, UNPUB; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Tewari M, 1996, CURR OPIN GENET DEV, V6, P39, DOI 10.1016/S0959-437X(96)90008-8; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAUCHI N, 1989, CANCER RES, V49, P1671; YAN MH, 1994, NATURE, V372, P798; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZIMMERMAN RJ, 1989, CANCER RES, V49, P1644	52	403	411	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					200	203		10.1126/science.275.5297.200	http://dx.doi.org/10.1126/science.275.5297.200			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985011				2022-12-28	WOS:A1997WC02200034
J	Rodnina, MV; Savelsbergh, A; Katunin, VI; Wintermeyer, W				Rodnina, MV; Savelsbergh, A; Katunin, VI; Wintermeyer, W			Hydrolysis of GTP by elongation factor G drives tRNA movement on the ribosome	NATURE			English	Article							CRYSTAL-STRUCTURE; TRANSFER-RNA; FACTOR TU; ESCHERICHIA-COLI; EF-TU; STEADY-STATE; FACTOR-II; TRANSLOCATION; TRANSLATION; MECHANISM	Elongation factor G (EF-G) is a GTPase that is involved in the translocation of bacterial ribosomes along messenger RNA during protein biosynthesis. In contrast to current models, EF-G-dependent GTP hydrolysis is shown to precede, and greatly accelerate, the rearrangement of the ribosome that leads to translocation. Domain IV of the EF-G structure is crucial for both rapid translocation and subsequent release of the factor from the ribosome. By coupling the free energy of GTP hydrolysis to translocation, EF-G serves as a motor protein to drive the directional movement of transfer and messenger RNAs on the ribosome.	UNIV WITTEN HERDECKE,INST MOL BIOL,D-58448 WITTEN,GERMANY; RUSSIAN ACAD SCI,ST PETERSBURG NUCL PHYS INST,GATCHINA 188350,RUSSIA	Witten Herdecke University; National Research Centre - Kurchatov Institute; Petersburg Nuclear Physics Institute; Russian Academy of Sciences			Rodnina, Marina V./AAD-4667-2019	Rodnina, Marina V./0000-0003-0105-3879; Savelsbergh, Andreas/0000-0002-6136-3230				Abel K, 1996, STRUCTURE, V4, P229, DOI 10.1016/S0969-2126(96)00027-5; Aevarsson A, 1995, J MOL EVOL, V41, P1096; AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Al-Karadaghi S, 1996, STRUCTURE, V4, P555, DOI 10.1016/S0969-2126(96)00061-5; BACA OG, 1976, BIOCHEMISTRY-US, V15, P4570, DOI 10.1021/bi00666a004; BELITSINA NV, 1975, FEBS LETT, V54, P35, DOI 10.1016/0014-5793(75)81062-3; Bemasconi C. F., 1976, RELAXATION KINETICS; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; Borowski C, 1996, P NATL ACAD SCI USA, V93, P4202, DOI 10.1073/pnas.93.9.4202; CUNDLIFFE E, 1990, RIBOSOME, P479; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; GAVRILOVA LP, 1976, J MOL BIOL, V101, P537, DOI 10.1016/0022-2836(76)90243-6; HOU Y, 1994, J BACTERIOL, V176, P123, DOI 10.1128/JB.176.1.123-129.1994; INOUEYOKOSAWA N, 1974, J BIOL CHEM, V249, P4321; Johanson U, 1996, J MOL BIOL, V258, P420, DOI 10.1006/jmbi.1996.0259; JOHANSON U, 1994, GENE, V143, P55, DOI 10.1016/0378-1119(94)90604-1; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; Liljas A, 1995, BIOCHEM CELL BIOL, V73, P1209, DOI 10.1139/o95-130; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MODOLELL J, 1977, EUR J BIOCHEM, V81, P491, DOI 10.1111/j.1432-1033.1977.tb11974.x; MODOLELL J, 1975, FEBS LETT, V60, P109, DOI 10.1016/0014-5793(75)80429-7; MOORE PB, 1995, SCIENCE, V270, P1453, DOI 10.1126/science.270.5241.1453; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Nyborg J, 1996, TRENDS BIOCHEM SCI, V21, P81, DOI 10.1016/0968-0004(96)30008-X; NYGARD O, 1985, BIOCHIM BIOPHYS ACTA, V824, P152, DOI 10.1016/0167-4781(85)90092-2; OMURA F, 1989, EUR J BIOCHEM, V180, P1, DOI 10.1111/j.1432-1033.1989.tb14607.x; PAULSEN H, 1986, BIOCHEMISTRY-US, V25, P2749, DOI 10.1021/bi00358a002; ROBERTSON JM, 1987, J MOL BIOL, V196, P525, DOI 10.1016/0022-2836(87)90030-1; ROBERTSON JM, 1986, J MOL BIOL, V189, P653, DOI 10.1016/0022-2836(86)90495-X; ROBERTSON JM, 1986, J MOL BIOL, V192, P351, DOI 10.1016/0022-2836(86)90370-0; RODNINA MV, 1995, EMBO J, V14, P2613, DOI 10.1002/j.1460-2075.1995.tb07259.x; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; Rodnina MV, 1996, J BIOL CHEM, V271, P646, DOI 10.1074/jbc.271.2.646; RODNINA MV, 1994, BIOCHEMISTRY-US, V33, P12267, DOI 10.1021/bi00206a033; ROSENDAHL G, 1995, NUCLEIC ACIDS RES, V23, P2396, DOI 10.1093/nar/23.13.2396; RYAN PC, 1991, J MOL BIOL, V221, P1257, DOI 10.1016/0022-2836(91)80125-E; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SCHLICHTING I, 1989, P NATL ACAD SCI USA, V86, P7687, DOI 10.1073/pnas.86.20.7687; Semenkov YP, 1996, P NATL ACAD SCI USA, V93, P12183, DOI 10.1073/pnas.93.22.12183; SERDYUK I, 1992, BIOCHIMIE, V74, P299, DOI 10.1016/0300-9084(92)90107-P; SPIRIN A, 1987, BIOCHIMIE, V69, P949, DOI 10.1016/0300-9084(87)90228-8; SPIRIN AS, 1969, COLD SPRING HARB SYM, V34, P197, DOI 10.1101/SQB.1969.034.01.026; SPIRIN AS, 1985, PROG NUCLEIC ACID RE, V32, P75, DOI 10.1016/S0079-6603(08)60346-3; SPIRIN AS, 1984, FEBS LETT, V165, P280, DOI 10.1016/0014-5793(84)80186-6; STARK H, IN PRESS CELL; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653	49	385	394	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1997	385	6611					37	41		10.1038/385037a0	http://dx.doi.org/10.1038/385037a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985244				2022-12-28	WOS:A1997WA73100040
J	Souba, WW				Souba, WW			Drug therapy - Nutritional support	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TOTAL PARENTERAL-NUTRITION; BONE-MARROW TRANSPLANTATION; HUMAN GROWTH-HORMONE; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; RANDOMIZED CONTROLLED TRIAL; GENERAL MEDICAL PATIENTS; MAJOR ABDOMINAL-TRAUMA; ACTIVE CROHNS-DISEASE; HEAD-INJURED PATIENTS; HUMAN SMALL-INTESTINE		MASSACHUSETTS GEN HOSP, NUTR SUPPORT SERV, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Souba, WW (corresponding author), MASSACHUSETTS GEN HOSP, DIV SURG ONCOL, COX BLDG, RM 626, 100 BLOSSOM ST, BOSTON, MA 02114 USA.							ABEL RM, 1973, NEW ENGL J MED, V288, P695, DOI 10.1056/NEJM197304052881401; ALEXANDER JW, 1980, ANN SURG, V192, P505, DOI 10.1097/00000658-198010000-00009; [Anonymous], 1989, Ann Intern Med, V110, P734; BAKER JP, 1982, NEW ENGL J MED, V306, P969, DOI 10.1056/NEJM198204223061606; BELLANTONE R, 1988, JPEN-PARENTER ENTER, V12, P195, DOI 10.1177/0148607188012002195; BISTRIAN BR, 1974, JAMA-J AM MED ASSOC, V230, P858, DOI 10.1001/jama.230.6.858; BISTRIAN BR, 1976, JAMA-J AM MED ASSOC, V235, P1567, DOI 10.1001/jama.235.15.1567; BORDER JR, 1987, ANN SURG, V206, P427, DOI 10.1097/00000658-198710000-00004; BOWER RH, 1995, CRIT CARE MED, V23, P436, DOI 10.1097/00003246-199503000-00006; BOWER RH, 1986, ARCH SURG-CHICAGO, V121, P1040; BRENNAN MF, 1994, ANN SURG, V220, P436, DOI 10.1097/00000658-199410000-00003; BYRNE TA, 1995, ANN SURG, V222, P243, DOI 10.1097/00000658-199509000-00003; CABRE E, 1990, GASTROENTEROLOGY, V98, P715, DOI 10.1016/0016-5085(90)90293-A; CERRA FB, 1985, JPEN-PARENTER ENTER, V9, P288, DOI 10.1177/0148607185009003288; CHANDRA RK, 1983, LANCET, V1, P688; CHRISTOU NV, 1995, ANN SURG, V222, P534; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; CUNNINGHAM JJ, 1990, AM J CLIN NUTR, V51, P553, DOI 10.1093/ajcn/51.4.553; DALY JM, 1992, SURGERY, V112, P56; DECICCO M, 1993, JPEN-PARENTER ENTER, V17, P513, DOI 10.1177/0148607193017006513; DETSKY AS, 1987, ANN INTERN MED, V107, P195, DOI 10.7326/0003-4819-107-2-195; DICKINSON RJ, 1980, GASTROENTEROLOGY, V79, P1199; Doglietto GB, 1996, ANN SURG, V223, P357, DOI 10.1097/00000658-199604000-00003; DRISCOLL JM, 1972, J PEDIATR-US, V81, P145, DOI 10.1016/S0022-3476(72)80394-9; FAN ST, 1994, NEW ENGL J MED, V331, P1547, DOI 10.1056/NEJM199412083312303; FEINSTEIN EI, 1981, MEDICINE, V60, P124, DOI 10.1097/00005792-198103000-00005; FONG YM, 1989, ANN SURG, V210, P449, DOI 10.1097/00000658-198910000-00005; GONZALEZHUIX F, 1993, GUT, V34, P778, DOI 10.1136/gut.34.6.778; GOODGAME JT, 1977, ANN SURG, V186, P651, DOI 10.1097/00000658-197711000-00018; GOUTTEBEL MC, 1986, DIGEST DIS SCI, V31, P718, DOI 10.1007/BF01296449; GRAHM TW, 1989, NEUROSURGERY, V25, P729, DOI 10.1227/00006123-198911000-00007; GRANT JP, 1984, ANN SURG, V200, P627, DOI 10.1097/00000658-198411000-00012; GREENBERG GR, 1988, GUT, V29, P1309, DOI 10.1136/gut.29.10.1309; GUEDON C, 1986, GASTROENTEROLOGY, V90, P373, DOI 10.1016/0016-5085(86)90935-2; HADLEY MN, 1986, NEUROSURGERY, V19, P367, DOI 10.1097/00006123-198609000-00006; HERRMANN FR, 1992, ARCH INTERN MED, V152, P125, DOI 10.1001/archinte.152.1.125; HEYLAND D, 1995, CRIT CARE MED, V23, P1055, DOI 10.1097/00003246-199506000-00010; Heymsfield SB, 1994, MODERN NUTR HLTH DIS, P812; INOUE Y, 1994, ANN SURG, V219, P715, DOI 10.1097/00000658-199406000-00016; INOUE Y, 1993, ANN SURG, V217, P604, DOI 10.1097/00000658-199306000-00002; KLEIN S, 1986, CANCER, V58, P1378, DOI 10.1002/1097-0142(19860915)58:6<1378::AID-CNCR2820580635>3.0.CO;2-S; KLIDJIAN AM, 1980, BRIT MED J, V281, P899, DOI 10.1136/bmj.281.6245.899; KOPPLE JD, 1994, AM J KIDNEY DIS, V24, P1002, DOI 10.1016/S0272-6386(12)81075-4; Koretz R L, 1995, Gastroenterology, V109, P1713; KORETZ RL, 1995, AM J RESP CRIT CARE, V151, P570, DOI 10.1164/ajrccm.151.2.7842222; KOTLER DP, 1991, AM J CLIN NUTR, V53, P149, DOI 10.1093/ajcn/53.1.149; KOTLER DP, 1990, JPEN-PARENTER ENTER, V14, P454, DOI 10.1177/0148607190014005454; Kudsk KA, 1996, ANN SURG, V223, P629, DOI 10.1097/00000658-199606000-00001; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; Lacey Janet M., 1996, Journal of Parenteral and Enteral Nutrition, V20, P74, DOI 10.1177/014860719602000174; Leonard C D, 1975, Urology, V6, P154, DOI 10.1016/0090-4295(75)90702-5; LI J, 1995, J TRAUMA, V39, P44, DOI 10.1097/00005373-199507000-00006; MCINTYRE PB, 1986, GUT, V27, P481, DOI 10.1136/gut.27.5.481; MESSING B, 1995, GASTROENTEROLOGY, V108, P1005, DOI 10.1016/0016-5085(95)90196-5; Monk DN, 1996, ANN SURG, V223, P395, DOI 10.1097/00000658-199604000-00008; MOORE EE, 1986, J TRAUMA, V26, P874, DOI 10.1097/00005373-198610000-00003; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; MOORE FA, 1992, ANN SURG, V216, P172, DOI 10.1097/00000658-199208000-00008; MULLER JM, 1982, LANCET, V1, P68; MULLIGAN K, 1992, FASEB J, V6, pA1942; NASRALLAH SM, 1980, LANCET, V2, P1276; NAVEAU S, 1986, HEPATOLOGY, V6, P270, DOI 10.1002/hep.1840060219; NAYLOR CD, 1989, GASTROENTEROLOGY, V97, P1033, DOI 10.1016/0016-5085(89)91517-5; NELSON J, 1995, NUTR CLIN PRACT, V4, P1; NORTON JA, 1988, J NEUROSURG, V68, P62, DOI 10.3171/jns.1988.68.1.0062; OMORAIN C, 1984, BRIT MED J, V288, P1859, DOI 10.1136/bmj.288.6434.1859; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; ROSE D, 1986, SURG GYNECOL OBSTET, V163, P345; SANDSTROM R, 1993, ANN SURG, V217, P185, DOI 10.1097/00000658-199302000-00013; SAVERYMUTTU S, 1985, GUT, V26, P994, DOI 10.1136/gut.26.10.994; SAX HC, 1987, AM J SURG, V153, P117, DOI 10.1016/0002-9610(87)90211-X; SCHLOERB PR, 1993, JPEN-PARENTER ENTER, V17, P407, DOI 10.1177/0148607193017005407; SOETERS PB, 1979, ANN SURG, V190, P189, DOI 10.1097/00000658-197908000-00012; STEHLE P, 1989, LANCET, V1, P231; SUCHNER U, 1990, ARCH INTERN MED, V150, P1225, DOI 10.1001/archinte.150.6.1225; SZELUGA DJ, 1987, CANCER RES, V47, P3309; VALDIVIESO M, 1987, CANCER, V59, P362, DOI 10.1002/1097-0142(19870115)59:2<362::AID-CNCR2820590233>3.0.CO;2-J; VANDERHULST RRWJ, 1993, LANCET, V341, P1363, DOI 10.1016/0140-6736(93)90939-E; VOERMAN HJ, 1992, ANN SURG, V216, P648, DOI 10.1097/00000658-199212000-00006; WEINSIER RL, 1979, AM J CLIN NUTR, V32, P418, DOI 10.1093/ajcn/32.2.418; WEISDORF SA, 1987, TRANSPLANTATION, V43, P833, DOI 10.1097/00007890-198743060-00012; WICKS C, 1994, LANCET, V344, P837, DOI 10.1016/S0140-6736(94)92824-X; WILLIFORD WO, 1991, NEW ENGL J MED, V325, P525; Wilmore DW, 1977, METABOLIC MANAGEMENT, P36; WINDSOR JA, 1988, ANN SURG, V208, P209, DOI 10.1097/00000658-198808000-00013; WOLFE RR, 1979, METABOLISM, V28, P1031, DOI 10.1016/0026-0495(79)90007-6; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668; ZIEGLER TR, 1992, J CLIN ENDOCR METAB, V74, P865, DOI 10.1210/jc.74.4.865; ZIEGLER TR, 1991, J AM SOC NEPHROL, V2, P1130; ZIEGLER TR, 1992, ANN INTERN MED, V116, P821, DOI 10.7326/0003-4819-116-10-821	90	198	207	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1997	336	1					41	48		10.1056/NEJM199701023360107	http://dx.doi.org/10.1056/NEJM199701023360107			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA496	8970939				2022-12-28	WOS:A1997WA49600007
J	Bellefroid, EJ; Bourguignon, C; Hollemann, T; Ma, QF; Anderson, DJ; Kintner, C; Pieler, T				Bellefroid, EJ; Bourguignon, C; Hollemann, T; Ma, QF; Anderson, DJ; Kintner, C; Pieler, T			X-MyT1, a Xenopus C2HC-type zinc finger protein with a regulatory function in neuronal differentiation	CELL			English	Article							NEUROGENIC GENE-DELTA; ACHAETE-SCUTE COMPLEX; NEURAL INDUCTION; BINDING-PROTEIN; CELL FATE; DROSOPHILA; EXPRESSION; EMBRYOS; NOTCH; ENHANCER	X-MyT1 is a C2HC-type zinc finger protein that we find to be involved in the primary selection of neuronal precursor cells in Xenopus. Expression of this gene is positively regulated by the bHLH protein X-NGNR-1 and negatively regulated by the Notch/Delta signal transduction pathway. X-MyT1 is able to promote ectopic neuronal differentiation and to confer insensitivity to lateral inhibition, but only in cooperation with bHLH transcription factors. Inhibition of X-MyT1 function inhibits normal neurogenesis as well as ectopic neurogenesis caused by overexpression of X-NGNR-1. On the basis of these findings, we suggest that X-MyT1 is a novel, essential element in the cascade of events that allows cells to escape lateral inhibition and to enter the pathway that leads to terminal neuronal differentiation.	SALK INST BIOL STUDIES,SAN DIEGO,CA 92186; CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125	Salk Institute; California Institute of Technology; Howard Hughes Medical Institute	Bellefroid, EJ (corresponding author), INST BIOCHEM & MOL ZELLBIOL,HUMBOLDTALLEE 23,D-37073 GOTTINGEN,GERMANY.							BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; Chitnis A, 1996, DEVELOPMENT, V122, P2295; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; FEDOROFF NV, 1977, COLD SPRING HARB SYM, V42, P1195; FERREIRO B, 1994, DEVELOPMENT, V120, P3649; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Heitzler P, 1996, DEVELOPMENT, V122, P161; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; JENNINGS B, 1995, DEVELOPMENT, V121, P3745; KIM JG, 1992, MOL CELL BIOL, V12, P5632, DOI 10.1128/MCB.12.12.5632; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KUNISCH M, 1994, P NATL ACAD SCI USA, V91, P10139, DOI 10.1073/pnas.91.21.10139; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; MARKMEYER P, 1990, GENE, V93, P129, DOI 10.1016/0378-1119(90)90146-I; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MUSCAVITCH MA, 1994, DEV BIOL, V166, P415; NIETFELD W, 1990, EMBO J, V9, P3699, DOI 10.1002/j.1460-2075.1990.tb07582.x; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OSCHWALD R, 1991, International Journal of Developmental Biology, V35, P399; SAHIN M, 1993, J NEUROSCI, V13, P4968; SKEATH JB, 1994, FASEB J, V8, P714, DOI 10.1096/fasebj.8.10.8050670; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VANDOREN M, 1992, GENE DEV, V6, P2592, DOI 10.1101/gad.6.12b.2592; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	37	190	197	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1191	1202		10.1016/S0092-8674(00)81815-2	http://dx.doi.org/10.1016/S0092-8674(00)81815-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980226	Bronze			2022-12-28	WOS:A1996WA54100008
J	Bannister, AJ; Kouzarides, T				Bannister, AJ; Kouzarides, T			The CBP co-activator is a histone acetyltransferase	NATURE			English	Article							E1A	THE CBP protein acts as a transcriptional adaptor for many different transcription factors by directly contacting DNA-bound activators(1-7). One mechanism by which CBP is thought to stimulate transcription is by recruiting the histone acetyltransferase (HAT) P/CAF to the promoters(8). Here we show that CBP has intrinsic HAT activity. The HAT domain of CBP is adjacent to the binding site for the transcriptional activator E1A. Although E1A displaces P/CAF from CBP, it does not disrupt the CBP-associated HAT activity. Thus E1A carries HAT activity when complexed with CBP. Targeting CBP-associated HAT activity to specific promoters may therefore be a mechanism by which E1A acts as a transcriptional activator.	UNIV CAMBRIDGE,WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QR,ENGLAND	University of Cambridge; University of Cambridge				Bannister, Andrew/0000-0002-6312-4436; Kouzarides, Tony/0000-0002-8918-4162	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Hagmeyer BM, 1996, ONCOGENE, V12, P1025; Janknecht R, 1996, ONCOGENE, V12, P1961; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P11, DOI 10.1016/0968-0004(96)80878-4; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; WONG HK, 1994, J VIROL, V68, P4910, DOI 10.1128/JVI.68.8.4910-4920.1994; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	13	1480	1513	0	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 19	1996	384	6610					641	643		10.1038/384641a0	http://dx.doi.org/10.1038/384641a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VZ296	8967953				2022-12-28	WOS:A1996VZ29600033
J	Barakat, MT; Scott, J; Hughes, JMB; Walport, M; Calam, J; Friedland, JS; Ind, PW; McKenna, C				Barakat, MT; Scott, J; Hughes, JMB; Walport, M; Calam, J; Friedland, JS; Ind, PW; McKenna, C			Grand rounds - Hammersmith Hospital - Persistent fever in pulmonary tuberculosis - Drug malabsorption should be considered	BRITISH MEDICAL JOURNAL			English	Editorial Material							MEDICATIONS				Barakat, MT (corresponding author), HAMMERSMITH HOSP,LONDON W12 0HS,ENGLAND.			Walport, Mark/0000-0001-7220-5273				ANKER N, 1981, EUR J RESPIR DIS, V62, P84; BERNING SE, 1992, NEW ENGL J MED, V327, P1817, DOI 10.1056/NEJM199212173272514; CUNHA BA, 1995, CHEST, V107, P1476; DIETERLEN P, 1986, ARCH FR PEDIATR, V43, P421; FRIEDLAND JS, 1995, CLIN EXP IMMUNOL, V100, P233; FRIEDLAND JS, 1994, BIOCHEM SOC T, V22, P310, DOI 10.1042/bst0220310; MITCHISON DA, 1993, AM REV RESPIR DIS, V147, P1062, DOI 10.1164/ajrccm/147.4.1062; MUTHUSWAMY P, 1995, CHEST, V107, P1621, DOI 10.1378/chest.107.6.1621; PATEL KB, 1995, NEW ENGL J MED, V332, P336, DOI 10.1056/NEJM199502023320518; PELOQUIN CA, 1993, MED CLIN N AM, V77, P1253, DOI 10.1016/S0025-7125(16)30191-2; PELOQUIN CA, 1993, NEW ENGL J MED, V329, P1122, DOI 10.1056/NEJM199310073291513; POLOSA K, 1984, BR J CLIN PHARM, V17, P481; PROUST AJ, 1971, MED J AUSTRALIA, V2, P85, DOI 10.5694/j.1326-5377.1971.tb50435.x; PUROHIT SD, 1987, TUBERCLE, V68, P151, DOI 10.1016/0041-3879(87)90034-1; SENDEROVITZ T, 1994, RESP MED, V88, P561, DOI 10.1016/S0954-6111(05)80002-2; SIEGLER DI, 1974, LANCET, V2, P197	16	11	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1996	313	7071					1543	1545						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY691	8978236				2022-12-28	WOS:A1996VY69100030
J	Birmingham, L; Mason, D; Grubin, D				Birmingham, L; Mason, D; Grubin, D			Prevalence of mental disorder in remand prisoners: Consecutive case study	BRITISH MEDICAL JOURNAL			English	Article							PSYCHIATRIC MORBIDITY; HEALTH; STATE	Objective-To define the prevalence of mental disorder and need for psychiatric treatment in new remand prisoners and to determine to what extent these are recognised and addressed in prison. Design-Study of consecutive male remand prisoners at reception using a semistructured psychiatric interview. Setting-Large remand prison for men (HMP Durham). Subjects-569 men aged 21 years and over on remand, awaiting trial. Main outcome mecrsures-Prevalence of mental disorder at reception, prisoners need for psychiatric treatment, identification of mental disorder by prison reception screening, and numbers placed appropriately in the prison hospital. Results-148 (26%) men had one or more current mental disorders (excluding substance misuse) including 24 who were acutely psychotic, The prison reception screening identified 34 of the men with mental disorder and six of those with acute psychosis. 168 men required psychiatric treatment, 50 of whom required urgent intervention; 16 required immediate transfer to psychiatric hospital. Of these 50, 17 were placed on the hospital wing because of mental disorder recognised at prison screening. Conclusion-Not only is the prevalence of mental disorder, in particular severe mental illness, high in this population, but the numbers identified at reception are low and subsequent management in prison is poor.			Birmingham, L (corresponding author), UNIV NEWCASTLE UPON TYNE,ST NICHOLASS HOSP,DEPT FORENS PSYCHIAT,GOSFORTH NE3 3XT,NORTHD,ENGLAND.							AMMONS RB, 1962, PSYCHOL REP, V11, P111, DOI 10.1177/003329416201100106; BLUGLASS R, 1988, BRIT MED J, V296, P1757, DOI 10.1136/bmj.296.6639.1757; COID JW, 1988, BRIT MED J, V296, P1779, DOI 10.1136/bmj.296.6639.1779; DAVIDSON M, 1995, BRIT J PSYCHIAT, V167, P545, DOI 10.1192/bjp.167.4.545; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; GUNN J, 1991, BRIT MED J, V303, P338, DOI 10.1136/bmj.303.6798.338; GUNN J, IN PRESS BMJ; Martin E, 1987, J R Coll Gen Pract, V37, P377; MAXWELL AE, 1977, BRIT J PSYCHIAT, V130, P79, DOI 10.1192/bjp.130.1.79; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MICHAELS D, 1992, HOSP COMMUNITY PSYCH, V43, P150; MITCHISON S, 1994, MED SCI LAW, V34, P324, DOI 10.1177/002580249403400410; PHILLIPS GT, 1987, BRIT J ADDICT, V82, P691; SMITH R, 1984, BRIT MED J, V288, P308, DOI 10.1136/bmj.288.6413.308; SMITH R, 1984, BRIT MED J, V288, P386, DOI 10.1136/bmj.288.6414.386; TAYLOR PJ, 1984, BRIT MED J, V288, P1945, DOI 10.1136/bmj.288.6435.1945; TEPLIN LA, 1984, AM PSYCHOL, V39, P794, DOI 10.1037/0003-066X.39.7.794	17	160	168	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1996	313	7071					1521	1524		10.1136/bmj.313.7071.1521	http://dx.doi.org/10.1136/bmj.313.7071.1521			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VY691	8978227	Green Published			2022-12-28	WOS:A1996VY69100020
J	Cook, DG; Peacock, JL; Feyerabend, C; Carey, IM; Jarvis, MJ; Anderson, HR; Bland, JM				Cook, DG; Peacock, JL; Feyerabend, C; Carey, IM; Jarvis, MJ; Anderson, HR; Bland, JM			Relation of caffeine intake and blood caffeine concentrations during pregnancy to fetal growth: Prospective population based study	BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT; MATERNAL SMOKING; SERUM COTININE; CONSUMPTION; ALCOHOL	Objectives-To examine the association of plasma caffeine concentrations during pregnancy with fetal growth and to compare this with relations with reported caffeine intake. Design-Prospective population based study. Setting-District general hospital, inner London. Subjects-Women booking for delivery between 1982 and 1984. Stored plasma was available for 1500 women who had provided a blood sample on at least one occasion and for 640 women who had provided. a sample on all three occasions (at booking, 28 weeks, and 36 weeks). Main outcome measure-Birth weight adjusted for gestational age, maternal height, parity, and sex of infant, The exposures of interest were reported caffeine consumption and blood caffeine concentration. Cigarette smoking was assessed by blood cotinine concentration, Results-Caffeine intake showed no changes during pregnancy, but blood caffeine concentrations rose by 75%., Although caffeine intake increased steadily with increasing cotinine concentration above 15 ng/ml, blood caffeine concentrations fell. Caffeine consumption was inversely related to adjusted birth weight, the estimated effect being a 1.3% fall in birth weight for a 1000 mg per week increase in intake (95% confidence interval 0.5% to 2.1%)., The apparent caffeine effect was confined to cigarette smokers, among whom the estimated effect was -1.6%/1000 mg a week (-2.9% to -0.2%) after adjustment for cotinine and -1.3% (-2.7% to 0.1%) after further adjustment for social class and alcohol intake, Adjusted birth weight mas unrelated to blood caffeine concentrations overall (P = 0.09, but a positive coefficient), after adjustment for cotinine (P = 0.73), or among current smokers (P = 0.45). Conclusions-Smokers consume more caffeine than non-smokers. Blood caffeine concentrations during pregnancy are not related to fetal growth, but caffeine intake is negatively associated with birth weight, with this effect being apparent only in smokers. The effect remains of borderline significance after adjustment for other factors. Prudent advice for pregnant women would be to reduce caffeine intake in conjunction with stopping smoking.	NEW CROSS HOSP, MED TOXICOL UNIT, LONDON, ENGLAND; UCL, DEPT EPIDEMIOL & PUBL HLTH, IMPERIAL CANC RES FUND, HLTH BEHAV UNIT, LONDON, ENGLAND	New Cross Hospital; Cancer Research UK; University of London; University College London	Cook, DG (corresponding author), UNIV LONDON ST GEORGES HOSP, SCH MED, DEPT PUBL HLTH SCI, LONDON SW17 0RE, ENGLAND.		Jarvis, Martin J/B-1034-2008; Anderson, Hugh R/A-7417-2016; Carey, Iain/O-6973-2014	Jarvis, Martin J/0000-0001-9238-8038; Carey, Iain/0000-0003-1099-8460; Peacock, Janet/0000-0002-0310-2518; Cook, Derek/0000-0002-9723-5759				ALDRIDGE A, 1981, SEMIN PERINATOL, V5, P310; ALSAMARRAE W, 1975, P NUTR SOC, V34, pA18; BARDY AH, 1993, BRIT J OBSTET GYNAEC, V100, P721, DOI 10.1111/j.1471-0528.1993.tb14262.x; BEAULACBAILLARGEON L, 1987, AM J OBSTET GYNECOL, V157, P1236, DOI 10.1016/S0002-9378(87)80301-0; BLAND JM, 1990, APPL STAT-J ROY ST C, V39, P229; BROOKE OG, 1989, BRIT MED J, V298, P795, DOI 10.1136/bmj.298.6676.795; DLUGOSZ L, 1992, EPIDEMIOL REV, V14, P83, DOI 10.1093/oxfordjournals.epirev.a036093; ESKENAZI B, 1995, AM J PUBLIC HEALTH, V85, P395, DOI 10.2105/AJPH.85.3.395; FENSTER L, 1991, AM J PUBLIC HEALTH, V81, P458, DOI 10.2105/AJPH.81.4.458; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; FORTIER I, 1993, AM J EPIDEMIOL, V137, P931, DOI 10.1093/oxfordjournals.aje.a116763; GRAHAM DM, 1978, NUTR REV, V36, P97, DOI 10.1111/j.1753-4887.1978.tb03717.x; HADDOW JE, 1987, BRIT J OBSTET GYNAEC, V94, P678, DOI 10.1111/j.1471-0528.1987.tb03174.x; JARVIS MJ, 1987, AM J PUBLIC HEALTH, V77, P1435, DOI 10.2105/AJPH.77.11.1435; KRISHNA K, 1978, BRIT J OBSTET GYNAEC, V85, P726, DOI 10.1111/j.1471-0528.1978.tb15591.x; Leviton A, 1996, EPIDEMIOLOGY, V7, P110, DOI 10.1097/00001648-199601000-00022; MCNEILL AD, 1987, BRIT J ADDICT, V82, P1355; Office of Population Censuses and Surveys, 1980, CLASS OCC; PARSONS WD, 1978, CLIN PHARMACOL THER, V24, P40; PEACOCK JL, 1991, J EPIDEMIOL COMMUN H, V45, P159, DOI 10.1136/jech.45.2.159; SHIONO PH, 1993, AM J EPIDEMIOL, V137, P951, DOI 10.1093/oxfordjournals.aje.a116765; Verma R C, 1983, Indian Pediatr, V20, P105	22	61	62	0	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 30	1996	313	7069					1358	1362		10.1136/bmj.313.7069.1358	http://dx.doi.org/10.1136/bmj.313.7069.1358			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW685	8956700	Green Published			2022-12-28	WOS:A1996VW68500022
J	Cohen, JE; Tilman, D				Cohen, JE; Tilman, D			Ecology - Biosphere 2 and biodiversity: The lessons so far	SCIENCE			English	Editorial Material									COLUMBIA UNIV,NEW YORK,NY 10027; UNIV MINNESOTA,ST PAUL,MN 55108	Columbia University; University of Minnesota System; University of Minnesota Twin Cities	Cohen, JE (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.		Tilman, David/ABD-5309-2021					Broecker WS, 1996, GSA TODAY, V6, P1; BURGESS T, BIODIVERSITY WORKING; DEMPSTER WF, 1993, TECH PAP SER SOC AUT; Macilwain C, 1996, NATURE, V380, P275, DOI 10.1038/380275a0; Odum EP, 1996, NATURE, V382, P18, DOI 10.1038/382018a0; Severinghaus JP., 1994, EOS, V75, P33, DOI [DOI 10.1029/94E000285, 10.1029/94EO00285]; WOLFGANG L, 1995, SCIENCE, V270, P1111	7	26	28	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1150	1151		10.1126/science.274.5290.1150	http://dx.doi.org/10.1126/science.274.5290.1150			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8966587				2022-12-28	WOS:A1996VT33500039
J	SCHACHTMAN, DP; SCHROEDER, JI; LUCAS, WJ; ANDERSON, JA; GABER, RF				SCHACHTMAN, DP; SCHROEDER, JI; LUCAS, WJ; ANDERSON, JA; GABER, RF			EXPRESSION OF AN INWARD-RECTIFYING POTASSIUM CHANNEL BY THE ARABIDOPSIS KAT1 CDNA	SCIENCE			English	Article							GUARD-CELL PROTOPLASTS; PLASMA-MEMBRANE; K+ CHANNELS; ION CHANNELS; SACCHAROMYCES-CEREVISIAE; SODIUM-CHANNEL; PATCH-CLAMP; VICIA-FABA; ANOMALOUS RECTIFICATION; VOLTAGE-DEPENDENCE	Inward-rectifying potassium channels located in the plasma membrane of higher plant and animal cells contribute to cellular homeostasis and excitability. The genes encoding this specific class of K+ channels have not been functionally identified. This report shows that a single messenger RNA transcript from the Arabidopsis thaliana KAT1 complementary DNA confers the functional expression of a hyperpolarization-activated K+ channel in Xenopus oocytes. The channels encoded by KAT1 are highly selective for K+ over other monovalent cations, are blocked by tetraethylammonium and barium, and have a single-channel conductance of 28 +/- 7 picosiemens with 118 millimolar K+ in the bathing solution. These functional characteristics, typical of inward-rectifying K+ channels in eukaryotic cells, demonstrate that KAT1 encodes an inward-rectifying K+ channel.	NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; UNIV CALIF DAVIS, DEPT BOT, DAVIS, CA 95616 USA	Northwestern University; University of California System; University of California San Diego; University of California System; University of California Davis	SCHACHTMAN, DP (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA.			Schachtman, Daniel/0000-0003-1807-4369; Schroeder, Julian/0000-0002-3283-5972				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BEZANILLA F, 1991, SCIENCE, V254, P679, DOI 10.1126/science.1948047; BLATT MR, 1992, J GEN PHYSIOL, V99, P615, DOI 10.1085/jgp.99.4.615; BLOOM AJ, 1986, PLANT PHYSIOL, V81, P67, DOI 10.1104/pp.81.1.67; BUSH DS, 1988, PLANTA, V176, P368, DOI 10.1007/BF00395417; CAO YW, 1992, PLANT CELL, V4, P961, DOI 10.1105/tpc.4.8.961; COLOMBO R, 1991, PLANT PHYSIOL, V97, P1130, DOI 10.1104/pp.97.3.1130; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; EPSTEIN E, 1972, MINERAL NUTRITION PL; FAIRLEYGRENOT KA, 1992, PLANTA, V186, P282, DOI 10.1007/BF00196258; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; HAGIWARA S, 1974, J MEMBRANE BIOL, V18, P61, DOI 10.1007/BF01870103; HAGIWARA S, 1978, J PHYSIOL-LONDON, V279, P167, DOI 10.1113/jphysiol.1978.sp012338; HAGIWARA S, 1983, MEMBRANE POTENTIAL D, P61; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HAYNES RJ, 1978, BIOL REV, V53, P465, DOI 10.1111/j.1469-185X.1978.tb00862.x; HEDRICH R, 1989, ANNU REV PLANT PHYS, V40, P539, DOI 10.1146/annurev.pp.40.060189.002543; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KATZ B, 1949, ARCH SCI PHYSIOL, V3, P285; KETCHUM KA, 1989, PLANT PHYSIOL, V89, P1184, DOI 10.1104/pp.89.4.1184; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KOCHIAN LV, 1988, ADV BOT RES, V15, P93; KOURIE J, 1992, PLANT PHYSIOL, V98, P1087, DOI 10.1104/pp.98.3.1087; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LINDAU M, 1986, J GEN PHYSIOL, V88, P349, DOI 10.1085/jgp.88.3.349; LOGOTHETIS DE, 1992, NEURON, V8, P531, DOI 10.1016/0896-6273(92)90281-H; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MATSUDA H, 1991, ANNU REV PHYSIOL, V53, P289, DOI 10.1146/annurev.ph.53.030191.001445; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; NEWMAN IA, 1987, PLANT PHYSIOL, V84, P1177, DOI 10.1104/pp.84.4.1177; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PARKER I, 1988, PROC R SOC SER B-BIO, V233, P191, DOI 10.1098/rspb.1988.0018; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; RAMOS J, 1985, ARCH MICROBIOL, V143, P88, DOI 10.1007/BF00414774; SCHACHTMAN DP, UNPUB; SCHOPPA NE, 1992, SCIENCE, V255, P1712, DOI 10.1126/science.1553560; SCHROEDER JI, 1988, J GEN PHYSIOL, V92, P667, DOI 10.1085/jgp.92.5.667; SCHROEDER JI, 1991, P NATL ACAD SCI USA, V88, P11583, DOI 10.1073/pnas.88.24.11583; SCHROEDER JI, 1987, P NATL ACAD SCI USA, V84, P4108, DOI 10.1073/pnas.84.12.4108; SCHROEDER JI, 1984, NATURE, V312, P361, DOI 10.1038/312361a0; SCHROEDER JI, 1989, NATURE, V338, P427, DOI 10.1038/338427a0; SENENAC H, 1992, SCIENCE, V256, P663; SLAYMAN CL, 1987, J BIOENERG BIOMEMBR, V19, P1; SUSSMAN MR, 1989, PLANT CELL, V1, P953, DOI 10.1105/tpc.1.10.953; TESTER M, 1990, NEW PHYTOL, V114, P305, DOI 10.1111/j.1469-8137.1990.tb00403.x; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	56	372	389	2	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1992	258	5088					1654	1658		10.1126/science.8966547	http://dx.doi.org/10.1126/science.8966547			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA896	8966547				2022-12-28	WOS:A1992KA89600039
J	Annas, GJ				Annas, GJ			Tobacco litigation as cancer prevention: Dealing with the devil	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				Annas GJ, 1996, NEW ENGL J MED, V335, P1779, DOI 10.1056/NEJM199612053352322; ANNAS GJ, 1992, NEW ENGL J MED, V327, P1604, DOI 10.1056/NEJM199211263272219; DAYNARD RA, 1996, BOSTON GLOBE    0211, P81; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; FEDER BJ, 1996, NY TIMES        0907, P38; FEDER BJ, 1996, NY TIMES        0728, pF1; FREEDMAN AM, 1996, WALL ST J       0126, pA1; GEYELIN M, 1996, WALL STREET J   0829, pB14; GEYELIN M, 1996, WALL ST J       0321, pB1; GEYELIN M, 1996, WALL ST J       0524, pA3; Glantz S.A., 1996, CIGARETTE PAPERS; Gray N, 1996, BRIT MED J, V313, P1348, DOI 10.1136/bmj.313.7069.1348; Grisham J., 1996, RUNAWAY JURY; HILTS PJ, 1996, SMOKE SCREEN TRUTH T, P195; HWANG S, 1996, WALL ST J       0430, pB1; HWANG SL, 1996, WALL STREET J   1022, pB12; HWANG SL, 1996, WALL ST J       0131, pA1; Kelder G E, 1996, J Am Med Womens Assoc (1972), V51, P57; KLUGER R, 1996, NY TIMES        0407, P28; KLUGER R, 1996, ASHES ASHES AM 100 Y; MACLACHLAN C, 1997, NATL LAW J      0106, pA7; MACLACHLAN C, 1996, NATL LAW J      0603, pA1; SUGARMAN SD, 1996, SCIENCE, V273, P744; TODD JS, 1995, JAMA-J AM MED ASSOC, V274, P256, DOI 10.1001/jama.274.3.256; WEISER B, 1996, WASHINGTON POST 1208, P15; WEISER B, 1996, WASHINTON POST  1208, P28; 1996, NATL LAW J      1021, pA5; 1996, AM MED NEWS     1014, P17	28	11	11	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1997	336	4					304	308		10.1056/NEJM199701233360421	http://dx.doi.org/10.1056/NEJM199701233360421			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE632	8995095	Green Published			2022-12-28	WOS:A1997WE63200031
J	Ali, JA; Lohman, TM				Ali, JA; Lohman, TM			Kinetic measurement of the step size of DNA unwinding by Escherichia coli UvrD helicase	SCIENCE			English	Article							GENE-PRODUCT; REP HELICASE; INDUCED DIMERIZATION; POLYMERASE-I; PROTEIN; MECHANISMS; BINDING; SYSTEM	The kinetic mechanism by which the DNA repair helicase UvrD of Escherichia coli unwinds duplex DNA was examined with the use of a series of oligodeoxynucleotides with duplex regions ranging from 10 to 40 base pairs. Single-turnover unwinding experiments showed distinct lag phases that increased with duplex length because partially unwound DNA intermediate states are highly populated during unwinding. Analysis of these kinetics indicates that UvrD unwinds duplex DNA in discrete steps, with an average ''step size'' of 4 to 5 base pairs (approximately one-half turn of the DNA helix). This suggests an unwinding mechanism in which alternating subunits of the dimeric helicase interact directly with duplex DNA.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045948] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45948, R01 GM045948] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali J., UNPUB; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; Bjornson KP, 1996, J MOL BIOL, V263, P411, DOI 10.1006/jmbi.1996.0585; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; GILCHRIST CA, 1987, NUCLEIC ACIDS RES, V15, P465, DOI 10.1093/nar/15.2.465; Gutfreund H., 1995, KINETICS LIFE SCI RE; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MAPLES VF, 1982, P NATL ACAD SCI-BIOL, V79, P5616, DOI 10.1073/pnas.79.18.5616; MATSON SW, 1986, J BIOL CHEM, V261, P169; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; RUNYON GT, 1990, P NATL ACAD SCI USA, V87, P6383, DOI 10.1073/pnas.87.16.6383; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; WONG I, 1992, J BIOL CHEM, V267, P7596; WONG I, 1993, J BIOL CHEM, V268, P20386; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; YAMAMOTO Y, 1986, J BIOCHEM-TOKYO, V99, P1579, DOI 10.1093/oxfordjournals.jbchem.a135631	26	230	233	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					377	380		10.1126/science.275.5298.377	http://dx.doi.org/10.1126/science.275.5298.377			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994032				2022-12-28	WOS:A1997WC87300043
J	Richards, MA; Ricard, Y; LithgowBertelloni, C; Spada, G; Sabadini, R				Richards, MA; Ricard, Y; LithgowBertelloni, C; Spada, G; Sabadini, R			An explanation for Earth's long-term rotational stability	SCIENCE			English	Article							TRUE POLAR WANDER; DYNAMIC EARTH; SUBDUCTION; VISCOSITY; TERTIARY	Paleomagnetic data show less than similar to 1000 kilometers of motion between the paleomagnetic and hotspot reference frames-that is, true polar wander-during the past 100 million years, which implies that Earth's rotation axis has been very stable. This long-term rotational stability can be explained by the slow rate ol change in the large-scale pattern of plate tectonic motions during Cenozoic and late Mesozoic time, provided that subducted lithosphere is a major component of the mantle density heterogeneity generated by convection. Therefore, it is unnecessary to invoke other mechanisms, such as sluggish readjustment of the rotational bulge, to explain the observed low rate of true polar wander.	ECOLE NORMALE SUPER LYON, DEPT GEOL, F-69364 LYON, FRANCE; CARNEGIE INST WASHINGTON, DEPT TERR MAGNETISM, WASHINGTON, DC 20015 USA; UNIV BOLOGNA, DIPARTIMENTO FIS, SETTORE GEOFIS, BOLOGNA, ITALY; UNIV MILAN, DIPARTIMENTO SCI TERRA, SEZIONE GEOFIS, I-20133 MILAN, ITALY	Ecole Normale Superieure de Lyon (ENS de LYON); Carnegie Institution for Science; University of Bologna; University of Milan	Richards, MA (corresponding author), UNIV CALIF BERKELEY, DEPT GEOL & GEOPHYS, BERKELEY, CA 94720 USA.		Lithgow-Bertelloni, Carolina/P-3952-2019; ricard, yanick/C-6287-2009; Lithgow-Bertelloni, Carolina/C-4827-2011; ricard, yanick/AAW-5649-2021	Lithgow-Bertelloni, Carolina/0000-0003-0924-6587; ricard, yanick/0000-0002-0998-4670; Lithgow-Bertelloni, Carolina/0000-0003-0924-6587; ricard, yanick/0000-0002-0998-4670; Spada, Giorgio/0000-0001-7615-4709				ANDREWS JA, 1985, J GEOPHYS RES-SOLID, V90, P7737, DOI 10.1029/JB090iB09p07737; BESSE J, 1991, J GEOPHYS RES-SOLID, V96, P4029, DOI 10.1029/90JB01916; CHASE CG, 1985, ANNU REV EARTH PL SC, V13, P97; DICKMAN SR, 1977, GEOPHYS J ROY ASTR S, V51, P229, DOI 10.1111/j.1365-246X.1977.tb04198.x; Engebretson D.C., 1992, GSA TODAY, P93; GOLD T, 1955, NATURE, V175, P526, DOI 10.1038/175526a0; GOLDREICH P, 1969, J GEOPHYS RES, V74, P2555, DOI 10.1029/JB074i010p02555; GORDON RG, 1987, ANNU REV EARTH PL SC, V15, P567; GURNIS M, 1986, THESIS AUSTR NATL U; HAGER BH, 1989, PHILOS T R SOC A, V328, P309, DOI 10.1098/rsta.1989.0038; JURDY DM, 1981, TECTONOPHYSICS, V74, P1, DOI 10.1016/0040-1951(81)90124-4; JURDY DM, 1983, J GEOPHYS RES, V88, P6395, DOI 10.1029/JB088iB08p06395; KING SD, 1992, GEOPHYS RES LETT, V19, P1551, DOI 10.1029/92GL01700; Lithgow-Bertelloni C, 1998, REV GEOPHYS, V36, P27, DOI 10.1029/97RG02282; LITHGOWBERTELLONI C, 1995, GEOPHYS RES LETT, V22, P1317, DOI 10.1029/95GL01325; LIVERMORE RA, 1984, GEOPHYS J ROY ASTR S, V79, P939, DOI 10.1111/j.1365-246X.1984.tb02878.x; Mitrovica JX, 1996, J GEOPHYS RES-SOL EA, V101, P555, DOI 10.1029/95JB03208; Morgan W.J., 1981, SEA VOLUME 7 OCEANIC, V7, P443; Munk W.H., 1960, ROTATION EARTH; RICARD Y, 1993, J GEOPHYS RES-SOL EA, V98, P21895, DOI 10.1029/93JB02216; RICARD Y, 1993, GEOPHYS J INT, V113, P284, DOI 10.1111/j.1365-246X.1993.tb00888.x; RICARD Y, 1984, ANN GEOPHYS, V2, P267; RICHARDS MA, 1984, J GEOPHYS RES, V89, P5987, DOI 10.1029/JB089iB07p05987; RICHARDS MA, 1992, NATURE, V355, P437, DOI 10.1038/355437a0; RICHARDS MA, 1991, NATO ADV SCI I C-MAT, V334, P571; RICHARDS MA, 1994, UNPUB, V75, P67; SABADINI R, 1989, NATURE, V339, P373, DOI 10.1038/339373a0; SABADINI R, 1981, GEOPHYS J ROY ASTR S, V66, P553, DOI 10.1111/j.1365-246X.1981.tb04890.x; SABADINI R, 1984, J GEOPHYS RES, V89, P7609, DOI 10.1029/JB089iB09p07609; SPADA G, 1992, NATURE, V360, P452, DOI 10.1038/360452a0; SPADA G, 1992, THESIS U BOLOGNA; TACKLEY PJ, 1994, THESIS CALTECH	32	57	57	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 17	1997	275	5298					372	375		10.1126/science.275.5298.372	http://dx.doi.org/10.1126/science.275.5298.372			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994030				2022-12-28	WOS:A1997WC87300041
J	Schatz, BR				Schatz, BR			Information retrieval in digital libraries: Bringing search to the net	SCIENCE			English	Article								A digital library enables users to interact effectively with information distributed across a network. These network information systems support search and display of items from organized collections. In the historical evolution of digital libraries, the mechanisms for retrieval of scientific literature have been particularly important. Grand visions in 1960 led first to the development of text search, from bibliographic databases to full-text retrieval. Next, research prototypes catalyzed the rise of document search, from multimedia browsing across local-area networks to distributed search on the Internet. By 2010, the visions will be realized, with concept search enabling semantic retrieval across large collections.	UNIV ILLINOIS,BECKMAN INST ADV SCI & TECHNOL,NATL CTR SUPERCOMP APPLICAT,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	Schatz, BR (corresponding author), UNIV ILLINOIS,UNIV LIB,DIGITAL LIB RES PROGRAM,URBANA,IL 61801, USA.							BORGES JL, LIBR BABEL; Bush Vannevar, 1945, ATLANTIC, P101, DOI DOI 10.1145/227181.227186; Chen HC, 1996, IEEE T PATTERN ANAL, V18, P771, DOI 10.1109/34.531798; Chen HC, 1997, J AM SOC INFORM SCI, V48, P17, DOI 10.1002/(SICI)1097-4571(199701)48:1<17::AID-ASI4>3.0.CO;2-4; FOX EA, 1995, COMMUN ACM, V38, P23; Goldberg A, 1983, SMALLTALK 80 LANGUAG; Herot C. F., 1980, ACM Transactions on Database Systems, V5, P493, DOI 10.1145/320610.320648; Kahle B., 1992, Electronic Networking: Research, Applications and Policy, V2, P59; KAHLE B, COMMUNICATION; KANTOR PB, 1994, ANNU REV INFORM SCI, V29, P53; Lancaster F. W., 1986, VOCABULARY CONTROL I; LANCASTER FW, 1973, INFORMATION RETRIEVA; LESK M, 1995, 7 AGES INFORMATION R; Licklider J.C.R, 1965, LIB FUTURE, pvi; LICKLIDER JCR, 1962, P AM FED INF PROCESS, V21, P113; LYNCH C, 1995, INTEROPERABILITY SCA; MARCUS RS, 1982, IEEE T SYST MAN CYB, V12, P116, DOI 10.1109/TSMC.1982.4308796; MCCARN DB, 1973, SCIENCE, V181, P318, DOI 10.1126/science.181.4097.318; MEADOW CT, 1988, DATABASE, P23; Nadis S, 1996, SCIENCE, V272, P1419, DOI 10.1126/science.272.5267.1419; Nelson Ted, 1981, LITERARY MACHINES; NELSON TH, 1972, ONLINE 72 C P, V1, P439; NIEHOFF RT, 1976, J AM SOC INFORM SCI, V27, P3, DOI 10.1002/asi.4630270102; Nyce, 1991, MEMEX HYPERTEXT VANN; OVERHAGE CFJ, 1965, INTREX; Salton G, 1971, SMART RETRIEVAL SYST; SALTON G, 1983, INTRO MODERN INFORMA; Schatz B, 1996, COMPUTER, V29, P28, DOI 10.1109/2.493454; SCHATZ B, 1987, P IEEE GLOBECOM 87, P1181; SCHATZ B, BUILDING INTERSPACE; Schatz B.R., 1996, IEEE COMPUT, V29, P22; SCHATZ BR, 1994, SCIENCE, V265, P895, DOI 10.1126/science.265.5174.895; SCHATZ BR, 1989, PROCEEDINGS : FIFTH INTERNATIONAL CONFERENCE ON DATA ENGINEERING, P188, DOI 10.1109/ICDE.1989.47214; SCHATZ BR, 1995, AM AGE INFORMATION F; SCHATZ BR, 1984, TMARH002487 BELLC; SUMMIT RK, 1967, P ACM NATIONAL M, P51; *U CA, 1989, 20 ANN S ARPANET U C; VANHERWINJNEN E, 1994, PRACTICAL SGML; Wells H. G., 1938, WORLD BRAIN; WILKS Y, 1996, COMMUN ACM, V39; WILLIAMS ME, 1986, J AM SOC INFORM SCI, V37, P204; WILLIAMS ME, 1985, SCIENCE, V228, P445, DOI 10.1126/science.3885395; [No title captured]	43	74	81	2	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					327	334		10.1126/science.275.5298.327	http://dx.doi.org/10.1126/science.275.5298.327			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WC873	8994022				2022-12-28	WOS:A1997WC87300033
J	Abbott, LF; Varela, JA; Sen, K; Nelson, SB				Abbott, LF; Varela, JA; Sen, K; Nelson, SB			Synaptic depression and cortical gain control	SCIENCE			English	Article							NEOCORTEX	Cortical neurons receive synaptic inputs from thousands of afferents that fire action potentials at rates ranging from less than 1 hertz to more than 200 hertz. Both the number of afferents and their large dynamic range can mask changes in the spatial and temporal pattern of synaptic activity, limiting the ability of a cortical neuron to respond to its inputs. Modeling work based on experimental measurements indicates that short-term depression of intracortical synapses provides a dynamic gain-control mechanism that allows equal percentage rate changes on rapidly and slowly firing afferents to produce equal postsynaptic responses. Unlike inhibitory and adaptive mechanisms that reduce responsiveness to all inputs, synaptic depression is input-specific, reading to a dramatic increase in the sensitivity of a neuron to subtle changes in the firing patterns of its afferents.	BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254	Brandeis University	Abbott, LF (corresponding author), BRANDEIS UNIV,VOLEN CTR,WALTHAM,MA 02254, USA.			Nelson, Sacha/0000-0002-0108-8599				Abbott L. F., 1996, Society for Neuroscience Abstracts, V22, P952; ARONIADOU VA, 1991, BRAIN RES, V562, P136, DOI 10.1016/0006-8993(91)91197-9; Barlow HB, 1989, NEURAL COMPUT, V1, P412, DOI 10.1162/neco.1989.1.3.412; Barlow HB, 1989, NEURAL COMPUT, V1, P295, DOI 10.1162/neco.1989.1.3.295; deCharms RC, 1996, NATURE, V381, P610, DOI 10.1038/381610a0; DEISZ RA, 1989, J PHYSIOL-LONDON, V412, P513, DOI 10.1113/jphysiol.1989.sp017629; FECHNER GT, 1880, ELEMENTE PSYCHOPHYSI; Gawne TJ, 1996, CEREB CORTEX, V6, P482, DOI 10.1093/cercor/6.3.482; GAWNE TJ, 1993, J NEUROSCI, V13, P2758; Hess G, 1996, J NEUROPHYSIOL, V75, P1765, DOI 10.1152/jn.1996.75.5.1765; MAGLEBY KL, 1982, J GEN PHYSIOL, V80, P613, DOI 10.1085/jgp.80.4.613; Markram H, 1996, NATURE, V382, P807, DOI 10.1038/382807a0; Nelson S. B., 1993, Society for Neuroscience Abstracts, V19, P629; Nelson S. B., 1996, Society for Neuroscience Abstracts, V22, P952; NELSON SB, 1996, IN PRESS P COMP NEUR; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; SOFTKY WR, 1992, NEURAL COMPUT, V4, P643, DOI 10.1162/neco.1992.4.5.643; SOFTKY WR, 1993, J NEUROSCI, V13, P334; Stratford KJ, 1996, NATURE, V382, P258, DOI 10.1038/382258a0; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X; TROYER TW, IN PRESS NEURAL COMP; Tsodyks M., 1995, NETWORK, V6, P1; TSODYKS MV, 1996, LECT NOTES COMPUTER, P445; TSODYKS MV, IN PRESS P NATL ACAD; [No title captured]	25	1167	1180	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					220	224						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985017				2022-12-28	WOS:A1997WC02200041
J	Aichbichler, BW; Zerr, CH; SantaAna, CA; Porter, JL; Fordtran, JS				Aichbichler, BW; Zerr, CH; SantaAna, CA; Porter, JL; Fordtran, JS			Proton-pump inhibition of gastric chloride secretion in congenital chloridorrhea	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIARRHEA		BAYLOR UNIV,MED CTR,DEPT INTERNAL MED,DALLAS,TX 75246; COLUMBIA INDEPENDENCE REG HLTH CTR,INDEPENDENCE,MO	Baylor University; Baylor University Medical Center					NIDDK NIH HHS [5-R01-DK37172-05] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037172] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIEBERDORF FA, 1972, J CLIN INVEST, V51, P1058; BROCKLEHURST JR, 1978, MED J AUSTRALIA, V1, P504; Chaptal J, 1967, Ann Pediatr (Paris), V14, P326; DARROW DC, 1945, J PEDIATR-US, V26, P519, DOI 10.1016/S0022-3476(45)80079-3; DAVIS GR, 1980, J CLIN INVEST, V66, P1326, DOI 10.1172/JCI109985; EVANSON JM, 1965, GUT, V6, P29, DOI 10.1136/gut.6.1.29; FELDMAN M, 1991, AM J PHYSIOL, V261, pG320, DOI 10.1152/ajpgi.1991.261.2.G320; FORDTRAN JS, 1973, J CLIN INVEST, V52, P645, DOI 10.1172/JCI107226; GAMBLE JL, 1945, J PEDIATR-US, V26, P509, DOI 10.1016/S0022-3476(45)80078-1; GORDEN P, 1973, ANN INTERN MED, V78, P876, DOI 10.7326/0003-4819-78-6-876; HOGLUND P, 1995, AM J HUM GENET, V57, P95; HOGLUND P, 1994, AM J HUM GENET, V55, P747; HOLMBERG C, 1975, J CLIN INVEST, V56, P302, DOI 10.1172/JCI108094; HOLMBERG C, 1977, ARCH DIS CHILD, V52, P255, DOI 10.1136/adc.52.4.255; HOLMBERG C, 1977, J PEDIATR-US, V91, P738, DOI 10.1016/S0022-3476(77)81026-3; Jeune M, 1967, Pediatrie, V22, P663; MAYATEPEK E, 1992, J PEDIATR GASTR NUTR, V14, P319, DOI 10.1097/00005176-199204000-00014; MINFORD AMB, 1980, ARCH DIS CHILD, V55, P70, DOI 10.1136/adc.55.1.70; NORIO R, 1971, Clinical Genetics, V2, P182; OWEN GM, 1964, J PEDIATR-US, V65, P849, DOI 10.1016/S0022-3476(64)80007-X; PASTERNA.A, 1966, LANCET, V2, P1047; PASTERNA.A, 1967, ACTA ENDOCRINOL-COP, V55, P1; PEARSON AJG, 1973, Q J MED, V42, P453; PERHEENTUPA J., 1965, ACTA PAEDIAT SCAND, VSuppl. 159, P119; RASKMADSEN J, 1976, SCAND J GASTROENTERO, V11, P377; ROSE NC, 1992, AM J PERINAT, V9, P398, DOI 10.1055/s-2007-999274; SCHILLER LR, 1982, J CLIN INVEST, V70, P999, DOI 10.1172/JCI110711; SOERGEL KH, 1969, GASTROINTESTINAL MOT, P81; TURNBERG LA, 1971, GUT, V12, P544, DOI 10.1136/gut.12.7.544; YSSING M, 1966, ACTA PAEDIATR SCAND, V55, P341, DOI 10.1111/j.1651-2227.1966.tb17664.x	30	44	47	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1997	336	2					106	109		10.1056/NEJM199701093360205	http://dx.doi.org/10.1056/NEJM199701093360205			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC481	8988888	Bronze			2022-12-28	WOS:A1997WC48100005
J	Messler, W; Stewart, CB				Messler, W; Stewart, CB			Episodic adaptive evolution of primate lysozymes	NATURE			English	Article							POSITIVE DARWINIAN SELECTION; STOMACH LYSOZYMES; NUCLEOTIDE SUBSTITUTIONS; FOREGUT FERMENTERS; DIVERGENCE; CONVERGENCE; NUMBERS; RATES; GENE	ALTHOUGH the darwinian concept of adaptation was established nearly a century ago, it has been difficult to demonstrate rigorously that the amino-acid differences between homologous proteins from different species have adaptive significance, There are currently two major types of sequence tests for positive darwinian selection on proteins from different species: sequence convergence, and neutral rate violation (reviewed in ref. 1). Lysozymes from the stomachs of cows and langur monkeys, two mammalian species displaying fermentation in the foregut, are an example(2,3) of amino-acid sequence convergence among homologous proteins(4,6). Here we combine tests of neutral rate violation with reconstruction of ancestral sequences to document an episode of positive selection on the lineage leading to the common ancestor of the foregut-fermenting colobine monkeys. This analysis also detected a previously unsuspected adaptive episode on the lineage leading to the common ancestor of the modern hominoid lysozymes. Both adaptive episodes were followed by episodes of negative selection. Thus this approach can detect adaptive and purifying episodes, and localize them to specific lineages during protein evolution.	SUNY ALBANY,DEPT BIOL SCI,ALBANY,NY 12222	State University of New York (SUNY) System; State University of New York (SUNY) Albany								Ausubel FM, 1988, MOL REPROD DEV; CHIVERS DJ, 1980, J MORPHOL, V166, P337, DOI 10.1002/jmor.1051660306; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Delson Eric, 1994, P11; DOBSON DE, 1984, J BIOL CHEM, V259, P1607; Endo T, 1996, MOL BIOL EVOL, V13, P685, DOI 10.1093/oxfordjournals.molbev.a025629; Felsenstein J., 1996, PHYLIP PHYLOGENY INF; Gillespie J.H., 1992, CAUSES MOL EVOLUTION; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; IRWIN DM, 1990, J BIOL CHEM, V265, P4944; JOLIES J, 1989, J MOL EVOL, V28, P528; KREITMAN M, 1995, ANNU REV ECOL SYST, V26, P403, DOI 10.1146/annurev.es.26.110195.002155; Kumar S., 1993, MEGA MOL EVOLUTIONAR; LEE Y, 1992, BIOL BULL, V182, P97, DOI 10.2307/1542183; LI WH, 1985, MOL BIOL EVOL, V2, P150; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; LI WH, 1991, FUNDAMENTALS MOL EVO; MADDISON WP, 1994, MACCRADE ANAL PHYLOG; NEI M, 1986, MOL BIOL EVOL, V3, P418; NEI M, 1989, MOL BIOL EVOL, V6, P290; Nei M., 1987, MOL EVOLUTIONARY GEN; STEWART CB, 1987, NATURE, V330, P401, DOI 10.1038/330401a0; STEWART CB, 1987, COLD SPRING HARB SYM, V52, P891, DOI 10.1101/SQB.1987.052.01.097; STEWART CB, 1986, LYSOZYME EVOLUTION O; SWANSON KW, 1991, J MOL EVOL, V33, P418, DOI 10.1007/BF02103133; SWANSON WJ, 1995, P NATL ACAD SCI USA, V92, P4957, DOI 10.1073/pnas.92.11.4957; SWOFFORD DL, IN PRESS PAUP PHYLOG; WOLFE KH, 1993, J MOL EVOL, V37, P441, DOI 10.1007/BF00178874; YANG ZH, 1995, GENETICS, V141, P1641; Yu M, 1996, MOL PHYLOGENET EVOL, V5, P298, DOI 10.1006/mpev.1996.0025	30	336	377	0	59	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1997	385	6612					151	154		10.1038/385151a0	http://dx.doi.org/10.1038/385151a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WB728	8990116				2022-12-28	WOS:A1997WB72800052
J	Ramsay, LE				Ramsay, LE			The hypertension detection and follow-up program - 17 years on	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MILD HYPERTENSION; BLOOD-PRESSURE; MANAGEMENT; REDUCTION; DISEASE; TRIALS				Ramsay, LE (corresponding author), ROYAL HALLAMSHIRE HOSP, DEPT MED & PHARMACOL, SECT CLIN PHARMACOL & THERAPEUT, L FLOOR, GLOSSOP RD, SHEFFIELD S10 2JF, S YORKSHIRE, ENGLAND.							[Anonymous], 1982, NEW ENGL J MED, V307, P976; [Anonymous], 1984, ARCH INTERN MED, V144, P1045; [Anonymous], 1980, LANCET, V1, P1261; [Anonymous], 1982, JAMA-J AM MED ASSOC, V247, P633; BLAUFOX MD, 1986, J HYPERTENS, V4, pS541; BORHANI NO, 1983, NEW ENGL J MED, V308, P524; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; *COR SERV COMM, 1995, GUID MAN MIDL RAIS B; EGGER M, 1995, J HYPERTENS, V13, P813, DOI 10.1097/00004872-199507000-00014; Fahey TP, 1996, BMJ-BRIT MED J, V313, P93, DOI 10.1136/bmj.313.7049.93; FREIS ED, 1982, NEW ENGL J MED, V307, P306; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GOVE S, 1983, NEW ENGL J MED, V308, P524; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HAMPTON JR, 1986, J HYPERTENS, V4, pS528; HARDY RJ, 1983, AM J EPIDEMIOL, V117, P566, DOI 10.1093/oxfordjournals.aje.a113579; HOES AW, 1995, J HYPERTENS, V13, P805; *HYP DET FOLL UP P, 1979, JAMA-J AM MED ASSOC, V242, P2562; Hypertension Detection and Follow-Up Program Cooperative Group, 1984, HYPERTENSION S1, V6; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; JOHANNESSON M, 1995, PHARMACOECONOMICS, V7, P242, DOI 10.2165/00019053-199507030-00008; KASS EH, 1982, BRIT J CLIN PHARMACO, V13, P81; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; LANGFORD HG, 1986, J HYPERTENS, V4, pS533; MADHAVAN S, 1981, ARCH INTERN MED, V141, P1583, DOI 10.1001/archinte.141.12.1583; MAXWELL MH, 1985, J CARDIOVASC PHARM, V7, pS5, DOI 10.1097/00005344-198507002-00002; MCALISTER NH, 1983, JAMA-J AM MED ASSOC, V249, P379, DOI 10.1001/jama.249.3.379; Moser M, 1996, J AM COLL CARDIOL, V27, P1214, DOI 10.1016/0735-1097(95)00606-0; MOSER M, 1986, AM J MED, V80, P1, DOI 10.1016/0002-9343(86)90845-4; MOSER M, 1985, J HYPERTENS, V3, P437; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; PEART WS, 1988, BRIT MED J, V296, P1565; PERRY HM, 1985, AM J CARDIOL, V56, pH75, DOI 10.1016/0002-9149(85)90548-X; PICKERING TG, 1983, JAMA-J AM MED ASSOC, V249, P399, DOI 10.1001/jama.249.3.399; RAMSAY LE, 1985, J HYPERTENS, V3, P449; RAMSAY LE, IN PRESS J HYPERTENS; RELMAN AS, 1980, NEW ENGL J MED, V302, P293, DOI 10.1056/NEJM198001313020511; WEBER MA, 1993, ARCH INTERN MED, V153, P149, DOI 10.1001/archinte.153.2.149; 1979, JAMA-J AM MED ASSOC, V242, P2572	40	12	13	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1997	277	2					167	170						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA650	8990345				2022-12-28	WOS:A1997WA65000040
J	Freeman, SM; Ramesh, R; Marrogi, AJ				Freeman, SM; Ramesh, R; Marrogi, AJ			Immune system in suicide-gene therapy	LANCET			English	Editorial Material							REGRESSION				Freeman, SM (corresponding author), TULANE UNIV,SCH MED,DEPT PATHOL,NEW ORLEANS,LA 70112, USA.							CARUSO M, 1993, P NATL ACAD SCI USA, V90, P7024, DOI 10.1073/pnas.90.15.7024; FREEMAN SM, 1993, CANCER RES, V53, P5274; FREEMAN SM, 1995, CANCER LETT, V92, P167, DOI 10.1016/0304-3835(95)03771-N; Freeman SM, 1996, SEMIN ONCOL, V23, P31; Freeman SM, 1992, HUM GENE THER, V3, P342; GANGANDEEP S, IN PRESS CANC GENE T; Ramesh R, 1996, EXP HEMATOL, V24, P829; RAMESH R, IN PRESS CANC GENE T; SANTODONATO L, 1996, HUM GENE THER, V7, P10; VILE RG, 1994, CANCER RES, V54, P6228	10	122	134	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					2	3		10.1016/S0140-6736(97)22001-5	http://dx.doi.org/10.1016/S0140-6736(97)22001-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988108				2022-12-28	WOS:A1997WA72500002
J	Huberman, BA; Lukose, RM; Hogg, T				Huberman, BA; Lukose, RM; Hogg, T			An economics approach to hard computational problems	SCIENCE			English	Article							CONSTRAINT SATISFACTION	A general method for combining existing algorithms into new programs that are unequivocally preferable to any of the component algorithms is presented. This method, based on notions of risk in economics, offers a computational portfolio design procedure that can be used for a wide range of problems. Tested by solving a canonical NP-complete problem, the method can be used for problems ranging from the combinatorics of DNA sequencing to the completion of tasks in environments with resource contention, such as the World Wide Web.			Huberman, BA (corresponding author), XEROX CORP, PALO ALTO RES CTR, DYNAM COMPUTAT GRP, 3333 COYOTE HILL RD, PALO ALTO, CA 94304 USA.							ALDOUS D, 1994, AN S FDN CO, P492, DOI 10.1109/SFCS.1994.365742; ALIZADEH F, 1994, 5TH P ANN ACM SIAM S, P489; ALT H, 1991, TR91057 INT COMP SCI; BOYER M, IN PRESS P WORKSH PH; CESABIANCHI N, 1993, 25TH P ANN ACM S THE, P382; CLEARWATER SH, 1991, SCIENCE, V254, P1181, DOI 10.1126/science.254.5035.1181; ERTEL W, 1992, LECT NOTES ARTIF INT, V590, P195; Garey M. R., 1970, COMPUTERS INTRACTABI; Gent IP, 1996, ARTIF INTELL, V81, P59, DOI 10.1016/0004-3702(95)00047-X; Grover L. K., 1996, Proceedings of the Twenty-Eighth Annual ACM Symposium on the Theory of Computing, P212, DOI 10.1145/237814.237866; HOGG T, 1994, PROCEEDINGS OF THE TWELFTH NATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE, VOLS 1 AND 2, P331; Hogg T, 1996, ARTIF INTELL, V81, P1, DOI 10.1016/0004-3702(95)00044-5; HOGG T, 1993, PROCEEDINGS OF THE ELEVENTH NATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE, P231; JOHNSON DS, 1991, OPER RES, V39, P378, DOI 10.1287/opre.39.3.378; LUBY M, 1993, TR93010 INT COMP SCI; LUBY M, 1993, TR93041 INT COMP SCI; Markowitz H, 1952, J FINANC, V7, P77, DOI 10.1111/j.1540-6261.1952.tb01525.x; Mezard M., 1987, WORLD SCI LECT NOT P, V9; MINTON S, 1992, ARTIF INTELL, V58, P161, DOI 10.1016/0004-3702(92)90007-K; Motwani R., 1995, RANDOMIZED ALGORITHM; REINELT G, 1994, LECT NOTES COMPUTER, V840; ROUMELIOTIS G, UNPUB; Selman B, 1996, ARTIF INTELL, V81, P273, DOI 10.1016/0004-3702(95)00056-9; Selman B., 1992, P 10 NAT C ART INT A, P440; SHARPE WF, 1987, PORTFOLIO THEORY CAP	26	206	211	2	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					51	54		10.1126/science.275.5296.51	http://dx.doi.org/10.1126/science.275.5296.51			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WA903	8974387				2022-12-28	WOS:A1997WA90300043
J	Dorsky, RI; Chang, WS; Rapaport, DH; Harris, WA				Dorsky, RI; Chang, WS; Rapaport, DH; Harris, WA			Regulation of neuronal diversity in the Xenopus retina by Delta signalling	NATURE			English	Article							CELL-FATE; DROSOPHILA EYE; FROG RETINA; IN-VITRO; NOTCH; DIFFERENTIATION; NEUROGENESIS; EXPRESSION; PHOTORECEPTORS; PROGENITORS	To generate the variety of mature neurons and glia found in the developing retina, the competence of pluripotent progenitor cells to respond to extracellular signals must be controlled. Delta, a ligand of the Notch receptor, is a candidate for regulating progenitor competence on the grounds that activation of the pathway involving Notch and Delta can inhibit cellular differentiation(1-6). Here we test this possibility in the developing Xenopus retina by misexpression of Delta messenger RNA. We find that Delta-misexpressing cells with wild-type neighbours adopt earlier fates, primarily becoming ganglion cells and cone photoreceptors. Progenitors transfected with Delta later in development also produce rod photoreceptors, but not the latest-generated cell types, demonstrating the importance of timing in Delta function. We conclude that Delta signalling in the vertebrate retina is a basic regulatory mechanism that can be used to generate neuronal diversity.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT SURG,DIV ANAT,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego								ADLER R, 1989, SCIENCE, V243, P391, DOI 10.1126/science.2911751; ALTSHULER D, 1992, DEVELOPMENT, V114, P947; AUSTIN CP, 1995, DEVELOPMENT, V121, P3637; BeleckyAdams T, 1996, DEV BIOL, V178, P304, DOI 10.1006/dbio.1996.0220; CABRERA CV, 1990, DEVELOPMENT, V109, P733; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; DORSKY RI, 1995, NEURON, V14, P487, DOI 10.1016/0896-6273(95)90305-4; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FUHRMANN S, 1995, DEVELOPMENT, V121, P2695; HARRIS WA, 1992, NEURON, V9, P357, DOI 10.1016/0896-6273(92)90174-C; Heitzler P, 1996, DEVELOPMENT, V122, P161; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; HOLT CE, 1990, NEURON, V4, P203, DOI 10.1016/0896-6273(90)90095-W; HUANG S, 1993, J NEUROSCI, V13, P3193; KELLEY MW, 1994, DEVELOPMENT, V120, P2091; KELLEY MW, 1995, DEVELOPMENT, V121, P3777; LAVAIL MM, 1991, J COMP NEUROL, V309, P86, DOI 10.1002/cne.903090107; LILLIEN L, 1995, NATURE, V377, P158, DOI 10.1038/377158a0; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; NYE JS, 1994, DEVELOPMENT, V120, P2421; PARKS AL, 1995, MECH DEVELOP, V50, P201, DOI 10.1016/0925-4773(94)00336-L; REH TA, 1989, J NEUROSCI, V9, P4179; REH TA, 1992, J NEUROBIOL, V23, P1067, DOI 10.1002/neu.480230811; REH TA, 1987, J NEUROSCI, V7, P3317; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; Waid D. K., 1995, Society for Neuroscience Abstracts, V21, P529; WATANABE T, 1992, DEVELOPMENT, V114, P899; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732	31	231	236	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1997	385	6611					67	70		10.1038/385067a0	http://dx.doi.org/10.1038/385067a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985247				2022-12-28	WOS:A1997WA73100050
J	Hess, EJ				Hess, EJ			Migraines in mice?	CELL			English	Review							PERIODIC PARALYSIS; CALCIUM CHANNELS; MAMMALIAN CNS; MUTATIONS				Hess, EJ (corresponding author), PENN STATE UNIV,COLL MED,DEPT ANAT & NEUROSCI,HERSHEY,PA 17033, USA.							BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CUMMINS TR, 1993, NEURON, V10, P667, DOI 10.1016/0896-6273(93)90168-Q; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; GRIGGS RC, 1995, ANN NEUROL, V37, P285, DOI 10.1002/ana.410370302; LLINAS R, 1989, ANN NY ACAD SCI, V560, P1203; NOEBELS JL, 1979, SCIENCE, V204, P1334, DOI 10.1126/science.572084; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; PEREZREYES E, 1995, KIDNEY INT, V48, P1111, DOI 10.1038/ki.1995.395; PTACEK LJ, 1994, CELL, V77, P863; Sidman RL., 1965, CATALOG NEUROLOGICAL, DOI [10.4159/harvard.9780674424326, DOI 10.4159/HARVARD.9780674424326]; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; Volsen SG, 1995, MOL BRAIN RES, V34, P271, DOI 10.1016/0169-328X(95)00234-J; Wheeler DB, 1995, PROG BRAIN RES, V105, P65; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	15	22	22	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1149	1151		10.1016/S0092-8674(00)81809-7	http://dx.doi.org/10.1016/S0092-8674(00)81809-7			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980220	Bronze			2022-12-28	WOS:A1996WA54100002
J	Nitta, AT; Davidson, PT; deKoning, ML; Kilman, RJ				Nitta, AT; Davidson, PT; deKoning, ML; Kilman, RJ			Misdiagnosis of multidrug-resistant tuberculosis possibly due to laboratory-related errors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYCOBACTERIUM-TUBERCULOSIS	Objective.-To describe 9 cases where a misdiagnosis of multidrug-resistant tuberculosis (MDR TB) was made, possibly due to laboratory-related errors. Design.-Case series. Setting.-Public and private hospitals, outpatient clinics, and mycobacteriology laboratories serving those institutions in Los Angeles County, Calif. Patients.-Consecutive sample of 70 patients diagnosed with MDR TB who were identified between August 1993 and August 1994 by the Multidrug-Resistant Unit within TB Control in Los Angeles County. Outcome Measure.-Detection of laboratory-related diagnostic errors. Results.-Pulmonary MDR TB was misdiagnosed in 9 (13%) of 70 patients. Reasons why the diagnoses appeared to be erroneous are as follows. growth of MDR TB from an old tuberculous lesion in a patient who was never treated for TB and whose diagnosis predated anti-TB drugs (1 case), documented contamination with Mycobacterium avium complex (1 case), suspected cross-contamination (1 case), suspected specimen mislabeling (1 case), successful treatment using drugs to which the isolate was reportedly resistant (4 cases), discrepant susceptibility test results on additional sputum specimens submitted by the patient (2 cases), and no clinical evidence of TB (3 cases). Conclusions.-These cases emphasize the diagnostic errors that can occur if mycobacterial susceptibility results are not correlated with all clinical data including other laboratory results for a given patient. We conclude that susceptibility results alone are not enough to dictate treatment, and that careful clinical correlation is necessary in making the diagnosis of MDR TB.	UNIV CALIF LOS ANGELES,SCH MED,HARBORVIEW MED CTR,DEPT MED,LOS ANGELES,CA; UNIV SO CALIF,DEPT MED,LOS ANGELES,CA; LOS ANGELES CTY DEPT HLTH SERV,PUBL HLTH PROGRAMS & SERV,PUBL HLTH LAB,LOS ANGELES,CA 90007	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Southern California	Nitta, AT (corresponding author), LOS ANGELES CTY DEPT HLTH SERV,PUBL HLTH PROGRAMS & SERV,TB CONTROL,2615 S GRAND AVE,ROOM 507,LOS ANGELES,CA 90007, USA.							BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BUTLER WR, 1994, J CLIN MICROBIOL, V32, P536, DOI 10.1128/JCM.32.2.536-538.1994; DESPOSO ND, 1982, AM REV RESPIR DIS, V125, P85; DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257; DUNLAP NE, 1995, AM J RESP CRIT CARE, V152, P1702, DOI 10.1164/ajrccm.152.5.7582316; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; HEWLETT D, 1995, JAMA-J AM MED ASSOC, V273, P916, DOI 10.1001/jama.273.12.916; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002; NOORDHOEK GT, 1994, J CLIN MICROBIOL, V32, P277, DOI 10.1128/JCM.32.2.277-284.1994; SCHLUGER NW, 1994, CHEST, V105, P1116, DOI 10.1378/chest.105.4.1116; TENOVER FC, 1993, J CLIN MICROBIOL, V31, P767, DOI 10.1128/JCM.31.4.767-770.1993; VARELDZIS BP, 1994, TUBERCLE LUNG DIS, V75, P1, DOI 10.1016/0962-8479(94)90096-5	13	29	30	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1996	276	24					1980	1983		10.1001/jama.276.24.1980	http://dx.doi.org/10.1001/jama.276.24.1980			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY689	8971069				2022-12-28	WOS:A1996VY68900032
J	Hardarson, T; Snorradottir, E				Hardarson, T; Snorradottir, E			Egil's or Paget's disease?	BRITISH MEDICAL JOURNAL			English	Article											Hardarson, T (corresponding author), UNIV HOSP,LANDSPITALINN,DEPT MED,IS-101 REYKJAVIK,ICELAND.							HAMPERL H, 1960, LEHRBUCH ALLGEMEINEN, P688; Palsson Hermann, 1976, EGILS SAGA	2	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1613	1614		10.1136/bmj.313.7072.1613	http://dx.doi.org/10.1136/bmj.313.7072.1613			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991006	Green Published			2022-12-28	WOS:A1996VZ81100037
J	Katan, MB; vantVeer, P				Katan, MB; vantVeer, P			Nutrition - But is it food?	LANCET			English	Article											Katan, MB (corresponding author), AGR UNIV WAGENINGEN, DEPT HUMAN NUTR & EPIDEMIOL, BOMENWEG 2, NL-6703 HD WAGENINGEN, NETHERLANDS.							Hunter DJ, 1996, NEW ENGL J MED, V334, P356, DOI 10.1056/NEJM199602083340603; MIETTINEN TA, 1995, NEW ENGL J MED, V333, P1308, DOI 10.1056/NEJM199511163332002; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Urgert R, 1996, BRIT MED J, V313, P1362, DOI 10.1136/bmj.313.7069.1362	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	1996	348			2			SII15	SII15						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973493				2022-12-28	WOS:A1996WA46300015
J	Henningfield, JE; Hariharan, M; Kozlowski, LT				Henningfield, JE; Hariharan, M; Kozlowski, LT			Nicotine content and health risks of cigars	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CIGARETTES; SMOKERS		UNIV MICHIGAN,SCH MED,DEPT PSYCHIAT,ANN ARBOR,MI; PENN STATE UNIV,COLL HLTH & HUMAN DEV,DEPT BIOBEHAV HLTH,UNIVERSITY PK,PA 16802	University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Henningfield, JE (corresponding author), NATL INST DRUG ABUSE,INTRAMURAL RES PROGRAM,BALTIMORE,MD 21224, USA.							BENOWITZ NL, 1994, NEW ENGL J MED, V331, P123, DOI 10.1056/NEJM199407143310212; GOTTSCHO AM, 1988, J ASSOC OFF ANA CHEM, V71, P1110; HARIHARAN M, 1991, CLIN CHEM, V37, P1276; HENNINGFIELD JE, 1994, JAMA-J AM MED ASSOC, V272, P312, DOI 10.1001/jama.272.4.312; Henningfield JE, 1995, TOB CONTROL, V4, P57, DOI DOI 10.1136/TC.4.1.57; HERLING S, 1988, PREV MED, V17, P73, DOI 10.1016/0091-7435(88)90073-4; OCKENE JK, 1987, AM J PUBLIC HEALTH, V77, P1412, DOI 10.2105/AJPH.77.11.1412; PETO R, 1994, MORTALITY SMOKING; *US DHHS, 1983, HLTH CONSEQUENCES SM; *US DHHS, 1984, HLTH CONSEQUENCES SM; *US DHHS, 1982, HLTH CONSEQUENCES SM; *US DHHS, 1988, HLTH CONSEQUENCES SM	12	25	25	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1996	276	23					1857	1858		10.1001/jama.1996.03540230007003	http://dx.doi.org/10.1001/jama.1996.03540230007003			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX522	8967995				2022-12-28	WOS:A1996VX52200002
J	Davies, E; Clarke, C; Hopkins, A				Davies, E; Clarke, C; Hopkins, A			Malignant cerebral glioma .1. Survival, disability, and morbidity after radiotherapy	BRITISH MEDICAL JOURNAL			English	Article							COST-BENEFIT-ANALYSIS; RADIATION-THERAPY; BRAIN; IRRADIATION; MANAGEMENT; TRIAL; ASTROCYTOMAS; SURGERY; GRADE-3; TUMORS	Objective-To describe survival, disability, and morbidity after radiotherapy for malignant glioma. Design-Two year prospective study with home interviews with patients and relatives. Setting-Seven neurosurgical and radiotherapy centres in London. Subjects-105 patients aged 21 to 75: 59 had biopsy; 46 had partial macroscopic resection; 92 received radiotherapy; and 13 received steroids alone. Main outcome measures-Survival, time free from disability, and changes in disability after treatment. Results-Six and 12 month survival for radiotherapy patients was 70% and 39%, respectively. Age, World Health Organisation clinical performance status, extent of surgery, and history of seizures before diagnosis each influenced survival. The Medical Research Council prognostic index was also significantly related to survival. Multivariate analysis showed that initial clinical performance status was the most important component of the index. Most (80%; 49/61) patients with a clinical performance status of 0, 1, or 2 lived at least six months before becoming permanently disabled. Most patients who had initially had a good clinical performance status (0-2) and who were alive six months after radiotherapy (68%; 36/52), however, had experienced either clinical deterioration or severe tiredness after treatment. In 17% (9/52) of these some permanent loss of function remained. These adverse effects were associated with increasing radiotherapy dose. Severely disabled patients (clinical performance status 3 or 4) gained little benefit. Conclusion-Severely disabled patients gain little physical benefit from radiotherapy, whereas those not so disabled may experience considerable adverse effects.	UNIV LONDON ST BARTHOLOMEWS HOSP MED COLL,DIRECTORATE NEUROSURG & CLIN NEUROSCI,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London	Davies, E (corresponding author), ROYAL COLL PHYSICIANS,RES UNIT,LONDON NW1 4LE,ENGLAND.			Davies, Elizabeth/0000-0003-2325-0849				BLEEHEN NM, 1991, BRIT J CANCER, V64, P769, DOI 10.1038/bjc.1991.396; BRADA M, 1989, BRIT J CANCER, V60, P1, DOI 10.1038/bjc.1989.207; BURGER PC, 1987, CANCER, V59, P1617, DOI 10.1002/1097-0142(19870501)59:9<1617::AID-CNCR2820590916>3.0.CO;2-X; CHANG CH, 1983, CANCER, V52, P997, DOI 10.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-2; CHOUCAIR AK, 1990, J NATL CANCER I, V82, P531, DOI 10.1093/jnci/82.6.531; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; Davies E, 1996, BMJ-BRIT MED J, V313, P1512, DOI 10.1136/bmj.313.7071.1512; FAITHFULL S, 1991, J ADV NURS, V16, P936; FREEMAN JE, 1973, BRIT MED J, V4, P523, DOI 10.1136/bmj.4.5891.523; GIBBERD FB, 1983, J NEUROL NEUROSUR PS, V46, P460, DOI 10.1136/jnnp.46.5.460; GREEN SB, 1983, CANCER TREAT REP, V67, P121; HUTTON JL, 1992, J NEUROL NEUROSUR PS, V55, P271, DOI 10.1136/jnnp.55.4.271; KRISTIANSEN K, 1981, CANCER, V47, P649, DOI 10.1002/1097-0142(19810215)47:4<649::AID-CNCR2820470405>3.0.CO;2-W; LEIBEL SA, 1987, J NEUROSURG, V66, P1, DOI 10.3171/jns.1987.66.1.0001; MAHONEY F I, 1965, Md State Med J, V14, P61; MCKERAN RO, 1980, BRAIN TUMOURS SCI BA, P194; MRC Brain Tumour Working Party, 1990, J NEUROONCOL, V9, P47; Nouri F., 1987, CLIN REHABIL, V1, P301, DOI [DOI 10.1177/026921558700100409, 10.1177/026921558700100409]; PICKARD JD, 1990, BRIT MED J, V301, P629, DOI 10.1136/bmj.301.6753.629; ROBINSON R, 1993, BRIT MED J, V307, P924, DOI 10.1136/bmj.307.6909.924; *ROYAL COLL PHYS, 1992, STAND ASS SCAL ELD; SHELINE GE, 1980, INT J RADIAT ONCOL, V6, P1215, DOI 10.1016/0360-3016(80)90175-3; Thomas D G, 1989, Br J Neurosurg, V3, P321, DOI 10.3109/02688698909002810; TODD NV, 1987, LANCET, V1, P611; VALK PE, 1991, AM J ROENTGENOL, V156, P689; WALKER MD, 1978, J NEUROSURG, V49, P333, DOI 10.3171/jns.1978.49.3.0333; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; WARA WM, 1991, COMPLICATIONS CANC M; WHITTLE IR, 1991, SURG NEUROL, V36, P106, DOI 10.1016/0090-3019(91)90227-Z; WHO, 1979, WHO HDB REP RES CANC; WROE SJ, 1986, BRIT MED J, V293, P1015, DOI 10.1136/bmj.293.6553.1015	31	42	42	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1996	313	7071					1507	1512		10.1136/bmj.313.7071.1507	http://dx.doi.org/10.1136/bmj.313.7071.1507			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY691	8978224	Green Published			2022-12-28	WOS:A1996VY69100016
J	McLellan, MF				McLellan, MF			Literature and medicine: The patient, the physician, and the poem	LANCET			English	Article									UNIV TEXAS,MED BRANCH,INST MED HUMANITIES,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston	McLellan, MF (corresponding author), UNIV TEXAS,MED BRANCH,DEPT ANESTHESIOL,GALVESTON,TX 77555, USA.			McLellan, Faith/0000-0003-0744-1450				Butow PN, 1996, CANCER-AM CANCER SOC, V77, P2630, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2630::AID-CNCR29>3.3.CO;2-K; CLEMENCEAU G, 1985, MONET RETROSPECTIVE, P350; CLEMENCEAU G, 1985, MONET RETROSPECTIVE, P175; ELLIOTT DB, 1993, OPHTHAL PHYSL OPT, V13, P82, DOI 10.1111/j.1475-1313.1993.tb00430.x; KAHN G, 1985, MONET RETROSPECTIVE, P225; MELEIS AI, 1983, WESTERN J MED, V138, P889; MONET C, 1966, COMMUNICATION, P379; PAULETTE L, 1993, HUM MED, V9, P13; Phillips RS, 1996, AM J MED, V100, P128, DOI 10.1016/S0002-9343(97)89450-8; Ravin J G, 1994, J Ophthalmic Nurs Technol, V13, P217; RAVIN JG, 1985, JAMA-J AM MED ASSOC, V354, P394; Sacks O, 1985, MAN WHO MISTOOK HIS, P87; SEITZ WC, C MONET	13	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1640	1641		10.1016/S0140-6736(96)09333-6	http://dx.doi.org/10.1016/S0140-6736(96)09333-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	VX876	8984308				2022-12-28	WOS:A1996VX87600023
J	Niessen, LC				Niessen, LC			Pericoronitis as a cause of tonsillitis	LANCET			English	Article											Niessen, LC (corresponding author), TEXAS A&M UNIV,BAYLOR COLL DENT,DEPT PUBL HLTH SCI,DALLAS,TX 75246, USA.							KRUGER GO, 1984, TXB ORAL SURG, P198; MOMBELLI A, 1990, J CLIN PERIODONTOL, V17, P48, DOI 10.1111/j.1600-051X.1990.tb01047.x; NITZAN DW, 1985, J ORAL MAXIL SURG, V43, P510, DOI 10.1016/S0278-2391(85)80029-X; Rajasuo A, 1996, CLIN INFECT DIS, V23, P51, DOI 10.1093/clinids/23.1.51; TOPAZIAN RG, 1994, ORAL MAXILLOFACIAL I, P309; WADE WG, 1991, ORAL MICROBIOL IMMUN, V6, P310, DOI 10.1111/j.1399-302X.1991.tb00499.x	6	3	4	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1602	1603		10.1016/S0140-6736(05)65690-5	http://dx.doi.org/10.1016/S0140-6736(05)65690-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8961986				2022-12-28	WOS:A1996VX87600005
J	Bhat, MA; Philp, AV; Glover, DM; Bellen, HJ				Bhat, MA; Philp, AV; Glover, DM; Bellen, HJ			Chromatid segregation at anaphase requires the barren product, a novel chromosome-associated protein that interacts with topoisomerase II	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; DROSOPHILA CYCLIN-A; CELL-CYCLE; NEURONAL PRECURSORS; MITOSIS; MELANOGASTER; GENE; EMBRYOGENESIS; MUTATIONS; PROGRESSION	We have isolated a Drosophila gene, barren (barr), required for sister-chromatid segregation in mitosis. barr encodes a novel protein that is present in proliferating cells and has homologs in yeast and human. Mitotic defects in barr embryos become apparent during cycle 16, resulting in a loss of PNS and CNS neurons. Centromeres move apart at the metaphase-anaphase transition and Cyclin B is degraded, but sister chromatids remain connected, resulting in chromatin bridging. This phenotype is similar to that described in TOP2 mutants in yeast. Barren protein localizes to chromatin throughout mitosis. Colocalization and biochemical experiments indicate that Barren associates with Topoisomerase II throughout mitosis and alters the activity of Topoisomerase II. We propose that this association is required for proper chromosomal segregation by facilitating the decatenation of chromatids at anaphase.	UNIV DUNDEE,DEPT ANAT & PHYSIOL,CRC,CELL CYCLE GENET GRP,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	Bhat, MA (corresponding author), BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030, USA.		; BHAT, MANZOOR/S-9273-2018	Bellen, Hugo/0000-0001-5992-5989; Glover, David/0000-0003-0956-0103; BHAT, MANZOOR/0000-0003-0989-1498				AULT JG, 1994, CURR OPIN CELL BIOL, V6, P41, DOI 10.1016/0955-0674(94)90114-7; BELLEN HJ, 1992, GENE DEV, V6, P2125, DOI 10.1101/gad.6.11.2125; BUCHENAU P, 1993, J CELL SCI, V104, P1175; BYERS TJ, 1987, J CELL BIOL, V105, P2103, DOI 10.1083/jcb.105.5.2103; CARMENA M, 1993, J CELL SCI, V105, P41; DANDREA RJ, 1993, MOL BIOL CELL, V4, P1161, DOI 10.1091/mbc.4.11.1161; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; KANIA A, 1995, GENETICS, V139, P1663; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KREUZER KN, 1980, CELL, V20, P245, DOI 10.1016/0092-8674(80)90252-4; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; MCINTOSH JR, 1991, COLD SH Q B, V56, P613; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MORIN N, 1994, EMBO J, V13, P4343, DOI 10.1002/j.1460-2075.1994.tb06754.x; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cellbio.1.1.289; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; PHILP AV, 1993, J CELL SCI, V106, P87; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; RICHARDSON HE, 1993, DEVELOPMENT, V119, P673; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SALZBERG A, 1994, NEURON, V13, P269, DOI 10.1016/0896-6273(94)90346-8; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Stratmann R, 1996, CELL, V84, P25, DOI 10.1016/S0092-8674(00)80990-3; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; WHALEN AM, 1991, J CELL BIOL, V112, P203, DOI 10.1083/jcb.112.2.203; WHITFIELD WGF, 1989, NATURE, V338, P337, DOI 10.1038/338337a0; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; ZIPURSKY SL, 1985, P NATL ACAD SCI USA, V82, P1855, DOI 10.1073/pnas.82.6.1855	44	243	246	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1103	1114		10.1016/S0092-8674(00)81804-8	http://dx.doi.org/10.1016/S0092-8674(00)81804-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978614	Bronze			2022-12-28	WOS:A1996VY44700015
J	Seiwert, SD				Seiwert, SD			RNA editing hints of a remarkable diversity in gene expression pathways (Reprinted)	SCIENCE			English	Reprint							MESSENGER-RNA; TRYPANOSOMA-BRUCEI; MITOCHONDRIA; GRNA; NUCLEOTIDES; INFORMATION; TRANSCRIPT; MOLECULES; DNA				Seiwert, SD (corresponding author), SEATTLE BIOMED RES INST,4 NICKERSON ST,SEATTLE,WA 98109, USA.							BASS B, 1993, RNA WORLD, P338; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; Corell RA, 1996, MOL CELL BIOL, V16, P1410; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; Kable ML, 1996, SCIENCE, V273, P1189, DOI 10.1126/science.273.5279.1189; KOSLOWSKY DJ, 1991, CELL, V67, P537, DOI 10.1016/0092-8674(91)90528-7; PILLER KJ, 1995, MOL CELL BIOL, V15, P2925; POLLARD VW, 1992, EMBO J, V11, P4429, DOI 10.1002/j.1460-2075.1992.tb05543.x; SEIWERT SD, 1994, SCIENCE, V266, P114, DOI 10.1126/science.7524149; SEIWERT SD, 1995, PARASITOL TODAY, V11, P362, DOI 10.1016/0169-4758(95)80004-2; Seiwert SD, 1996, CELL, V84, P831, DOI 10.1016/S0092-8674(00)81062-4; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; WARREN KS, 1988, BIOL PARASITISM, P2	20	2	2	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1636	1637		10.1126/science.274.5293.1636	http://dx.doi.org/10.1126/science.274.5293.1636			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8984633				2022-12-28	WOS:A1996VW71200042
J	Densmore, AL; Anderson, RS; McAdoo, BG; Ellis, MA				Densmore, AL; Anderson, RS; McAdoo, BG; Ellis, MA			Hillslope evolution by bedrock landslides	SCIENCE			English	Article							SELF-ORGANIZED CRITICALITY; SANDPILES; MODEL	Bedrock landsliding is a dominant geomorphic process in a number of high-relief landscapes, yet is neglected in landscape evolution models. A physical model of sliding in beans is presented, in which incremental lowering of one wall simulates baselevel fall and generates slides. Frequent small slides produce irregular hillslopes, on which steep toes and head scarps persist until being cleared by infrequent large slides. These steep segments are observed on hillslopes in high-relief landscapes and have been interpreted as evidence for increases in tectonic or climatic process rales. In certain cases, they may instead reflect normal hillslope evolution by landsliding.	UNIV CALIF SANTA CRUZ,DEPT EARTH SCI,SANTA CRUZ,CA 95064; UNIV MEMPHIS,CTR EARTHQUAKE RES & INFORMAT,MEMPHIS,TN 38152	University of California System; University of California Santa Cruz; University of Memphis	Densmore, AL (corresponding author), UNIV CALIF SANTA CRUZ,INST TECTON,SANTA CRUZ,CA 95064, USA.		Densmore, Alexander/A-1630-2012; Ellis, Michael/AAP-2039-2020; Ellis, Michael Alexander A/M-4505-2018	Densmore, Alexander/0000-0003-0629-6554; Ellis, Michael/0000-0002-6613-3565; Ellis, Michael Alexander A/0000-0002-6613-3565; Anderson, Robert/0000-0003-2759-4833				ANDERSON RS, 1994, J GEOPHYS RES-SOL EA, V99, P20161, DOI 10.1029/94JB00713; Arrowsmith JR, 1996, J GEOPHYS RES-SOL EA, V101, P6255, DOI 10.1029/95JB02583; AUGUSTINUS PC, 1992, EARTH SURF PROCESSES, V17, P39, DOI 10.1002/esp.3290170104; Burbank DW, 1996, NATURE, V379, P505, DOI 10.1038/379505a0; CARLSON JM, 1995, P NATL ACAD SCI USA, V92, P6712, DOI 10.1073/pnas.92.15.6712; CASHMAN SM, 1995, US GEOL SURV PROF PA, V1454, pB1; Frette V, 1996, NATURE, V379, P49, DOI 10.1038/379049a0; GIBBONS AB, 1984, GEOLOGY, V12, P327, DOI 10.1130/0091-7613(1984)12<327:POMSIA>2.0.CO;2; GRUMBACHER SK, 1993, AM J PHYS, V61, P329, DOI 10.1119/1.17264; HARBOR JM, 1992, GEOL SOC AM BULL, V104, P1364, DOI 10.1130/0016-7606(1992)104<1364:NMOTDO>2.3.CO;2; Hencher SR, 1987, SLOPE STABILITY GEOT, P145; HOVIUS N, IN PRESS GEOLOGY; HOWARD AD, 1994, WATER RESOUR RES, V30, P2261, DOI 10.1029/94WR00757; KELSEY HM, 1988, CATENA, V15, P433, DOI 10.1016/0341-8162(88)90063-X; Kirkby MJ, 1987, SLOPE STABILITY, P359; Kooi H, 1996, J GEOPHYS RES-SOL EA, V101, P3361, DOI 10.1029/95JB01861; MCADOO BG, 1996, AAPG BULL, V80, P605; MEGAHAN WF, 1978, FOREST SOILS LAND US, P116; MILLER DJ, 1993, THESIS U WASHINGTON; NELSON SW, 1993, US GEOL SURV B, V2107, P43; Pratson LF, 1996, GEOL SOC AM BULL, V108, P225, DOI 10.1130/0016-7606(1996)108<0225:AMFTHE>2.3.CO;2; ROSENDAHL J, 1993, PHYS REV E, V47, P1401, DOI 10.1103/PhysRevE.47.1401; SCHMIDT KM, 1995, SCIENCE, V270, P617, DOI 10.1126/science.270.5236.617; Selby M. J., 1993, HILLSLOPE MATERIALS; Selby M.J., 1980, Z GEOMORPHOL, V24, P31, DOI [10.1127/zfg/24/1984/31, DOI 10.1127/ZFG/24/1984/31]; SHIMAZAKI K, 1980, GEOPHYS RES LETT, V7, P279, DOI 10.1029/GL007i004p00279; STOOUT ML, 1984, GEOL SOC AM ABSTR, V16, P257; Terzaghi K., 1972, GEOTECHNIQUE, V12, P251, DOI [DOI 10.1680/GEOT.1962.12.4.251, 10.1680/geot.1962.12.4.251]; TUCKER GE, 1994, J GEOPHYS RES-SOL EA, V99, P12229, DOI 10.1029/94JB00320; WOLMAN MG, 1960, J GEOL, V68, P54, DOI 10.1086/626637; [No title captured]	31	91	94	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					369	372		10.1126/science.275.5298.369	http://dx.doi.org/10.1126/science.275.5298.369			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994029				2022-12-28	WOS:A1997WC87300040
J	Ozonoff, DM				Ozonoff, DM			Fields of controversy	LANCET			English	Editorial Material											Ozonoff, DM (corresponding author), BOSTON UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,BOSTON,MA 02130, USA.			Ozonoff, David/0000-0002-4281-4171				FEYCHTING M, 1994, EPIDEMIOLOGY, V5, P501; MOULDER JE, 1996, IEEE ENG MED BIOL, V4, P31; *NAT RES COUNC, 1996, POSS HLTH EFF EXP RE; POOLE C, 1996, IEEE ENG MED BIOL, V4, P41; Verkasalo PK, 1996, BRIT MED J, V313, P1047, DOI 10.1136/bmj.313.7064.1047; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681	6	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					74	74		10.1016/S0140-6736(05)60881-1	http://dx.doi.org/10.1016/S0140-6736(05)60881-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996415	hybrid			2022-12-28	WOS:A1997WB80000006
J	Songaila, A; Wampler, EJ; Cowie, LL				Songaila, A; Wampler, EJ; Cowie, LL			A high deuterium abundance in the early Universe	NATURE			English	Article							CLOUDS	INTERGALACTIC gas clouds at high redshifts have element abundances that are close to primordial, The ratio of deuterium to hydrogen (D/H) within such clouds-which is determined from absorption lines in the spectra of more distant quasars that lie along the same line of sight-provides the best estimate of the density of baryons (Omega(B)) in the Universe. Previous estimates of D/H in the early Universe have yielded values that differ by about an order of magnitude(1-7), with the lower values(6,7) implying a high density of baryons that may be difficult to reconcile with both estimates of the primordial abundances of other light elements (especially He-4) and the known number of light neutrinos(8-10). The accuracy of such D/H determinations is heavily dependent on the inferred column density of neutral hydrogen in the absorbing clouds, Here we report an independent measurement of the neutral hydrogen column density in the cloud towards the quasar Q1937 - 1009, for which one of the low D/H values was derived(6). Our measurement requires a substantial revision to the D/H value reported previously; we obtain a lower limit of D/H > 4 x 10(-5) for this cloud, which implies Omega(B) < 0.016 for a Hubble constant of 100 km s(-1) Mpc(-1). This reduced upper limit for the baryon density relieves any conflict with standard Big Bang nucleosynthesis(6).	NATL ASTRON OBSERV,MITAKA,TOKYO 181,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ)	Songaila, A (corresponding author), UNIV HAWAII,INST ASTRON,2680 WOODLAWN DR,HONOLULU,HI 96822, USA.							BURLES S, UNPUB SCIENCE; CARSWELL RF, 1994, MON NOT R ASTRON SOC, V268, pL1, DOI 10.1093/mnras/268.1.L1; FIELDS BD, 1996, NEW ASTRON, V1, P77; HATA N, IN PRESS PHYS REV D; MADAU P, STSC1085 SPAC TEL SC; PRESS WH, 1993, ASTROPHYS J, V414, P64, DOI 10.1086/173057; Rugers M, 1996, ASTRON J, V111, P2135, DOI 10.1086/117949; Rugers M, 1996, ASTROPHYS J, V459, pL1, DOI 10.1086/309931; SONGAILA A, 1994, NATURE, V368, P599, DOI 10.1038/368599a0; STEIGMAN G, IN PRESS CRISIS CONF; Tytler D, 1996, NATURE, V381, P207, DOI 10.1038/381207a0; TYTLER D, IN PRESS ORIGIN MATT; Wampler EJ, 1996, ASTRON ASTROPHYS, V316, P33; Wampler EJ, 1996, NATURE, V383, P308, DOI 10.1038/383308a0	14	64	64	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1997	385	6612					137	139		10.1038/385137a0	http://dx.doi.org/10.1038/385137a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WB728	8990115	Green Submitted			2022-12-28	WOS:A1997WB72800046
J	Chehab, FF; Mounzih, K; Lu, RH; Lim, ME				Chehab, FF; Mounzih, K; Lu, RH; Lim, ME			Early onset of reproductive function in normal female mice treated with leptin	SCIENCE			English	Article							WEIGHT	Numerous studies have revealed an association between nutritional status, adiposity, and reproductive maturity. The role of leptin, a hormone secreted from adipose tissue, in the onset of reproductive function was investigated. Normal prepubertal female mice injected with leptin grew at a slower rate than controls as a result of the hormone's thinning effects, but they reproduced up to 9 days earlier than controls and showed earlier maturation of the reproductive tract. These results suggest that leptin acts as a signal triggering puberty, thus supporting the hypothesis that fat accumulation enhances maturation of the reproductive tract.			Chehab, FF (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT LAB MED,505 PARNASSUS AVE,SAN FRANCISCO,CA 94143, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007636] Funding Source: NIH RePORTER; NHLBI NIH HHS [HLS 53762] Funding Source: Medline; NIDDK NIH HHS [DK 07636] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; FRISCH RE, 1980, FED PROC, V39, P2395; FRISCH RE, 1974, SCIENCE, V185, P949, DOI 10.1126/science.185.4155.949; FRISCH RE, 1970, SCIENCE, V169, P397, DOI 10.1126/science.169.3943.397; FRISCH RE, 1980, NEW ENGL J MED, V303, P17, DOI 10.1056/NEJM198007033030105; FRISCH RE, 1975, P NATL ACAD SCI USA, V72, P4172, DOI 10.1073/pnas.72.10.4172; JOHNSTON FE, 1971, SCIENCE, V174, P1148, DOI 10.1126/science.174.4014.1148; KENNEDY GC, 1957, J ENDOCRINOL, V16, P9, DOI 10.1677/joe.0.0160009; KENNEDY GC, 1963, J PHYSIOL-LONDON, V166, P408, DOI 10.1113/jphysiol.1963.sp007112; KENNEDY GC, 1963, J PHYSIOL-LONDON, V166, P395, DOI 10.1113/jphysiol.1963.sp007111; ZACHARIA.L, 1970, AM J OBSTET GYNECOL, V108, P833, DOI 10.1016/0002-9378(70)90552-1	11	665	710	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					88	90		10.1126/science.275.5296.88	http://dx.doi.org/10.1126/science.275.5296.88			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974400				2022-12-28	WOS:A1997WA90300056
J	Wirth, MJ; Fairbank, RWP; Fatunmbi, HO				Wirth, MJ; Fairbank, RWP; Fatunmbi, HO			Mixed self-assembled monolayers in chemical separations	SCIENCE			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; SILICA SURFACES; CAPILLARY ELECTROPHORESIS; HORIZONTAL POLYMERIZATION; ALKYLSILOXANE MONOLAYERS; TRIFUNCTIONAL SILANES; DERIVATIZED SILICA; STATIONARY PHASES; TEMPERATURE; ADSORPTION	Chemical separations of many biomolecules and pharmaceuticals are limited by their electrostatic interaction with the surfaces of the separation medium. Mixed self-assembled monolayers of octadecyl and methyl chains organize into a dense, two-dimensionally cross-linked network over the chromatographic silica surface to reduce acid dissociation of the surface silanols, Molecular models predict that two-dimensional cross-linking is sterically possible for pure methylsiloxane monolayers, silicon-29 nuclear magnetic resonance measurements show that cross-linking predominates for mixed monolayers of primarily methylsiloxane, and chromatographic measurements confirm that electrostatic interactions are reduced when the monolayer is primarily methylsiloxane. Chromatographic separation of genetic variants of a highly charged protein, cytochrome c, demonstrates the promise of self-assembled monolayers in separations of biomolecules.	SEPARAT METHODS TECHNOL,NEWARK,DE 19711		Wirth, MJ (corresponding author), UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716, USA.							ALLARA DL, 1995, LANGMUIR, V11, P2357, DOI 10.1021/la00007a007; BAIN CD, 1989, J AM CHEM SOC, V111, P321, DOI 10.1021/ja00183a049; Bard A. J., 1980, ELECTROCHEMICAL METH; BRZOSKA JB, 1994, LANGMUIR, V10, P4367, DOI 10.1021/la00023a072; CHEN M, 1992, J CHROMATOGR, V602, P227, DOI 10.1016/0021-9673(92)80085-9; COX GB, 1993, J CHROMATOGR A, V656, P353, DOI 10.1016/0021-9673(93)80809-M; Dayhoff MO, 1978, ATLAS PROTEIN SEQUEN, V5; ENGELHARDT H, 1991, J CHROMATOGR, V544, P371, DOI 10.1016/S0021-9673(01)83996-0; FAIRBANK RWP, 1995, ANAL CHEM, V67, P3879, DOI 10.1021/ac00117a010; FAIRBANK RWP, UNPUB; FATUNMBI HO, 1993, ANAL CHEM, V65, P2048, DOI 10.1021/ac00063a020; FLINN DH, 1994, COLLOID SURFACE A, V87, P163, DOI 10.1016/0927-7757(94)80065-0; FOTI G, 1989, J CHROMATOGR, V461, P243, DOI 10.1016/S0021-9673(00)94290-0; GUN J, 1986, J COLLOID INTERF SCI, V112, P457, DOI 10.1016/0021-9797(86)90114-1; HUANG MX, 1994, J MICROCOLUMN SEP, V6, P571, DOI 10.1002/mcs.1220060607; Huang XY, 1996, ANAL CHEM, V68, P4119, DOI 10.1021/ac960587t; KITAGAWA S, 1995, J MICROCOLUMN SEP, V7, P59, DOI 10.1002/mcs.1220070109; KOHLER J, 1987, J CHROMATOGR, V385, P125, DOI 10.1016/S0021-9673(01)94628-X; KOHLER J, 1986, J CHROMATOGR, V352, P275, DOI 10.1016/S0021-9673(01)83386-0; MOAZ R, 1984, J COLLOID INTERF SCI, V100, P465; NAWROCKI J, 1991, CHROMATOGRAPHIA, V31, P177, DOI 10.1007/BF02274570; NEUE UD, 1994, LC GC-MAG SEP SCI, V12, P468; OHTSU Y, 1989, J CHROMATOGR, V481, P147, DOI 10.1016/S0021-9673(01)96760-3; PARIKH AN, 1994, J PHYS CHEM-US, V98, P7577, DOI 10.1021/j100082a031; Patten TE, 1996, SCIENCE, V272, P866, DOI 10.1126/science.272.5263.866; REN FY, 1995, ANAL CHEM, V67, P3441, DOI 10.1021/ac00115a012; SAGIV J, 1980, J AM CHEM SOC, V102, P92, DOI 10.1021/ja00521a016; SANDER LC, 1984, ANAL CHEM, V56, P504, DOI 10.1021/ac00267a047; SILBERZAN P, 1991, LANGMUIR, V7, P1647, DOI 10.1021/la00056a017; SINDORF DW, 1983, J AM CHEM SOC, V105, P3767, DOI 10.1021/ja00350a003; TERLINGEN JGA, 1993, J COLLOID INTERF SCI, V155, P55, DOI 10.1006/jcis.1993.1009; TRIPP CP, 1992, LANGMUIR, V8, P1961, DOI 10.1021/la00044a014; TUEL A, 1990, LANGMUIR, V6, P770, DOI 10.1021/la00094a009; WAITE SW, 1994, ANAL CHEM, V66, P2052, DOI 10.1021/ac00085a021; WASSERMAN SR, 1989, LANGMUIR, V5, P1074, DOI 10.1021/la00088a035; WELSCH T, 1990, J CHROMATOGR, V506, P97, DOI 10.1016/S0021-9673(01)91570-5; WIRTH MJ, 1992, ANAL CHEM, V64, P2783, DOI 10.1021/ac00046a022; WIRTH MJ, 1993, ANAL CHEM, V65, P822, DOI 10.1021/ac00054a029; Wirth MJ, 1996, J LIQ CHROMATOGR R T, V19, P2799, DOI 10.1080/10826079608015111	39	170	175	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					44	47		10.1126/science.275.5296.44	http://dx.doi.org/10.1126/science.275.5296.44			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974384				2022-12-28	WOS:A1997WA90300040
J	Lambert, H				Lambert, H			Popular therapeutics and medical preferences in rural north India	LANCET			English	Editorial Material							SYSTEMS; PERSPECTIVE				Lambert, H (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.							BANERJI D, 1973, EC POLIT WKLY, V8, P2261; Beals A., 1980, ASIAN MED SYSTEMS, P194; CHAVUNDUKA GL, 1986, PROFESSIONALIZATION; KLEINMAN A, 1980, COMP STUDIES HLTH SY, V3, P71; Kleinman A., 1980, COMP STUDIES HLTH SY; LAMBERT H, 1992, SOC SCI MED, V34, P1069, DOI 10.1016/0277-9536(92)90280-4; LAMBERT H, IN PRESS W MED CONTE; LAST M, 1981, SOC SCI MED-MED ANTH, V15, P387, DOI 10.1016/0160-7987(81)90064-8; LAST M, 1991, MED ANTHR CONT THEOR, P349; LESLIE C, 1980, SOC SCI MED-MED ANTH, V14, P191, DOI 10.1016/0160-7987(80)90044-7; LESLIE C, 1980, ASIAN MED SYSTEMS; LESLIE CM, 1992, PATHS ASIAN MED KNOW, P3; NICHTER M, 1980, SOC SCI MED-MED ANTH, V14, P225, DOI 10.1016/0160-7987(80)90048-4; NICHTER M, 1989, ANTHR INT HLTH S ASI; PRESS I, 1980, SOC SCI MED-MED ANTH, V14, P45, DOI 10.1016/0160-7987(80)90040-X; WAXLERMORRISON NE, 1988, SOC SCI MED, V27, P531, DOI 10.1016/0277-9536(88)90377-2; WORSLEY P, 1982, ANNU REV ANTHROPOL, V11, P315, DOI 10.1146/annurev.an.11.100182.001531; ZIMMERMAN F, 1987, JUNGLE AROMA MEATS E	18	24	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1706	1709		10.1016/S0140-6736(96)07135-8	http://dx.doi.org/10.1016/S0140-6736(96)07135-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973437				2022-12-28	WOS:A1996VZ76600017
J	Kannus, P; Parkkari, J; Niemi, S; Palvanen, M				Kannus, P; Parkkari, J; Niemi, S; Palvanen, M			Epidemiology of osteoporotic ankle fractures in elderly persons in Finland	ANNALS OF INTERNAL MEDICINE			English	Article							AGE-ADJUSTED INCIDENCE; HIP-FRACTURES; RISK; PREVENTION; WOMEN	Background: Although osteoporotic or minimal trauma fractures among elderly persons are a major public health problem worldwide, epidemiologic information on these fractures is limited. Objective: To determine the current trend in the number and incidence of osteoporotic ankle fractures in the elderly. A fracture was defined as osteoporotic only if it occurred as a result of minimal trauma in a person 60 years of age or older. Design: National hospital discharge register. Setting: Finland, a country with approximately 5 million inhabitants. Participants: All patients 60 years of age or older who were admitted to hospitals in Finland for primary treatment of first osteoporotic ankle fracture in 1970 to 1972, 1974, 1975, 1978 to 1980, 1983 to 1985, 1988 to 1989, and 1991 to 1994. Measurements: The number and the age-specific and age-adjusted incidence of osteoporotic ankle fractures in each year of the study. Results: For the study period, the number and incidence (per 100 000 persons) of osteoporosis-related ankle fractures in Finnish persons 60 years of age or older increased considerably (370 and 57, respectively, in 1970 compared with 1243 and 130, respectively, in 1994). The age-adjusted incidence of these fractures also increased in women, from 66 in 1970 to 162 in 1994, and in men, from 38 in 1970 to 82 in 1994. Conclusion: The number of osteoporotic ankle fractures in Finland is increasing at a rate that cannot be explained simply by demographic changes. Vigorous preventive measures are needed to control the increasing burden of this type of fracture.			Kannus, P (corresponding author), UKK INST HLTH PROMOT RES, KAUPINPUISTONKATU 1, FIN-33500 TAMPERE, FINLAND.							Aro S, 1990, Duodecim, V106, P1443; BENGNER U, 1986, ACTA ORTHOP SCAND, V57, P35, DOI 10.3109/17453678608993211; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; DALY PJ, 1987, ACTA ORTHOP SCAND, V58, P539, DOI 10.3109/17453678709146395; GREENSPAN SL, 1994, JAMA-J AM MED ASSOC, V271, P128, DOI 10.1001/jama.271.2.128; JONES G, 1994, OSTEOPOROSIS INT, V4, P277, DOI 10.1007/BF01623352; KANNUS P, 1995, LANCET, V346, P50, DOI 10.1016/S0140-6736(95)92679-8; LAURITZEN JB, 1993, OSTEOPOROSIS INT, V3, P127, DOI 10.1007/BF01623273; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; LUTHJE P, 1995, ACTA ORTHOP SCAND, V66, P245; MELTON LJ, 1993, BONE, V14, pS1; MELTON LJ, 1981, CLIN ORTHOP RELAT R, V155, P43; MeltonIII L. J., 1988, OSTEOPOROSIS ETIOLOG, P133; OBRANT KJ, 1989, CALCIFIED TISSUE INT, V44, P157, DOI 10.1007/BF02556558; *OFF STAT FINL, 1994, STRUCT POP VIT STAT, P1970; PARKKARI J, 1994, CALCIFIED TISSUE INT, V55, P342, DOI 10.1007/BF00299311; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; ROSE SH, 1982, CLIN ORTHOP RELAT R, V168, P24; Salmela R, 1987, SAIRAALA, V49, P480; Thorngren K G, 1994, Disabil Rehabil, V16, P119	20	60	64	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1996	125	12					975	978		10.7326/0003-4819-125-12-199612150-00007	http://dx.doi.org/10.7326/0003-4819-125-12-199612150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX768	8967708				2022-12-28	WOS:A1996VX76800008
J	Jones, DA; West, RR				Jones, DA; West, RR			Psychological rehabilitation after myocardial infarction: Multicentre randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							FOLLOW-UP; QUESTIONNAIRE	Objective-To evaluate rehabilitation after myocardial infarction. Design-Randomised controlled trial of rehabilitation in unselected myocardial infarction patients in six centres, baseline data being collected on admission and by structured interview (of patients and spouses) shortly after discharge and outcome being assessed by structured interview at six months and clinical examination at 12 months. Setting-Six district general hospitals. Subjects-All 2328 eligible patients admitted over two years with confirmed myocardial infarction and discharged home within 28 days. Interventions-Rehabilitation programmes comprising psychological therapy, counselling, relaxation training, and stress management training over seven weekly group outpatient sessions for patients and spouses. Main outcome measures-Anxiety, depression, quality of life, morbidity, use of medication, and mortality. Results-At six months there were no significant differences between rehabilitation patients and controls in reported anxiety (prevalence 33%) or depression (19%). Rehabilitation patients reported a lower frequency of angina (median three versus four episodes a week), medication, and physical activity. At 12 months there were no differences in clinical complications, clinical sequelae, or mortality. Conclusions-Rehabilitation programmes based on psychological therapy, counselling, relaxation training, and stress management seem to offer little objective benefit to patients who have experienced myocardial infarction compared with previous reports of smaller trials.	UNIV WALES COLL MED,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University	Jones, DA (corresponding author), UNIV WALES COLL MED,LLANDOUGH HOSP,CARDIFF CF64 2XX,S GLAM,WALES.							ADSETT CA, 1968, CAN MED ASSOC J, V99, P577; BEDFORD A, 1976, BRIT J SOC CLIN PSYC, V15, P387, DOI 10.1111/j.2044-8260.1976.tb00050.x; *BRIT ASS CARD REH, 1995, GUID CARD REH; Cay E L, 1982, Adv Cardiol, V29, P108; COURSOL A, 1986, PROF PSYCHOL-RES PR, V17, P136, DOI 10.1037/0735-7028.17.2.136; DELLBORG M, 1994, EUR HEART J, V15, P5, DOI 10.1093/oxfordjournals.eurheartj.a060379; DIXHOORN JV, 1990, J PSYCHOSOM RES, V34, P327; *EUR SOC CARD WORK, 1992, EUR HEART J SUPPL, V13, P1; FRASURESMITH N, 1989, PSYCHOSOM MED, V51, P485, DOI 10.1097/00006842-198909000-00002; FRIEDMAN M, 1984, AM HEART J, V108, P237, DOI 10.1016/0002-8703(84)90606-9; HORGAN J, 1992, BRIT HEART J, V67, P412; IBRAHIM MA, 1974, INT J PSYCHIAT MED, V5, P253, DOI 10.2190/DW1M-9N7K-EXJF-JEYB; Jones, 1990, HLTH TRENDS, V22, P164; KELLERMANN JJ, 1967, J CHRON DIS, V20, P815, DOI 10.1016/0021-9681(67)90094-X; LEVINE SA, 1952, JAMA-J AM MED ASSOC, V148, P1365, DOI 10.1001/jama.1952.02930160001001; LLOYD GG, 1978, BRIT MED J, V2, P1953; MAYOU R, 1978, J PSYCHOSOM RES, V22, P447, DOI 10.1016/0022-3999(78)90068-5; MAYOU R, 1981, LANCET, V2, P1399; *MULT POST RES GRO, 1983, NEW ENGL J MED, V309, P331; NAISMITH LD, 1979, BRIT MED J, V1, P439, DOI 10.1136/bmj.1.6161.439; NORRIS RM, 1974, BRIT HEART J, V36, P786; *OFF POP CENS SURV, 1980, GEN HOUS SURV 1972; Office for Population Censuses and Surveys Social Survey Division, 1975, GEN HOUS SURV 1972; RAHE RH, 1979, PSYCHOSOM MED, V41, P229, DOI 10.1097/00006842-197905000-00006; ROSE GA, 1965, MILBANK FUND Q, V43, P32, DOI 10.2307/3348873; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; STERN MJ, 1983, ARCH INTERN MED, V143, P1719, DOI 10.1001/archinte.143.9.1719; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; THOMPSON DR, 1990, J PSYCHOSOM RES, V34, P237, DOI 10.1016/0022-3999(90)90080-N; Townsend P., 1979, POVERTY UK; WEST RR, 1993, J ROY COLL PHYS LOND, V27, P111; West RR, 1995, CARDIAC REHABILITATI, P184; *WHO, 1983, REH COMPR SEC PREV M; *WHO EXP COMM, 1964, WHO TECH REP SER, V270, P3; YARNELL JWG, 1983, HUM NUTR-APPL NUTR, V37, P103	35	188	189	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1996	313	7071					1517	1521		10.1136/bmj.313.7071.1517	http://dx.doi.org/10.1136/bmj.313.7071.1517			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VY691	8978226	Green Published			2022-12-28	WOS:A1996VY69100019
J	Doupe, AJ				Doupe, AJ			Plasticity of a different feather?	SCIENCE			English	Editorial Material							GILL-WITHDRAWAL REFLEX; LONG-TERM HABITUATION; APLYSIA-CALIFORNICA; SONGBIRD FOREBRAIN; PROTEIN-SYNTHESIS; MEMORY; DISSECTION		UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	Doupe, AJ (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA.							BYRNE JH, 1982, J NEUROPHYSIOL, V48, P431, DOI 10.1152/jn.1982.48.2.431; CAREW TJ, 1972, SCIENCE, V175, P451, DOI 10.1126/science.175.4020.451; CASTELLUCCI VF, 1978, SCIENCE, V202, P1306, DOI 10.1126/science.214854; CHEW SJ, 1995, P NATL ACAD SCI USA, V92, P3406, DOI 10.1073/pnas.92.8.3406; Chew SJ, 1996, P NATL ACAD SCI USA, V93, P1950, DOI 10.1073/pnas.93.5.1950; Chew SJ, 1996, SCIENCE, V274, P1909, DOI 10.1126/science.274.5294.1909; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DEZAZZO J, 1995, TRENDS NEUROSCI, V18, P212, DOI 10.1016/0166-2236(95)93905-D; FREEMAN FM, 1995, NEUROBIOL LEARN MEM, V63, P291, DOI 10.1006/nlme.1995.1034; GRECKSCH G, 1980, PHARMACOL BIOCHEM BE, V12, P663, DOI 10.1016/0091-3057(80)90145-8; LI L, 1993, J NEUROPHYSIOL, V69, P1918, DOI 10.1152/jn.1993.69.6.1918; MELLO C, 1995, J NEUROSCI, V15, P6919; MELLO CV, 1992, P NATL ACAD SCI USA, V89, P6818, DOI 10.1073/pnas.89.15.6818; MILLER EK, 1994, SCIENCE, V263, P520, DOI 10.1126/science.8290960; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; RANKIN CH, 1992, BEHAV NEUROSCI, V106, P239, DOI 10.1037/0735-7044.106.2.239; Ringo JL, 1996, BEHAV BRAIN RES, V76, P191, DOI 10.1016/0166-4328(95)00197-2; Sobotka S, 1996, J NEUROSCI, V16, P4222; Stripling R., 1995, Society for Neuroscience Abstracts, V21, P959; Stripling R., 1994, Society for Neuroscience Abstracts, V20, P165; THOMPSON RW, 1964, PSYCHOL REV, V173, P16; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; WICKELGREN WA, 1972, J MATH PSYCHOL, V9, P418, DOI 10.1016/0022-2496(72)90015-6	24	1	1	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 13	1996	274	5294					1851	1853		10.1126/science.274.5294.1851	http://dx.doi.org/10.1126/science.274.5294.1851			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VY200	8984646				2022-12-28	WOS:A1996VY20000027
J	Dawson, A; Elias, DJ; Rubenson, D; Bartz, SH; Garver, PR; Kay, AC; Bloor, CM; Beutler, E				Dawson, A; Elias, DJ; Rubenson, D; Bartz, SH; Garver, PR; Kay, AC; Bloor, CM; Beutler, E			Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepatopulmonary syndrome	ANNALS OF INTERNAL MEDICINE			English	Article							INVOLVEMENT; RISK		SCRIPPS CLIN & RES FDN, DIV CHEST & CRIT CARE MED, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, MED CTR, SAN DIEGO, CA 92103 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA	Scripps Research Institute; University of California System; University of California San Diego; Scripps Research Institute	Dawson, A (corresponding author), SCRIPPS CLIN & RES FDN, DIV CHEST & CRIT CARE MED, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00833] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BERGER M, 1985, J AM COLL CARDIOL, V6, P359, DOI 10.1016/S0735-1097(85)80172-8; BEUTLER E, 1991, NEW ENGL J MED, V325, P1354; BEUTLER E, 1995, BLOOD CELL MOL DIS, V21, P86, DOI 10.1006/bcmd.1995.0012; BEUTLER E, 1991, BLOOD, V78, P1183; BURROWS B, 1988, AM REV RESPIR DIS, V138, P829, DOI 10.1164/ajrccm/138.4.829; EDELL ES, 1989, AM REV RESPIR DIS, V140, P1631, DOI 10.1164/ajrccm/140.6.1631; ERIKSSON S, 1986, NEW ENGL J MED, V314, P736, DOI 10.1056/NEJM198603203141202; Kerem E, 1996, EUR RESPIR J, V9, P340, DOI 10.1183/09031936.96.09020340; KROWKA MJ, 1990, CHEST, V97, P1165, DOI 10.1378/chest.97.5.1165; KROWKA MJ, 1990, HEPATOLOGY, V11, P138, DOI 10.1002/hep.1840110123; LANGE PA, 1995, ANN INTERN MED, V122, P521, DOI 10.7326/0003-4819-122-7-199504010-00008; Lee R. E., 1982, GaAs IC Symposium. IEEE Gallium Arsenide Integrated Circuit Symposium. Technical Digest 1982, P177; LEE RE, 1988, LAB INVEST, V58, pA54; PELINI M, 1994, ANN INTERN MED, V121, P196, DOI 10.7326/0003-4819-121-3-199408010-00006; ROBERTS WC, 1967, CIRCULATION, V35, P783, DOI 10.1161/01.CIR.35.4.783; SCHNEIDER EL, 1977, AM J MED, V63, P475, DOI 10.1016/0002-9343(77)90288-1; THEISE ND, 1990, AM J PEDIAT HEMATOL, V12, P74; ZIMRAN A, 1992, MEDICINE, V71, P337, DOI 10.1097/00005792-199211000-00002	18	36	37	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1996	125	11					901	904		10.7326/0003-4819-125-11-199612010-00005	http://dx.doi.org/10.7326/0003-4819-125-11-199612010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV541	8967670				2022-12-28	WOS:A1996VV54100005
J	Wootton, R				Wootton, R			Telemedicine: A cautious welcome	BRITISH MEDICAL JOURNAL			English	Article											Wootton, R (corresponding author), BELFAST CITY HOSP,INST TELEMED & TELECARE,UNIV FLOOR,BELFAST BT9 7AB,ANTRIM,NORTH IRELAND.		Wootton, Richard/F-7609-2014	Wootton, Richard/0000-0002-2666-3596				Allen A, 1995, J Telemed Telecare, V1, P34; Amenta F, 1996, J Telemed Telecare, V2, P125, DOI 10.1258/1357633961929907; [Anonymous], 1995, LANCET, V345, P73; Bagshaw M, 1996, J Telemed Telecare, V2 Suppl 1, P36, DOI 10.1258/1357633961929213; Bergmo T S, 1996, J Telemed Telecare, V2, P136, DOI 10.1258/1357633961929952; Brahams D, 1995, J Telemed Telecare, V1, P196; Darkins A, 1996, J Telemed Telecare, V2, P93, DOI 10.1258/1357633961929853; Darkins A, 1996, J Telemed Telecare, V2, P179, DOI 10.1258/1357633961930022; DOOLITTLE GC, 1996, P TEL 96 13 14 NOV 1, P33; Fisk NM, 1996, BRIT J OBSTET GYNAEC, V103, P1092, DOI 10.1111/j.1471-0528.1996.tb09588.x; GRAY WP, 1996, P TEL 96 13 14 NOV 1, P59; Halvorsen PA, 1996, BRIT MED J, V312, P1333, DOI 10.1136/bmj.312.7042.1333; HOARE J, 1992, TIDAL WAVE NEW TECHN; Jameson D G, 1995, J Telemed Telecare, V1, P111; Jennett P A, 1995, J Telemed Telecare, V1, P69; Tachakra S, 1996, J Telemed Telecare, V2 Suppl 1, P56, DOI 10.1258/1357633961929286; TANGALOS E, 1995, P WORLD C TEL TOUL 3, P173; WILLICH T, 1995, TELEMEDICINE TODAY, V3, P26; Wyatt JC, 1996, BRIT MED J, V313, P1380, DOI 10.1136/bmj.313.7069.1380; Zimnik P R, 1996, Telemed J, V2, P241, DOI 10.1089/tmj.1.1996.2.241	20	120	121	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1996	313	7069					1375	1377		10.1136/bmj.313.7069.1375	http://dx.doi.org/10.1136/bmj.313.7069.1375			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW685	8956707	Green Published			2022-12-28	WOS:A1996VW68500029
J	Onrust, R; Herzmark, P; Chi, P; Garcia, PD; Lichtarge, O; Kingsley, C; Bourne, HR				Onrust, R; Herzmark, P; Chi, P; Garcia, PD; Lichtarge, O; Kingsley, C; Bourne, HR			Receptor and beta gamma binding sites in the alpha subunit of the retinal G protein transducin	SCIENCE			English	Article							NUCLEOTIDE EXCHANGE; CRYSTAL-STRUCTURE; GTP HYDROLYSIS; RHODOPSIN; ACTIVATION; GDP; FLUORESCENCE; MECHANISM; MUTATION; COMPLEX	Transmembrane receptors for hormones, neurotransmitters, light, and odorants mediate their cellular effects by activating heterotrimeric guanine nucleotide-binding proteins (G proteins), Crystal structures have revealed contact surfaces between G protein subunits, but not the surfaces or molecular mechanism through which G alpha beta gamma responds to activation by transmembrane receptors, Such a surface was identified from the results of testing 100 mutant alpha subunits of the retinal G protein transducin for their ability to interact with rhodopsin, Sites at which alanine substitutions impaired this interaction mapped to two distinct G alpha surfaces: a beta gamma-binding surface and a putative receptor-interacting surface. On the basis of these results a mechanism for receptor-catalyzed exchange of guanosine diphosphate for guanosine triphosphate is proposed.	UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,PROGRAM BIOMED SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [CA-54427] Funding Source: Medline; NIGMS NIH HHS [GM-27800] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027800, R01GM027800] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOUME HR, 1991, NATURE, V349, P117; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DENKER BM, 1992, J BIOL CHEM, V267, P9998; DENKER BM, 1995, BIOCHEMISTRY-US, V34, P5544, DOI 10.1021/bi00016a028; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; QUILLIAM LA, 1995, P NATL ACAD SCI USA, V92, P1272, DOI 10.1073/pnas.92.5.1272; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; VUONG TM, 1984, NATURE, V311, P659, DOI 10.1038/311659a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1	38	192	193	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					381	384		10.1126/science.275.5298.381	http://dx.doi.org/10.1126/science.275.5298.381			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994033				2022-12-28	WOS:A1997WC87300044
J	Estrada, J; Boronat, M; Mielgo, M; Magallon, R; Millan, I; Diez, S; Lucas, T; Barcelo, B				Estrada, J; Boronat, M; Mielgo, M; Magallon, R; Millan, I; Diez, S; Lucas, T; Barcelo, B			The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOLLOW-UP; DIFFERENTIAL-DIAGNOSIS; ADENOMAS; MICROSURGERY; RADIOTHERAPY; THERAPY	Background Irradiation of the pituitary is widely considered the most appropriate treatment for patients with Cushing's disease in whom transsphenoidal microsurgery has been unsuccessful. However, there is little information about the long-term efficacy of this treatment. Methods We used external pituitary radiation to treat 30 adult patients with persistent or recurrent Cushing's disease after unsuccessful transsphenoidal surgery. The mean (+/-SD) dose of radiation was 50+/-1 Gy. Pituitary and adrenal function was assessed every six months after radiation therapy. Remission was defined as the regression of symptoms and signs of Cushing's syndrome, normal urinary cortisol excretion, and a low plasma cortisol concentration in the morning after the administration of 1 mg of dexamethasone at midnight. Results Twenty-five patients (83 percent) had remissions during a median follow-up of 42 months (range, 18 to 114). The remissions began 6 to 60 months after radiation therapy, but in most cases (22 patients) remission occurred during the first 2 years. None of the 25 patients had a relapse of Cushing's disease after remission was achieved. There was no relation between the response to radiotherapy and sex, age, urinary cortisol excretion before radiotherapy, the interval between surgery and radiotherapy, whether a pituitary adenoma was found by pathological examination, or tumor size. Seventeen patients had a deficiency of growth hormone after radiation therapy, 10 had a deficiency of gonadotropins, 4 had a deficiency of thyrotropin, and 1 had a deficiency of corticotropin. Conclusions Pituitary irradiation is an effective and well-tolerated treatment for patients with Cushing's disease in whom transsphenoidal surgery is unsuccessful. (C) 1997, Massachusetts Medical Society.	UNIV AUTONOMA MADRID, CLIN PUERTA DE HIERRO, DEPT RADIAT ONCOL, MADRID 28035, SPAIN; UNIV AUTONOMA MADRID, CLIN PUERTA DE HIERRO, DEPT BIOSTAT, MADRID 28035, SPAIN	Autonomous University of Madrid; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda; Autonomous University of Madrid; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Estrada, J (corresponding author), UNIV AUTONOMA MADRID, CLIN PUERTA DE HIERRO, SERV ENDOCRINOL, DEPT ENDOCRINOL, MADRID 28035, SPAIN.		Boronat, Mauro/I-2851-2017	Boronat, Mauro/0000-0001-8535-8543				BENEDETTI J, 1990, BMDP STATISTICAL SOF, V2, P739; BOCHICCHIO D, 1995, J CLIN ENDOCR METAB, V80, P3114, DOI 10.1210/jcem.80.11.7593411; BRADA M, 1993, CLIN ENDOCRINOL, V38, P571, DOI 10.1111/j.1365-2265.1993.tb02137.x; BURCH WM, 1985, ARCH INTERN MED, V145, P1106, DOI 10.1001/archinte.145.6.1106; CARPENTER PC, 1988, ENDOCRIN METAB CLIN, V17, P445, DOI 10.1016/S0889-8529(18)30412-2; FAHLBUSCH R, 1986, J ROY SOC MED, V79, P262, DOI 10.1177/014107688607900504; HOWLETT TA, 1989, CLIN ENDOCRINOL, V31, P309, DOI 10.1111/j.1365-2265.1989.tb01255.x; HUGHES MN, 1993, INT J RADIAT ONCOL, V27, P1035, DOI 10.1016/0360-3016(93)90520-6; JENNINGS AS, 1977, NEW ENGL J MED, V297, P957, DOI 10.1056/NEJM197711032971801; LAMBERTS SWJ, 1995, J CLIN ENDOCR METAB, V80, P3111, DOI 10.1210/jc.80.11.3111; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; LITTLEY MD, 1990, CLIN ENDOCRINOL, V33, P445, DOI 10.1111/j.1365-2265.1990.tb03883.x; MAMPALAM TJ, 1988, ANN INTERN MED, V109, P487, DOI 10.7326/0003-4819-109-6-487; MCCANCE DR, 1993, CLIN ENDOCRINOL, V38, P79, DOI 10.1111/j.1365-2265.1993.tb00976.x; MURAYAMA M, 1992, J CLIN ENDOCR METAB, V75, P935, DOI 10.1210/jc.75.3.935; NELSON JC, 1978, AM J MED SCI, V275, P165, DOI 10.1097/00000441-197803000-00006; NUGENT CA, 1965, ARCH INTERN MED, V116, P172, DOI 10.1001/archinte.1965.03870020012006; OLDFIELD EH, 1991, NEW ENGL J MED, V325, P897, DOI 10.1056/NEJM199109263251301; OLDFIELD EH, 1992, NEW ENGL J MED, V326, P1172; ORTH DN, 1971, NEW ENGL J MED, V285, P243, DOI 10.1056/NEJM197107292850501; ORTH DN, 1995, NEW ENGL J MED, V332, P791, DOI 10.1056/NEJM199503233321207; PIETERS GFFM, 1989, J CLIN ENDOCR METAB, V69, P1122, DOI 10.1210/jcem-69-6-1122; SCHTEINGART DE, 1980, ANN INTERN MED, V92, P613, DOI 10.7326/0003-4819-92-5-613; SHARPE GF, 1985, CLIN ENDOCRINOL, V22, P169, DOI 10.1111/j.1365-2265.1985.tb01078.x; TINDALL GT, 1990, J NEUROSURG, V72, P363, DOI 10.3171/jns.1990.72.3.0363; TRAINER PJ, 1993, CLIN ENDOCRINOL, V38, P73, DOI 10.1111/j.1365-2265.1993.tb00975.x; TYRRELL JB, 1994, ENDOCRIN METAB CLIN, V23, P925, DOI 10.1016/S0889-8529(18)30075-6; TYRRELL JB, 1986, ANN INTERN MED, V104, P180, DOI 10.7326/0003-4819-104-2-180; VICENTE A, 1991, ACTA ENDOCRINOL-COP, V125, P470, DOI 10.1530/acta.0.1250470; YOUNG WF, 1988, MAYO CLIN PROC, V63, P256, DOI 10.1016/S0025-6196(12)65099-X	30	243	248	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1997	336	3					172	177		10.1056/NEJM199701163360303	http://dx.doi.org/10.1056/NEJM199701163360303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC266	8988897				2022-12-28	WOS:A1997WC26600003
J	Drobniewski, F				Drobniewski, F			Is death inevitable with multiresistant TB plus HIV infection?	LANCET			English	Editorial Material							MULTIDRUG-RESISTANT TUBERCULOSIS		UNIV LONDON KINGS COLL,SCH MED,DEPT MICROBIOL,LONDON SE22 8QF,ENGLAND	University of London; King's College London	Drobniewski, F (corresponding author), UNIV LONDON KINGS COLL,SCH MED,PHLS MYCOBACTERIUM REFERENCE UNIT,LONDON SE22 8QF,ENGLAND.							Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P330; DROBNIEWSKI FA, 1995, J MED MICROBIOL, V43, P85, DOI 10.1099/00222615-43-2-85; Drobniewski FA, 1996, BRIT J HOSP MED, V56, P204; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; Miller R, 1996, LANCET, V348, P307, DOI 10.1016/S0140-6736(95)11037-2; SALOMON N, 1995, CLIN INFECT DIS, V21, P1245, DOI 10.1093/clinids/21.5.1245; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; TELZAK EE, 1995, NEW ENGL J MED, V333, P907, DOI 10.1056/NEJM199510053331404; TURETT GS, 1995, CLIN INFECT DIS, V21, P1238, DOI 10.1093/clinids/21.5.1238; 1991, MMWR-MORBID MORTAL W, V40, P585	10	33	35	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					71	72		10.1016/S0140-6736(05)60878-1	http://dx.doi.org/10.1016/S0140-6736(05)60878-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996412				2022-12-28	WOS:A1997WB80000003
J	Robinson, MS; Lucey, PG				Robinson, MS; Lucey, PG			Recalibrated Mariner 10 color mosaics: Implications for Mercurian volcanism	SCIENCE			English	Article							REFLECTANCE SPECTRA; SURFACE; SPECTROSCOPY; BASALT	Recalibration of Mariner 10 color image data allows the identification of distinct color units on the mercurian surface. We analyze these data in terms of opaque mineral abundance, iron content, and soil maturity and find color units consistent with the presence of volcanic deposits on Mercury's surface. Additionally, materials associated with some impact craters have been excavated from a layer interpreted to be deficient in opaque minerals within the crust, possibly analogous to the lunar anorthosite crust. These observations suggest that Mercury has undergone complex differentiation like the other terrestrial planets and the Earth's moon.	UNIV HAWAII,HAWAII INST GEOPHYS & PLANETOL,HONOLULU,HI 96822	University of Hawaii System	Robinson, MS (corresponding author), US GEOL SURVEY,2255 N GEMINI DR,FLAGSTAFF,AZ 86001, USA.		Robinson, Mark/ABI-6841-2020					ADAMS JB, 1974, J GEOPHYS RES, V79, P4829, DOI 10.1029/JB079i032p04829; BENESH M, 1973, 615148 JET PROP LAB; CHARETTE MP, 1974, J GEOPHYS RES, V79, P1605, DOI 10.1029/JB079i011p01605; CINTALA MJ, 1992, J GEOPHYS RES-PLANET, V97, P947, DOI 10.1029/91JE02207; DANIELSON GE, 1975, J GEOPHYS RES, V80, P2357, DOI 10.1029/JB080i017p02357; DZURISIN D, 1978, J GEOPHYS RES, V83, P4883, DOI 10.1029/JB083iB10p04883; HAPKE B, 1975, J GEOPHYS RES, V80, P2431, DOI 10.1029/JB080i017p02431; HAPKE B, 1977, PHYS EARTH PLANET IN, V15, P264, DOI 10.1016/0031-9201(77)90035-8; HAPKE B, 1975, MOON PLANETS, V13, P339, DOI 10.1007/BF00567525; HAPKE B, 1986, ICARUS, V67, P264, DOI 10.1016/0019-1035(86)90108-9; HAPKE B, 1976, J ATMOS SCI, V33, P1803, DOI 10.1175/1520-0469(1976)033<1803:POVFM>2.0.CO;2; HAPKE B, 1980, P LUNAR PLANET SCI C, V11, P817; HAWKE BR, 1978, P LUNAR PLANET SCI C, P3285; HELFENSTEIN P, 1987, ICARUS, V72, P343; JEANLOZ R, 1995, SCIENCE, V268, P1455, DOI 10.1126/science.7770770; KEIFFER WS, 1987, ICARUS, V72, P477; Lucey P.G., 1996, LUNAR PLANET SCI, V27, P781; MCCORD TB, 1972, ICARUS, V17, P585, DOI 10.1016/0019-1035(72)90024-3; MCEWEN AS, 1993, LUNAR PLANET SCI, V24, P955; MORRIS RV, 1980, P LUNAR PLANET SCI C, V11, P1697; MURRAY BC, 1975, J GEOPHYS RES, V80, P2342, DOI 10.1029/JB080i017p02342; MURRAY BC, 1974, SCIENCE, V185, P169, DOI 10.1126/science.185.4146.169; RAVA B, 1987, ICARUS, V71, P397, DOI 10.1016/0019-1035(87)90037-6; ROBINSON MS, 1992, J GEOPHYS RES-PLANET, V97, P18265, DOI 10.1029/92JE01934; SOHA JM, 1975, J GEOPHYS RES, V80, P2394, DOI 10.1029/JB080i017p02394; SPOHN T, 1991, ICARUS, V90, P222, DOI 10.1016/0019-1035(91)90103-Z; SPRAGUE AL, 1994, ICARUS, V109, P156, DOI 10.1006/icar.1994.1083; Spudis P.D., 1978, P LUNAR PLANET SCI C, P3379; Spudis P.D., 1988, MERCURY, P118; STROM RG, 1977, PHYS EARTH PLANET IN, V15, P156, DOI 10.1016/0031-9201(77)90028-0; Veverka J., 1988, MERCURY, P37; VILAS F, 1984, ICARUS, V59, P60, DOI 10.1016/0019-1035(84)90055-1; VILAS F, 1976, ICARUS, V28, P593, DOI 10.1016/0019-1035(76)90132-9; VILAS F, 1985, ICARUS, V64, P133, DOI 10.1016/0019-1035(85)90044-2; VILAS F, 1988, MERCURY, P59; WELLS E, 1977, SCIENCE, V195, P977, DOI 10.1126/science.195.4282.977; WILHELMS DE, 1976, ICARUS, V28, P551, DOI 10.1016/0019-1035(76)90128-7	37	135	136	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					197	200		10.1126/science.275.5297.197	http://dx.doi.org/10.1126/science.275.5297.197			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985010				2022-12-28	WOS:A1997WC02200033
J	Svoboda, K; Denk, W; Kleinfeld, D; Tank, DW				Svoboda, K; Denk, W; Kleinfeld, D; Tank, DW			In vivo dendritic calcium dynamics in neocortical pyramidal neurons	NATURE			English	Article							ACTION-POTENTIALS; SYNAPTIC ACTIVATION; HIPPOCAMPAL-NEURONS; CORTICAL-NEURONS; CELL DENDRITES; RAT; CA1; PROPAGATION; MICROSCOPY; FREQUENCY	THE dendrites of mammalian pyramidal neurons contain a rich collection of active conductances that can support Na+ and Ca2+ action potentials (for a review see ref, 1), The presence, site of initiation, and direction of propagation of Na+ and Ca2+ action potentials are, however, controversial(2), and seem to be sensitive to resting membrane potential, ionic composition, and degree of channel inactivation, and depend on the intensity and pattern of synaptic stimulation, This makes it difficult to extrapolate from in vitro experiments to the situation in the intact brain, Here we show that two-photon excitation laser scanning microscopy(3) can penetrate the highly scattering tissue of the intact brain. We used this property to measure sensory stimulus-induced dendritic [Ca2+] dynamics of layer 2/3 pyramidal neurons of the rat primary vibrissa (Sm1) cortex in vivo. Simultaneous recordings of intracellular voltage and dendritic [Ca2+] dynamics during whisker stimulation or current injection showed increases in [Ca2+] only in coincidence with Na+ action potentials, The amplitude of these [Ca2+] transients at a given location was approximately proportional to the number of Na+ action potentials in a short burst, The amplitude for a given number of action potentials was greatest in the proximal apical dendrite rand declined steeply,vith increasing distance from the soma, with little Ca2+ accumulation in the most distal branches, in layer 1.	AT&T BELL LABS,LUCENT TECHNOL,BIOL COMPUTAT RES DEPT,MURRAY HILL,NJ 07974	Alcatel-Lucent; Lucent Technologies; AT&T; Nokia Corporation; Nokia Bell Labs			denk, winfried/I-6627-2012					ANDREASEN M, 1993, J NEUROPHYSIOL, V69, P1966, DOI 10.1152/jn.1993.69.6.1966; ANDREASEN M, 1995, J PHYSIOL-LONDON, V483, P421, DOI 10.1113/jphysiol.1995.sp020595; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; Buzsaki G, 1996, P NATL ACAD SCI USA, V93, P9921, DOI 10.1073/pnas.93.18.9921; CALLAWAY JC, 1995, J NEUROPHYSIOL, V74, P1395, DOI 10.1152/jn.1995.74.4.1395; CARVELL GE, 1988, BRAIN RES, V448, P186, DOI 10.1016/0006-8993(88)91118-3; CARVELL GE, 1990, J NEUROSCI, V10, P2638; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DENK W, 1994, J NEUROSCI METH, V54, P151, DOI 10.1016/0165-0270(94)90189-9; Feller MB, 1996, J NEUROPHYSIOL, V76, P381, DOI 10.1152/jn.1996.76.1.381; GUTFREUND Y, 1995, J PHYSIOL-LONDON, V483, P621, DOI 10.1113/jphysiol.1995.sp020611; Helmchen F, 1996, BIOPHYS J, V70, P1069, DOI 10.1016/S0006-3495(96)79653-4; HIRSCH JA, 1995, NATURE, V378, P612, DOI 10.1038/378612a0; JAFFE DB, 1992, NATURE, V357, P244, DOI 10.1038/357244a0; KIM HG, 1995, J NEUROPHYSIOL, V74, P1810, DOI 10.1152/jn.1995.74.4.1810; KIM HG, 1993, J NEUROSCI, V13, P5301, DOI 10.1523/JNEUROSCI.13-12-05301.1993; Kleinfeld D, 1996, J COMP NEUROL, V375, P89, DOI 10.1002/(SICI)1096-9861(19961104)375:1<89::AID-CNE6>3.0.CO;2-K; MAGEE JC, 1995, SCIENCE, V268, P301, DOI 10.1126/science.7716525; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; REGEHR WG, 1994, CURR BIOL, V4, P436, DOI 10.1016/S0960-9822(00)00096-8; REUVENI I, 1993, J NEUROSCI, V13, P4609; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; Tsubokawa H, 1996, J NEUROPHYSIOL, V76, P2896, DOI 10.1152/jn.1996.76.5.2896; TURNER RW, 1991, J NEUROSCI, V11, P2270; WONG RKS, 1979, P NATL ACAD SCI USA, V76, P986, DOI 10.1073/pnas.76.2.986; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0; YUSTE R, 1994, NEURON, V13, P23, DOI 10.1016/0896-6273(94)90457-X; Yuste R, 1996, NEURON, V16, P701, DOI 10.1016/S0896-6273(00)80091-4	30	595	610	1	51	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1997	385	6612					161	165		10.1038/385161a0	http://dx.doi.org/10.1038/385161a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WB728	8990119				2022-12-28	WOS:A1997WB72800055
J	Loh, E; Couch, FJ; Hendricksen, C; Farid, L; Kelly, PF; Acker, MA; Tomaszewski, JE; Malkowicz, SB; Weber, BL				Loh, E; Couch, FJ; Hendricksen, C; Farid, L; Kelly, PF; Acker, MA; Tomaszewski, JE; Malkowicz, SB; Weber, BL			Development of donor-derived prostate cancer in a recipient following orthotopic heart transplantation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATTERNS	Objective.-To report the development of metastatic prostate cancer in a heart transplant recipient without a primary focus in the recipient prostate gland; to present genetic evidence suggesting transplantation of the malignancy from the donor. Design.-Histological analysis of donor prostate and recipient prostate and rib, Molecular genetic analysis of prostate and kidney tissue from the donor and peripheral blood leukocytes and rib tissue from the transplant recipient. Setting.-University of Pennsylvania Medical Center. Results.-Multiple biopsies of recipient prostate were negative for malignancy but recipient rib contained prostatic adenocarcinoma with osteoblastic bone response, Molecular genetic analysis of recipient rib specimen, which contained both histologically normal and neoplastic cells, was shown to contain a combination of alleles from the donor and recipient at 4 loci. Conclusion.-Although this is a single case report of an uncommon event, genotyping of polymorphic dinucleotide repeat elements from 4 different chromosomal regions provides strong evidence that the tumor cells arose from donor tissue and were transplanted along with the cardiac allograft.	UNIV PENN,SCH MED,DEPT MED,STELLAR CHANCE LABS,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT SURG,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania								BAQUERO A, 1988, TRANSPLANT P, V20, P98; BARNARD C N, 1967, South African Medical Journal, V41, P1271; CIANCIO G, 1995, J UROLOGY, V153, P158, DOI 10.1097/00005392-199501000-00056; DANOVITCH G, 1994, CLIN TRANSPLANT 1993, P393; GAO X, 1995, CANCER RES, V55, P1002; HSIEH TC, 1995, EXP CELL RES, V218, P137, DOI 10.1006/excr.1995.1140; JEREMY D, 1972, TRANSPLANTATION, V13, P619, DOI 10.1097/00007890-197206000-00015; KIRCHWEGER R, 1994, INT J CANCER, V56, P193, DOI 10.1002/ijc.2910560208; MARSH JW, 1987, TRANSPLANTATION, V44, P449, DOI 10.1097/00007890-198709000-00025; PENN I, 1988, TRANSPLANT P, V20, P739; PENN I, 1991, TRANSPLANT P, V23, P2629; PENN I, 1988, TRANSPLANT P, V20, P885; SCHLITT HJ, 1994, LANCET, V343, P1469, DOI 10.1016/S0140-6736(94)92584-4; STARZL TE, 1993, NEW ENGL J MED, V328, P801; SWINNEN LJ, 1990, NEW ENGL J MED, V323, P1723, DOI 10.1056/NEJM199012203232502; TERASAKI PI, 1993, J HEART LUNG TRANSPL, V12, pS328	16	78	79	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1997	277	2					133	137		10.1001/jama.277.2.133	http://dx.doi.org/10.1001/jama.277.2.133			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA650	8990338				2022-12-28	WOS:A1997WA65000033
J	Kern, D; Kern, G; Neef, H; Tittmann, K; KillenbergJabs, M; Wikner, C; Schneider, G; Hubner, G				Kern, D; Kern, G; Neef, H; Tittmann, K; KillenbergJabs, M; Wikner, C; Schneider, G; Hubner, G			How thiamine diphosphate is activated in enzymes	SCIENCE			English	Article							YEAST PYRUVATE DECARBOXYLASE; DEPENDENT ENZYME; 3-DIMENSIONAL STRUCTURE; TRANSKETOLASE; CATALYSIS; C(2)-PROTON; RESOLUTION; PYROPHOSPHATE; EXCHANGE; OXIDASE	The controversial question of how thiamine diphosphate, the biologically active form of vitamin B-1, is activated in different enzymes has been addressed. Activation of the coenzyme was studied by measuring thermodynamics and kinetics of deprotonation at the carbon in the 2-position (C2) of thiamine diphosphate in the enzymes pyruvate decarboxylase and transketolase by use of nuclear magnetic resonance spectroscopy, proton/deuterium exchange, coenzyme analogs, and site-specific mutant enzymes. Interaction of a glutamate with the nitrogen in the 1'-position in the pyrimidine ring activated the 4'-amino group to act as an efficient proton acceptor for the C2 proton. The protein component accelerated the deprotonation of the C2 atom by several orders of magnitude, beyond the rate of the overall enzyme reaction. Therefore, the earlier proposed concerted mechanism or stabilization of a C2 carbanion can be excluded.	UNIV HALLE WITTENBERG,INST BIOCHEM,D-06120 HALLE,GERMANY; KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN	Martin Luther University Halle Wittenberg; Karolinska Institutet				Schneider, Gunter/0000-0003-0622-5713				ALVAREZ FJ, 1991, J AM CHEM SOC, V113, P8402, DOI 10.1021/ja00022a030; Arjunan P, 1996, J MOL BIOL, V256, P590, DOI 10.1006/jmbi.1996.0111; BOITEUX A, 1970, FEBS LETT, V9, P293, DOI 10.1016/0014-5793(70)80381-7; BRESLOW R, 1958, J AM CHEM SOC, V80, P3719, DOI 10.1021/ja01547a064; BRINGERMEYER S, 1986, ARCH MICROBIOL, V146, P105, DOI 10.1007/BF00402334; CRANE EJ, 1993, J AM CHEM SOC, V115, P8912, DOI 10.1021/ja00073a004; CROSBY J, 1970, J AM CHEM SOC, V92, P5707, DOI 10.1021/ja00722a027; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; GOLBIK R, 1991, BIOORG CHEM, V19, P10, DOI 10.1016/0045-2068(91)90039-R; HARRIS TK, 1995, BIOCHEMISTRY-US, V34, P13994, DOI 10.1021/bi00043a005; HARRIS TK, 1995, BIOCHEMISTRY-US, V34, P14001, DOI 10.1021/bi00043a006; HOLZER H, 1959, ANGEW CHEM INT EDIT, V71, P776, DOI 10.1002/ange.19590712406; HUBNER G, 1978, EUR J BIOCHEM, V92, P175, DOI 10.1111/j.1432-1033.1978.tb12735.x; JORDAN F, 1982, ANN NY ACAD SCI, V378, P14; JORDAN F, 1978, J AM CHEM SOC, V100, P2532; KEMP DS, 1970, J AM CHEM SOC, V92, P2554, DOI 10.1021/ja00711a062; KOGA J, 1995, BBA-PROTEIN STRUCT M, V1249, P1, DOI 10.1016/0167-4838(95)00011-I; KONIG S, 1994, J BIOL CHEM, V269, P10879; KONIG S, IN PRESS BIOCHEMISTR; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; MULLER YA, 1994, J MOL BIOL, V237, P315, DOI 10.1006/jmbi.1994.1233; MULLER YA, 1993, SCIENCE, V259, P965, DOI 10.1126/science.8438155; NEEF H, 1973, J PRAKT CHEM, V315, P701, DOI 10.1002/prac.19733150415; NIKKOLA M, 1994, J MOL BIOL, V238, P387, DOI 10.1006/jmbi.1994.1299; PETZOLD DR, 1976, STUD BIOPHYS, V54, P159; SCHELLENBERGER A, 1967, ANGEW CHEM INT EDIT, V6, P1024, DOI 10.1002/anie.196710241; SCHELLENBERGER A, 1967, H-S Z PHYSIOL CHEM, V348, P501, DOI 10.1515/bchm2.1967.348.1.501; SCHELLENBERGER A, 1970, CHEM BER, V123, P1489; SCHELLENBERGER A, 1985, BIOCHEM EDUC, V13, P160; SCHNEIDER G, 1993, BIOORG CHEM, V21, P109, DOI 10.1006/bioo.1993.1012; WASHABAUGH MW, 1988, BIOCHEMISTRY-US, V27, P5044, DOI 10.1021/bi00414a015; WIKNER C, 1994, J BIOL CHEM, V269, P32144; WIKNER C, UNPUB; ZEHENDER H, 1985, FEBS LETT, V180, P51, DOI 10.1016/0014-5793(85)80228-3	34	235	237	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					67	70		10.1126/science.275.5296.67	http://dx.doi.org/10.1126/science.275.5296.67			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974393				2022-12-28	WOS:A1997WA90300049
J	Birdsall, MA; Farquhar, CM; White, HD				Birdsall, MA; Farquhar, CM; White, HD			Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization	ANNALS OF INTERNAL MEDICINE			English	Article							HEART-DISEASE; CARDIOVASCULAR-DISEASE; INSULIN RESISTANCE; FOLLOW-UP; RISK; FRAMINGHAM; PREVALENCE; EXCESS	Background: Women with polycystic ovaries have associated risk factors for coronary artery disease. It is unknown whether women with more extensive coronary artery disease are more likely to have polycystic ovaries. Objective: To determine whether women who have more extensive coronary artery disease as seen on coronary angiography are more likely to have polycystic ovaries appearing on ultrasonography than are women with less severe coronary disease. Design: Prevalence study of women who had had coronary angiography. Setting: Women referred for coronary angiography for assessment of chest pain or valvular disease in Auckland, New Zealand, during a 2-year period. Patients: 143 women 60 years of age or younger who had had coronary angiography. Women who had previously had bilateral oophorectomy were excluded. Measurements: The extent of coronary artery disease assessed by quantitative angiography was compared with the presence or absence of polycystic ovaries. Pelvic ultrasonography was done without knowledge of the extent of coronary artery disease. Assessment of angiograms was blinded. Insulin resistance and gonadotropin, testosterone, and serum lipid levels were also measured. Results: Polycystic ovaries were found in 42% of women and were associated with hirsutism; previous hysterectomy; higher free testosterone, triglyceride, and C-peptide levels; and lower high-density lipoprotein cholesterol levels. Women with polycystic ovaries had more extensive coronary artery disease than women with normal ovaries (number of segments with >50% stenosis, 1.7 [95% CI, 1.1 to 2.3] compared with 0.82 [CI, 0.54 to 1.1]; P < 0.01). On logistic regression analysis, the extent of coronary artery disease (P = 0.032) and family history of heart disease (P = 0.022) were predictors of the presence of polycystic ovaries. Conclusions: In women having coronary angiography, those with more extensive coronary artery disease were more likely to have polycystic ovaries on ultrasonography than were those with less extensive disease. Visualization of polycystic ovaries by sonography was associated with distinct metabolic and endocrine abnormalities. Further study is required to evaluate whether surgery or hormone replacement therapy can modify the risk.	GREEN LANE HOSP, DEPT CARDIOL, AUCKLAND 1003, NEW ZEALAND; NATL WOMENS HOSP, AUCKLAND 1003, NEW ZEALAND; UNIV AUCKLAND, AUCKLAND 1, NEW ZEALAND	University of Auckland				Farquhar, Cynthia/0000-0002-3685-3553				ADAMS J, 1986, BRIT MED J, V293, P355, DOI 10.1136/bmj.293.6543.355; Birdsall MA, 1996, CLIN ENDOCRINOL, V44, P269, DOI 10.1046/j.1365-2265.1996.676498.x; CASTELLI WP, 1984, AM J MED, V76, P4, DOI 10.1016/0002-9343(84)90952-5; CASTELLI WP, 1986, AM HEART J, V112, P432, DOI 10.1016/0002-8703(86)90296-6; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; CONWAY GS, 1989, CLIN ENDOCRINOL, V30, P459, DOI 10.1111/j.1365-2265.1989.tb00446.x; DAHLGREN E, 1992, FERTIL STERIL, V57, P505; DUNAIF A, 1989, DIABETES, V38, P1165, DOI 10.2337/diabetes.38.9.1165; FARQUHAR CM, 1994, AUST NZ J OBSTET GYN, V34, P67, DOI 10.1111/j.1479-828X.1994.tb01041.x; FERRIMAN D, 1961, J CLIN ENDOCR METAB, V21, P1440, DOI 10.1210/jcem-21-11-1440; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; POLSON DW, 1988, LANCET, V1, P870; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; VLIETSTRA RE, 1982, ARTERIOSCLEROSIS, V2, P208, DOI 10.1161/01.ATV.2.3.208; WILD RA, 1985, J CLIN ENDOCR METAB, V61, P946, DOI 10.1210/jcem-61-5-946; WILD RA, 1990, FERTIL STERIL, V54, P255; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102	18	238	250	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1997	126	1					32	35		10.7326/0003-4819-126-1-199701010-00005	http://dx.doi.org/10.7326/0003-4819-126-1-199701010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA165	8992921				2022-12-28	WOS:A1997WA16500005
J	Burnum, JF				Burnum, JF			Trial by self-assessment	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1997	126	1					84	85		10.7326/0003-4819-126-1-199701010-00013	http://dx.doi.org/10.7326/0003-4819-126-1-199701010-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA165	8992928				2022-12-28	WOS:A1997WA16500013
J	Steele, A; Gowrishankar, M; Abrahamson, S; Mazer, CD; Feldman, RD; Halperin, ML				Steele, A; Gowrishankar, M; Abrahamson, S; Mazer, CD; Feldman, RD; Halperin, ML			Postoperative hyponatremia despite near-isotonic saline infusion: A phenomenon of desalination	ANNALS OF INTERNAL MEDICINE			English	Article							ANTI-DIURETIC HORMONE; PLASMA SODIUM CONCENTRATION; INAPPROPRIATE SECRETION; SURGERY; WOMEN	Background: It is widely presumed that the development of postoperative hyponatremia (which may be severe) results from administration of hypotonic fluids while antidiuretic hormone is acting. Objective: To show that hyponatremia would occur in patients 24 hours after surgery if only near-isotonic solutions are given and to evaluate the mechanisms responsible for hyponatremia in this setting. Design: Prospective cohort study. Setting: University medical center. Patients: 22 women who were having uncomplicated gynecologic surgery with infusion of near-isotonic solutions only (sodium chloride, 154 mmol/L, or Ringer lactate [sodium, 130 mmol/L, and potassium, 4 mmol/L]). Measurements: Plasma electrolyte levels were measured at the time of induction of anesthesia and 24 hours later. Data on the balance of water and electrolytes were obtained for the same 24-hour period. Results: At the time of induction of anesthesia, the plasma sodium concentration was 140 +/- 1 mmol/L; 24 hours later, it decreased in 21 of 22 patients (mean decrease, 4.2 +/- 0.4 mmol/L [P < 0.001]; lowest level, 131 mmol/L in 2 patients). The urine remained hypertonic (peak sodium plus potassium concentration in urine, 294 +/- 9 mmol/L) in all patients for the first 16 hours after induction of anesthesia. Conclusions: Postoperative hyponatremia occurred within 24 hours of induction of anesthesia when only near-isotonic fluids were infused. Hyponatremia was generally caused by generation of electrolyte-free water during excretion of hypertonic urine-a desalination process. This electrolyte-free water was retained in the body because of the actions of antidiuretic hormone. If the pathophysiology of this hyponatremic state is understood, recommendations for its prevention and treatment can be deduced.	UNIV TORONTO, ST MICHAELS HOSP, TORONTO, ON M5B 1A6, CANADA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto			Feldman, Ross/G-3293-2011	Mazer, Cyril David/0000-0003-2566-4308				ARIEFF AI, 1986, NEW ENGL J MED, V314, P1529, DOI 10.1056/NEJM198606123142401; Ayus JC, 1996, NEUROLOGY, V46, P323, DOI 10.1212/WNL.46.2.323; AYUS JC, 1992, ANN INTERN MED, V117, P891, DOI 10.7326/0003-4819-117-11-891; CHUNG HM, 1986, ARCH INTERN MED, V146, P333, DOI 10.1001/archinte.146.2.333; COWLEY D M, 1988, Australian and New Zealand Journal of Surgery, V58, P485, DOI 10.1111/j.1445-2197.1988.tb06240.x; DECAUX G, 1980, AM J MED, V69, P99, DOI 10.1016/0002-9343(80)90506-9; DECAUX G, 1981, NEW ENGL J MED, V304, P329, DOI 10.1056/NEJM198102053040605; EDELMAN IS, 1958, J CLIN INVEST, V37, P1236, DOI 10.1172/JCI103712; GOLDBERG M, 1981, MED CLIN N AM, V65, P251, DOI 10.1016/S0025-7125(16)31523-1; Gowrishankar M, 1996, KIDNEY INT, V50, P1490, DOI 10.1038/ki.1996.463; GOWRISHANKAR M, 1997, IN PRESS J AM SOC NE; GUY AJ, 1987, BRIT J SURG, V74, P1027, DOI 10.1002/bjs.1800741123; HALPERIN ML, 1985, AM J PHYSIOL, V248, pF607, DOI 10.1152/ajprenal.1985.248.4.F607; HALPERIN ML, 1986, AM J NEPHROL, V6, P241, DOI 10.1159/000167170; HANTMAN D, 1973, ANN INTERN MED, V78, P870, DOI 10.7326/0003-4819-78-6-870; Harrigan MR, 1996, NEUROSURGERY, V38, P152, DOI 10.1097/00006123-199601000-00035; IRVIN TT, 1972, LANCET, V2, P1159; MEBUST WK, 1989, J UROLOGY, V141, P243, DOI 10.1016/S0022-5347(17)40731-2; NELSON PB, 1981, J NEUROSURG, V55, P938, DOI 10.3171/jns.1981.55.6.0938; Oh MS, 1995, FLUID ELECTROLYTE AC, P1; Robertson Gary L., 1993, P99; ROSCOE JM, 1975, CAN MED ASSOC J, V112, P452; ROSE BD, 1986, AM J MED, V81, P1033, DOI 10.1016/0002-9343(86)90401-8; THOMAS TH, 1979, BRIT J SURG, V66, P540, DOI 10.1002/bjs.1800660806; TINDALL SF, 1981, BRIT J SURG, V68, P639, DOI 10.1002/bjs.1800680911; WRIGHT HK, 1962, SURG GYNECOL OBSTET, V115, P553	26	182	192	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1997	126	1					20	25		10.7326/0003-4819-126-1-199701010-00003	http://dx.doi.org/10.7326/0003-4819-126-1-199701010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA165	8992919				2022-12-28	WOS:A1997WA16500003
J	Folkman, J; DAmore, PA				Folkman, J; DAmore, PA			Blood vessel formation: What is its molecular basis?	CELL			English	Review							ENDOTHELIAL-CELLS; TYROSINE KINASE; MICE; VASCULOGENESIS; HEMATOPOIESIS; BETA		HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	Folkman, J (corresponding author), CHILDRENS HOSP,300 LONGWOOD AVE,BOSTON,MA 02115, USA.		D'Amore, Patricia A/G-5660-2017	D'Amore, Patricia A/0000-0001-9652-8974				ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DUMONT DJ, 1992, ONCOGENE, V7, P1471; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FLAMME I, 1992, DEVELOPMENT, V116, P435; Folkman J., 1996, CANC MED, V1, P181; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; HIRSCHI KK, 1996, RES, V32, P687; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Rohovsky Stephanie A., 1996, Surgical Forum, V47, P390; SAENZ NC, 1991, LAB INVEST, V65, P15; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888	17	1025	1088	0	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1153	1155		10.1016/S0092-8674(00)81810-3	http://dx.doi.org/10.1016/S0092-8674(00)81810-3			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980221	Bronze			2022-12-28	WOS:A1996WA54100003
J	McNaughton, M; Barry, MJ				McNaughton, M; Barry, MJ			Controversies in prostate cancer screening - Analogies to the early lung cancer screening debate	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICARE PROVIDE REIMBURSEMENT; DIGITAL RECTAL EXAMINATION; DETECTION PROGRAM; BREAST-CANCER; ANTIGEN; PREVALENCE; TRIAL; SERUM; MANAGEMENT; DIAGNOSIS	The current debate regarding early detection and aggressive treatment of prostate cancer is fueled by the absence of controlled studies defining the risks and benefits of prostate cancer screening, and by the lack of adequately powered trials demonstrating the benefit of curative treatment for early-stage prostate cancer. Pending the results of clinical trials in 10 to 15 years, advocates of early detection of prostate cancer with digital rectal examination and prostate-specific antigen have compared prostate cancer screening with the effective strategy of breast cancer screening, implying that prostate cancer screening should similarly reduce cancer mortality. They have also cited the high burden of disease, the acceptable operating characteristics of digital rectal examination and prostate-specific antigen, a stage shift among cases detected by screening, and the theoretical curability of early-stage disease as sufficient reasons to proceed with screening. These arguments, however, are reminiscent of earlier arguments in favor of lung cancer screening with chest x-ray examination and sputum cytology, a practice ultimately proven ineffective in clinical trials. We reviewed published articles on lung and prostate cancer screening and identified many parallels. While prostate cancer screening may one day prove effective, analogies between the current prostate cancer screening controversy and the older lung cancer screening debate should inject some caution regarding widespread dissemination of prostate cancer screening without experimental evidence that such screening does more good than harm.	MASSACHUSETTS GEN HOSP, MED PRACTICES EVALUAT CTR, DIV GEN MED, MED SERV, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital					BHP HRSA HHS [5T32 PE11001-08] Funding Source: Medline	BHP HRSA HHS		*ACS WORKSH ORG CO, 1974, CANCER S, V33, P1759; ADAMI HO, 1994, LANCET, V343, P958, DOI 10.1016/S0140-6736(94)90071-X; ADRIOLE GL, 1993, SEMIN UROL, V11, P50; *AM CANC SOC, 1980, CA-CANCER J CLIN, V30, P199; BAILAR JC, 1984, AM REV RESPIR DIS, V130, P541; BARRY MJ, 1995, UROLOGY, V46, P445, DOI 10.1016/S0090-4295(99)80255-6; BARRY MJ, 1995, UROLOGY, V46, P2, DOI 10.1016/S0090-4295(99)80151-4; BARRY MJ, 1995, UROLOGY, V46, P277, DOI 10.1016/S0090-4295(99)80208-8; BARRY MJ, 1994, J UROLOGY, V152, P1903, DOI 10.1016/S0022-5347(17)32411-4; BARRY MJ, 1995, UROLOGY, V46, P125; Bean I W, 1967, CA Cancer J Clin, V17, P215, DOI 10.3322/canjclin.17.5.215; BENOIT RM, 1995, UROLOGY, V46, P533, DOI 10.1016/S0090-4295(99)80267-2; BENOIT RM, 1994, UROLOGY, V44, P795, DOI 10.1016/S0090-4295(94)80160-6; BERLIN NI, 1984, AM REV RESPIR DIS, V130, P545; BERLIN NI, 1974, CANCER, V33, P1744, DOI 10.1002/1097-0142(197406)33:6+<1744::AID-CNCR2820330711>3.0.CO;2-Z; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; BOUCOT K R, 1948, J Am Med Womens Assoc, V3, P485; BOUCOT KR, 1959, NEW ENGL J MED, V260, P742, DOI 10.1056/NEJM195904092601503; BOUCOT KR, 1955, DIS CHEST, V27, P369, DOI 10.1378/chest.27.4.369; BRETT AS, 1995, J GEN INTERN MED, V10, P266, DOI 10.1007/BF02599885; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CATALONA WJ, 1993, UROLOGY, V42, P113, DOI 10.1016/0090-4295(93)90632-K; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; Chodak G W, 1993, Semin Urol, V11, P47; CHODAK GW, 1993, UROLOGY, V42, P116, DOI 10.1016/0090-4295(93)90633-L; EDDY DM, 1989, ANN INTERN MED, V111, P232, DOI 10.7326/0003-4819-111-3-232; EDDY DM, 1993, JAMA-J AM MED ASSOC, V270, P520; FLEHINGER BJ, 1984, AM REV RESPIR DIS, V130, P555; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; FONTANA RS, 1986, J OCCUP ENVIRON MED, V28, P746, DOI 10.1097/00043764-198608000-00038; FONTANA RS, 1991, CANCER-AM CANCER SOC, V67, P1155, DOI 10.1002/1097-0142(19910215)67:4+<1155::AID-CNCR2820671509>3.0.CO;2-0; FONTANA RS, 1975, CHEST, V67, P511, DOI 10.1378/chest.67.5.511; FONTANA RS, 1984, AM REV RESPIR DIS, V130, P561; FROST JK, 1984, AM REV RESPIR DIS, V130, P549; GOHAGAN JK, 1994, J UROLOGY, V152, P1905, DOI 10.1016/S0022-5347(17)32412-6; HAHN DL, 1993, J FAM PRACTICE, V37, P432; JACOBSEN SJ, 1995, JAMA-J AM MED ASSOC, V274, P1445, DOI 10.1001/jama.274.18.1445; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; LEDERLE FA, 1994, ARCH INTERN MED, V154, P2397, DOI 10.1001/archinte.154.21.2397; LILIENFE.A, 1966, CANCER RES, V26, P2083; LITTRUP PJ, 1994, CANCER-AM CANCER SOC, V74, P2016, DOI 10.1002/1097-0142(19941001)74:7+<2016::AID-CNCR2820741705>3.0.CO;2-J; MELAMED MR, 1984, CHEST, V86, P44, DOI 10.1378/chest.86.1.44; METTLIN C, 1993, CANCER, V72, P1050, DOI 10.1002/1097-0142(19930801)72:3+<1050::AID-CNCR2820721318>3.0.CO;2-J; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; Miller A B, 1993, J Public Health Policy, V14, P403, DOI 10.2307/3342875; *NCI, 1978, NCI CONS C SEPT 18 2, P32; OVERHOLT RH, 1951, NEW ENGL J MED, V245, P555, DOI 10.1056/NEJM195110112451502; OVERHOLT RH, 1950, AM REV TUBERC PULM, V62, P491; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PARTIN AW, 1994, J UROLOGY, V152, P1358, DOI 10.1016/S0022-5347(17)32422-9; POTOSKY AL, 1995, JAMA-J AM MED ASSOC, V273, P548, DOI 10.1001/jama.273.7.548; Prorok P, 1994, Can J Oncol, V4 Suppl 1, P98; REICH JM, 1993, ARCH INTERN MED, V153, P1933, DOI 10.1001/archinte.1993.00410160107012; RITCHIE JP, 1993, UROLOGY, V42, P365; RUCKLE HC, 1994, MAYO CLIN PROC, V69, P59, DOI 10.1016/S0025-6196(12)61614-0; SACKETT DL, 1975, LANCET, V2, P357, DOI 10.1016/S0140-6736(75)92790-7; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P153; SCAMMAN CL, 1951, NEW ENGL J MED, V244, P541, DOI 10.1056/NEJM195104122441502; SCARDINO PT, 1994, MY PROSTATE ME, P209; STONE NN, 1994, UROLOGY, V44, P18, DOI 10.1016/S0090-4295(94)80239-4; TAYLOR WF, 1981, CANCER, V47, P1114, DOI 10.1002/1097-0142(19810301)47:5+<1114::AID-CNCR2820471309>3.0.CO;2-N; TOCKMAN MS, 1986, CHEST, V89, pS324, DOI 10.1378/chest.89.4_Supplement.324S-a; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P119; VICTOR AB, 1955, DIS CHEST, V27, P389, DOI 10.1378/chest.27.4.389; WALSH PC, 1992, J UROLOGY, V147, P853, DOI 10.1016/S0022-5347(17)37404-9; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; WILT TJ, 1994, J UROLOGY, V152, P1910, DOI 10.1016/S0022-5347(17)32413-8; WOOLF SH, 1995, NEW ENGL J MED, V333, P1401, DOI 10.1056/NEJM199511233332107; WOOLF SH, 1994, J UROLOGY, V152, P1685, DOI 10.1016/S0022-5347(17)32361-3; WOOLNER LB, 1981, MAYO CLIN PROC, V56, P544; 1984, AM REV RESPIR DIS, V130, P565	72	63	63	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1996	276	24					1976	1979						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY689	8971068				2022-12-28	WOS:A1996VY68900031
J	Kuhn, M				Kuhn, M			Emergency medicine - New techniques and toilet plungers	LANCET			English	Article											Kuhn, M (corresponding author), ROYAL ADELAIDE HOSP,EMERGENCY DEPT,N TERRACE,ADELAIDE,SA 5000,AUSTRALIA.							Baxt WG, 1996, LANCET, V347, P12, DOI 10.1016/S0140-6736(96)91555-X; Mateer JR, 1996, ANN EMERG MED, V27, P283, DOI 10.1016/S0196-0644(96)70260-3; Mulcahy B, 1996, ACAD EMERG MED, V3, P114, DOI 10.1111/j.1553-2712.1996.tb03397.x; Stiell IG, 1996, JAMA-J AM MED ASSOC, V275, P1417, DOI 10.1001/jama.275.18.1417; Williams RM, 1996, NEW ENGL J MED, V334, P642, DOI 10.1056/NEJM199603073341007	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348			2			SII5	SII5						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973483				2022-12-28	WOS:A1996WA46300005
J	Simini, B				Simini, B			Anaesthesia - Starved, sleepless, cold, and in pain	LANCET			English	Article																		Hirose M, 1996, ANESTH ANALG, V82, P1166, DOI 10.1097/00000539-199606000-00011; RosenbergAdamsen S, 1996, BRIT J ANAESTH, V76, P552, DOI 10.1093/bja/76.4.552; Russell GN, 1996, ANESTH ANALG, V83, P228, DOI 10.1097/00000539-199608000-00005; Sellden E, 1996, BRIT J ANAESTH, V76, P227, DOI 10.1093/bja/76.2.227; Tramer M, 1996, BRIT J ANAESTH, V76, P186, DOI 10.1093/bja/76.2.186	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348			2			SII1	SII1						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973479				2022-12-28	WOS:A1996WA46300001
J	Bates, E; Elman, J				Bates, E; Elman, J			Learning rediscovered	SCIENCE			English	Editorial Material							LANGUAGE		UNIV CALIF SAN DIEGO, DEPT PSYCHOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	Bates, E (corresponding author), UNIV CALIF SAN DIEGO, DEPT COGNIT SCI, LA JOLLA, CA 92093 USA.		Elman, Jeffrey L/A-9858-2008	Elman, Jeffrey L/0000-0002-8072-2294				Chomsky N, 1980, RULES REPRESENTATION; CRAIN S, 1991, BEHAV BRAIN SCI, V14, P597, DOI 10.1017/S0140525X00071491; ELMAN JL, 1993, COGNITION, V48, P71, DOI 10.1016/0010-0277(93)90058-4; ELMAN JL, 1988, J ACOUST SOC AM, V83, P1615, DOI 10.1121/1.395916; Elman JL, 1996, RETHINKING INNATENES; FENSON L, 1994, MONOGR SOC RES CHILD, V59, pR5; JUSCZYK PW, 1993, J MEM LANG, V32, P402, DOI 10.1006/jmla.1993.1022; LIGHTFOOT D, 1980, LANGUAGE LOTTERY; Lund K, 1996, BEHAV RES METH INSTR, V28, P203, DOI 10.3758/BF03204766; MEHLER J, 1986, CR ACAD SCI III-VIE, V303, P637; NEWMEYER FJ, 1980, LINGUISTIC THEORY AM; PIATTELLIPALMARINI M, 1989, COGNITION, V31, P1, DOI 10.1016/0010-0277(89)90016-4; Saffran JR, 1996, SCIENCE, V274, P1926, DOI 10.1126/science.274.5294.1926; [No title captured]	14	76	76	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1849	1850		10.1126/science.274.5294.1849	http://dx.doi.org/10.1126/science.274.5294.1849			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VY200	8984644				2022-12-28	WOS:A1996VY20000025
J	Brentlinger, PE				Brentlinger, PE			Health sector response to security threats during the civil war in El Salvador	BRITISH MEDICAL JOURNAL			English	Article								During the recent civil war in El Salvador, as in other modern wars, human rights abuses adversely affected health workers, patients, and medical facilities. The abuses themselves have been described in reports of human rights advocacy organisations but health sector adaptations to a hostile wartime environment have not. Agencies engaged in health work during the civil war adapted tactics such as training of community based lay health workers, use of simple technology, concealment of patients and medical supplies, denunciation of human rights abuses, and multilevel negotiations in order to continue providing services. The Salvadorean experience may serve as a helpful case study for medical personnel working in wars elsewhere.						Brentlinger, Paula/0000-0002-4865-8915				ACHESON D, 1993, BRIT MED J, V307, P44, DOI 10.1136/bmj.307.6895.44; ARNSON C, 1991, ELSALVADOR HUMAN RIG; BERISTAIN C, 1992, AFIRMACIN RESISTENCI; CERMERLIC EZ, 1995, JAMA-J AM MED ASSOC, V274, P386; Clements Charles., 1984, WITNESS WAR AM DOCTO; DEVIN J, 1992, VIOLATION MED NEUTRA, P104; EISENBERG C, 1983, NEW ENGL J MED, V308, P1028; EISENBERG C, 1990, EL SALVADOR HLTH CAR; GARFIELD RM, 1987, AM J PUBLIC HEALTH, V77, P615, DOI 10.2105/AJPH.77.5.615; GELLHORN A, 1983, NEW ENGL J MED, V308, P1043, DOI 10.1056/NEJM198304283081736; *INT COMM MED NEUT, 1991, VIOL MED NEUTR EL SA; KALSHOVEN F, 1992, VIOLATION MED NEUTRA, P21; MAGARRELL L, 1992, VIOLATION MED NEUTRA, P55; Metzi Francisco, 1988, CAMINOS CHALATENANGO; NEIER A, 1983, 3 SUPPLEMENT REPORT; Roberts A, 1989, DOCUMENTS LAWS WAR; SUMMERFIELD D, 1988, LANCET, V2, P360; *UN, 1993, COMISIN VERDAD EL SA; *UN, 1993, COM VERD EL SALV IOC; *UN, 1993, COM VERD EL SALV LOC; Werner D., 1992, THERE IS NO DOCTOR; *WORLD MED ASS, 1987, DAN MED B, V34, P321	22	10	10	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1996	313	7070					1470	1474		10.1136/bmj.313.7070.1470	http://dx.doi.org/10.1136/bmj.313.7070.1470			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX612	8973238	Green Published			2022-12-28	WOS:A1996VX61200038
J	Costantino, RF; Desharnais, RA; Cushing, JM; Dennis, B				Costantino, RF; Desharnais, RA; Cushing, JM; Dennis, B			Chaotic dynamics in an insect population	SCIENCE			English	Article							MODELS	A nonlinear demographic model was used to predict the population dynamics of the flour beetle Tribolium under laboratory conditions and to establish the experimental protocol that would reveal chaotic behavior, With the adult mortality rate experimentally set high, the dynamics of animal abundance changed from equilibrium to quasiperiodic cycles to chaos as adult-stage recruitment rates were experimentally manipulated. These transitions in dynamics corresponded to those predicted by the mathematical model. Phase-space graphs of the data together with the deterministic model attractors provide convincing evidence of transitions to chaos.	CALIF STATE UNIV LOS ANGELES,DEPT BIOL & MICROBIOL,LOS ANGELES,CA 90032; UNIV RHODE ISL,DEPT BIOL SCI,KINGSTON,RI 02881; UNIV ARIZONA,DEPT MATH,TUCSON,AZ 85721; UNIV IDAHO,DEPT FISH & WILDLIFE RESOURCES,MOSCOW,ID 83844	California State University System; California State University Los Angeles; University of Rhode Island; University of Arizona; Idaho; University of Idaho				Desharnais, Robert/0000-0003-2874-6835; Cushing, Jim/0000-0003-1844-661X				BERRYMAN AA, 1989, TRENDS ECOL EVOL, V4, P26, DOI 10.1016/0169-5347(89)90014-1; Costantino R. F., 1991, POPULATION DYNAMICS; COSTANTINO RF, 1995, NATURE, V375, P227, DOI 10.1038/375227a0; DENNIS B, 1995, ECOL MONOGR, V65, P261, DOI 10.2307/2937060; ELLNER S, 1995, AM NAT, V145, P343, DOI 10.1086/285744; GODFRAY HCJ, 1990, PHILOS T ROY SOC B, V330, P221, DOI 10.1098/rstb.1990.0194; GODFRAY HCJ, 1993, TRENDS ECOL EVOL, V8, P43, DOI 10.1016/0169-5347(93)90155-I; HASSELL MP, 1990, POPULATION REGULATIO; HASTINGS A, 1993, ANNU REV ECOL SYST, V24, P1, DOI 10.1146/annurev.es.24.110193.000245; KAREIVA P, 1989, PERSPECTIVES ECOLOGI; MAY RM, 1974, SCIENCE, V186, P645, DOI 10.1126/science.186.4164.645; MAY RM, 1976, AM NAT, V110, P573, DOI 10.1086/283092; POOL R, 1989, SCIENCE, V243, P310, DOI 10.1126/science.243.4889.310; Sokoloff, 1977, BIOL TRIBOLIUM, V3; Sokoloff A, 1974, BIOL TRIBOLIUM, VII; Sokoloff A, 1972, BIOL TRIBOLIUM, V1; TONG H, 1992, J R STAT SOC B, V54, P301; Tong H, 1990, NONLINEAR TIME SERIE	18	286	297	3	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					389	391		10.1126/science.275.5298.389	http://dx.doi.org/10.1126/science.275.5298.389			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994036				2022-12-28	WOS:A1997WC87300047
J	MasucciMagoulas, L; Goldberg, IJ; Bisgaier, CL; Serajuddin, H; Francone, OL; Breslow, JL; Tall, AR				MasucciMagoulas, L; Goldberg, IJ; Bisgaier, CL; Serajuddin, H; Francone, OL; Breslow, JL; Tall, AR			A mouse model with features of familial combined hyperlipidemia	SCIENCE			English	Article							SERUM TRIGLYCERIDE LEVELS; APOLIPOPROTEIN-A-I; AIV GENE-CLUSTER; TRANSGENIC MICE; PLASMA-LIPOPROTEINS; LPL GENE; CHOLESTEROL; HYPERTRIGLYCERIDEMIA; EXPRESSION; POLYMORPHISMS	Familial combined hyperlipidemia (FCHL) is a common inherited lipid disorder, affecting 1 to 2 percent of the population in Westernized societies. Individuals with FCHL have large quantities of very low density lipoprotein (VLDL) and low density lipoprotein (LDL) and develop premature coronary heart disease. A mouse model displaying some of the features of FCHL was created by crossing mice carrying the human apolipoprotein C-III (APOC3) transgene with mice deficient in the LDL receptor. A synergistic interaction between the apolipoprotein C-III and the LDL receptor defects produced large quantities of VLDL and LDL and enhanced the development of atherosclerosis. This mouse model may provide clues to the origin of human FCHL.	COLUMBIA UNIV,DEPT MED,NEW YORK,NY 10032; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES,DEPT VASC & CARDIAC DIS,ANN ARBOR,MI 48105; PFIZER INC,DIV CENT RES,DEPT METAB DIS,GROTON,CT 06340; ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,NEW YORK,NY 10021	Columbia University; Pfizer; Pfizer; Rockefeller University			Breslow, Jan L/B-7544-2008; Tall, Alan/AAT-8528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006, P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 21006, HL 54591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AAITOSETALA K, 1992, J CLIN INVEST, V90, P1889; AaltoSetala K, 1996, J LIPID RES, V37, P1802; AGELLON LB, 1991, J BIOL CHEM, V266, P10796; BABIRAK SP, 1992, ARTERIOSCLER THROMB, V12, P1176, DOI 10.1161/01.ATV.12.10.1176; BRUNS GAP, 1984, ARTERIOSCLEROSIS, V4, P97, DOI 10.1161/01.ATV.4.2.97; BRUNZELL JD, 1983, J LIPID RES, V24, P147; BRUNZELL JD, 1984, ARTERIOSCLEROSIS, V4, P79, DOI 10.1161/01.ATV.4.2.79; CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CHIESA G, 1993, J CLIN INVEST, V32, P23747; CULLEN P, 1994, ARTERIOSCLER THROMB, V14, P1233, DOI 10.1161/01.ATV.14.8.1233; DallingaThie GM, 1996, J LIPID RES, V37, P136; DAMMERMAN M, 1993, P NATL ACAD SCI USA, V90, P4562, DOI 10.1073/pnas.90.10.4562; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; FIELDING CJ, 1995, J LIPID RES, V36, P211; GAGNE E, 1994, ARTERIOSCLER THROMB, V14, P1250, DOI 10.1161/01.ATV.14.8.1250; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; GRUNDY SM, 1987, ARTERIOSCLEROSIS, V7, P203; Haubenwallner S, 1995, J LIPID RES, V36, P2541; HAYDEN MR, 1987, AM J HUM GENET, V40, P421; HAYEK T, 1995, J CLIN INVEST, V96, P2071, DOI 10.1172/JCI118255; ISHIBASHI S, 1994, J CLIN INVEST, V92, P833; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JI ZS, 1994, J BIOL CHEM, V269, P2764; JIANG XC, 1992, J CLIN INVEST, V90, P1290, DOI 10.1172/JCI115993; KIEFT KA, 1991, J LIPID RES, V32, P859; Li WW, 1995, J CLIN INVEST, V96, P2601, DOI 10.1172/JCI118324; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SCHACHTER NS, 1996, J CLIN INVEST, V98, P846; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; VENKATESAN S, 1993, ARTERIOSCLER THROMB, V13, P1110, DOI 10.1161/01.ATV.13.7.1110; WOJCIECHOWSKI AP, 1991, NATURE, V349, P161, DOI 10.1038/349161a0; XU CF, 1994, CLIN GENET, V46, P385; YANG WS, 1995, P NATL ACAD SCI USA, V92, P4462, DOI 10.1073/pnas.92.10.4462; ZENG Q, 1994, HUM GENET, V95, P371	34	111	112	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					391	394		10.1126/science.275.5298.391	http://dx.doi.org/10.1126/science.275.5298.391			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994037				2022-12-28	WOS:A1997WC87300048
J	Penton, A; Selleck, SB; Hoffmann, FM				Penton, A; Selleck, SB; Hoffmann, FM			Regulation of cell cycle synchronization by decapentaplegic during Drosophila eye development	SCIENCE			English	Article							G2-M TRANSITION; GENE-PRODUCT; DPP; HEDGEHOG; PROTEIN; ENCODES; COMPARTMENT; EXPRESSION; SCHNURRI; PATTERN	In the developing Drosophila eye, differentiation is coordinated with synchronized progression through the cell cycle. Signaling mediated by the transforming growth factor-beta-related gene decapentaplegic (dpp) was required for the synchronization of the cell cycle but not for cell fate specification. DPP may affect cell cycle synchronization by promoting cell cycle progression through the G(2)-M phases. This synchronization is critical for the precise assembly of the eye.	UNIV WISCONSIN,SCH MED,MCARDLE LAB CANC RES,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,GENET LAB,MADISON,WI 53706; UNIV ARIZONA,ARIZONA RES LABS,DIV NEUROBIOL,TUCSON,AZ 85721; UNIV ARIZONA,DEPT MOL & CELLULAR BIOL,TUCSON,AZ 85721	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Arizona; University of Arizona				Hoffmann, F. Michael/0000-0002-2770-9656				ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1992, DEVELOPMENT, V115, P21; BROWN NL, 1991, DEVELOPMENT, V113, P1245; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; FISCHERVIZE JA, 1994, DEVELOPMENT, V120, P2609; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEBERLEIN U, 1995, NATURE, V373, P709, DOI 10.1038/373709a0; Jackson SG, UNPUB; JARMAN AP, 1994, NATURE, V369, P398, DOI 10.1038/369398a0; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; Milan M, 1996, P NATL ACAD SCI USA, V93, P640, DOI 10.1073/pnas.93.2.640; NAKATO H, 1995, DEVELOPMENT, V121, P3687; PENTON A, UNPUB; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; STAEHLINGHAMPTON K, 1995, DEVELOPMENT, V121, P3393; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; WILLIAMS JA, 1991, GENE DEV, V5, P2481, DOI 10.1101/gad.5.12b.2481; WOLFF T, 1993, DEV DROSOPHILA MELAN, V2, P1277; XU T, 1993, DEVELOPMENT, V117, P1223; ZECCA M, 1995, DEVELOPMENT, V121, P2265	29	70	71	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					203	206		10.1126/science.275.5297.203	http://dx.doi.org/10.1126/science.275.5297.203			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985012				2022-12-28	WOS:A1997WC02200035
J	Vinger, PF; Parver, L; Alfaro, DV; Woods, T; Abrams, BS				Vinger, PF; Parver, L; Alfaro, DV; Woods, T; Abrams, BS			Shatter resistance of spectacle lenses	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PENETRATING EYE INJURIES; OCULAR INJURIES	Objective.-To evaluate the relative strength and shatter resistance of spectacle tenses currently used in sunglasses and dress, sports, and industrial eyewear. Design.-Seven lenses that met the US American National Standards institute (ANSI) Z80 standards for dress glasses (made of high-index plastic, allyl resin plastic, heat tempered glass, chemically tempered glass, and polycarbonate, and with center thickness ranging from 1 mm to 2.2 mm) and 4 lenses that met ANSI Z87 standards for industrial safety eyewear (allyl resin plastic, heat-tempered glass, chemically tempered glass, and polycarbonate, all with 3.0-mm center thickness) were tested for impact resistance to 5 projectiles (air gun pellets, golf bails, tennis balls, lacrosse balls, and baseballs). Main Outcome Measures.-Impact energy required to shatter spectacle lenses. Results.-Based on 348 lens impacts, dress and industrial lenses made from glass, allyl resin plastic, and high-index plastic shattered at impact energies less than those expected to be encountered from the test projectiles during their routine use. Polycarbonate lenses demonstrated resistance to impact for all tested projectiles exceeding the impact potential expected during routine use. Conclusions.-Under the test conditions of this study, polycarbonate lenses demonstrated greater impact resistance than other commonly used spectacle lenses that conform to prevailing eyewear standards. These findings suggest that current ANSI Z80 and ANSI Z87 standards should be reevaluated.	TUFTS UNIV,SCH MED,MEDFORD,MA 02155; JOHNS HOPKINS UNIV,WILMER EYE INST,BETHESDA,MD; UNIFORMED SERV UNIV HLTH SCI,F EDWARD HEBERT SCH MED,BETHESDA,MD 20814; CUNY,NEW YORK CITY TECH COLL,NEW YORK,NY 10021; OHIO STATE UNIV,COLUMBUS,OH 43210	Tufts University; Johns Hopkins University; Johns Hopkins Medicine; Uniformed Services University of the Health Sciences - USA; City University of New York (CUNY) System; University System of Ohio; Ohio State University								*AM NAT STAND I, 1986, AM NAT STAND OPHTH N; *AM NAT STAND I, 1989, AM NAT STAND PRACT O; *AM NAT STAND I, 1995, AM NAT STAND OPHTH P; CHRISTIANSON MD, 1977, CAN J OPHTHALMOL, V12, P300; COLE MD, 1988, BRIT J OPHTHALMOL, V72, P511, DOI 10.1136/bjo.72.7.511; DANNENBERG AL, 1992, ARCH OPHTHALMOL-CHIC, V110, P843, DOI 10.1001/archopht.1992.01080180115038; FONG LP, 1993, AM AC OPHTH M NOV 19; GAULT JA, 1995, J TRAUMA, V38, P494, DOI 10.1097/00005373-199504000-00005; INGRAM DV, 1973, BRIT J OPHTHALMOL, V57, P434, DOI 10.1136/bjo.57.6.434; KATZ J, 1993, ARCH OPHTHALMOL-CHIC, V111, P1564, DOI 10.1001/archopht.1993.01090110130038; KEENEY AH, 1972, AM J OPHTHALMOL, V73, P289, DOI 10.1016/0002-9394(72)90149-3; KEENEY AH, 1972, ARCH OPHTHALMOL-CHIC, V88, P2; KEENEY AH, 1971, AM J OPHTHALMOL, V72, P152, DOI 10.1016/0002-9394(71)91606-0; KEENEY AH, 1972, AM J OPHTHALMOL, V74, P662, DOI 10.1016/0002-9394(72)90827-6; *NAT EL INJ SURV S, 1996, US CONS PROD SAF COM; OFFUTT RL, 1974, ANN OPHTHALMOL, V6, P357; ORLANDO RG, 1991, PHYSICIAN SPORTSMED, V19, P62; PATEL BCK, 1991, ACTA OPHTHALMOL, V69, P377; *US DEP LAB BUR LA, 1980, 597 US DEP LAB BUR L; *US EYE INJ REG, 1996, US EYE INJ REG ANN R; VINGER PF, 1978, JAMA-J AM MED ASSOC, V239, P2575, DOI 10.1001/jama.239.24.2575; VINGER PF, 1994, CLIN OPHTHALMOL, V5, P1; VINGER PF, 1996, ASTM STP, V1313; 1970, JAMA-J AM MED ASSOC, V213, P2071	24	26	26	1	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1997	277	2					142	144		10.1001/jama.277.2.142	http://dx.doi.org/10.1001/jama.277.2.142			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA650	8990340				2022-12-28	WOS:A1997WA65000035
J	Graham, SM; Daley, HM; Ngwira, B				Graham, SM; Daley, HM; Ngwira, B			Finger clubbing and HIV infection in Malawian children	LANCET			English	Article											Graham, SM (corresponding author), UNIV MALAWI,COLL MED,DEPT PAEDIAT,BLANTYRE 3,MALAWI.			Graham, Stephen/0000-0003-3525-2294				REEVE PA, 1987, THORAX, V42, P986, DOI 10.1136/thx.42.12.986	1	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					31	31		10.1016/S0140-6736(05)62164-2	http://dx.doi.org/10.1016/S0140-6736(05)62164-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988127				2022-12-28	WOS:A1997WA72500021
J	Oliver, JD; vanderWal, FJ; Bulleid, NJ; High, S				Oliver, JD; vanderWal, FJ; Bulleid, NJ; High, S			Interaction of the thiol-dependent reductase ERp57 with nascent glycoproteins	SCIENCE			English	Article							PHOSPHOLIPASE-C-ALPHA; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; QUALITY-CONTROL; PROTEINS; CALNEXIN; ASSOCIATION; FORM; CALRETICULIN; DEGRADATION	Calnexin and calreticulin interact specifically with newly synthesized glycoproteins in the endoplasmic reticulum (ER) and function as molecular chaperones. The carbohydrate-specific interactions between ER components and glycoproteins synthesized in isolated canine pancreatic microsomes were analyzed using a cross-linking approach. A carbohydrate-dependent interaction between newly synthesized glycoproteins, the thiol-dependent reductase ERp57, and either calnexin or calreticulin was identified. The interaction between ERp57 and the newly synthesized glycoproteins required trimming of the N-linked oligosaccharide side chain. Thus, it is likely that ERp57 functions as part of the glycoprotein-specific quality control machinery operating in the lumen of the ER.	UNIV MANCHESTER,SCH BIOL SCI,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Manchester				High, Stephen/0000-0002-4532-8152; Bulleid, Neil/0000-0002-9839-5279; van der Wal, Fimme/0000-0002-6859-1252				ABRIOLA C, 1905, J CELL BIOL, V130, P771; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BULLEID NJ, 1990, BIOCHEM J, V268, P777, DOI 10.1042/bj2680777; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARLOW E, 1988, NTIBODIES LAB MANUAL; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; HIRANO N, 1994, BIOCHEM BIOPH RES CO, V204, P375, DOI 10.1006/bbrc.1994.2469; HIRANO N, 1995, EUR J BIOCHEM, V234, P336, DOI 10.1111/j.1432-1033.1995.336_c.x; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KLAPPA P, 1995, EUR J BIOCHEM, V232, P755, DOI 10.1111/j.1432-1033.1995.tb20870.x; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; Oliver JD, 1996, J BIOL CHEM, V271, P13691, DOI 10.1074/jbc.271.23.13691; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; SRIVASTAVA SP, 1991, J BIOL CHEM, V266, P20337; SRIVASTAVA SP, 1993, BIOCHEM BIOPH RES CO, V193, P971, DOI 10.1006/bbrc.1993.1720; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; URADE R, 1992, J BIOL CHEM, V267, P15152	25	334	340	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					86	88		10.1126/science.275.5296.86	http://dx.doi.org/10.1126/science.275.5296.86			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974399				2022-12-28	WOS:A1997WA90300055
J	Andreotti, AH; Bunnell, SC; Feng, S; Berg, LJ; Schreiber, SL				Andreotti, AH; Bunnell, SC; Feng, S; Berg, LJ; Schreiber, SL			Regulatory intramolecular association in a tyrosine kinase of the Tec family	NATURE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; SH3 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; GENE; PROTEIN; BINDING; EXPRESSION; PEPTIDES; INTERLEUKIN-2; SPECTROSCOPY	THE T-cell-specific tyrosine kinase Itk is a member of the Tec family of non-receptor tyrosine kinases(1-7), and is required for signalling through the T-cell antigen receptor (TCR)(8). The role of Itk in TCR Signalling and the manner in which Itk activity is regulated are not well understood. Substrate binding and enzymatic activity of the structurally related Src kinases are regulated by an intramolecular interaction between the Src-homology-2 (SH2) domain and a phosphotyrosine(9,10). Although Itk also contains SH3, SH2 and tyrosine kinase domains, it lacks the corresponding regulatory phosphorylation site, and therefore must be regulated by an alternative mechanism. The proline-rich sequence adjacent to the SH3 domain of Tec family kinases contains an SH3 ligand, potentially allowing a different intramolecular interaction. By using multidimensional nuclear magnetic resonance we have determined the structure of a fragment of Itk, confirming that these domains interact intramolecularly. Formation of this intramolecular SH3-ligand complex prevents the Itk SH3 domain and proline-rich region from interacting with their respective protein ligands, Sam68 and Grb-2. We believe that this structure represents the first example of an intramolecular interaction between an SH3 domain and a proline-rich ligand, and has implications for the regulation of Tec family kinases.	HARVARD UNIV, HOWARD HUGHES MED INST, DEPT CHEM & CHEM BIOL, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, DEPT MOL & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	Harvard University; Howard Hughes Medical Institute; Harvard University				Bunnell, Stephen/0000-0001-6887-0828				Anafi M, 1996, J BIOL CHEM, V271, P21365, DOI 10.1074/jbc.271.35.21365; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; BRUNGER AT, 1992, XPLOR 3 1; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHEN JK, 1994, BIOORG MED CHEM LETT, V4, P1755, DOI 10.1016/S0960-894X(00)80375-3; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Liao XC, 1995, IMMUNITY, V3, P757, DOI 10.1016/1074-7613(95)90065-9; MANO H, 1993, ONCOGENE, V8, P417; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANAKA N, 1993, FEBS LETT, V324, P1, DOI 10.1016/0014-5793(93)81520-A; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	30	229	235	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 2	1997	385	6611					93	97		10.1038/385093a0	http://dx.doi.org/10.1038/385093a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985255				2022-12-28	WOS:A1997WA73100058
J	Kang, JM; Rebek, J				Kang, JM; Rebek, J			Acceleration of a Diels-Alder reaction by a self-assembled molecular capsule	NATURE			English	Article							MICELLAR CATALYSIS	THE interior of cage-like molecules can be considered to provide a new phase of matter(1,2), in which it becomes possible to stabilize reactive intermediates(3) and to observe new forms of stereoisomerism(4). Cage-like molecular complexes that self-assemble through weak intermolecular forces are dynamic species(5,6), encapsulating guest molecules reversibly. They can persist over timescales ranging from microseconds to hours, long enough for chemical processes to take place within them. Here we report the acceleration of a Diels-Alder reaction bg encapsulation of the reactants in a self-assembling molecular capsule(7,8). Although product inhibition (lack of dissociation) prevents the system from showing true catalytic behaviour, there is clear evidence for a rate increase of over two orders of magnitude owing to the effective enhancement of concentration inside the capsule.	Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA; MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA	Scripps Research Institute; Massachusetts Institute of Technology (MIT)								BRAUN R, 1986, TETRAHEDRON LETT, V27, P1285, DOI 10.1016/S0040-4039(00)84239-2; BRESLOW R, 1988, J AM CHEM SOC, V110, P5613, DOI 10.1021/ja00225a003; BRESLOW R, 1983, TETRAHEDRON LETT, V24, P1901, DOI 10.1016/S0040-4039(00)81801-8; CRAM DJ, 1991, ANGEW CHEM INT EDIT, V30, P1024, DOI 10.1002/anie.199110241; GAREL L, 1993, ANGEW CHEM INT EDIT, V32, P1169, DOI 10.1002/anie.199311691; GRIECO PA, 1983, TETRAHEDRON LETT, V24, P1897, DOI 10.1016/S0040-4039(00)81800-6; Grieco PA, 1996, J AM CHEM SOC, V118, P2095, DOI 10.1021/ja9531992; HILVERT D, 1989, J AM CHEM SOC, V111, P9261, DOI 10.1021/ja00208a037; Kang JM, 1996, NATURE, V382, P239, DOI 10.1038/382239a0; KELLY TR, 1990, TETRAHEDRON LETT, V31, P3381, DOI 10.1016/S0040-4039(00)97402-1; Kirby A.J., 1980, ADV PHYS ORG CHEM, V17, P183; MCCURDY A, 1992, J AM CHEM SOC, V114, P10314, DOI 10.1021/ja00052a031; MEISSNER R, IN PRESS J AM CHEM S; MEISSNER RS, 1995, SCIENCE, V270, P1485, DOI 10.1126/science.270.5241.1485; MOCK WL, 1989, J ORG CHEM, V54, P5302, DOI 10.1021/jo00283a024; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; SHERMAN JC, 1989, J AM CHEM SOC, V111, P4527, DOI 10.1021/ja00194a074; SINGH VK, 1988, SYNTHETIC COMMUN, V18, P567, DOI 10.1080/00397918808064013; TIMMERMAN P, 1994, ANGEW CHEM INT EDIT, V33, P2345, DOI 10.1002/anie.199423451; Valdes C, 1995, J AM CHEM SOC, V117, P12733, DOI 10.1021/ja00156a010; WALTER CJ, 1993, J CHEM SOC CHEM COMM, P459; WYLER R, 1993, ANGEW CHEM INT EDIT, V32, P1699, DOI 10.1002/anie.199316991	22	480	483	3	121	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 2	1997	385	6611					50	52		10.1038/385050a0	http://dx.doi.org/10.1038/385050a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985245				2022-12-28	WOS:A1997WA73100044
J	Bartlett, JG				Bartlett, JG			Update in infectious diseases	ANNALS OF INTERNAL MEDICINE			English	Article							KAPOSIS-SARCOMA; HUMAN HERPESVIRUS; DNA-SEQUENCES				Bartlett, JG (corresponding author), JOHNS HOPKINS UNIV, SCH MED, ROSS RES BLDG, ROOM 1159, 720 RUTLAND AVE, BALTIMORE, MD 21205 USA.							BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; Butler JC, 1996, J INFECT DIS, V174, P986, DOI 10.1093/infdis/174.5.986; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599; Doern GV, 1996, ANTIMICROB AGENTS CH, V40, P1208, DOI 10.1128/AAC.40.5.1208; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; LEVY JA, 1995, LANCET, V346, P786, DOI 10.1016/S0140-6736(95)91611-3; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; Moore RD, 1996, PHARMACOECONOMICS, V10, P109, DOI 10.2165/00019053-199610020-00002; MULLOOLY JP, 1994, ANN INTERN MED, V121, P947, DOI 10.7326/0003-4819-121-12-199412150-00008; PablosMendez A, 1996, JAMA-J AM MED ASSOC, V276, P1223, DOI 10.1001/jama.276.15.1223; RADY PL, 1995, LANCET, V345, P1339, DOI 10.1016/S0140-6736(95)92538-4; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; Smith PG, 1996, SCIENCE, V273, P748, DOI 10.1126/science.273.5276.748; 1996, MMWR MORB MORTAL S1, V45, P1	18	9	9	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1997	126	1					48	56		10.7326/0003-4819-126-1-199701010-00007	http://dx.doi.org/10.7326/0003-4819-126-1-199701010-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA165	8992923				2022-12-28	WOS:A1997WA16500007
J	Rice, PA; Yang, SW; Mizuuchi, K; NAsh, HA				Rice, PA; Yang, SW; Mizuuchi, K; NAsh, HA			Crystal structure of an IHF-DNA complex: A protein-induced DNA u-turn	CELL			English	Article							INTEGRATION HOST FACTOR; ESCHERICHIA-COLI; BINDING PROTEINS; ADENINE TRACT; MINOR-GROOVE; HU PROTEIN; SITES; LATTICE; MUTANTS; RECOMBINATION	Integration host factor (IHF) is a small heterodimeric protein that specifically binds to DNA and functions as an architectural factor in many cellular processes in prokaryotes. Here, we report the crystal structure of IHF complexed with 35 bp of DNA. The DNA is wrapped around the protein and bent by >160 degrees, thus reversing the direction of the helix axis within a very short distance. Much of the bending occurs at two large kinks where the base stacking is interrupted by intercalation of a proline residue. IHF contacts the DNA exclusively via the phosphodiester backbone and the minor groove and relies heavily on indirect readout to recognize its binding sequence. One such readout involves a six-base A tract, providing evidence for the importance of a narrow minor groove.	NIMH,MOL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Rice, PA (corresponding author), NIDDK,MOL BIOL LAB,NIH,BETHESDA,MD 20892, USA.							BERMAN HM, 1994, CURR OPIN STRUC BIOL, V4, P345, DOI 10.1016/S0959-440X(94)90102-3; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; *DAR LAB, 1979, CCP4 SERC UK DAR LAB; DICKERSON RE, 1994, P NATL ACAD SCI USA, V91, P3579, DOI 10.1073/pnas.91.9.3579; DIGABRIELE AD, 1989, P NATL ACAD SCI USA, V86, P1816, DOI 10.1073/pnas.86.6.1816; DIGABRIELE AD, 1993, J MOL BIOL, V231, P1024, DOI 10.1006/jmbi.1993.1349; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; GOODMAN SD, 1992, P NATL ACAD SCI USA, V89, P11910, DOI 10.1073/pnas.89.24.11910; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GOOSEN N, 1995, MOL MICROBIOL, V16, P1, DOI 10.1111/j.1365-2958.1995.tb02386.x; GRANSTON AE, 1993, J MOL BIOL, V234, P45, DOI 10.1006/jmbi.1993.1562; HALES LM, 1994, BIOCHIMIE, V76, P1030, DOI 10.1016/0300-9084(94)90027-2; HALES LM, 1994, J BACTERIOL, V176, P2999, DOI 10.1128/JB.176.10.2999-3006.1994; Hales LM, 1996, NUCLEIC ACIDS RES, V24, P1780, DOI 10.1093/nar/24.9.1780; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; Lavoie BD, 1996, CELL, V85, P761, DOI 10.1016/S0092-8674(00)81241-6; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE EC, 1992, EMBO J, V11, P305, DOI 10.1002/j.1460-2075.1992.tb05053.x; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Luisi B., 1995, DNA PROTEIN STRUCTUR, P1; MENGERITSKY G, 1993, J MOL BIOL, V231, P646, DOI 10.1006/jmbi.1993.1316; Minor W., 1993, XDISPLAYF PROGRAM; MIRZABEKOV AD, 1979, P NATL ACAD SCI USA, V76, P1118, DOI 10.1073/pnas.76.3.1118; MOLINALOPEZ JA, 1994, J BIOL CHEM, V269, P25419; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; Nash Howard A., 1996, P149; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; NUNESDUBY SE, 1995, J MOL BIOL, V253, P228, DOI 10.1006/jmbi.1995.0548; Oberto J, 1996, J BACTERIOL, V178, P293, DOI 10.1128/jb.178.1.293-297.1996; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Parekh BS, 1996, P NATL ACAD SCI USA, V93, P1173, DOI 10.1073/pnas.93.3.1173; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; PEREZMARTIN J, 1994, J BIOL CHEM, V269, P22657; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROTH A, 1994, BIOCHIMIE, V76, P917, DOI 10.1016/0300-9084(94)90016-7; SCHULTZ SC, 1990, J MOL BIOL, V213, P159, DOI 10.1016/S0022-2836(05)80128-7; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; STOFER E, 1994, BIOPOLYMERS, V34, P337, DOI 10.1002/bip.360340305; STRAUSS JK, 1994, SCIENCE, V266, P1829, DOI 10.1126/science.7997878; SUZUKI M, 1995, NUCLEIC ACIDS RES, V23, P2083, DOI 10.1093/nar/23.12.2083; Suzuki M, 1996, NUCLEIC ACIDS RES, V24, P2767, DOI 10.1093/nar/24.14.2767; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; TOUSSAINT B, 1994, BIOCHIMIE, V76, P951, DOI 10.1016/0300-9084(94)90020-5; VIS H, 1995, J MOL BIOL, V254, P692, DOI 10.1006/jmbi.1995.0648; WANG SQ, 1995, BIOCHEMISTRY-US, V34, P13082, DOI 10.1021/bi00040a020; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; Werner MH, 1996, SCIENCE, V271, P778, DOI 10.1126/science.271.5250.778; WHITE SW, 1989, PROTEINS, V5, P281, DOI 10.1002/prot.340050405; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; YANG SW, 1994, P NATL ACAD SCI USA, V91, P12183, DOI 10.1073/pnas.91.25.12183; Yang SW, 1995, EMBO J, V14, P6292, DOI 10.1002/j.1460-2075.1995.tb00319.x; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911; ZULIANELLO L, 1995, J BIOL CHEM, V270, P17902, DOI 10.1074/jbc.270.30.17902	66	657	678	3	41	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1295	1306		10.1016/S0092-8674(00)81824-3	http://dx.doi.org/10.1016/S0092-8674(00)81824-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980235	Bronze			2022-12-28	WOS:A1996WA54100017
J	Stevens, CF				Stevens, CF			Spatial learning and memory: The beginning of a dream	CELL			English	Review							POTENTIATION				Stevens, CF (corresponding author), SALK INST BIOL STUDIES,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.							Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11	6	19	20	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1147	1148		10.1016/S0092-8674(00)81808-5	http://dx.doi.org/10.1016/S0092-8674(00)81808-5			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980219	Bronze			2022-12-28	WOS:A1996WA54100001
J	Jouanguy, E; Altare, F; Lamhamedi, S; Revy, P; Emile, JF; Newport, M; Levin, M; Blanche, S; Seboun, E; Fischer, A; Casanova, JL				Jouanguy, E; Altare, F; Lamhamedi, S; Revy, P; Emile, JF; Newport, M; Levin, M; Blanche, S; Seboun, E; Fischer, A; Casanova, JL			Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; MYCOBACTERIUM-TUBERCULOSIS; HUMAN-MONOCYTES; IMMUNE-RESPONSE; MICE; CYTOKINES; MACROPHAGES; PROLIFERATION; EXPRESSION; RESISTANCE		HOP NECKER ENFANTS MALAD, INSERM, U429, F-75015 PARIS, FRANCE; HOP NECKER ENFANTS MALAD, DEPT PATHOL, F-75015 PARIS, FRANCE; ST MARYS HOSP, UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT PEDIAT, LONDON, ENGLAND; GENETHON LABS, EVRY, FRANCE; HOP NECKER ENFANTS MALAD, UNITE IMMUNOL & HEMATOL PEDIAT, PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Imperial College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite			Jouanguy, Emmanuelle/H-7901-2017; altare, frederic/K-8664-2015; Revy, Patrick/H-8137-2017; Casanova, Jean-Laurent/I-3418-2017	Jouanguy, Emmanuelle/0000-0002-7358-9157; altare, frederic/0000-0002-5077-4616; Casanova, Jean-Laurent/0000-0002-7782-4169; Newport, Melanie/0000-0002-8946-7525; Revy, Patrick/0000-0003-0758-8022; Levin, Michael/0000-0003-2767-6919				ABEL L, 1988, AM J HUM GENET, V42, P256; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BACH EA, 1995, SCIENCE, V270, P1215, DOI 10.1126/science.270.5239.1215; Bermudez Luiz E., 1995, Trends in Microbiology, V3, P22, DOI 10.1016/S0966-842X(00)88864-2; BOULEY DM, 1995, J IMMUNOL, V155, P3964; CASANOVA JL, 1995, LANCET, V346, P581, DOI 10.1016/S0140-6736(95)91421-8; Casanova JL, 1996, PEDIATRICS, V98, P774; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243; CROWLE AJ, 1990, RES MICROBIOL, V141, P231, DOI 10.1016/0923-2508(90)90035-O; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DENIS M, 1991, EUR J IMMUNOL, V21, P391, DOI 10.1002/eji.1830210221; DENIS M, 1991, CLIN EXP IMMUNOL, V84, P200, DOI 10.1111/j.1365-2249.1991.tb08149.x; DOUVAS GS, 1985, INFECT IMMUN, V50, P1; EMILE JF, IN PRESS J PATHOL; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FIETTE L, 1995, J EXP MED, V181, P2069, DOI 10.1084/jem.181.6.2069; FLESCH IEA, 1993, IMMUNOBIOLOGY, V189, P316, DOI 10.1016/S0171-2985(11)80364-5; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2; Guleria I, 1996, NAT MED, V2, P334, DOI 10.1038/nm0396-334; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; LOUE A, 1984, ADV TUBERC RES, V21, P107; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; MURRAY HW, 1994, AM J MED, V97, P459, DOI 10.1016/0002-9343(94)90326-3; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; RILEY RJ, 1995, CLIN EXP IMMUNOL, V99, P1; ROOK GAW, 1986, IMMUNOLOGY, V57, P159; ROOK GAW, 1986, IMMUNOLOGY, V59, P333; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; STEAD WW, 1992, ANN INTERN MED, V116, P937, DOI 10.7326/0003-4819-116-11-937; SWIHART K, 1995, J EXP MED, V181, P961, DOI 10.1084/jem.181.3.961; TSUJI M, 1995, J IMMUNOL, V154, P5338; ZHAO YX, 1995, J IMMUNOL, V155, P5736	38	693	711	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 26	1996	335	26					1956	1961		10.1056/NEJM199612263352604	http://dx.doi.org/10.1056/NEJM199612263352604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA160	8960475				2022-12-28	WOS:A1996WA16000004
J	Berwick, DM; Winickoff, DE				Berwick, DM; Winickoff, DE			The truth about doctors' handwriting: A prospective study	BRITISH MEDICAL JOURNAL			English	Article							PRESCRIPTIONS	Objective-To determine whether doctors have worse handwriting than other health professionals. Design-Comparison of handwriting samples collected prospectively in a standardised 10 seconds' task. Setting-Courses on quality improvement. Subjects-209 health care professionals attending the courses, including 82 doctors. Main outcome measures-Legibility rated on a four-point scale by four raters. Results-The handwriting of doctors was no less legible than that of non-doctors. Significantly lower legibility than average was associated with being an executive and being male. Overall legibility scores were normally distributed, with median legibility equivalent to a rating between ''fair'' and ''good?'' Conclusion-This study fails to support the conventional wisdom that doctors' handwriting is worse than others'. Illegible writing is, however, an important cause of waste and hazard in medical care, but efforts to improve the safety and efficiency of written communication must approach the problem systemically and assume that the problems are in inherent in average human writing-rather than treating doctors as if they were a special subpopulation.	UNIV CAMBRIDGE,CAMBRIDGE CB2 1TN,ENGLAND	University of Cambridge	Berwick, DM (corresponding author), INST HLTHCARE IMPROVEMENT,BOSTON,MA 02215, USA.							BRAHAMS D, 1989, LANCET, V1, P510; FENELLY WA, 1975, N YORK J DENT, V45, P73; HALPERN NA, 1991, CRIT CARE MED, V19, P433, DOI 10.1097/00003246-199103000-00027; *I MED, 1991, COMP BAS MED REC ESS; MULLAN K, 1989, J ROY COLL GEN PRACT, V39, P347; SANDERS S, 1991, LANCET, V337, P56; WHITE KB, 1986, NEW ENGL J MED, V314, P390; 1979, JAMA-J AM MED ASSOC, V242, P2429	8	53	54	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1657	1658		10.1136/bmj.313.7072.1657	http://dx.doi.org/10.1136/bmj.313.7072.1657			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991021	Green Published			2022-12-28	WOS:A1996VZ81100060
J	Chapman, S				Chapman, S			Wrath	BRITISH MEDICAL JOURNAL			English	Article											Chapman, S (corresponding author), UNIV SYDNEY,WESTMEAD HOSP,DEPT PUBL HLTH & COMMUNITY MED,WESTMEAD,NSW 2145,AUSTRALIA.							[Anonymous], MATTHEW, V3; *BIBLE, JAMES, V1; *BIBLE, EPHESIANS, V5; *BIBLE, ECCLESIASTES, V54; Chapman S, 1996, BRIT MED J, V313, P97, DOI 10.1136/bmj.313.7049.97; Glantz S.A., 1996, CIGARETTE PAPERS; MACDONALD V, 1996, SUNDAY TELEGRAP 0310	7	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1593	1594		10.1136/bmj.313.7072.1593	http://dx.doi.org/10.1136/bmj.313.7072.1593			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8990997	Green Published			2022-12-28	WOS:A1996VZ81100020
J	McCormick, J				McCormick, J			Sloth	BRITISH MEDICAL JOURNAL			English	Article											McCormick, J (corresponding author), TRINITY COLL DUBLIN,DEPT COMMUNITY HLTH & GEN PRACTICE,DUBLIN 2,IRELAND.							MCCORMICK JS, 1988, LANCET, V2, P26; 1966, OXFORD DICT QUOTATIO	2	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1596	1596		10.1136/bmj.313.7072.1596	http://dx.doi.org/10.1136/bmj.313.7072.1596			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991000	Green Published			2022-12-28	WOS:A1996VZ81100023
J	McFarland, HF				McFarland, HF			Complexities in the treatment of autoimmune disease	SCIENCE			English	Editorial Material							GAMMA-INTERFERON; ENCEPHALOMYELITIS; RESPONSES; PROTEIN				McFarland, HF (corresponding author), NIH,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892, USA.							Blanas E, 1996, SCIENCE, V274, P1707, DOI 10.1126/science.274.5293.1707; Brocke S, 1996, NATURE, V379, P343, DOI 10.1038/379343a0; Genain CP, 1996, SCIENCE, V274, P2054, DOI 10.1126/science.274.5295.2054; Hemmer B, 1996, J NEUROSCI RES, V45, P852; KATZ JD, 1995, SCIENCE, V268, P1185, DOI 10.1126/science.7761837; Lee MS, 1996, J EXP MED, V183, P2663, DOI 10.1084/jem.183.6.2663; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; LIDER O, 1989, J IMMUNOL, V142, P748; LINNINGTON C, 1988, AM J PATHOL, V130, P443; LUBLIN FD, 1993, AUTOIMMUNITY, V16, P267, DOI 10.3109/08916939309014645; PANITCH HS, 1987, NEUROLOGY, V37, P1097, DOI 10.1212/WNL.37.7.1097; RAMANATHAN S, 1996, J IMMUNOL, V157, P1767; TSUCHIDA T, 1994, P NATL ACAD SCI USA, V91, P10859, DOI 10.1073/pnas.91.23.10859	13	53	57	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2037	2038		10.1126/science.274.5295.2037	http://dx.doi.org/10.1126/science.274.5295.2037			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8984662				2022-12-28	WOS:A1996VY97400033
J	Bonn, D				Bonn, D			Surfactants and babies: Slippery little things	LANCET			English	News Item																		1996, DRUGS, V51, P226	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1650	1650		10.1016/S0140-6736(05)65703-0	http://dx.doi.org/10.1016/S0140-6736(05)65703-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8984309				2022-12-28	WOS:A1996VX87600032
J	Brooke, D; Taylor, C; Gunn, J; Maden, A				Brooke, D; Taylor, C; Gunn, J; Maden, A			Point prevalence of mental disorder in unconvicted male prisoners in England and Wales	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To determine prevalence of mental disorder among male unconvicted prisoners and to assess the treatment needs of this population. Design-Semi-structured interview and case note review of randomly selected cross section of male remand population. Non-attenders were replaced by the next name on prison roll. Setting-Three young offenders' institutions and 13 adult men's prisons. Subjects-750 prisoners, representing 9.4% cross sectional sample of male unconvicted population. Main outcome measures-Prevalence of ICD-10 diagnoses of mental disorder, and associated treatment needs. Results-Psychiatric disorder was diagnosed in 369 (63%) inmates. The main diagnoses were: substance misuse, 285 (38%); neurotic illness, 192 (26%); personality disorder, 84 (11%); psychosis, 36 (5%); other and uncertain, 36 (0.5%). Subjects could have more than one diagnosis. The average refusal rate was 18%. In total 414 inmates (55%) were judged to have an immediate treatment need: transfer to an NHS bed, 64 (9%); treatment by prison health care services, 131 (17%); motivational interviewing for substance misuse, 115 (15%); and therapeutic community placement, 104 (14%). Conclusions-Mental disorder was common among male unconvicted prisoners. Psychosis was present st four or five times the level found in the general population. Extrapolation of our results suggests that remand population as a whole probably contains about 680 men who need transfer to hospital for psychiatric treatment, including about 380 prisoners with serious mental illness.	INST PSYCHIAT,DEPT FORENS PSYCHIAT,LONDON SE5 8AF,ENGLAND	University of London; King's College London								AMMONS RB, 1962, PSYCHOL REP, V11, P111, DOI 10.1177/003329416201100106; BOWDEN P, 1978, BRIT J PSYCHIAT, V132, P320; COID JW, 1988, BRIT MED J, V296, P1779, DOI 10.1136/bmj.296.6639.1779; DOOLEY E, 1990, BRIT J PSYCHIAT, V156, P40, DOI 10.1192/bjp.156.1.40; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; GUNN J, 1991, BRIT MED J, V303, P338, DOI 10.1136/bmj.303.6798.338; HARDING T, 1989, BRIT J PSYCHIAT, V155, P36, DOI 10.1192/bjp.155.1.36; *HOM OFF, 1995, CMND2893; LIEBLING A, 1992, SUICIDES PRISON, P42; MADEN A, 1993, CRIMINAL BEHAV MENTA, V3, pR3; Maden A, 1996, MENTAL DISORDER REMA; Meltzer H, 1994, B OPCS; *NW LOND MENT HLTH, 1994, REP IND PAN INQ EX C; *RES STAT DEP HOM, 1995, HOM OFF STAT B, V2095; Ritchie J., 1994, REPORT INQUIRY CARE; ROBERTSON G, 1994, BRIT J PSYCHIAT, V164, P55, DOI 10.1192/bjp.164.1.55; Royal College of Physicians Royal College of General Practitioners and Royal College of Psychiatrists, 1992, REP WORK PART 3 MED; TEPLIN LA, 1990, AM J PUBLIC HEALTH, V80, P663, DOI 10.2105/AJPH.80.6.663; WOODLEY L, 1995, WOODLEY TEAM REPORT; 1992, HLTH NATION STRATEGY	20	153	162	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1996	313	7071					1524	1527		10.1136/bmj.313.7071.1524	http://dx.doi.org/10.1136/bmj.313.7071.1524			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VY691	8978228	Green Published			2022-12-28	WOS:A1996VY69100021
J	Kuroda, MI; Villeneuve, AM				Kuroda, MI; Villeneuve, AM			Promiscuous chromosomal proteins: Complexes about sex	SCIENCE			English	Editorial Material							DOSAGE COMPENSATION; CAENORHABDITIS-ELEGANS; X-CHROMOSOME; CONDENSATION; FAMILY; YEAST; SEGREGATION; DEFINES; MITOSIS		STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305	Stanford University	Kuroda, MI (corresponding author), BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT CELL BIOL,HOUSTON,TX 77030, USA.							CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; CHUANG PT, 1986, SCIENCE, V274, P1736; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; GUACCI V, 1993, COLD SPRING HARB SYM, V58, P677, DOI 10.1101/SQB.1993.058.01.075; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HODGKIN J, 1986, MOL GEN GENET, V192, P452; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; KLEIN RD, 1993, CELL, V72, P349, DOI 10.1016/0092-8674(93)90113-5; Lieb JD, 1996, SCIENCE, V274, P1732, DOI 10.1126/science.274.5293.1732; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; LYON MF, 1995, ADV GENOME BIOL, V4, P119; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; PLENEFISCH JD, 1989, GENETICS, V121, P57; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587	17	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1633	1634		10.1126/science.274.5293.1633	http://dx.doi.org/10.1126/science.274.5293.1633			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8984631				2022-12-28	WOS:A1996VW71200039
J	Sepkowitz, KA				Sepkowitz, KA			Occupationally acquired infections in health care workers .2.	ANNALS OF INTERNAL MEDICINE			English	Review							HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; CREUTZFELDT-JAKOB DISEASE; CLOSTRIDIUM-DIFFICILE INFECTION; TO-PERSON TRANSMISSION; ROUND STRUCTURED VIRUS; CARBON-DIOXIDE LASER; CHILD DAY-CARE; NEW-YORK-CITY; B-VIRUS	Background: Hearth care workers are at occupational risk for a vast array of infections that cause substantial illness and occasional deaths. Despite this, few studies have examined the incidence, prevalence, or exposure-associated rates of infection or have considered infection-specific interventions recommended to maintain worker safety. Objective: To characterize the type and frequency of infections, the recommended interventions, and the costs of protecting health care workers. Part II of this two-part review focuses on infections caused by bloodborne organisms, organisms spread through the oral-fecal route, and organisms spread through direct contact. It also reviews established interventions for controlling transmission. Data Sources: A MEDLINE search and examination of infectious disease and infection control journals. Data Selection: All English-language articles and meeting abstracts published from January 1983 to February 1996 related to occupationally acquired infections among health care workers were reviewed. Outbreak- and non-outbreak-associated incidence and prevalence rates were derived, as were costs to prevent, control, and treat infections in health care workers. Data Synthesis: Occupational transmission to health care workers was identified for numerous diseases, including infections caused by bloodborne organisms (human immunodeficiency virus, hepatitis B virus, hepatitis C virus, Ebola virus), organisms spread through the oral-fecal route (salmonella, hepatitis A virus), and organisms spread through direct contact (herpes simplex virus, Sarcoptes scabiei). Most outbreak-associated attack rates range from 15% to 40%. Occupational transmission is usually associated with violation of one or more of three basic principles of infection control: handwashing, Vaccination of health care workers, and prompt placement of infectious patients into appropriate isolation. Conclusions: The risk for occupationally acquired infections is an unavoidable part of daily patient care. Occupationally acquired infections cause substantial illness and occasional deaths among health care workers. Further studies are needed to enhance compliance with established infection control approaches. As health care is being reformed, the risk for and costs of occupationally acquired infection must be considered.	CORNELL MED CTR, NEW YORK, NY USA	Cornell University	Sepkowitz, KA (corresponding author), MEM SLOAN KETTERING CANC CTR, INFECT DIS SERV, 1275 YORK AVE, BOX 288, NEW YORK, NY 10021 USA.							ADAMS G, 1981, AM J EPIDEMIOL, V113, P126, DOI 10.1093/oxfordjournals.aje.a113076; ADLER SP, 1986, PEDIATR INFECT DIS J, V5, P239, DOI 10.1097/00006454-198603000-00016; ADLER SP, 1989, NEW ENGL J MED, V321, P1290, DOI 10.1056/NEJM198911093211903; AHLFORS K, 1981, ACTA PAEDIATR SCAND, V70, P819, DOI 10.1111/j.1651-2227.1981.tb06233.x; ALQARAWI SM, 1995, EPIDEMIOL INFECT, V114, P41, DOI 10.1017/S095026880005189X; ALTER MJ, 1994, INFECT CONT HOSP EP, V15, P742; ALTER MJ, 1993, INFECT AGENT DIS, V2, P155; ALTER MJ, 1986, J INFECT DIS, V153, P1149, DOI 10.1093/infdis/153.6.1149; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; ALTMAN LK, 1995, NY TIMES        0512, pA6; ANSARI SA, 1991, AM J INFECT CONTROL, V19, P243, DOI 10.1016/S0196-6553(05)80256-1; ARMSTRONG D, 1969, J AMER MED ASSOC, V209, P265, DOI 10.1001/jama.209.2.265; ARNOW PM, 1991, PEDIATR INFECT DIS J, V10, P355, DOI 10.1097/00006454-199105000-00002; ARTENSTEIN AW, 1991, REV INFECT DIS, V13, P288; ARTENSTEIN MS, 1968, MIL MED, V133, P474, DOI 10.1093/milmed/133.6.474; AZIMI PH, 1986, AM J DIS CHILD, V140, P23, DOI 10.1001/archpedi.1986.02140150025024; BAINE WB, 1973, J INFECT DIS, V128, P357, DOI 10.1093/infdis/128.3.357; BALCAREK KB, 1990, JAMA-J AM MED ASSOC, V263, P840, DOI 10.1001/jama.263.6.840; BALFOUR CL, 1986, JAMA-J AM MED ASSOC, V256, P1909, DOI 10.1001/jama.256.14.1909; BAPTISTE R, 1987, INFECT CONT HOSP EP, V8, P364, DOI 10.1017/S0195941700067424; BARON RC, 1983, B WORLD HEALTH ORGAN, V61, P997; BARRY M, 1995, NEW ENGL J MED, V333, P294, DOI 10.1056/NEJM199508033330505; BAUM SG, 1966, NEW ENGL J MED, V274, P934, DOI 10.1056/NEJM196604282741704; BEERS LM, 1989, INFECT CONT HOSP EP, V10, P147, DOI 10.1086/645989; BENDALL RP, 1995, J HOSP INFECT, V30, P51, DOI 10.1016/0195-6701(95)90248-1; BERGBRANT IM, 1994, ACTA DERM-VENEREOL, V74, P393; BLACKMAN JA, 1987, PEDIATR INFECT DIS J, V6, P725, DOI 10.1097/00006454-198708000-00006; BLAGBURN BL, 1983, J INFECT DIS, V148, P772, DOI 10.1093/infdis/148.4.772; BLEICHER JN, 1987, PLAST RECONSTR SURG, V80, P420, DOI 10.1097/00006534-198709000-00013; BRADY MT, 1986, AM J INFECT CONTROL, V14, P197, DOI 10.1016/0196-6553(86)90117-3; BRADY MT, 1987, INFECT CONT HOSP EP, V8, P329, DOI 10.1017/S0195941700066431; BREWER MA, 1995, PEDIATR INFECT DIS J, V14, P258, DOI 10.1097/00006454-199504000-00002; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; BRUMMITT CF, 1988, J INFECT DIS, V158, P423, DOI 10.1093/infdis/158.2.423; BURKHOLDER BT, 1995, PEDIATR INFECT DIS J, V14, P261, DOI 10.1097/00006454-199504000-00003; BURNEY MI, 1980, AM J TROP MED HYG, V29, P941, DOI 10.4269/ajtmh.1980.29.941; CAFFERKEY MT, 1993, J HOSP INFECT, V24, P109, DOI 10.1016/0195-6701(93)90072-8; CALCUTT JA, 1995, AM J INFECT CONTROL, V23, P122; CAMPELLO C, 1992, INFECTION, V20, P224, DOI 10.1007/BF02033064; CAPPS RB, 1952, ARCH INTERN MED, V89, P6, DOI 10.1001/archinte.1952.00240010016002; CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; CARTMILL TDI, 1994, J HOSP INFECT, V27, P1, DOI 10.1016/0195-6701(94)90063-9; CASEMORE DP, 1994, FOLIA PARASIT, V41, P17; CDC, 1994, MMWR RECOMM REP, V43, P1; CHADWICK PR, 1994, J HOSP INFECT, V26, P251, DOI 10.1016/0195-6701(94)90015-9; CHAMBERLAND ME, 1991, JAMA-J AM MED ASSOC, V266, P3459, DOI 10.1001/jama.266.24.3459; CHOI M, 1990, J AM GERIATR SOC, V38, P531, DOI 10.1111/j.1532-5415.1990.tb02403.x; CHONG J, 1994, AM J GASTROENTEROL, V89, P1987; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; CLAYDON SM, 1993, AM J FOREN MED PATH, V14, P253, DOI 10.1097/00000433-199309000-00016; CLEVELAND JL, 1995, J AM DENT ASSOC, V126, P593, DOI 10.14219/jada.archive.1995.0237; CLEVELAND JL, 1995, INFECT CONT HOSP EP, V16, P7; Collins C. H., 1988, LAB ACQUIRED INFECT; COOK GC, 1994, T ROY SOC TROP MED H, V88, P712, DOI 10.1016/0035-9203(94)90244-5; COOPER BW, 1992, INFECT CONT HOSP EP, V13, P82, DOI 10.1086/646477; CUNNINGHAM SJ, 1994, EPIDEMIOL INFECT, V112, P195, DOI 10.1017/S0950268800057563; CURRENT WL, 1983, NEW ENGL J MED, V308, P1252, DOI 10.1056/NEJM198305263082102; DATTA NAOMI, 1960, JOUR HYG, V58, P229; DECKER MD, 1995, INFECT CONT HOSP EP, V16, P365; DELMEE M, 1989, LANCET, V2, P1095, DOI 10.1016/S0140-6736(89)91102-1; DELUCA M, 1992, LANCET, V339, P1364; DEMMLER GJ, 1987, J INFECT DIS, V156, P9, DOI 10.1093/infdis/156.1.9; DENES AE, 1978, JAMA-J AM MED ASSOC, V239, P210, DOI 10.1001/jama.239.3.210; DIEKEMA DJ, 1995, INFECT CONT HOSP EP, V16, P292; DIENSTAG JL, 1982, AM J EPIDEMIOL, V115, P26, DOI 10.1093/oxfordjournals.aje.a113277; DOEBBELING BN, 1992, NEW ENGL J MED, V327, P88, DOI 10.1056/NEJM199207093270205; DOEBBELING BN, 1993, AM J PUBLIC HEALTH, V83, P1679, DOI 10.2105/AJPH.83.12.1679; DOMART M, 1995, 35 INT C ANT AG CHEM, P269; DRUSIN LM, 1987, ARCH DIS CHILD, V62, P690, DOI 10.1136/adc.62.7.690; DRYJANSKI J, 1986, AM J MED, V80, P751, DOI 10.1016/0002-9343(86)90839-9; DUMOULIN GC, 1983, ANESTHESIOLOGY, V59, P51, DOI 10.1097/00000542-198307000-00010; DUPONT HL, 1991, INFECT CONT HOSP EP, V12, P707; DUPONT HL, 1989, J INFECT DIS, V159, P1126, DOI 10.1093/infdis/159.6.1126; DUTHIE R, 1994, J HOSP INFECT, V26, P129, DOI 10.1016/0195-6701(94)90055-8; DWORSKY ME, 1983, NEW ENGL J MED, V309, P950, DOI 10.1056/NEJM198310203091604; Edwards G F, 1993, Commun Dis Rep CDR Rev, V3, pR40; EICKHOFF TC, 1994, ANN INTERN MED, V120, P310; EISENSTEIN AB, 1963, JAMA-J AM MED ASSOC, V185, P171, DOI 10.1001/jama.1963.03060030029020; ELLIS G, 1955, Anaesthesia, V10, P78, DOI 10.1111/j.1365-2044.1955.tb00344.x; FARR B, 1990, JAMA-J AM MED ASSOC, V264, P185, DOI 10.1001/jama.264.2.185; FELDMAN RE, 1975, JAMA-J AM MED ASSOC, V232, P1228, DOI 10.1001/jama.232.12.1228; FISHERHOCH SP, 1995, LANCET, V346, P472, DOI 10.1016/S0140-6736(95)91323-8; FLOWERS RH, 1988, INFECT CONT HOSP EP, V9, P491, DOI 10.2307/30146544; FORSETER G, 1993, AM J INFECT CONTROL, V21, P5, DOI 10.1016/0196-6553(93)90200-N; FRIEDLANDER WJ, 1990, REV INFECT DIS, V12, P191; FRIEDMAN HM, 1984, PEDIATR INFECT DIS J, V3, P233, DOI 10.1097/00006454-198405000-00010; GARDEN JM, 1988, JAMA-J AM MED ASSOC, V259, P1199, DOI 10.1001/jama.259.8.1199; Garner JS, 1996, AM J INFECT CONTROL, V24, P24; Gay FP, 1933, J INFECT DIS, V53, P287, DOI 10.1093/infdis/53.3.287; GEAR JSS, 1975, BRIT MED J, V4, P489, DOI 10.1136/bmj.4.5995.489; GENEWEIN A, 1993, LANCET, V342, P841, DOI 10.1016/0140-6736(93)92698-S; GERBERDING JL, 1992, CLIN INFECT DIS, V14, P1179, DOI 10.1093/clinids/14.6.1179; GERBERDING JL, 1987, J INFECT DIS, V156, P1, DOI 10.1093/infdis/156.1.1; Gerberding JL, 1996, ANN INTERN MED, V125, P497, DOI 10.7326/0003-4819-125-6-199609150-00011; GERBERDING JL, 1995, NEW ENGL J MED, V332, P444, DOI 10.1056/NEJM199502163320707; GERMANAUD J, 1993, EUR J CLIN MICROBIOL, V12, P572, DOI 10.1007/BF01970972; GIBAS A, 1992, AM J EPIDEMIOL, V136, P603, DOI 10.1093/oxfordjournals.aje.a116538; GINSBURG CM, 1976, AM J EPIDEMIOL, V104, P571, DOI 10.1093/oxfordjournals.aje.a112332; GLICKMAN LT, 1977, AM J PUBLIC HEALTH, V67, P1193, DOI 10.2105/AJPH.67.12.1193; GLOSTER HM, 1995, J AM ACAD DERMATOL, V32, P436, DOI 10.1016/0190-9622(95)90065-9; GOODMAN RA, 1982, AM J MED, V73, P220, DOI 10.1016/0002-9343(82)90182-6; GOODMAN RA, 1991, JAMA-J AM MED ASSOC, V265, P2377, DOI 10.1001/jama.265.18.2377; GORMAN DG, 1992, NEUROLOGY, V42, P463, DOI 10.1212/WNL.42.2.463; GREAVES WL, 1980, INFECT CONT HOSP EP, V1, P381, DOI 10.1017/S0195941700053467; HADLER SC, 1985, INFECT CONT HOSP EP, V6, P24, DOI 10.1017/S0195941700062457; Harpaz R, 1996, NEW ENGL J MED, V334, P549, DOI 10.1056/NEJM199602293340901; HARRIS RW, 1969, AM J EPIDEMIOL, V89, P264, DOI 10.1093/oxfordjournals.aje.a120939; HATHERLEY LI, 1986, INFECT CONT HOSP EP, V7, P452, DOI 10.1017/S0195941700064948; HAWORTH FLM, 1995, LANCET, V346, P1361, DOI 10.1016/S0140-6736(95)92371-3; HEIMBERGER T, 1995, INFECT CONT HOSP EP, V16, P412; HENDERSON DK, 1995, SURG CLIN N AM, V75, P1175; HENDERSON DK, 1994, MANDELL DOUGLAS BENN, P2632; HERBERT AM, 1992, LANCET, V339, P305; HERRUZOCABRERA R, 1993, EUR J EPIDEMIOL, V9, P442, DOI 10.1007/BF00157404; HICKS CG, 1985, AM J INFECT CONTROL, V13, P1, DOI 10.1016/0196-6553(85)90002-1; HO HC, 1978, LANCET, V1, P710; HOFMANN F, 1992, VACCINE, V10, pS82, DOI 10.1016/0264-410X(92)90552-U; HOLMES GP, 1990, ANN INTERN MED, V112, P833, DOI 10.7326/0003-4819-112-11-833; Horton R, 1995, Br J Nurs, V4, P930; HUANG P, 1995, ANN INTERN MED, V123, P409, DOI 10.7326/0003-4819-123-6-199509150-00002; IPPOLITO G, 1993, ARCH INTERN MED, V153, P1451, DOI 10.1001/archinte.153.12.1451; JACKSON MM, 1985, AM J INFECT CONTROL, V13, P21, DOI 10.1016/0196-6553(85)90005-7; JAFFE HW, 1994, ANN INTERN MED, V121, P855, DOI 10.7326/0003-4819-121-11-199412010-00005; JANKOVIC N, 1994, INT J ARTIF ORGANS, V17, P137, DOI 10.1177/039139889401700302; JANZEN J, 1978, J INFECT DIS, V137, P261, DOI 10.1093/infdis/137.3.261; JARVIS WR, 1994, LANCET, V344, P1311, DOI 10.1016/S0140-6736(94)90687-4; JIMENEZLUCHO VE, 1995, AM J INFECT CONTROL, V23, P44, DOI 10.1016/0196-6553(95)90008-X; JOCHEN ABB, 1992, LANCET, V339, P304, DOI 10.1016/0140-6736(92)91373-G; JOHNSON JE, 1967, NEW ENGL J MED, V277, P842, DOI 10.1056/NEJM196710192771603; JOHNSON JE, 1966, AM J MED, V41, P391, DOI 10.1016/0002-9343(66)90085-4; JOHNSON WM, 1981, J OCCUP ENVIRON MED, V23, P367; KENNEDY FM, 1993, EPIDEMIOL INFECT, V110, P247, DOI 10.1017/S0950268800068163; KHABBAZ RF, 1994, NEW ENGL J MED, V330, P172, DOI 10.1056/NEJM199401203300304; KHURIBULOS NA, 1994, INFECT CONT HOSP EP, V15, P311; KIEL FW, 1993, INFECT CONT HOSP EP, V14, P268; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KJOLEN H, 1992, J HOSP INFECT, V21, P61, DOI 10.1016/0195-6701(92)90154-E; KLEIN BS, 1984, JAMA-J AM MED ASSOC, V252, P2716, DOI 10.1001/jama.252.19.2716; KLEIN RS, 1991, LANCET, V338, P1539, DOI 10.1016/0140-6736(91)92369-D; KOCH KL, 1985, ANN INTERN MED, V102, P593, DOI 10.7326/0003-4819-102-5-593; KUH C, 1950, JAMA-J AM MED ASSOC, V143, P631, DOI 10.1001/jama.1950.02910420019006; KUHLS TL, 1987, AM J PUBLIC HEALTH, V77, P1306, DOI 10.2105/AJPH.77.10.1306; LANGE JMA, 1990, NEW ENGL J MED, V322, P1375, DOI 10.1056/NEJM199005103221907; LANPHEAR BP, 1994, INFECT CONT HOSP EP, V15, P745; LANPHEAR BP, 1993, CLIN INFECT DIS, V16, P10, DOI 10.1093/clinids/16.1.10; LARSON E, 1991, INFECT CONT HOSP EP, V12, P422; LARSON E, 1989, AM J INFECT CONTROL, V17, P83, DOI 10.1016/0196-6553(89)90022-9; LARSON E, 1995, J HOSP INFECT, V30, P88, DOI 10.1016/0195-6701(95)90010-1; LEIBOWITZ S, 1949, JAMA-J AM MED ASSOC, V140, P1331, DOI 10.1001/jama.1949.82900520001006; LETTAU LA, 1992, INFECT CONT HOSP EP, V13, P77; LETTAU LA, 1986, ANN INTERN MED, V104, P631, DOI 10.7326/0003-4819-104-5-631; LEVINE JF, 1988, J AM VET MED ASSOC, V193, P1413; LEWIS TL, 1973, NEW ENGL J MED, V289, P645, DOI 10.1056/NEJM197309272891301; LIN SK, 1994, J GASTROEN HEPATOL, V9, P319, DOI 10.1111/j.1440-1746.1994.tb01249.x; LINNEMANN CC, 1985, INFECT CONT HOSP EP, V6, P221, DOI 10.1017/S0195941700061567; LUND S, 1994, AM J INFECT CONTROL, V22, P352, DOI 10.1016/0196-6553(94)90034-5; LYERLY HK, 1995, J AM COLL SURGEONS, V180, P91; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MARRANCONI F, 1992, INFECTION, V20, P111, DOI 10.1007/BF01711079; MAST EE, 1993, HEPATITIS B VACCINES, P295; Mastaj L A, 1994, Compendium, V15, P78; MASTAJ LA, 1994, COMPENDIUM, V15, P76; MASTAJ LA, 1994, COMPENDIUM, V15, P78; MATHIS S, 1996, INFECT CONT HOSP EP, V17, pP33; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; MEYER GS, 1993, ARCH INTERN MED, V153, P2439, DOI 10.1001/archinte.153.21.2439; MEYERS JD, 1975, JAMA-J AM MED ASSOC, V231, P1049, DOI 10.1001/jama.231.10.1049; MILLER DC, 1988, NEW ENGL J MED, V318, P853, DOI 10.1056/NEJM198803313181312; MISHU B, 1994, J INFECT DIS, V169, P547, DOI 10.1093/infdis/169.3.547; MITCHELL HM, 1989, SCAND J GASTROENTERO, V24, P396, DOI 10.3109/00365528909093065; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1002/hep.1840160502; MOHLEBOETANI JC, 1995, AM J PUBLIC HEALTH, V85, P812, DOI 10.2105/AJPH.85.6.812; MONATH TP, 1973, AM J TROP MED HYG, V22, P773, DOI 10.4269/ajtmh.1973.22.773; MOORE RM, 1993, AM IND HYG ASSOC J, V54, P113, DOI 10.1080/15298669391354423; MOSLEY JW, 1993, AM J PUBLIC HEALTH, V83, P1664, DOI 10.2105/AJPH.83.12.1664; MURPH JR, 1991, JAMA-J AM MED ASSOC, V265, P603, DOI 10.1001/jama.265.5.603; MURPHY O, 1995, J HOSP INFECT, V30, P225, DOI 10.1016/S0195-6701(95)90318-6; MUYEMBE T, 1995, LANCET, V345, P1448, DOI 10.1016/S0140-6736(95)92640-2; NEAL KR, 1994, EPIDEMIOL INFECT, V112, P595, DOI 10.1017/S0950268800051293; NEWSOM SWB, 1993, J HOSP INFECT, V23, P175, DOI 10.1016/0195-6701(93)90023-S; NIU MT, 1993, AM J KIDNEY DIS, V22, P568, DOI 10.1016/S0272-6386(12)80930-9; NOBLE RC, 1984, JAMA-J AM MED ASSOC, V252, P2711, DOI 10.1001/jama.252.19.2711; OLIPHANT JW, 1949, AM J HYG, V49, P76, DOI 10.1093/oxfordjournals.aje.a119261; OSTERHOLM MT, 1985, JAMA-J AM MED ASSOC, V254, P3207; OWENS DK, 1992, AM J MED, V92, P503, DOI 10.1016/0002-9343(92)90747-Y; PALMER AE, 1987, J MED PRIMATOL, V16, P99; PALMER SR, 1983, BRIT MED J, V287, P891, DOI 10.1136/bmj.287.6396.891; PANLILIO AL, 1995, J AM COLL SURGEONS, V180, P16; PASTERNAK J, 1994, INFECT CONT HOSP EP, V15, P540; PATON S, 1991, INFECT CONT HOSP EP, V12, P710; PATTERSON WB, 1985, ANN INTERN MED, V102, P658, DOI 10.7326/0003-4819-102-5-658; PECKHAM CS, 1986, J CLIN PATHOL, V39, P318, DOI 10.1136/jcp.39.3.318; PEGUES DA, 1993, INFECT CONT HOSP EP, V14, P87, DOI 10.2307/30147166; Petersen N J, 1980, Ann N Y Acad Sci, V353, P157, DOI 10.1111/j.1749-6632.1980.tb18918.x; PETROSILLO N, 1995, AM J INFECT CONTROL, V23, P278, DOI 10.1016/0196-6553(95)90057-8; PETROSILLO N, 1995, J HOSP INFECT, V30, P273, DOI 10.1016/0195-6701(95)90262-7; PIKE RM, 1979, ANNU REV MICROBIOL, V33, P41, DOI 10.1146/annurev.mi.33.100179.000353; POLAND GA, 1990, ARCH INTERN MED, V150, P44, DOI 10.1001/archinte.150.1.44; POLISH LB, 1993, AM J INFECT CONTROL, V21, P196, DOI 10.1016/0196-6553(93)90031-X; POLYWKA S, 1991, INFECTION, V19, P81, DOI 10.1007/BF01645572; PURO V, 1995, AM J INFECT CONTROL, V23, P273, DOI 10.1016/0196-6553(95)90056-X; PURO V, 1995, INFECT CONT HOSP EP, V16, P324; RAE AJ, 1994, J HOSP INFECT, V27, P241, DOI 10.1016/0195-6701(94)90132-5; RAO GG, 1995, J HOSP INFECT, V30, P1, DOI 10.1016/0195-6701(95)90244-9; Reed Elizabeth, 1993, Journal of Emergency Medicine, V11, P9, DOI 10.1016/0736-4679(93)90003-P; REID JA, 1990, J HOSP INFECT, V16, P81, DOI 10.1016/0195-6701(90)90052-P; REIFF A, 1989, EUR J CLIN MICROBIOL, V8, P592, DOI 10.1007/BF01968135; REISSLEVY EA, 1994, MED J AUSTRALIA, V160, P524; REYBROUCK G, 1986, J HOSP INFECT, V8, P5, DOI 10.1016/0195-6701(86)90100-3; RICHARDSON JH, 1987, J MED PRIMATOL, V16, P83; RIORDAN T, 1986, J HOSP INFECT, V8, P296, DOI 10.1016/0195-6701(86)90126-X; ROECKEL IE, 1977, ANN CLIN LAB SCI, V7, P405; ROOME AJ, 1993, JAMA-J AM MED ASSOC, V270, P2931, DOI 10.1001/jama.270.24.2931; Rota JS, 1996, J INFECT DIS, V173, P32, DOI 10.1093/infdis/173.1.32; ROTTER ML, 1984, INFECT CONT HOSP EP, V5, P18, DOI 10.1017/S0195941700058744; ROWE NH, 1982, J AM DENT ASSOC, V105, P471, DOI 10.14219/jada.archive.1982.0363; Sabin AB, 1934, J EXP MED, V59, P115, DOI 10.1084/jem.59.2.115; Samore MH, 1996, AM J MED, V100, P32, DOI 10.1016/S0002-9343(96)90008-X; SAWYER MH, 1994, J INFECT DIS, V169, P91, DOI 10.1093/infdis/169.1.91; SCHOENE WC, 1981, ARCH NEUROL-CHICAGO, V38, P473, DOI 10.1001/archneur.1981.00510080035002; SCHROEDER SA, 1968, NEW ENGL J MED, V279, P674, DOI 10.1056/NEJM196809262791303; SEGAL HE, 1979, MIL MED, V144, P792; SELWYN S, 1991, J HOSP INFECT, V18, P5, DOI 10.1016/0195-6701(91)90004-R; SEMMELWEIS P, 1941, MED CLASSICS, V5, P350; Sepkowitz KA, 1996, ANN INTERN MED, V125, P826, DOI 10.7326/0003-4819-125-10-199611150-00007; SEPKOWITZ KA, 1995, CLIN INFECT DIS, V20, P232, DOI 10.1093/clinids/20.2.232; SHANSON DC, 1980, LANCET, V2, P596; SHAPIRO CN, 1992, VACCINE, V10, pS59, DOI 10.1016/0264-410X(92)90545-U; SINGHNAZ N, 1993, PEDIATR INFECT DIS J, V12, P922, DOI 10.1097/00006454-199311000-00006; SITWELL L, 1988, NEW ENGL J MED, V318, P854; SMITH CET, 1987, J HOSP INFECT, V9, P39, DOI 10.1016/0195-6701(87)90093-4; SMITH DH, 1982, LANCET, V1, P816; SMITH JR, 1991, BRIT J OBSTET GYNAEC, V98, P124, DOI 10.1111/j.1471-0528.1991.tb13356.x; SOLVAS JG, 1987, J HOSP INFECT, V9, P43, DOI 10.1016/0195-6701(87)90094-6; STANDAERT SM, 1994, INFECT CONT HOSP EP, V15, P22; STEELMAN VM, 1994, AM J INFECT CONTROL, V22, P312, DOI 10.1016/0196-6553(94)90019-1; STEERE AC, 1975, LANCET, V1, P319; STERN H, 1959, LANCET, V2, P871; STEVENSON P, 1994, J HOSP INFECT, V26, P261, DOI 10.1016/0195-6701(94)90016-7; STRIMLING MO, 1989, LANCET, V2, P866, DOI 10.1016/S0140-6736(89)93034-1; STRUVE J, 1994, SCAND J GASTROENTERO, V29, P360, DOI 10.3109/00365529409094850; SUZUKI K, 1994, J INFECT DIS, V170, P1575, DOI 10.1093/infdis/170.6.1575; TEMPLETON GL, 1995, ANN INTERN MED, V122, P922, DOI 10.7326/0003-4819-122-12-199506150-00005; Thomas DL, 1996, AM J MED, V100, P41, DOI 10.1016/S0002-9343(96)90009-1; THOMAS DL, 1993, ARCH INTERN MED, V153, P1705, DOI 10.1001/archinte.153.14.1705; THOMAS MC, 1987, INFECT CONT HOSP EP, V8, P427, DOI 10.1017/S0195941700066613; TOLKOFFRUBIN NE, 1978, ANN INTERN MED, V89, P625, DOI 10.7326/0003-4819-89-5-625; TRUMBULL ML, 1951, JAMA-J AM MED ASSOC, V145, P965, DOI 10.1001/jama.1951.02920310021005; VALENTI WM, 1995, AM J INFECT CONTROL, V23, P78, DOI 10.1016/0196-6553(95)90098-5; VALENTI WM, 1986, AM J INFECT CONTROL, V14, P20, DOI 10.1016/0196-6553(86)90078-7; VANZEE BE, 1975, AM J MED, V58, P803, DOI 10.1016/0002-9343(75)90635-X; VESLEY D, 1988, AM J PUBLIC HEALTH, V78, P1213, DOI 10.2105/AJPH.78.9.1213; VOSS A, 1995, INFECT CONT HOSP EP, V16, P4; VOTRA EM, 1983, AM J INFECT CONTROL, V11, P10, DOI 10.1016/S0196-6553(83)80008-X; WEHRLE PF, 1956, PEDIATRICS, V17, P237; WEISS Y, 1994, J HOSP INFECT, V26, P211, DOI 10.1016/0195-6701(94)90044-2; WENZEL RP, 1991, J HOSP INFECT, V18, P65, DOI 10.1016/0195-6701(91)90265-A; WERNER BG, 1982, ANN INTERN MED, V97, P367, DOI 10.7326/0003-4819-97-3-367; WEST DJ, 1984, AM J MED SCI, V287, P26, DOI 10.1097/00000441-198403000-00006; WILLIAMS WW, 1984, AM J INFECT CONTROL, V12, P34, DOI 10.1016/0196-6553(84)90071-3; WOOD RC, 1993, JAMA-J AM MED ASSOC, V270, P2935, DOI 10.1001/jama.270.24.2935; WURTZ R, 1994, AM J INFECT CONTROL, V22, P228, DOI 10.1016/0196-6553(94)99001-8; YEAGER AS, 1975, J CLIN MICROBIOL, V2, P448; ZAZA S, 1995, J INFECT DIS, V172, P1542, DOI 10.1093/infdis/172.6.1542; ZUCKERMAN AJ, 1995, AM J INFECT CONTROL, V23, P286, DOI 10.1016/0196-6553(95)90058-6; ZUCKERMAN J, 1994, LANCET, V343, P1618, DOI 10.1016/S0140-6736(94)93064-3; 1987, MMWR-MORBID MORTAL W, V36, P687; 1987, MMWR-MORBID MORTAL W, V36, P680; 1995, MMWR-MORBID MORTAL W, V44, P381; 1995, MMWR-MORBID MORTAL W, V44, P929; 1995, MMWR-MORBID MORTAL W, V44, P475; 1995, MMWR-MORBID MORTAL W, V44, P468; 1991, MMWR-MORBID MORTAL W, V40, P46; 1977, MMWR-MORBID MORTAL W, V26, P77; 1996, MMWR-MORBID MORTAL W, V45, P13; 1990, LANCET, V336, P1103; 1951, BRIT MED J, V1, P288; 1996, MMWR-MORBID MORTAL W, V45, P468; 1996, HIV AIDS SURVEILLANC, V7, P21; 1995, MMWR-MORBID MORTAL W, V43, P1; 1981, MMWR-MORBID MORTAL W, V29, P629	281	106	110	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1996	125	11					917	928		10.7326/0003-4819-125-11-199612010-00008	http://dx.doi.org/10.7326/0003-4819-125-11-199612010-00008			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV541	8967673				2022-12-28	WOS:A1996VV54100008
J	Waters, D; Danska, J; Hardy, K; Koster, F; Qualls, C; Nickell, D; Nightingale, S; Gesundheit, N; Watson, D; Schade, D				Waters, D; Danska, J; Hardy, K; Koster, F; Qualls, C; Nickell, D; Nightingale, S; Gesundheit, N; Watson, D; Schade, D			Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						acquired immunodeficiency syndrome; weight loss; cachexia; insulin-like growth factor I; domatotropin	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; BODY-COMPOSITION; WHOLE-BODY; FACTOR-I; MEGESTROL-ACETATE; DEFICIENT ADULTS; PROTEIN-TURNOVER; RANDOM DROPOUTS; CACHEXIA; MASS	Objective: To increase lean body mass and improve health status in patients with wasting associated with the acquired immunodeficiency syndrome (AIDS) by treatment with recombinant human growth hormone (rhGH), recombinant human insulin-like growth factor 1 (rhlGF-1), or both. Design: Randomized, double-blind, placebo-controlled clinical trial. Setting: University of New Mexico Clinical Research Center and University of Texas Southwestern Medical Center. Patients: 60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention. Patients were divided into four groups of 15 patients each. Intervention: Group 1 received 1.4 mg of rhGH once daily plus placebo twice daily; group 2 received 5 mg of rhlGF-1 twice daily plus placebo once daily; group 3 received 5 mg of rhlGF-1 twice daily plus 1.4 mg of rhGH once daily; and group 4 received placebo three times daily. Measurements: Body weight, body composition, muscle strength, protein catabolism, quality of life, and immune status were assessed at baseline, and changes in these variables were measured at 6 and 12 weeks. Results: At 6 weeks, lean body mess had increased and total fat mass had decreased in the groups receiving rhGH, rhlGF-1, or both. Group 3 had the greatest changes in lean body mass (mean +/- SE, 3.2 +/- 0.59 kg; P < 0.001); only in this group were changes in body mass maintained at 12 weeks. Only patients in group 1 had improvement in muscular strength of the knees and upper body (P = 0.04) and quality of life (P = 0.01). Immunologic function did not Improve In any group. Conclusions: Growth factor therapy had significantly increased lean body mass and decreased fat mass by 6 weeks, but these improvements persisted for 12 weeks only in group 3. Growth factor therapy at the dosages used in this study is not recommended because the magnitude of weight gain was modest and improvements, in quality-of-life measures varied.	UNIV NEW MEXICO, SCH MED, DEPT MED ENDOCRINOL, ALBUQUERQUE, NM 87131 USA; UNIV TEXAS, SW MED CTR, DALLAS, TX USA	University of New Mexico; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000633, M01RR000997] Funding Source: NIH RePORTER; NCRR NIH HHS [5MO1 RR00997-18, 5MO1 RR00633] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BINDMAN AB, 1990, MED CARE, V28, P1142, DOI 10.1097/00005650-199012000-00003; BINNERTS A, 1992, CLIN ENDOCRINOL, V37, P79, DOI 10.1111/j.1365-2265.1992.tb02287.x; BOLLINGER RC, 1992, J INFECT DIS, V165, P913, DOI 10.1093/infdis/165.5.913; CHRISTIANSEN JS, 1991, HORM RES, V36, P66; CHWALS WJ, 1991, CRIT CARE MED, V19, P1317, DOI 10.1097/00003246-199110000-00015; CLARK R, 1993, J CLIN INVEST, V92, P540, DOI 10.1172/JCI116621; COTTERILL AM, 1992, CLIN ENDOCRINOL, V37, P11, DOI 10.1111/j.1365-2265.1992.tb02277.x; CUNEO RC, 1991, J APPL PHYSIOL, V70, P688, DOI 10.1152/jappl.1991.70.2.688; DIGGLE P, 1994, APPL STAT-J ROY ST C, V43, P49; DIGGLE PJ, 1989, BIOMETRICS, V45, P1255, DOI 10.2307/2531777; GRUNFELD C, 1992, SEMIN LIVER DIS, V12, P175, DOI 10.1055/s-2007-1007389; HELLERSTEIN MK, 1990, SEMIN ONCOL, V17, P17; HICKEY MS, 1989, BASIC GUIDELINES NUT; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOLLOWAY L, 1994, J CLIN ENDOCR METAB, V79, P470, DOI 10.1210/jc.79.2.470; JORGENSEN JOL, 1989, LANCET, V1, P1221; KOTLER DP, 1985, AM J CLIN NUTR, V42, P1255, DOI 10.1093/ajcn/42.6.1255; KRENTZ AJ, 1993, J ACQ IMMUN DEF SYND, V6, P245; KUPFER SR, 1993, J CLIN INVEST, V91, P391, DOI 10.1172/JCI116212; LAMBERTS SWJ, 1992, CLIN ENDOCRINOL, V37, P111, DOI 10.1111/j.1365-2265.1992.tb02293.x; LIEBERMAN SA, 1994, J CLIN ENDOCR METAB, V78, P404, DOI 10.1210/jc.78.2.404; MONTGOMERY DC, 1984, DESIGN ANAL EXPT, P192; MULLIGAN K, 1993, J CLIN ENDOCR METAB, V77, P956, DOI 10.1210/jc.77.4.956; MURPHY WJ, 1992, P NATL ACAD SCI USA, V89, P4481, DOI 10.1073/pnas.89.10.4481; OSTER MH, 1994, ANN INTERN MED, V121, P400, DOI 10.7326/0003-4819-121-6-199409150-00002; PACY PJ, 1991, CLIN SCI, V80, P345, DOI 10.1042/cs0800345; RIDOUT MS, 1991, BIOMETRICS, V47, P1617, DOI 10.2307/2532413; SCHWENK WF, 1984, ANAL BIOCHEM, V141, P101; SLOSMAN DO, 1992, RADIOLOGY, V185, P593, DOI 10.1148/radiology.185.2.1410379; THOMPSON GN, 1989, AM J PHYSIOL, V256, pE631, DOI 10.1152/ajpendo.1989.256.5.E631; VANLOAN M, 1987, HUM BIOL, V59, P299; VONROENN JH, 1994, ANN INTERN MED, V121, P393, DOI 10.7326/0003-4819-121-6-199409150-00001; VONROENN JH, 1990, SEMIN ONCOL, V17, P13; WOLF RF, 1992, SURGERY, V112, P284; WU AW, 1991, MED CARE, V29, P786, DOI 10.1097/00005650-199108000-00011; 1987, MMWR MORB MORTAL S1, V36, pS1	36	115	117	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1996	125	11					865	+		10.7326/0003-4819-125-11-199612010-00001	http://dx.doi.org/10.7326/0003-4819-125-11-199612010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV541	8967666				2022-12-28	WOS:A1996VV54100001
J	Choo, V				Choo, V			Understanding acute leukaemias	LANCET			English	Editorial Material																		Dolk H, 1997, AM J EPIDEMIOL, V145, P10, DOI 10.1093/oxfordjournals.aje.a009026; Dolk H, 1997, AM J EPIDEMIOL, V145, P1, DOI 10.1093/oxfordjournals.aje.a009025	2	0	0	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					74	74		10.1016/S0140-6736(05)60882-3	http://dx.doi.org/10.1016/S0140-6736(05)60882-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996416				2022-12-28	WOS:A1997WB80000007
J	Pippard, MJ				Pippard, MJ			Detection of iron overload	LANCET			English	Editorial Material							HEMOCHROMATOSIS; METABOLISM				Pippard, MJ (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT MOL & CELLULAR PATHOL,DUNDEE DD1 9SY,SCOTLAND.							BRITTENHAM GM, 1994, NEW ENGL J MED, V331, P567, DOI 10.1056/NEJM199409013310902; Bulaj ZJ, 1996, NEW ENGL J MED, V335, P1799, DOI 10.1056/NEJM199612123352403; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; GIRELLI D, 1995, BRIT J HAEMATOL, V90, P931, DOI 10.1111/j.1365-2141.1995.tb05218.x; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; Powell W.L., 1994, IRON METABOLISM HLTH; SIBILLE JC, 1988, HEPATOLOGY, V8, P296, DOI 10.1002/hep.1840080218; Worwood M, 1994, IRON METABOLISM HLTH, P449	10	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					73	74		10.1016/S0140-6736(05)60880-X	http://dx.doi.org/10.1016/S0140-6736(05)60880-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996414				2022-12-28	WOS:A1997WB80000005
J	Ho, YS; Swenson, L; Derewenda, U; Serre, L; Wei, YY; Dauter, Z; Hattori, M; Adachi, T; Aoki, J; Arai, H; Inoue, K; Derewenda, ZS				Ho, YS; Swenson, L; Derewenda, U; Serre, L; Wei, YY; Dauter, Z; Hattori, M; Adachi, T; Aoki, J; Arai, H; Inoue, K; Derewenda, ZS			Brain acetylhydrolase that inactivates platelet-activating factor is a G-protein-like trimer	NATURE			English	Article							DIEKER LISSENCEPHALY GENE; NEURONAL MIGRATION; NERVOUS-SYSTEM; LIS-1 GENE; SUBUNIT; EXPRESSION; MESSENGER; PURIFICATION; PRODUCT	THE platelet-activating factor PAF (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a potent lipid first messenger active in general cell activation, fertilization, inflammatory and allergic reactions, asthma, HIV pathogenesis, carcinogenesis, and apoptosis(1-5). There is substantial evidence that PAF is involved in intracellular signalling, but the pathways are poorly understood. Inactivation of PAF is carried out by specific intra- and extracellular acetylhydrolases(6) (PAF-AHs), a subfamily of phospholipases A2 that remove the sn-2 acetyl group, Mammalian brain contains at least three intracellular isoforms, of which PAF-AH(Ib) is the best characterized(7-9). This isoform contains a heterodimer of two homologous catalytic subunits alpha(1) and alpha(2), each of relative molecular mass 26K, and a non-catalytic 45K beta-subunit, a homologue of the beta-subunit of trimeric G proteins. We now report the crystal structure of the bovine alpha(1) subunit of PAF-AH(Ib) at 1.7 Angstrom resolution in complex with a reaction product, acetate, The tertiary fold of this protein is closely reminiscent of that found in p21(ras) and other GTPases. The active site is made up of a trypsin-like triad of Ser 47, His 195 and Asp 192, Thus, the intact PAF-AH(Ib) molecule is an unusual G-protein-like (alpha(1)/alpha(2))beta trimer.	UNIV VIRGINIA,HLTH SCI CTR,DEPT MOL PHYSIOL & BIOL PHYS,CHARLOTTESVILLE,VA 22906; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA; EUROPEAN MOL BIOL LAB,OUTSTN,D-22603 HAMBURG,GERMANY; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT HLTH CHEM,BUNKYO KU,TOKYO 113,JAPAN	University of Virginia; University of Alberta; European Molecular Biology Laboratory (EMBL); University of Tokyo			Hattori, Mitsuharu/F-3859-2010	Hattori, Mitsuharu/0000-0002-0503-4969; SERRE, laurence/0000-0002-6794-1492; Aoki, Junken/0000-0001-9435-1896				ADACHI H, 1995, BIOCHEM BIOPH RES CO, V214, P180, DOI 10.1006/bbrc.1995.2272; BAZAN NG, 1995, NEUROCHEM INT, V26, P435, DOI 10.1016/0197-0186(94)00138-K; BENNETT SAL, 1993, CARCINOGENESIS, V14, P1289, DOI 10.1093/carcin/14.7.1289; DEREWENDA ZS, 1995, J AM CHEM SOC, V117, P2104, DOI 10.1021/ja00112a029; DEREWENDA ZS, 1994, ADV PROTEIN CHEM, V45, P1; ELAZZOUZI B, 1993, BIOCHEM BIOPH RES CO, V190, P320, DOI 10.1006/bbrc.1993.1050; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KUMAR R, 1988, BIOCHIM BIOPHYS ACTA, V963, P375, DOI 10.1016/0005-2760(88)90304-9; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V26, P282; MIZUGUCHI M, 1995, AM J PATHOL, V147, P1142; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OFLAHERTY JT, 1989, PLATELET ACTIVATING, P117; PANETTA T, 1987, BIOCHEM BIOPH RES CO, V149, P580, DOI 10.1016/0006-291X(87)90407-4; REINER O, 1995, J NEUROSCI, V15, P3730; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Stafforini DM, 1996, BBA-LIPID LIPID MET, V1301, P161, DOI 10.1016/0005-2760(96)00040-9; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; VENABLE ME, 1993, J LIPID RES, V34, P691; WANG DS, 1995, BIOCHEM BIOPH RES CO, V209, P622, DOI 10.1006/bbrc.1995.1545; XIANG X, 1995, MOL BIOL CELL, V6, P297, DOI 10.1091/mbc.6.3.297; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	30	160	163	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1997	385	6611					89	93		10.1038/385089a0	http://dx.doi.org/10.1038/385089a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985254				2022-12-28	WOS:A1997WA73100057
J	Read, TE; Read, JD; Butterly, LF				Read, TE; Read, JD; Butterly, LF			Importance of adenomas 5 mm or less in diameter that are detected by sigmoidoscopy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIMINUTIVE COLONIC POLYPS; COLORECTAL POLYPS; FLEXIBLE SIGMOIDOSCOPY; CLINICAL-SIGNIFICANCE; RECTOSIGMOID POLYPS; LARGE BOWEL; RISK; NEOPLASMS; CANCER; COLONOSCOPY	Background The need for colonoscopy in patients with adenomas 5 mm or less in diameter that are detected by sigmoidoscopy is controversial. Methods We prospectively determined the prevalence of proximal colonic neoplasms in asymptomatic patients at average risk for colorectal cancer, each of whose index lesion on screening fiberoptic sigmoidoscopy was a benign adenoma. Polyps found on sigmoidoscopy underwent biopsy, and colonoscopy was recommended to all patients with neoplastic polyps. Rectosigmoid adenomas were classified as diminutive (less than or equal to 5 mm in diameter), small (6 to 10 mm in diameter), or large (greater than or equal to 11 mm in diameter). Results Of 3496 consecutive patients referred for sigmoidoscopy, 311 had neoplastic rectosigmoid polyps; 108 of these patients were excluded from the analysis because of a history of colonic neoplasia, symptoms, prior colonic evaluation, or incomplete follow-up data. The remaining 203 patients made up the study group, and all underwent colonoscopy. Neoplasms were found in the proximal colon in 40 of 137 patients (29 percent) with diminutive index polyps, 15 of 52 patients (29 percent) with small index polyps, and 8 of 14 patients (57 percent) with large index polyps. Advanced neoplasms (adenomas greater than or equal to 10 mm in diameter, adenomas with a villous component or moderate-to-severe dysplasia, carcinoma in situ, or frank carcinoma) were found in 8 patients (6 percent), 5 patients (10 percent), and 4 patients (29 percent), respectively. Two patients with diminutive index polyps had proximal carcinoma in situ, and two had proximal stage I carcinomas; one patient with a large index polyp had proximal stage III carcinoma. Conclusions The substantial prevalence of proximal colonic neoplasms, including advanced lesions, in asymptomatic average-risk patients with rectosigmoid adenomas less than or equal to 5 mm in diameter warrants colonoscopy in these patients. (C)1997, Massachusetts Medical Society.	LAHEY HITCHCOCK MED CTR,GASTROENTEROL SECT,BURLINGTON,MA 01805; LAHEY HITCHCOCK MED CTR,DEPT COLON SURG,BURLINGTON,MA 01805; LAHEY HITCHCOCK MED CTR,DEPT RECTAL SURG,BURLINGTON,MA 01805	Lahey Hospital & Medical Center; Lahey Hospital & Medical Center; Lahey Hospital & Medical Center								ACHKAR E, 1988, ANN INTERN MED, V109, P880, DOI 10.7326/0003-4819-109-11-880; ARMINSKI T. C., 1964, DIS COLON RECTUM, V7, P249, DOI 10.1007/BF02630528; ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; Blatt LJ., 1961, DIS COLON RECTUM, V4, P277; BOND JH, 1994, ANN INTERN MED, V120, P347, DOI 10.7326/0003-4819-120-4-199402150-00032; BOND JH, 1993, GASTROINTEST ENDOSC, V39, P592, DOI 10.1016/S0016-5107(93)70184-4; BOND JH, 1993, ANN INTERN MED, V119, P836, DOI 10.7326/0003-4819-119-8-199310150-00010; BRADY PG, 1993, GASTROINTEST ENDOSC, V39, P481, DOI 10.1016/S0016-5107(93)70155-8; CORREA P, 1977, CANCER, V39, P2258; EIDE TJ, 1978, CANCER, V42, P2839, DOI 10.1002/1097-0142(197812)42:6<2839::AID-CNCR2820420645>3.0.CO;2-Y; ELLIS CN, 1993, DIS COLON RECTUM, V36, P8; GROSSMAN S, 1989, GASTROENTEROLOGY, V96, P299, DOI 10.1016/0016-5085(89)91551-5; HOFF G, 1985, SCAND J GASTROENTERO, V20, P351, DOI 10.3109/00365528509091663; LEVIN B, 1992, CA-CANCER J CLIN, V42, P296, DOI 10.3322/canjclin.42.5.296; LIEBERMAN DA, 1991, AM J GASTROENTEROL, V86, P946; OPELKA FG, 1992, DIS COLON RECTUM, V35, P178, DOI 10.1007/BF02050675; PENNAZIO M, 1993, DIS COLON RECTUM, V36, P1121, DOI 10.1007/BF02052260; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; REX DK, 1992, GASTROENTEROLOGY, V102, P317, DOI 10.1016/0016-5085(92)91817-N; REX DK, 1991, GASTROENTEROLOGY, V100, P64, DOI 10.1016/0016-5085(91)90583-7; RICKERT RR, 1979, CANCER-AM CANCER SOC, V43, P1847, DOI 10.1002/1097-0142(197905)43:5<1847::AID-CNCR2820430538>3.0.CO;2-L; ROSEN L, 1992, DIS COLON RECTUM, V35, P391; RYAN ME, 1989, GASTROINTEST ENDOSC, V35, P85, DOI 10.1016/S0016-5107(89)72714-0; SANDLER RS, 1995, J CLIN GASTROENTEROL, V20, P317, DOI 10.1097/00004836-199506000-00013; SPENCER RJ, 1984, MAYO CLIN PROC, V59, P305, DOI 10.1016/S0025-6196(12)61425-6; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; TEDESCO FJ, 1982, GASTROINTEST ENDOSC, V28, P1, DOI 10.1016/S0016-5107(82)72954-2; TRIPP MR, 1987, CANCER, V60, P1599, DOI 10.1002/1097-0142(19871001)60:7<1599::AID-CNCR2820600730>3.0.CO;2-I; URBANSKI SJ, 1988, DIS COLON RECTUM, V31, P58, DOI 10.1007/BF02552572; Varma J R, 1989, J Am Board Fam Pract, V2, P204; WILLIAMS AR, 1982, GUT, V23, P835, DOI 10.1136/gut.23.10.835; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; ZARCHY TM, 1994, GASTROENTEROLOGY, V106, P1501, DOI 10.1016/0016-5085(94)90403-0	33	154	163	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1997	336	1					8	12		10.1056/NEJM199701023360102	http://dx.doi.org/10.1056/NEJM199701023360102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA496	8970934				2022-12-28	WOS:A1997WA49600002
J	Thompson, DC; Rivara, FP; Thompson, RS				Thompson, DC; Rivara, FP; Thompson, RS			Effectiveness of bicycle safety helmets in preventing head injuries - A case-control study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CYCLE HELMETS; COLLISIONS; AUSTRALIA; CHILDREN; VICTORIA	Objectives.-To examine the protective effectiveness of bicycle helmets in 4 different age groups of bicyclists, in crashes involving motor vehicles, and by helmet type and certification standards. Research Design.-Prospective case-control study Setting.-Emergency departments (EDs) in 7 Seattle, Wash, area hospitals between March 1, 1992, and August 31, 1994. Participants.-Case subjects were all bicyclists treated in EDs for head injuries, all who were hospitalized, and all who died at the scene. Control subjects were bicyclists treated for nonhead injuries. Main Results.-There were 3390 injured bicyclists in the study; 29% of cases and 56% of controls were helmeted. Risk of head injury in helmeted vs unhelmeted cyclists adjusted for age and motor vehicle involvement indicate a protective effect of 69% to 74% for helmets for 3 different categories of head injury: any head injury (odds ratio [OR], 0.31; 95% confidence interval [CI], 0.26-0.37), brain injury (OR, 0.35; 95% CI, 0.25-0.48), or severe brain injury (OR, 0.26; 95% CI, 0.14-0.48). Adjusted ORs for each of 4 age groups (<6 y, 6-12 y, 13-19 y, and greater than or equal to 20 years) indicate similar revels of helmet protection by age (OR range, 0.27-0.40). Helmets were equally effective in crashes involving motor vehicles (OR, 0.31; 95% CI, 0.20-0.48) and those not involving motor vehicles (OR, 0.32; 95% CI, 0.20-0.39). There was no effect modification by age or motor vehicle involvement (P=.7 and P=.3). No significant differences were found for the protective effect of hard-shell, thin-shell, or no-shell helmets (P=.5). Conclusions.-Bicycle helmets, regardless of type, provide substantial protection against head injuries for cyclists or all ages involved in crashes, including crashes involving motor vehicles.	UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; GRP HLTH COOPERAT PUGET SOUND,DEPT PREVENT CARE,SEATTLE,WA 98121	University of Washington; University of Washington Seattle; Group Health Cooperative	Thompson, DC (corresponding author), UNIV WASHINGTON,DEPT PEDIAT,HARBORVIEW INJURY PREVENT & RES CTR,325 9TH AVE,BOX 359960,SEATTLE,WA 98104, USA.							Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BRESLOW NE, 1980, INT AGENCY RES CANC, V32, P190; CAMERON MH, 1994, ACCIDENT ANAL PREV, V26, P325, DOI 10.1016/0001-4575(94)90006-X; COTE TR, 1992, PEDIATRICS, V89, P1216; Henderson M, 1996, EFFECTIVENESS BICYCL; Hillman M, 1993, CYCLE HELMETS CASE; MAIMARIS C, 1994, BRIT MED J, V308, P1537, DOI 10.1136/bmj.308.6943.1537; MCCARTHY M, 1992, BRIT MED J, V305, P881, DOI 10.1136/bmj.305.6858.881; MCDERMOTT F, 1994, BRIT MED J, V309, P877, DOI 10.1136/bmj.309.6958.877b; MCDERMOTT FT, 1993, J TRAUMA, V34, P834, DOI 10.1097/00005373-199306000-00015; *NAT CTR HLTH STAT, 1991, DHHS PUBL; PITT WR, 1994, BRIT MED J, V308, P177, DOI 10.1136/bmj.308.6922.177; RIVARA FP, 1994, PEDIATRICS, V93, P567; *SAS I INC, 1989, SASLANG PROC US VERS; SPAITE DW, 1991, J TRAUMA, V31, P1510, DOI 10.1097/00005373-199111000-00008; TEASDALE G, 1974, LANCET, V2, P81; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1471, DOI 10.2105/AJPH.80.12.1471; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1974, DOI 10.1001/jama.276.24.1974; THOMPSON DC, 1994, J TRAUMA, V36, P463; THOMPSON DC, IN PRESS INJ PREV; Thompson DC, 1996, EPIDEMIOLOGY SPORTS, P98; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; *TRIAN INC, 1989, TRI CODE 5 0 PERS CO; VULCAN AP, 1992, WORLD J SURG, V16, P389, DOI 10.1007/BF02104437; WACHTEL A, 1994, ITE J, V64, P30; [No title captured]	27	224	225	0	36	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1996	276	24					1968	1973		10.1001/jama.276.24.1968	http://dx.doi.org/10.1001/jama.276.24.1968			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY689	8971066				2022-12-28	WOS:A1996VY68900029
J	Fonseka, C				Fonseka, C			To err was fatal	BRITISH MEDICAL JOURNAL			English	Article											Fonseka, C (corresponding author), UNIV KELANIYA,RAGAMA,SRI LANKA.							Rahula Walpola, 1959, WHAT BUDDHA TAUGHT; RASMUSSEN J, 1974, ERGONOMICS, V17, P293, DOI 10.1080/00140137408931355; Sacks O., 1986, MAN WHO MISTOOK HIS; SLANEY JK, 1988, LOGIC MED, P17; SMITH R, 1995, BRIT MED J, V311, P1240, DOI 10.1136/bmj.311.7015.1240	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1640	1642		10.1136/bmj.313.7072.1640	http://dx.doi.org/10.1136/bmj.313.7072.1640			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991017	Green Published			2022-12-28	WOS:A1996VZ81100051
J	Kurumbail, RG; Stevens, AM; Gierse, JK; McDonald, JJ; Stegeman, RA; Pak, JY; Gildehaus, D; Miyashiro, JM; Penning, TD; Seibert, K; Isakson, PC; Stallings, WC				Kurumbail, RG; Stevens, AM; Gierse, JK; McDonald, JJ; Stegeman, RA; Pak, JY; Gildehaus, D; Miyashiro, JM; Penning, TD; Seibert, K; Isakson, PC; Stallings, WC			Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents	NATURE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN-G/H SYNTHASE; CRYSTAL-STRUCTURE; ASPIRIN	PROSTAGLANDINS and glucocorticoids are potent mediators of inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs) exert their effects by inhibition of prostaglandin production. The pharmacological target of NSAIDs is cyclooxygenase (COX, also known as PGH synthase), which catalyses the first committed step in arachidonic-acid metabolism(1,2). Two isoforms of the membrane protein COX are known(3): COX-1, which is constitutively expressed in most tissues, is responsible for the physiological production of prostaglandins(4); and COX-2, which is induced by cytokines, mitogens and endotoxins in inflammatory cells(5), is responsible for the elevated production of prostaglandins during inflammation(6,7). The structure of ovine COX-1 complexed with several NSAIDs has been determined(8-10). Here we report the structures of unliganded murine COX-2 and complexes with flurbiprofen, indomethacin and SC-558, a selective COX-2 inhibitor, determined at 3.0 to 25 Angstrom resolution. These structures explain the structural basis for the selective inhibition of COX-2, and demonstrate some of the conformational changes associated with time-dependent inhibition.	GD SEARLE & CO,SKOKIE,IL 60077	Pfizer	Kurumbail, RG (corresponding author), GD SEARLE & CO,700 CHESTERFIELD PKWY N,ST LOUIS,MO 63198, USA.							BERTENSHAW SR, 1995, BIOORG MED CHEM LETT, V5, P2919, DOI 10.1016/0960-894X(95)00512-R; Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; Black WC, 1996, BIOORG MED CHEM LETT, V6, P725, DOI 10.1016/0960-894X(96)00100-X; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DIETZ R, 1988, EUR J BIOCHEM, V171, P320; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GANS KR, 1990, J PHARMACOL EXP THER, V254, P180; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HOOGSTEE.K, 1970, J ORG CHEM, V35, P521, DOI 10.1021/jo00827a057; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KULMACZ RJ, 1985, J BIOL CHEM, V260, P2572; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; Loll PJ, 1996, BIOCHEMISTRY-US, V35, P7330, DOI 10.1021/bi952776w; LOLL PJ, 1995, NAT STRUCT BIOL, V2, P637, DOI 10.1038/nsb0895-637; Marnett L. J., 1991, PEROXIDASES CHEM BIO, V1, P293; MASTENER JL, 1994, P NATL ACAD SCI USA, V91, P3228; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; OTTO JC, 1995, J LIPID MEDIAT CELL, V12, P139, DOI 10.1016/0929-7855(95)00015-I; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; SMITH WL, 1994, MET IONS BIOL SYST, V30, P163; VAN JR, 1971, NATURE-NEW BIOL, V231, P232; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046	30	1444	1499	2	124	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 19	1996	384	6610					644	648		10.1038/384644a0	http://dx.doi.org/10.1038/384644a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VZ296	8967954				2022-12-28	WOS:A1996VZ29600034
J	Schectman, G; Hiatt, J				Schectman, G; Hiatt, J			Dose-response characteristics of cholesterol-lowering drug therapies: Implications for treatment	ANNALS OF INTERNAL MEDICINE			English	Review							DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-ARTERY DISEASE; SUSTAINED-RELEASE NIACIN; SHORT-TERM EFFICACY; PRIMARY HYPERCHOLESTEROLEMIA; NICOTINIC-ACID; MODERATE HYPERCHOLESTEROLEMIA; HEART-DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIC SUBJECTS	Purpose: To develop an optimal treatment strategy that reduces low-density lipoprotein (LDL) cholesterol levels and improves adherence to therapy by reviewing clinical trials that define the dose-response characteristics for 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), bile acid sequestrants, and niacin. Data Sources: Data were obtained from a MEDLINE search of the English-language literature published from 1975 through November 1995 and from an extensive bibliography review. Study Selection: Controlled, clinical trials were reviewed if they evaluated 1) the effectiveness and toxicity of one LDL cholesterol-lowering agent (statins, bile acid sequestrants, or niacin, at two or more doses) or 2) monotherapy with two LDL cholesterol-lowering agents at defined doses used alone and in combination. Studies that had fewer than 10 patients in a treatment group or that selected patients on the basis of previous response to therapy were not included. Data Extraction: Trials were reviewed for overall methodology, inclusion and exclusion criteria, sources of bias, and outcomes. Data Synthesis: Dose-response relations for bile acid sequestrants and statins are nonlinear, and most of their LDL cholesterol-lowering effects can be obtained with lower doses. The few dose-response studies of niacin that have been done suggest that most of niacin's high-density lipoprotein cholesterol-increasing effect can also be achieved with relatively low doses, but higher doses are needed to substantially reduce LDL cholesterol levels. If bile acid sequestrants or niacin are added to statin therapy, the effect of combined therapy on LDL cholesterol levels is additive. Conclusion: The nonlinear dose-response relation of statins, bile acid sequestrants, and niacin and their additive LDL cholesterol-lowering effect when used together suggest a strategy for treating hypercholesterolemia that may optimize effectiveness while minimizing adverse effects and cost.	VET ADM MED CTR, MILWAUKEE, WI 53295 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Schectman, G (corresponding author), MED COLL WISCONSIN, FROEDTERT MEM LUTHERAN HOSP EAST, DIV GEN INTERNAL MED, BOX 135, MILWAUKEE, WI 53226 USA.							ALDERMAN JD, 1989, AM J CARDIOL, V64, P725, DOI 10.1016/0002-9149(89)90754-6; ANDRADE SE, 1995, NEW ENGL J MED, V332, P1125, DOI 10.1056/NEJM199504273321703; ANGELIN B, 1981, ATHEROSCLEROSIS, V38, P33, DOI 10.1016/0021-9150(81)90101-5; [Anonymous], 1993, Arch Intern Med, V153, P1321; Bowman W., 1980, TXB PHARM, Vsecond; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; Caggiula AW, 1996, ARCH INTERN MED, V156, P1205, DOI 10.1001/archinte.156.11.1205; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; Davidson MH, 1996, ARCH INTERN MED, V156, P305, DOI 10.1001/archinte.156.3.305; DAVIGNON J, 1994, AM J CARDIOL, V73, P339, DOI 10.1016/0002-9149(94)90005-1; DENKE MA, 1995, ARCH INTERN MED, V155, P17, DOI 10.1001/archinte.155.1.17; DENKE MA, 1995, ARCH INTERN MED, V155, P393, DOI 10.1001/archinte.155.4.393; FARMER JA, 1992, CLIN THER, V14, P708; FERDER LF, 1993, AM J CARDIOL, V71, P810, DOI 10.1016/0002-9149(93)90829-2; FRAUNFELDER FW, 1995, BRIT J OPHTHALMOL, V79, P54, DOI 10.1136/bjo.79.1.54; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GIBBONS LW, 1995, AM J MED, V99, P378, DOI 10.1016/S0002-9343(99)80185-5; GRAY DR, 1994, ANN INTERN MED, V121, P252, DOI 10.7326/0003-4819-121-4-199408150-00003; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HAGEN E, 1994, EUR J CLIN PHARMACOL, V46, P445; HEUDEBERT GR, 1993, ARCH INTERN MED, V153, P1828, DOI 10.1001/archinte.153.15.1828; HUNNINGHAKE DB, 1981, METABOLISM, V30, P605, DOI 10.1016/0026-0495(81)90140-2; HUNNINGHAKE DB, 1993, NEW ENGL J MED, V328, P1213, DOI 10.1056/NEJM199304293281701; ILLINGWOUTH DR, 1994, ARCH INTERN MED, V154, P1586, DOI 10.1001/archinte.154.14.1586; JACOBSON TA, 1994, AM J CARDIOL, V74, P149, DOI 10.1016/0002-9149(94)90088-4; JACOTOT B, 1994, BRIT J CLIN PHARMACO, V38, P257, DOI 10.1111/j.1365-2125.1994.tb04350.x; KEECH A, 1994, EUR HEART J, V15, P255, DOI 10.1093/oxfordjournals.eurheartj.a060485; KEENAN JM, 1991, ARCH INTERN MED, V151, P1424, DOI 10.1001/archinte.151.7.1424; KEENAN JM, 1992, J FAM PRACTICE, V34, P313; KING JM, 1994, AM J MED, V97, P323, DOI 10.1016/0002-9343(94)90298-4; KINOSIAN B, 1994, ANN INTERN MED, V121, P641, DOI 10.7326/0003-4819-121-9-199411010-00002; KNOPP RH, 1985, METABOLISM, V34, P642, DOI 10.1016/0026-0495(85)90092-7; LAROSA JC, 1994, ARCH INTERN MED, V154, P529, DOI 10.1001/archinte.154.5.529; LAVIE CJ, 1992, AM J CARDIOL, V69, P1083, DOI 10.1016/0002-9149(92)90868-Y; LEITERSDORF E, 1993, EUR J CLIN PHARMACOL, V45, P513, DOI 10.1007/BF00315307; LURIA MH, 1988, ARCH INTERN MED, V148, P2493, DOI 10.1001/archinte.148.11.2493; MartinJadraque R, 1996, ARCH INTERN MED, V156, P1081, DOI 10.1001/archinte.156.10.1081; MCKENNEY JM, 1994, JAMA-J AM MED ASSOC, V271, P672, DOI 10.1001/jama.271.9.672; MCPHERSON R, 1992, CLIN THER, V14, P276; *NAT CHOL ED PROGR, 1984, CIRCULATION, V89, P1333; PEDERSEN TR, 1994, LANCET, V344, P1383; RADER JI, 1992, AM J MED, V92, P77, DOI 10.1016/0002-9343(92)90018-7; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RIFKIND BM, 1990, AM J CARDIOL, V66, pA3, DOI 10.1016/0002-9149(90)90561-E; RUBINS HB, 1995, AM J CARDIOL, V75, P1196, DOI 10.1016/S0002-9149(99)80761-9; SAITO Y, 1991, ARTERIOSCLER THROMB, V11, P816, DOI 10.1161/01.ATV.11.4.816; SALZMAN C, 1995, J CLIN PSYCHIAT, V56, P18; SCHAEFER EJ, 1995, ARTERIOSCL THROM VAS, V15, P1079, DOI 10.1161/01.ATV.15.8.1079; SCHECTMAN G, 1993, AM J CARDIOL, V71, P759, DOI 10.1016/0002-9149(93)90820-3; Schectman G, 1996, J GEN INTERN MED, V11, P277, DOI 10.1007/BF02598268; SCHROTT HG, 1995, AM J CARDIOL, V75, P34, DOI 10.1016/S0002-9149(99)80523-2; SCLAR DA, 1991, CLIN THER, V13, P436; SEMPOS CT, 1993, JAMA-J AM MED ASSOC, V269, P3009, DOI 10.1001/jama.269.23.3009; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SIMONS LA, 1992, MED J AUSTRALIA, V157, P455, DOI 10.5694/j.1326-5377.1992.tb137306.x; SPRECHER DL, 1994, ANN INTERN MED, V120, P537, DOI 10.7326/0003-4819-120-7-199404010-00002; SQUIRES RW, 1992, MAYO CLIN PROC, V67, P855, DOI 10.1016/S0025-6196(12)60824-6; STALENHOEF AFH, 1993, J INTERN MED, V234, P77, DOI 10.1111/j.1365-2796.1993.tb00708.x; STEIN E, 1990, ARCH INTERN MED, V150, P341, DOI 10.1001/archinte.150.2.341; STEINHAGENTHIESSEN E, 1994, CARDIOLOGY, V85, P244, DOI 10.1159/000176682; SUPERKO HR, 1992, AM J CARDIOL, V70, P135, DOI 10.1016/0002-9149(92)91264-5; TOBERT JA, 1988, JAMA-J AM MED ASSOC, V260, P359; TUOMILEHTO J, 1994, J CARDIOVASC PHARM, V24, P941, DOI 10.1097/00005344-199424060-00012; VACEK JL, 1995, AM J CARDIOL, V76, P182, DOI 10.1016/S0002-9149(99)80056-3; VECCHIO TJ, 1982, ARCH INTERN MED, V142, P721, DOI 10.1001/archinte.142.4.721; VEGA GL, 1994, ARCH INTERN MED, V154, P73, DOI 10.1001/archinte.154.1.73; VESSBY B, 1982, ATHEROSCLEROSIS, V44, P61, DOI 10.1016/0021-9150(82)90053-3; WIKLUND O, 1990, J INTERN MED, V228, P241, DOI 10.1111/j.1365-2796.1990.tb00225.x; WITZTUM JL, 1979, METABOLISM, V28, P221, DOI 10.1016/0026-0495(79)90067-2	70	61	62	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1996	125	12					990	1000		10.7326/0003-4819-125-12-199612150-00011	http://dx.doi.org/10.7326/0003-4819-125-12-199612150-00011			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX768	8967711				2022-12-28	WOS:A1996VX76800011
J	Cittanova, ML; Leblanc, I; Legendre, C; Mouquet, C; Riou, B; Coriat, P				Cittanova, ML; Leblanc, I; Legendre, C; Mouquet, C; Riou, B; Coriat, P			Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients	LANCET			English	Article							STARCH	Background Hydroxyethylstarch used as a plasma-volume expander in brain-dead kidney donors has been suggested to induce osmotic-nephrosis-like lesions. We have studied its effect on kidney-transplant function. Methods 52 patients who had received hydroxyethylstarch or iodinated contrast-media before brain death were excluded. 69 other brain-dead patients were prospectively included over 18 months and randomised into two groups. In the hydroxyethylstarch-gelatin group, patients received hydroxyethylstarch up to 33 mL/kg for colloid plasma-volume expansion, and afterwards received modified fluid gelatin. In the gelatin-only group, patients received only modified fluid gelatin as colloid plasma-volume expander. Multiple organs were procured in 29 cases, which included the kidneys in 27 cases (hydroxyethylstarch-gelatin 15, gelatin-only 12). Findings There were no significant differences in the characteristics of patients between the two groups of kidney donors or of recipients (except for a small imbalance in sex in the recipients). During the first 8 days after transplantation, nine of 27 (33%) patients required extrarenal haemodialysis or haemodiafiltration in the hydroxyethylstarch-gelatin group compared with one of 20 (5%) in the gelatin-only group (p=0.029). Serum creatinine concentrations were significantly lower in the gelatin-only group than in the other group (p=0.009). 10 days after transplantation, mean (SD) serum creatinine was, respectively, 145 (70) and 312 (259) mu mol/L. Interpretation These data suggest that hydroxyethylstarch used as a plasma-volume expander in brain-dead donors impairs immediate renal function in kidney-transplant recipients.	HOP NECKER ENFANTS MALAD,SERV TRANSPLANTAT & REANIMAT,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Cittanova, ML (corresponding author), HOP LA PITIE SALPETRIERE,DEPT ANESTHESIE REANIMAT,F-75651 PARIS 13,FRANCE.			Leblanc, Isabelle/0000-0003-0086-3853				BAATARD R, 1993, TRANSPLANTATION, V55, P31, DOI 10.1097/00007890-199301000-00007; BARON JF, 1992, PLASMA VOLUME EXPANS, P121; BODENHAM A, 1989, INTENS CARE MED, V15, P340; CARLIER M, 1983, TRANSPLANTATION, V36, P455, DOI 10.1097/00007890-198310000-00021; CECKA JM, 1992, TRANSPLANTATION, V53, P59, DOI 10.1097/00007890-199201000-00011; CORONEL B, 1994, ANN FR ANESTH, V13, P10, DOI 10.1016/S0750-7658(94)80181-9; DAWIDSON I, 1987, CRIT CARE MED, V15, P631, DOI 10.1097/00003246-198707000-00001; DISCALA VA, 1965, ANN INTERN MED, V63, P767, DOI 10.7326/0003-4819-63-5-767; FEIGENBAUM H, 1986, ECHOCARDIOGR-J CARD, P621; GJERTSON DW, 1992, TRANSPLANTATION, V53, P357, DOI 10.1097/00007890-199202010-00018; GOLDSTEIN D, 1983, CRIT CARE MED, V21, P228; HOFFMANN RM, 1989, TRANSPLANTATION, V47, P32, DOI 10.1097/00007890-198901000-00008; Kofke WA., 1993, TXB TRAUMA ANESTHESI, P994; LEGENDRE C, 1993, LANCET, V342, P248, DOI 10.1016/0140-6736(93)92345-T; LUKSZA AR, 1979, BMJ-BRIT MED J, V1, P1316, DOI 10.1136/bmj.1.6174.1316; MAUNSBACH AB, 1962, LAB INVEST, V11, P421; OBRIEN PC, 1988, MAYO CLIN PROC, V63, P1245, DOI 10.1016/S0025-6196(12)65412-3; RIOU B, 1995, BRIT J ANAESTH, V74, P424, DOI 10.1093/bja/74.4.424; RIOU B, 1995, CIRCULATION, V92, P409, DOI 10.1161/01.CIR.92.3.409; SOLOMON R, 1994, NEW ENGL J MED, V331, P1416, DOI 10.1056/NEJM199411243312104; WALDHAUSEN P, 1991, Acta Medica Austriaca, V18, P52; WILLMS CD, 1991, TRANSPLANT P, V23, P1338	22	304	314	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1620	1622		10.1016/S0140-6736(96)07588-5	http://dx.doi.org/10.1016/S0140-6736(96)07588-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8961992				2022-12-28	WOS:A1996VX87600011
J	Prasad, N; Isles, C				Prasad, N; Isles, C			Fortnightly review: Ambulatory blood pressure monitoring: A guide for general practitioners	BRITISH MEDICAL JOURNAL			English	Review							BRITISH-HYPERTENSION-SOCIETY; LEFT-VENTRICULAR HYPERTROPHY; WHITE COAT HYPERTENSION; MEASURING DEVICES; MANAGEMENT; DISEASE; HEART; MICROALBUMINURIA; BORDERLINE; DIAGNOSIS		DUMFRIES & GALLOWAY ROYAL INFIRM,DEPT MED,DUMFRIES DG1 4AP,SCOTLAND									APPEL LJ, 1993, ANN INTERN MED, V118, P867, DOI 10.7326/0003-4819-118-11-199306010-00008; *ASS ADV MED INSTR, 1987, AM NAT STAND EL AUT; Aylett M, 1996, J HUM HYPERTENS, V10, P17; AYLETT MJ, 1994, FAM PRACT, V11, P197, DOI 10.1093/fampra/11.2.197; Bidlingmeyer I, 1996, J HYPERTENS, V14, P327, DOI 10.1097/00004872-199603000-00009; CAVALLINI MC, 1995, HYPERTENSION, V26, P413, DOI 10.1161/01.HYP.26.3.413; COATS AJS, 1990, J HYPERTENS, V8, pS17; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOPE G, 1993, BRIT J GEN PRACT, V43, P83; DAVIES RJO, 1994, BRIT MED J, V308, P820, DOI 10.1136/bmj.308.6932.820; DESIMONE G, 1994, J HYPERTENS, V12, P1129; DEVEREUX RB, 1991, J HYPERTENS, V9, pS34; GIACONI S, 1989, AM J HYPERTENS, V2, P259, DOI 10.1093/ajh/2.4.259; Glen SK, 1996, LANCET, V348, P654, DOI 10.1016/S0140-6736(96)02303-3; GOSSE P, 1993, HYPERTENSION, V22, P766, DOI 10.1161/01.HYP.22.5.766; HANNEDOUCHE T, 1994, BRIT MED J, V309, P833, DOI 10.1136/bmj.309.6958.833; HARRISON D W, 1992, Biomedical Instrumentation and Technology, V26, P325; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; JULIUS S, 1990, HYPERTENSION, V16, P617, DOI 10.1161/01.HYP.16.6.617; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MANCIA G, 1983, LANCET, V2, P695; MANCIA G, IN PRESS CIRCULATION; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; McGrath BP, 1996, LANCET, V348, P630, DOI 10.1016/S0140-6736(05)65069-6; MIDDEKE M, 1994, BRIT MED J, V308, P630, DOI 10.1136/bmj.308.6929.630; MILLAR JA, 1995, J HYPERTENS, V13, P175; OBRIEN E, 1995, HYPERTENSION, V26, P835, DOI 10.1161/01.HYP.26.5.835; OBRIEN E, 1990, J HYPERTENS, V8, P607, DOI 10.1097/00004872-199007000-00004; OBRIEN E, IN PRESS J HUMAN HYP; PADFIELD PL, 1987, LANCET, V2, P322; PERLOFF D, 1989, J HYPERTENS, V7, pS3; PERLOFF D, 1983, JAMA-J AM MED ASSOC, V249, P2792, DOI 10.1001/jama.249.20.2792; PERLOFF D, 1991, J HYPERTENS, V9, pS33; PETRIE JC, 1990, RECOMMENDATIONS BLOO; PICKERING TG, 1990, J HYPERTENS        S, V7, pS141; PRASAD N, 1995, J HYPERTENS, V13, P219; REDON J, 1995, 7 EUR M HYP MIL 9 12; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SHIMADA K, 1990, HYPERTENSION, V16, P692, DOI 10.1161/01.HYP.16.6.692; SOKOLOW M, 1966, CIRCULATION, V34, P279; Staessen JA, 1996, NEPHROL DIAL TRANSPL, V11, P241, DOI 10.1093/oxfordjournals.ndt.a027247; STEWART MJ, 1992, CLIN SCI, V83, P1; STEWART MJ, 1995, J HYPERTENS, V13, P297; VERDECCHIA P, 1990, CIRCULATION, V81, P528, DOI 10.1161/01.CIR.81.2.528; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; WALMA EP, 1995, J HUM HYPERTENS, V9, P169	46	23	23	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1996	313	7071					1535	1541		10.1136/bmj.313.7071.1535	http://dx.doi.org/10.1136/bmj.313.7071.1535			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY691	8978234	Green Published			2022-12-28	WOS:A1996VY69100028
J	Heptonstall, J; Barnes, J; Burton, E; Chattopadyhay, B; McMillan, L; Sullivan, K; Tarling, R; Viniker, D; Boxall, E; Cartmill, I; Chatterjea, M; Neill, R; Collins, M; Gill, N; Ngui, SL; Parker, C; Ryan, M; Teo, CG; Coyle, P; Craske, J; Paver, K; Gilson, R; Hawkins, A; Tedder, R; Watts, P; Zuckerman, M; Morris, D; Nazareth, B				Heptonstall, J; Barnes, J; Burton, E; Chattopadyhay, B; McMillan, L; Sullivan, K; Tarling, R; Viniker, D; Boxall, E; Cartmill, I; Chatterjea, M; Neill, R; Collins, M; Gill, N; Ngui, SL; Parker, C; Ryan, M; Teo, CG; Coyle, P; Craske, J; Paver, K; Gilson, R; Hawkins, A; Tedder, R; Watts, P; Zuckerman, M; Morris, D; Nazareth, B			Transmission of hepatitis B to patients from four infected surgeons without hepatitis B e antigen	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS; PRECORE; ASSAY	Background Transmission of hepatitis B virus (HBV) to patients by infected surgeons who carry hepatitis B e antigen (HBeAg) has been documented repeatedly. In the United Kingdom HBeAg-positive surgeons are not permitted to perform certain procedures that carry a risk that patients might be exposed to the blood of a health care worker. There are no practice restrictions for carriers of hepatitis B surface antigen without detectable HBeAg, un less transmission has been demonstrated. Methods In four unconnected cases of acute hepatitis B, surgery was identified as a possible source, so we tested the surgical teams for serologic markers of HBV infection. In each case a surgeon was found to be infected with the virus. HBV DNA was amplified by a nested polymerase chain reaction from serum from the four infected surgeons and the four patients, and direct nucleotide sequencing of two regions of the HBV genome was performed. Alternative sources of infection were ruled out. Other patients on whom three of the surgeons had recently performed procedures were offered testing. Results All four surgeons were carriers of HBV, but none had detectable serum HBeAg. The nucleotide sequences of HBV DNA from the surgeons were indistinguishable from those from the corresponding patients. The screening of other exposed patients identified at least two other patients who had probably acquired hepatitis B infection from one of these surgeons. Conclusions Surgeons who are carriers of HBV without detectable serum HBeAg can transmit HBV to patients during procedures. (C) 1997, Massachusetts Medical Society.	BIRMINGHAM HEARTLANDS HOSP, BIRMINGHAM B9 5ST, W MIDLANDS, ENGLAND; ROCHDALE HLTH AUTHOR, DEPT PUBL HLTH, ROCHDALE, ENGLAND; ROCHDALE TRUST, ROCHDALE, ENGLAND; ROYAL VICTORIA HOSP, REG VIRUS LAB, BELFAST BT12 6BA, ANTRIM, NORTH IRELAND; WITHINGTON HOSP, PUBL HLTH LAB, MANCHESTER M20 8LR, LANCS, ENGLAND; UCL, SCH MED, DEPT VIROL, LONDON W1N 8AA, ENGLAND; UCL, SCH MED, DEPT SEXUALLY TRANSMITTED DIS, LONDON W1N 8AA, ENGLAND; UNIV MANCHESTER, SCH MED, DIV VIROL, MANCHESTER M13 9PT, LANCS, ENGLAND; REDBRIDGE & WALTHAM FOREST HLTH AUTHOR, DEPT PUBL HLTH, ILFORD, ESSEX, ENGLAND; WHIPPS CROSS HOSP & CHEST CLIN, PUBL HLTH LAB, LONDON E11 1NR, ENGLAND; WHIPPS CROSS HOSP & CHEST CLIN, FOREST HLTH TRUST, LONDON E11 1NR, ENGLAND; CENT PUBL HLTH LAB, PUBL HLTH LAB SERV, CTR COMMUNICABLE DIS SURVEILLANCE, LONDON NW9 5HT, ENGLAND; CENT PUBL HLTH LAB, DIV VIRUS REFERENCE, LONDON NW9 5HT, ENGLAND	Heart of England NHS Foundation Trust; University of Birmingham; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of Manchester; University of London; Queen Mary University London; University of London; Queen Mary University London; Public Health England; Public Health England	Heptonstall, J (corresponding author), PUBL HLTH LAB SERV, CTR COMMUNICABLE DIS SURVEILLANCE, 61 COLINDALE AVE, LONDON NW9 5EQ, ENGLAND.		Gilson, Richard J C/C-5123-2009					CARMAN WF, 1989, LANCET, V2, P588; Crawshaw S C, 1994, Commun Dis Rep CDR Rev, V4, pR125; FERNS RB, 1985, J VIROL METHODS, V11, P231, DOI 10.1016/0166-0934(85)90112-0; Harpaz R, 1996, NEW ENGL J MED, V334, P549, DOI 10.1056/NEJM199602293340901; HAWKINS AE, 1994, J MED VIROL, V44, P13, DOI 10.1002/jmv.1890440105; HAWKINS AE, 1994, J MED VIROL, V43, P5, DOI 10.1002/jmv.1890430103; Heptonstall J, 1991, CDR (Lond Engl Rev), V1, pR81; HEPTONSTALL J, 1994, INFECT CONT HOSP EP, V15, P344; Johnston B L, 1992, Can Commun Dis Rep, V18, P89; *NAT HLTH SERV MAN, 1993, NAT HLTH SERV MAN EX; POLAKOFF S, 1986, BRIT MED J, V293, P33, DOI 10.1136/bmj.293.6538.33; POLAKOFF S, 1986, BRIT MED J, V293, P37, DOI 10.1136/bmj.293.6538.37; PRENTICE MB, 1992, BRIT MED J, V304, P761, DOI 10.1136/bmj.304.6829.761; PUGH JC, 1986, J MED VIROL, V20, P229, DOI 10.1002/jmv.1890200305; *UK HLTH DEP, 1993, PROT HLTH CAR WORK P; ULRICH PP, 1990, J MED VIROL, V32, P109, DOI 10.1002/jmv.1890320208; WELCH J, 1989, LANCET, V1, P205; WHITBY K, 1995, J VIROL METHODS, V51, P75, DOI 10.1016/0166-0934(94)00144-6; ZUCKERMAN MA, 1995, J INFECT DIS, V172, P1080, DOI 10.1093/infdis/172.4.1080; 1991, BRIT MED J, V303, P184; 1991, MMWR-MORBID MORTAL W, V40, P1	21	113	115	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1997	336	3					178	184		10.1056/NEJM199701163360304	http://dx.doi.org/10.1056/NEJM199701163360304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC266	8992352	Bronze			2022-12-28	WOS:A1997WC26600004
J	Hlatky, MA; Rogers, WJ; Johnstone, I; Boothroyd, D; Brooks, MM; Pitt, B; Reeder, G; Ryan, T; Smith, H; Whitlow, P; Wiens, R; Mark, DB				Hlatky, MA; Rogers, WJ; Johnstone, I; Boothroyd, D; Brooks, MM; Pitt, B; Reeder, G; Ryan, T; Smith, H; Whitlow, P; Wiens, R; Mark, DB			Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REVASCULARIZATION INVESTIGATION BARI; ACTIVITY STATUS INDEX; ARTERY-DISEASE; FUNCTIONAL-CAPACITY; FOLLOW-UP; OF-LIFE; THERAPY; TRIAL; HEALTH; METAANALYSIS	Background Randomized trials comparing coronary angioplasty with bypass surgery in patients with multivessel coronary disease have shown no significant differences in overall rates of death and myocardial infarction. We compared quality of life, employment, and medical care costs during five years of follow-up among patients treated with an gioplasty or bypass surgery. Methods A total of 934 of the 1829 patients enrolled in the randomized Bypass Angioplasty Revascularization Investigation participated in this study. Detailed data on quality of life were collected annually, and economic data were collected quarterly. Results During the first three years of follow-up, functional-status scores on the Duke Activity Status Index, which measures the ability to perform common activities of daily living, improved more in patients assigned to surgery than in those assigned to angioplasty (P<0.05). Other measures of quality of life improved equally in both groups throughout the follow-up period. Patients in the angioplasty group returned to work five weeks sooner than did patients in the surgery group (P<0.001). The initial mean cost of angioplasty was 65 percent that of surgery ($21,113 vs. $32,347, P<0.001), but after five years the total medical cost of angioplasty was 95 percent that of surgery ($56,225 vs. $58,889), a difference of $2,664 (P=0.047). The five-year cost of angioplasty was significantly lower than that of surgery among patients with two-vessel disease ($52,930 vs. $58,498, P<0.05), but not among patients with three-vessel disease ($60,918 vs. $59,430). After five years of follow-up, surgery had an overall cost-effectiveness ratio of $26,117 per year of life added, but unacceptable ratios of $100,000 or more per year of life added could not be excluded (P=0.13). Surgery appeared particularly cost effective in treating patients with diabetes because of their significantly improved survival. Conclusions In patients with multivessel coronary disease, coronary-artery bypass surgery is associated with a better quality of life for three years than coronary angioplasty, after the initial morbidity caused by the procedure. Coronary angioplasty has a lower five-year cost than bypass surgery only in patients with two-vessel coronary disease. (C) 1997, Massachusetts Medical Society.	UNIV ALABAMA,MED CTR,BIRMINGHAM,AL 35294; UNIV PITTSBURGH,GRAD SCH PUBL HLTH,PITTSBURGH,PA; UNIV MICHIGAN,SCH MED,ANN ARBOR,MI; MAYO CLIN,ROCHESTER,MN; BOSTON UNIV,SCH MED,BOSTON,MA 02118; CLEVELAND CLIN FDN,CLEVELAND,OH 44195; ST LOUIS UNIV,SCH MED,ST LOUIS,MO; DUKE UNIV,SCH MED,DURHAM,NC	University of Alabama System; University of Alabama Birmingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Michigan System; University of Michigan; Mayo Clinic; Boston University; Cleveland Clinic Foundation; Saint Louis University; Duke University	Hlatky, MA (corresponding author), STANFORD UNIV,SCH MED,STANFORD,CA 94305, USA.			Boothroyd, Derek Brian/0000-0001-5387-6995; Brooks, Maria/0000-0002-2030-7873; Hlatky, Mark/0000-0003-4686-9441; Mark, Daniel/0000-0001-6340-8087	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL038610] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38610] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, STAT ABSTRACT US 199, V115; BOURASSA MG, 1995, AM J CARDIOL, V75, pC3, DOI 10.1016/S0002-9149(99)80389-0; *BYP ANG REV INV, 1996, NEW ENGL J MED, V335, P217; *CABRI TRIAL PART, 1995, LANCET, V346, P1179; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; EFRON B, 1991, SCIENCE, V253, P390, DOI 10.1126/science.253.5018.390; Efron B., 1994, MONOGRAPHS STAT APPL; Etzioni R, 1996, J CLIN EPIDEMIOL, V49, P95, DOI 10.1016/0895-4356(96)89259-6; *EUR COR SURG STUD, 1982, LANCET, V2, P1173; Ferguson JJ, 1996, CIRCULATION, V93, P843, DOI 10.1161/01.CIR.93.5.843; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; Goldman L, 1996, J AM COLL CARDIOL, V27, P1020, DOI 10.1016/0735-1097(96)87734-5; GOY JJ, 1994, LANCET, V343, P1449, DOI 10.1016/S0140-6736(94)92579-8; GRUNTZIG AR, 1979, NEW ENGL J MED, V301, P61, DOI 10.1056/NEJM197907123010201; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; HLATKY MA, 1990, CIRCULATION, V82, P208; HLATKY MA, 1995, AM J CARDIOL, V75, pC34; JANG GC, 1984, AM J CARDIOL, V53, pC52, DOI 10.1016/0002-9149(84)90746-X; KELLY ME, 1985, J AM COLL CARDIOL, V5, P16, DOI 10.1016/S0735-1097(85)80079-6; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; MARK DB, 1994, ANN INTERN MED, V120, P111, DOI 10.7326/0003-4819-120-2-199401150-00003; MARK DB, 1992, CIRCULATION, V86, P1485, DOI 10.1161/01.CIR.86.5.1485; NELSON CL, 1991, AM J CARDIOL, V68, P973, DOI 10.1016/0002-9149(91)90423-I; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PEDUZZI P, 1987, AM J CARDIOL, V59, P1017, DOI 10.1016/0002-9149(87)90841-1; POCOCK SJ, 1995, LANCET, V346, P1184, DOI 10.1016/S0140-6736(95)92897-9; REEDER GS, 1984, NEW ENGL J MED, V311, P1157, DOI 10.1056/NEJM198411013111805; *RITA TRIAL PART, 1993, LANCET, V341, P573; Rodriguez A, 1996, J AM COLL CARDIOL, V27, P1178, DOI 10.1016/0735-1097(95)00592-7; RODRIGUEZ A, 1993, J AM COLL CARDIOL, V22, P1060, DOI 10.1016/0735-1097(93)90416-X; ROGERS WJ, 1995, AM J CARDIOL, V75, pC9; ROGERS WJ, 1990, CIRCULATION, V82, P1647, DOI 10.1161/01.CIR.82.5.1647; SCHAFF HV, 1995, AM J CARDIOL, V75, pC18; SCULPHER MJ, 1994, LANCET, V344, P927, DOI 10.1016/S0140-6736(94)92274-8; SIM I, 1995, AM J CARDIOL, V76, P1025, DOI 10.1016/S0002-9149(99)80289-6; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; Stewart AL, 1992, MEASURING FUNCTIONIN; Torrance GW, 1987, METHODS EC EVALUATIO; Ware JE, 1993, SF36 HLTH SURVEY MAN; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WEINTRAUB WS, 1995, CIRCULATION, V92, P2831, DOI 10.1161/01.CIR.92.10.2831; WILLIAMS DO, 1995, AM J CARDIOL, V75, pC27; [No title captured]; 1984, CIRCULATION S, V5, P1	46	258	261	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1997	336	2					92	99		10.1056/NEJM199701093360203	http://dx.doi.org/10.1056/NEJM199701093360203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC481	8988886				2022-12-28	WOS:A1997WC48100003
J	Agrawal, R; West, C; Conway, GS; Page, ML; Jacobs, HS				Agrawal, R; West, C; Conway, GS; Page, ML; Jacobs, HS			Pregnancy after treatment with three recombinant gonadotropins	LANCET			English	Article							INVITRO FERTILIZATION		SERONO LABS UK LTD,WELWYN GARDEN CIT,HERTS,ENGLAND		Agrawal, R (corresponding author), MIDDLESEX HOSP,UCL SCH MED,DEPT MED,DIV REPROD ENDOCRINOL,LONDON W1N 8AF,ENGLAND.		Jacobs, Howard/A-9845-2009					GERMOND M, 1992, LANCET, V339, P1170, DOI 10.1016/0140-6736(92)90770-4; HULL M, 1994, LANCET, V344, P334, DOI 10.1016/S0140-6736(94)91373-0; Imthurn B, 1996, LANCET, V348, P332, DOI 10.1016/S0140-6736(05)64499-6; MACDOUGALL MJ, 1993, HUM REPROD, V8, P233, DOI 10.1093/oxfordjournals.humrep.a138029; MCCLURE N, 1994, LANCET, V344, P235, DOI 10.1016/S0140-6736(94)93001-5	5	23	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					29	30		10.1016/S0140-6736(05)62162-9	http://dx.doi.org/10.1016/S0140-6736(05)62162-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988125				2022-12-28	WOS:A1997WA72500019
J	Benador, D; Benador, N; Slosman, D; Mermillod, B; Girardin, E				Benador, D; Benador, N; Slosman, D; Mermillod, B; Girardin, E			Are younger children at highest risk of renal sequelae after pyelonephritis?	LANCET			English	Article							URINARY-TRACT INFECTION; SCINTIGRAPHY; REFLUX	Background The general belief about the relation between risk of renal sequelae after pyelonephritis and age is that infants are at highest risk and children older than 5 years at tower risk. This assumption has led to differences in treatment based on age. The aim of this prospective study was to investigate the occurrence of renal lesions in children aged 0-16 years. Methods Between May, 1994, and January, 1996, all children aged 0-16 years who were admitted to our department with a diagnosis of probable pyelonephritis and a positive urine culture were included in this prospective study. All patients received antibiotics for 7-21 days. During the acute phase of urinary-tract infection, scintigraphy with technetium-99m-dimercaptosuccinic acid (DMSA) and ultrasonography were done. Voiding cystourethrography was undertaken at least 6 weeks after the end of antibiotic treatment. When scintigraphy showed renal parenchymal lesions, repeat scintigraphy was done after at least 2 months to assess the progression of renal lesions. For the analysis, children were grouped by age according to presumed risk of renal sequelae after pyelonephritis: high risk (<1 year), moderate risk (1-5 years), low risk (>5 years). Findings 201 patients were enrolled in the study (119 <1 year, 47 aged 1-5 years, 35 >5 years). During the acute phase of urinary-tract infection, renal lesions were found in 66 (55%) infants under 1 year, in 37 (79%) children aged 1-5 years, and in 24 (69%) children older than 5 years. Of these 127 children, 108 underwent repeat scintigraphy after an average of 3 months (50 <1 year, 36 aged 1-5 years, 22 >5 years). Overall, renal scars were found on repeat scintigraphy in 20 (40%) infants under 1 year, in 31 (86%) children aged 1-5 years, and in 14 (64%) children older than 5 years. 38 (36%) of these 65 patients had vesicoureteric reflux. Among 88 children who had a first documented urinary-tract infection and underwent repeat scintigraphy, renal scars were found in 20 (43%) under 1 year, in 26 (84%) aged 1-5 years, and in eight (80%) older than 5 years. Interpretation This study did not confirm the conventional view that the risk of renal scars after pyelonephritis diminishes with age, We believe that ail children, irrespective of age, will benefit from any measure that prevents the development of renal sequelae.	HOP CANTONAL GENEVA,DEPT RADIOL,CH-1211 GENEVA 14,SWITZERLAND; HOP CANTONAL GENEVA,DEPT INFORMAT,CH-1211 GENEVA 14,SWITZERLAND	University of Geneva; University of Geneva	Benador, D (corresponding author), HOP CANTONAL GENEVA,DEPT PAEDIAT,CH-1211 GENEVA 14,SWITZERLAND.			Girardin, Eric/0000-0002-5443-3640				BENADOR D, 1994, J PEDIATR-US, V124, P17, DOI 10.1016/S0022-3476(94)70248-9; CHABAN C, 1995, INFECT UROL, V8, P114; FRASER IR, 1995, CLIN NEPHROL, V43, P159; GLAUSER MP, 1987, PEDIATR NEPHROL, V1, P615, DOI 10.1007/BF00853599; GLEESON FV, 1991, ARCH DIS CHILD, V66, P1282, DOI 10.1136/adc.66.11.1282; GOLDRAICH NP, 1989, PEDIATR NEPHROL, V3, P1, DOI 10.1007/BF00859614; GORDON I, 1995, LANCET, V346, P489, DOI 10.1016/S0140-6736(95)91328-9; HAYCOCK GB, 1986, ARCH DIS CHILD, V61, P1155, DOI 10.1136/adc.61.12.1155; HOBERMAN A, 1993, J PEDIATR-US, V123, P17, DOI 10.1016/S0022-3476(05)81531-8; JACOBSON SH, 1989, BMJ-BRIT MED J, V299, P703, DOI 10.1136/bmj.299.6701.703; JAKOBSSON B, 1992, ARCH DIS CHILD, V67, P1338, DOI 10.1136/adc.67.11.1338; MARTINELL J, 1995, PEDIATR NEPHROL, V9, P131, DOI 10.1007/BF00860724; MERRICK MV, 1980, BRIT J RADIOL, V53, P544, DOI 10.1259/0007-1285-53-630-544; OIBING H, 1992, J UROLOGY, V148, P1653; PATEL K, 1993, PEDIATR RADIOL, V23, P506, DOI 10.1007/BF02012131; RUSHTON HG, 1992, J UROLOGY, V148, P1726, DOI 10.1016/S0022-5347(17)37014-3; SMELLIE J, 1975, KIDNEY INT, V8, P565; SMELLIE JM, 1985, BRIT MED J, V290, P1957, DOI 10.1136/bmj.290.6486.1957; SPENCER JR, 1986, UROL CLIN N AM, V13, P661	19	149	154	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					17	19		10.1016/S0140-6736(96)06126-0	http://dx.doi.org/10.1016/S0140-6736(96)06126-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988117				2022-12-28	WOS:A1997WA72500011
J	Deslys, JP; Lasmezas, CI; Streichenberger, N; Hill, A; Collinge, J; Dormont, D; Kopp, N				Deslys, JP; Lasmezas, CI; Streichenberger, N; Hill, A; Collinge, J; Dormont, D; Kopp, N			New variant Creutzfeldt-Jakob disease in France	LANCET			English	Article									HOP NEUROL,LYON,FRANCE; ST MARYS,UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,NEUROGENET UNIT,LONDON,ENGLAND	CHU Lyon; Imperial College London	Deslys, JP (corresponding author), CEA,SERV NEUROVIROL,DSV,DRM,SSA,BP 6,F-92265 FONTENAY ROSES,FRANCE.		Hill, Andrew F/B-4527-2009; Hill, Andrew F./AAH-2854-2020; Hill, Andrew F./GZL-4124-2022	Hill, Andrew F/0000-0001-5581-2354; Hill, Andrew F./0000-0001-5581-2354				Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Kopp N, 1996, LANCET, V348, P1239, DOI 10.1016/S0140-6736(05)65510-9; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	4	39	40	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					30	31		10.1016/S0140-6736(05)62163-0	http://dx.doi.org/10.1016/S0140-6736(05)62163-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988126				2022-12-28	WOS:A1997WA72500020
J	Lane, ME; Sauer, K; Wallace, K; Jan, YN; Lehner, CF; Vaessin, H				Lane, ME; Sauer, K; Wallace, K; Jan, YN; Lehner, CF; Vaessin, H			Dacapo, a cyclin-dependent kinase inhibitor, stops cell proliferation during Drosophila development	CELL			English	Article							DNA-SYNTHESIS; POTENTIAL MEDIATOR; P21; EXPRESSION; CDK; DIFFERENTIATION; EMBRYOGENESIS; GENE; P21(CIP1); PROTEIN	Most cell types in multicellular eukaryotes exit from the mitotic cell cycle before terminal differentiation. We show that the dacapo gene is required to arrest the epidermal cell proliferation at the correct developmental stage during Drosophila embryogenesis. dacapo encodes an inhibitor of cyclin E/cdk2 complexes with similarity to the vertebrate Cip/Kip inhibitors. dacapo is transiently expressed beginning late in the G2 phase preceding the terminal division (mitosis 16). Mutants unable to express the inhibitor fail to arrest cell proliferation after mitosis 16 and progress through an extra division cycle. Conversely, premature dacapo expression in transgenic embryos results in a precocious G1 arrest.	MAX PLANCK GESELL,FRIEDRICH MIESCHER LAB,D-72076 TUBINGEN,GERMANY; OHIO STATE UNIV,DEPT MOL GENET,CTR NEUROBIOTECHNOL,COLUMBUS,OH 43210; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	Eberhard Karls University of Tubingen; Max Planck Society; University System of Ohio; Ohio State University; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco				Jan, Yuh Nung/0000-0003-1367-6299; Wallace, Kenneth/0000-0001-7897-6984				BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chen IT, 1996, ONCOGENE, V12, P595; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FINLEY RL, 1996, JP NATL ACAD SCI US, V93, P3011; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HEBERLEIN U, 1995, CELL, V81, P987, DOI 10.1016/S0092-8674(05)80003-0; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; JIANG HP, 1994, ONCOGENE, V9, P3397; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Pirrotta V., 1986, DROSOPHILA PRACTICAL, P83; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; SAUER K, 1996, IN PRESS MOL BIOL CE; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shou WY, 1996, MOL BIOL CELL, V7, P457, DOI 10.1091/mbc.7.3.457; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SMITH AV, 1991, DEVELOPMENT, V112, P997; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	49	276	276	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1225	1235		10.1016/S0092-8674(00)81818-8	http://dx.doi.org/10.1016/S0092-8674(00)81818-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980229	Bronze			2022-12-28	WOS:A1996WA54100011
J	Conroy, RM; ElmoreMeegan, M; Joyce, T; McGuigan, KG; Barnes, J				Conroy, RM; ElmoreMeegan, M; Joyce, T; McGuigan, KG; Barnes, J			Solar disinfection of drinking water and diarrhoea in Maasai children: A controlled field trial	LANCET			English	Article								Background Solar radiation reduces the bacterial content of water, and may therefore offer a method for disinfection of drinking water that requires few resources and no expertise. Methods We distributed plastic water bottles to 206 Maasai children aged 5-16 years whose drinking water was contaminated with faecal coliform bacteria. Children were instructed to fill the bottle with water and leave it in full sunlight on the roof of the hut (solar group), or to keep their filled bottles indoors in the shade (control group). A Maasai-speaking fieldworker who lived in the community interviewed the mother of each child once every 2 weeks for 12 weeks. Occurrence and severity of diarrhoea was recorded at each follow-up visit. Findings Among the 108 children in households allocated solar treatment, diarrhoea was reported in 439 of the 2-week reporting periods during the 12-week trial (average 4.1 [SD 1.2] per child). By comparison, the 98 children in the control households reported diarrhoea during 444 2-week reporting periods (average 4.5 [1.2] per child). Diarrhoea severe enough to prevent performance of duties occurred during 186 reporting periods in the solar group and during 222 periods in the control group (average 1.7 [1.2] vs 2.3 [1.4]). After adjustment for age, solar treatment of drinking water was associated with a reduction in all diarrhoea episodes (odds ratio 0.66 [0.50-0.87]) and in episodes of severe diarrhoea (0.65 [0.50-0.86]). Interpretation Our findings suggest that solar disinfection of water may significantly reduce morbidity in communities with no other means of disinfection of drinking water, because of lack of resources or in the event of a disaster.	ROYAL COLL SURGEONS IRELAND,DEPT TROP MED & INT HLTH,DUBLIN 2,IRELAND; ROYAL COLL SURGEONS IRELAND,DEPT PHYS,DUBLIN 2,IRELAND; ICROSS,RURAL HLTH PROGRAMMES,NGONG,KENYA	Royal College of Surgeons - Ireland; Royal College of Surgeons - Ireland	Conroy, RM (corresponding author), ROYAL COLL SURGEONS IRELAND,DEPT EPIDEMIOL & PREVENT MED,MERCER BLDG,DUBLIN 2,IRELAND.		Conroy, Ronan/C-6416-2008; McGuigan, Kevin G/A-3656-2010	Conroy, Ronan/0000-0001-5983-8682; McGuigan, Kevin G/0000-0002-3775-8339				ACRA A, 1980, LANCET, V2, P1257; Acra A., 1989, WATER DISINFECTION S; BINDER DA, 1983, INT STAT REV, V51, P279, DOI 10.2307/1402588; Downes A, 1877, P ROY SOC LONDON, V26, P488; ELTINGE JL, 1996, STATA TECHNICAL B, V31, P26; Joyce TM, 1996, APPL ENVIRON MICROB, V62, P399, DOI 10.1128/AEM.62.2.399-402.1996; MORLEY D, 1988, LANCET, V2, P686; 1989, SOLAR DISINFECTION D	8	141	144	2	26	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1695	1697		10.1016/S0140-6736(96)02309-4	http://dx.doi.org/10.1016/S0140-6736(96)02309-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973432				2022-12-28	WOS:A1996VZ76600012
J	Lundeberg, T				Lundeberg, T			Electrical stimulation techniques	LANCET			English	Editorial Material							NERVE-STIMULATION		KAROLINSKA INST,DEPT REHABIL MED,STOCKHOLM,SWEDEN	Karolinska Institutet	Lundeberg, T (corresponding author), KAROLINSKA INST,DEPT PHYSIOL & PHARMACOL,STOCKHOLM,SWEDEN.							ANDERSSON S, 1995, MED HYPOTHESES, V45, P271, DOI 10.1016/0306-9877(95)90117-5; Bosch JLHR, 1996, LANCET, V348, P717, DOI 10.1016/S0140-6736(96)04437-6; LUNDEBERG T, 1988, LANCET, V2, P712; LUNDEBERG TCM, 1992, ANN PLAS SURG, V29, P328, DOI 10.1097/00000637-199210000-00009; MEYERSON BA, 1996, PAIN 1996 UPDATED RE, P207	5	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1672	1673		10.1016/S0140-6736(05)65815-1	http://dx.doi.org/10.1016/S0140-6736(05)65815-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973423				2022-12-28	WOS:A1996VZ76600003
J	Portegies, P; Enting, RH				Portegies, P; Enting, RH			Neurology - Prions, oestrogens, PCR, and the brain	LANCET			English	Article											Portegies, P (corresponding author), UNIV AMSTERDAM, ACAD MED CTR, DEPT NEUROL, NL-1105 AZ AMSTERDAM, NETHERLANDS.							Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Cinque P, 1996, AIDS, V10, P951, DOI 10.1097/00002030-199610090-00004; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	1996	348			2			SII14	SII14						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973492				2022-12-28	WOS:A1996WA46300014
J	Saunders, C				Saunders, C			A personal therapeutic journey	BRITISH MEDICAL JOURNAL			English	Article											Saunders, C (corresponding author), ST CHRISTOPHERS HOSPICE,LONDON SE26 6DZ,ENGLAND.							Carter, 1976, SCI FDN ONCOLOGY, P673; KEARNEY M, 1992, Palliative Medicine, V6, P39, DOI 10.1177/026921639200600107; SAUNDERS C, 1963, P ROY SOC MED, V56, P195, DOI 10.1177/003591576305600322; SAUNDERS C, 1972, CONTACT, V38, P12; SEALE C, 1995, SOCIOLOGY, V29, P597, DOI 10.1177/0038038595029004003; TWYCROSS RG, 1977, PAIN, V3, P93, DOI 10.1016/0304-3959(77)90072-0; *WHO, 1990, REP CANC PAIN REL PA, P11; World Health Organization, 1996, CANC PAIN REL	8	76	78	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1599	1601		10.1136/bmj.313.7072.1599	http://dx.doi.org/10.1136/bmj.313.7072.1599			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991003	Green Published			2022-12-28	WOS:A1996VZ81100027
J	Curb, JD; Pressel, SL; Cutler, JA; Savage, PJ; Applegate, WB; Black, H; Camel, G; Davis, BR; Frost, PH; Gonzalez, N; Guthrie, G; Oberman, A; Rutan, GH; Stamler, J				Curb, JD; Pressel, SL; Cutler, JA; Savage, PJ; Applegate, WB; Black, H; Camel, G; Davis, BR; Frost, PH; Gonzalez, N; Guthrie, G; Oberman, A; Rutan, GH; Stamler, J			Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EUROPEAN WORKING PARTY; HIGH BLOOD-PRESSURE; MORTALITY; MORBIDITY; THERAPY; TRIAL	Objective.-To assess the effect of low-dose, diuretic-based antihypertensive treatment on major cardiovascular disease (CVD) event rates in older, non-insulin-treated diabetic patients with isolated systolic hypertension (ISH), compared with nondiabetic patients. Design.-Double-blind, randomized, placebo-controlled trial: the Systolic Hypertension in the Elderly Program (SHEP). Setting.-Multiple clinical and support centers in the United States. Participants.-A total of 4736 men and women aged 60 years and older at baseline with ISH (systolic blood pressure [BP], greater than or equal to 160 mm Hg; diastolic BP, <90 mm Hg) al baseline, 583 non-insulin-dependent diabetic patients and 4149 nondiabetic patients (4 additional patients not so classifiable were randomized but not included in these analyses). Diabetes mellitus defined as physician diagnosis, taking oral hypoglycemic drugs, fasting glucose level of 7.8 mmol/L or more (greater than or equal to 140 mg/dL), or any combination of these characteristics. Intervention.-The active treatment group received a low dose of chlorthalidone (12.5-25.0 mg/d) with a step-up to atenolol (25.0-50.0 mg/d) or reserpine (0.05-0.10 mg/d) if needed. The placebo group received placebo and any active antihypertensive drugs prescribed by patient's private physician for persistently high BP. Main Outcome Measures.-The 5-year rates of major CVD events, nonfatal plus fatal stroke, nonfatal myocardial infarction (MI) and fatal coronary heart disease (CHD), major CHD events, and all-cause mortality. Results.-The SHEP antihypertensive drug regimen lowered BP of both diabetic and nondiabetic patients, with few adverse effects. For both diabetic and nondiabetic patients, all outcome rates were lower for participants randomized to the active treatment group than for those randomized to the placebo group, Thus, 5-year major CVD rate was lower by 34% for active treatment compared with placebo, both for diabetic patients (95% confidence interval [CI], 6%-54%) and nondiabetic patients (95% CI, 21%-45%). Absolute risk reduction with active treatment compared with placebo was twice as great for diabetic vs nondiabetic patients (101/1000 vs 51/1000 randomized participants at the 5-year follow-up), reflecting the higher risk of diabetic patients. Conclusion.-Low-dose diuretic-based (chlorthalidone) treatment is effective in preventing major CVD events, cerebral and cardiac, in both non-insulin-treated diabetic and nondiabetic cider patients with ISH.	UNIV HAWAII, JOHN A BURNS SCH MED, HONOLULU, HI 96822 USA; UNIV TEXAS, SCH PUBL HLTH, HOUSTON, TX USA; NHLBI, BETHESDA, MD 20892 USA; UNIV TENNESSEE, MEMPHIS, TN 38163 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, CHICAGO, IL 60612 USA; WASHINGTON UNIV, SCH MED, ST LOUIS, MO USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA; UNIV KENTUCKY, LEXINGTON, KY USA; UNIV ALABAMA, BIRMINGHAM, AL USA; VET AFFAIRS MED CTR, MEMPHIS, TN USA; NORTHWESTERN UNIV, CHICAGO, IL 60611 USA; SYSTOL HYPERTENS ELDERLY PROGRAM COORDINATING CTR, HOUSTON, TX 77030 USA	University of Hawaii System; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Tennessee System; University of Tennessee Health Science Center; Rush University; Washington University (WUSTL); University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities; University of Kentucky; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; Northwestern University								AMERY A, 1985, LANCET, V1, P1349; AMERY A, 1986, POSTGRAD MED J, V62, P919, DOI 10.1136/pgmj.62.732.919; BENGTSSON C, 1992, J INTERN MED, V231, P583, DOI 10.1111/j.1365-2796.1992.tb01243.x; BLACK HR, 1993, HYPERTENSION, V21, P335; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; DONAHUE RP, 1990, HORM METAB RES, V22, P46; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; *HYP DET FOLL UP P, 1979, PROG CARDIOVASC D S1, V242, P2572; *HYP DET FOLL UP P, 1986, PROD CARDIOVASC D S1, V29, P3; *HYP DET FOLL UP P, 1979, JAMA-J AM MED ASSOC, V242, P2562; KLEIN R, 1989, ARCH INTERN MED, V149, P266, DOI 10.1001/archinte.149.2.266; Kostis JB, 1995, AM J HYPERTENS, V8, P1147, DOI 10.1016/0895-7061(95)00363-0; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; PROBSTFIELD JL, 1991, JAMA-J AM MED ASSOC, V265, P3255; PROBSTFIELD JL, 1988, J CLIN EPIDEMIOL, V41, P1197; *SYST HYP ELD PROG, HYPERTENSION S2, V17, P1; WARRAM JH, 1991, ARCH INTERN MED, V151, P1350, DOI 10.1001/archinte.151.7.1350	20	674	690	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1996	276	23					1886	1892		10.1001/jama.276.23.1886	http://dx.doi.org/10.1001/jama.276.23.1886			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX522	8968014				2022-12-28	WOS:A1996VX52200036
J	Davies, E; Clarke, C; Hopkins, A				Davies, E; Clarke, C; Hopkins, A			Malignant cerebral glioma .2. Perspectives of patients and relatives on the value of radiotherapy	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; CANCER-PATIENTS; BAD-NEWS; CHEMOTHERAPY; PREFERENCES; COMMUNICATE; HEALTHY; TRIAL	Objective-To explore the experiences patients and relatives after the diagnosis treatment of malignant cerebral glioma. Design-Two year prospective study with home interviews, Setting-Six neurosurgery and radiotherapy centres in London, Subjects-75 patients and 66 close relatives interviewed at diagnosis, 58 patients interviewed after radiotherapy, and 27 interviewed after recurrence, Main outcome measures-Awareness of likely prognosis, distress, dissatisfaction with radiotherapy and perception of severe problems in everyday life, Results-As they began radiotherapy most patients understood that they suffered from a brain tumour (95%; 71/75), but only one quarter (19/75) seemed fully aware of the poor prognosis. Others were unaware (43%; 32/75) or only partly aware (32%; 24/75), The more aware patients were more distressed. Relatives were three times more Likely to be aware of the prognosis (67%; 44/66) and were more distressed, Although 39% (29/75) of patients initially made negative comments about radiotherapy, only 17% (13/75) were completely dissatisfied, The decision to accept radiotherapy could be discussed directly with 19 fully aware patients, Twelve found radiotherapy acceptable if it were medically advised or if it improved survival. Assessed by their own reports of problems only 40% of patients achieved a period of stability or remission, yet dissatisfaction with treatment did not increase. Conclusion-Most patients with malignant glioma initially seemed unaware or only partly aware of the poor prognosis. Relatives were more aware, more distressed, and often concerned to protect patients from full awareness, which made it difficult to explore with patients directly the possible trade off between quality and length of life, Conceptualising the question as a rational choice ignores the social and emotional context of life threatening disease.	UNIV LONDON ST BARTHOLOMEWS HOSP MED COLL, DIRECTORATE NEUROSURG & CLIN NEUROSCI, LONDON EC1A 7BE, ENGLAND	University of London; Queen Mary University London	Davies, E (corresponding author), ROYAL COLL PHYSICIANS, RES UNIT, LONDON NW1 4LE, ENGLAND.			Davies, Elizabeth/0000-0003-2325-0849				BLEEHEN NM, 1991, BRIT J CANCER, V64, P769, DOI 10.1038/bjc.1991.396; BREETVELT IS, 1991, SOC SCI MED, V32, P981, DOI 10.1016/0277-9536(91)90156-7; BRENNAN P, 1992, BMJ-BRIT MED J, V304, P1491, DOI 10.1136/bmj.304.6840.1491; Brown G., 1978, SOCIAL ORIGINS DEPRE; BROWN GW, 1966, HUM RELAT, V19, P241, DOI 10.1177/001872676601900301; CASSILETH BR, 1984, NEW ENGL J MED, V311, P506, DOI 10.1056/NEJM198408233110805; Davies E, 1996, BRIT MED J, V313, P1507, DOI 10.1136/bmj.313.7071.1507; DAVIES E, 1993, NEUROLOGICAL REHABIL, P535; EBRAHIM S, 1995, SOC SCI MED, V41, P1383, DOI 10.1016/0277-9536(95)00116-O; FALLOWFIELD L, 1995, PSYCHO-ONCOLOGY, V4, P197, DOI 10.1002/pon.2960040305; FALLOWFIELD L, 1993, LANCET, V341, P476, DOI 10.1016/0140-6736(93)90219-7; Glaser B.G., 1966, AWARENESS DYING; *GOV COMM, 1992, CHOIC HLTH CAR; Hinton J, 1972, DYING; KREITLER S, 1993, SOC SCI MED, V36, P547, DOI 10.1016/0277-9536(93)90415-Z; KUBLERROSS E, 1992, DEATH DYING; MACKILLOP WJ, 1988, BRIT J CANCER, V58, P355, DOI 10.1038/bjc.1988.218; MAGUIRE P, 1988, BRIT MED J, V297, P972, DOI 10.1136/bmj.297.6654.972; MAGUIRE P, 1988, BRIT MED J, V297, P907, DOI 10.1136/bmj.297.6653.907; MCGEE HM, 1991, PSYCHOL MED, V21, P749, DOI 10.1017/S0033291700022388; OBOYLE CA, 1992, LANCET, V339, P1088, DOI 10.1016/0140-6736(92)90673-Q; OCONNOR AM, 1989, J CLIN EPIDEMIOL, V42, P119, DOI 10.1016/0895-4356(89)90085-1; Office of Population Censuses and Surveys, 1991, STAND OCC CLASS; ROSSER R, 1992, MEASURES QUALITY LIF, P81; ROSSER RM, 1990, MEASURING OUTCOMES M, P1; *ROYAL COLL PHYS, 1995, SETT PRIOR NHS FRAM; Salander P, 1996, SOC SCI MED, V42, P985, DOI 10.1016/0277-9536(95)00204-9; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; WALKER MD, 1978, J NEUROSURG, V49, P333, DOI 10.3171/jns.1978.49.3.0333; Williams A, 1992, MEASURES QUALITY LIF, P21; World Health Organisation, 1979, HDB REP RES CANC TRE	31	58	58	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 14	1996	313	7071					1512	1516		10.1136/bmj.313.7071.1512	http://dx.doi.org/10.1136/bmj.313.7071.1512			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VY691	8978225	Green Published			2022-12-28	WOS:A1996VY69100017
J	Koyama, H; Raines, EW; Bornfeldt, KE; Roberts, JM; Ross, R				Koyama, H; Raines, EW; Bornfeldt, KE; Roberts, JM; Ross, R			Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors	CELL			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; CYCLIN-DEPENDENT KINASES; EXTRACELLULAR-MATRIX; CELL-CYCLE; SIGNALING PATHWAYS; GROWTH; RAPAMYCIN; ACTIVATION; EXPRESSION; INTEGRIN	Arterial smooth muscle cells (SMCs) are arrested in the G1 phase of the cell cycle on polymerized type I collagen fibrils, while monomer collagen supports SMC proliferation. Cyclin E-associated kinase and cyclin-dependent kinase 2 (cdk2) phosphorylation are inhibited on polymerized collagen, and levels of the cdk2 inhibitors p27(Kip1) p21(Cip1/Waf1) increased compared with SMCs on monomer collagen. p27(Kip1) associates with the cyclin E-cdk2-p21(Cip1/Waf1) complex in SMCs on polymerized collagen. Monovalent blocking antibodies to alpha 2 integrins, integrins that mediate adhesion to both forms of collagen, mimic these effects on monomer collagen. Furthermore, polymerized collagen rapidly suppresses p70 S6 kinase, a possible regulator of p27(Kip1). Thus, fibrillar collagen specifically regulates early integrin signaling that may lead to up-regulation of cdk2 inhibitors and inhibition of SMC proliferation.	FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104	Fred Hutchinson Cancer Center	Koyama, H (corresponding author), UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195, USA.		Koyama, Hidenori/AAU-2346-2020; Bornfeldt, Karin/AAI-2241-2019	Koyama, Hidenori/0000-0001-7930-2228; Bornfeldt, Karin/0000-0001-9208-6523	NHLBI NIH HHS [HL18645] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; ALBERS MW, 1993, J BIOL CHEM, V268, P22825; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COULTER A, 1983, J IMMUNOL METHODS, V59, P199, DOI 10.1016/0022-1759(83)90031-5; CYBULSKY AV, 1993, AM J PHYSIOL, V264, pC323, DOI 10.1152/ajpcell.1993.264.2.C323; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HANSEN LK, 1994, MOL BIOL CELL, V5, P967, DOI 10.1091/mbc.5.9.967; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MARTIN GR, 1990, PEPTIDE GROWTH FACTO, P463; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORICE WG, 1993, J BIOL CHEM, V268, P22737; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P50755; RANA B, 1994, MOL CELL BIOL, V14, P5858, DOI 10.1128/MCB.14.9.5858; REKHTER MD, 1995, AM J PATHOL, V147, P668; RHUDY RW, 1988, J CELL PHYSIOL, V137, P185, DOI 10.1002/jcp.1041370123; SCHOR SL, 1980, J CELL SCI, V41, P159; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SKINNER MP, 1994, AM J PATHOL, V145, P1070; SPORN MB, 1990, PEPTIDE GROWTH FACTO, P3; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	45	442	451	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1069	1078		10.1016/S0092-8674(00)81801-2	http://dx.doi.org/10.1016/S0092-8674(00)81801-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978611	Bronze			2022-12-28	WOS:A1996VY44700012
J	Savulescu, J; Chalmers, I; Blunt, J				Savulescu, J; Chalmers, I; Blunt, J			Are research ethics committees behaving unethically? Same suggestions for improving performance and accountability	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; PUBLICATION BIAS; SCIENTIFIC MISCONDUCT; CUMULATIVE METAANALYSIS; MYOCARDIAL-INFARCTION; DRUG TRIALS; STANDARDS; REGISTRY; QUALITY; CARE	The results of recent empirical investigations in research synthesis imply that research ethics committees are behaving unethically by endorsing new research which is unnecessary and by acquiescing in biased under-reporting of research which they have approved. The performance and accountability of research ethics committees would be improved if they required those proposing research to present systematic reviews of relevant previous research in support of their applications; to summarise the results of these reviews in the information prepared for potential participants; to register new controlled trials at inception; and to ensure that the results of these trials are made publicly available within a reasonable period of time after completion of data collection.	NHS RES & DEV PROGRAMME, OXFORD OX2 7LG, ENGLAND; SALFORD & TRAFFORD HLTH AUTHOR, ECCLES M30 0NJ, ENGLAND		Savulescu, J (corresponding author), OXFORD RADCLIFFE HOSP, CLIN ETH PROJECT, OXFORD OX3 9RP, ENGLAND.							ALBERTI KGMM, 1995, BRIT MED J, V311, P639, DOI 10.1136/bmj.311.7006.639; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; ASSENDELFT WJJ, 1995, JAMA-J AM MED ASSOC, V274, P1942, DOI 10.1001/jama.274.24.1942; BAUM ML, 1981, NEW ENGL J MED, V305, P795, DOI 10.1056/NEJM198110013051404; BEAUCHAMP TL, 1978, ETHICAL ISSUES DEATH, P246; BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P196; BENDALL C, 1994, STANDARD OPERATING P; CHALMERS I, 1993, LANCET, V342, P1116, DOI 10.1016/0140-6736(93)92099-F; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; CHALMERS I, 1995, BRIT MED J, V311, P262, DOI 10.1136/bmj.311.6999.262b; CHALMERS I, 1996, EVIDENCE BASED MED, V1, P39; Chalmers I, 1995, SYSTEMATIC REV; CHALMERS I, 1993, DRUG COSTS TREATMENT, P14; *COMM DEP HUM SERV, 1995, GUID PHARM IND PREP; *COUNC INT ORG MED, 1993, INT ETH GUID BIOM RE; Council for International Organizations of Medical Sciences, 1991, INT GUID ETH REV EP; Delamothe T, 1996, BRIT MED J, V312, P1241, DOI 10.1136/bmj.312.7041.1241; DEMELKER HE, 1993, LANCET, V342, P621, DOI 10.1016/0140-6736(93)91449-V; DEMETS DL, 1991, CONTROLLED CLIN TRIA, V127, P53; DENNY WF, 1995, NEW ENGL J MED, V332, P61; [Department of Health DoH], 1991, LOC RES ETH COMM; DICKERSIN K, 1992, CONTROL CLIN TRIALS, V13, P170, DOI 10.1016/0197-2456(92)90022-R; Dickersin K, 1993, ONLINE J CURR CLIN T, V31, P4967; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; ENKIN M, 1989, EFFECTIVE CARE PREGN, P1246; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Freedman Benjamin, 1990, IRB, V12, P1, DOI 10.2307/3564541; Freedman Benjamin, 1987, IRB, V9, P7, DOI 10.2307/3563623; GARFIELD P, 1995, BRIT MED J, V311, P660, DOI 10.1136/bmj.311.7006.660; GILBERT C, 1989, BRIT MED J, V299, P1437, DOI 10.1136/bmj.299.6713.1437; GOTZSCHE PC, 1987, BRIT MED J, V295, P654, DOI 10.1136/bmj.295.6599.654; HARLAN WR, 1994, JAMA-J AM MED ASSOC, V271, P1729, DOI 10.1001/jama.271.22.1729; HENRY D, 1995, BMJ-BRIT MED J, V310, P1279, DOI 10.1136/bmj.310.6990.1279; HERXHEIMER A, 1993, J MED ETHICS, V19, P211, DOI 10.1136/jme.19.4.211; *HIGH ED FUND COUN, 1995, 1996 RES ASS EX CRIT; *HOUS LORDS, 1994, REP SEL COMM MED ETH, P19; JACOBSEN G, 1995, J ROY COLL PHYS LOND, V29, P405; KOOPMANS PP, 1995, BRIT MED J, V310, P1305, DOI 10.1136/bmj.310.6990.1305; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LAU J, 1995, J CLIN EPIDEMIOL, V48, P45, DOI 10.1016/0895-4356(94)00106-Z; Lock Stephen P., 1991, FUTURE MED J, P127; McNeill P. M., 1993, ETHICS HUMAN EXPERIM; *MED RES COUNC CAN, 1987, GUID RES INV HUM SUB, P49; Medical Research Council, 1992, RESP INV HUM PART MA; MIDDLE C, 1995, BRIT MED J, V311, P659, DOI 10.1136/bmj.311.7006.659; MILNE R, 1993, J EPIDEMIOL COMMUN H, V47, P169, DOI 10.1136/jech.47.3.169; Milne R, 1995, Health Trends, V27, P120; MOHER D, 1995, JAMA-J AM MED ASSOC, V274, P1962, DOI 10.1001/jama.274.24.1962; MOHER D, 1993, LANCET, V342, P1116; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; *NAT COUNC BIOETH, 1995, NCBHR COMMUNIQUE, V6, P3; Oxman A. D., 1995, SYSTEMATIC REV, P75; OXMAN AD, 1993, ANN NY ACAD SCI, V703, P125, DOI 10.1111/j.1749-6632.1993.tb26342.x; OXMAN AD, 1993, JAMA-J AM MED ASSOC, V270, P2093; PEARN J, 1995, BRIT MED J, V310, P1313, DOI 10.1136/bmj.310.6990.1313; PEARN J, 1996, NEW SCI         0106, P40; RACHELS J, 1975, NEW ENGL J MED, V292, P78, DOI 10.1056/NEJM197501092920206; Riordan FAI, 1996, BRIT MED J, V312, P185; Roberts J, 1996, BMJ-BRIT MED J, V312, P133; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; SCHERER RW, 1994, JAMA-J AM MED ASSOC, V272, P158, DOI 10.1001/jama.272.2.158; SHAPIRO MF, 1989, JAMA-J AM MED ASSOC, V261, P2505, DOI 10.1001/jama.261.17.2505; SHAPIRO MF, 1985, NEW ENGL J MED, V312, P731, DOI 10.1056/NEJM198503143121128; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; SIMPSON J, 1996, CF NEWS          SUM, P13; Smith GD, 1996, BRIT MED J, V312, P1479, DOI 10.1136/bmj.312.7044.1479c; STEINBOCK B, 1980, KILLING LETTING DIE; Vandenbroucke J P, 1995, Ned Tijdschr Geneeskd, V139, P1476; Weijer C, 1996, NEW SCI, V149, P47; WEIJER C, 1995, CAN MED ASSOC J, V152, P1973; WHILE AE, 1995, BRIT MED J, V311, P661, DOI 10.1136/bmj.311.7006.661; World Medical Association, 1989, DECL HELS; 1980, LANCET, V106, P1	74	152	153	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 30	1996	313	7069					1390	1393		10.1136/bmj.313.7069.1390	http://dx.doi.org/10.1136/bmj.313.7069.1390			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW685	8956711	Green Published			2022-12-28	WOS:A1996VW68500038
J	Lasmezas, CI; Deslys, JP; Robain, O; Jaegly, A; Beringue, V; Peyrin, JM; Fournier, JG; Hauw, JJ; Rossier, J; Dormont, D				Lasmezas, CI; Deslys, JP; Robain, O; Jaegly, A; Beringue, V; Peyrin, JM; Fournier, JG; Hauw, JJ; Rossier, J; Dormont, D			Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein	SCIENCE			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; JAKOB-DISEASE AGENT; SCRAPIE AGENT; PRP; REPLICATION; STRAIN; NEURODEGENERATION; ACCUMULATION; MECHANISMS; RESISTANT	The agent responsible for transmissible spongiform encephalopathies (TSEs) is thought to be a malfolded, protease-resistant version (PrPres) of the normal cellular prion protein (PrP). The interspecies transmission of bovine spongiform encephalopathy (BSE) to mice was studied. Although all of the mice injected with homogenate from BSE-infected cattle brain exhibited neurological symptoms and neuronal death, more than 55 percent had no detectable PrPres. During serial passage, PrPres appeared after the agent became adapted to the new host. Thus, PrPres may be involved in species adaptation, but a further unidentified agent may actually transmit BSE.	HOP ST VINCENT DE PAUL,INSERM,U29,F-75674 PARIS 14,FRANCE; HOP LA PITIE SALPETRIERE,INSERM,U153,F-75651 PARIS 13,FRANCE; HOP LA PITIE SALPETRIERE,INSERM,U360,LAB ESCOUROLLE,F-75651 PARIS 13,FRANCE; ECOLE SUPER PHYS & CHIM IND VILLE PARIS,CNRS,URA 2054,F-75231 PARIS 5,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Lasmezas, CI (corresponding author), CEA,SERV NEUROVIROL,DSV,DRM,SSA,BP 6,60-68 AVE GEN LECLERC,F-92265 FONTENAY ROSES,FRANCE.			Peyrin, Jean-Michel/0000-0002-0108-1266; Peyrin, Jean-Michel/0000-0002-8705-8672				Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; BRUCE ME, 1993, BRIT MED BULL, V49, P822, DOI 10.1093/oxfordjournals.bmb.a072649; BRUCE ME, 1987, J GEN VIROL, V68, P79, DOI 10.1099/0022-1317-68-1-79; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COLLINGE J, 1995, LANCET, V346, P569, DOI 10.1016/S0140-6736(95)91405-6; DAWSON M, 1990, VET REC, V127, P338; Dickinson A. G., 1976, Slow virus diseases of animals and man,, P209; DICKINSON AG, 1989, UNCONVENTIONAL VIRUS, P446; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; FOSTER JD, 1993, VET REC, V133, P339, DOI 10.1136/vr.133.14.339; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; KIMBERLIN RH, 1978, J GEN VIROL, V39, P487, DOI 10.1099/0022-1317-39-3-487; KIMBERLIN RH, 1987, J GEN VIROL, V68, P1875, DOI 10.1099/0022-1317-68-7-1875; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lasmezas CI, 1996, NATURE, V381, P743, DOI 10.1038/381743a0; Lasmezas CI, 1996, J GEN VIROL, V77, P1601, DOI 10.1099/0022-1317-77-7-1601; MANUELIDIS L, 1994, ANN NY ACAD SCI, V724, P259, DOI 10.1111/j.1749-6632.1994.tb38916.x; Manuelidis L, 1996, VIROLOGY, V216, P46, DOI 10.1006/viro.1996.0033; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Riesner D, 1996, J VIROL, V70, P1714, DOI 10.1128/JVI.70.3.1714-1722.1996; SAKAGUCHI S, 1995, J VIROL, V69, P7586, DOI 10.1128/JVI.69.12.7586-7592.1995; SKLAVIADIS TK, 1989, J VIROL, V63, P1212, DOI 10.1128/JVI.63.3.1212-1222.1989; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; WELLS GAH, 1995, BRAIN PATHOL, V5, P91, DOI 10.1111/j.1750-3639.1995.tb00580.x; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WYATT JM, 1990, VET REC, V126, P513; XI YG, 1992, NATURE, V356, P598, DOI 10.1038/356598a0	34	486	496	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					402	405		10.1126/science.275.5298.402	http://dx.doi.org/10.1126/science.275.5298.402			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994041				2022-12-28	WOS:A1997WC87300052
J	Musti, AM; Treier, M; Bohmann, D				Musti, AM; Treier, M; Bohmann, D			Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases	SCIENCE			English	Article							PROTEIN-DEGRADATION; ACTIVATION DOMAIN; HA-RAS; PATHWAY; PROTEASOME; AUGMENTS	The proto-oncogene-encoded transcription factor c-Jun activates genes in response to a number of inducers that act through mitogen-activated protein kinase (MAPK) signal transduction pathways. The activation of c-Jun after phosphorylation by MAPK is accompanied by a reduction in c-Jun ubiquitination and consequent stabilization of the protein. These results illustrate the relevance of regulated protein degradation in the signal-dependent central oi gene expression.	EUROPEAN MOL BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Treier, Mathias/AAD-6388-2021; Musti, Anna Maria/M-2520-2019	MUSTI, Anna Maria/0000-0003-1443-2739				BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; ISAKSSON A, 1996, BIOCHIM BIOPHYS ACTA, V1288, P21; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; Peverali FA, 1996, EMBO J, V15, P3943, DOI 10.1002/j.1460-2075.1996.tb00768.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Treier Mathias, 1996, P297, DOI 10.1002/9783527615032.ch11; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6	17	406	412	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					400	402		10.1126/science.275.5298.400	http://dx.doi.org/10.1126/science.275.5298.400			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994040				2022-12-28	WOS:A1997WC87300051
J	Rubin, LJ				Rubin, LJ			Current concepts - Primary pulmonary hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INHALED NITRIC-OXIDE; CONTINUOUS INTRAVENOUS PROSTACYCLIN; HEART-LUNG TRANSPLANTATION; ARTERIAL-PRESSURE; FOLLOW-UP; VASODILATOR; SURVIVAL; EPOPROSTENOL; EXPRESSION; REGRESSION		UNIV MARYLAND, SCH MED, DEPT MED, DIV PULM & CRIT CARE MED, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore								Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; BARST RJ, 1986, CHEST, V89, P497, DOI 10.1378/chest.89.4.497; Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; BARST RJ, 1994, ANN INTERN MED, V121, P409, DOI 10.7326/0003-4819-121-6-199409150-00003; BOURDILLON PDV, 1976, BRIT HEART J, V38, P264; BRENOT F, 1993, BRIT HEART J, V70, P537; CHRISTMAN BW, 1992, NEW ENGL J MED, V327, P70, DOI 10.1056/NEJM199207093270202; DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; EDWARDS BS, 1987, J AM COLL CARDIOL, V10, P1233, DOI 10.1016/S0735-1097(87)80123-7; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; GROVES BM, 1993, NATO ADV SCI INST SE, P317; HARRIS P, 1977, HUMAN PULMONARY CIRC, P651; HIGENBOTTAM TW, 1993, BRIT HEART J, V70, P366; Hosenpud JD, 1996, J HEART LUNG TRANSPL, V15, P655; KERSTEIN D, 1995, CIRCULATION, V91, P2028, DOI 10.1161/01.CIR.91.7.2028; Kshettry VR, 1996, CHEST, V110, P704, DOI 10.1378/chest.110.3.704; LEIER CV, 1983, CIRCULATION, V67, P155, DOI 10.1161/01.CIR.67.1.155; LLOYD JE, 1988, AM REV RESPIR DIS, V138, P952; LOOGEN F, 1985, COR VASA, V27, P111; LOYD JE, 1995, AM J RESP CRIT CARE, V152, P93, DOI 10.1164/ajrccm.152.1.7599869; MARTINDURAN R, 1986, AM J CARDIOL, V57, P859, DOI 10.1016/0002-9149(86)90627-2; MCDONNELL PJ, 1983, AM REV RESPIR DIS, V127, P437, DOI 10.1164/arrd.1983.127.4.437; MELOT C, 1983, CHEST, V83, P203, DOI 10.1378/chest.83.2.203; MORGAN JM, 1991, CIRCULATION, V84, P1145, DOI 10.1161/01.CIR.84.3.1145; NALL KC, 1991, AM J MED, V91, P97, DOI 10.1016/0002-9343(91)90082-9; NALL KC, 1991, AM J MED, V91, P670; NELSON DM, 1983, OBSTET GYNECOL, V62, pS58; NICOD P, 1987, ANN INTERN MED, V107, P565, DOI 10.7326/0003-4819-107-4-565; OAKLEY C, 1968, LANCET, V1, P890; Olschewski H, 1996, ANN INTERN MED, V124, P820, DOI 10.7326/0003-4819-124-9-199605010-00006; PACKER M, 1984, J AM COLL CARDIOL, V4, P890, DOI 10.1016/S0735-1097(84)80048-0; PALEVSKY HI, 1989, CIRCULATION, V80, P1207, DOI 10.1161/01.CIR.80.5.1207; PASQUE MK, 1991, CIRCULATION, V84, P2275, DOI 10.1161/01.CIR.84.6.2275; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; PETITPRETZ P, 1994, CIRCULATION, V89, P2722, DOI 10.1161/01.CIR.89.6.2722; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RICH S, 1986, ANN INTERN MED, V105, P499, DOI 10.7326/0003-4819-105-4-499; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; RICH S, 1987, CIRCULATION, V76, P135, DOI 10.1161/01.CIR.76.1.135; RUBIN LJ, 1993, CHEST, V104, P236, DOI 10.1378/chest.104.1.236; RUBIN LJ, 1990, ANN INTERN MED, V112, P485, DOI 10.7326/0003-4819-112-7-485; RUBIN LJ, 1982, CIRCULATION, V66, P334, DOI 10.1161/01.CIR.66.2.334; Saji T, 1996, AM J CARDIOL, V78, P244, DOI 10.1016/S0002-9149(96)90408-7; SCHAIBERGER PH, 1993, CHEST, V104, P614, DOI 10.1378/chest.104.2.614; SITBON O, 1995, AM J RESP CRIT CARE, V151, P384, DOI 10.1164/ajrccm.151.2.7842196; SNELL GI, 1995, AM J RESP CRIT CARE, V151, P1263; SPEICH R, 1991, CHEST, V100, P1268, DOI 10.1378/chest.100.5.1268; VOELKEL NF, 1997, PRIMARY PULMONARY HY, P83; WAGENVOORT CA, 1960, CIRCULATION, V22, P535, DOI 10.1161/01.CIR.22.4.535; WEIR EK, 1989, AM REV RESPIR DIS, V140, P1623, DOI 10.1164/ajrccm/140.6.1623; WOOD P, 1958, BRIT HEART J, V20, P557; ZOBEL G, 1995, PEDIATR RES, V38, P198, DOI 10.1203/00006450-199508000-00011	54	979	1049	0	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1997	336	2					111	117		10.1056/NEJM199701093360207	http://dx.doi.org/10.1056/NEJM199701093360207			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC481	8988890				2022-12-28	WOS:A1997WC48100007
J	Bateson, MC				Bateson, MC			Bile acid research and applications	LANCET			English	Editorial Material											Bateson, MC (corresponding author), GEN HOSP,BISHOP AUCKLAND DL14 6AD,DURHAM,ENGLAND.								0	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					5	6		10.1016/S0140-6736(05)62157-5	http://dx.doi.org/10.1016/S0140-6736(05)62157-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988112				2022-12-28	WOS:A1997WA72500006
J	Helfand, M; Marton, KI; ZimmerGembeck, MJ; Sox, HC				Helfand, M; Marton, KI; ZimmerGembeck, MJ; Sox, HC			History of visible rectal bleeding in a primary care population - Initial assessment and 10-year follow-up	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTRAST BARIUM ENEMA; FLEXIBLE SIGMOIDOSCOPY; COLORECTAL-CANCER; GENERAL-PRACTICE; SYMPTOMS; COLONOSCOPY; PREVALENCE; DIAGNOSIS; SYSTEMS	Objective.-To determine whether a complaint of visible rectal bleeding that is elicited by a screening review of systems merits investigation and to assess the accuracy of a defined protocol to evaluate bleeding, Design.-Prospective cohort study. Setting.-Primary care clinics in a veterans medical center. Patients.-We used an 8-item review of systems to identify 297 individuals with visible rectal bleeding; 201 (68%) of these individuals completed a specified protocol consisting of double-contrast barium enema (DCBE) examination, rigid sigmoidoscopy, and follow-up visit after 6 to 12 months. Ten years later we ve rifled the diagnosis in 131 (93%) of 141 patients whose initial evaluation suggested no cause, or a benign anorectal cause, of bleeding. Main Outcome Measures.-Final diagnoses after 2 and 10 years; sensitivity and specificity of symptoms, DCBE, and rigid sigmoidoscopy. Results.-We diagnosed serious disease in 48 (24%) of the 201 patients; 26 had polyps, 9 had inflammatory bowel disease, and 13 (6.5%) had colon cancer. Symptoms did not predict the diagnosis. Neither DCBE nor rigid sigmoidoscopy atone was sufficiently sensitive to be used alone, but the combination of DCBE and rigid sigmoidoscopy had a sensitivity of 0.96 and a specificity of 0.76 for the diagnosis of polyps, cancer, or inflammatory bowel disease. Conclusions.-Self-reported rectal bleeding detected by means of a review of systems was associated with a high likelihood of important pathology. Physicians should ask all adults about visible rectal bleeding and should visualize the entire colon in those who report bleeding.	VET AFFAIRS MED CTR,DEPT MED,PORTLAND,OR; ST MARYS HOSP,DEPT MED,SAN FRANCISCO,CA; DARTMOUTH COLL SCH MED,DEPT MED,HANOVER,NH	US Department of Veterans Affairs; Veterans Health Administration (VHA); Dartmouth College	Helfand, M (corresponding author), OREGON HLTH SCI UNIV,CTR BIOMED INFORMAT COMMUN,BICC-504,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.		Zimmer-Gembeck, Melanie/H-3031-2015	Zimmer-Gembeck, Melanie/0000-0001-9100-010X				BOLAND BJ, 1995, AM J MED SCI, V309, P194, DOI 10.1097/00000441-199504000-00002; BREWSTER NT, 1994, BRIT J SURG, V81, P445, DOI 10.1002/bjs.1800810341; CROSLAND A, 1995, BRIT MED J, V311, P486, DOI 10.1136/bmj.311.7003.486; DENT OF, 1986, DIS COLON RECTUM, V29, P243, DOI 10.1007/BF02553027; EDDY DM, 1991, COMMON SCREENING TES, P286; FIJTEN GH, 1995, FAM PRACT, V12, P279, DOI 10.1093/fampra/12.3.279; FIJTEN GH, 1994, BRIT J GEN PRACT, V44, P320; FIJTEN GH, 1993, FAM PRACT, V10, P283, DOI 10.1093/fampra/10.3.283; FOUTCH PG, 1995, AM J GASTROENTEROL, V90, P564; GOULSTON KJ, 1986, LANCET, V2, P261; IRVINE EJ, 1988, GUT, V29, P1188, DOI 10.1136/gut.29.9.1188; MANT A, 1989, DIS COLON RECTUM, V32, P191, DOI 10.1007/BF02554525; MITCHELL TL, 1992, J GEN INTERN MED, V7, P393, DOI 10.1007/BF02599154; RANSOHOFF DF, 1990, JAMA-J AM MED ASSOC, V264, P76, DOI 10.1001/jama.264.1.76; REX DK, 1990, GASTROENTEROLOGY, V98, P855, DOI 10.1016/0016-5085(90)90007-N; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SILMAN AJ, 1983, BRIT J SURG, V70, P721, DOI 10.1002/bjs.1800701209	17	61	63	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1997	277	1					44	48		10.1001/jama.277.1.44	http://dx.doi.org/10.1001/jama.277.1.44			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ767	8980209				2022-12-28	WOS:A1997VZ76700028
J	Laureno, R; Karp, BI				Laureno, R; Karp, BI			Myelinolysis after correction of hyponatremia	ANNALS OF INTERNAL MEDICINE			English	Article							CENTRAL PONTINE MYELINOLYSIS; BLOOD-BRAIN-BARRIER; RAPID CORRECTION; EXTRAPONTINE MYELINOLYSIS; LIVER-TRANSPLANTATION; SERUM SODIUM; RATS; DEMYELINATION; MANAGEMENT; DIAGNOSIS	Myelinolysis is a neurologic disorder that can occur after rapid correction of hyponatremia. Initially named ''central pontine myelinolysis,'' this disease is now known to also affect extrapontine brain areas. Manifestations of myelinolysis usually evolve several days after correction of hyponatremia. Typical features are disorders of upper motor neurons, spastic quadriparesis and pseudobulbar palsy, and mental disorders ranging from mild confusion to coma. Death may occur. The motor and localizing signs of myelinolysis differ from the generalized encephalopathy that is caused by untreated hyponatremia. Experiments have duplicated the clinical and pathologic features of myelinolysis by rapidly reversing hyponatremia in animals. Myelinolysis is more likely to occur after the treatment of chronic rather than acute hyponatremia and is more likely to occur with a rapid rate of correction. The exact pathogenesis of myelinolysis has not been determined. Optimal management of hyponatremic patients involves weighing the risk for illness and death from untreated hyponatremia against the risk for myelinolysis due to correction of hyponatremia. Experiments in animals and clinical experience suggest that correction of chronic hyponatremia should be kept at a rate less than 10 mmol/L in any 24-hour period.	NINCDS, NIH, OFF CLIN DIRECTOR, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Laureno, R (corresponding author), WASHINGTON HOSP CTR, ROOM 2A44, 110 IRVING ST NW, WASHINGTON, DC 20010 USA.							ADAMS DH, 1987, LANCET, V1, P949; ADAMS RD, 1959, ARCH NEURO PSYCHIATR, V81, P154, DOI 10.1001/archneurpsyc.1959.02340140020004; ADLER S, 1994, J AM SOC NEPHROL, V5, P935; BURCAR PJ, 1977, NEUROLOGY, V27, P223, DOI 10.1212/WNL.27.3.223; CLUITMANS FHM, 1990, AM J MED, V88, P161, DOI 10.1016/0002-9343(90)90467-R; ESTOL CJ, 1989, NEUROLOGY, V39, P493, DOI 10.1212/WNL.39.4.493; FERRIRO JA, 1992, ACTA NEUROPATHOL, V84, P1, DOI 10.1007/BF00427209; GRAFTON ST, 1988, J NEUROL NEUROSUR PS, V51, P1354, DOI 10.1136/jnnp.51.10.1354; GRAY DS, 1987, CAN J NEUROL SCI, V14, P243; ILLOWSKY BP, 1987, BRAIN, V110, P855, DOI 10.1093/brain/110.4.855; INGRAM DA, 1986, J NEUROL, V233, P23, DOI 10.1007/BF00313986; KARP BI, 1993, MEDICINE, V72, P359, DOI 10.1097/00005792-199311000-00001; KLEINSCHMIDTDEMASTERS BK, 1982, J NEUROPATH EXP NEUR, V41, P67, DOI 10.1097/00005072-198201000-00007; KLEINSCHMIDTDEMASTERS BK, 1981, SCIENCE, V211, P1068, DOI 10.1126/science.7466381; KURTZ I, 1995, J CLIN INVEST, V95, P441, DOI 10.1172/JCI117681; LAURENO R, 1981, T AM NEUROL ASSOC, V106, P98; Laureno R, 1980, Trans Am Neurol Assoc, V105, P354; LAURENO R, 1983, ANN NEUROL, V13, P232, DOI 10.1002/ana.410130303; MASCALCHI M, 1993, CLIN RADIOL, V47, P137, DOI 10.1016/S0009-9260(05)81191-2; MICKEL HS, 1990, BIOCHEM BIOPH RES CO, V172, P92, DOI 10.1016/S0006-291X(05)80177-9; MORLAN L, 1990, EUR NEUROL, V30, P149, DOI 10.1159/000117333; NORENBERG MD, 1984, ANN NEUROL, V15, P544, DOI 10.1002/ana.410150606; NORENBERG MD, 1982, ANN NEUROL, V11, P128, DOI 10.1002/ana.410110204; RAGLAND RL, 1989, J COMPUT ASSIST TOMO, V13, P316, DOI 10.1097/00004728-198903000-00025; RIGGS JE, 1989, ARCH PATHOL LAB MED, V113, P1386; ROJIANI AM, 1994, ACTA NEUROPATHOL, V88, P287; ROSENBLOOM S, 1984, AM J NEURORADIOL, V5, P110; SCHROTH G, 1984, NEURORADIOLOGY, V26, P149, DOI 10.1007/BF00339865; SINGH N, 1994, MEDICINE, V73, P110, DOI 10.1097/00005792-199403000-00004; SOUPART A, 1994, J AM SOC NEPHROL, V5, P374; Soupart A, 1996, J NEUROPATH EXP NEUR, V55, P594, DOI 10.1097/00005072-199605000-00011; SOUPART A, 1994, KIDNEY INT, V45, P193, DOI 10.1038/ki.1994.23; Soupart A, 1996, J NEUROPATH EXP NEUR, V55, P106, DOI 10.1097/00005072-199601000-00011; STERNS RH, 1993, AM J PHYSIOL, V264, pF833, DOI 10.1152/ajprenal.1993.264.5.F833; STERNS RH, 1989, KIDNEY INT, V35, P69, DOI 10.1038/ki.1989.9; STERNS RH, 1994, J AM SOC NEPHROL, V4, P1522; STERNS RH, 1986, NEW ENGL J MED, V314, P1535, DOI 10.1056/NEJM198606123142402; THOMPSON AJ, 1988, NEURORADIOLOGY, V30, P175, DOI 10.1007/BF00395621; TOMLINSON BE, 1976, Q J MED, V45, P373; TREIG T, 1988, Neurology, V38, P333; VERBALIS JG, 1993, BRAIN RES, V606, P19, DOI 10.1016/0006-8993(93)91564-9; VERBALIS JG, 1988, KIDNEY INT, V34, P351, DOI 10.1038/ki.1988.188; VERBALIS JG, 1989, BAILLIERE CLIN ENDOC, V3, P499, DOI 10.1016/S0950-351X(89)80013-8; VERBALIS JG, 1991, KIDNEY INT, V39, P1274, DOI 10.1038/ki.1991.161; VIDEEN JS, 1995, J CLIN INVEST, V95, P788, DOI 10.1172/JCI117728; WIJDICKS EFM, 1994, ANN NEUROL, V35, P626, DOI 10.1002/ana.410350520; WRIGHT DG, 1979, BRAIN, V102, P361, DOI 10.1093/brain/102.2.361; WSZOLEK ZK, 1989, TRANSPLANTATION, V48, P1006, DOI 10.1097/00007890-198912000-00023; Wu Chia-Lun, 1992, Journal of the Formosan Medical Association, V91, P1013	49	259	272	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1997	126	1					57	62		10.7326/0003-4819-126-1-199701010-00008	http://dx.doi.org/10.7326/0003-4819-126-1-199701010-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA165	8992924				2022-12-28	WOS:A1997WA16500008
J	Mariner, WK				Mariner, WK			State regulation of managed care and the Employee Retirement Income Security Act	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							REFORM		BOSTON UNIV,SCH PUBL HLTH,BOSTON,MA 02118	Boston University	Mariner, WK (corresponding author), BOSTON UNIV,SCH MED,BOSTON,MA 02118, USA.			Mariner, Wendy/0000-0001-5176-5917				ANNAS GJ, 1995, NEW ENGL J MED, V333, P1647, DOI 10.1056/NEJM199512143332420; BUTLER P, 1996, PRIVATE SECTOR HLTH; CALDWELL B, 1996, EMPLOYEE BENEFIT PLA, V51, P48; CHIRBAMARTIN MA, 1994, HEALTH AFFAIR, V13, P142, DOI 10.1377/hlthaff.13.2.142; DALLEK G, 1995, HMO LAWS, V1; FRANCESCONI GA, 1995, WASH U L Q, V73, P227; FREUDENHEIM M, 1996, NY TIMES        0519, P22; *GEN ACC OFF, 1995, GAOHEHS95167; Mariner WK, 1996, AM J PUBLIC HEALTH, V86, P863, DOI 10.2105/AJPH.86.6.863; MARINER WK, 1995, J LAW MED ETHICS, V23, P236, DOI 10.1111/j.1748-720X.1995.tb01360.x; MARINER WK, 1992, NEW ENGL J MED, V327, P1682, DOI 10.1056/NEJM199212033272312; MASHAW JL, 1994, CONN LAW REV, V28, P161; SILVERMAN C, 1995, EBRI DATABOOK EMPLOY; WOOLHANDLER S, 1995, NEW ENGL J MED, V333, P1706, DOI 10.1056/NEJM199512213332510	14	39	39	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 26	1996	335	26					1986	1990		10.1056/NEJM199612263352610	http://dx.doi.org/10.1056/NEJM199612263352610			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WA160	8960481				2022-12-28	WOS:A1996WA16000010
J	Crawshaw, R				Crawshaw, R			Greed	BRITISH MEDICAL JOURNAL			English	Article																		CHAUCER G, 1973, OXFORD ANTHOLOGY ENG, P145; CRAWSHAW R, 1985, WESTERN J MED, V142, P267; HERBERMANN CG, 1910, CATHOLIC ENCY, P18	3	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1596	1597		10.1136/bmj.313.7072.1596a	http://dx.doi.org/10.1136/bmj.313.7072.1596a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991001	Green Published			2022-12-28	WOS:A1996VZ81100024
J	Dally, A				Dally, A			The lancet and the gum-lancet: 400 years of teething babies	LANCET			English	Article											Dally, A (corresponding author), WELLCOME INST HIST MED,183 EUSTON RD,LONDON NW1 2BE,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARN SONS, 1873, INSTR MAK CAT SURG I, P45; BENNION E, 1979, ANTIQUE MED INSTRUME, P40; BURCHARD HH, 1898, TXB DENTAL PATHOLOGY, P183; BURCHARD HH, 1912, TXB DENTAL PATHOLOGY, P195; BURNET J, 1918, BR J CHILD DIS, V15, P28; CADOGAN W, 1748, ESSAY NURSING MANAGE, P31; COLYER JF, 1938, DENT SURG PATHOLOGY, P1; GROSS SD, 1967, B HIST MED, V41, P244; Hall M, 1844, LANCET, V1, P244; HALL M, 1842, LANCET, V2, P508; Holt E, 1896, DIS INFANCY CHILDHOO, P243; Hunter J, 1835, WORKS J HUNTER, V2, P34; Hurlock J., 1742, PRACTICAL TREATISE D; JACOBI A, 1898, THERAPEUTICS INFANCY, P363; JOLL B, 1984, BRIT MED J, V2, P901; MEIGS JF, 1883, DIS CHILDREN; Owen E, 1884, Br Med J, V2, P901; Oyejide C O, 1991, Afr Dent J, V5, P31; Pare Ambroise, 1649, ORIGINAL WORK PUBLIS; Rasmussen P, 1992, Int J Paediatr Dent, V2, P151; SCULTET J, 1675, ARCENAL CHIRURG, P11; SIGERIST H, 1933, GREAT DOCTORS, P130; Sims JM, 1884, STORY MY LIFE, P140; SMALE M, 1901, DIS INJURIES TEETH, P6; STEEDMAN C, 1990, CHILDHOOD CULTURE CL; THEOBALD J, 1972, PAEDIATRICS, V50, P298; UNDERWOOD M, 1734, TREATISE DIS CHILDRE; WEST C, 1859, LECT DIS INFANCY CHI, P519; WRAY D, 1980, BR DENT J, V7, P169; 1884, BRIT MED J, V2, P1108; 1884, LANCET, V2, P827; 1884, BRIT MED J, V2, P1318; 1884, BRIT MED J, V2, P1053; 1911, 74 REG GEN, P39	34	7	8	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1710	1711		10.1016/S0140-6736(96)05105-7	http://dx.doi.org/10.1016/S0140-6736(96)05105-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973438				2022-12-28	WOS:A1996VZ76600018
J	Janssens, S; VandeWerf, F				Janssens, S; VandeWerf, F			Cardiology - Acute coronary syndromes: Virchow's triad revisited	LANCET			English	Article											Janssens, S (corresponding author), CATHOLIC UNIV LEUVEN,UNIV HOSP GASTHUISBERG,DEPT CARDIOL,B-3000 LOUVAIN,BELGIUM.							Collen D, 1996, CIRCULATION, V93, P857, DOI 10.1161/01.CIR.93.5.857; Hoffmann R, 1996, CIRCULATION, V94, P1247, DOI 10.1161/01.CIR.94.6.1247; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; STEPHENS NG, 1996, LANCET, V347, P782	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348			2			SII2	SII2						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973480				2022-12-28	WOS:A1996WA46300002
J	Stenson, B				Stenson, B			Promoting attachment, providing memories	BRITISH MEDICAL JOURNAL			English	Article											Stenson, B (corresponding author), ROYAL EDINBURGH INFIRM,SIMPSON MEM MATERN PAVIL,NEONATAL UNIT,EDINBURGH EH3 9YN,MIDLOTHIAN,SCOTLAND.								0	0	0	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1615	1615		10.1136/bmj.313.7072.1615	http://dx.doi.org/10.1136/bmj.313.7072.1615			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991007	Green Published			2022-12-28	WOS:A1996VZ81100038
J	Otipoby, KL; Andersson, KB; Draves, KE; Klaus, SJ; Farr, AG; Kerner, JD; Perlmutter, RM; Law, CL; Clark, EA				Otipoby, KL; Andersson, KB; Draves, KE; Klaus, SJ; Farr, AG; Kerner, JD; Perlmutter, RM; Law, CL; Clark, EA			CD22 regulates thymus-independent responses and the lifespan of B cells	NATURE			English	Article							TYROSINE-PHOSPHATASE 1C; ANTIGEN RECEPTOR; T-CELLS; ADHESION MOLECULE; STEM-CELLS; ACTIVATION; ASSOCIATION; LIGANDS; MARROW; GENE	THE B-lymphocyte-restricted glycoprotein CD22 is expressed on mature IgM(+) IgD(+) B cells(1-3), and is capable of binding to ligands on T and B cells(2,4-7). CD22 can interact with both the B-cell antigen receptor (BCR) complex(8,9) and signalling molecules, including the protein tyrosine phosphatase SHP1 (PTP1C, SHP)(10-12), a putative negative regulator of BCR signalling(13,14). Thus CD22 may facilitate interactions with lymphocytes and regulate the threshold of BCR signalling(1,11,13). To define the in vivo function of CD22, we generated CD22-deficient mice. Here we show that CD22 is required for normal antibody responses to thymus-independent antigens and regulates the lifespan of mature B cells.	UNIV WASHINGTON,MED CTR,DEPT MICROBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,MED CTR,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,MED CTR,DEPT BIOL STRUCT,SEATTLE,WA 98195; UNIV WASHINGTON,MED CTR,DEPT BIOCHEM & MED,SEATTLE,WA 98195; UNIV WASHINGTON,MED CTR,HOWARD HUGHES MED INST,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle				Clark, Edward A/0000-0001-8061-5475				ALLMAN DM, 1993, J IMMUNOL, V151, P4431; ANDERSSON KB, IN PRESS EUR J IMMUN; CAMPBELL MA, 1995, EUR J IMMUNOL, V25, P1573, DOI 10.1002/eji.1830250616; COOKE MP, 1994, J EXP MED, V179, P425, DOI 10.1084/jem.179.2.425; Cyster JG, 1995, IMMUNITY, V3, P691, DOI 10.1016/1074-7613(95)90059-4; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; FULCHER DA, 1994, J EXP MED, V179, P125, DOI 10.1084/jem.179.1.125; Fulcher DA, 1996, J EXP MED, V183, P2313, DOI 10.1084/jem.183.5.2313; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; HANASAKI K, 1994, J BIOL CHEM, V269, P10637; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; LAW CL, 1993, J IMMUNOL, V151, P175; LAW CL, 1994, IMMUNOL TODAY, V15, P442, DOI 10.1016/0167-5699(94)90275-5; LAW CL, 1995, J IMMUNOL, V155, P3368; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MULLER U, 1994, CELL, V79, P755, DOI 10.1016/0092-8674(94)90066-3; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; RAMTHELL JC, 1996, CELL, V87, P319; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TORRES RM, 1992, J IMMUNOL, V149, P2641; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137	31	339	343	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 19	1996	384	6610					634	637		10.1038/384634a0	http://dx.doi.org/10.1038/384634a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VZ296	8967951				2022-12-28	WOS:A1996VZ29600031
J	McCann, JB; James, A; Wilson, S; Dunn, G				McCann, JB; James, A; Wilson, S; Dunn, G			Prevalence of psychiatric disorders in young people in the care system	BRITISH MEDICAL JOURNAL			English	Article									WARNEFORD HOSP,HIGHFIELD FAMILY & ADOLESCENT UNIT,OXFORD OX3 7JX,ENGLAND; INST PSYCHIAT,DEPT BIOSTAT & COMP,LONDON SE5 8AF,ENGLAND	University of London; King's College London	McCann, JB (corresponding author), LEIGH HOUSE HOSP,CHANDLERS FORD,EASTLEIGH SO53 1JY,HANTS,ENGLAND.							ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; BAMFORD F, 1988, PHYSICAL MENTAL HLTH; CHAMBERS W, 1985, ARCH GEN PSYCHIAT, V42, P606; PICKLES A, 1995, STAT METHODS MED RES, V4, P75; Wolkind S., 1994, CHILD ADOL PSYCH CL, P252	5	156	156	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1996	313	7071					1529	1530		10.1136/bmj.313.7071.1529	http://dx.doi.org/10.1136/bmj.313.7071.1529			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VY691	8978231	Green Published			2022-12-28	WOS:A1996VY69100024
J	Taylor, SI; Barr, V; Reitman, M				Taylor, SI; Barr, V; Reitman, M			Medicine - Does leptin contribute to diabetes caused by obesity?	SCIENCE			English	Editorial Material							GENE-PRODUCT; PROTEIN				Taylor, SI (corresponding author), NIDDKD,DIABET BRANCH,BETHESDA,MD 20892, USA.		Reitman, Marc/B-4448-2013	Reitman, Marc/0000-0002-0426-9475				Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	15	57	59	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 15	1996	274	5290					1151	1152		10.1126/science.274.5290.1151	http://dx.doi.org/10.1126/science.274.5290.1151			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VT335	8966588				2022-12-28	WOS:A1996VT33500040
J	Coulston, GW; Bare, SR; Kung, H; Birkeland, K; Bethke, GK; Harlow, R; Herron, N; Lee, PL				Coulston, GW; Bare, SR; Kung, H; Birkeland, K; Bethke, GK; Harlow, R; Herron, N; Lee, PL			The kinetic significance of V5+ in n-butane oxidation catalyzed by vanadium phosphates	SCIENCE			English	Article							MALEIC-ANHYDRIDE; SELECTIVE OXIDATION; PYROPHOSPHATE; STATE	Maleic anhydride, a precursor to polyester resins, is made by oxidation oi n-butane over vanadium phosphate catalysis. This system is of general interest because it is the only heterogeneously catalyzed, alkane-selective oxidation reaction in commercial use. Time-resolved in situ x-ray absorption spectroscopy shows that when either alpha(1)-VOPO4/SiO2 or (VO)(2)P2O7/SiO2 catalysts are exposed to n-butane, the rate of maleic anhydride formation is proportional to the rate oi decay of V5+ species in the catalyst. Thus V5+ species are kinetically significant for the production of maleic anhydride and not just for the production of by-products. The results also suggest that V5+ species may play a role in the initial hydrogen abstraction from n-butane, the rate-determining step in the reaction sequence. V4+ sites appear to be responsible for by-product formation.	NORTHWESTERN UNIV, IPATIEFF LAB, EVANSTON, IL 60208 USA; ARGONNE NATL LAB, DIV MAT SCI, ARGONNE, IL 60439 USA	Northwestern University; United States Department of Energy (DOE); Argonne National Laboratory	Coulston, GW (corresponding author), DUPONT CO INC, WILMINGTON, DE 19880 USA.							BEJ SK, 1992, IND ENG CHEM RES, V31, P2075, DOI 10.1021/ie00009a002; BORDES E, 1993, CATAL TODAY, V16, P27, DOI 10.1016/0920-5861(93)85003-I; CENTI G, 1993, CATAL TODAY, V16, P5, DOI 10.1016/0920-5861(93)85002-H; COULSTON G, UNPUB; EBNER JR, 1993, CATAL TODAY, V16, P51, DOI 10.1016/0920-5861(93)85005-K; Felthouse T.R., 2000, KIRK OTHMER ENCYCL C, V15, DOI [10.1002/0471238961.1301120506051220.a01.pub2, DOI 10.1002/0471238961.1301120506051220.A01.PUB2]; FERNANDEZGARCIA M, 1995, J PHYS CHEM-US, V99, P12565, DOI 10.1021/j100033a032; Froment G. F., 1979, CHEM REACTOR ANAL DE; GAI PL, 1995, SCIENCE, V267, P661, DOI 10.1126/science.267.5198.661; HERRON N, UNPUB; HODNETT BK, 1993, CATAL TODAY, V16, P131, DOI 10.1016/0920-5861(93)85013-P; HUTCHINGS GJ, 1994, NATURE, V368, P41, DOI 10.1038/368041a0; LEE PL, 1994, REV SCI INSTRUM, V65, P1, DOI 10.1063/1.1144778; Malinowski ER., 1991, FACTOR ANAL CHEM, V2; Mars P., 1954, CHEM ENG SCI, V3, P41; MISONO M, 1990, STUD SURF SCI CATAL, V55, P605; SCHIOTT B, 1993, CATAL TODAY, V16, P79, DOI 10.1016/0920-5861(93)85008-N; SOEJARTO A, IN PRESS CAN J CHEM; Tamaru K., 1991, CATAL SCI TECHNOL, P87; TRIFIRO F, 1993, CATAL TODAY, V16, P91, DOI 10.1016/0920-5861(93)85009-O; WONG J, 1984, PHYS REV B, V30, P5596, DOI 10.1103/PhysRevB.30.5596	21	175	186	3	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					191	193		10.1126/science.275.5297.191	http://dx.doi.org/10.1126/science.275.5297.191			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985008				2022-12-28	WOS:A1997WC02200031
J	Griffies, SM; Bryan, K				Griffies, SM; Bryan, K			Predictability of North Atlantic multidecadal climate variability	SCIENCE			English	Article							OCEAN-ATMOSPHERE MODEL; CIRCULATION	Atmospheric weather systems become unpredictable beyond a few weeks, but climate variations can be predictable over much longer periods because of the coupling of the ocean and atmosphere. With the use of a global coupled ocean-atmosphere model, it is shown that the North Atlantic may have climatic predictability on the order of a decade or longer. These results suggest that variations of the dominant multidecadal sea surface temperature patterns in the North Atlantic, which have been associated with changes in climate over Eurasia, can be predicted if an adequate and sustainable system for monitoring the Atlantic Ocean exists.	PRINCETON UNIV, ATMOSPHER & OCEAN SCI PROGRAM, PRINCETON, NJ 08544 USA	National Oceanic Atmospheric Admin (NOAA) - USA; Princeton University	Griffies, SM (corresponding author), PRINCETON UNIV, GEOPHYS FLUID DYNAM LAB, ROUTE 1, FORRESTAL CAMPUS, PRINCETON, NJ 08542 USA.		Griffies, Stephen Matthew/N-9144-2019	Griffies, Stephen Matthew/0000-0002-3711-236X				*CLIVAR SCI PLAN, 1995, 89 WORLD CLIM RES PR; DELWORTH T, 1993, J CLIMATE, V6, P1993, DOI 10.1175/1520-0442(1993)006<1993:IVOTTC>2.0.CO;2; DELWORTH TL, IN PRESS GEOPHYS RES; FOLLAND CK, 1986, NATURE, V320, P602, DOI 10.1038/320602a0; Fu LL, 1996, B AM METEOROL SOC, V77, P2625, DOI 10.1175/1520-0477(1996)077<2625:GOCFSA>2.0.CO;2; Gordon AL, 1992, EOS, V73, P161; GRIFFIES SM, 1995, J CLIMATE, V8, P2440, DOI 10.1175/1520-0442(1995)008<2440:ALTODB>2.0.CO;2; Hansen DV, 1996, J GEOPHYS RES-OCEANS, V101, P8749, DOI 10.1029/95JC03841; LEVITUS S, 1990, J GEOPHYS RES-OCEANS, V95, P5233, DOI 10.1029/JC095iC04p05233; Lorenz E. N., 1973, Journal of Applied Meteorology, V12, P543, DOI 10.1175/1520-0450(1973)012<0543:OTEOER>2.0.CO;2; Lorenz EN, 1965, TELLUS, V17, P321, DOI [10.3402/tellusa.v17i3.9076, DOI 10.3402/TELLUSA.V17I3.9076]; MANABE S, 1991, J CLIMATE, V4, P785, DOI 10.1175/1520-0442(1991)004<0785:TROACO>2.0.CO;2; MANN ME, 1994, J GEOPHYS RES-ATMOS, V99, P25819, DOI 10.1029/94JD02396; NEELIN JD, 1994, ANNU REV FLUID MECH, V26, P617, DOI DOI 10.1146/ANNUREV.FL.26.010194.003153; PALMER T, 1996, NATO ADV STUDY I DEC, P83; STOMMEL H, 1961, TELLUS, V13, P224, DOI 10.1111/j.2153-3490.1961.tb00079.x; TALLEY LD, 1982, J PHYS OCEANOGR, V12, P1189, DOI 10.1175/1520-0485(1982)012<1189:DACOLS>2.0.CO;2; WEAVER AJ, 1992, TRENDS PHYS OCEANOGR, V1, P15	18	169	170	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 10	1997	275	5297					181	184		10.1126/science.275.5297.181	http://dx.doi.org/10.1126/science.275.5297.181			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985005				2022-12-28	WOS:A1997WC02200028
J	Bochkarev, A; Pfuetzner, RA; Edwards, AM; Frappier, L				Bochkarev, A; Pfuetzner, RA; Edwards, AM; Frappier, L			Structure of the single-stranded-DNA-binding domain of replication protein A bound to DNA	NATURE			English	Article							CRYSTAL-STRUCTURE; GENE-V; REFINEMENT	THE single-stranded-DNA-binding proteins (SSBs) are essential fur DNA function in prokaryotic and eukaryotic cells, mitochondria, phages and viruses(1,2). The structures of four SSBs have been solved(3-7), but the molecular details of the interaction of SSBs with DNA remain speculative. We report here the crystal structure at 2.4 Angstrom resolution of the single-stranded-DNA-binding domain of human replication protein A (RPA) bound to DNA. Replication protein a is a heterotrimeric SSB that is highly conserved in eukaryotes. The largest subunit, RPA70, binds to single-stranded (ss)DNA(8,9) and mediates interactions with many cellular and viral proteins(10). The DNA-binding domain, which ties in the middle of RPA70, comprises two structurally homologous subdomains oriented in tandem. The ssDNA lies in a channel that extends from one subdomain lo the other. The structure of each RPA70 subdomain is similar to those of the bacteriophage SSBs, indicating that the mechanism of ssDNA-binding is conserved.	MCMASTER UNIV,INST MOL BIOL & BIOTECHNOL,CANC RES GRP,HAMILTON,ON L8N 3Z5,CANADA	McMaster University				Edwards, Aled/0000-0002-4782-6016				ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; BARWELL JA, 1995, J BIOL CHEM, V270, P20556, DOI 10.1074/jbc.270.35.20556; Blackwell LJ, 1996, MOL CELL BIOL, V16, P4798; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FOLKERS PJM, 1994, J MOL BIOL, V236, P229, DOI 10.1006/jmbi.1994.1132; FOLMER RHA, 1995, EMBO J, V14, P4132, DOI 10.1002/j.1460-2075.1995.tb00087.x; FUREY W, IN PRESS METH ENZYMO; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P5586, DOI 10.1021/bi9526995; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karpel R.L., 1990, BIOL NONSPECIFIC DNA, P103; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; KOMBERG A, 1992, DNA REPLICATION; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; PFUETZNER RA, IN PRESS J BIOL CHEM; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SKINNER MM, 1994, P NATL ACAD SCI USA, V91, P2071, DOI 10.1073/pnas.91.6.2071; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TUCKER PA, 1994, EMBO J, V13, P2994, DOI 10.1002/j.1460-2075.1994.tb06598.x; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61	24	473	485	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1997	385	6612					176	181		10.1038/385176a0	http://dx.doi.org/10.1038/385176a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WB728	8990123				2022-12-28	WOS:A1997WB72800059
J	McDonough, JE; Hager, CL; Rosman, B				McDonough, JE; Hager, CL; Rosman, B			Health care reform stages a comeback in Massachusetts	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											McDonough, JE (corresponding author), MASSACHUSETTS HOUSE REPRESENTAT, STATE HOUSE, JOINT COMM HLTH CARE, RM 130, BOSTON, MA 02133 USA.							BLENDON RJ, 1995, MASSACHUSETTS RESIDE; CHALOUPKA FJ, 1995, 5012 NAT BUR EC RES; CRITTENDEN RA, 1995, HEALTH AFFAIR, V14, P302, DOI 10.1377/hlthaff.14.2.302; *DEP HLTH HUM SERV, 1989, CDC DHHS PUBL; HOLOHAN J, 1995, HEALTH AFFAIR, V14, P199, DOI 10.1377/hlthaff.14.1.199; IGLEHART JK, 1995, NEW ENGL J MED, V332, P1727, DOI 10.1056/NEJM199506223322525; *JW MCC I, 1996, PUBL OP SURV COND; Kingdon JohnW., 1995, AGENDAS ALTERNATIVES, V2nd ed.; KOGAN MD, 1995, JAMA-J AM MED ASSOC, V274, P1429, DOI 10.1001/jama.274.18.1429; Lynch BS., 1994, GROWING TOBACCO FREE; Swartz K, 1996, INQUIRY-J HEALTH CAR, V33, P5; SWEANOR D, 1992, TOBACCO CONTROL S, V1, pS31; Weissman JS., 1994, FALLING SAFETY NET I; 1993, MMWR-MORBID MORTAL W, V42, P645	14	16	17	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1997	336	2					148	151		10.1056/NEJM199701093360222	http://dx.doi.org/10.1056/NEJM199701093360222			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC481	8988895				2022-12-28	WOS:A1997WC48100032
J	Luijckx, GJ; Vies, J; deBaets, M; Buchwald, B; Troost, J				Luijckx, GJ; Vies, J; deBaets, M; Buchwald, B; Troost, J			Guillain-Barre syndrome in mother and newborn child	LANCET			English	Article									MAASTRICHT UNIV,DEPT IMMUNOL,MAASTRICHT,NETHERLANDS; UNIV WURZBURG,NEUROL KLIN,D-8700 WURZBURG,GERMANY	Maastricht University; University of Wurzburg	Luijckx, GJ (corresponding author), UNIV HOSP,DEPT NEUROL,NL-6202 AZ MAASTRICHT,NETHERLANDS.							ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707; Buchwald B, 1995, NEUROSCI LETT, V201, P163, DOI 10.1016/0304-3940(95)12155-2; HARTUNG HP, 1995, MUSCLE NERVE, V18, P137, DOI 10.1002/mus.880180202; Hughes R.A., 1990, GUILLAIN BARRE SYNDR; Jones HR, 1996, J CHILD NEUROL, V11, P4, DOI 10.1177/088307389601100102	5	36	36	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					27	27		10.1016/S0140-6736(97)24001-8	http://dx.doi.org/10.1016/S0140-6736(97)24001-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988121				2022-12-28	WOS:A1997WA72500015
J	Duan, H; Dixit, VM				Duan, H; Dixit, VM			RAIDD is a new 'death' adaptor molecule	NATURE			English	Article							PROGRAMMED CELL-DEATH; C-ELEGANS; PROTEIN; GENE; INTERACTS; APOPTOSIS; ENCODES; DOMAIN; FAS	THE effector arm of the the cell-death pathway is composed of cysteine proteases belonging to the ICE/CED-3 family(1,2). In metazoan cells these exist as inactive polypeptide precursors (zymogens), each composed of a prodomain, which is cleaved to activate the protease, and a large and small catalytic subunit. The coupling of these 'death' proteases to signalling pathways is probably mediated by adaptor molecules that contain protein-protein interaction motifs such as the death domain(1). Were we describe such an adaptor molecule, RAIDD, which has an unusual bipartite architecture comprising a carboxy-terminal death domain that binds to the homologous domain in RIP, a serine/threonine kinase component of the death pathway(3,4). The amino-terminal domain is surprisingly homologous with the sequence of the prodomain of two ICE/CED-3 family members, human ICH-1 (ref. 5) and Caenorhabditis elegans CED-3 (ref. 6). This similar region mediates the binding of RAIDD to ICH-1 and CED-3, serving as a direct link to the death proteases, indicating that the prodomain may, through homophilic interactions, determine the specificity of binding of ICE/CED-3 zymogens to regulatory adaptor molecules. Finally, alternations in the sequence of the N-terminal domain that are equivalent to inactivating mutations in the C. elegans ced-3 gene(7,8) prevent homophilic binding, highlighting the potentially primordial nature of this interaction.	UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326				CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; Sambrook J., 2002, MOL CLONING LAB MANU; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	16	454	482	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1997	385	6611					86	89		10.1038/385086a0	http://dx.doi.org/10.1038/385086a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985253	Green Published			2022-12-28	WOS:A1997WA73100056
J	Tsien, JZ; Huerta, PT; Tonegawa, S				Tsien, JZ; Huerta, PT; Tonegawa, S			The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory	CELL			English	Article							LONG-TERM POTENTIATION; II MUTANT MICE; TARGETED DISRUPTION; PERFORANT PATH; DENTATE GYRUS; AREA CA1; RAT; NEURONS; IMPAIRMENT; BLOCKADE	We have produced a mouse strain in which the deletion of the NMDAR1 gene is restricted to the CA1 pyramidal cells of the hippocampus by using a new and general method that allows CA1-restricted gene knockout. The mutant mice grow into adulthood without obvious abnormalities. Adult mice lack NMDA receptor-mediated synaptic currents and long-term potentiation in the CA1 synapses and exhibit impaired spatial memory but unimpaired nonspatial learning. Our results strongly suggest that activity-dependent modifications of CA1 synapses, mediated by NMDA receptors, play an essential role in the acquisition of spatial memories.			Tsien, JZ (corresponding author), MIT,CTR CANC RES,HOWARD HUGHES MED INST,CTR LEARNING & MEMORY,DEPT BIOL,CAMBRIDGE,MA 02139, USA.			Huerta, Patricio/0000-0003-0270-2308	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925] Funding Source: NIH RePORTER; NINDS NIH HHS [NS32925] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; BUTCHER SP, 1991, EXP BRAIN RES, V83, P521; Cain DP, 1996, BEHAV NEUROSCI, V110, P86, DOI 10.1037/0735-7044.110.1.86; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHEN C, 1997, IN PRESS ANN REV NEU; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; de No RL, 1934, J PSYCHOL NEUROL, V46, P113; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EMPSON RM, 1995, J PHYSIOL-LONDON, V484, P707, DOI 10.1113/jphysiol.1995.sp020697; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; Gerlai R, 1996, TRENDS NEUROSCI, V19, P177, DOI 10.1016/S0166-2236(96)20020-7; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; HANSE E, 1992, EUR J NEUROSCI, V4, P1191, DOI 10.1111/j.1460-9568.1992.tb00144.x; HEBB DO, 1949, ORG BEHAVIOR; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; HESTRIN S, 1996, EXCITATORY AMINO ACI, P53; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; HUERTA PT, 1995, NEURON, V15, P1053, DOI 10.1016/0896-6273(95)90094-2; Huerta PT, 1996, NEUROREPORT, V7, P1685, DOI 10.1097/00001756-199607080-00032; KAWASE E, 1994, INT J DEV BIOL, V38, P385; KOLB B, 1994, CEREB CORTEX, V6, P664; KONTGEN F, 1993, INT IMMUNOL, V5, P957, DOI 10.1093/intimm/5.8.957; LEDERMANN B, 1991, EXP CELL RES, V197, P254, DOI 10.1016/0014-4827(91)90430-3; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; MARR D, 1971, PHILOS T ROY SOC B, V262, P23, DOI 10.1098/rstb.1971.0078; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Morris RGM, 1991, LONG TERM POTENTIATI, P267; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NostenBertrand M, 1996, NATURE, V379, P826, DOI 10.1038/379826a0; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; POKORNY J, 1981, BRAIN RES BULL, V7, P113, DOI 10.1016/0361-9230(81)90075-7; POKORNY J, 1981, BRAIN RES BULL, V7, P121, DOI 10.1016/0361-9230(81)90076-9; Rawlins J.N.P., 1996, EXCITATORY AMINO ACI, P275; Sakmann Bert, 1995, P199; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Squire L. R., 1987, MEMORY BRAIN; STANFIELD BB, 1979, J COMP NEUROL, V185, P423, DOI 10.1002/cne.901850303; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	54	1347	1411	2	159	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1327	1338		10.1016/S0092-8674(00)81827-9	http://dx.doi.org/10.1016/S0092-8674(00)81827-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980238	Bronze			2022-12-28	WOS:A1996WA54100020
J	Alberts, DS; Liu, PY; Hannigan, EV; OToole, R; Williams, SD; Young, JA; Franklin, EW; ClarkePearson, DL; Malviya, VK; DuBeshter, B; Adelson, MD; Hoskins, WJ				Alberts, DS; Liu, PY; Hannigan, EV; OToole, R; Williams, SD; Young, JA; Franklin, EW; ClarkePearson, DL; Malviya, VK; DuBeshter, B; Adelson, MD; Hoskins, WJ			Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED TRIAL; CHEMOTHERAPY; CARCINOMA; THIOSULFATE; TUMORS	Background Intravenous platinum-based chemotherapy is the standard primary therapy for advanced ovarian cancer. We conducted a phase 3 trial to compare the effects of intraperitoneal and intravenous cisplatin on the survival of women with previously untreated, stage III, epithelial ovarian cancer. Methods The patients underwent an initial exploratory laparotomy and resection of all tumor masses larger than 2 cm. Within four weeks after surgery, six courses of intravenous cyclophosphamide (600 mg per square meter of body-surface area per course) plus either intraperitoneal cisplatin (100 mg per square meter) or intravenous cisplatin (100 mg per square meter) were administered at three-week intervals. Results Of 654 randomized patients, 546 were eligible for the study. The estimated median survival was significantly longer in the group receiving intraperitoneal cisplatin (49 months; 95 percent confidence interval, 42 to 56) than in the group receiving intravenous cisplatin (41 months; 95 percent confidence interval, 34 to 47). The risk of death was tower in the intraperitoneal group than in the intravenous group (hazard ratio, 0.76; 95 percent confidence interval, 0.61 to 0.96; P=0.02). Moderate-to-severe tinnitus, clinical hearing loss, and neuromuscular toxic effects were significantly more frequent in the intravenous group. Conclusions As compared with intravenous cisplatin, intraperitoneal cisplatin significantly improves survival and has significantly fewer toxic effects in patients with stage ill ovarian cancer and residual tumor masses of 2 cm or less. (C) 1996, Massachusetts Medical Society.	UNIV ARIZONA,TUCSON,AZ; SW ONCOL GRP,CTR STAT,SEATTLE,WA; UNIV TEXAS,MED BRANCH,GALVESTON,TX 77550; OHIO STATE UNIV,CTR HLTH,COLUMBUS,OH 43210; GYNECOL ONCOL GRP,PHILADELPHIA,PA 19107; INDIANA UNIV,SCH MED,INDIANAPOLIS,IN; EASTERN COOPERAT ONCOL GRP,BOSTON,MA; CANC CARE ASSOCIATES,TULSA,OK; ATLANTA REG COMMUNITY CLIN ONCOL PROGRAM,ATLANTA,GA; WAYNE STATE UNIV,MED CTR,DETROIT,MI 48202; UNIV ROCHESTER,SCH MED,ROCHESTER,NY	University of Arizona; Southwest Oncology Group; University of Texas System; University of Texas Medical Branch Galveston; University System of Ohio; Ohio State University; Indiana University System; Indiana University-Purdue University Indianapolis; Detroit Medical Center; Wayne State University; University of Rochester					NATIONAL CANCER INSTITUTE [U10CA045450, U10CA038926, U10CA032102] Funding Source: NIH RePORTER; NCI NIH HHS [CA38926, CA45450, CA32102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COX DR, 1972, J R STAT SOC B, V34, P187; DEDRICK RL, 1978, CANCER TREAT REP, V62, P1; GOEL R, 1989, J NATL CANCER I, V81, P1552, DOI 10.1093/jnci/81.20.1552; HOWELL SB, 1982, ANN INTERN MED, V97, P845, DOI 10.7326/0003-4819-97-6-845; HOWELL SB, 1987, J CLIN ONCOL, V5, P1607, DOI 10.1200/JCO.1987.5.10.1607; KIRMANI S, 1991, J CLIN ONCOL, V9, P649, DOI 10.1200/JCO.1991.9.4.649; LOS G, 1989, CANCER RES, V49, P3380; MARKMAN M, 1986, CANCER TREAT REV, V13, P219, DOI 10.1016/0305-7372(86)90007-1; MARKMAN M, 1990, CHEMOTHERAPY GYNECOL, P375; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; MILLER BA, 1993, NIH PUBLICATION; NEIJT JP, 1987, J CLIN ONCOL, V5, P1157, DOI 10.1200/JCO.1987.5.8.1157; OMURA GA, 1989, J CLIN ONCOL, V7, P457, DOI 10.1200/JCO.1989.7.4.457; PICCART MJ, 1985, SEMIN ONCOL, V12, P90; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; WINGO PA, 1995, CA-CANCER J CLIN, V45, P127	16	961	994	0	34	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 26	1996	335	26					1950	1955		10.1056/NEJM199612263352603	http://dx.doi.org/10.1056/NEJM199612263352603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA160	8960474				2022-12-28	WOS:A1996WA16000003
J	Sinaiko, AR				Sinaiko, AR			Hypertension in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BLOOD-PRESSURE MEASUREMENT; LEFT-VENTRICULAR MASS; FAMILIAL AGGREGATION; OBESE ADOLESCENTS; CHILDHOOD PREDICTORS; FASTING INSULIN; WEIGHT-LOSS; ASSOCIATION; FITNESS; PREVALENCE				Sinaiko, AR (corresponding author), UNIV MINNESOTA, SCH MED, DEPT PEDIAT, 420 DELAWARE ST SE, BOX 491 UMHC, MINNEAPOLIS, MN 55455 USA.							[Anonymous], 1987, PEDIATRICS, V79, P1; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BIRON P, 1978, PEDIATR CLIN N AM, V25, P29; BLUMENTHAL S, 1977, PEDIATRICS, V59, P797; BRANDAO AP, 1992, HYPERTENSION, V19, P214; BURKE GL, 1987, CIRCULATION, V75, P106, DOI 10.1161/01.CIR.75.1.106; BURNS TL, 1992, PEDIATRICS, V89, P262; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; Falkner B, 1996, PEDIATRICS, V98, P649; FIXLER DE, 1979, PEDIATRICS, V64, P579; FIXLER DE, 1983, PEDIATRICS, V72, P459; Georgieff MK, 1996, PEDIATR NEPHROL, V10, P152; GOMEZMARIN O, 1991, CONTROL CLIN TRIALS, V12, P408, DOI 10.1016/0197-2456(91)90020-M; GOMEZMARIN O, 1992, J HYPERTENS, V10, P1235; GUTIN B, 1990, JAMA-J AM MED ASSOC, V264, P1123, DOI 10.1001/jama.264.9.1123; HEGVI T, 1994, J PEDIATR, V124, P627; HIMMELMANN A, 1994, J HYPERTENS, V12, P89; HOFMAN A, 1987, HYPERTENSION, V9, P188, DOI 10.1161/01.HYP.9.2.188; JIANG XZ, 1995, ARCH INTERN MED, V155, P190, DOI 10.1001/archinte.155.2.190; JIANG XZ, 1993, ARCH INTERN MED, V153, P323, DOI 10.1001/archinte.153.3.323; JULIUS S, 1990, JAMA-J AM MED ASSOC, V264, P354; KANAI H, 1990, INT J OBESITY, V14, P1047; LAUER RM, 1991, HYPERTENSION, V18, P74, DOI 10.1161/01.HYP.18.3_Suppl.I74; LAW CM, 1994, J HYPERTENS, V12, P1329; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LEVINE RS, 1994, BMJ-BRIT MED J, V308, P298, DOI 10.1136/bmj.308.6924.298; LONDE S, 1975, J PEDIATR-US, V87, P896, DOI 10.1016/S0022-3476(75)80901-2; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAHONEY LT, 1991, AM J HYPERTENS, V4, pS608, DOI 10.1093/ajh/4.11S.608S; MCCAFFREY FM, 1991, AM J DIS CHILD, V145, P177, DOI 10.1001/archpedi.1991.02160020069020; MUNGER RG, 1988, J HYPERTENS, V6, P647, DOI 10.1097/00004872-198808000-00008; NELSON MJ, 1992, AM J EPIDEMIOL, V136, P633, DOI 10.1093/oxfordjournals.aje.a116543; PARK, 1988, PEDIATRICS, V81, P683; PARK MK, 1987, PEDIATRICS, V79, P907; PORTMAN RJ, 1994, PEDIATR NEPHROL, V8, P367, DOI 10.1007/BF00866367; PRINEAS RJ, 1984, NHLBI WORKSHOP JUVEN, P21; RAMES LK, 1978, PEDIATRICS, V61, P245; ROCCHINI AP, 1989, HYPERTENSION, V14, P367, DOI 10.1161/01.HYP.14.4.367; ROCCHINI AP, 1992, HYPERTENSION, V19, P615, DOI 10.1161/01.HYP.19.6.615; ROCCHINI AP, 1989, NEW ENGL J MED, V321, P580, DOI 10.1056/NEJM198908313210905; ROCCHINI AP, 1988, PEDIATRICS, V82, P16; ROSNER B, 1993, J PEDIATR-US, V123, P871, DOI 10.1016/S0022-3476(05)80382-8; SHEA S, 1994, PEDIATRICS, V94, P465; SINAIKO AR, 1989, J PEDIATR-US, V114, P664, DOI 10.1016/S0022-3476(89)80718-8; SINAIKO AR, 1994, PEDIATR NEPHROL, V8, P603, DOI 10.1007/BF00858144; SINAIKO AR, 1982, HYPERTENSION, V4, P299, DOI 10.1161/01.HYP.4.2.299; STAMLER J, 1991, HYPERTENSION, V18, P95, DOI 10.1161/01.HYP.18.3_Suppl.I95; Taittonen L, 1996, AM J HYPERTENS, V9, P193, DOI 10.1016/0895-7061(95)00345-2; TRIEBER FA, 1993, AM J HYPERTENS, V6, P505, DOI 10.1093/ajh/6.6.505; WAREHAM JA, 1987, AM J DIS CHILD, V141, P1108, DOI 10.1001/archpedi.1987.04460100086034; ZINNER SH, 1985, HYPERTENSION, V7, P411, DOI 10.1161/01.HYP.7.3_Pt_1.411	51	137	151	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 26	1996	335	26					1968	1973		10.1056/NEJM199612263352607	http://dx.doi.org/10.1056/NEJM199612263352607			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA160	8960478				2022-12-28	WOS:A1996WA16000007
J	Peabody, JW; Bickel, SR; Lawson, JS				Peabody, JW; Bickel, SR; Lawson, JS			The Australian health care system - Are the incentives down under right side up?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TECHNOLOGY; POLICY		VET AFFAIRS MED CTR,DIV GEN INTERNAL MED,LOS ANGELES,CA; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,LOS ANGELES,CA 90024; UNIV NEW S WALES,SCH HLTH SERV MANAGEMENT,KENSINGTON,NSW,AUSTRALIA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Los Angeles; University of New South Wales Sydney	Peabody, JW (corresponding author), RAND CORP,1700 MAIN ST,SANTA MONICA,CA 90407, USA.		lawson, james/AAD-9727-2020					ADAMS T, 1992, Journal of Public Health Policy, V13, P97, DOI 10.2307/3343061; ALTMAN S, 1991, HEALTH AFFAIR, V10, P129, DOI 10.1377/hlthaff.10.3.129; *AM MED ASS, 1996, SURV DAT RES PHYS CH; ARNOLD PC, 1988, JAMA-J AM MED ASSOC, V259, P2903; *AUSTR HLTH INS CO, 1996, ANN REP 1995 196 HLT; *AUSTR HLTH INS CO, 1995, ANN REP 1994 1995 HL; *AUSTR I HLTH WELF, 1995, NAT HLTH LAB FORC B, V3; *AUSTR I HLTH WELF, 1994, AUSTR HLTH 1994, P116; COLLOPY BT, 1991, BRIT MED J, V303, P1523, DOI 10.1136/bmj.303.6816.1523; COLLOPY BT, 1993, AUSTR DEV NATL QUALI, P510; *COMM EC DEV AUSTR, 1993, PLAN HLTH POL REF RE, P22; COOPER WE, 1993, ETHOL ECOL EVOL, V5, P1, DOI 10.1080/08927014.1993.9523112; DONALDSON C, 1991, HLTH POLICY, V17, P1761; GILLETT S, 1994, WAITING LISTS NATL S, P170; HAILEY DM, 1990, HEALTH POLICY, V14, P177, DOI 10.1016/0168-8510(90)90032-9; HAILEY DM, 1993, HEALTH POLICY, V25, P243, DOI 10.1016/0168-8510(93)90018-K; *ICI AUSTR OP, 1994, MED GUID UND MED, P5; JOHNSON J, 1991, HOSPITALS       0305, P42; KASSIRER JP, 1995, NEW ENGL J MED, V333, P1348, DOI 10.1056/NEJM199511163332009; LABONTE R, 1987, CAN MED ASSOC J, V136, P888; Lawson J S, 1995, Aust Health Rev, V18, P116; LAWSON J S, 1991, World Health Forum, V12, P96; Lawson J S, 1993, Physician Exec, V19, P17; Lawson J S, 1993, Aust Health Rev, V16, P353; MACKEY P, 1990, PHARM BENEFITS SEHEN; *NAT HLTH STRAT, 1991, 2 NAT HLTH SERV; *ORG EC COOP DEV, 1993, ORG EC COOP DEV HLTH, P55; *ORG EC COOP DEV, 1994, REF HLTH CAR SYST RE, P55; PEABODY J, 1994, HLTH POLICY, V30, P29; PEABODY JW, 1995, JAMA-J AM MED ASSOC, V273, P777, DOI 10.1001/jama.273.10.777; *PRIV HLTH INS ADM, 1996, AUSTR HLTH 1996; Richardson J, 1988, Int J Technol Assess Health Care, V4, P407; RICHARDSON J, 1991, 5 COMM DEP HLTH; Schieber G J, 1992, Health Care Financ Rev, V13, P1; SCHIEBER GJ, 1991, HEALTH AFFAIR, V10, P22, DOI 10.1377/hlthaff.10.3.22; SCHWARTZ WB, 1987, JAMA-J AM MED ASSOC, V257, P220, DOI 10.1001/jama.257.2.220; SMITH CS, 1994, SOC SCI MED, V38, P1653, DOI 10.1016/0277-9536(94)90067-1; STEWART ME, 1994, HLTH CARE FINANC REV, V16, P247; *WHO, 1994, WORLD HLTH STAT ANN; *WHO, 1994, WHO S; *WORLD BANK, 1995, WORLD DEV REP	41	23	23	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1996	276	24					1944	1950		10.1001/jama.276.24.1944	http://dx.doi.org/10.1001/jama.276.24.1944			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VY689	8971055				2022-12-28	WOS:A1996VY68900014
J	Chan, A; McPhee, AJ				Chan, A; McPhee, AJ			Neonatal medicine - A safer leap into this dangerous world	LANCET			English	Article									WOMENS & CHILDRENS HOSP, DEPT NEONATAL MED, ADELAIDE, SA 5006, AUSTRALIA	Womens & Childrens Hospital Australia	Chan, A (corresponding author), S AUSTRALIAN HLTH COMMISS, PREGNANCY OUTCOME UNIT, POB 6, RUNDLE MALL, ADELAIDE, SA 5000, AUSTRALIA.							Field D, 1996, LANCET, V348, P75; Findlay RD, 1996, PEDIATRICS, V97, P48; Fleming PJ, 1996, BMJ-BRIT MED J, V313, P191, DOI 10.1136/bmj.313.7051.191; *MAT HLTH SAF MOTH, 1996, MOTH BAB PACK IMPL S; vonKries R, 1996, BRIT MED J, V313, P199, DOI 10.1136/bmj.313.7051.199	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	1996	348			2			SII12	SII12						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973490				2022-12-28	WOS:A1996WA46300012
J	Eskola, J; Olander, RM; Hovi, T; Litmanen, L; Peltola, S; Kayhty, H				Eskola, J; Olander, RM; Hovi, T; Litmanen, L; Peltola, S; Kayhty, H			Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine	LANCET			English	Article							YOUNG INFANTS; TETANUS TOXOIDS; DIPHTHERIA; SAFETY; SYRINGE; POLYSACCHARIDE; RESPONSES; AGE	Background Inclusion of new vaccines in vaccination programmes for children would be easier if they could be combined with existing vaccines. Vaccines containing acellular pertussis in the diphtheria/tetanus/pertussis (DTP-a) combination are expected to replace the conventional whole-cell vaccines (DTP-w). We tested the immunogenicity and safety of a combination of DTP-a with the Haemophilus influenzae type b (Hib) conjugate of Hib capsular polysaccharide and tetanus toxid (PRP-T), and inactivated poliovirus vaccine (IPV). Methods 120 infants were enrolled and randomised to four groups to receive DTP-a at ages 2, 4, and 6 months. At 4 and 6 months they also received Hib conjugate and IPV, either as separate injections or mixed with DTP-a. All injections were given intramuscularly in the anterolateral area of the thigh. Any reactions after each Vaccination were noted by the parents. EIA was used to measure titres of diphtheria, tetanus, and pertussis antibodies, RIA for Hib anticapsular antibodies, and microneutralisation assay for poliovirus antibodies from serum samples collected at the ages of 2, 4, 6, and 7 months. Findings There were 30 infants in each group. Only mild adverse events were reported. There was a tendency towards slightly lower concentrations of filamentous haemagglutinin, tetanus, and poliovirus 1 antibodies when the vaccines were mixed. However, there was a more pronounced difference (p = 4 x 10(-8)) in Hib antibodies between groups receiving Hib capsular polysaccharide mixed with DTP-a (geometric mean concentrations 0.37 mu g/mL and 0.56 mu g/mL) compared with groups receiving the vaccines separately (3.10 mu g/mL and 3.94 mu g/mL). Interpretation Administration of premixed DTP-a, Hib conjugate, and IPV affect the immune response significantly. The mechanism of this interference is not clear. The immunogenicity of ail antigens must be tested before new combinations can be accepted for vaccination programmes for infants.	SALO HLTH CTR,SALO,FINLAND		Eskola, J (corresponding author), NATL PUBL HLTH INST,SF-00300 HELSINKI,FINLAND.							ALBRECHT P, 1984, REV INFECT DIS, V6, P540; [Anonymous], 35 INT C ANT AG CHEM; AVENDANO A, 1993, PEDIATR INFECT DIS J, V12, P638, DOI 10.1097/00006454-199308000-00003; CLEMENS JD, 1992, JAMA-J AM MED ASSOC, V267, P673, DOI 10.1001/jama.267.5.673; DAGAN R, 1994, PEDIATR INFECT DIS J, V13, P356, DOI 10.1097/00006454-199405000-00005; EDWARDS KM, 1995, PEDIATRICS, V96, P548; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; FERRECCIO C, 1991, PEDIATR INFECT DIS J, V10, P764, DOI 10.1097/00006454-199110000-00009; GOLD R, 1994, PEDIATR INFECT DIS J, V13, P348, DOI 10.1097/00006454-199405000-00004; GRANOFF DM, 1993, J INFECT DIS, V168, P663, DOI 10.1093/infdis/168.3.663; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; GREENBERG DP, 1995, 35 INT C ANT AG CHEM; Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602; KAPLAN SL, 1994, J PEDIATR-US, V124, P323, DOI 10.1016/S0022-3476(94)70328-0; KAYHTY H, 1991, AM J DIS CHILD, V145, P223; Kurikka S, 1996, J PEDIATR-US, V128, P524, DOI 10.1016/S0022-3476(96)70364-5; MAKELA PH, 1977, J INFECT DIS S, V190, P43; Manclark CR, 1986, MANUAL CLIN LAB IMMU, V3rd, P388; Melville-Smith ME, 1990, ELISA CLIN MICROBIOL, P136; MILLER MA, 1995, PEDIATRICS, V95, P522; MULHOLLAND EK, 1993, PEDIATR INFECT DIS J, V12, P632, DOI 10.1097/00006454-199308000-00002; PARADISO PR, 1993, PEDIATRICS, V92, P827; PICHICHERO ME, 1995, PEDIATRICS, V96, P588; SCHEIFELE D, 1993, CAN MED ASSOC J, V149, P1105; Schmitt HJ, 1996, JAMA-J AM MED ASSOC, V275, P37, DOI 10.1001/jama.275.1.37; SHINEFIELD H, 1995, 35 INT C ANT AG CHEM; TROLLFORS B, 1995, NEW ENGL J MED, V333, P1045, DOI 10.1056/NEJM199510193331604; WARD J, 1990, NEW ENGL J MED, V323, P1393, DOI 10.1056/NEJM199011153232006; WATEMBERG N, 1991, PEDIATR INFECT DIS J, V10, P758, DOI 10.1097/00006454-199110000-00008	29	130	136	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1688	1692		10.1016/S0140-6736(96)04356-5	http://dx.doi.org/10.1016/S0140-6736(96)04356-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973430				2022-12-28	WOS:A1996VZ76600010
J	Holm, S; Evans, M				Holm, S; Evans, M			Product names, proper claims? More ethical issues in the marketing of drugs	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To analyse the explicit or implicit claims embodied in the proprietary names of pharmaceutical products. Design-Linguistic and ethical analysis of proprietary names of pharmaceutical products marketed in the UK and in Denmark. Results and conclusions-A number of drugs have names that allude to their indication or actions. Such names may be problematic, however, because they often promise more than the drug can deliver. Taking into account, firstly, the type of allusion and its degree of sophistication, and, secondly, the seriousness of the indication may help in identifying the most problematic drug names.	UNIV COLL SWANSEA,CTR PHILOSOPHY & HLTH CARE,SWANSEA SA2 8PP,W GLAM,WALES	Swansea University	Holm, S (corresponding author), UNIV COPENHAGEN,DEPT MED PHILOSOPHY & CLIN THEORY,DK-2200 COPENHAGEN N,DENMARK.			Holm, Soren/0000-0002-7200-5607				ARONSON JK, 1994, BRIT MED J, V308, P1140, DOI 10.1136/bmj.308.6937.1140; *BRIT MED ASS ROYA, 1995, BRIT NAT FORM; FABER J, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92954-Z; JACK DB, 1991, BRIT MED J, V303, P1606, DOI 10.1136/bmj.303.6817.1606; *LAEG FORL, 1995, LAEG MED; MCNULTY H, 1979, BRIT MED J, V2, P836, DOI 10.1136/bmj.2.6194.836; Spigset Olav, 1995, Tidsskrift for den Norske Laegeforening, V115, P380	7	10	10	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1627	1629		10.1136/bmj.313.7072.1627	http://dx.doi.org/10.1136/bmj.313.7072.1627			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991014	Green Published			2022-12-28	WOS:A1996VZ81100046
J	Proctor, RN				Proctor, RN			The anti-tobacco campaign of the Nazis: A little known aspect of public health in Germany, 1933-45	BRITISH MEDICAL JOURNAL			English	Article							SMOKING; DEATH	Historians and epidemiologists have only recently begun to explore the Nazi anti-tobacco movement. Germany had the world's strongest antismoking movement in the 1930s and early 1940s, encompassing bans on smoking in public spaces, bans on advertising, restrictions on tobacco rations for women, and the world's most refined tobacco epidemiology, linking tobacco use with the already evident epidemic of lung cancer. The anti-tobacco campaign must be understood against the backdrop of the Nazi quest for racial and bodily purity, which also motivated many other public health efforts of the era.			Proctor, RN (corresponding author), PENN STATE UNIV,DEPT HIST,UNIVERSITY PK,PA 16802, USA.							Annas George J., 1992, NAZI DOCTORS NUREMBE; BAUER D, 1937, AUF WACHT, P19; BORGERS D, 1995, BRIT MED J, V310, P1536, DOI 10.1136/bmj.310.6993.1536a; CHARMAN T, 1989, GERMAN HOME FRONT 19; *ERK BEK TAB, 1941, DTSCH ARZTEBL, V71, P183; FROMME W, 1948, HYGIENE 1, P36; GOEDEL A, 1944, KRIEGSCHIRURGIE, V1; Kater MH, 1989, DOCTORS HITLER; KITTEL W, 1944, WEHRHYGIENE; KLARNER W, 1940, RAUCHEN EINE SUCHT I; *KOSM, 1933, BILD DOK UNS ZEIT; LEE PN, 1975, TOBACCO CONSUMPTION; MULLER F. H., 1939, ZEITSCHR KREBSJORSCH, V49, P57; PETO R, 1995, BRIT MED J, V310, P396, DOI 10.1136/bmj.310.6976.396a; Picker Henry, 1951, HITLERS TISCHGESPRAC; PRITZKOLEIT K, 1961, EINER WOGE GOLD TRIM; PROCTOR RN, IN PRESS J EPIDEMIOL; Proctor Robert N., 1988, RACIAL HYGIENE MED N; RECKERT FK, 1942, TABAKWARENKUNDE TABA; REID G, 1939, GENUSSGIFTE, V35, P64; SCHAIRER E, 1943, Z KREBSFORSCH, V54, P261; SMITH GD, 1995, BRIT MED J, V310, P396, DOI 10.1136/bmj.310.6976.396; *WERB DTSCH WIRTSC, 1939, VOLKSGESUNDHEIT WERB; 1939, JAMA-J AM MED ASSOC, V113, P1144; 1944, INFORMATIONSDIEN APR, P60; 1941, VERTRAUENSARZT, V9, P196; 1941, OFF GESUNDHEITSDIENS, V7, P488; 1940, GENUSSGIFTE, V36, P59	28	40	40	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1996	313	7070					1450	1453		10.1136/bmj.313.7070.1450	http://dx.doi.org/10.1136/bmj.313.7070.1450			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX612	8973234	Green Published			2022-12-28	WOS:A1996VX61200034
J	Vollmann, J; Winau, R				Vollmann, J; Winau, R			Informed consent in human experimentation before the Nuremberg code	BRITISH MEDICAL JOURNAL			English	Article								The issue of ethics with respect to medical experimentation in Germany during the 1930s and 1940s was crucial at the Nuremberg trials and related trials of doctors and public health officials. Those involved in horrible crimes attempted to excuse themselves by arguing that there were no explicit rules governing medical research on human beings in Germany during the period and that research practices in Germany were not different from those in allied countries. In this context the Nuremberg code of 1947 is generally regarded as the first document to set out ethical regulations in human experimentation based on informed consent. New research, however, indicates that ethical issues of informed consent in guidelines for human experimentation were recognised as early as the nineteenth century. These guidelines shed light on the still contentious issue of when the concepts of autonomy, informed consent, and therapeutic and non-therapeutic research first emerged. This issue assumes renewed importance in the context of current attempts to assess liability and responsibility for the abuse of people in various experiments conducted since the second world war in the United States, Canada, Russia, and other nations.			Vollmann, J (corresponding author), FREE UNIV BERLIN,INST HIST MED,D-12203 BERLIN,GERMANY.							Advisory Committee on Human Radiation Experiments, 1995, FIN REP; Annas G J, 1992, Health Matrix Clevel, V2, P119; [Anonymous], 1986, HIST THEORY INFORM C; BEECHER HK, 1966, NEW ENGL J MED, V274, P1354, DOI 10.1056/NEJM196606162742405; CAPLAN AL, 1991, MED WENT MAD BIOETHI; Elkeles B, 1985, Medizinhist J, V20, P135; Jones JH, 1981, BAD BLOOD TUSKEGEE S; Kater MH, 1989, DOCTORS HITLER; Katz J., 1984, SILENT WORLD DOCTOR; Katz J., 1972, EXPT HUMAN BEINGS; Lederer Susan, 1995, SUBJECTED SCI HUMAN; LUTHER E, 1967, HIPOKRATISCHE ETHOS; Mitscherlich Alexander, 1949, WISSENSCHAFT OHNE ME; Moll Albert, 1902, ARZTLICHE ETHIK; Muller-Hill B, 1984, TODLICHE WISSENSCHAF; *OFF REG TUB GERM, 1991, JAMA-J AM MED ASSOC, V16, P492; PARNICK MS, 1991, MAKING HLTH CARE DEC, V3; SASS HM, 1983, J MED PHILOS, V8, P99, DOI 10.1093/jmp/8.2.99; SCHULTZ JH, 1986, A MOLLS ARZTLICHE ET; Smith R, 1996, BRIT MED J, V312, P789; TASHIRO E, 1991, WAAGE VENUS VENEROLO; VOLLMANN J, IN PRESS INFORMED CO; WINAU R, 1986, VERSUCHE MENSCHEN	23	196	207	2	27	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1996	313	7070					1445	1447		10.1136/bmj.313.7070.1445	http://dx.doi.org/10.1136/bmj.313.7070.1445			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX612	8973233	Green Published			2022-12-28	WOS:A1996VX61200031
J	Weindling, P				Weindling, P			Human guinea pigs and the ethics of experimentation: The BMJ's correspondent at the Nuremberg medical trial	BRITISH MEDICAL JOURNAL			English	Article								Though the Nuremberg medical trial was a United States military tribunal, British forensic pathologists supplied extensive evidence for the trial. The BMJ had a correspondent at the trial, and he endorsed a utilitarian legitimation of clinical experiments, justifying the medical research carried out under Nazism as of long term scientific benefit despite the human costs. The British supported an international medical commission to evaluate the ethics and scientific quality of German research. Medical opinions differed over whether German medical atrocities should be given publicity or treated in confidence. The BMJ's correspondent warned against medical researchers being taken over by a totalitarian state, and these arguments were used to oppose the NHS and any state control over medical research.			Weindling, P (corresponding author), UNIV OXFORD,WELLCOME UNIT HIST MED,OXFORD OX2 6PE,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Annas George J., 1992, NAZI DOCTORS NUREMBE; Blacker CP, 1952, EUGEN REV, V44, P9; *BRIT MED ASS, 1947, WAR CRIM MED STAT CO; Caplan A. L., 1992, MED WENT MAD; *FOR OFF, 1949, SCI RES GER MED WAR; FRASER FR, 1933, COMMUNICATION   0602; *INT SCI COMM INV, PROT FIAT M KEW, P471; KREBS H, 1945, COMMUNICATION   0813; LOVELL R, 1992, CHURCHILLS DOCTORS B, P289; Mant A. K., 1949, MED LEG J, V17, P99; MCGUCKEN W, 1984, SCI SOC STATE SOCIAL, P269; *MED UN, 1950, TRIALS WAR CRIM NUR, V1; *MED UN, 1950, TRIALS WAR CRIM NUER, V2, P91; MELLANBY K, 1947, BRIT MED J, V1, P148, DOI 10.1136/bmj.1.4490.148; MELLANBY K, 1943, SCABIES; MELLANBY K, 1973, HUMAN GUINEA PIGS, P187; MELLANBY K, 1973, HUMAN GUINEA PIGS, P181; MELLANBY K, 1973, HUMAN GUINEA PIGS, P196; MELLANBY K, 1945, HUMAN GUINEA PIGS; MELLANBY K, 1973, HUMAN GUINEA PIGS, P184; MELLANBY K, 1945, HUMAN GUINEA PIGS, P8; MELLANBY K, 1946, LANCET, V2, P850; VAUGHAN J, 1945, INT C MIL MED 4 JUN; VAUGHAN J, 1945, COMMUNICATION   0524; VAUGHAN J, 1945, LANCET, V1, P724; WEBSTER C, 1993, DOCTORS POLITICS SOC, P212; WEBSTER C, 1988, PROBLEMS HLTH CARE, V1, P99; Weindling P, 1996, VACCINIA, VACCINATION, VACCINOLOGY, P341; WEINDLING PJ, 1996, MED ETHIK ZEICHEN AU, P31; 1947, BRIT MED J, V1, P143; 1946, LANCET, V2, P961; 1946, LANCET, V2, P798	32	26	27	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1996	313	7070					1467	1470		10.1136/bmj.313.7070.1467	http://dx.doi.org/10.1136/bmj.313.7070.1467			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	VX612	8973237	Green Published			2022-12-28	WOS:A1996VX61200037
J	Dunsmuir, RA; Allan, DB; Davidson, LAG				Dunsmuir, RA; Allan, DB; Davidson, LAG			Increased incidence of primary total hip replacement in rural communities	BRITISH MEDICAL JOURNAL			English	Article									SO GEN NHS TRUST,GLASGOW,LANARK,SCOTLAND; VICTORIA INFIRM NHS TRUST,GLASGOW,LANARK,SCOTLAND		Dunsmuir, RA (corresponding author), ROYAL COLL PHYS & SURG GLASGOW,GLASGOW G2 5RJ,LANARK,SCOTLAND.							CRAIG J, 1985, POPULATION TRENDS, V39, P16; GAVIN S, 1993, SCOTTISH NEEDS ASSES; 1995, REGISTRAR GEN SCOTLA	3	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1996	313	7069					1370	1370		10.1136/bmj.313.7069.1370	http://dx.doi.org/10.1136/bmj.313.7069.1370			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW685	8956705	Green Published			2022-12-28	WOS:A1996VW68500027
J	Colman, H; Nabekura, J; Lichtman, JW				Colman, H; Nabekura, J; Lichtman, JW			Alterations in synaptic strength preceding axon withdrawal	SCIENCE			English	Article							FROG NEUROMUSCULAR-JUNCTION; LONG-TERM POTENTIATION; TRANSMITTER RELEASE; SKELETAL-MUSCLE; NERVOUS-SYSTEM; ACETYLCHOLINE; ELIMINATION; INNERVATION; RECEPTORS; SYNAPSES	Permanent removal of axonal input to postsynaptic cells helps shape the pattern of neuronal connections in response to experience, but the process is poorly understood. Intracellular recording from newborn and adult mouse muscle fibers temporarily innervated by two axons showed an increasing disparity in the synaptic strengths of the two inputs before one was eliminated. The connection that survived gained strength by increasing the amount of neurotransmitter released (quantal content), whereas the input that was subsequently removed became progressively weaker, because of a reduction in quantal content and a reduction in quantal efficacy associated with reduced postsynaptic receptor density. Once the synaptic strengths of two inputs began to diverge, complete axonal withdrawal of the weaker input occurred within 1 to 2 days, These experiments provide a link between experience-driven changes in synaptic strength and long-term changes in connectivity in the mammalian nervous system.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Colman, Howard/L-5433-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034448, R01NS020364] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 34448, NS 20364] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBUQUERQUE EX, 1976, EXP NEUROL, V51, P536, DOI 10.1016/0014-4886(76)90179-5; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BALICEGORDON RJ, 1993, NEURON, V11, P801, DOI 10.1016/0896-6273(93)90110-D; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BETZ W, 1977, J PHYSIOL-LONDON, V270, P75, DOI 10.1113/jphysiol.1977.sp011939; BETZ WJ, 1989, J PHYSIOL-LONDON, V418, P25, DOI 10.1113/jphysiol.1989.sp017827; BIXBY JL, 1981, J NEUROCYTOL, V10, P81, DOI 10.1007/BF01181746; BRENNER HR, 1976, J PHYSIOL-LONDON, V260, P159, DOI 10.1113/jphysiol.1976.sp011509; BRENNER HR, 1976, J PHYSIOL-LONDON, V260, P143, DOI 10.1113/jphysiol.1976.sp011508; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; COTMAN CW, 1981, PHYSIOL REV, V61, P684, DOI 10.1152/physrev.1981.61.3.684; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P370, DOI 10.1113/jphysiol.1954.sp005114; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DENNIS MJ, 1981, DEV BIOL, V81, P266, DOI 10.1016/0012-1606(81)90290-6; ELMQVIST D, 1965, J PHYSIOL-LONDON, V177, P463, DOI 10.1113/jphysiol.1965.sp007605; GLAVINOVIC MI, 1987, J NEUROPHYSIOL, V58, P230, DOI 10.1152/jn.1987.58.1.230; GREENOUGH WT, 1988, TRENDS NEUROSCI, V11, P142, DOI 10.1016/0166-2236(88)90139-7; HARRIS JB, 1979, J PHYSIOL-LONDON, V296, P245, DOI 10.1113/jphysiol.1979.sp013003; HARTZELL HC, 1975, J PHYSIOL-LONDON, V251, P427, DOI 10.1113/jphysiol.1975.sp011102; JANSEN JKS, 1990, PROG NEUROBIOL, V34, P39, DOI 10.1016/0301-0082(90)90025-C; KATZ B, 1973, J PHYSIOL-LONDON, V231, P549, DOI 10.1113/jphysiol.1973.sp010248; KIDOKORO Y, 1980, DEV BIOL, V78, P231, DOI 10.1016/0012-1606(80)90332-2; KIDOKORO Y, 1980, DEV BIOL, V78, P464, DOI 10.1016/0012-1606(80)90347-4; KOMELIUSSEN H, 1976, J NEUROCYTOL, V5, P591; KUNO M, 1971, J PHYSIOL-LONDON, V213, P545, DOI 10.1113/jphysiol.1971.sp009399; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Lichtman Jeff W., 1995, Seminars in Developmental Biology, V6, P195, DOI 10.1016/S1044-5781(06)80029-0; Linden D J, 1993, Curr Opin Neurobiol, V3, P401, DOI 10.1016/0959-4388(93)90133-J; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; MAGLEBY KL, 1975, J PHYSIOL-LONDON, V244, P467, DOI 10.1113/jphysiol.1975.sp010808; MALGAROLI A, 1995, SCIENCE, V268, P1624, DOI 10.1126/science.7777862; NEGRETE J, 1972, NATURE-NEW BIOL, V235, P158, DOI 10.1038/newbio235158a0; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; PURVES D, 1980, SCIENCE, V210, P153, DOI 10.1126/science.7414326; REDFERN PA, 1970, J PHYSIOL-LONDON, V209, P701, DOI 10.1113/jphysiol.1970.sp009187; RICH MM, 1989, J NEUROSCI, V9, P1781, DOI 10.1523/jneurosci.09-05-01781.1989; ROSENTHAL JL, 1977, J PHYSIOL-LONDON, V270, P299, DOI 10.1113/jphysiol.1977.sp011953; SHAW G, 1986, EUR J CELL BIOL, V42, P1; SOHA JM, 1987, DEV BIOL, V123, P136, DOI 10.1016/0012-1606(87)90435-0; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; TAXT T, 1983, ACTA PHYSIOL SCAND, V117, P557, DOI 10.1111/j.1748-1716.1983.tb07226.x	42	214	215	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					356	361		10.1126/science.275.5298.356	http://dx.doi.org/10.1126/science.275.5298.356			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994026				2022-12-28	WOS:A1997WC87300037
J	Deeks, SG; Smith, M; Holodniy, M; Kahn, JO				Deeks, SG; Smith, M; Holodniy, M; Kahn, JO			HIV-1 protease inhibitors - A review for clinicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							IMMUNODEFICIENCY-VIRUS PROTEASE; IN-VIVO; PROTEINASE; RESISTANCE; RITONAVIR; VARIANTS; ABT-538; TYPE-1	Objective.-The clinical care of people infected with human immunodeficiency virus (HIV) has been substantially affected by the introduction of HIV-specific protease inhibitors (PIs). The 4 PIs available are saquinavir mesylate, ritonavir, indinavir sulfate, and nelfinavir mesylate. Comparison studies have not been reported; therefore, an assessment of the available data to aid clinicians and patients in choosing appropriate treatment will be presented. Data Sources.-A systematic review of peer-reviewed publications, abstracts from national and international conferences, and product registration information through September 1996. Study Selection and Data Extraction.-Criteria used to select studies include their relevance to PIs, having been published in the English language, and pertinence for clinicians. Data quality and validity included the venue of the publication and relevance to clinical care. Data Synthesis.-Oral adminstration of ritonavir, indinavir, or nelfinavir generates sustainable drug serum levels to effectively inhibit the protease enzyme; however, saquinavir may not generate sustained levels necessary to inhibit the protease enzyme. Patients treated with ritonavir, indinavir, or nelfinavir experience similar reductions in viral load and increases in CD4(+) lymphocytes; smaller effects occur among those treated with saquinavir. Two randomized placebo-controlled studies conducted among patients with severe immune system suppression and substantial zidovudine treatment experience demonstrated reduced HIV disease progression and reduced mortality with PI treatment. Genotypic resistance to PIs occurs; the clinical relevance of resistance is unclear. The costs of these agents including required monitoring impose new and substantial costs. Conclusions.-The PIs have emerged as critical drugs for people with HIV infection. Optimal use involves combination with reverse transcriptase inhibitors. Resistance develops to each agent, and cross-resistance is likely. These agents must be used at full doses with attention to ensuring patient compliance. The expense of these agents may be offset by forestalling disease progression and death and returning people to productive life. Selecting the initial PI must be individualized, and factors to consider include proven activity, possible toxicities, dosing regimens, drug interactions, and costs.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,SAN FRANCISCO,CA 94110; KAISER FAMILY FDN,PALO ALTO,CA; VET AFFAIRS PALO ALTO HLTH CARE SYST,PALO ALTO,CA; STANFORD UNIV,PALO ALTO,CA 94304	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University				Holodniy, Mark/0000-0002-6655-7982				*ABB PHARM, NORV RIT PACK INS; *ABB PHARM, 1996, NORV RIT PACK INS; *AG PHARM, VIR NELF MES AG1343; [Anonymous], CRIX IND SULF PACK I; BERRY P, 1996, 11 INT C AIDS JUL 7; BOUCHER C, 1996, 5 INT WORKSH HIV DRU; CAMERON DW, 1996, 11 INT C AIDS JUL 7; CAMERON W, 1996, 3 C RETR OPP INF JAN; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; COHEN C, 1996, 36 INT C ANT AG CHEM; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CONDRA JH, 1996, 11 INT C AIDS JUL 7; CONDRA JH, 1996, 3 C RETR OPP INF JAN; CRAIG JC, 1991, ANTIVIR RES, V16, P295, DOI 10.1016/0166-3542(91)90045-S; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; EBERLE J, 1995, AIDS RES HUM RETROV, V11, P671, DOI 10.1089/aid.1995.11.671; EMINI E, 1996, 11 INT C AIDS JUL 7; FORNATARO K, 1995, ACCESS PROJECT REPOR; GATHE J, 1996, 11 INT C AIDS JUL 7; GULICK R, 1996, 3 C RETR OPP INF JAN; GULICK RM, 1996, 11 INT C AIDS JUL 7; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HEATHCHIOZZI M, 1996, 3 C RETR OPP INF JAN; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; *INF MARK SYST AM, 1996, NAT PRESCR AUD; Jacobsen H, 1996, J INFECT DIS, V173, P1379, DOI 10.1093/infdis/173.6.1379; KELLY JF, 1996, FISCAL STATUS STATE; KEMPF DJ, 1991, ANTIMICROB AGENTS CH, V35, P2209, DOI 10.1128/AAC.35.11.2209; KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KORNEYEVA M, 1996, 11 INT C AIDS JUL 7; LALEZARI J, 1996, 11 INT C AIDS JUL 7; MARKOWITZ M, 1995, J VIROL, V69, P701, DOI 10.1128/JVI.69.2.701-706.1995; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; MARKOWITZ M, 1996, 11 INT C AIDS JUL 7; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; MONTANER J, 1996, 36 INT C ANT AG CHEM; NABULSI A, 1996, 11 INT C AIDS JUL 7; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; NORBECK D, 1995, 35 INT C ANT AG CHEM; PATICK AK, 1966, 5 INT WORKSH HIV DRU; *PEOPL AIDS HLTH G, 1996, PROT INH AT A GLANC; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PERELSON AS, 1996, 11 INT C AIDS JUL 7; POLLARD R, 1996, 11 INT C AIDS JUL 7; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; *ROCH LAB HOFFM LA, INV SAQ MES PACK INS; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; SALMINEN MO, 1996, 11 INT C AIDS JUL 7; Schapiro JM, 1996, ANN INTERN MED, V124, P1039, DOI 10.7326/0003-4819-124-12-199606150-00003; VACA JP, 1994, P NATL ACAD SCI USA, V91, P4096; WINSLOW R, 1996, WALL ST J       0402, pA2; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	58	648	657	0	184	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1997	277	2					145	153		10.1001/jama.277.2.145	http://dx.doi.org/10.1001/jama.277.2.145			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA650	8990341				2022-12-28	WOS:A1997WA65000036
J	Barnett, AH; Owens, DR				Barnett, AH; Owens, DR			Insulin analogues	LANCET			English	Article							SOLUBLE HUMAN INSULIN; MONOMERIC INSULINS; PHARMACOKINETICS; ABSORPTION; BASAL; IDDM		BIRMINGHAM HEARTLANDS HOSP,NHS TRUST TEACHING,BIRMINGHAM B9 5SS,W MIDLANDS,ENGLAND; UNIV WALES,COLL MED,DIABET RES UNIT,PENARTH,S GLAM,WALES; LLANDOUGH HOSP & COMMUNITY NHS TRUST,PENARTH,S GLAM,WALES	Heart of England NHS Foundation Trust; University of Birmingham	Barnett, AH (corresponding author), UNIV BIRMINGHAM,DEPT MED,BIRMINGHAM B9 5SS,W MIDLANDS,ENGLAND.							ANDERSON J, 1994, DIABETES, V43, pA61; ANDERSON JH, 1995, DIABETES, V44, pA228; ANDERSON JH, 1994, DIABETOLOGIA, V37, pA169; BRANGE J, 1988, NATURE, V333, P679, DOI 10.1038/333679a0; BRANGE J, 1990, DIABETES CARE, V13, P923, DOI 10.2337/diacare.13.9.923; BREMS DN, 1992, PROTEIN ENG, V5, P527, DOI 10.1093/protein/5.6.527; CISZAK E, 1995, STRUCTURE, V3, P615, DOI 10.1016/S0969-2126(01)00195-2; COATES PA, 1995, DIABETES, V44, pA130; DeFelippis M.R., 1996, DIABETES S2, V45, p74A; DIMARCHI RD, 1994, HORM RES, V41, P93, DOI 10.1159/000183967; DREJER K, 1992, DIABETES METAB REV, V8, P259, DOI 10.1002/dmr.5610080305; FINEBERG SE, 1995, DIABETES S1, V44, pA23; GALLOWAY JA, 1994, DIABETES ANN, V8, P277; Hansen BF, 1996, BIOCHEM J, V315, P271; HEINEMANN L, 1993, DIABETIC MED, V10, P535, DOI 10.1111/j.1464-5491.1993.tb00116.x; HOWEY DC, 1994, DIABETES, V43, P396, DOI 10.2337/diabetes.43.3.396; JORGENSEN S, 1989, BRIT MED J, V299, P415, DOI 10.1136/bmj.299.6696.415; KANG S, 1991, DIABETES CARE, V14, P571, DOI 10.2337/diacare.14.7.571; KANG S, 1991, DIABETES CARE, V14, P1057, DOI 10.2337/diacare.14.11.1057; KANG S, 1991, DIABETES CARE, V14, P942, DOI 10.2337/diacare.14.11.942; KOTSANOS JG, 1994, 15 INT DIAB FED C S1, V43, pA155; Markussen J, 1996, DIABETOLOGIA, V39, P281; NIELSEN FS, 1995, DIABETOLOGIA, V38, P592, DOI 10.1007/BF00400729; OWENS DR, 1986, THESIS LANCASTER; PEKAR AH, 1972, BIOCHEMISTRY-US, V11, P4013, DOI 10.1021/bi00772a001; Pfutzner A, 1996, EXP CLIN ENDOCR DIAB, V104, P25; RIBEL U, 1990, DIABETES, V39, P1033, DOI 10.2337/diabetes.39.9.1033; Round P. M., 1996, Diabetologia, V39, pA24; ROWE R, 1996, DIABETES S2, V45, pA71; SHAW WN, 1991, DIABETES S1, V40, pA464; SLIEKER LJ, 11 EL LILL CO; SLIEKER LJ, 1994, INSULIN IGF I ANALOG, P25; SLIEKER LJ, 1991, DIABETES S1, V40, pA168; TALAULICAR M, 1996, DIABETES STOFFWECH H, V5, P3; TORLONE E, 1994, DIABETOLOGIA, V37, P713, DOI 10.1007/s001250050169; Torlone E, 1996, DIABETES CARE, V19, P945, DOI 10.2337/diacare.19.9.945; TORLONE E, 1995, DIABETOLOGIA, V38, pA190; ZIMMERMANN J, 1994, DIABETES S1, V4, pA166; ZINMAN B, 1989, NEW ENGL J MED, V321, P363	39	103	118	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					47	51		10.1016/S0140-6736(96)06032-1	http://dx.doi.org/10.1016/S0140-6736(96)06032-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988131				2022-12-28	WOS:A1997WA72500046
J	Lund, JN; Scholefield, JH				Lund, JN; Scholefield, JH			A randomised, prospective, double-blind, placebo-controlled trial of glyceryl trinitrate ointment in treatment of anal fissure	LANCET			English	Article							INTERNAL SPHINCTEROTOMY; TOPICAL NITROGLYCERIN	Background Anal fissure is most commonly treated surgically by internal anal sphincterotomy. However, there is some concern over the effects of this procedure on continence. Nitric oxide donors such as glyceryl trinitrate (GTN) have been shown to cause a reversible chemical sphincterotomy capable of healing fissures in a small series of cases. This study reports a prospective, randomised, double-blind, placebo-controlled trial to test the hypothesis that topical GTN is the best first-line treatment for chronic anal fissure. Methods 80 consecutive patients were randomised to receive treatments with topical 0.2% GTN ointment or placebo. Maximum anal resting pressure (MARP) was measured with a constantly perfused side-hole catheter before and after the first application of trial ointment. Anodermal blood flow was measured during manometry by laser Doppler flowmetry. After initial treatments, patients were given a supply of ointment (either GTN or placebo) to be applied to the lower anal canal twice daily. Patients were reviewed 2-weekly. At the initial and follow up visits patients were asked to record pain experienced on defaecation on a linear analogue pain score. Endpoints were healing of the fissure or condition after 8 weeks of treatment. Findings After 8 weeks, healing was observed in 26/38 (68%) patients treated with GTN and in 3/39 (8%) patients treated with placebo (p<0.0001, chi(2) test). Linear analogue pain score fell significantly in both groups after 2 weeks of treatment. This fail was maintained in those treated with GTN but pain scores returned to pre-treatment values by 4 weeks on treatment with placebo. MARP fell significantly from a mean of 115.9 (SD 31.6) to 75.9 (30.1) cm H2O (p<0.001, Student's paired t-test) in patients treated with GTN but no change was seen in MARP after placebo. Anodermal blood flow measured by laser Doppler flowmetry significantly increased after application of GTN ointment but was unaffected by placebo. Interpretation Topical GTN provides rapid, sustained relief of pain in patients with anal fissure, Over two-thirds of patients treated in this way avoided surgery which would otherwise have been required for healing. Long-term follow up is needed to assess the risk of recurrent fissure in patients with GTN.	UNIV NOTTINGHAM HOSP,DEPT SURG,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham			Lund, Jonathan/K-6631-2019	Lund, Jonathan/0000-0001-5195-2181	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABCARIAN H, 1980, DIS COLON RECTUM, V23, P31, DOI 10.1007/BF02587197; FREZZA EE, 1992, INT J COLORECTAL DIS, V7, P188, DOI 10.1007/BF00341218; FUNG HL, 1993, AM J CARDIOL, V72, pC9, DOI 10.1016/0002-9149(93)90249-C; GIBBONS CP, 1986, BRIT J SURG, V73, P443, DOI 10.1002/bjs.1800730609; GORFINE SR, 1995, DIS COLON RECTUM, V38, P453, DOI 10.1007/BF02148842; GORFINE SR, 1995, NEW ENGL J MED, V333, P1156, DOI 10.1056/NEJM199510263331718; GORFINE SR, 1995, DIS COLON RECTUM, V38, P456; JENSEN SL, 1986, BRIT MED J, V292, P1167, DOI 10.1136/bmj.292.6529.1167; KHUBCHANDANI IT, 1989, BRIT J SURG, V76, P431, DOI 10.1002/bjs.1800760504; KLOSTERHALFEN B, 1989, DIS COLON RECTUM, V32, P43, DOI 10.1007/BF02554725; LOCK MR, 1977, BRIT J SURG, V64, P355, DOI 10.1002/bjs.1800640516; LODER PB, 1994, BRIT J SURG, V81, P1386, DOI 10.1002/bjs.1800810949; Lund JN, 1996, BRIT J SURG, V83, P776, DOI 10.1002/bjs.1800830615; Lund JN, 1996, GASTROENTEROLOGY, V110, pA711; MANGIONE NJ, 1994, AM HEART J, V128, P137, DOI 10.1016/0002-8703(94)90020-5; Milito G, 1983, Ital J Surg Sci, V13, P275; OKelly TJ, 1996, ANN ROY COLL SURG, V78, P31; Schouten WR, 1996, BRIT J SURG, V83, P63, DOI 10.1002/bjs.1800830120; SCHOUTEN WR, 1995, DIS COLON RECTUM, V37, pP9; SULTAN AH, 1994, DIS COLON RECTUM, V37, P1031, DOI 10.1007/BF02049319; Watson SJ, 1996, BRIT J SURG, V83, P771, DOI 10.1002/bjs.1800830614	21	257	266	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					11	14		10.1016/S0140-6736(96)06090-4	http://dx.doi.org/10.1016/S0140-6736(96)06090-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988115				2022-12-28	WOS:A1997WA72500009
J	Andreopoulos, S				Andreopoulos, S			The folly of teaching-hospital mergers	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									STANFORD UNIV,MED CTR,STANFORD,CA 94305	Stanford University								ANDREOPOULOS S, 1996, STANFORD REPORT 0529, P3; FAGIN CM, 1996, NY TIMES        0822, pA22; HOWART G, 1996, STAR TRIBUNE    0806, pA1; JONES RF, 1996, ACAD MED, V71, P299; Kuttner R, 1996, NEW ENGL J MED, V335, P446, DOI 10.1056/NEJM199608083350620; LAGNADO L, 1996, WALL STREET J   0725, pB11; LUMSDON K, 1995, HOSP HEALTH NETWORK, V69, P44; MENDELSON MA, 1974, TENDER LOVING GREED; MOYNIHAN DP, 1996, NY TIMES        0806, pA16; *PEW HLTH PROF COM, 1995, 3 UCSF CTR HLTH PROF, P1; PHAM A, 1996, BOSTON GLOBE    0713, pB65; Reardon J, 1995, J ECON ISSUES, V29, P1063, DOI 10.1080/00213624.1995.11505740; ROUSH W, 1995, SCIENCE, V268, P1553; ROUSH W, 1995, SCIENCE, V268, P968, DOI 10.1126/science.7754390; Thompson JC, 1996, ANN SURG, V223, P453, DOI 10.1097/00000658-199605000-00001; WALLACE A, 1996, LOS ANGELES TIM 0719, pA3; WATANABE ME, 1996, SCIENTIST       0401, P1	17	30	30	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1997	336	1					61	64		10.1056/NEJM199701023360111	http://dx.doi.org/10.1056/NEJM199701023360111			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA496	8970943				2022-12-28	WOS:A1997WA49600012
J	vanWassenaer, AG; Kok, JH; deVijlder, JJM; Briet, JM; Smit, BJ; Tamminga, P; vanBaar, A; Dekker, FW; Vulsma, T				vanWassenaer, AG; Kok, JH; deVijlder, JJM; Briet, JM; Smit, BJ; Tamminga, P; vanBaar, A; Dekker, FW; Vulsma, T			Effects of thyroxine supplementation on neurologic development in infants born at less than 30 weeks' gestation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-DISTRESS SYNDROME; BIRTH-WEIGHT INFANTS; PREMATURE-INFANTS; THYROID-HORMONES; PRETERM INFANTS; AGE; HYPOTHYROXINEMIA; TRIIODOTHYRONINE; HYPOTHYROIDISM; ULTRASOUND	Background Premature infants who have transient hypothyroxinemia in the first weeks of life may have developmental delay and neurologic dysfunction. Whether thyroxine treatment during this period results in improved developmental outcomes is not known. Methods We carried out a randomized, placebo-controlled, double-blind trial of thyroxine supplementation in 200 infants born at less than 30 weeks' gestation. Thyroxine (8 mu g per kilogram of birth weight) or placebo was administered daily, starting 12 to 24 hours after birth, for six weeks. Plasma free thyroxine concentrations were measured weekly for the first eight weeks after birth. Scores on the Bayley Mental and Psychomotor Development Indexes and neurologic function were assessed at 6, 12, and 24 months of age (corrected for prematurity). Results Mortality and morbidity up to the time of discharge from the hospital were similar in the study groups. At 24 months of age, 157 infants were evaluated. Overall, neither mental nor psychomotor scores differed significantly between the study groups at any time, nor was the frequency of abnormal neurologic outcome significantly different. In thyroxine-treated infants born at gestational ages of less than 27 weeks, the score on the Bayley Mental Development Index at 24 months of age was 18 points higher than the score for the infants with similar gestational ages at birth in the placebo group (P=0.01); for thyroxine-treated infants born at 27 weeks or later, the mental-development score was 10 points lower than that of their counterparts in the placebo group (P=0.03). There was no relation between the initial plasma free thyroxine concentration and the effect of treatment. Conclusions In infants born before 30 weeks' gestation, thyroxine supplementation does not improve the developmental outcome at 24 months. (C)1997, Massachusetts Medical Society.	UNIV AMSTERDAM,ACAD MED CTR,DEPT PEDIAT ENDOCRINOL,NL-1100 DE AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,NL-1100 DE AMSTERDAM,NETHERLANDS; EMMA CHILDRENS HOSP,AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Emma Children's Hospital; University of Amsterdam	vanWassenaer, AG (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT NEONATOL,POB 22700,NL-1100 DE AMSTERDAM,NETHERLANDS.		Dekker, Friedo W/B-6452-2011; van Baar, Anneloes/L-8236-2013	Dekker, Friedo W/0000-0002-2433-2494; van Baar, Anneloes/0000-0002-3498-9019				BELLABARBA D, 1984, BIOL NEONATE, V45, P41; CHOWDHRY P, 1984, PEDIATRICS, V73, P301; CUESTAS RA, 1978, J PEDIATR-US, V92, P963, DOI 10.1016/S0022-3476(78)80378-3; DenOuden AL, 1996, PEDIATR RES, V39, P142, DOI 10.1203/00006450-199601000-00021; DEVRIES LS, 1992, BEHAV BRAIN RES, V49, P1, DOI 10.1016/S0166-4328(05)80189-5; DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5; FISHER DA, 1990, PEDIATR CLIN N AM, V37, P1297; Frank JE, 1996, J PEDIATR-US, V128, P548, DOI 10.1016/S0022-3476(96)70368-2; GARDNER MJ, 1989, STAT CONFIDENCE CONF; HACK M, 1994, NEW ENGL J MED, V331, P753, DOI 10.1056/NEJM199409223311201; HADEED AJ, 1981, PEDIATRICS, V68, P494; Harkavy K L, 1991, J Perinatol, V11, P117; HEMPEL MS, 1993, THESIS U GRONINGEN G; JACOBSEN BB, 1979, ACTA PAEDIATR SCAND, V68, P257, DOI 10.1111/j.1651-2227.1979.tb04998.x; KOK JH, 1985, THESIS U AMSTERDAM A; LEVENE MI, 1981, ARCH DIS CHILD, V56, P900, DOI 10.1136/adc.56.12.900; LUCAS A, 1988, ARCH DIS CHILD, V63, P1201, DOI 10.1136/adc.63.10.1201; MERCADO M, 1988, EARLY HUM DEV, V16, P131, DOI 10.1016/0378-3782(88)90093-X; NICHOLSON JL, 1972, SCIENCE, V176, P530, DOI 10.1126/science.176.4034.530; Reuss ML, 1996, NEW ENGL J MED, V334, P821, DOI 10.1056/NEJM199603283341303; SILVA JE, 1984, J CLIN INVEST, V74, P1035, DOI 10.1172/JCI111471; TIMIRAS PS, 1989, BIOL NEONATE, V55, P376; Touwen B.C., 1976, NEUROLOGICAL DEV INF; UHRMANN S, 1981, ARCH DIS CHILD, V56, P214, DOI 10.1136/adc.56.3.214; VANDERMEULEN BF, 1983, BOS 2 30 BAYLEYONTWI; VANWASSENAER AG, 1993, ACTA ENDOCRINOL-COP, V129, P139, DOI 10.1530/acta.0.1290139; VEEN S, 1991, LANCET, V338, P33, DOI 10.1016/0140-6736(91)90015-H; VOLPE JJ, 1987, MAJOR PROBLEMS CLIN, V22, P331	28	201	201	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1997	336	1					21	26		10.1056/NEJM199701023360104	http://dx.doi.org/10.1056/NEJM199701023360104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA496	8970936	Green Published			2022-12-28	WOS:A1997WA49600004
J	Gamble, TR; Vajdos, FF; Yoo, SH; Worthylake, DK; Houseweart, M; Sundquist, WI; Hill, CP				Gamble, TR; Vajdos, FF; Yoo, SH; Worthylake, DK; Houseweart, M; Sundquist, WI; Hill, CP			Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CIS-TRANS ISOMERASE; X-RAY STRUCTURE; CYCLOSPORINE-A; PARTICLE FORMATION; BINDING-PROTEIN; HOMOLOG NINAA; SUBSTRATE; COMPLEX; INFECTIVITY	The HIV-1 capsid protein forms the conical core structure at the center of the mature virion. Capsid also binds the human peptidyl prolyl isomerase, cyclophilin A, thereby packaging the enzyme into the virion. Cyclophilin A subsequently performs an essential function in HIV-1 replication, possibly helping to disassemble the capsid core upon infection. We report the 2.36 Angstrom crystal structure of the N-terminal domain of HIV-1 capsid (residues 1-151) in complex with human cyclophilin A. A single exposed capsid loop (residues 85-93) binds in the enzyme's active site, and Pro-90 adopts an unprecedented trans conformation. The structure suggests how cyclophilin A can act as a sequence-specific binding protein and a nonspecific prolyl isomerase. In the crystal lattice, capsid molecules assemble into continuous planar strips. Side by side association of these strips may allow capsid to form the surface of the viral core. Cyclophilin A could then function by weakening the association between capsid strips, thereby promoting disassembly of the viral core.	UNIV UTAH,DEPT BIOCHEM,SALT LAKE CITY,UT 84103	Utah System of Higher Education; University of Utah				Vajdos, Felix/0000-0002-8256-2087				Aberham C, 1996, J VIROL, V70, P3536, DOI 10.1128/JVI.70.6.3536-3544.1996; ANDERSON SK, 1993, P NATL ACAD SCI USA, V90, P542, DOI 10.1073/pnas.90.2.542; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; BILLICH A, 1995, J VIROL, V69, P2451, DOI 10.1128/JVI.69.4.2451-2461.1995; Braaten D, 1996, J VIROL, V70, P3551, DOI 10.1128/JVI.70.6.3551-3560.1996; Braaten D, 1996, J VIROL, V70, P5170, DOI 10.1128/JVI.70.8.5170-5176.1996; Braaten D, 1996, J VIROL, V70, P4220, DOI 10.1128/JVI.70.7.4220-4227.1996; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Colgan J, 1996, J VIROL, V70, P4299, DOI 10.1128/JVI.70.7.4299-4310.1996; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DORFMAN T, 1994, J VIROL, V68, P8180, DOI 10.1128/JVI.68.12.8180-8187.1994; DORFMAN T, 1993, J VIROL, V67, P6159, DOI 10.1128/JVI.67.10.6159-6169.1993; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FRANKE EK, 1994, J VIROL, V68, P5300, DOI 10.1128/JVI.68.8.5300-5305.1994; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; GELDERBLOM HR, 1992, MEMBRANE INTERACTION, P33; Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; HUNTER E, 1994, SEMIN VIROL, V5, P71, DOI 10.1006/smvy.1994.1008; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOWETT JBM, 1992, J GEN VIROL, V73, P3079, DOI 10.1099/0022-1317-73-12-3079; KAKALIS LT, 1994, BIOCHEMISTRY-US, V33, P1495, DOI 10.1021/bi00172a028; KALLEN J, 1992, FEBS LETT, V300, P286, DOI 10.1016/0014-5793(92)80865-E; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KE HM, 1993, P NATL ACAD SCI USA, V90, P3324, DOI 10.1073/pnas.90.8.3324; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MCCLURE MA, 1991, MOL BIOL EVOL, V8, P835; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; MYERS G, 1995, HUMAN RETROVIRUSES A; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PFLUGL G, 1993, NATURE, V361, P91, DOI 10.1038/361091a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REICIN AS, 1995, J VIROL, V69, P642, DOI 10.1128/JVI.69.2.642-650.1995; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHUTKOWSKI M, 1995, BIOCHEMISTRY-US, V34, P13016, DOI 10.1021/bi00040a012; STAMNES M A, 1992, Trends in Cell Biology, V2, P272, DOI 10.1016/0962-8924(92)90200-7; STEINKASSERER A, 1995, J VIROL, V69, P814, DOI 10.1128/JVI.69.2.814-824.1995; SYKES K, 1993, P NATL ACAD SCI USA, V90, P5853, DOI 10.1073/pnas.90.12.5853; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; THERIAULT Y, 1993, NATURE, V361, P88, DOI 10.1038/361088a0; TRABER R, 1994, ANTIVIR CHEM CHEMOTH, V5, P331, DOI 10.1177/095632029400500507; VONPOBLOTZKI A, 1993, VIROLOGY, V193, P981, DOI 10.1006/viro.1993.1210; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WANG CT, 1993, J VIROL, V67, P4264, DOI 10.1128/JVI.67.7.4264-4273.1993; Weisman R, 1996, EMBO J, V15, P447, DOI 10.1002/j.1460-2075.1996.tb00377.x; WOLFENDEN R, 1991, CHEMTRACTS BIOCH MOL, V2, P52; Zhao YD, 1996, BIOCHEMISTRY-US, V35, P7356, DOI 10.1021/bi9602775; Zhao YD, 1996, BIOCHEMISTRY-US, V35, P7362, DOI 10.1021/bi960278x	60	596	612	4	36	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1285	1294		10.1016/S0092-8674(00)81823-1	http://dx.doi.org/10.1016/S0092-8674(00)81823-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980234	Bronze			2022-12-28	WOS:A1996WA54100016
J	Sauer, F; Wassarman, DA; Rubin, GM; Tjian, R				Sauer, F; Wassarman, DA; Rubin, GM; Tjian, R			TAF(II)s mediate activation of transcription in the Drosophila embryo	CELL			English	Article							COACTIVATOR REQUIREMENTS; BINDING PROTEIN; BICOID PROTEIN; COMPLEX; HUNCHBACK; EXPRESSION; PROMOTER; ANTERIOR; PATTERN; EYE	Mutations in the genes for two highly conserved TAFs, TAF(II)60 and TAF(II)110, reduce transcription of Bicoid-dependent target genes in vivo. By means of several distinct genetic test systems, specific activator-TAF interactions are shown to support both simple and synergistic enhancement of transcription in the embryo. These studies provide in vivo evidence that TAFs can serve as coactivators to receive gene-specific transcriptional activation signals. This genetic system also presents the opportunity to study the function of basal transcription components in regulating development of complex organisms.			Sauer, F (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOL & CELL BIOL,BERKELEY,CA 94720, USA.			Rubin, Gerald/0000-0001-8762-8703				Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BOWTELL DDL, 1989, P NATL ACAD SCI USA, V86, P6245, DOI 10.1073/pnas.86.16.6245; BRONNER G, 1994, NATURE, V369, P664, DOI 10.1038/369664a0; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1990, DEVELOPMENT, V109, P811; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HOCH M, 1993, CURR OPIN GENET DEV, V3, P566, DOI 10.1016/0959-437X(93)90092-4; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Jackle H, 1993, CURR OPIN CELL BIOL, V5, P505, DOI 10.1016/0955-0674(93)90017-K; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; Karim FD, 1996, GENETICS, V143, P315; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MARGOLIS JS, 1995, DEVELOPMENT, V121, P3067; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; MOSES K, 1991, GENE DEV, V5, P583, DOI 10.1101/gad.5.4.583; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SAUER F, 1995, SCIENCE, V270, P1825, DOI 10.1126/science.270.5243.1825; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; STJOHNSTON D, 1992, CELL, V68, P201; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thummel CS, 1992, DROS INF SERV, V71, P150; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235	45	63	65	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1271	1284		10.1016/S0092-8674(00)81822-X	http://dx.doi.org/10.1016/S0092-8674(00)81822-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980233	Bronze			2022-12-28	WOS:A1996WA54100015
J	deCraen, AJM; Roos, PJ; deVries, AL; Kleijnen, J				deCraen, AJM; Roos, PJ; deVries, AL; Kleijnen, J			Effect of colour of drugs: Systematic review of perceived effect of drugs and of their effectiveness	BRITISH MEDICAL JOURNAL			English	Article							CAPSULE COLOR; EXPECTATIONS	Objectives-To assess the impact of the colour of a drug's formulation on its perceived effect and its effectiveness and to examine whether antidepressant drugs available in the Netherlands are different in colour fi om hypnotic, sedative, and anxiolytic drugs. Design-Systematic review of 12 published studies, Six studies examined the perceived action of different coloured drugs and six the influence of the colour of a drug on its effectiveness. The colours of samples of 49 drugs affecting the central nervous system were assessed using a colour atlas. Main outcome measures-Perceived stimulant action versus perceived depressant action of colour of drugs; the trials that assessed the effect of drugs in different colours were done in patients with different diseases and had different outcome measures. Results-The studies on perceived action of coloured drugs showed that red, yellow, and orange are associated with a stimulant effect, while blue and green are related to a tranquillising effect. The trials that assessed the impact of the colour of drugs on their effectiveness showed inconsistent differences between colours. The quality of the methods of these trials was variable. Hypnotic, sedative, and anxiolytic drugs were more likely than antidepressants to be green, blue, or purple. Conclusion-Colours affect the perceived action of a drug and seem to influence the effectiveness of a drug. Moreover, a relation exists between the colouring of drugs that affect the central nervous system and the indications for which they are used. Research contributing to a better understanding of the effect of the colour of drugs is warranted.	UNIV AMSTERDAM,ACAD MED CTR,DEPT HOSP PHARM,NL-1100 DE AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam	deCraen, AJM (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,POB 22700,NL-1100 DE AMSTERDAM,NETHERLANDS.							ADAMS FM, 1973, J CROSS CULT PSYCHOL, V4, P135, DOI 10.1177/002202217300400201; BLACKWELL B, 1972, LANCET, V1, P1279; BUCKALEW LW, 1982, PERCEPT MOTOR SKILL, V55, P915, DOI 10.2466/pms.1982.55.3.915; BUCKALEW LW, 1982, J CLIN PSYCHOPHARM, V2, P245; BUCKALEW LW, 1991, DRUG DEVELOP RES, V23, P101, DOI 10.1002/ddr.430230202; CATTANEO AD, 1970, EUR J CLIN PHARMACOL, V3, P43, DOI 10.1007/BF00560290; HURDLE ADF, 1956, LANCET, V1, P836; HUSKISSON EC, 1974, BMJ-BRIT MED J, V4, P196, DOI 10.1136/bmj.4.5938.196; HUSSAIN MZ, 1972, BRIT J PSYCHIAT, V120, P507, DOI 10.1192/bjp.120.558.507; *INT MED STAT, 1994, MED IND; JACOBS KW, 1979, PERCEPT MOTOR SKILL, V49, P367, DOI 10.2466/pms.1979.49.2.367; JOLLY H, 1958, LANCET, V1, P1308; KLEIJNEN J, 1994, LANCET, V344, P1347, DOI 10.1016/S0140-6736(94)90699-8; LUCCHELLI PE, 1978, EUR J CLIN PHARMACOL, V13, P153, DOI 10.1007/BF00609760; Nagao Y, 1968, Shikwa Gakuho, V68, P139; *REICHS AUSSCH LIE, DTSCH I GUT KENNZ EV; SALLIS RE, 1984, PERCEPT MOTOR SKILL, V58, P897, DOI 10.2466/pms.1984.58.3.897; SCHAPIRA K, 1970, BMJ-BRIT MED J, V2, P446, DOI 10.1136/bmj.2.5707.446; SEBELLICO A, 1989, Bollettino Societa Italiana Biologia Sperimentale, V65, P685	19	178	181	3	24	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1624	1626		10.1136/bmj.313.7072.1624	http://dx.doi.org/10.1136/bmj.313.7072.1624			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991013	Green Published			2022-12-28	WOS:A1996VZ81100045
J	Mosley, JG; Gibbs, ACC				Mosley, JG; Gibbs, ACC			Premature grey hair and hair loss among smokers: A new opportunity for health education?	BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION; BALDNESS		CHRISTIE HOSP,CTR CANC EPIDEMIOL,MANCHESTER M20 4QL,LANCS,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Mosley, JG (corresponding author), LEIGH INFIRM,LEIGH WN7 1HS,LANCS,ENGLAND.							ARMITAGE P, 1994, STAT METHODS MED RES, P515; BULPITT CJ, 1994, AGING-CLIN EXP RES, V6, P181, DOI 10.1007/BF03324236; LESKO SM, 1993, JAMA-J AM MED ASSOC, V269, P998, DOI 10.1001/jama.269.8.998; MODEL D, 1985, BMJ-BRIT MED J, V291, P1760, DOI 10.1136/bmj.291.6511.1760; SCHNOHR P, 1995, AM HEART J, V130, P1003, DOI 10.1016/0002-8703(95)90201-5	5	49	49	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1616	1616		10.1136/bmj.313.7072.1616	http://dx.doi.org/10.1136/bmj.313.7072.1616			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991008	Green Published			2022-12-28	WOS:A1996VZ81100039
J	Nieuwenhuis, HK; Sixma, JJ				Nieuwenhuis, HK; Sixma, JJ			Haematology - New irons in the fire	LANCET			English	Article											Nieuwenhuis, HK (corresponding author), UNIV UTRECHT HOSP,DEPT HAEMATOL,POB 85500,NL-3508 GA UTRECHT,NETHERLANDS.							Barrett AJ, 1996, BRIT J HAEMATOL, V93, P754, DOI 10.1046/j.1365-2141.1996.d01-1713.x; Bhatia S, 1996, NEW ENGL J MED, V334, P745, DOI 10.1056/NEJM199603213341201; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Santos M, 1996, J EXP MED, V184, P1975, DOI 10.1084/jem.184.5.1975	5	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348			2			SII9	SII9						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973487				2022-12-28	WOS:A1996WA46300009
J	Nylenna, M; Aasland, OG; Falkum, E				Nylenna, M; Aasland, OG; Falkum, E			Survey of Norwegian doctors' cultural activities	LANCET			English	Article								Background During the past few decades the need for humanities in medical education has been increasingly emphasised. We sought to find out how doctors meet their cultural needs during their spare time, in comparison with other university graduates. We also aimed, in this Norwegian survey, to analyse differences between doctors according to various professional characteristics. Methods 1041 Norwegian doctors (71% of those approached) reported their cultural activities through a postal survey. Their replies were compared with those of 224 university graduates who had taken part in a similar survey by Statistics Norway in 1991. Findings The doctors spent less time than the other graduates on reading newspapers and watching television, though they were more musically active and 18% play at least one instrument regularly. No other differences were apparent. The more time doctors spent on medical reading, the more time they also devoted to non-medical reading. No systematic differences in cultural activity according to medical specialty were found, but women were more culturally active than men. Interpretation The high work-load and demands of medical practice do not limit doctors' cultural life. Spare-time cultural activities among doctors seem to be determined more by personal than by professional characteristics.	NORWEGIAN PROGRAM PHYSICIAN HLTH & WELF,OSLO,NORWAY; NORWEGIAN MED ASSOC,N-0107 OSLO,NORWAY		Nylenna, M (corresponding author), JOURNAL NORWEGIAN MED ASSOC,LYSAKER,NORWAY.							Aasland O G, 1994, Tidsskr Nor Laegeforen, V114, P3052; Aasland Olaf Gjerlow, 1993, Tidsskrift for den Norske Laegeforening, V113, P3737; Calman K, 1996, LANCET, V347, P1499, DOI 10.1016/S0140-6736(96)90665-0; CHARON R, 1995, ANN INTERN MED, V122, P599, DOI 10.7326/0003-4819-122-8-199504150-00008; COLES R, 1987, JAMA-J AM MED ASSOC, V257, P1644, DOI 10.1001/jama.257.12.1644; Falkum E, 1996, SHAPING PROFESSION P, P481; Hofoss Dag, 1994, Tidsskrift for den Norske Laegeforening, V114, P3059; Horowitz HW, 1996, LANCET, V347, P447, DOI 10.1016/S0140-6736(96)90015-X; Karasek R., 1990, HLTH WORK STRESS PRO; McLellan MF, 1996, LANCET, V348, P109, DOI 10.1016/S0140-6736(96)03521-0; RISKA E, 1994, HLTH PROFESSIONS STA, P200; ROTHMAN DJ, 1991, STRANGER BEDSIDE, P137; SPIEGL F, 1990, BRIT MED J, V301, P1454, DOI 10.1136/bmj.301.6766.1454; VAAGE OF, 1992, 9212 STAT NORW; WARREN KS, 1984, ANN INTERN MED, V101, P697, DOI 10.7326/0003-4819-101-5-697	15	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1692	1694		10.1016/S0140-6736(96)06459-8	http://dx.doi.org/10.1016/S0140-6736(96)06459-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973431				2022-12-28	WOS:A1996VZ76600011
J	Ribera, E; GomezJimenez, J; Cortes, E; delValle, O; Planes, A; GonzalezAlujas, MT; Almirante, B; Ocana, I; Pahissa, A				Ribera, E; GomezJimenez, J; Cortes, E; delValle, O; Planes, A; GonzalezAlujas, MT; Almirante, B; Ocana, I; Pahissa, A			Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						Staphylococcus aureus; cloxacillin; gentamicins; endocarditis, bacterial; substance abuse, intravenous	COMBINATION ANTIBIOTIC-THERAPY; INTRAVENOUS DRUG-ABUSERS; INFECTIVE ENDOCARDITIS; BACTERIAL-ENDOCARDITIS; HEROIN-ADDICTS; USERS; SINGLE	Background: It is often difficult to administer extended antibiotic therapy in the hospital for right-sided Staphylococcus aureus endocarditis. Although the effectiveness of single-drug therapy given for 4 to 6 weeks and that of two-drug therapy given for 2 weeks have been shown, no data are available on the effectiveness of short-course single-drug therapy. Objective: To compare the efficacy of cloxacillin alone with that of cloxacillin plus gentamicin for the 2-week treatment of right-sided S. aureus endocarditis in intravenous drug users. Design: Open, randomized study. Setting: An academic tertiary care hospital in Barcelona, Spain. Patients: 90 consecutive intravenous drug users who had isolated tricuspid valve endocarditis caused by methicillin-susceptible S. aureus, had no allergy to study medications, and had no systemic infectious complications that required prolonged therapy. An efficacy subset consisted of 74 of these patients who did not meet an exclusion criterion. Intervention: Cloxacillin (2 g intravenously every 4 hours for 14 days) alone or combined with gentamicin (1 mg/kg of body weight intravenously every 8 hours for 7 days). Measurements: Clinical or microbiological evidence of active infection after 2 weeks of therapy, relapse of staphylococcal infection, or death. Results: In an analysis of the efficacy subset, treatment was successful in 34 of the 38 patients who received cloxacillin alone (89% [95% CI, 75% to 97%]) and 31 of the 36 patients who received cloxacillin plus gentamicin (86% [CI, 71% to 95%]). Three patients died: one in the cloxacillin group and two in the combination therapy group. Of the 37 patients who completed 2-week treatment with cloxacillin, 34 (92%) were cured, and 3 (8%) needed prolonged treatment to cure the infection. Of the 34 patients who completed 2-week treatment with cloxacillin plus gentamicin, 32 (94%) were cured and 2 (6%) required treatment for 4 weeks. One patient in the combination group had relapse. Conclusions: A penicillinase-resistant penicillin used as single-agent therapy for 2 weeks was effective for most patients with isolated tricuspid endocarditis caused by methicillin-susceptible S. aureus. Adding gentamicin did not appear to provide any therapeutic advantages. Additional studies to confirm the therapeutic equivalence of short-course therapy with penicillinase-resistant penicillin alone and therapy with combined regimens are warranted.	UNIV AUTONOMA BARCELONA, HOSP GEN VALLE HEBRON, SERV CARDIOL, BARCELONA 08035, SPAIN	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron	Ribera, E (corresponding author), UNIV AUTONOMA BARCELONA, HOSP GEN VALLE HEBRON, SERV ENFERMEDADES INFECCIOSAS, BARCELONA 08035, SPAIN.		Ferrandos, Montserrat/H-7889-2012	Almirante, Benito/0000-0002-1189-2361; Ribera, Esteban/0000-0002-3752-8808; Ocana, Inma/0000-0003-3699-0790				ABRAMS B, 1979, ANN INTERN MED, V90, P789, DOI 10.7326/0003-4819-90-5-789; BANKS T, 1973, AM J MED, V55, P444, DOI 10.1016/0002-9343(73)90201-5; BAYER AS, 1990, CHEST, V98, P200, DOI 10.1378/chest.98.1.200; CHAMBERS HF, 1988, ANN INTERN MED, V109, P619, DOI 10.7326/0003-4819-109-8-619; DESAXE MJ, 1978, ZBL BAKT-INT J MED M, V241, P46; DINUBILE MJ, 1994, ANN INTERN MED, V121, P873, DOI 10.7326/0003-4819-121-11-199412010-00009; Espinosa F J, 1993, Enferm Infecc Microbiol Clin, V11, P235; FRIMODTMOLLER N, 1987, ACTA MED SCAND, V222, P175; HECHT SR, 1992, ANN INTERN MED, V117, P560, DOI 10.7326/0003-4819-117-7-560; KORZENIOWSKI O, 1982, ANN INTERN MED, V97, P496, DOI 10.7326/0003-4819-97-4-496; LAPUMA J, 1988, ARCH INTERN MED, V148, P1809, DOI 10.1001/archinte.148.8.1809; MENDA KB, 1973, ANN INTERN MED, V78, P25, DOI 10.7326/0003-4819-78-1-25; MILLER MH, 1978, ANTIMICROB AGENTS CH, V14, P336, DOI 10.1128/AAC.14.3.336; MIRO JM, 1989, ANN INTERN MED, V110, P497; OLSSON RA, 1962, ANN INTERN MED, V57, P755, DOI 10.7326/0003-4819-57-5-755; PARKER RH, 1980, ANN INTERN MED, V93, P832, DOI 10.7326/0003-4819-93-6-832; RIBERA E, 1990, MED CLIN-BARCELONA, V95, P5; ROBBINS MJ, 1986, AM HEART J, V111, P128, DOI 10.1016/0002-8703(86)90564-8; Sande M A, 1992, INFECTIVE ENDOCARDIT, P345; SANDE MA, 1976, J LAB CLIN MED, V88, P118; SANDE MA, 1980, ANN INTERN MED, V92, P390, DOI 10.7326/0003-4819-92-3-390; *TASK FORC STUD IN, 1990, ENFERM INFEC MICR CL, V8, P514; TORRESTORTOSA M, 1994, EUR J CLIN MICROBIOL, V13, P559, DOI 10.1007/BF01971306; TUAZON CU, 1975, ARCH INTERN MED, V135, P1555, DOI 10.1001/archinte.135.12.1555; WATANAKUNAKORN C, 1977, AM J MED SCI, V273, P133, DOI 10.1097/00000441-197703000-00002; WATANAKUNAKORN C, 1974, ANTIMICROB AGENTS CH, V6, P802, DOI 10.1128/AAC.6.6.802	26	120	126	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1996	125	12					969	+		10.7326/0003-4819-125-12-199612150-00005	http://dx.doi.org/10.7326/0003-4819-125-12-199612150-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX768	8967707				2022-12-28	WOS:A1996VX76800007
J	Brahams, D				Brahams, D			Loss of chance of survival	LANCET			English	Article											Brahams, D (corresponding author), OLD SQ CHAMBERS,1 VERULAM BLDG,GRAYS INN,LONDON WC1R 5LQ,ENGLAND.								0	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1604	1604		10.1016/S0140-6736(05)65692-9	http://dx.doi.org/10.1016/S0140-6736(05)65692-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8961988				2022-12-28	WOS:A1996VX87600007
J	Gregor, A; Cull, A				Gregor, A; Cull, A			Radiotherapy for malignant glioma - Quality as well as quantity of life is important and must be formally assessed	BRITISH MEDICAL JOURNAL			English	Editorial Material									WESTERN GEN HOSP,IMPERIAL CANC RES FUND,MED ONCOL UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	Gregor, A (corresponding author), UNIV EDINBURGH,IMPERIAL CANC RES FUND,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; CROSSEN JR, 1994, J CLIN ONCOL, V12, P627, DOI 10.1200/JCO.1994.12.3.627; Cull A, 1996, BRIT J CANCER, V74, P1674, DOI 10.1038/bjc.1996.608; Davies E, 1996, BRIT MED J, V313, P1507, DOI 10.1136/bmj.313.7071.1507; Davies E, 1996, BMJ-BRIT MED J, V313, P1512, DOI 10.1136/bmj.313.7071.1512; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; MRC Brain Tumour Working Party, 1990, J NEUROONCOL, V9, P47; MULLHEARN RK, 1983, J CLIN CHILD PSYCHOL, V12, P66; Osoba D, 1996, QUAL LIFE RES, V5, P139, DOI 10.1007/BF00435979; SNEEUW KCA, IN PRESS MED CARE; SNEEUW KCA, IN PRESS J CLIN ONCO; VALK PE, 1991, AM J ROENTGENOL, V156, P689; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; WHITEHEAD CME, 1991, PROG PLANN, V36, P1, DOI 10.1016/0305-9006(91)90003-K	14	7	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1996	313	7071					1500	1501		10.1136/bmj.313.7071.1500	http://dx.doi.org/10.1136/bmj.313.7071.1500			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VY691	8978218	Green Published			2022-12-28	WOS:A1996VY69100004
J	Forster, R; Mattis, AE; Kremmer, E; Wolf, E; Brem, G; Lipp, M				Forster, R; Mattis, AE; Kremmer, E; Wolf, E; Brem, G; Lipp, M			A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen	CELL			English	Article							PROTEIN-COUPLED RECEPTOR; HUMAN INTERLEUKIN-8 RECEPTOR; PRIMARY IMMUNE-RESPONSE; GERMINAL-CENTERS; FUNCTIONAL EXPRESSION; CD40 LIGAND; MICE; (4-HYDROXY-3-NITROPHENYL)ACETYL; DIFFERENTIATION; RECIRCULATION	We describe the phenotype of gene-targeted mice lacking the putative chemokine receptor BLR1. In normal mice, this receptor is expressed on mature B cells and a subpopulation of T helper cells. Blr1 mutant mice tack inguinal lymph nodes and possess no or only a few phenotypically abnormal Peyer's patches. The migration of lymphocytes into splenic follicles is severely impaired, resulting in morphologically altered primary lymphoid follicles. Furthermore, activated B cells fail to migrate from the T cell-rich zone into B cell follicles of the spleen, and despite high numbers of germinal center founder cells, no functional germinal centers develop in this organ. Our results identify the putative chemokine receptor BLR1 as the first G protein-coupled receptor involved in B cell migration and localization of these cells within specific anatomic compartments.	GSF MUNICH,RES CTR,INST IMMUNOL,D-81377 MUNICH,GERMANY; UNIV MUNICH,CTR GENE,INST MOL ANIM BREEDING,D-81375 MUNICH,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Forster, R (corresponding author), MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY.		Förster, Reinhold/D-6770-2011; Lipp, Martin/G-2235-2010	Wolf, Eckhard/0000-0002-0430-9510; Lipp, Martin/0000-0002-0087-2672; Forster, Reinhold/0000-0001-6190-7923				BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; BRELINSKA R, 1982, CELL TISSUE RES, V226, P155, DOI 10.1007/BF00217090; BURGSTAHLER R, 1995, BIOCHEM BIOPH RES CO, V215, P737, DOI 10.1006/bbrc.1995.2525; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CRAIG SW, 1971, J EXP MED, V134, P188, DOI 10.1084/jem.134.1.188; CYSTER JG, 1995, J EXP MED, V182, P581, DOI 10.1084/jem.182.2.581; DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FORSTER R, 1994, BLOOD, V84, P830; FORSTER R, 1993, BIOCHEM BIOPH RES CO, V196, P1496, DOI 10.1006/bbrc.1993.2421; FREEDMAN AS, 1990, SCIENCE, V249, P1030, DOI 10.1126/science.1697696; GRAY D, 1988, IMMUNOLOGY, V65, P73; GROOM AC, 1990, SPLEEN STRUCTURE FUN, P45; Hedrick JA, 1996, CURR OPIN IMMUNOL, V8, P343, DOI 10.1016/S0952-7915(96)80123-3; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JACOB J, 1992, J EXP MED, V176, P679, DOI 10.1084/jem.176.3.679; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; JAZIN EE, 1993, REGUL PEPTIDES, V47, P247, DOI 10.1016/0167-0115(93)90392-L; KAISER E, 1993, EUR J IMMUNOL, V23, P2532, DOI 10.1002/eji.1830231023; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; PELLAS TC, 1990, AM J ANAT, V187, P355, DOI 10.1002/aja.1001870405; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; ROSE ML, 1980, NATURE, V284, P364, DOI 10.1038/284364a0; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SPANGRUDE GJ, 1984, J IMMUNOL, V132, P354; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; VONDERHEIDE RH, 1990, EUR J IMMUNOL, V20, P79, DOI 10.1002/eji.1830200112; Wagner N, 1996, NATURE, V382, P366, DOI 10.1038/382366a0; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	44	906	927	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1037	1047		10.1016/S0092-8674(00)81798-5	http://dx.doi.org/10.1016/S0092-8674(00)81798-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978608	Bronze			2022-12-28	WOS:A1996VY44700009
J	Qian, F; Watnick, TJ; Onuchic, LF; Germino, GG				Qian, F; Watnick, TJ; Onuchic, LF; Germino, GG			The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I	CELL			English	Article							HUMAN ANDROGEN-RECEPTOR; GENETIC-HETEROGENEITY; 2ND GENE; LOCALIZATION; PKD1; CHILDHOOD; MUTATIONS; DELETION; LOCUS	Autosomal dominant polycystic kidney disease (ADPKD) is a common disease and an important cause of renal failure. It is characterized by considerable intrafamilial phenotypic variation and focal cyst formation. To elucidate the molecular basis for these observations, we have developed a novel method for isolating renal cystic epithelia from single cysts and have used it to show that individual renal cysts in ADPKD are monoclonal. Loss of heterozygosity was discovered within a subset of cysts for two closely linked polymorphic markers located within the PKD1 gene. Genetic analysis revealed that it was the normal haplotype that was lost. This study provides a molecular explanation for the focal nature of cyst formation and a probable mechanism whereby mutations cause disease. The high rate at which ''second hits'' must occur to account for the large number of cysts observed suggests that unique structural features of the PKD1 gene may be responsible for its mutability.			Qian, F (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV NEPHROL,720 RUTLAND ST,BALTIMORE,MD 21205, USA.		Onuchic, Luiz Fernando/H-1589-2012	Onuchic, Luiz Fernando/0000-0002-4053-5419; Germino, Gregory/0000-0002-3609-5588	NIDDK NIH HHS [DK48006] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK048006, R01DK048006] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN RC, 1992, AM J HUM GENET, V51, P1229; BLYTH H, 1971, J MED GENET, V8, P257, DOI 10.1136/jmg.8.3.257; BOGDANOVA N, 1995, HUM GENET, V95, P645; DAOUST MC, 1995, GENOMICS, V25, P733, DOI 10.1016/0888-7543(95)80020-M; DEALMEIDA S, 1995, HUM GENET, V96, P83, DOI 10.1007/BF00214191; *EUR POL KIDN DIS, 1994, CELL, V77, P881; EVAN AP, 1992, CYSTIC KIDNEY, P21; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FICK GM, 1993, J AM SOC NEPHROL, V3, P1863; FICK GM, 1994, KIDNEY INT, V45, P1153, DOI 10.1038/ki.1994.153; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; GILLILAND DG, 1991, P NATL ACAD SCI USA, V88, P6848, DOI 10.1073/pnas.88.15.6848; HANDLER JS, 1979, P NATL ACAD SCI USA, V76, P4151, DOI 10.1073/pnas.76.8.4151; HUFF V, 1991, AM J HUM GENET, V48, P997; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; IAKOUBOVA OA, 1995, GENOMICS, V26, P107, DOI 10.1016/0888-7543(95)80088-4; *INT POL KIDN DIS, 1995, CELL, V81, P289; KAARIAINEN H, 1987, J MED GENET, V24, P474, DOI 10.1136/jmg.24.8.474; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; NAROD S, 1991, CLIN GENET, V39, P125; Peral B, 1996, HUM MOL GENET, V5, P539, DOI 10.1093/hmg/5.4.539; Peral B, 1996, AM J HUM GENET, V58, P86; PERAL B, 1995, HUM MOL GENET, V4, P569, DOI 10.1093/hmg/4.4.569; PETERS DJM, 1993, NAT GENET, V5, P359, DOI 10.1038/ng1293-359; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; RAO BS, 1988, NUCLEIC ACIDS RES, V16, P8077, DOI 10.1093/nar/16.16.8077; RAVINE D, 1992, LANCET, V340, P1330, DOI 10.1016/0140-6736(92)92503-8; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; SCHAFER K, 1994, KIDNEY INT, V46, P134, DOI 10.1038/ki.1994.253; SNAREY A, 1994, AM J HUM GENET, V55, P365; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802; WILLMAN CL, 1994, NEW ENGL J MED, V331, P154, DOI 10.1056/NEJM199407213310303; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023; ZERRES K, 1993, J MED GENET, V30, P583, DOI 10.1136/jmg.30.7.583; 1995, HUM MOL GENET, V4, P575	38	468	481	2	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					979	987		10.1016/S0092-8674(00)81793-6	http://dx.doi.org/10.1016/S0092-8674(00)81793-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978603	hybrid			2022-12-28	WOS:A1996VY44700004
J	HanauskeAbel, HM				HanauskeAbel, HM			Not a slippery slope or sudden subversion: German medicine and national socialism in 1933	BRITISH MEDICAL JOURNAL			English	Review							NAZI VICTIMS; EUTHANASIA	The history of medicine this century is darkened by the downfall of the German medical profession, exposed during the doctors' trial at Nuremberg in 1946. Relying largely on documents published during 1933 in German medical journals, this paper examines two widely accepted notions of those events, metaphorically termed ''slippery slope'' and ''sudden subversion.'' The first connotes a gradual slide over infinitesimal steps until, suddenly, all footing is lost; the second conveys forced take over of the profession's leadership and values. Both concepts imply that the medical profession itself became the victim of circumstances. The slippery slope concept is a prominent figure of argument in the current debate on bioethics. The evidence presented here, however, strongly suggests that the German medical community set its own course in 1933. In some respects this course even outpaced the new government, which had to rein in the profession's eager pursuit of enforced eugenic sterilisations. In 1933 the convergence of political, scientific, and economic forces dramatically changed the relationship between the medical community and the government. That same convergence is occurring again and must be approached with great caution if medicine is to remain focused on the preservation of physical and medical integrity.			HanauskeAbel, HM (corresponding author), CORNELL UNIV MED COLL,DEPT PEDIAT,MATRIX BIOL LAB,NEW YORK,NY 10021, USA.							ALEXANDER L, 1949, NEW ENGL J MED, V241, P39, DOI 10.1056/NEJM194907142410201; ALY G, 1987, BEITRAGE NATL GESUND, V4, P14; ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; Angell M., 1992, NAZI DOCTORS NUREMBE, P276; BLEKER J, 1987, ZEIT            1106, P47; BOAG JW, 1982, PHYS MED BIOL, V27, P201, DOI 10.1088/0031-9155/27/2/001; BOGERTS B, 1988, ARCH GEN PSYCHIAT, V45, P774; Buchanan A, 1996, HASTINGS CENT REP, V26, P25, DOI 10.2307/3527929; BURGESS JA, 1993, J MED ETHICS, V19, P169, DOI 10.1136/jme.19.3.169; CHILDS D, 1970, GERMANY 1918, P52; CRAIG GA, 1980, GERMANY 1866 1945, P534; Derr P G, 1989, Issues Law Med, V4, P487; DICKMAN S, 1989, NATURE, V339, P498, DOI 10.1038/339498c0; DICKMAN S, 1989, NATURE, V337, P195, DOI 10.1038/337195a0; DICKMAN S, 1989, NATURE, V340, P175; ECKEL P, 1933, MED KLIN, V29, P1228; FADEN R, 1996, HASTINGS CTR REP, V16, P5; GERSHON ES, 1988, ARCH GEN PSYCHIAT, V45, P774; GILBERT M, 1985, HOLOCAUST HIST JEWS; GOHRBAND F, 1943, ZENTRALBL CHIR, V70, P1553; Grodin MA., 1992, NAZI DOCTORS NUREMBE, P121; HADRICH J, 1934, DTSCH ARZTEBL, V64, P1245; HAEDENKAMP K, 1933, ARZTL MITT, V34, P375; HAEDENKAMP K, 1933, ARZTL MITT, V34, P512; HAEDENKAMP K, 1933, ARZTL MITT, V34, P309; HAEDENKAMP K, 1933, ARZTL MITT, V34, P417; HAEDENKAMP K, 1933, DTSCH ARZTEBL, V63, P6; HAEDENKAMP K, 1933, ARZTL MITT, V34, P223; HALLERVORDEN J, 1993, NEUROLOGY, V43, P1452; HALTER H, 1988, SPIEGEL         0620, P112; HANAUSKEABEL HM, 1986, LANCET, V2, P271; HANAUSKEABEL HM, 1988, BERLINER ARZTE MITTE, P136; HANAUSKEABEL HM, 1991, PSR Q, V1, P127; Holborn Hajo, 1982, HIST MODERN GERMANY, V3; IVY AC, 1948, SCIENCE, V108, P1, DOI 10.1126/science.108.2792.1; JACHERTZ N, 1983, DTSCH ARZTEBL, V80, P23; JONES JH, 1981, BAD BLOOD SCANDOLOUS; KATER MH, 1987, GER STUD REV, V10, P31, DOI 10.2307/1430442; Kater MH, 1989, DOCTORS HITLER; KATER MH, 1983, NAZI PARTY SOCIAL PR, P77; KATER MH, 1993, CTR EUR HIST, V25, P407; KLEE E, 1986, ARZTE JURISTEN ANDER, P78; Klee Ernst, 1983, EUTHANASIE NS STAAT; Kummel Werner F., 1985, ARZTE NATIONALSOZIAL, P56; Litton Robert Jay, 1986, NAZI DOCTORS MED KIL; LOMMEL F, 1933, DTSCH ARTZEBL, V63, P221; MACKLIN R, 1992, MED WENT MAD BIOETHI, P173; McCally Michael, 1994, Med Glob Surviv, V1, P4; MONK R, 1990, L WITTGENSTEIN DUTY, P394; Muller-Hill B, 1984, TODLICHE WISSENSCHAF; Peiffer J, 1991, BRAIN PATHOL, V1, P125, DOI 10.1111/j.1750-3639.1991.tb00649.x; Proctor RN, 1988, RACIAL HYGIENE MED N, P95; Proctor Robert N, 1990, S WIESENTHAL GENT AN, V7, P145; REICHEL W, 1989, LANCET, V2, P1321; SASS HM, 1983, J MED PHILOS, V8, P99, DOI 10.1093/jmp/8.2.99; SCHNEIDER H, 1933, DTSCH ARZTEBL, V62, P13; SCHNEIDER K, 1993, NY TIMES        1228; SEIDELMAN WE, 1989, HASTINGS CENT REP, V19, P5, DOI 10.2307/3561978; SHEVELL M, 1992, NEUROLOGY, V42, P2214, DOI 10.1212/WNL.42.11.2214; SHEVELL MI, 1994, NEUROLOGY, V44, P350, DOI 10.1212/WNL.44.2.350; Shoenberg D., 1990, KAPITZA CAMBRIDGE MO; STAUDER A, 1933, DTSCH ARZTEBL, V62, P183; STAUDER A, 1933, DTSCH ARZTEBL, V62, P132; STOCK U, 1987, ZEIT            1106, P46; TOHSCHUS OD, 1933, NY TIMES        1221, P1; VALENTIN E, 1936, INT ARZTL B, V3, P57; VILMAR K, 1987, DTSCH ARZTEBL, V84, pC767; WAGNER G, 1933, DTSCH ARZTEBL, V63, P218; WAGNER G, 1933, DTSCH ARZTEBL, V63, P131; WALDER K, 1933, DTSCH ARZTEBL, V62, P217; WALDER K, 1933, DTSCH ARZTEBL, V62, P255; WEINGART P, 1989, OSIRIS, V5, P260, DOI 10.1086/368690; WEINGART P, 1988, RASSE BLUT GENE GESC, P188; WITTGENSTEIN L, 1995, CAMBRIDGE LETT, P293; WITTGENSTEIN L, 1977, VERMISCHTE BEMERKUNG, P107; WUTTKEGRONEBERG W, 1980, MED NATIONALSOZIALIS, P380; 1933, MED KLIN, V29, P628; 1933, MED KLIN, V29, P1032; 1933, JAMA-J AM MED ASSOC, V101, P295; 1933, DTSCH ARZTEBL, V62, P225; 1933, JAMA-J AM MED ASSOC, V100, P1616; 1996, HUMAN RAD EXPT, P1; 1933, MED KLIN, V29, P691; 1933, MUNCHEN MED WOCHEN, V80, P517; 1937, INT ARZTL B, V4, P82; 1933, MED KLIN, V29, P594; 1935, INT ARZTL B, V2, P94; 1980, MED NATL ARBEITSBUCH, P347; 1934, EUGEN NEWS, V19, P140; 1933, MED KLIN, V29, P175; 1933, JAMA-J AM MED ASSOC, V101, P1087; 1933, JAMA-J AM MED ASSOC, V100, P1877; 1933, JAMA-J AM MED ASSOC, V100, P2029; 1990, MED NATL; 1993, SPIEGEL         0125, P195; 1933, DTSCH ARZTEBL, V63, P75; 1993, MED DRITTEN REICH, P1; 1933, JAMA-J AM MED ASSOC, V102, P710; 1933, ARZTL MITT, V34, P374; 1993, ZEIT            0122, P22; 1933, JAMA-J AM MED ASSOC, V101, P1402; 1993, NY TIMES        0206, P21; 1933, DTSCH ARZTEBL, V62, P141; 1933, JAMA-J AM MED ASSOC, V100, P1706; 1935, INT ARZTL B, V2, P47; 1933, DTSCH ARZTEBL, V62, P195; 1980, MED NATL ARBEITSBUCH, P25; 1933, DTSCH ARZTEBL, V62, P153; 1933, DTSCH ARZTEBL, V63, P133; 1934, JAMA-J AM MED ASSOC, V102, P551; 1987, EUTHANASIE ZENTRALE, V4; 1933, JAMA-J AM MED ASSOC, V101, P943; 1993, WASHINGTON POST 0123, pA18; 1988, SPIEGEL         0118, P76	114	57	58	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1996	313	7070					1453	1463		10.1136/bmj.313.7070.1453	http://dx.doi.org/10.1136/bmj.313.7070.1453			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	VX612	8973235	Green Published			2022-12-28	WOS:A1996VX61200035
J	Moirand, R; Mortaji, AM; Loreal, O; Paillard, F; Brissot, P; Deugnier, Y				Moirand, R; Mortaji, AM; Loreal, O; Paillard, F; Brissot, P; Deugnier, Y			A new syndrome of liver iron overload with normal transferrin saturation	LANCET			English	Article							HEMOCHROMATOSIS; DISEASE; POPULATION; DIAGNOSIS; FERRITIN; INDEX; SERUM; RISK	Background We investigated patients who had unexplained hepatic iron overload and normal transferrin saturation. Methods 65 patients with a median liver iron concentration of 85 mu mol/g dry weight of liver (normal <36 mu mol/g), hyperferritinaemia (566 mu g/L; normal <400 mu g/L), and normal transferrin saturations (32%) were compared with genetic haemochromatosis (GH) controls including homozygous (matched for sex and serum ferritin concentration) and heterozygous individuals. Relatives of patients who had ratios of liver iron concentration to age greater than 1.9 were also studied. Findings The 65 patients were significantly older and had significantly less hepatic iron overload than individuals with genetic haemochromatosis. The frequency of HLA-A3 antigen was significantly lower in these patients than in individuals with homozygous (p<0.0001) or heterozygous (p<0.0002) GH. Five HLA-identical siblings of the patients had normal serum ferritin concentrations. Most of the patients (95%) had one or more of the following conditions; obesity, hyperlipidaemia, abnormal glucose metabolism, or hypertension. Interpretation We have found a new non-HLA-linked iron-overload syndrome which suggests a link between iron excess and metabolic disorders. The current diagnostic criteria for genetic haemochromatosis should be reviewed.	HOP PONTCHAILLOU,CLIN MALAD FOIE,F-35033 RENNES,FRANCE; CHRU PONTCHAILLOU,INSERM,U49,RENNES,FRANCE; CHRU HOTEL DIEU,SERV CARDIOL A,RENNES,FRANCE	CHU Rennes; CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Rennes			Loreal, Olivier/G-3366-2013	Loreal, Olivier/0000-0002-7428-3766; Moirand, Romain/0000-0002-5346-5755				BACON BR, 1992, NEW ENGL J MED, V326, P126, DOI 10.1056/NEJM199201093260208; BACON BR, 1994, GASTROENTEROLOGY, V107, P1103, DOI 10.1016/0016-5085(94)90235-6; BARRY M, 1971, LANCET, V1, P100; BASSETT ML, 1986, HEPATOLOGY, V6, P24, DOI 10.1002/hep.1840060106; BONKOVSKY HL, 1990, GASTROENTEROLOGY, V99, P1079, DOI 10.1016/0016-5085(90)90629-F; BRISSOT P, 1981, GASTROENTEROLOGY, V80, P557; BRISSOT P, 1991, OXFORD TXB CLIN HEPA, P948; CONRAD ME, 1993, AM J HEMATOL, V43, P234, DOI 10.1002/ajh.2830430315; Despres Jean-Pierre, 1994, Current Opinion in Lipidology, V5, P274, DOI 10.1097/00041433-199408000-00006; DEUGNIER YM, 1992, GASTROENTEROLOGY, V102, P2050, DOI 10.1016/0016-5085(92)90331-R; DIBISCEGLIE AM, 1992, GASTROENTEROLOGY, V102, P2108, DOI 10.1016/0016-5085(92)90339-Z; DINNEEN SF, 1992, IRISH J MED SCI, V161, P636, DOI 10.1007/BF02983771; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; GANDON Y, 1994, RADIOLOGY, V193, P533, DOI 10.1148/radiology.193.2.7972774; HANN HWL, 1992, CANCER, V70, P2051, DOI 10.1002/1097-0142(19921015)70:8<2051::AID-CNCR2820700806>3.0.CO;2-1; LEGGETT BA, 1990, CLIN CHEM, V36, P1350; NILSSEN O, 1994, AM J EPIDEMIOL, V139, P787, DOI 10.1093/oxfordjournals.aje.a117075; PETO TEA, 1983, LANCET, V1, P375; POWELL LW, 1990, GASTROENTEROLOGY, V98, P1625, DOI 10.1016/0016-5085(90)91100-K; REAVEN GM, 1988, DIABETES, V37, P1495; ROLLANDCACHERA MF, 1991, EUR J CLIN NUTR, V45, P13; SIMON M, 1988, J HEPATOL, V6, P116, DOI 10.1016/S0168-8278(88)80471-9; SIMON M, 1977, GASTROENTEROLOGY, V73, P655; STEVENS RG, 1988, NEW ENGL J MED, V319, P1047, DOI 10.1056/NEJM198810203191603; SUMMERS KM, 1990, HEPATOLOGY, V12, P20, DOI 10.1002/hep.1840120105; Tavill A S, 1990, Prog Liver Dis, V9, P281	27	282	287	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					95	97		10.1016/S0140-6736(96)06034-5	http://dx.doi.org/10.1016/S0140-6736(96)06034-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996422				2022-12-28	WOS:A1997WB80000013
J	Johnston, S; Hoult, S; Chan, CA				Johnston, S; Hoult, S; Chan, CA			Falling again	LANCET			English	Article							ELDERLY PEOPLE; HYPOPITUITARISM		SOUTHMEAD GEN HOSP,DEPT MED,BRISTOL BS10 5NB,AVON,ENGLAND	Southmead Hospital								BELCHETZ PE, 1985, BRIT MED J, V291, P247, DOI 10.1136/bmj.291.6490.247; KOVACS K, 1980, J GERONTOL, V35, P16, DOI 10.1093/geronj/35.1.16; MANSELL P, 1993, BRIT MED J, V307, P253, DOI 10.1136/bmj.307.6898.253; RAE P, 1993, BRIT MED J, V307, P177, DOI 10.1136/bmj.307.6897.177; TAYAL SC, 1994, AGE AGEING, V23, P320, DOI 10.1093/ageing/23.4.320	5	4	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					26	26		10.1016/S0140-6736(96)10056-8	http://dx.doi.org/10.1016/S0140-6736(96)10056-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988120				2022-12-28	WOS:A1997WA72500014
J	Ettinger, WH; Burns, R; Messier, SP; Applegate, W; Rejeski, WJ; Morgan, T; Shumaker, S; Berry, MJ; OToole, M; Monu, J; Craven, T				Ettinger, WH; Burns, R; Messier, SP; Applegate, W; Rejeski, WJ; Morgan, T; Shumaker, S; Berry, MJ; OToole, M; Monu, J; Craven, T			A randomized trial comparing aerobic exercise and resistance exercise with a health education program in older adults with knee osteoarthritis - The Fitness Arthritis and Seniors Trial (FAST)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OSTEO-ARTHRITIS; DISABILITY; PERFORMANCE; MANAGEMENT	Objective.-To determine the effects of structured exercise programs on self-reported disability in older adults with knee osteoarthritis. Setting and Design.-A randomized, single-blind clinical trial lasting 18 months conducted at 2 academic medical centers, Participants.-A total of 439 community-dwelling adults, aged 60 years or order, with radiographically evident knee osteoarthritis, pain, and self-reported physical disability. Interventions.-An aerobic exercise program, a resistance exercise program, and a health education program. Main Outcome Measures.-The primary outcome was self-reported disability score (range, 1-5). The secondary outcomes were knee pain score (range, 1-6), performance measures of physical function, x-ray score, aerobic capacity, and knee muscle strength. Results.-A total of 365 (83%) participants completed the trial, Overall compliance with the exercise prescription was 68% in the aerobic training group and 70% in the resistance training group. Postrandomization, participants in the aerobic exercise group had a 10% lower adjusted mean (+/-SE) score on the physical disability questionnaire (1.71+/-0.03 vs 1.90+/-0.04 units; P<.001), a 12% lower score on the knee pain questionnaire (2.1+/-0.05 vs 2.4+/-0.05 units; P=.001), and performed better (mean [+/-SE]) on the 6-minute walk test (1507+/-16 vs 1349+/-16 ft; P<,001), mean (+/-SE) time to climb and descend stairs (12.7+/-0.4 vs 13.9+/-0.4 seconds; P=.05), time to lift and carry 10 pounds (9.1+/-0.2 vs 10.0+/-0.1 seconds; P<,001), and mean (+/-SE) time to get in and out of a car (8.7+/-0.3 vs 10.6+/-0.3 seconds; P<.001) than the health education group, The resistance exercise group had an 8% lower score on the physical disability questionnaire (1.74+/-0.04 vs 1.90+/-0.03 units; P=.003), 8% lower pain score (2.2+/-0.06 vs 2,4+/-0.05 units; P=.02), greater distance on the 6-minute walk (1406+/-17 vs 1349+/-16 ft; P=.02), faster times on the lifting and carrying task (9.3+/-0.1 vs 10.0+/-0.16 seconds; P=.001), and the car task (9.0+/-0.3 vs 10.6+/-0.3 seconds; P=.003) than the health education group. There were no differences in x-ray scores between either exercise group and the health education group, Conclusions.-Older disabled persons with osteoarthritis of the knee had modest improvements in measures of disability, physical performance, and pain from participating in either an aerobic or a resistance exercise program. These data suggest that exercise should be prescribed as part of the treatment for knee osteoarthritis.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT INTERNAL MED, WINSTON SALEM, NC 27103 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PUBL HLTH SCI, WINSTON SALEM, NC 27103 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT RADIOL, WINSTON SALEM, NC 27103 USA; WAKE FOREST UNIV, DEPT HLTH & SPORT SCI, WINSTON SALEM, NC 27103 USA; UNIV TENNESSEE, DEPT INTERNAL MED, MEMPHIS, TN USA; UNIV TENNESSEE, DEPT PREVENT MED, MEMPHIS, TN USA; UNIV TENNESSEE, DEPT ORTHOPAED SURG, MEMPHIS, TN USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center			Monu, Johnny U. V./AAC-3030-2020	Monu, Johnny U. V./0000-0002-4600-9217	NCRR NIH HHS [M01-RR00211] Funding Source: Medline; NIA NIH HHS [P60AG10484] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG010484] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTMAN RD, 1987, ARTHRITIS RHEUM-US, V30, P1214, DOI 10.1002/art.1780301103; Armstrong S J, 1993, Osteoarthritis Cartilage, V1, P89, DOI 10.1016/S1063-4584(05)80023-8; Berry MJ, 1996, MED SCI SPORT EXER, V28, P808, DOI 10.1097/00005768-199607000-00006; BRANDT KD, 1993, TXB RHEUMATOLOGY, P1385; Buchner DM, 1993, TOP GERIATR REHABIL, V8, P1; BUCKWALTER JA, 1995, J RHEUMATOL, V22, P13; Chamberlain M A, 1982, Int Rehabil Med, V4, P101; DAVIS MA, 1991, J RHEUMATOL, V18, P591; Elward K, 1992, Clin Geriatr Med, V8, P35; ETTINGER WH, 1994, MED SCI SPORT EXER, V26, P1435; ETTINGER WH, 1994, J AM GERIATR SOC, V42, P1035, DOI 10.1111/j.1532-5415.1994.tb06206.x; FELSON DT, 1987, ARTHRITIS RHEUM, V30, P914, DOI 10.1002/art.1780300811; FISHER NM, 1993, ARCH PHYS MED REHAB, V74, P840, DOI 10.1016/0003-9993(93)90011-X; FISHER NM, 1994, ARCH PHYS MED REHAB, V75, P792; FISHER NM, 1991, ARCH PHYS MED REHAB, V72, P365; FLETCHER GF, 1990, CIRCULATION, V82, P2286, DOI 10.1161/01.CIR.82.6.2286; HIRANO PC, 1994, PATIENT EDUC COUNS, V24, P9, DOI 10.1016/0738-3991(94)90024-8; Hochberg M C, 1996, Arthritis Care Res, V9, P170, DOI 10.1002/1529-0131(199606)9:3<170::AID-ANR1790090304>3.0.CO;2-K; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1541, DOI 10.1002/art.1780381104; Jan M H, 1991, J Formos Med Assoc, V90, P1008; KING AC, 1991, JAMA-J AM MED ASSOC, V266, P1535, DOI 10.1001/jama.266.11.1535; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; KUJALA UM, 1995, ARTHRITIS RHEUM, V38, P539, DOI 10.1002/art.1780380413; LaCroix AZ, 1996, J AM GERIATR SOC, V44, P113, DOI 10.1111/j.1532-5415.1996.tb02425.x; LANE N, 1992, B RHEUM DIS, V41, P5; LORIG KR, 1993, ARTHRITIS RHEUM, V36, P439, DOI 10.1002/art.1780360403; MINOR MA, 1989, ARTHRITIS RHEUM, V32, P1396, DOI 10.1002/anr.1780321108; REJESKI WJ, 1995, J RHEUMATOL, V22, P1124; REJESKI WJ, 1995, OSTEOARTHR CARTILAGE, V3, P157, DOI 10.1016/S1063-4584(05)80050-0; Spector TD, 1996, ARTHRITIS RHEUM, V39, P988, DOI 10.1002/art.1780390616; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; VERBRUGGE LM, 1991, J GERONTOL, V46, pS71, DOI 10.1093/geronj/46.2.S71; WEINBERGER M, 1991, J RHEUMATOL, V18, P849; [No title captured]	34	971	986	2	160	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1997	277	1					25	31		10.1001/jama.277.1.25	http://dx.doi.org/10.1001/jama.277.1.25			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VZ767	8980206				2022-12-28	WOS:A1997VZ76700025
J	Rotenberg, A; Mayford, M; Hawkins, RD; Kandel, ER; Muller, RU				Rotenberg, A; Mayford, M; Hawkins, RD; Kandel, ER; Muller, RU			Mice expressing activated CaMKII lack low frequency LTP and do not form stable place cells in the CA1 region of the hippocampus	CELL			English	Article							SPATIAL FIRING PATTERNS; FREELY-BEHAVING RATS; COMPLEX-SPIKE CELLS; MOVING RATS; ENVIRONMENT; UNITS	To relate different forms of synaptic plasticity to the formation and maintenance of place cells in the hippocampus, we have recorded place cells in freely behaving, transgenic mice that express a mutated Ca2+-independent form of CaM Kinase II. These mice have normal long-term potentiation (LTP) at 100 Hz, but they lack LTP in response to stimulation at 5-10 Hz and are impaired on spatial memory tasks. In these transgenic mice, the place cells in the CA1 region have three important differences from those of wild types: they are less common, less precise, and less stable. These findings suggest that LTP in the 5-10 Hz range may be important for the maintenance of place-field stability and that this stability may be essential for the storage of spatial memory.	COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, NEW YORK STATE PSYCHIAT INST, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University; New York State Psychiatry Institute	Rotenberg, A (corresponding author), SUNY HLTH SCI CTR, DEPT PHYSIOL, DOWNSTATE MED CTR, BOX 31, BROOKLYN, NY 11203 USA.			Mayford, Mark/0000-0002-9001-5024				BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BLISS TV, 1973, J PHYSL, V232, P2331; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bostock E, 1991, Hippocampus, V1, P193, DOI 10.1002/hipo.450010207; EICHENBAUM H, 1989, J NEUROSCI, V9, P2764; HILL AJ, 1978, EXP NEUROL, V62, P282, DOI 10.1016/0014-4886(78)90058-4; Kubie J. L., 1992, Society for Neuroscience Abstracts, V18, P1062; KUBIE JL, 1990, J NEUROSCI, V10, P1110; KUBIE JL, 1984, PHYSIOL BEHAV, V32, P115, DOI 10.1016/0031-9384(84)90080-5; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MULLER RU, 1987, J NEUROSCI, V7, P1951; MULLER RU, 1989, J NEUROSCI, V9, P4101; MULLER RU, 1987, J NEUROSCI, V7, P1935; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKEEFE J, 1976, EXP NEUROL, V51, P78, DOI 10.1016/0014-4886(76)90055-8; OLTON DS, 1978, PHYSIOL BEHAV, V20, P597, DOI 10.1016/0031-9384(78)90252-4; QUIRK GJ, 1992, J NEUROSCI, V12, P1945; RANCK JB, 1973, EXP NEUROL, V41, P462, DOI 10.1016/0014-4886(73)90290-2; SCHACTER DL, 1994, MEMORY SYSTEMS BRAIN; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SHARP PE, 1995, J NEUROSCI, V15, P173; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Taube JS, 1995, HIPPOCAMPUS, V5, P569, DOI 10.1002/hipo.450050608; THOMPSON LT, 1989, J NEUROSCI, V9, P2382; THOMPSON LT, 1990, BRAIN RES, V509, P299, DOI 10.1016/0006-8993(90)90555-P; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	28	187	189	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 27	1996	87	7					1351	1361		10.1016/S0092-8674(00)81829-2	http://dx.doi.org/10.1016/S0092-8674(00)81829-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980240	hybrid			2022-12-28	WOS:A1996WA54100022
J	Friedman, L; Wiechers, IR				Friedman, L; Wiechers, IR			Psychiatry - The brain hallucinates and gets caught in the web	LANCET			English	Article											Friedman, L (corresponding author), CASE WESTERN RESERVE UNIV, DEPT PSYCHIAT, CLEVELAND, OH 44106 USA.							Gorwood P, 1996, AM J PSYCHIAT, V153, P1173; JACOBSEN R, 1996, NY TIMES CYBERT 1013; McCreadie R. G., 1996, British Journal of Psychiatry, V168, P221, DOI 10.1192/bjp.168.2.221; MOJTABAI R, 1995, AM J PSYCHIAT, V152, P1804; SILBERSWEIG DA, 1995, NATURE, V378, P176, DOI 10.1038/378176a0	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	1996	348			2			SII21	SII21						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WA463	8973499				2022-12-28	WOS:A1996WA46300021
J	GomezReino, JJ; Carreira, PE				GomezReino, JJ; Carreira, PE			Rheumatology - Inflammation and HIV infection: A friendly connection	LANCET			English	Article									HOSP UNIV DOCE DE OCTUBRE, RES UNIT, MADRID, SPAIN	Hospital Universitario 12 de Octubre	GomezReino, JJ (corresponding author), HOSP UNIV DOCE DE OCTUBRE, RHEUMATOL UNIT, MADRID, SPAIN.		Carreira, Patricia E/D-4429-2018; Gomez-Reino, Juan/ABI-2853-2020	Carreira, Patricia E/0000-0001-8279-3806; 				DargentMolina P, 1996, LANCET, V348, P145, DOI 10.1016/S0140-6736(96)01440-7; Fries JF, 1996, ARTHRITIS RHEUM, V39, P616, DOI 10.1002/art.1780390412; Greenwald RA, 1996, ARTHRITIS RHEUM, V39, P1455, DOI 10.1002/art.1780390904; ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002; tenWolde S, 1996, LANCET, V347, P347, DOI 10.1016/S0140-6736(96)90535-8	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	1996	348			2			SII24	SII24						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973502				2022-12-28	WOS:A1996WA46300024
J	Greenwood, B; Elliott, A				Greenwood, B; Elliott, A			Tropical medicine - Not a white elephant	LANCET			English	Article											Greenwood, B (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, KEPPEL ST, LONDON WC1E 7HT, ENGLAND.			Elliott, Alison/0000-0003-2818-9549				Barrett PJ, 1996, BRIT MED J, V313, P525, DOI 10.1136/bmj.313.7056.525; Fine PEM, 1996, LANCET, V348, P17, DOI 10.1016/S0140-6736(96)02166-6; Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893; Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888; Trape JF, 1996, PARASITOL TODAY, V12, P236, DOI 10.1016/0169-4758(96)10015-6	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	1996	348			2			SII27	SII27						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973505				2022-12-28	WOS:A1996WA46300027
J	Gudjonsson, B				Gudjonsson, B			Critical look at resection for pancreatic cancer	LANCET			English	Editorial Material											Gudjonsson, B (corresponding author), MED CLIN,ALFHEIMUM 74,IS-104 REYKJAVIK,ICELAND.							BRAMHALL SR, 1995, BRIT J SURG, V82, P111, DOI 10.1002/bjs.1800820137; BRENNAN MF, 1994, ANN SURG, V220, P436, DOI 10.1097/00000658-199410000-00003; Conlon KC, 1996, ANN SURG, V223, P273, DOI 10.1097/00000658-199603000-00007; GALLITANO A, 1968, CANCER-AM CANCER SOC, V22, P939, DOI 10.1002/1097-0142(196811)22:5<939::AID-CNCR2820220507>3.0.CO;2-E; GUDJONSSON B, 1995, J AM COLL SURGEONS, V181, P483; Nagakawa T, 1996, CANCER, V77, P640, DOI 10.1002/(SICI)1097-0142(19960215)77:4<640::AID-CNCR9>3.0.CO;2-K; YEO CJ, 1995, ANN SURG, V221, P721, DOI 10.1097/00000658-199506000-00011	7	8	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1676	1676		10.1016/S0140-6736(05)65818-7	http://dx.doi.org/10.1016/S0140-6736(05)65818-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973426				2022-12-28	WOS:A1996VZ76600006
J	Mackenbach, JP				Mackenbach, JP			Dances of death, occupational mortality statistics, and social critique	BRITISH MEDICAL JOURNAL			English	Article								In the late middle ages and early renaissance dances of death were a popular art form. Despite important differences in outlook, the moral messages of these art forms and of modern analyses of socioeconomic inequalities in mortality overlap considerably. This theme has survived in modern dances of death, which are popular in certain parts of Europe, especially in Germany and other German speaking countries in central Europe, and are clearly inspired by the late medieval and early renaissance examples. In the modern dances of death, however, unlike their historical counterparts, social critique (crtiticism of social inequality) is almost absent, although they include representations of differences between people in social position. Remarkably, references to socioeconomic inequalities in mortality, which have been documented extensively, are also uncommon in the modern examples. This raises important questions about public perception of social inequality in general and socioeconomic inequalities in mortality in particular, and it suggests that modern Western society has not developed the cultural means of conveying the moral message that follows from research into socioeconomic inequalities in health.			Mackenbach, JP (corresponding author), ERASMUS UNIV ROTTERDAM,DEPT PUBL HLTH,POB 1738,NL-3000 DR ROTTERDAM,NETHERLANDS.							Benzeval M, 1995, TACKLING INEQUALITIE; BROOS K, 1988, TIJD ONDES MES HOUT; Carmichael A.G., 1986, PLAGUE POOR RENAISSA; Cipolla CM, 1972, ANN DEM HIST, V3, P197; CLARK JM, 1950, DANCE DEATH MIDDLE A; Corvisier Andre, 1969, REV HIST MODERNE CON, V16, P489; GRIESHABER HAP, 1990, TOTENTANZ BASEL; Hammerstein Reinhold, 1980, TANZ MUSIK TODES MIT; Holbein H, 1971, DANCE DEATH; HUIZINGA J, 1976, WANING MIDDLE AGES; KAISER G, 1974, EUPHORION, V68, P337; KAISER G, 1982, TANZENDE TOD; Kurtz Leonard Paul, 1934, DANCE DEATH MACABRE; MACKENBACH JP, 1995, AM J PUBLIC HEALTH, V85, P1285, DOI 10.2105/AJPH.85.9.1285; MALE E, 1986, RELIG FRANCE LATE MI; MARMOT MG, 1986, LANCET, V2, P274; MOSER F, 1995, TOTENTANZ; *OFF POP CENS SURV, 1986, OCC MORT 1979 80 198; Perrenoud A, 1975, POPULATION, V30, P211; Rosenfeld Hellmut, 1974, MITTELALTERLICHE TOT, V3; SCHUSTER E, 1992, BILD TOD GRAPHIKSAMM; Tamboer A., 1989, DODENDANS KUNSTEN; Townsend P., 1988, INEQUALITIES HLTH BL	23	0	0	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1587	1591		10.1136/bmj.313.7072.1587	http://dx.doi.org/10.1136/bmj.313.7072.1587			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8990994	Green Published			2022-12-28	WOS:A1996VZ81100016
J	Morris, RE				Morris, RE			Transplantation - Beware: Shifting paradigms ahead	LANCET			English	Article											Morris, RE (corresponding author), STANFORD UNIV, SCH MED, DEPT CARDIOTHORAC SURG, STANFORD, CA 94305 USA.							Allan, 1996, Mol Diagn, V1, P209; Brazelton TR, 1996, CURR OPIN IMMUNOL, V8, P710, DOI 10.1016/S0952-7915(96)80090-2; Hisanaga M, 1996, TRANSPLANTATION, V61, P40, DOI 10.1097/00007890-199601150-00010; Keown P, 1996, TRANSPLANTATION, V61, P1029; VanBuskirk AM, 1996, TRANSPLANTATION, V62, P300, DOI 10.1097/00007890-199607270-00026	5	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	1996	348			2			SII26	SII26						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973504				2022-12-28	WOS:A1996WA46300026
J	Wessely, S				Wessely, S			Pride	BRITISH MEDICAL JOURNAL			English	Article											Wessely, S (corresponding author), UNIV LONDON KINGS COLL,SCH MED,DEPT PSYCHOL MED,LONDON SE5 9PJ,ENGLAND.		Wessely, Simon C/A-8713-2008	Wessely, Simon Charles/0000-0002-6743-9929				BROWN JD, 1995, J PERS SOC PSYCHOL, V68, P712, DOI 10.1037/0022-3514.68.4.712; Capps D., 1989, PASTORAL PSYCHOL, V37, P229; Capps D., 1992, PASTORAL PSYCHOL, V40, P209; GIBBON E., 1968, DECLINE FALL ROMAN E; HOWARTH D, 1972, WATERLOO NEAR RUN TH; Hughes Robert, 1993, CULTURE COMPLAINT FR; Hume David, 1902, ENQUIRIES HUMAN UNDE; KEMPER TD, 1987, AM J SOCIOL, V93, P263, DOI 10.1086/228745; LAZARUS RS, 1991, AM PSYCHOL, V46, P819, DOI 10.1037/0003-066X.46.8.819; TAYLOR SE, 1988, PSYCHOL BULL, V103, P193, DOI 10.1037/0033-2909.103.2.193	10	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1594	1595		10.1136/bmj.313.7072.1594	http://dx.doi.org/10.1136/bmj.313.7072.1594			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VZ811	8990998	Green Published			2022-12-28	WOS:A1996VZ81100021
J	Nathwani, D; Davey, P				Nathwani, D; Davey, P			Intravenous antimicrobial therapy in the community: Underused, inadequately resourced, or irrelevant to health care in Britain?	BRITISH MEDICAL JOURNAL			English	Article							PARENTERAL ANTIBIOTICS; PROMOTE QUALITY; HOME TREATMENT; INFECTIONS; FEASIBILITY; MANAGEMENT; INSURANCE; SECONDARY; ECONOMY; 1990S	The NHS Executive is keen to promote ''hospital at home'' services in Britain, as part of its philosophy of keeping more care in the community and also to relieve the increasing demand for hospital beds. One such service is the provision of intravenous antimicrobial therapy in the community. Yet, compared with the United States, where home or outpatient intravenous antimicrobial therapy programmes are well developed, experience in Britain and Europe is limited, reflecting a difference in cultural attitudes and healthcare structures between the two continents. Only a few units in Britain currently run home intravenous antimicrobial therapy programmes, and several issues need to be addressed if more treatment is to be provided outside hospital. These include an assessment of the need for community intravenous antibiotic treatment and which patient groups many benefit. The main motive for community intravenous treatment should be better patient care and not simply a reduction in healthcare costs. At present the pace of change is being set by a few clinical enthusiasts and by commercial organisations, whereas the NHS deserves a more organised strategy for purchasing treatment with intravenous antibiotics in the community.	KINGS CROSS HOSP,INFECT & IMMUNODEFICIENCY SERV,DUNDEE DD3 8EA,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT CLIN PHARMACOL,MED MONITORING UNIT,DUNDEE DD1 9SY,SCOTLAND	University of Dundee								ANTONISKIS A, 1978, WESTERN J MED, V128, P203; Bakker W, 1993, Ned Tijdschr Geneeskd, V137, P2486; BALINSKY W, 1989, AM J MED, V87, P301, DOI 10.1016/S0002-9343(89)80155-X; COULTER A, 1995, BRIT MED J, V311, P1447, DOI 10.1136/bmj.311.7018.1447; CRAIG WA, 1993, HOSP PRACT, V28, P16, DOI 10.1080/21548331.1993.11442930; CRUMP BJ, 1995, BRIT MED J, V310, P509, DOI 10.1136/bmj.310.6978.509; Davey PG, 1996, J ANTIMICROB CHEMOTH, V37, P623, DOI 10.1093/jac/37.3.623; DONABEDIAN A, 1966, MILBANK Q, V4, P155; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; FINCH R, 1995, HOME OUTPATIENT MANA; GILL S, 1993, BR J NURSING, V3, P767; GRAHAM DR, 1993, INFECT DIS CLIN PRAC, V2, P158; HALLS GA, 1993, J ANTIMICROB CHEMOTH, V31, P985, DOI 10.1093/jac/31.6.985; Kayley J, 1996, J ANTIMICROB CHEMOTH, V37, P1023, DOI 10.1093/jac/37.5.1023; KOHLER JA, 1991, POSTGRADUATE UPDATE, V42, P950; KRAVITZ GR, 1993, HOSP PRACT, V28, P21, DOI 10.1080/21548331.1993.11442931; KUNKEL MJ, 1993, HOSP PRACT, V28, P33, DOI 10.1080/21548331.1993.11442933; LOWSON K, 1993, CLIN MANAGEMENT, V2, P8; MALIK IA, 1995, AM J MED, V98, P224, DOI 10.1016/S0002-9343(99)80367-2; MILKOVICH G, 1995, INT J ANTIMICROB AG, V5, P27, DOI 10.1016/0924-8579(94)00049-Z; NATHWANI D, 1995, HOSP UPDATE, V21, P2; *NHS MAN EX, 1995, EL955 NHSME; NOLET B, 1993, INFECT DIS CLIN PRAC, V3, P225; Parker S E, 1992, Pharmacoeconomics, V1, P103, DOI 10.2165/00019053-199201020-00007; POSTEMA CA, 1995, INT J ANTIMICROB AG, V5, P39, DOI 10.1016/0924-8579(94)00055-Y; RUBINSTEIN E, 1993, HOSP FORMUL, V28, P46; SCHRIJVERS G, 1995, INT J ANTIMICROB AG, V5, P45, DOI 10.1016/0924-8579(94)00056-Z; SHAUGHNESSY PW, 1989, QUALITY CARE INDICAT; SIMMONS B, 1990, INFECT CONT HOSP EP, V11, P362; Thickson N D, 1993, Pharmacoeconomics, V3, P220, DOI 10.2165/00019053-199303030-00005; WELCH J, 1990, GENITOURIN MED, V66, P460	32	17	17	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1996	313	7071					1541	1543		10.1136/bmj.313.7071.1541	http://dx.doi.org/10.1136/bmj.313.7071.1541			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY691	8978235	Green Published			2022-12-28	WOS:A1996VY69100029
J	Gissler, M; Hemminki, E; Lonnqvist, J				Gissler, M; Hemminki, E; Lonnqvist, J			Suicides after pregnancy in Finland, 1987-94: Register linkage study	BRITISH MEDICAL JOURNAL			English	Article							POSTNATAL DEPRESSION; THERAPEUTIC-ABORTION; MATERNAL MORTALITY; COMPLICATIONS; WOMEN	Objective-To determine rates of suicide associated with pregnancy by the type of pregnancy. Design-Register linkage study. information on suicides in women of reproductive age was Linked with the Finnish birth, abortion, and hospital discharge registers to find out how many women who committed suicide had had a completed pregnancy during her last year of life. Setting-Nationwide data from Finland. Subjects-Women who committed suicide in 1987-94. Results-There were 73 suicides associated with pregnancy, representing 5.4% of all suicides in women in this age group. The mean annual suicide rate was 11.3 per 100 000. The suicide rate associated with birth was significantly lower (5.9) and the rates associated with miscarriage (18.1) and induced abortion (34.7) were significantly higher than in the population. The risk associated with birth was higher among teenagers and that associated with abortion was increased in all age groups. Women who had committed a suicide tended to come from lower social classes and were more Likely to be unmarried than other women who had had a completed pregnancy. Conclusions-The increased risk of suicide after an induced abortion indicates either common risk factors for both or harmful effects of induced abortion on mental health.	NATL RES & DEV CTR WEL & HLTH STAKES,HLTH SERV RES UNIT,HELSINKI 00531,FINLAND; NATL PUBL HLTH INST,DEPT MENTAL HLTH,SF-00300 HELSINKI,FINLAND	Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare	Gissler, M (corresponding author), NATL RES & DEV CTR WEL & HLTH STAKES,UNIT STAT REGISTERS & INFORMAT SYST,POB 220,HELSINKI 00531,FINLAND.			Gissler, Mika/0000-0001-8254-7525				ADLER NE, 1992, AM PSYCHOL, V47, P1194, DOI 10.1037/0003-066X.47.10.1194; [Anonymous], 1992, INT STAT CLASS DIS R, V1-3; APPLEBY L, 1991, BRIT MED J, V302, P137, DOI 10.1136/bmj.302.6769.137; BOUVIERCOLLE MH, 1991, INT J EPIDEMIOL, V20, P717, DOI 10.1093/ije/20.3.717; Brown S, 1994, MISSING VOICES EXPER; COX JL, 1993, BRIT J PSYCHIAT, V163, P27, DOI 10.1192/bjp.163.1.27; GISSLER M, 1995, SCAND J SOC MED, V23, P75, DOI 10.1177/140349489502300113; GISSLER M, 1996, INT J EPIDEMIOL, V2, P376; GREER HS, 1976, BRIT J PSYCHIAT, V128, P74, DOI 10.1192/bjp.128.1.74; HEDEGAARD M, 1993, BMJ-BRIT MED J, V307, P234, DOI 10.1136/bmj.307.6898.234; Heikkinen ME, 1995, BRIT J PSYCHIAT, V167, P747, DOI 10.1192/bjp.167.6.747; HOGBERG U, 1994, OBSTET GYNECOL, V84, P240; Keskimaki I, 1991, INT J HLTH SCI, V2, P15, DOI DOI 10.1177/1403494812456637; KLEINER GJ, 1984, SUICIDE PREGNANCY, P23; Lonnqvist Jouko, 1977, SUICIDE HELSINKI EPI; MURRAY D, 1995, BRIT J PSYCHIAT, V166, P595, DOI 10.1192/bjp.166.5.595; SCOTT D, 1992, CHILD ABUSE NEGLECT, V16, P345, DOI 10.1016/0145-2134(92)90044-R; STACK JM, 1990, EARLY PREGNANCY FAIL, P212; *STAT FINL, 1989, DEATH CAUS 1987 1994; STEIN A, 1989, BRIT MED J, V298, P1073, DOI 10.1136/bmj.298.6680.1073; SURTEES PG, 1983, BRIT J PSYCHIAT, V142, P238, DOI 10.1192/bjp.142.3.238; WHO, 1995, WORLD HLTH STAT ANN; ZOLESE G, 1992, BRIT J PSYCHIAT, V160, P742, DOI 10.1192/bjp.160.6.742	23	145	149	0	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1996	313	7070					1431	1434		10.1136/bmj.313.7070.1431	http://dx.doi.org/10.1136/bmj.313.7070.1431			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VX612	8973229	Green Published			2022-12-28	WOS:A1996VX61200025
J	Grunwald, DJ				Grunwald, DJ			A Fin-de-Siecle achievement: Charting new waters in vertebrate biology	SCIENCE			English	Editorial Material							DROSOPHILA-MELANOGASTER; LARVAL CUTICLE; ZYGOTIC LOCI; EMBRYONIC INDUCTION; FLOOR PLATE; ZEBRAFISH; MUTATIONS; CHROMOSOME; PATTERN				Grunwald, DJ (corresponding author), UNIV UTAH,DEPT HUMAN GENET,ECCLES INST HUMAN GENET,SALT LAKE CITY,UT 84112, USA.							Abdelilah S, 1996, DEVELOPMENT, V123, P217; Baier H, 1996, DEVELOPMENT, V123, P415; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; Brand M, 1996, DEVELOPMENT, V123, P129; Brand M, 1996, DEVELOPMENT, V123, P179; BUMCROT DA, 1995, CURR BIOL, V5, P612, DOI 10.1016/S0960-9822(95)00123-0; Chen JN, 1996, DEVELOPMENT, V123, P293; Currie PD, 1996, NATURE, V382, P452, DOI 10.1038/382452a0; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; Driever W, 1996, DEVELOPMENT, V123, P37; FurutaniSeiki M, 1996, DEVELOPMENT, V123, P229; Granato M, 1996, DEVELOPMENT, V123, P399; Haffter P, 1996, DEVELOPMENT, V123, P1; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; Halpern ME, 1995, DEVELOPMENT, V121, P4257; Hammerschmidt M, 1996, DEVELOPMENT, V123, P95; Hammerschmidt M, 1996, DEVELOPMENT, V123, P143; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; Heisenberg CP, 1996, DEVELOPMENT, V123, P191; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; Jiang YJ, 1996, DEVELOPMENT, V123, P205; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; Kane DA, 1996, DEVELOPMENT, V123, P57; Kane DA, 1996, DEVELOPMENT, V123, P47; Karlstrom RO, 1996, DEVELOPMENT, V123, P427; Kelsh RN, 1996, DEVELOPMENT, V123, P369; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KIMELMAN D, 1992, DEVELOPMENT, V116, P1; KIMMEL CB, 1989, NATURE, V337, P358, DOI 10.1038/337358a0; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Knapik EW, 1996, DEVELOPMENT, V123, P451; Malicki J, 1996, DEVELOPMENT, V123, P275; Malicki J, 1996, DEVELOPMENT, V123, P263; MULLINS MC, 1994, CURR BIOL, V4, P189, DOI 10.1016/S0960-9822(00)00048-8; Mullins MC, 1996, DEVELOPMENT, V123, P81; Neuhauss SCF, 1996, DEVELOPMENT, V123, P357; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; Odenthal J, 1996, DEVELOPMENT, V123, P391; Odenthal J, 1996, DEVELOPMENT, V123, P103; OPITZ JM, 1994, AM J MED GENET, V49, P14, DOI 10.1002/ajmg.1320490105; Pack M, 1996, DEVELOPMENT, V123, P321; Piotrowski T, 1996, DEVELOPMENT, V123, P345; Placzek M, 1996, CURR BIOL, V6, P526, DOI 10.1016/S0960-9822(02)00533-X; POSTLETHWAIT JH, 1994, SCIENCE, V264, P699, DOI 10.1126/science.8171321; PYERITZ RE, 1989, AM J MED GENET, V34, P124, DOI 10.1002/ajmg.1320340120; Ransom DG, 1996, DEVELOPMENT, V123, P311; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; Schier AF, 1996, DEVELOPMENT, V123, P165; Schilling TF, 1996, DEVELOPMENT, V123, P329; SMITH DW, 1988, RECOGNIZABLE PATTERN; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; SOLNICAKREZEL L, 1994, GENETICS, V136, P1401; SolnicaKrezel L, 1996, DEVELOPMENT, V123, P67; Stainier DYR, 1996, DEVELOPMENT, V123, P285; Stemple DL, 1996, DEVELOPMENT, V123, P117; Trowe T, 1996, DEVELOPMENT, V123, P439; vanEeden FJM, 1996, DEVELOPMENT, V123, P255; vanEeden FJM, 1996, DEVELOPMENT, V123, P153; WEINSTEIN BM, 1995, NAT MED, V1, P1143, DOI 10.1038/nm1195-1143; WEINSTEIN BW, 1986, DEVELOPMENT, V123, P303; Whitfield TT, 1996, DEVELOPMENT, V123, P241; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158	62	25	25	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1634	1635		10.1126/science.274.5293.1634	http://dx.doi.org/10.1126/science.274.5293.1634			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8984632				2022-12-28	WOS:A1996VW71200040
J	Horton, R				Horton, R			Prizes, publications, and promotion	LANCET			English	Editorial Material																		Huston P, 1996, LANCET, V347, P1024, DOI 10.1016/S0140-6736(96)90153-1; Tritsmans L, 1996, LANCET, V347, P1628, DOI 10.1016/S0140-6736(96)91115-0	2	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1996	348	9039					1398	1398		10.1016/S0140-6736(05)67500-9	http://dx.doi.org/10.1016/S0140-6736(05)67500-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8965589				2022-12-28	WOS:A1996VU98600008
J	Anand, AC; Reddy, PS; Salprasad, GS; Kher, SK				Anand, AC; Reddy, PS; Salprasad, GS; Kher, SK			Does non-dysenteric intestinal amoebiasis exist?	LANCET			English	Article							IRRITABLE-BOWEL-SYNDROME; ENTAMOEBA-HISTOLYTICA; INVASIVE AMEBIASIS; MORPHOLOGY; ADHERENCE; DIAGNOSIS	Background Chronic abdominal pain and frequent bowel disturbance are common symptoms experienced by more than 15% of apparently healthy people. In areas endemic for Entamoeba histolytica infection, these symptoms are often diagnosed as non-dysenteric intestinal amoebiasis even though no causal relation between such symptoms and E histolytica has been established and clinical presentation of non-dysenteric intestinal amoebiasis and irritable bowel syndrome (IBS) is not distinct. This study was done to assess the clinical significance of E histolytica infection in causation of such symptoms. Methods Patients with symptoms suggestive of non-dysenteric intestinal amoebiasis were recruited from a survey to assess the prevalence of abdominal symptoms in the general population (group A; n=78) and from medical outpatient clinics (group B; n=66). Participants who had symp toms as well as symptom-free controls (group C; n=100) were clinically examined and underwent stool examination, amoebic serology, colonoscopic examination, histopathological examination of colonoscopic biopsy samples, and a trial of antiamoebic therapy (only for participants with symptoms) with metronidazole and mebendazole. Findings There were no significant differences between the 144 patients with symptoms and the 100 symptom-free controls in the proportion with E histolytica in stools (26 [18%] vs 18 [18%]), serological evidence of E histolytica infection (61 [42%] vs 41 [41%]), colonoscopic abnormalities (five of 66 vs one of 33), or histopathological abnormalities (36 [49%] of 73 vs ten [30%] of 33). Cyst positive and cyst-negative individuals showed no significant difference in serological evidence of E histolytic infection, histological abnormalities, or response to therapeutic trial with metronidazole. A diagnosis of IBS was suggested on the basis of consensus criteria and Kruis diagnostic index in 127 of 144 patients with symptoms. The diagnosis of non-dysenteric intestinal amoebiasis could be made in only one patient, who had relapse of symptoms within 6 weeks of antiamoebic therapy and therefore the relapse did not meet criteria for the diagnosis of non-dysenteric intestinal amoebiasis. More than 60% of cyst-positive as well as cyst-negative patients with symptoms showed either complete or partial response to treatment strategy for IBS. Interpretation Chronic bowel symptoms, such as pain in abdomen and frequent bowel disturbance, have no association with either past or present infection with E histolytica. Most patients with such symptoms are likely to have IBS. The clinical entity of non-dysenteric intestinal amoebiasis, if it exists, must be extremely rare.	ARMED FORCES MED COLL, DEPT PATHOL, PUNE 411040, MAHARASHTRA, INDIA; ARMED FORCES MED COLL, DEPT SOCIAL & PREVENT MED, PUNE 411040, MAHARASHTRA, INDIA; ARMED FORCES MED COLL, DEPT MICROBIOL, PUNE 411040, MAHARASHTRA, INDIA	Armed Forces Medical College; Armed Forces Medical College; Armed Forces Medical College	Anand, AC (corresponding author), ARMED FORCES MED COLL, DEPT MED, PUNE 411040, MAHARASHTRA, INDIA.		Anand, Anil C/E-4704-2017; Anand, Anil/AAM-5028-2020	Anand, Anil C/0000-0001-7105-1540; Anand, Anil/0000-0001-7105-1540				ABRAHAM P, 1991, INDIAN J GASTROENT S, V10, pA2; Bordie A K, 1972, J Indian Med Assoc, V58, P451; Drossman D., 1990, GASTR INT, V3, P159; DROSSMAN DA, 1988, GASTROENTEROLOGY, V95, P701, DOI 10.1016/S0016-5085(88)80017-9; GILAT T, 1972, DIG DIS, V17, P37; JALAN N, 1988, NATL MED J INDIA, V1, P128; Kamath P S, 1991, Indian J Gastroenterol, V10, P59; KESSEL JF, 1965, AM J TROP MED HYG, V14, P540, DOI 10.4269/ajtmh.1965.14.540; KINGHAM JGC, 1991, GUT, V32, P234, DOI 10.1136/gut.32.3.234; KRUIS W, 1984, GASTROENTEROLOGY, V87, P1; LYNN RB, 1993, NEW ENGL J MED, V329, P1940, DOI 10.1056/NEJM199312233292608; MADAN S, 1981, INDIAN J PEDIATR, V49, P327; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; MATHAN MM, 1985, GUT, V26, P710, DOI 10.1136/gut.26.7.710; MATHUR A, 1966, J INDIAN MED ASSOC, V46, P651; MILLER MJ, 1951, T ROY SOC TROP MED H, V45, P131, DOI 10.1016/S0035-9203(51)90704-3; NANDA R, 1984, LANCET, V2, P301; OSEASOHN RO, 1956, GASTROENTEROLOGY, V31, P246; RAVDIN JI, 1994, GUT, V35, P1018, DOI 10.1136/gut.35.8.1018; RAVDIN JI, 1990, J INFECT DIS, V162, P768, DOI 10.1093/infdis/162.3.768; SAPRO JJ, 1939, AM J TROP MED HYG, V19, P497; SCHAPIRO M M, 1959, Mil Med, V124, P196; SCHUSTER MM, 1993, GASTROINTESTINAL DIS, P917; VARIYAM EP, 1989, DIGEST DIS SCI, V34, P732, DOI 10.1007/BF01540345; WHITEHEAD R, 1975, DIGESTION, V13, P129, DOI 10.1159/000197701; *WHO, 1981, WHO TECHN REP SER, V666, P8; *WHO, 1969, WHO TECHN REP SER, V421, P1; 1985, LANCET, V1, P732	28	27	31	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 11	1997	349	9045					89	92		10.1016/S0140-6736(96)06121-1	http://dx.doi.org/10.1016/S0140-6736(96)06121-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996420				2022-12-28	WOS:A1997WB80000011
J	Hill, AF; Zeidler, M; Ironside, J; Collinge, J				Hill, AF; Zeidler, M; Ironside, J; Collinge, J			Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy	LANCET			English	Article									WESTERN GEN HOSP,NATL CJD SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; ST MARYS HOSP,DEPT NEUROL,LONDON,ENGLAND	University of Edinburgh; Imperial College London	Hill, AF (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCH MED,NEUROGENET UNIT,LONDON W2 1PG,ENGLAND.		Hill, Andrew F./GZL-4124-2022; Hill, Andrew F./AAH-2854-2020; Hill, Andrew F/B-4527-2009	Hill, Andrew F./0000-0001-5581-2354; Hill, Andrew F/0000-0001-5581-2354; Ironside, James/0000-0001-5869-2108				BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; KIMBERLIN RH, 1988, J GEN VIROL, V69, P2953, DOI 10.1099/0022-1317-69-12-2953; Schreuder BEC, 1996, NATURE, V381, P563, DOI 10.1038/381563a0; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	5	369	381	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					99	100		10.1016/S0140-6736(97)24002-X	http://dx.doi.org/10.1016/S0140-6736(97)24002-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996424				2022-12-28	WOS:A1997WB80000015
J	Fan, W; Boston, BA; Kesterson, RA; Hruby, VJ; Cone, RD				Fan, W; Boston, BA; Kesterson, RA; Hruby, VJ; Cone, RD			Role of melanocortinergic neurons in feeding and the agouti obesity syndrome	NATURE			English	Article							MELANOCYTE-STIMULATING-HORMONE; MESSENGER-RNA; ALPHA-MELANOTROPIN; MOLECULAR-CLONING; NEUROPEPTIDE-Y; RECEPTOR; GENE; MOUSE; EXPRESSION; BRAIN	DOMINANT alleles at the agouti locus (A) cause an obesity syndrome in the mouse, as a consequence of ectopic expression of the agouti peptide(1-6). This peptide, normally only found in the skin, is a high-affinity antagonist of the melanocyte-stimulating hormone receptor (MC1-R)(7), thus explaining the inhibitory effect of agouti on eumelanin pigment synthesis, The agouti peptide is also an antagonist of the hypothalamic melanocortin-4 receptor (MC4-R)(7-9). To test the hypothesis that agouti causes obesity by antagonism of hypothalamic melanocortin receptors(7), we identified cyclic melanocortin analogues(10) that are potent agonists or antagonists of the neural MC3 (refs 11, 12) and MC4 receptors. Intracerebroventricular administration of the agonist, MTII, inhibited feeding in four models of hyperphagia: fasted C57BL/6J, ob/ob, and A(Y) mice, and mice injected with neuropeptide Y. Co-administration of the specific melanocortin antagonist and agouti-mimetic SHU9119 completely blocked this inhibition. Furthermore, administration of SHU9119 significantly enhanced nocturnal feeding, or feeding stimulated by a prior fast. Our data show that melanocortinergic neurons exert a tonic inhibition of feeding behaviour. Chronic disruption of this inhibitory signal is a likely explanation of the agouti obesity syndrome.	OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT PEDIAT, PORTLAND, OR 97201 USA; UNIV ARIZONA, DEPT CHEM, TUCSON, AZ 85721 USA	Oregon Health & Science University; Oregon Health & Science University; University of Arizona								ALOBEIDI F, 1989, J MED CHEM, V32, P2555, DOI 10.1021/jm00132a010; BERGENDAHL M, 1992, NEUROENDOCRINOLOGY, V56, P913, DOI 10.1159/000126324; BRADY LS, 1990, NEUROENDOCRINOLOGY, V52, P441, DOI 10.1159/000125626; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1993, J BIOL CHEM, V268, P8246; HRUBY VJ, 1995, J MED CHEM, V38, P3454, DOI 10.1021/jm00018a005; HUSZAR D, IN PRESS CELL; JACOBOWITZ DM, 1978, P NATL ACAD SCI USA, V75, P6300, DOI 10.1073/pnas.75.12.6300; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KESTERSAN RA, UNPUB MOL ENDOCRINOL; KLEBIG ML, 1995, P NATL ACAD SCI USA, V92, P4728, DOI 10.1073/pnas.92.11.4728; Kucera GT, 1996, DEV BIOL, V173, P162, DOI 10.1006/dbio.1996.0014; LAURSEN SE, 1986, J PHARMACOL METHOD, V16, P355, DOI 10.1016/0160-5402(86)90038-0; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; PENY WL, 1995, GENETICS, V140, P267; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; STEINER RA, 1994, J NEUROENDOCRINOL, V6, P603, DOI 10.1111/j.1365-2826.1994.tb00625.x; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; WATSON SJ, 1978, NATURE, V275, P226, DOI 10.1038/275226a0; WILDING JPH, 1993, ENDOCRINOLOGY, V132, P1939, DOI 10.1210/en.132.5.1939; WILSON BD, 1995, HUM MOL GENET, V4, P223, DOI 10.1093/hmg/4.2.223; WOLFF GL, 1963, GENETICS, V48, P1041	28	1608	1695	2	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 9	1997	385	6612					165	168		10.1038/385165a0	http://dx.doi.org/10.1038/385165a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WB728	8990120				2022-12-28	WOS:A1997WB72800056
J	Evans, JSO; Hu, Z; Jorgensen, JD; Argyriou, DN; Short, S; Sleight, AW				Evans, JSO; Hu, Z; Jorgensen, JD; Argyriou, DN; Short, S; Sleight, AW			Compressibility, phase transitions, and oxygen migration in zirconium tungstate, ZrW2O8	SCIENCE			English	Article							BOND-VALENCE PARAMETERS; THERMAL-EXPANSION; POWDER	In situ neutron diffraction experiments show that at pressures above 2 kilobars, cubic zirconium tungstate (ZrW2O8) undergoes a quenchable phase transition to an orthorhombic phase, the structure of which has been solved from powder diffraction data. This phase transition can be reversed by heating at 393 kelvin and 1 atmosphere and involves the migration of oxygen atoms in the lattice. The high-pressure phase shows negative thermal expansion from 20 to 300 kelvin. The relative thermal expansion and compressibilities of the cubic and orthorhombic forms can be explained in terms of the ''cross-bracing'' between polyhedra that occurs as a result of the phase transition.	OREGON STATE UNIV,DEPT CHEM,CORVALLIS,OR 97331; ARGONNE NATL LAB,DIV INTENSE PULSED NEUTRON SOURCE,ARGONNE,IL 60439; ARGONNE NATL LAB,DIV MAT SCI,ARGONNE,IL 60439; ARGONNE NATL LAB,SCI & TECHNOL CTR SUPERCONDUCT,ARGONNE,IL 60439	Oregon State University; United States Department of Energy (DOE); Argonne National Laboratory; United States Department of Energy (DOE); Argonne National Laboratory; United States Department of Energy (DOE); Argonne National Laboratory			Evans, John SO/E-6345-2012; Argyriou, Dimitrios/AAC-7860-2020	Evans, John SO/0000-0001-6305-6341; 				ALTOMARE A, 1994, J APPL CRYSTALLOGR, V27, P435, DOI 10.1107/S002188989400021X; Altomare A, 1995, J APPL CRYSTALLOGR, V28, P842, DOI 10.1107/S0021889895005619; BRESE NE, 1991, ACTA CRYSTALLOGR B, V47, P192, DOI 10.1107/S0108768190011041; BROWN ID, 1985, ACTA CRYSTALLOGR B, V41, P244, DOI 10.1107/S0108768185002063; BROWN ID, 1976, ACTA CRYSTALLOGR B, V32, P1957, DOI 10.1107/S0567740876006869; GIDDY AP, 1993, ACTA CRYSTALLOGR A, V49, P697, DOI 10.1107/S0108767393002545; HAMMONDS KD, 1996, M MINERAL, V81, P1057; JORGENSEN JD, 1989, J APPL CRYSTALLOGR, V22, P321, DOI 10.1107/S002188988900289X; JORGENSEN JD, 1990, PHYSICA C, V171, P93, DOI 10.1016/0921-4534(90)90460-V; JORGENSEN JE, 1986, PHYS REV B, V33, P4793, DOI 10.1103/PhysRevB.33.4793; LE BAIL A, 1988, MATER RES BULL, V23, P447, DOI 10.1016/0025-5408(88)90019-0; SLEIGHT AW, 1996, CHEM MATER, V8, P2809; SLEIGHT AW, 1995, Patent No. 5514360; Suortti P, 1972, J APPL CRYSTALLOGR, V5, P325; SWAINSON IP, 1995, PHYS CHEM MINER, V22, P61, DOI 10.1007/BF00202681; TAYLOR D, 1984, BRIT CERAM TRANS J, V83, P92; VISSER JW, 1969, J APPL CRYSTALLOGR, V2, P89, DOI 10.1107/S0021889869006649	18	317	363	4	124	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					61	65		10.1126/science.275.5296.61	http://dx.doi.org/10.1126/science.275.5296.61			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974391				2022-12-28	WOS:A1997WA90300047
J	Luban, J				Luban, J			Absconding with the chaperone: Essential cyclophilin-gag interaction in HIV-1 virions	CELL			English	Review							PROTEIN; BINDS		COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University	Luban, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,701 W 168TH ST,NEW YORK,NY 10032, USA.			Luban, Jeremy/0000-0001-5650-4054				Aberham C, 1996, J VIROL, V70, P3536, DOI 10.1128/JVI.70.6.3536-3544.1996; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Braaten D, 1996, J VIROL, V70, P3551, DOI 10.1128/JVI.70.6.3551-3560.1996; Braaten D, 1996, J VIROL, V70, P5170, DOI 10.1128/JVI.70.8.5170-5176.1996; Dorfman T, 1996, J VIROL, V70, P5751, DOI 10.1128/JVI.70.9.5751-5757.1996; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	16	113	118	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1157	1159		10.1016/S0092-8674(00)81811-5	http://dx.doi.org/10.1016/S0092-8674(00)81811-5			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980222	hybrid			2022-12-28	WOS:A1996WA54100004
J	Hargreaves, DH				Hargreaves, DH			A training culture in surgery	BRITISH MEDICAL JOURNAL			English	Article											Hargreaves, DH (corresponding author), UNIV CAMBRIDGE,TRAINING DOCTORS HOSP PROJECT,CAMBRIDGE CB2 1QA,ENGLAND.							GRANT J, 1989, BRIT MED J, V299, P1263, DOI 10.1136/bmj.299.6710.1263; HARGREAVES DH, IN PRESS JOB TRAININ; Harvey-Jones J, 1994, ALL TOGETHER NOW; Trotter W., 1941, COLLECTED PAPERS W T; Watkins K.E., 1993, SCULPTING LEARNING O	5	25	25	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1635	1639		10.1136/bmj.313.7072.1635	http://dx.doi.org/10.1136/bmj.313.7072.1635			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991016	Green Published			2022-12-28	WOS:A1996VZ81100050
J	Shelley, WB; Shelley, ED				Shelley, WB; Shelley, ED			Dermatology - On their shoulders, we proudly stand	LANCET			English	Article											Shelley, WB (corresponding author), MED COLL OHIO,DIV DERMATOL,TOLEDO,OH 43699, USA.							Bonn D, 1996, LANCET, V348, P1090, DOI 10.1016/S0140-6736(05)64424-8; Fitzpatrick RE, 1996, ARCH DERMATOL, V132, P395, DOI 10.1001/archderm.132.4.395; Gupta MA, 1996, J AM ACAD DERMATOL, V34, P1030, DOI 10.1016/S0190-9622(96)90284-4; Huntley AC, 1996, J AM ACAD DERMATOL, V34, P125, DOI 10.1016/S0190-9622(96)90845-2; Smith JB, 1996, J AM ACAD DERMATOL, V34, P717	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348			2			SII3	SII3						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973481				2022-12-28	WOS:A1996WA46300003
J	Friederich, PW; Sanson, BJ; Simioni, P; Zanardi, S; Huisman, MV; Kindt, I; Prandoni, P; Buller, HR; Girolami, A; Prins, MH				Friederich, PW; Sanson, BJ; Simioni, P; Zanardi, S; Huisman, MV; Kindt, I; Prandoni, P; Buller, HR; Girolami, A; Prins, MH			Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: Implications for prophylaxis	ANNALS OF INTERNAL MEDICINE			English	Article						thrombophlebitis; pregnancy complications, hematologic; protein C; protein S deficiency; antithrombins	ANTITHROMBIN-III DEFICIENCY; DEEP-VEIN THROMBOSIS; PROTEIN-C DEFICIENCY; CONGENITAL DEFICIENCY; MATERNAL MORTALITY; HEPARIN-THERAPY; PREVENTION; PUERPERIUM; FAMILIES; SURGERY	Background: It has been reported that women with an inherited deficiency of antithrombin, protein C, or protein S have an increased risk for developing venous thromboembolic disease during pregnancy and the postpartum period. However, because the available data on risk are flawed, it is difficult to define a rational, efficacious, and safe policy about prophylaxis for venous thromboembolism in these women. Objective: To determine the frequency of venous thromboembolism during pregnancy and the postpartum period in women with heritable deficiencies of anticoagulant factors. Design: Retrospective cohort study. Setting: University outpatient clinics in the Netherlands and Italy. Participants: 129 otherwise asymptomatic female family members of patients with a history of venous thromboembolism and an established deficiency of antithrombin, protein C, or protein S. Measurements: Medical history, with specific attention to episodes of venous thromboembolism and obstetric history, was taken. The anticoagulant factor status of the study participants was determined. if a patient had an episode of venous thromboembolism, subsequent pregnancies in that patient were not analyzed. Results: Of the 129 women who participated in the study, 60 had anticoagulant factor deficiency and 69 did not. In the nondeficient group, 198 pregnancies occurred; 1 of these (0.5%) was complicated by an episode of venous thromboembolism during the postpartum period. In the deficient group, 169 pregnancies occurred; 7 of these (4.1%) were complicated by an episode of venous thromboembolism during the third trimester of pregnancy (2 pregnancies [1.2%]) and the postpartum period (5 pregnancies [3.0%]). The risk for venous thromboembolism was increased eightfold in deficient women compared with nondeficient women (hazard ratio, 8.0 [95% CI, 1.2 to 184]). Conclusions: Anticoagulant factor-deficient women have an increased risk for venous thromboembolism during pregnancy and the postpartum period. Although data from an appropriate randomized clinical trial are lacking, the frequency of venous thromboembolism seen in deficient women might justify the use of anticoagulative prophylaxis during the third trimester of pregnancy and the postpartum period.	UNIV AMSTERDAM, ACAD MED CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, NL-1105 AZ AMSTERDAM, NETHERLANDS; UNIV PADUA, IST SEMEIOT MED, I-35100 PADUA, ITALY; UNIV AMSTERDAM, ACAD MED CTR, CTR HEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLA, NL-1105 AZ AMSTERDAM, NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Padua; University of Amsterdam; Academic Medical Center Amsterdam			Simioni, Paolo/AAC-5416-2022; SIMIONI, PAOLO/AAC-5438-2022	SIMIONI, PAOLO/0000-0002-6744-383X				AARO LA, 1966, OBSTET GYNECOL, V28, P553; AIACH M, 1995, THROMB HAEMOSTASIS, V74, P81; ALLAART CF, 1995, BRIT MED J, V311, P910; ANDERSON DR, 1991, THROMB HAEMOSTASIS, V65, P248; BARBOUR LA, 1994, AM J OBSTET GYNECOL, V170, P862, DOI 10.1016/S0002-9378(94)70299-3; BLONDELHILL E, 1992, THROMB RES, V65, P193, DOI 10.1016/0049-3848(92)90239-7; BROEKMANS AW, 1983, NEW ENGL J MED, V309, P340, DOI 10.1056/NEJM198308113090604; COMP PC, 1986, BLOOD, V68, P881; CONARD J, 1990, THROMB HAEMOSTASIS, V63, P319; CONARD J, 1987, THROMB HAEMOSTASIS, V58, P39; DAHLMAN TC, 1993, AM J OBSTET GYNECOL, V168, P1265, DOI 10.1016/0002-9378(93)90378-V; DESTEFANO V, 1994, THROMB HAEMOSTASIS, V71, P799; DOUGLAS AS, 1990, SCOT MED J, V35, P108, DOI 10.1177/003693309003500406; EVARTS CM, 1971, J BONE JOINT SURG AM, VA 53, P1271, DOI 10.2106/00004623-197153070-00002; GALLUS AS, 1973, NEW ENGL J MED, V288, P545, DOI 10.1056/NEJM197303152881103; GINSBERG JS, 1992, THROMB HAEMOSTASIS, V67, P519; GIROLAMI A, 1990, ACTA HAEMATOL-BASEL, V84, P162; GONZALEZ R, 1985, THROMB RES, V39, P637, DOI 10.1016/0049-3848(85)90245-2; HALL JG, 1980, AM J MED, V68, P122, DOI 10.1016/0002-9343(80)90181-3; HELLGREN M, 1982, GYNECOL OBSTET INVES, V14, P127, DOI 10.1159/000299460; HULL RD, 1990, ANN INTERN MED, V112, P663, DOI 10.7326/0003-4819-112-9-663; KAUNITZ AM, 1985, OBSTET GYNECOL, V65, P605; KIERKEGAARD A, 1983, ACTA OBSTET GYN SCAN, V62, P239, DOI 10.3109/00016348309155799; MALM J, 1988, BRIT J HAEMATOL, V68, P437, DOI 10.1111/j.1365-2141.1988.tb04232.x; NEERHOF MG, 1993, AM J PERINAT, V10, P311, DOI 10.1055/s-2007-994748; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; ROSENDAAL FR, 1991, LANCET, V337, P260, DOI 10.1016/0140-6736(91)90867-O; SACHS BP, 1987, NEW ENGL J MED, V316, P667, DOI 10.1056/NEJM198703123161105; TREFFERS PE, 1983, INT J GYNECOL OBSTET, V21, P327, DOI 10.1016/0020-7292(83)90024-3; VANDENBELT AG, IN PRESS CLIN APPL H; VILLASAN.U, 1965, AM J OBSTET GYNECOL, V93, P142, DOI 10.1016/0002-9378(65)90308-X; WEENINK GH, 1982, THROMB RES, V26, P281, DOI 10.1016/0049-3848(82)90293-6	33	194	199	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1996	125	12					955	+		10.7326/0003-4819-125-12-199612150-00003	http://dx.doi.org/10.7326/0003-4819-125-12-199612150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX768	8967705				2022-12-28	WOS:A1996VX76800005
J	Bonten, MJM; Hayden, MK; Nathan, C; vanVoorhis, J; Matushek, M; Slaughter, S; Rice, T; Weinstein, RA				Bonten, MJM; Hayden, MK; Nathan, C; vanVoorhis, J; Matushek, M; Slaughter, S; Rice, T; Weinstein, RA			Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci	LANCET			English	Article							HIGH-LEVEL RESISTANCE; STREPTOCOCCUS-FAECALIS; NOSOCOMIAL INFECTION; FAECIUM BACTEREMIA; RISK-FACTORS; D-ALANINE; GENTAMICIN; OUTBREAK	Background Vancomycin-resistant enterococci (VRE) have emerged as nosocomial pathogens during the past 5 years, but little is known about the epidemiology of VRE. We investigated colonisation of patients and environmental contamination with VRE in an endemic setting to assess the importance of different sources of colonisation. Methods Between April 12, and May 29, 1995, cultures from body sites (rectum, groin, arm, oropharynx, trachea, and stomach) and from environmental surfaces (bedrails, drawsheet, blood-pressure cuff, urine containers, and enteral feed) were obtained dairy from ail newly admitted Ventilated patients in our medical intensive-care unit (MICU). Rectal cultures were obtained from all nonventilated patients in the MICU. Strain types of VRE were determined by pulsed-field gel electrophoresis. Findings There were 97 admissions of 92 patients, of whom 38 required mechanical ventilation. Colonisation with VRE on admission was more common in Ventilated than in non-ventilated patients (nine [24%] vs three [6%], p<0.05). Of the nine ventilated patients colonised with VRE on admission, one acquired a new strain of VRE in the MICU. Of the 29 ventilated patients who were not colonised with VRE on admission, 12 (41%) acquired VRE in the MICU. The median time to acquisition of VRE was 5 days (interquartile range 3-8). Of the 13 Ventilated patients who acquired VRE, 11 (85%) were colonised with VRE by cross-colonisation, VRE were isolated from 157 (12%) of 1294 environmental cultures. The rooms of 13 patients were contaminated with VRE, but only three (23%) of these patients subsequently acquired colonisation with VRE. Pulsed-field gel electrophoresis of 262 isolates showed 20 unique strain types of VRE. Interpretation Frequent colonisation with VRE on MICU admission and subsequent cross-colonisation are important factors in the endemic spread of VRE, Persistent VRE colonisation in the gastrointestinal tract and on the skin, the presence of multiple-strain types of VRE, and environmental contamination may all contribute to the spread of VRE.	COOK CTY HOSP,DIV INFECT DIS,CHICAGO,IL 60612; RUSH MED COLL,CHICAGO,IL 60612	John H Stroger Junior Hospital Cook County; Rush University				Hayden, Mary/0000-0002-4603-8501				BINGEN EH, 1991, J CLIN MICROBIOL, V29, P1888, DOI 10.1128/JCM.29.9.1888-1892.1991; BOYCE JM, 1994, J CLIN MICROBIOL, V32, P1148, DOI 10.1128/JCM.32.5.1148-1153.1994; BRISSONNOEL A, 1990, ANTIMICROB AGENTS CH, V34, P924, DOI 10.1128/AAC.34.5.924; CDC, 1993, MMWR-MORBID MORTAL W, V42, P597; CHOW JW, 1993, J CLIN MICROBIOL, V31, P1609, DOI 10.1128/JCM.31.6.1609-1611.1993; DUTKAMALEN S, 1992, GENE, V112, P53, DOI 10.1016/0378-1119(92)90302-6; EDMOND MB, 1995, CLIN INFECT DIS, V20, P1126, DOI 10.1093/clinids/20.5.1126; EVERS S, 1993, GENE, V124, P143, DOI 10.1016/0378-1119(93)90779-3; GOERING RV, 1993, INFECT CONT HOSP EP, V14, P595; HANDWERGER S, 1993, CLIN INFECT DIS, V16, P750, DOI 10.1093/clind/16.6.750; LIVORNESE LL, 1992, ANN INTERN MED, V117, P112, DOI 10.7326/0003-4819-117-2-112; MONTECALVO MA, 1994, ANTIMICROB AGENTS CH, V38, P1363, DOI 10.1128/AAC.38.6.1363; MORRIS JG, 1995, ANN INTERN MED, V123, P250, DOI 10.7326/0003-4819-123-4-199508150-00002; MURRAY BE, 1990, J CLIN MICROBIOL, V28, P2059, DOI 10.1128/JCM.28.9.2059-2063.1990; NASHKIN CA, 1995, INFECT CONT HOSP EP, V16, P577; *NAT COMM CLIN LAB, 1993, M2A3 NAT COMM CLIN L; National Committee for Clinical Laboratory standards, 1993, M7A3 NAT COMM CLIN L; NAVARRO F, 1994, ANTIMICROB AGENTS CH, V38, P1788, DOI 10.1128/AAC.38.8.1788; RHINEHART E, 1990, NEW ENGL J MED, V323, P1814, DOI 10.1056/NEJM199012273232606; Slaughter S, 1996, ANN INTERN MED, V125, P448, DOI 10.7326/0003-4819-125-6-199609150-00004; SWENSON JM, 1993, P 33 INT C ANT AG CH, P263; UTTLEY AHC, 1988, LANCET, V1, P57; UTTLEY AHC, 1989, EPIDEMIOL INFECT, V103, P173, DOI 10.1017/S0950268800030478; ZERVOS MJ, 1987, ANN INTERN MED, V106, P687, DOI 10.7326/0003-4819-106-5-687; ZERVOS MJ, 1986, J INFECT DIS, V153, P1075, DOI 10.1093/infdis/153.6.1075	25	278	294	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1615	1619		10.1016/S0140-6736(96)02331-8	http://dx.doi.org/10.1016/S0140-6736(96)02331-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8961991				2022-12-28	WOS:A1996VX87600010
J	English, M; New, L; Peshu, N; Marsh, K				English, M; New, L; Peshu, N; Marsh, K			Video assessment of simple respiratory signs	BRITISH MEDICAL JOURNAL			English	Article							MALARIA		KEMRI,KILIFI UNIT,CLIN RES CTR,KILIFI,KENYA					English, Michael/0000-0002-7427-0826				ENGLISH M, 1995, ARCH DIS CHILD, V72, P334, DOI 10.1136/adc.72.4.334; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102; TAYLOR TE, 1993, Q J MED, V86, P99; World Health Organization, 1990, AC RESP INF CHILDR C	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1996	313	7071					1527	1528		10.1136/bmj.313.7071.1527	http://dx.doi.org/10.1136/bmj.313.7071.1527			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY691	8978229	Green Published			2022-12-28	WOS:A1996VY69100022
J	Julian, DG; Chamberlain, DA; Pocock, SJ				Julian, DG; Chamberlain, DA; Pocock, SJ			A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): A multicentre unblinded randomised clinical trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare aspirin with anticoagulation with regard to risk of cardiac death and reinfarction in patients who received anistreplase thrombolysis for myocardial infarction. Design-A multicentre unblinded randomised clinical trial. Setting-38 hospitals in six countries. Subjects-1036 patients who had been treated with anistreplase for myocardial infarction were randomly assigned to either aspirin (150 mg daily) or anticoagulation (intravenous heparin followed by warfarin or other oral anticoagulant). The trial was stopped earlier than originally intended because of the slowing rate of recruitment. Main outcome measure-Cardiac death or recurrent myocardial infarction at 30 days. Results-After 30 days cardiac death or reinfarction, occurred in 11.0% (57/517) of the patients treated with anticoagulation and 11.2% (58/519) of the patients treated with aspirin (odds ratio 1.02, 95% confidence interval 0.69 to 1.50, P=0.92). Corresponding findings at three months were 13.2% (68/517) and 12.1% (63/519) (0.91, 0.63 to 1.32, P=0.67). Patients receiving anticoagulation were more likely than patients receiving aspirin to have had severe bleeding or a stroke by three months (3.9% v 1.7% (0.44, 0.20 to 0.97, P=0.04)). Conclusion-No evidence of a difference in the incidence of cardiac events was found between the two treatment groups, though the trial is too small to claim treatment equivalence confidently. A higher incidence of severe bleeding events and strokes was detected in the group receiving anticoagulation, suggesting that aspirin may be the drug of choice for most patients in this context.	ROYAL SUSSEX CTY HOSP, BRIGHTON BN2 5BE, E SUSSEX, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND	University of Brighton; University of London; London School of Hygiene & Tropical Medicine								ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; CAIRNS JA, 1995, JAMA-J AM MED ASSOC, V273, P965; JONKER JJC, 1994, LANCET, V343, P499; MEIJER A, 1993, CIRCULATION, V87, P1524, DOI 10.1161/01.CIR.87.5.1524; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302	5	53	56	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 7	1996	313	7070					1429	1431		10.1136/bmj.313.7070.1429	http://dx.doi.org/10.1136/bmj.313.7070.1429			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX612	8973228	Green Published			2022-12-28	WOS:A1996VX61200024
J	James, P; Pfund, C; Craig, EA				James, P; Pfund, C; Craig, EA			Functional specificity among Hsp70 molecular chaperones	SCIENCE			English	Article							SHOCK COGNATE PROTEIN; PEPTIDE-BINDING; ATPASE; HSC70; BIP; FRAGMENT; REVEALS	Molecular chaperones of the 70-kilodalton heat shock protein (Hsp70) class bind to partially unfolded polypeptide substrates and participate in a wide variety of cellular processes. Differences in peptide-binding specificity among Hsp70s have led to the hypothesis that peptide binding determines specific Hsp70 functions. Protein domains were identified that were required for two separate functions of a yeast Hsp70 family. The peptide-binding domain was not required for either of these specific Hsp70 functions, which suggests that peptide-binding specificity plays little or no role in determining Hsp70 functions in vivo.	UNIV WISCONSIN,DEPT BIOMOL CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CRAIG E, 1995, PROTEIN KINESIS DYNA, V15, P441; CRAIG EA, 1985, MOL CELL BIOL, V5, P3517, DOI 10.1128/MCB.5.12.3517; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; HAUS U, 1993, EMBO J, V12, P3763, DOI 10.1002/j.1460-2075.1993.tb06054.x; HUANG SP, 1993, J BIOL CHEM, V268, P2063; JAMES P, UNPUB; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; Morimoto R. I., 1994, COLD SPRING HARBOR M; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; TSAI MY, 1994, J BIOL CHEM, V269, P5958; WALDRON C, 1977, BIOCHEM J, V168, P409, DOI 10.1042/bj1680409; WANG TF, 1993, J BIOL CHEM, V268, P26049; WIECH H, 1993, J BIOL CHEM, V268, P7414; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; ZIEGELHOFFER T, UNPUB	23	174	177	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					387	389		10.1126/science.275.5298.387	http://dx.doi.org/10.1126/science.275.5298.387			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994035				2022-12-28	WOS:A1997WC87300046
J	Miles, S; Parker, K				Miles, S; Parker, K			Men, women, and health insurance	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARE SYSTEM; MEDICAID; BENEFITS; GENDER; MOTHERS				Miles, S (corresponding author), UNIV MINNESOTA,CTR BIOMED ETH,MINNEAPOLIS,MN 55414, USA.							*A GUTTM I, 1993, UN UN INS COV REPR H; *AG HLTH CAR POL R, 1995, NAT MED EXP SURV, V43; *AG HLTH CAR POL R, 1992, NAT MED EXP SURV, V1; *AG HLTH CAR POL R, 1992, NAT MED EXP SURV, V6; BENNEFIELD RL, 1996, CURRENT POPULATI P70; BENNEFIELD RL, 1995, CURRENT POPULATI P60; BIRENZA J, 1996, TRIAL, V32, P14; Butler RN, 1996, NEW ENGL J MED, V334, P794, DOI 10.1056/NEJM199603213341211; Cherouny P, 1996, OBSTET GYNECOL, V87, P328, DOI 10.1016/0029-7844(95)00442-4; CLANCY CM, 1992, JAMA-J AM MED ASSOC, V268, P1918, DOI 10.1001/jama.268.14.1918; COHEN MA, 1994, HEALTH AFFAIR, V13, P127, DOI 10.1377/hlthaff.13.4.127; COUGHLIN TA, 1994, J HEALTH POLIT POLIC, V19, P837, DOI 10.1215/03616878-19-4-837; *DEP COMM, 1995, DYN EC WELL BEING LA; *DEP HLTH HUM SERV, 1989, PHS DHHS PUBL; DIMEO J, 1992, PENSION WORLD    OCT, P28; Harer WB, 1996, OBSTET GYNECOL, V87, P453; HOLAHAN J, 1993, HEALTH AFFAIR, V12, P177, DOI 10.1377/hlthaff.12.3.177; HOLAHAN J, 1995, CHANGING COMPOSITION; IGLEHART JK, 1992, NEW ENGL J MED, V327, P1467, DOI 10.1056/NEJM199211123272027; IGLEHART JK, 1992, NEW ENGL J MED, V326, P1715, DOI 10.1056/NEJM199206183262526; IGLEHART JK, 1993, NEW ENGL J MED, V328, P896, DOI 10.1056/NEJM199303253281226; JECKER NS, 1993, J HEALTH POLIT POLIC, V18, P657, DOI 10.1215/03616878-18-3-657; JENSEN GA, 1992, MED CARE, V30, P598, DOI 10.1097/00005650-199207000-00003; JENSEN GA, 1992, GERONTOLOGIST, V32, P693, DOI 10.1093/geront/32.5.693; *MED MED, 1995, HLTH CARE FINANCE S; MEYER MH, 1994, GENDER SOC, V8, P8, DOI 10.1177/089124394008001002; MONHEIT AC, 1989, PHS DHHS PUBLCIATION; MORRISEY MA, 1993, ANNU REV PUBL HEALTH, V14, P271, DOI 10.1146/annurev.pu.14.050193.001415; SCHORR AL, 1990, NEW ENGL J MED, V323, P543, DOI 10.1056/NEJM199008233230811; SECCOMBE K, 1992, GENDER SOC, V6, P283, DOI 10.1177/089124392006002009; SECCOMBE K, 1993, SOCIOL QUART, V34, P557, DOI 10.1111/j.1533-8525.1993.tb00106.x; SHORT P, 1990, PHS DHHS PUBLICATION; SHORT PF, 1995, JAMA-J AM MED ASSOC, V274, P1302; SOFAER S, 1990, WOMEN HEALTH, V16, P47, DOI 10.1300/J013v16n03_04; STONE RI, 1989, WOMENS STUDIES Q, V17, P20; TALLON JR, 1987, WOMEN HEALTH, V12, P119; WOLFE BL, 1995, J HUM RESOUR, V30, P42, DOI 10.2307/146190	37	23	23	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1997	336	3					218	221		10.1056/NEJM199701163360312	http://dx.doi.org/10.1056/NEJM199701163360312			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WC266	8988905				2022-12-28	WOS:A1997WC26600012
J	Rodionov, VI; Borisy, GG				Rodionov, VI; Borisy, GG			Microtubule treadmilling in vivo	SCIENCE			English	Article							DYNAMIC INSTABILITY; PIGMENT TRANSPORT; FISH MELANOPHORES; LIVING CELLS; CHROMATOPHORES; INVIVO; CENTROSOME; DIRECTION; TURNOVER; POLARITY	In vivo, cytoplasmic microtubules are nucleated and anchored by their minus ends at the centrosome and are believed to turn over by a mechanism termed dynamic instability: depolymerization and repolymerization at their plus ends. In cytoplasmic fragments of fish melanophores, microtubules were shown to detach from their nucleation site and depolymerize from their minus ends. Free microtubules moved toward the periphery by treadmilling-growth at one end and shortening from the opposite end. Frequent release from nucleation sites may be a general properly of centrosomes and permit a minus-end mechanism of microtubule turnover and treadmilling.	UNIV WISCONSIN,MOL BIOL LAB,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Borisy, Gary/0000-0002-0266-8018	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025062, R37GM025062] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25062] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD FJ, 1995, J CELL SCI, V108, P2761; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; FUJII R, 1993, INT REV CYTOL, V143, P191; GYOEVA FK, 1987, J CELL SCI, V88, P649; HAIMO LT, 1994, BIOESSAYS, V16, P727, DOI 10.1002/bies.950161007; KITANISHIYUMURA T, 1987, CELL MOTIL CYTOSKEL, V6, P106; MARGOLIS RL, 1981, NATURE, V293, P705, DOI 10.1038/293705a0; MCBEATH E, 1990, EUR J CELL BIOL, V52, P1; MCNIVEN MA, 1988, J CELL BIOL, V106, P1593, DOI 10.1083/jcb.106.5.1593; MCNIVEN MA, 1986, J CELL BIOL, V103, P1547, DOI 10.1083/jcb.103.4.1547; MCNIVEN MA, 1984, CELL, V37, P753, DOI 10.1016/0092-8674(84)90411-2; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; RODIONOV VI, 1994, J CELL BIOL, V126, P1455, DOI 10.1083/jcb.126.6.1455; RODIONOV VI, UNPUB; SAMMAK PJ, 1987, J CELL BIOL, V104, P395, DOI 10.1083/jcb.104.3.395; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; SCHLIWA M, 1983, AM ZOOL, V23, P479; SCHULZE E, 1988, NATURE, V334, P356, DOI 10.1038/334356a0; SCHULZE E, 1987, J CELL BIOL, V104, P277, DOI 10.1083/jcb.104.2.277; SOLTYS BJ, 1985, J CELL BIOL, V100, P1682, DOI 10.1083/jcb.100.5.1682; VOROBJEV IA, 1983, EUR J CELL BIOL, V30, P149; ZHAI Y, 1995, J CELL BIOL, V131, P721, DOI 10.1083/jcb.131.3.721	24	135	137	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					215	218		10.1126/science.275.5297.215	http://dx.doi.org/10.1126/science.275.5297.215			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985015				2022-12-28	WOS:A1997WC02200039
J	DelRio, JA; Heimrich, B; Borrell, V; Forster, E; Drakew, A; Alcantara, S; Nakajima, K; Miyata, T; Ogawa, M; Mikoshiba, K; Derer, P; Frotscher, M; Soriano, E				DelRio, JA; Heimrich, B; Borrell, V; Forster, E; Drakew, A; Alcantara, S; Nakajima, K; Miyata, T; Ogawa, M; Mikoshiba, K; Derer, P; Frotscher, M; Soriano, E			A role for Cajal-Retzius cells and reelin in the development of hippocampal connections	NATURE			English	Article							POSTNATAL MURINE HIPPOCAMPUS; SUBPLATE NEURONS; IN-VITRO; ORGANIZATION; PROTEIN; AXONS; PROJECTIONS; GUIDANCE; TISSUE	DURING development ache nervous system, specific recognition molecules provide the cues necessary for the formation of neural connections, In some regions, guiding cues for axonal pathfinding and target selection are provided by specific cells that exist only transiently during development, such as the floorplate or the cortical subplate(1-4). In the hippocampus, distinct groups of fibres innervate different layers(5). We have tested the hypothesis that transient neurons in the hippocampus(6,7) provide positional information for the targeting of these fibres, Here we report that ablation of Cajal-Retzius cells in organotypic slice cultures of hippocampus prevented the ingrowth of entorhinal but not of commissural afferents. Experiments Inhibiting ReeIin (an extracellular matrix protein expressed by Cajal-Retzius cells) and analysis of reeler mutant mice showed dramatic abnormalities in the development of entorhinal afferents, Thus Cajal-Retzius cells and reelin are essential for the formation of layer-specific hippocampal connections.	UNIV BARCELONA,FAC BIOL,DEPT ANIM & PLANT CELL BIOL,BARCELONA 08028,SPAIN; UNIV FREIBURG,INST ANAT 1,D-79001 FREIBURG,GERMANY; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOL NEUROBIOL LAB,TSUKUBA,IBARAKI 305,JAPAN; KOCHI MED SCH,DEPT PHYSIOL,NANKO KU,KOCHI 783,JAPAN; UNIV TOKYO,INST MED SCI,DEPT MOL NEUROBIOL,MINATO KU,TOKYO 108,JAPAN; UNIV PARIS 06,DEV NEUROBIOL LAB,F-75005 PARIS,FRANCE	University of Barcelona; University of Freiburg; RIKEN; Kochi University; University of Tokyo; UDICE-French Research Universities; Sorbonne Universite			del rio, jose antonio/L-9232-2014; Nakajima, Kazunori/L-3396-2013; Soriano, Eduardo/AAB-3216-2019; Del Rio Fernandez, Jose A/AAD-1121-2020; Alcantara, Soledad/K-3648-2014; Mikoshiba, Katsuhiko/N-7943-2015; Borrell, Victor/U-1802-2017; MIYATA, TAKAKI/I-7066-2014	del rio, jose antonio/0000-0002-5214-4909; Nakajima, Kazunori/0000-0003-1864-9425; Soriano, Eduardo/0000-0002-3204-9285; Alcantara, Soledad/0000-0003-3313-2715; Borrell, Victor/0000-0002-7833-3978; 				Amaral David G., 1995, P443; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DARCANGELO G, IN PRESS J NEUROSCI; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; FROTSCHER M, 1993, P NATL ACAD SCI USA, V90, P10400, DOI 10.1073/pnas.90.21.10400; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GHOSH A, 1992, SCIENCE, V255, P1441, DOI 10.1126/science.1542795; GHOSH A, 1990, NATURE, V347, P179, DOI 10.1038/347179a0; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GUENET JL, 1981, MOUSE NEWS LETT, V41; GULYAS AI, 1993, NATURE, V366, P683, DOI 10.1038/366683a0; HERMANN K, 1995, P NATL ACAD SCI USA, V92, P11244; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; Kennedy Timothy E., 1995, Current Opinion in Neurobiology, V5, P83, DOI 10.1016/0959-4388(95)80091-3; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LI D, 1993, NEUROSCIENCE, V52, P799, DOI 10.1016/0306-4522(93)90530-S; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SONANO E, 1989, J COMP NEUROL, V281, P586; SORIANO E, 1994, J COMP NEUROL, V342, P571, DOI 10.1002/cne.903420406; SORIANO E, 1991, J HISTOCHEM CYTOCHEM, V39, P255, DOI 10.1177/39.3.1671576; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; SUPER H, 1994, J COMP NEUROL, V344, P101, DOI 10.1002/cne.903440108; SUPER H, IN PRESS DEV BRAIN R; VOMOV JJ, 1991, EXP NEUROL, V114, P11	29	383	397	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1997	385	6611					70	74		10.1038/385070a0	http://dx.doi.org/10.1038/385070a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985248				2022-12-28	WOS:A1997WA73100051
J	Farrall, M				Farrall, M			Mapping genetic susceptibility to multiple sclerosis	LANCET			English	Editorial Material											Farrall, M (corresponding author), UNIV OXFORD,WELLCOME TRUST CTR HUMAN GENET,OXFORD OX3 7BN,ENGLAND.							DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; *MULT SCLER GEN GR, 1996, NAT GENET, V13, P469; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Robertson NP, 1996, BRAIN, V119, P449, DOI 10.1093/brain/119.2.449; SADOVNICK AD, 1988, AM J MED GENET, V29, P533, DOI 10.1002/ajmg.1320290310; Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; SUAREZ BK, 1994, GENETIC APPROACHES M	9	9	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1674	1675		10.1016/S0140-6736(05)65817-5	http://dx.doi.org/10.1016/S0140-6736(05)65817-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973425				2022-12-28	WOS:A1996VZ76600005
J	Huang, BH; Eberstadt, M; Olejniczak, ET; Meadows, RP; Fesik, SW				Huang, BH; Eberstadt, M; Olejniczak, ET; Meadows, RP; Fesik, SW			NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain	NATURE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; PROGRAMMED CELL-DEATH; DISTANCE GEOMETRY; TNF RECEPTOR; PROTEINS; APOPTOSIS; INTERACTS; ANTIGEN; BINDING; LIGAND	PROGRAMMED cell death (apoptosis) mediated by the cytokine receptor Fas is critical for the removal of autoreactive T cells(1), the mechanism of immune privilege(2,3), and for maintenance of immune-system homeostasis(4). Signalling of programmed cell death involves the self-association of a conserved cytoplasmic region of Fas called the death domain(5-7) and interaction with another death-domain-containing protein, FADD(8) (also known as MORT1)(9). Although death domains are found in several proteins(10), their three dimensional structure and the manner in which they interact is unknown, Here we describe the solution structure of the Fas death domain, as determined by NMR spectroscopy, The structure consists of six antiparallel, amphipathic a-helices arranged in a novel fold, From the structure and from site-directed mutagenesis, we have identified the region of the death domain involved in self-association and binding to the downstream signalling partner FADD.	ABBOTT LABS,DIV PHARMACEUT DISCOVERY,ABBOTT PK,IL 60064	Abbott Laboratories								BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1992, XPLOR 3 1 MANUAL; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; DILLON PJ, 1990, BIOTECHNIQUES, V9, P298; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; GOLDSTEIN P, 1995, CELL, V84, P185; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; HSU H, 1995, CELL, V81, P535; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KIM JS, 1993, PROTEIN SCI, V2, P348; KLEYWEGT GJ, 1995, STRUCTURE, V3, P535, DOI 10.1016/S0969-2126(01)00187-3; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005	30	311	321	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 19	1996	384	6610					638	641		10.1038/384638a0	http://dx.doi.org/10.1038/384638a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VZ296	8967952				2022-12-28	WOS:A1996VZ29600032
J	Jowell, PS; Baillie, J; Branch, MS; Affronti, J; Browning, CL; Bute, BP				Jowell, PS; Baillie, J; Branch, MS; Affronti, J; Browning, CL; Bute, BP			Quantitative assessment of procedural competence - A prospective study of training in endoscopic retrograde cholangiopancreatography	ANNALS OF INTERNAL MEDICINE			English	Article							SPHINCTEROTOMY; COMPLICATIONS; PHYSICIANS; SKILLS	Background: Endoscopic retrograde cholangiopancreatography (ERCP) is a technically demanding procedure that can cause substantial complications. Competence in performing ERCP and the learning curve for achieving competence are poorly understood. Objective: To evaluate the number of supervised ERCPs that physicians must do to achieve procedural competence. Competence was defined as a 0.8 probability of successfully completing specific technical components of ERCP and an overall grading of competence as judged by the attending physician. Design: Prospective study. Setting: University training program for gastroenterologists. Participants: 17 gastroenterology fellows at various stages of training. Measures: Experienced therapeutic endoscopists prospectively graded gastroenterology fellows during 1796 consecutive ERCPs. Fellows were graded on their overall level of competence for the procedure and on specific technical components of ERCP. Results: Grading data were available for 1450 ERCPs (81%). The number of ERCPs done before adequate skill was achieved was 160 for cholangiography, 140 for pancreatography, 160 for deep cannulation of the pancreatic duct, 120 for stone extraction, and 60 for stent insertion. Fellows achieved overall competence after completing 180 to 200 ERCPs. The predicted probability of overall competence was 0.8 after 137 ERCPs and 0.9 after 185 ERCPs. Conclusions: At least 180 ERCPs were required before these gastroenterology fellows could be considered competent in ERCP. This number is much greater than that previously recommended, and these findings have substantial implications for training guidelines and issues of competence and certification in ERCP. The methods used to define and evaluate competence in ERCP could also be used to assess competence in other medical procedures.	VET AFFAIRS MED CTR, DURHAM, NC 27705 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Jowell, PS (corresponding author), DUKE UNIV, MED CTR, BOX 3662, DURHAM, NC 27710 USA.							*AM SOC GASTR END, 1994, GUID ADV END TRAIN, P1026; BAILLIE J, 1993, ANN INTERN MED, V118, P73, DOI 10.7326/0003-4819-118-1-199301010-00014; Baillie J, 1994, Gastrointest Endosc Clin N Am, V4, P409; BAILLIE J, 1995, GASTROINTEST ENDOSC, V42, P373, DOI 10.1016/S0016-5107(95)70144-3; Bond J H, 1995, Gastrointest Endosc Clin N Am, V5, P337; CASS OW, 1993, ANN INTERN MED, V118, P40, DOI 10.7326/0003-4819-118-1-199301010-00008; COTTON PB, 1991, GASTROINTEST ENDOSC, V37, P383, DOI 10.1016/S0016-5107(91)70740-2; Freeman ML, 1996, NEW ENGL J MED, V335, P909, DOI 10.1056/NEJM199609263351301; FRIEDMAN LS, 1995, GASTROINTEST ENDOSC, V42, P371, DOI 10.1016/S0016-5107(95)70143-5; HAWES R, 1986, AM J MED, V80, P465, DOI 10.1016/0002-9343(86)90721-7; LAMBERT ME, 1991, BRIT J SURG, V78, P473, DOI 10.1002/bjs.1800780427; MARSHALL JB, 1995, GASTROINTEST ENDOSC, V42, P287, DOI 10.1016/S0016-5107(95)70123-0; SHERMAN S, 1991, GASTROENTEROLOGY, V101, P1068, DOI 10.1016/0016-5085(91)90735-4; *SOC AM GASTR END, 1992, GRANT PRIV GASTR END, P11; VAIRA D, 1989, LANCET, V2, P431; VENNES JA, 1992, GASTROINTEST ENDOSC, V38, P746; WIGTON RS, 1990, ANN INTERN MED, V113, P540, DOI 10.7326/0003-4819-113-7-540; WOLFINGER R, 1993, J STAT COMPUT SIM, V48, P233, DOI 10.1080/00949659308811554	18	240	242	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1996	125	12					983	989		10.7326/0003-4819-125-12-199612150-00009	http://dx.doi.org/10.7326/0003-4819-125-12-199612150-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX768	8967710				2022-12-28	WOS:A1996VX76800010
J	Dorman, P; Sandercock, P				Dorman, P; Sandercock, P			TPA within 3 hours of acute ischaemic stroke?	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; THROMBOLYTIC THERAPY; HEMORRHAGE; HEMATOMA; TRIAL				Dorman, P (corresponding author), UNIV EDINBURGH, NEUROSCI TRIALS UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		sandercock, peter/GQI-3167-2022	sandercock, peter/0000-0001-8484-0135				Adams HP, 1996, STROKE, V27, P1711; Bogousslavsky J, 1996, CEREBROVASC DIS, V6, P315; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; HUNT D, 1992, LANCET, V339, P753; LEVY DE, 1994, STROKE, V25, P291, DOI 10.1161/01.STR.25.2.291; *NAT I NEUR DIS ST, 1995, NEW ENGL J MED, V33, P1581; SIMOONS ML, 1993, LANCET, V342, P1523, DOI 10.1016/S0140-6736(05)80089-3; SIX AJ, 1990, AM J CARDIOL, V65, P119, DOI 10.1016/0002-9149(90)90071-8; WARDLAW JM, 1996, COCHRANE DATABASE SY	9	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 14	1996	348	9042					1600	1601		10.1016/S0140-6736(05)65688-7	http://dx.doi.org/10.1016/S0140-6736(05)65688-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8961984				2022-12-28	WOS:A1996VX87600003
J	Harris, CM; Scrivener, G				Harris, CM; Scrivener, G			Fundholders' prescribing costs: The first five years	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To determine whether the first five waves of English fundholding practices have reduced their prescribing costs relative to nonfundholding practices, and the duration of any reduction achieved. Design-Analysis of item and cost data for all general practices in England in the six years from April 1990 to March 1996. The practices of each of the first five waves were identified at the Prescription Pricing Authority. Setting-All general practices in England. Main outcome measures-Changes and rates of change in net ingredient cost per prescribing unit, and changes in number of items per prescribing unit in fundholding practices, before and after fundholding, relative to continuing nonfundholders. Results-Absolute prescribing costs increased over the six years, by 66% in the continuing non-fundholders and by 56-59% for fundholders. Successive waves of fundholders showed a similar pattern of change: a small relative reduction in the pre-fundholding year, maximum relative reduction in the first year, and a declining relative reduction in the second and third years. After this, their increases in costs were largely similar to those of non-fundholders. The number of items dispensed remained stable over the six years in all groups. Conclusions-The real budgets operated by fundholders were associated with a reduction in costs of about 6% relative to continuing nonfundholders, and this saving seemed to be retained during the study. The relative reduction was small compared with the absolute increase seen in all groups and disappeared after the third year of fundholding. It was brought about by lowering the average cost per item rather than by giving fewer items.	UNIV LEEDS,RES SCH MED,PRESCRIBING RES UNIT,LEEDS LS2 9NZ,W YORKSHIRE,ENGLAND	University of Leeds								*AUD COMM, 1994, PRESCR IMPR MOR RAT; BOGLE SM, 1994, BRIT MED J, V308, P637, DOI 10.1136/bmj.308.6929.637; BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; BROWN SS, 1995, BRIT MED J, V311, P1543; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; WEINER J, 1990, GP BUDGET HOLDING UK; *WHO COLL CTR DRUG, 1991, GUID DEF DAIL DOS; WILSON RPH, 1995, BRIT MED J, V311, P1347, DOI 10.1136/bmj.311.7016.1347; 1996, BRIT MED J, V312, P848	9	53	54	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1996	313	7071					1531	1534		10.1136/bmj.313.7071.1531	http://dx.doi.org/10.1136/bmj.313.7071.1531			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY691	8978232	Green Published			2022-12-28	WOS:A1996VY69100026
J	Heringlake, S; Osterkamp, S; Trautwein, C; Tillmann, HL; Boker, K; Muerhoff, S; Mushahwar, IK; Hunsmann, G; Manns, MP				Heringlake, S; Osterkamp, S; Trautwein, C; Tillmann, HL; Boker, K; Muerhoff, S; Mushahwar, IK; Hunsmann, G; Manns, MP			Association between fulminant hepatic failure and a strain of GBV virus C	LANCET			English	Article							RNA; PHOSPHORYLATION; PROTEIN; GENOME; SERUM	Background The GB virus C (GBV-C) and the hepatitis G virus (HGV) have been detected in patients with acute indeterminant hepatitis and post-transfusion hepatitis. However, the role of the new hepatitis viruses in the aetiology of fulminant hepatitis is little understood, We investigated the presence of GBV-C/HGV in patients with fulminant hepatic failure. Methods Serum samples from 22 German patients with fulminant hepatic failure and 106 symptom-free blood donors (controls) were studied for presence of GBV-C RNA by seminested reverse transcriptase PCR. Primer sequences were derived from the published gene sequences of the conserved NS3 region of the GBV-C prototype and the published isolates. Nucleotide and aminoacid sequences of GBV-C-positive isolates, the central RNA, and the published HGV and GBV-C prototype sequences were compared by multiple sequence alignment. We also compared the GBV-C sequences of virus-positive patients who had fulminant hepatic failure with those of 19 patients with chronic hepatitis from our centre, In addition, we searched databases and published papers for further GBV-C helicase sequences in patients with non-fulminant hepatitis. Findings GBV-C RNA was detected in 11 (50%) of the 22 patients with fulminant hepatic failure and in five (4.7%) of 106 control-group blood donors. Among the patients with fulminant hepatic failure, six of seven with fulminant hepatitis B and five of ten with fulminant non-A-E hepatitis were positive for GBV-C RNA. Analysis of nucleic acid sequences showed six mutations at defined positions in all 11 patients with fulminant hepatic failure who were positive for GBV-C, None of-these mutations were found in the five GBV-C-positive control-group blood donors, Of the six nucleotide changes, four caused no aminoacid changes, whereas two mutations at position 100 (G to T) and 102 (T to C) led to an alanine to serine change in the predicted translation product. However, comparison with GBV-C sequences of patients with non-fulminant hepatitis showed that this aminoacid mutation was not specific for fulminant hepatic failure, The sequence-motif containing the six nucleotide mutations detected in all patients with fulminant hepatic failure was found in only two of 19 German patients with chronic hepatitis from our centre, and in only one of 88 GBV-C sequences from non-fulminant patients reported by others. Interpretation The frequency of GBV-C RNA is higher in fulminant hepatic failure than in any other group of patients with hepatitis, particularly in patients with fulminant hepatitis B or fulminant non-A-E hepatitis. A specific strain of GBV-C may occur in serum of German patients with fulminant hepatic failure.	HANNOVER MED SCH, DEPT GASTROENTEROL & HEPATOL, D-30625 HANNOVER, GERMANY; GERMAN PRIMATE CTR, DEPT VIROL & IMMUNOL, GOTTINGEN, GERMANY; ABBOTT LABS, HEPATITIS VIRUS DISCOVERY GRP, N CHICAGO, IL 60064 USA	Hannover Medical School; Deutsches Primatenzentrum (DPZ); Abbott Laboratories								Egawa K, 1996, J MED VIROL, V49, P110, DOI 10.1002/(SICI)1096-9071(199606)49:2&lt;110::AID-JMV7&gt;3.0.CO;2-8; FERAY C, 1993, GASTROENTEROLOGY, V104, P549, DOI 10.1016/0016-5085(93)90425-C; Fiordalisi G, 1996, J INFECT DIS, V174, P181, DOI 10.1093/infdis/174.1.181; HADLER SC, 1984, ANN INTERN MED, V100, P339, DOI 10.7326/0003-4819-100-3-339; Heringlake S, 1996, J HEPATOL, V25, P239, DOI 10.1016/S0168-8278(96)80081-X; KANAI A, 1995, FEBS LETT, V376, P221, DOI 10.1016/0014-5793(95)01283-X; Kao JH, 1996, J INFECT DIS, V174, P410, DOI 10.1093/infdis/174.2.410; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; Masuko K, 1996, NEW ENGL J MED, V334, P1485, DOI 10.1056/NEJM199606063342301; MICHITAKA K, 1994, GASTROENTEROLOGY, V106, P1603, DOI 10.1016/0016-5085(94)90417-0; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; Pereira S, 1995, J BIOL CHEM, V270, P30401, DOI 10.1074/jbc.270.51.30401; Sallie R, 1996, LANCET, V347, P1552, DOI 10.1016/S0140-6736(96)90704-7; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; SIMONS JN, IN PRESS INFECT AGEN; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Tsuda F, 1996, J MED VIROL, V49, P248, DOI 10.1002/(SICI)1096-9071(199607)49:3&lt;248::AID-JMV15&gt;3.0.CO;2-8; WIDELL A, 1991, J MED VIROL, V35, P253, DOI 10.1002/jmv.1890350409; YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7	21	214	215	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 14	1996	348	9042					1626	1629		10.1016/S0140-6736(96)04413-3	http://dx.doi.org/10.1016/S0140-6736(96)04413-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8961994				2022-12-28	WOS:A1996VX87600013
J	Nelson, EAS; Yu, LM				Nelson, EAS; Yu, LM			Poverty focused assistance: New category of development aid	LANCET			English	Editorial Material									CHINESE UNIV HONG KONG,CTR CLIN TRIALS & EPIDEMIOL RES,SHATIN,HONG KONG	Chinese University of Hong Kong	Nelson, EAS (corresponding author), CHINESE UNIV HONG KONG,DEPT PAEDIAT,SHATIN,HONG KONG.		Yu, LM/J-4284-2012; Nelson, E Anthony S/ABF-4238-2020	Nelson, E Anthony S/0000-0002-2521-3403; Yu, Ly-Mee/0000-0003-0331-7364				GARNER P, 1995, BRIT MED J, V311, P72, DOI 10.1136/bmj.311.6997.72; *HUM DEV REP OFF, 1994, COUNTR HUM DEV IND 1; LOGIE DE, 1993, BRIT MED J, V307, P41, DOI 10.1136/bmj.307.6895.41; NELSON EAS, 1994, BRIT MED J, V308, P481, DOI 10.1136/bmj.308.6926.481; *OV DEV ADM, 1993, BRIT AID STAT 1988 8; RANDEL J, 1994, ACTIONAID        MAY; United Nations Development Programme, 1996, HUM DEV REP 1996, P1; 1994, ECONOMIST       1105, P60	8	12	12	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1642	1643		10.1016/S0140-6736(96)06389-1	http://dx.doi.org/10.1016/S0140-6736(96)06389-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VX876	8961996				2022-12-28	WOS:A1996VX87600024
J	Aylward, PE; Wilcox, RG; Horgan, JH; White, HD; Granger, CB; Califf, RM; Topol, EJ				Aylward, PE; Wilcox, RG; Horgan, JH; White, HD; Granger, CB; Califf, RM; Topol, EJ			Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction - A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article						hypertension; myocardial infarction; cerebrovascular disorders; thrombolytic therapy	TISSUE PLASMINOGEN-ACTIVATOR; INTRACRANIAL HEMORRHAGE; INTRACEREBRAL HEMORRHAGE; RISK; ERA	Background: Despite concern that hypertension increases the risk for intracranial hemorrhage during thrombolysis for acute myocardial infarction, the exact nature of the risk remains unclear. Objective: To assess the effects of previous hypertension and blood pressure at study entry on the outcomes of patients who had acute myocardial infarction and received thrombolysis. Design: Randomized trial. Setting: 1081 hospitals in 15 countries. Patients: 41 021 patients who had myocardial infarction accompanied by ST-segment elevation and who presented to hospitals within 6 hours of symptom onset. Intervention: One of four thrombolytic regimens. Main Outcome Measures: Mortality, stroke subtypes, and death plus disabling stroke in patients with previous hypertension and as functions of blood pressure at entry. Logistic regression analysis of relations among blood pressure at entry, baseline characteristics, and treatment effects. Results: The incidence of total stroke and intracranial hemorrhage increased as systolic blood pressure at entry increased and was particularly high for systolic pressures of about 175 mm Hg or more (incidence of total stroke, 3.4% compared with 1.17% for pressures between 100 and 124 mm Hg). Patients who had systolic blood pressure of 175 mm Hg or more at entry and who received accelerated alteplase therapy had a lower rate of death within 30 days (4.3% compared with 7.8%; P = 0.044) and a lower rate of death plus disabling stroke (4.9% compared with 8.9%; P = 0.031) than patients treated with streptokinase, despite having higher rates of total and hemorrhagic stroke (incidence of hemorrhagic stroke, 2.3% compared with 1.5%). Assumptions based on previous trials and rates of stroke from the GUSTO-I (Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries) trial suggest that in hypertensive patients with low risk for death from cardiac causes (no previous infarction, Killip class I), the risk-to-benefit ratio with thrombolysis is about unity, with about 13 lives saved per 1000 persons treated at the risk of about 13 intracranial hemorrhages. Conclusions: Patients with myocardial infarction and very elevated blood pressure who have thrombolysis and patients with myocardial infarction who do not have elevated blood pressure have a similar risk for death, but the risk for stroke is higher in the former group. Future studies should assess 1) the risk-to-benefit ratio of thrombolysis in these patients, especially those at low risk for death from cardiac causes, and 2) whether decreasing elevated blood pressure before thrombolysis reduces the incidence of stroke without increasing mortality rates.	DUKE UNIV, MED CTR, DURHAM, NC 27710 USA; QUEENS MED CTR, NOTTINGHAM NG7 2UH, ENGLAND; FLINDERS MED CTR, BEDFORD PK, SA, AUSTRALIA; BEAUMONT HOSP, DUBLIN 9, IRELAND; GREEN LANE HOSP, AUCKLAND 3, NEW ZEALAND; CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA	Duke University; University of Nottingham; Flinders Medical Centre; Cleveland Clinic Foundation			Granger, Christopher B/D-3458-2014	Granger, Christopher B/0000-0002-0045-3291; Aylward, Philip/0000-0002-5358-8552; Topol, Eric/0000-0002-1478-4729				[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; CARLSON SE, 1988, ARCH NEUROL-CHICAGO, V45, P1070, DOI 10.1001/archneur.1988.00520340024005; DEJAEGERE PP, 1992, J AM COLL CARDIOL, V19, P289, DOI 10.1016/0735-1097(92)90480-B; DEVLIN TF, 1986, 11TH P ANN SAS US GR, P646; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; GORE JM, 1995, CIRCULATION, V92, P2811, DOI 10.1161/01.CIR.92.10.2811; HUNT D, 1992, LANCET, V339, P753; KASE CS, 1992, AM J MED, V92, P384, DOI 10.1016/0002-9343(92)90268-G; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; LEW AS, 1985, CIRCULATION, V72, P1321, DOI 10.1161/01.CIR.72.6.1321; MAGGIONI A, 1991, BMJ-BRIT MED J, V302, P1428, DOI 10.1136/bmj.302.6790.1428; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; OCONNOR CM, 1990, J AM COLL CARDIOL, V16, P533, DOI 10.1016/0735-1097(90)90338-P; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SELKER HP, 1994, CIRCULATION, V90, P1657, DOI 10.1161/01.CIR.90.4.1657; SIMOONS ML, 1993, LANCET, V342, P1523, DOI 10.1016/S0140-6736(05)80089-3; SLEIGHT P, 1993, EUR HEART J, V14, P41, DOI 10.1093/eurheartj/14.suppl_G.41; SMITH PL, 1979, AM STAT, V33, P57, DOI 10.2307/2683222; WHITE HD, 1994, CIRCULATION, V89, P61, DOI 10.1161/01.CIR.89.1.61; WILCOX RG, 1988, LANCET, V2, P525; 1993, LANCET, V329, P673	24	38	38	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1996	125	11					891	+		10.7326/0003-4819-125-11-199612010-00004	http://dx.doi.org/10.7326/0003-4819-125-11-199612010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV541	8967669				2022-12-28	WOS:A1996VV54100004
J	Grubb, BP				Grubb, BP			It should once again see light	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Grubb, BP (corresponding author), MED COLL OHIO, DEPT MED, POB 10008, 3000 ARLINGTON AVE, TOLEDO, OH 43699 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1996	125	11					935	936		10.7326/0003-4819-125-11-199612010-00011	http://dx.doi.org/10.7326/0003-4819-125-11-199612010-00011			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV541	8967676				2022-12-28	WOS:A1996VV54100011
J	Jang, MS; Cai, EN; Udeani, GO; Slowing, KV; Thomas, CF; Beecher, CWW; Fong, HHS; Farnsworth, NR; Kinghorn, AD; Mehta, RG; Moon, RC; Pezzuto, JM				Jang, MS; Cai, EN; Udeani, GO; Slowing, KV; Thomas, CF; Beecher, CWW; Fong, HHS; Farnsworth, NR; Kinghorn, AD; Mehta, RG; Moon, RC; Pezzuto, JM			Cancer chemopreventive activity of resveratrol, a natural product derived from grapes	SCIENCE			English	Article							CORONARY HEART-DISEASE; TRANS-RESVERATROL; ALCOHOL; WINE; CARCINOGENESIS; CONSUMPTION; PREVENTION; ACTIVATION; STILBENES; MORTALITY	Resveratrol, a phytoalexin found in grapes and other food products, was purified and shown to have cancer chemopreventive activity in assays representing three major stages of carcinogenesis. Resveratrol was found to act as an antioxidant and antimutagen and to induce phase II drug-metabolizing enzymes (anti-initiation activity); it mediated anti-inflammatory effects and inhibited cyclooxygenase and hydroperoxidase functions (antipromotion activity); and it induced human promyelocytic leukemia cell differentiation (antiprogression activity). In addition, it inhibited the development of preneoplastic lesions in carcinogen-treated mouse mammary glands in culture and inhibited tumorigenesis in a mouse skin cancer model. These data suggest that resveratrol, a common constituent of the human diet, merits investigation as a potential cancer chemopreventive agent in humans.	UNIV ILLINOIS,COLL PHARM,DEPT MED CHEM & PHARMACOGNOSY,CHICAGO,IL 60612; UNIV ILLINOIS,DEPT PHARM,CHICAGO,IL 60612; UNIV COMPLUTENSE MADRID,DEPT FARMACOL,E-28040 MADRID,SPAIN; UNIV ILLINOIS,COLL MED,DEPT SURG ONCOL,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Complutense University of Madrid; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Slowing, Karla V/I-1135-2015	Slowing, Karla V/0000-0002-8106-2240; Kinghorn, A. Douglas/0000-0002-6647-8707; Udeani, George/0000-0001-5797-7849	NCI NIH HHS [P01 CA48112] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA048112] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARICHI H, 1982, CHEM PHARM BULL, V30, P1766; DERCKS W, 1989, PHYSIOL MOL PLANT P, V34, P289; Ector BJ, 1996, AM J ENOL VITICULT, V47, P57; GERHAUSER C, 1995, NAT MED, V1, P260, DOI 10.1038/nm0395-260; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; GOLDBERG DM, 1995, AM J ENOL VITICULT, V46, P159; GOLDBERG DM, 1995, CLIN CHEM, V41, P14; GOLDBERG DM, 1995, CLIN CHIM ACTA, V237, P155, DOI 10.1016/0009-8981(95)06069-P; GOODWIN JS, 1984, AM J MED, V77, P7, DOI 10.1016/S0002-9343(84)80086-8; JAYATILAKE GS, 1993, J NAT PROD, V56, P1805, DOI 10.1021/np50100a021; JEANDET P, 1991, AM J ENOL VITICULT, V42, P41; KIMURA Y, 1985, BIOCHIM BIOPHYS ACTA, V834, P275; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; KLATSKY AL, 1994, ALCOHOL CLIN EXP RES, V18, P88, DOI 10.1111/j.1530-0277.1994.tb00886.x; KUDO T, 1980, GANN, V71, P260; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; MANNILA E, 1993, PHYTOCHEMISTRY, V33, P813, DOI 10.1016/0031-9422(93)85280-5; MOON RC, 1990, CHEM BIOL SYNTHETIC, P501; PACEASCIAK CR, 1995, CLIN CHIM ACTA, V235, P207, DOI 10.1016/0009-8981(95)06045-1; PLESCIA OJ, 1975, P NATL ACAD SCI USA, V72, P1848, DOI 10.1073/pnas.72.5.1848; POLLARD M, 1983, CANCER LETT, V21, P57, DOI 10.1016/0304-3835(83)90082-4; PROCHASKA HJ, 1988, ANAL BIOCHEM, V169, P328, DOI 10.1016/0003-2697(88)90292-8; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; RomeroPerez AI, 1996, J AGR FOOD CHEM, V44, P2124, DOI 10.1021/jf9507654; SHAMON LA, 1995, ANTICANCER RES, V14, P1775; SHARMA S, 1994, CANCER RES, V54, P5848; SIEMANN EH, 1992, AM J ENOL VITICULT, V43, P49; SLOWING K, 1994, J ETHNOPHARMACOL, V43, P9, DOI 10.1016/0378-8741(94)90110-4; SPORN MB, 1979, FED PROC, V38, P2528; SUH N, 1995, ANTICANCER RES, V15, P233; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; VANDEROUDERAA FJG, 1982, METHOD ENZYMOL, V86, P60; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WATTENBERG LW, 1993, CANCER RES, V53, P5890; WILD D, 1987, CARCINOGENESIS, V8, P541, DOI 10.1093/carcin/8.4.541; ZENSER TV, 1983, J PHARMACOL EXP THER, V227, P545; ZHANG YS, 1994, P NATL ACAD SCI USA, V91, P3147, DOI 10.1073/pnas.91.8.3147	37	4071	4441	24	939	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					218	220		10.1126/science.275.5297.218	http://dx.doi.org/10.1126/science.275.5297.218			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985016				2022-12-28	WOS:A1997WC02200040
J	Bartholomew, MM; Jansen, RW; Jeffers, LJ; Reddy, KR; Johnson, LC; Bunzendahl, H; Condreay, LD; Tzakis, AG; Schiff, ER; Brown, NA				Bartholomew, MM; Jansen, RW; Jeffers, LJ; Reddy, KR; Johnson, LC; Bunzendahl, H; Condreay, LD; Tzakis, AG; Schiff, ER; Brown, NA			Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation	LANCET			English	Article							CHAIN-REACTION ASSAY; INVITRO	Background Orthotopic liver transplantation for end-stage hepatitis-B-virus (HBV) infection is commonly complicated by recurrence of HBV, Lamivudine, a cytosine nucleoside analogue, has been shown to suppress HBV infection. We report the development of resistance to lamivudine in three patients who underwent transplantation for end-stage liver disease secondary to hepatitis B. Methods Two of the patients received lamivudine for recurrent HBV infection after transplantation, whereas the third patient began treatment 1 month before transplantation in an attempt to prevent HBV recurrence after transplantation. The three patients initially responded well to treatment, but viral recurrence occurred after 9-10 months of treatment in all patients. HBV DNA was amplified from serum and sequenced through a conserved polymerase domain-the tyrosine, methionine, aspartate, aspartate (YMDD) locus. We assessed the susceptibility of HBV to lamivudine by infecting primary human hepatocytes with serum taken before the start of treatment and after recurrence in varying concentrations of lamivudine. Findings DNA sequencing showed a common mutation within the YMDD locus of the HBV polymerase gene in all during lamivudine treatment. In hepatocyte infected with pretreatment serum, HBV DNA concentrations were reduced to less than 6% of those in control cultures by addition of lamivudine in concentrations as low as 0.03 mu mol/L. By contrast, in cultures treated with serum taken after recurrence, HBV DNA concentrations did not fall below 20% of control values, even with lamivudine at 30 mu mol/L. Interpretation Resistance to lamivudine has been reported in HIV patients with mutations in the YMDD locus of the polymerase gene. Our findings indicate a common mechanism of lamivudine resistance for HIV and HBV that involves similar point mutations in homologous domains of the viral polymerases.	GLAXO WELLCOME INC,RES TRIANGLE PK,NC 27709; UNIV MIAMI,SCH MED,DIV HEPATOL,MIAMI,FL; UNIV MIAMI,SCH MED,DIV TRANSPLANT SURG,MIAMI,FL; VET AFFAIRS MED CTR,MIAMI,FL 33125; UNIV N CAROLINA,SCH MED,DEPT SURG,CHAPEL HILL,NC; UNIV N CAROLINA,SCH MED,DEPT ABDOMINAL TRANSPLANTAT,CHAPEL HILL,NC	GlaxoSmithKline; University of Miami; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine								Condreay LD, 1996, ANTIMICROB AGENTS CH, V40, P520, DOI 10.1128/AAC.40.2.520; DAVIES SE, 1991, HEPATOLOGY, V13, P150, DOI 10.1002/hep.1840130122; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495; FURMAN PA, 1992, ANTIMICROB AGENTS CH, V36, P2686, DOI 10.1128/AAC.36.12.2686; Grellier L, 1996, LANCET, V348, P1212, DOI 10.1016/S0140-6736(96)04444-3; JANSEN RW, 1993, ANTIMICROB AGENTS CH, V37, P441, DOI 10.1128/AAC.37.3.441; KANEKO S, 1989, P NATL ACAD SCI USA, V86, P312, DOI 10.1073/pnas.86.1.312; Ling R, 1996, HEPATOLOGY, V24, P711, DOI 10.1053/jhep.1996.v24.pm0008781347; SAMUEL D, 1993, NEW ENGL J MED, V329, P1842, DOI 10.1056/NEJM199312163292503; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; Tipples GA, 1996, HEPATOLOGY, V24, P714, DOI 10.1053/jhep.1996.v24.pm0008781348; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; TODO S, 1991, HEPATOLOGY, V13, P619, DOI 10.1002/hep.1840130402; Tyrrell D. L. J., 1993, Clinical and Investigative Medicine, V16, pB77; VANTHIEL DH, 1994, HEPATOLOGY, V20, pS20, DOI 10.1002/hep.1840200707	17	387	413	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					20	22		10.1016/S0140-6736(96)02266-0	http://dx.doi.org/10.1016/S0140-6736(96)02266-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988118	hybrid			2022-12-28	WOS:A1997WA72500012
J	PadmaNathan, H; Hellstrom, WJG; Kaiser, FE; Labasky, RF; Lue, TF; Nolten, WE; Norwood, PC; Peterson, CA; Shabsigh, R; Tam, PY; Place, VA; Gesundheit, N				PadmaNathan, H; Hellstrom, WJG; Kaiser, FE; Labasky, RF; Lue, TF; Nolten, WE; Norwood, PC; Peterson, CA; Shabsigh, R; Tam, PY; Place, VA; Gesundheit, N			Treatment of men with erectile dysfunction with transurethral alprostadil	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	53rd Annual Meeting of the American-Geriatrics-Society	MAY 01-05, 1996	CHICAGO, IL	Amer Geriatr Soc			HUMAN CORPUS CAVERNOSUM; INTRACAVERNOUS INJECTION; PENILE ERECTION; IMPOTENCE; PROSTAGLANDIN-E1; PHARMACOTHERAPY; MANAGEMENT; RELAXATION; METABOLISM; E2	Background Erectile dysfunction in men is common. We evaluated a system by which alprostadil (prostaglandin E(1)) is delivered transurethrally to treat this disorder. Methods Alprostadil was delivered transurethrally in a double-blind, placebo-controlled study of 1511 men, 27 to 88 years of age, who had chronic erectile dysfunction from various organic causes. The men were first tested in the clinic with up to four doses of the drug (125, 250, 500, and 1000 mu g); those who had sufficient responses were randomly assigned to treatment with either the effective dose of alprostadil or placebo for three months at home. Results During in-clinic testing, 996 men (65.9 per cent) had erections sufficient for intercourse. Of these men, 961 reported the results of at least one home treatment; 299 of the 461 treated with alprostadil (64.9 percent) had intercourse successfully at least once, as compared with 93 of the 500 who received placebo (18.6 percent, P<0.001). On average, 7 of 10 alprostadil administrations were followed by intercourse in men responsive to treatment. The efficacy of alprostadil was similar regardless of age or the cause of erectile dysfunction, including vascular disease, diabetes, surgery, and trauma (P<0.001 for all comparisons with placebo). The most common side effect was mild penile pain, which occurred after 10.8 percent of alprostadil treatments, but the pain rarely resulted in refusal to continue in the study. Hypotension occurred in the clinic in 3.3 percent of men receiving alprostadil. Hypotension-related symptoms were uncommon at home. No men had priapism or penile fibrosis. Conclusions In men with erectile dysfunction, transurethral alprostadil therapy resulted in erections in the clinic and in intercourse at home. (C)1997, Massachusetts Medical Society.	VIVUS INC, DEPT CLIN RES, MENLO PK, CA 94025 USA; UNIV SO CALIF, DEPT UROL, LOS ANGELES, CA 90089 USA; MALE CLIN, SANTA MONICA, CA USA; TULANE UNIV, MED CTR, DEPT UROL, NEW ORLEANS, LA USA; ST LOUIS UNIV, SCH MED, DIV GERIATR MED, ST LOUIS, MO 63104 USA; UNIV UTAH, DIV UROL, SALT LAKE CITY, UT USA; UNIV CALIF SAN FRANCISCO, DEPT UROL, SAN FRANCISCO, CA 94143 USA; UNIV WISCONSIN, ENDOCRINOL SECT, MADISON, WI USA; PEACHWOOD MED GRP, CLOVIS, CA USA; COLUMBIA PRESBYTERIAN MED CTR, DEPT UROL, NEW YORK, NY USA	University of Southern California; Tulane University; Saint Louis University; Utah System of Higher Education; University of Utah; University of California System; University of California San Francisco; University of Wisconsin System; University of Wisconsin Madison; Columbia University; NewYork-Presbyterian Hospital				Hellstrom, Wayne/0000-0003-1284-959X				BEJANY DE, 1993, J UROLOGY, V150, P190, DOI 10.1016/S0022-5347(17)35433-2; BRODERICK GA, 1992, J UROLOGY, V147, P57, DOI 10.1016/S0022-5347(17)37132-X; CAVALLINI G, 1991, J UROLOGY, V146, P50, DOI 10.1016/S0022-5347(17)37712-1; COOKSON MS, 1993, J UROLOGY, V149, P1308, DOI 10.1016/S0022-5347(17)36376-0; DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83; Efron B., 1994, MONOGRAPHS STAT APPL; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; Fleiss JL, 1981, STAT METHODS RATES P; HAMBERG M, 1972, J BIOL CHEM, V247, P3495; HAMBERG M, 1971, J BIOL CHEM, V246, P6713; HEDLUND H, 1985, J UROLOGY, V134, P1245, DOI 10.1016/S0022-5347(17)47704-4; ISHII N, 1989, J UROLOGY, V141, P323, DOI 10.1016/S0022-5347(17)40754-3; KERFOOT WW, 1991, J UROLOGY, V146, P1022, DOI 10.1016/S0022-5347(17)37992-2; KIM ED, 1995, J UROLOGY, V153, P1828, DOI 10.1016/S0022-5347(01)67323-3; KRANE RJ, 1989, NEW ENGL J MED, V321, P1648, DOI 10.1056/NEJM198912143212406; LAKIN MM, 1990, J UROLOGY, V143, P1138, DOI 10.1016/S0022-5347(17)40208-4; LEHMANN EL, 1975, NONPARAMETRICS; LEVINE SB, 1989, J UROLOGY, V141, P54, DOI 10.1016/S0022-5347(17)40585-4; Linet OI, 1996, NEW ENGL J MED, V334, P873, DOI 10.1056/NEJM199604043341401; LUE TF, 1987, J UROLOGY, V137, P829, DOI 10.1016/S0022-5347(17)44267-4; LUE TF, 1988, CONT MANAGEMENT IMPO, P39; LUE TF, 1992, CAMPBELLS UROLOGY, V1, P709; MEINHARDT W, 1993, J UROLOGY, V149, P1285, DOI 10.1016/S0022-5347(17)36369-3; MONTAGUE DK, 1987, J UROLOGY, V138, P68, DOI 10.1016/S0022-5347(17)42992-2; MORALES A, 1993, HOSP PRACT, V28, P15, DOI 10.1080/21548331.1993.11442898; MORLEY JE, 1993, ADV INTERNAL MED, V38, P151; PADMANATHAN H, 1987, WORLD J UROL, V5, P160, DOI 10.1007/BF00326824; PALMER LS, 1994, J UROLOGY, V152, P1308, DOI 10.1016/S0022-5347(17)32573-9; PAOLETTI R, 1986, PROSTAGLANDIN E1 ATH, P3; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; Rossi D, 1993, Prog Urol, V3, P796; ROY AC, 1989, BRIT J UROL, V64, P180, DOI 10.1111/j.1464-410X.1989.tb05984.x; Steers W D, 1990, Semin Urol, V8, P66; TRIGOROCHA F, 1994, NEUROUROL URODYNAM, V13, P71, DOI 10.1002/nau.1930130110; VANAHLEN H, 1994, J UROLOGY, V151, P1227, DOI 10.1016/S0022-5347(17)35218-7; VIRAG R, 1991, J UROLOGY, V145, P287, DOI 10.1016/S0022-5347(17)38316-7; VONHEYDEN B, 1993, J UROLOGY, V149, P1288, DOI 10.1016/S0022-5347(17)36370-X; WALDHAUSER M, 1988, J UROLOGY, V140, P525, DOI 10.1016/S0022-5347(17)41709-5; WOLFSON B, 1993, UROLOGY, V42, P73, DOI 10.1016/0090-4295(93)90345-B; 1994, MED LETT DRUGS THER, V36, P115	40	381	395	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1997	336	1					1	7		10.1056/NEJM199701023360101	http://dx.doi.org/10.1056/NEJM199701023360101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WA496	8970933				2022-12-28	WOS:A1997WA49600001
J	Gostin, LO; Lazzarini, Z; Jones, S; Flaherty, K				Gostin, LO; Lazzarini, Z; Jones, S; Flaherty, K			Prevention of HIV/AIDS and other blood-borne diseases among injection drug users - A national survey on the regulation of syringes and needles	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; COMMUNITY PHARMACIES; EXCHANGE PROGRAM; HIV-INFECTION; UNITED-STATES; SAN-FRANCISCO; RISK BEHAVIOR; AIDS; CONNECTICUT	We report the results of a survey of laws and regulations governing the sale and possession of needles and syringes in the United States and its territories and discuss legal and public health proposals to increase the availability of sterile syringes, as a human immunodeficiency virus (HIV) transmission prevention measure, for persons who continue to inject drugs. Every state, the District of Columbia (DC), and the Virgin islands (VI) have enacted state or local laws or regulations that restrict the sale, distribution, or possession of syringes, Drug paraphernalia laws prohibiting the sale, distribution, and/or possession of syringes known to be used to introduce illicit drugs into the body exist in 47 states, DC, and VI. Syringe prescription laws prohibiting the sale, distribution, and possession of syringes without a valid medical prescription exist in 8 states and VI. Pharmacy regulations or practice guidelines restrict access to syringes in 23 states. We discuss the following legal and public health approaches to improve the availability of sterile syringes to prevent blood-borne disease among injection drug users: (1) clarify the legitimate medical purpose of sterile syringes for the prevention of HIV and other blood-borne infections; (2) modify drug paraphernalia laws to exclude syringes; (3) repeal syringe prescription laws; (4) repeal pharmacy regulations and practice guidelines restricting the sale of sterile syringes; (5) promote professional training of pharmacists, other health professionals, and law enforcement officers about the prevention of blood-borne infections; (6) permit local discretion in establishing syringe exchange programs; and (7) design community programs for safe syringe disposal.	GEORGETOWN JOHNS HOPKINS PROGRAM LAW & PUBL HLTH, WASHINGTON, DC USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA USA	Johns Hopkins University; Harvard University; Harvard T.H. Chan School of Public Health; Centers for Disease Control & Prevention - USA								*ABA AIDS COORD CO, 1988, AIDS LEG ISS; ALLEN DM, 1992, AM J PUBLIC HEALTH, V82, P541, DOI 10.2105/AJPH.82.4.541; ALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259; *AM MED ASS, 1996, PHYS GUID HIV PREV; *AM MED ASS, 1996, INTR DRUG US SYR SUB; BLACK JL, 1986, NEW ENGL J MED, V314, P446; BRUNEAU J, 1996, P 11 INT C AIDS JUL; Burris S, 1996, AM J PUBLIC HEALTH, V86, P1161, DOI 10.2105/AJPH.86.8_Pt_1.1161; *CDCP, 1996, HIV AIDS SURV 1995; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P969; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P849; CELENTANO DD, 1991, AM J PUBLIC HEALTH, V81, P1291, DOI 10.2105/AJPH.81.10.1291; Centers for Disease Control and Prevention, 1996, MMWR-MORBID MORTAL W, V45, P392; CHAISSON RE, 1987, AM J PUBLIC HEALTH, V77, P169, DOI 10.2105/AJPH.77.2.169; CHEEVERS J, 1995, LOS ANGELES TIM 0109, pA1; CHERUBIN CE, 1993, ANN INTERN MED, V119, P1017, DOI 10.7326/0003-4819-119-10-199311150-00009; CLARK C, 1994, SAN DIEGO UNION 0629, pB1; *COMM MED LAW, 1986, LEG NONPR SAL HYP NE; COMPTON WM, 1992, AM J PUBLIC HEALTH, V82, P595, DOI 10.2105/AJPH.82.4.595; CROATTO JP, 1987, AUST J PHARM, V68, P602; DESJARLAIS DC, 1985, NEW ENGL J MED, V313, P1476; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; DONOGHOE MC, 1989, AIDS, V3, P267, DOI 10.1097/00002030-198905000-00003; ETTELSON R, 1991, PHARM TIMES, V57, P107; FELDMAN HIV, 1988, NIDA MONOGRAPH, V80; FERNANDEZ MA, 1993, ALEPH, VOL 8, PT 2, P44; FRIEDLAND GH, 1987, NEW ENGL J MED, V317, P1125, DOI 10.1056/NEJM198710293171806; Garfein RS, 1996, AM J PUBLIC HEALTH, V86, P655, DOI 10.2105/AJPH.86.5.655; GLANZ A, 1989, BRIT MED J, V299, P1076, DOI 10.1136/bmj.299.6707.1076; GLEGHORN AA, 1995, J ACQ IMMUN DEF SYND, V10, P97; GOSTIN L, 1991, HARVARD CIVIL RIGHTS, V26, P113; GOSTIN LO, 1993, DIMENSIONS HIV PREVE; GROSECLOSE SL, 1995, J ACQ IMMUN DEF SYND, V10, P82; GRUND JPC, 1995, J ACQ IMMUN DEF SYND, V10, P104, DOI 10.1097/00042560-199509000-00016; HAGAN H, 1991, JAMA-J AM MED ASSOC, V266, P1646, DOI 10.1001/jama.1991.03470120048019; HAHN RA, 1989, JAMA-J AM MED ASSOC, V261, P2677, DOI 10.1001/jama.261.18.2677; HARTGERS C, 1989, AIDS, V3, P571, DOI 10.1097/00002030-198909000-00003; HAVERKOS HW, 1994, J ACQ IMMUN DEF SYND, V7, P741; Heimer R., 1994, AIDS and Public Policy Journal, V9, P59; HOGE P, 1994, SACRAMENTO BEE  1205, pA1; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; JARLAIS DCD, 1988, AM PSYCHOL, V43, P865, DOI 10.1037/0003-066X.43.11.865; JARLAIS DCD, 1994, JAMA-J AM MED ASSOC, V271, P121, DOI 10.1001/jama.271.2.121; KAPLAN EH, 1992, J ACQ IMMUN DEF SYND, V5, P163; Koester S., 1990, International Journal on Drug Policy, V1, P28; KOESTER SK, 1994, HUM ORGAN, V53, P286; LJUNGBERG B, 1991, J ACQ IMMUN DEF SYND, V4, P890; LURIE P, 1993, PUBLIC HLTH IMPACT N, V1; MAGURA S, 1989, AM J PUBLIC HEALTH, V79, P459, DOI 10.2105/AJPH.79.4.459; MUSTO DF, 1987, AM DISEASE ORIGINS N; *NAT COMM AIDS, 1991, TWIN EP SUBST US HIV; NELSON KE, 1991, JAMA-J AM MED ASSOC, V266, P2259, DOI 10.1001/jama.266.16.2259; NEWMEYER JA, 1988, J PSYCHOACTIVE DRUGS, V20, P185, DOI 10.1080/02791072.1988.10524493; NORMAND J, 1995, PREVENTING HIV TRANS; Paone D, 1995, J Am Med Womens Assoc (1972), V50, P109; PASCAL C, 1988, NIDA MONOGRAPH, V80; Prevots DR, 1996, AM J EPIDEMIOL, V143, P733, DOI 10.1093/oxfordjournals.aje.a008807; RICE DP, 1991, PUBLIC HEALTH REP, V106, P280; SINGER M, 1995, J ACQ IMMUN DEF SYND, V10, P104, DOI 10.1097/00042560-199509000-00015; STRYKER J, 1989, J HEALTH POLIT POLIC, V14, P719, DOI 10.1215/03616878-14-4-719; TURNER CF, 1989, AIDS SEXUAL BEHAV IN; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; USA Council of State and Territorial Epidemiologists, 1987, Morbidity and Mortality Weekly Report, V36, P1; VALLEROY LA, 1995, J ACQ IMMUN DEF SYND, V10, P73; VEAL GR, 1981, GEORGIA LAW REV, V16, P137; WATTERS JK, 1994, JAMA-J AM MED ASSOC, V271, P115, DOI 10.1001/jama.271.2.115; Zellmer W A, 1994, Am Pharm, VNS34, P48	67	102	102	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1997	277	1					53	62		10.1001/jama.277.1.53	http://dx.doi.org/10.1001/jama.277.1.53			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VZ767	8980211				2022-12-28	WOS:A1997VZ76700030
J	Ruhnke, GW				Ruhnke, GW			Physician Supply and the Shifting Paradigm of Medical Student Choice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Stanford Univ, Sch Med, Stanford, CA USA	Stanford University	Ruhnke, GW (corresponding author), Stanford Univ, Sch Med, Stanford, CA USA.							*ASS AM MED COLL, 1996, AAMC DAT BOOK STAT I; EBELL MH, 1989, JAMA-J AM MED ASSOC, V262, P1630, DOI 10.1001/jama.1989.03430120080018; FUCHS VR, 1978, J HUM RESOUR, V13, P35, DOI 10.2307/145247; GOLDBERG JH, 1995, MED ECON        0911, P184; KASSEBAUM DG, 1993, ACAD MED, V68, P934, DOI 10.1097/00001888-199312000-00019; LUFT HS, 1990, HOSP VOLUME PHYSSICI; Miller RS, 1996, JAMA-J AM MED ASSOC, V275, P708, DOI 10.1001/jama.275.9.708; *NAT RES MATCH PRO, 1991, NRMP DAT; REINHARDT UE, 1994, INQUIRY-J HEALTH CAR, V31, P250; Rivo ML, 1996, NEW ENGL J MED, V334, P892, DOI 10.1056/NEJM199604043341405; ROTHENTHAL MP, 1994, JAMA-J AM MED ASSOC, V271, P914; Ruhnke GW, 1996, HEALTH AFFAIR, V15, P113, DOI 10.1377/hlthaff.15.1.113; SCHROEDER SA, 1993, NEW ENGL J MED, V328, P961, DOI 10.1056/NEJM199304013281312; STREETEN P, 1989, JOAN ROBINSON MONDER, P723; TADOV AR, 1983, NEW ENGL J MED, V308, P1235; *US DHHS, 1981, SUMM REP GRAD MED ED; Weinber JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WHITCOMB ME, 1986, NEW ENGL J MED, V314, P710, DOI 10.1056/NEJM198603133141111	18	11	11	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1997	277	1					70	71		10.1001/jama.277.1.70	http://dx.doi.org/10.1001/jama.277.1.70			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ767	8980216				2022-12-28	WOS:A1997VZ76700034
J	Saah, AJ; Hoover, DR				Saah, AJ; Hoover, DR			''Sensitivity'' and ''specificity'' reconsidered: The meaning of these terms in analytical and diagnostic settings	ANNALS OF INTERNAL MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; IMMUNODEFICIENCY-VIRUS INFECTION; BLOOD MONONUCLEAR-CELLS; TREPONEMA-PALLIDUM; HIV-1 INFECTION; PROVIRAL DNA; AMPLIFICATION; NEUROSYPHILIS; RELIABILITY; CULTURE	Imprecise usage of the terms ''sensitivity'' and ''specificity'' produces confusion in the diagnostic use of sophisticated laboratory test results. ''Analytical sensitivity'' represents the smallest amount of substance in a sample that can accurately be measured by an assay. ''Analytical specificity'' refers to the ability of an assay to measure one particular organism or substance, rather than others, in a sample. An assay's analytical sensitivity and analytical specificity are distinct from that assay's clinical diagnostic sensitivity and diagnostic specificity. ''Diagnostic sensitivity'' is the percentage of persons who have a given disorder who are identified by the assay as positive for the disorder. High analytical sensitivity does not guarantee acceptable diagnostic sensitivity. ''Diagnostic specificity'' is the percentage of persons who do not have a given condition who are identified by the assay as negative for the condition. False-positive reactions occur because of sample contamination and diminish the diagnostic specificity of the assay. The terms ''sensitivity'' and ''specificity'' should be used with the requisite adjectives because the ''diagnostic'' and the ''analytical'' meanings of these terms are very different.			Saah, AJ (corresponding author), JOHNS HOPKINS UNIV, SCH PUBL HLTH, 615 N WOLFE ST, ROOM E6006, BALTIMORE, MD 21205 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035042] Funding Source: NIH RePORTER; NIAID NIH HHS [U01-AI-35042] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMBRUSTER DA, 1994, CLIN CHEM, V40, P1233; BABU PG, 1993, PCR METH APPL, V3, P63; BOURNIQUE B, 1992, MOL CELL PROBE, V6, P443, DOI 10.1016/0890-8508(92)90040-5; CANDOTTI D, 1991, AIDS, V5, P1003, DOI 10.1097/00002030-199108000-00012; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CLEWLEY JP, 1989, J VIROL METHODS, V25, P179, DOI 10.1016/0166-0934(89)90031-1; COUTLEE F, 1991, MOL CELL PROBE, V5, P241, DOI 10.1016/0890-8508(91)90046-M; CUZICK J, 1995, LANCET, V345, P1533, DOI 10.1016/S0140-6736(95)91086-7; DEROSSI A, 1991, AIDS, V5, P15, DOI 10.1097/00002030-199101000-00002; GARCIAFERRER FJ, 1995, AM J OPHTHALMOL, V119, P7, DOI 10.1016/S0002-9394(14)73807-3; GORDON SM, 1994, NEW ENGL J MED, V331, P1469, DOI 10.1056/NEJM199412013312201; HOROWITZ HW, 1994, NEW ENGL J MED, V331, P1488, DOI 10.1056/NEJM199412013312204; MACGREGOR RR, 1995, CLIN INFECT DIS, V21, P122, DOI 10.1093/clinids/21.1.122; NOCTON JJ, 1994, NEW ENGL J MED, V330, P229, DOI 10.1056/NEJM199401273300401; NOORDHOEK GT, 1991, J CLIN MICROBIOL, V29, P1976, DOI 10.1128/JCM.29.9.1976-1984.1991; NOORDHOEK GT, 1993, NEW ENGL J MED, V329, P2036, DOI 10.1056/NEJM199312303292713; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; Owens DK, 1996, ANN INTERN MED, V124, P803, DOI 10.7326/0003-4819-124-9-199605010-00004; ROSENTHAL N, 1994, NEW ENGL J MED, V331, P315, DOI 10.1056/NEJM199408043310508; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANCHEZ PJ, 1993, J INFECT DIS, V167, P148, DOI 10.1093/infdis/167.1.148; Tietz N.W., 1985, TXB CLIN CHEM, V1st ed.; TOSSWILL JHC, 1994, LANCET, V343, P1431, DOI 10.1016/S0140-6736(94)92554-2; Vandamme A M, 1994, Verh K Acad Geneeskd Belg, V56, P231; YENI P, 1996, STATUS TRENDS GLOBAL; ZAAIJER HL, 1993, LANCET, V341, P722, DOI 10.1016/0140-6736(93)90488-3	26	153	163	2	43	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1997	126	1					91	94		10.7326/0003-4819-126-1-199701010-00026	http://dx.doi.org/10.7326/0003-4819-126-1-199701010-00026			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA165	8992938				2022-12-28	WOS:A1997WA16500026
J	VandenAckerveken, G; Marois, E; Bonas, U				VandenAckerveken, G; Marois, E; Bonas, U			Recognition of the bacterial avirulence protein AvrBs3 occurs inside the host plant cell	CELL			English	Article							CAMPESTRIS PV VESICATORIA; T-DNA TRANSFER; NUCLEAR-LOCALIZATION; HYPERSENSITIVE RESPONSE; DISEASE RESISTANCE; GENE AVRBS3; AGROBACTERIUM-TUMEFACIENS; HRP PATHWAY; PLASMID; ELICITOR	The molecular mechanism by which bacterial avirulence genes mediate recognition by resistant host plants has been enigmatic for more than a decade. In this paper we provide evidence that the Xanthomonas campestris pv. vesicatoria avirulence protein AvrBs3 is recognized inside the plant cell. Transient expression of avrBs3 in pepper leaves, using Agrobacterium tumefaciens for gene delivery, results in hypersensitive cell death, specifically on plants carrying the resistance gene Bs3. In addition, for its intracellular recognition, AvrBs3 requires nuclear localization signals that are present in the C-terminal region of the protein. We propose that AvrBs3 is translocated into plant cells via the Xanthomonas Hrp type III secretion system and that nuclear factors are involved in AvrBs3 perception.	CNRS, INST SCI VEGETALES, F-91198 GIF SUR YVETTE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Marois, Eric/H-9246-2016; Marois, Eric/AAZ-5549-2021; Van den Ackerveken, Guido/B-8568-2011	Marois, Eric/0000-0003-4147-3747; Marois, Eric/0000-0003-4147-3747; Van den Ackerveken, Guido/0000-0002-0183-8978				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARLAT M, 1994, EMBO J, V13, P543, DOI 10.1002/j.1460-2075.1994.tb06292.x; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BONAS U, 1989, MOL GEN GENET, V218, P127, DOI 10.1007/BF00330575; BONAS U, 1993, MOL GEN GENET, V238, P261, DOI 10.1007/BF00279555; BONAS U, 1991, MOL PLANT MICROBE IN, V4, P81, DOI 10.1094/MPMI-4-081; BROWN I, 1993, MOL PLANT MICROBE IN, V6, P376, DOI 10.1094/MPMI-6-376; BUNDOCK P, 1995, EMBO J, V14, P3206, DOI 10.1002/j.1460-2075.1995.tb07323.x; CITOVSKY V, 1992, SCIENCE, V256, P1802, DOI 10.1126/science.1615325; Dangl J L, 1994, Curr Top Microbiol Immunol, V192, P99; DEBLAERE R, 1985, NUCLEIC ACIDS RES, V13, P4777, DOI 10.1093/nar/13.13.4777; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FENSELAU S, 1992, MOL PLANT MICROBE IN, V5, P390, DOI 10.1094/MPMI-5-390; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; Fullner KJ, 1996, J BACTERIOL, V178, P1498, DOI 10.1128/jb.178.6.1498-1504.1996; Fullner KJ, 1996, SCIENCE, V273, P1107, DOI 10.1126/science.273.5278.1107; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; Gopalan S, 1996, PLANT CELL, V8, P1095, DOI 10.1105/tpc.8.7.1095; Hakansson S, 1996, MOL MICROBIOL, V20, P593, DOI 10.1046/j.1365-2958.1996.5251051.x; HE SY, 1993, CELL, V73, P1255, DOI 10.1016/0092-8674(93)90354-S; HERBERS K, 1992, NATURE, V356, P172, DOI 10.1038/356172a0; HOWARD EA, 1992, CELL, V68, P109, DOI 10.1016/0092-8674(92)90210-4; ISHII N, 1994, J VIROL, V68, P8209, DOI 10.1128/JVI.68.12.8209-8216.1994; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KANG KI, 1994, P NATL ACAD SCI USA, V91, P340, DOI 10.1073/pnas.91.1.340; KEEN NT, 1991, THEOR APPL GENET, V81, P133, DOI 10.1007/BF00226123; KEEN NT, 1990, MOL PLANT MICROBE IN, V3, P112, DOI 10.1094/MPMI-3-112; KNOOP V, 1991, J BACTERIOL, V173, P7142, DOI 10.1128/jb.173.22.7142-7150.1991; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lacy G. H., 1982, PHYTOPATHOGENIC PROK, V2, P149; LESSL M, 1994, CELL, V77, P321, DOI 10.1016/0092-8674(94)90146-5; Lindsay W P, 1993, Trends Microbiol, V1, P181, DOI 10.1016/0966-842X(93)90088-9; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; Mittler R, 1996, TRENDS MICROBIOL, V4, P10, DOI 10.1016/0966-842X(96)81499-5; MURILLO J, 1994, PLASMID, V31, P275, DOI 10.1006/plas.1994.1029; PERSSON C, 1995, MOL MICROBIOL, V18, P135, DOI 10.1111/j.1365-2958.1995.mmi_18010135.x; POHLNER J, 1995, MOL MICROBIOL, V17, P1073, DOI 10.1111/j.1365-2958.1995.mmi_17061073.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROSQVIST R, 1994, EMBO J, V13, P964, DOI 10.1002/j.1460-2075.1994.tb06341.x; Rossi L., 1993, Plant Molecular Biology Reporter, V11, P220, DOI 10.1007/BF02669849; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SORY MP, 1994, MOL MICROBIOL, V14, P583, DOI 10.1111/j.1365-2958.1994.tb02191.x; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; STASKAWICZ BJ, 1984, P NATL ACAD SCI-BIOL, V81, P6024, DOI 10.1073/pnas.81.19.6024; VANCANNEYT G, 1990, MOL GEN GENET, V220, P245, DOI 10.1007/BF00260489; VANDERKROL AR, 1991, PLANT CELL, V3, P667, DOI 10.1105/tpc.3.7.667; VANLAREBEKE G, 1974, NATURE, V252, P169; VARAGONA MJ, 1992, PLANT CELL, V4, P1213, DOI 10.1105/tpc.4.10.1213; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WEI ZM, 1992, SCIENCE, V257, P85, DOI 10.1126/science.1621099; Wengelnik K, 1996, J BACTERIOL, V178, P1061, DOI 10.1128/jb.178.4.1061-1069.1996; YANG YN, 1995, MOL PLANT MICROBE IN, V8, P627, DOI 10.1094/MPMI-8-0627; ZUPAN JR, 1995, PLANT PHYSIOL, V107, P1041, DOI 10.1104/pp.107.4.1041	54	278	310	1	32	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 27	1996	87	7					1307	1316		10.1016/S0092-8674(00)81825-5	http://dx.doi.org/10.1016/S0092-8674(00)81825-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980236	Bronze			2022-12-28	WOS:A1996WA54100018
J	Bygren, LO; Konlaan, BB; Johansson, SE				Bygren, LO; Konlaan, BB; Johansson, SE			Attendance at cultural events, reading books or periodicals, and making music or singing in a choir as determinants for survival: Swedish interview survey of living conditions	BRITISH MEDICAL JOURNAL			English	Article							EXPRESSION	Objectives-To investigate the possible influence of attendance at cultural events, reading books or periodicals, making music or singing in a choir as determinants for survival. Design-A simple random sample was drawn of 15 198 individuals aged 16-74 years. Of these, 85% (12 982) were interviewed by trained non-medical interviewers between 1982 and 1983 about cultural activities. They were followed up with respect to survival until 31 December 1991. Setting-Swedish interview survey of living conditions comprising a random sample of the adult Swedish population. Subjects-12 675 people interviewed between 1982 and 1983. Main outcome measures-Survival of subjects after controlling for eight confounding variables: age, sex, education level, income, long term disease, social network, smoking, and physical exercise. Results-6301 men and 6374 women were followed up; 533 men and 314 women died during this period. The control variables influenced survival in the expected directions except for social network for men; a significant negative effective was found when the analysis was made separately for men and women. We found an influence on mortality when the eight control variables were controlled for in people who rarely attended events compared with those attending most often, the relative risk being 1.57 (95% confidence interval 1.18 to 2.09). Conclusion-Attendance at cultural events may have a positive influence on survival. Long term follow up of large samples with confounders that are well controlled for and with the cultural stimulation more highly specified should be used to try to falsify the hypothesis before experiments start.	SWEDISH CENT BUR STAT,S-11581 STOCKHOLM,SWEDEN		Bygren, LO (corresponding author), UMEA UNIV,DEPT SOCIAL MED,S-90185 UMEA,SWEDEN.							ADER R, 1995, LANCET, V345, P99, DOI 10.1016/S0140-6736(95)90066-7; Beck S L, 1991, Oncol Nurs Forum, V18, P1327; BERRY DS, 1993, PSYCHOTHER PSYCHOSOM, V59, P11, DOI 10.1159/000288640; CENTERWALL BS, 1992, JAMA-J AM MED ASSOC, V267, P3059; Drees L, 1969, Nervenarzt, V40, P517; Evers S, 1992, Acta Paedopsychiatr, V55, P157; KLEINBAUM DG, 1995, SURVIVAL ANAL; NUETZEL EJ, 1995, PSYCHOANAL QUART, V64, P345, DOI 10.1080/21674086.1995.11927456; OLSSON T, 1995, NEUROSCI LETT, V189, P113, DOI 10.1016/0304-3940(95)11467-B; Proctor R C, 1976, Am J Sports Med, V4, P78, DOI 10.1177/036354657600400205; SCHACHERL P, 1970, RIV SPERIMENTALE FRE, V94, P801; SCHORR JA, 1993, ADV NURS SCI, V15, P27, DOI 10.1097/00012272-199306000-00004; Searle John, 1995, NEW YORK REV    1116, P54; SEKI JR, 1995, J ENDOCRINOL, V145, P201; *STAT SWED, 1986, TECHN REP; Struyf D, 1983, Acta Psychiatr Belg, V83, P443; SYNDER S, 1991, ADOLESCENCE, V26, P121; THORET Y, 1994, SOINS PSYCHIAT, V162, P29; WATKINS AD, 1995, QJM-MON J ASSOC PHYS, V88, P283; WICKSTROM BM, 1993, PSYCHOTHER PSYCHOSOM, V60, P195	20	188	190	0	30	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1577	1580		10.1136/bmj.313.7072.1577	http://dx.doi.org/10.1136/bmj.313.7072.1577			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VZ811	8990990	Green Published			2022-12-28	WOS:A1996VZ81100011
J	Ray, JG; Vermeulen, MJ				Ray, JG; Vermeulen, MJ			Mizspellin and Medline	BRITISH MEDICAL JOURNAL			English	Article									UNIV TORONTO,DEPT COMMUNITY HLTH,TORONTO,ON,CANADA	University of Toronto	Ray, JG (corresponding author), MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON,ON L8S 4L8,CANADA.							FUNK ME, 1983, B MED LIBR ASSOC, V71, P176; HAYNES RB, 1994, J AM MED INFORM ASSN, V1, P447, DOI 10.1136/jamia.1994.95153434; LOWE HJ, 1994, JAMA-J AM MED ASSOC, V271, P1103, DOI 10.1001/jama.271.14.1103; 1996, ACP J CLUB, V124, P88	4	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1658	1659		10.1136/bmj.313.7072.1658	http://dx.doi.org/10.1136/bmj.313.7072.1658			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VZ811	8991022	Green Published			2022-12-28	WOS:A1996VZ81100061
J	Barthold, SW				Barthold, SW			Globalisation of lyme borreliosis	LANCET			English	Article							BURGDORFERI; CALIFORNIA; DISEASE; TICKS				Barthold, SW (corresponding author), YALE UNIV,SCH MED,COMPARAT MED SECT,NEW HAVEN,CT 06520, USA.							ANDERSON JF, 1990, J WILDLIFE DIS, V26, P1, DOI 10.7589/0090-3558-26.1.1; ANDERSON JF, 1989, J CLIN MICROBIOL, V27, P13, DOI 10.1128/JCM.27.1.13-20.1989; ASSOUS MV, 1994, FEMS MICROBIOL LETT, V121, P93, DOI 10.1111/j.1574-6968.1994.tb07081.x; BROWN RN, 1992, SCIENCE, V256, P1439, DOI 10.1126/science.1604318; Bunikis J, 1996, J CLIN MICROBIOL, V34, P364, DOI 10.1128/JCM.34.2.364-368.1996; DEMAERSCHALCK I, 1995, J CLIN MICROBIOL, V33, P602, DOI 10.1128/JCM.33.3.602-608.1995; DYKHUIZEN DE, 1993, P NATL ACAD SCI USA, V90, P10163, DOI 10.1073/pnas.90.21.10163; FILIPPOVA NA, 1991, MODERN ACAROLOGY, V1, P109; Guttman DS, 1996, J CLIN MICROBIOL, V34, P652, DOI 10.1128/JCM.34.3.652-656.1996; MAUPIN GO, 1994, J INFECT DIS, V170, P636, DOI 10.1093/infdis/170.3.636; NAKAO M, 1992, AM J TROP MED HYG, V47, P505, DOI 10.4269/ajtmh.1992.47.505; ZINGG BC, 1993, J CLIN MICROBIOL, V31, P3109, DOI 10.1128/JCM.31.12.3109-3114.1993	12	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1603	1604		10.1016/S0140-6736(05)65691-7	http://dx.doi.org/10.1016/S0140-6736(05)65691-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8961987	hybrid			2022-12-28	WOS:A1996VX87600006
J	Arancio, O; Kiebler, M; Lee, CJ; LevRam, V; Tsien, RY; Kandel, ER; Hawkins, RD				Arancio, O; Kiebler, M; Lee, CJ; LevRam, V; Tsien, RY; Kandel, ER; Hawkins, RD			Nitric oxide acts directly in the presynaptic neuron to produce long-term potentiation in cultured hippocampal neurons	CELL			English	Article							CYCLIC-GMP FORMATION; TRANSMITTER RELEASE; SYNAPSES; ENHANCEMENT; DEPRESSION; MECHANISM; MESSENGER; PATHWAY	Nitric oxide (NO) has been proposed to act as a retrograde messenger during long-term potentiation (LTP) in the CA1 region of hippocampus, but the inaccessibility of the presynaptic terminal has prevented a definitive test of this hypothesis. Because both sides of the synapse are accessible in cultured hippocampal neurons, we have used this preparation to investigate the role of NO. We examined LTP following intra- or extracellular application of an NO scavanger, an inhibitor of NO synthase, and a membrane-impermeant NO donor that releases NO only upon photolysis with UV light. Our results indicate that NO is produced in the postsynaptic neuron, travels through the extracellular space, and acts directly in the presynaptic neuron to produce long-term potentiation, supporting the hypothesis that NO acts as a retrograde messenger during LTP.	NEW YORK STATE PSYCHIAT INST & HOSP,NEW YORK,NY 10032; HOWARD HUGHES MED INST,NEW YORK,NY 10032; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST 0647,DEPT PHARMACOL,LA JOLLA,CA 92093	New York State Psychiatry Institute; Howard Hughes Medical Institute; University of California System; University of California San Diego	Arancio, O (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032, USA.		arancio, ottavio/AAB-7959-2019	arancio, ottavio/0000-0001-6335-164X; Lee, C Justin/0000-0002-3555-0980; Kiebler, Michael/0000-0002-8850-6297	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH050733] Funding Source: NIH RePORTER; NIMH NIH HHS [MH50733] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARANCIO O, 1995, NATURE, V376, P74, DOI 10.1038/376074a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BOULTON CL, 1994, EUR J NEUROSCI, V6, P1528, DOI 10.1111/j.1460-9568.1994.tb00543.x; EAST SJ, 1991, NEUROSCI LETT, V123, P17, DOI 10.1016/0304-3940(91)90147-L; EAST SJ, 1990, EUR J PHARMACOL, V184, P311, DOI 10.1016/0014-2999(90)90623-E; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; GORBUNOV NV, 1995, BIOCHEMISTRY-US, V34, P6689, DOI 10.1021/bi00020a014; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; Hawkins RD, 1996, NEURON, V16, P465, DOI 10.1016/S0896-6273(00)80064-1; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; LEVRAM V, 1995, NEURON, V15, P407, DOI 10.1016/0896-6273(95)90044-6; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MAKINGS LR, 1994, J BIOL CHEM, V269, P6282; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; Meffert MK, 1996, NEURON, V16, P1229, DOI 10.1016/S0896-6273(00)80149-X; MURPHEY RK, 1994, J NEUROBIOL, V25, P595, DOI 10.1002/neu.480250602; MURPHY KPSJ, 1994, NEUROPHARMACOLOGY, V33, P1375, DOI 10.1016/0028-3908(94)90039-6; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; POPOV S, 1992, J NEUROSCI, V12, P77; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHUMAN EM, 1994, P NATL ACAD SCI USA, V91, P11958, DOI 10.1073/pnas.91.25.11958; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; Vogel A.I., 1989, TXB QUANTITATIVE INO; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	29	305	314	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1025	1035		10.1016/S0092-8674(00)81797-3	http://dx.doi.org/10.1016/S0092-8674(00)81797-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978607	hybrid			2022-12-28	WOS:A1996VY44700008
J	Seidelman, WE				Seidelman, WE			Nuremberg lamentation: For the forgotten victims of medical science	BRITISH MEDICAL JOURNAL			English	Article							NAZI GERMANY; ETHICS	Fifty years after the Nuremberg medical trial there remain many unanswered questions about the role of the German medical profession during the Third Reich. Other than the question of human experimentation, important ethical challenges arising from medicine in Nazi Germany which have continuing relevance were not addressed at Nuremberg. The underlying moral question is that of the exercise of professional power and its impact on vulnerable people seeking medical care. Sensitisation to the obligations of professional power may be achieved by an annual commemoration and lament to the memory of the victims of medical abuse which would serve as a recurring reminder of the physician's vulnerability and fallibility.	WELLESLEY CENT HOSP,TORONTO,ON,CANADA; UNIV TORONTO,DEPT FAMILY & COMMUNITY MED,TORONTO,ON M5S 1A1,CANADA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto								ALEXANDER L, 1945, APO, V413; Aly G., 1994, CLEANSING FATHERLAND; BECK W, 1989, LANCET, V1, P1441; BEECHER HK, 1966, NEW ENGL J MED, V274, P1354, DOI 10.1056/NEJM196606162742405; BONNER TN, 1963, AM DOCTORS GERMAN UN; Burleigh Michael, 1994, EUTHANASIA GERMANY 1; CONEY S, 1988, UNFORTUNATE EXPT AUC; DICKMAN S, 1990, NATURE, V345, P192, DOI 10.1038/345192a0; *EB U TUB ABDR, 1990, BERICH KOMM UB PROP; ERNST E, 1995, ANN INTERN MED, V122, P789, DOI 10.7326/0003-4819-122-10-199505150-00009; FATTUROSSO V, 1977, B WHO S2, V55, P133; Friedlander Henry, 1995, ORIGINS NAZI GENOCID; GRODIN MA, 1993, HASTINGS CENT REP, V23, P8, DOI 10.2307/3562583; HANAUSKEABEL HM, 1986, LANCET, V2, P271; Jones JH, 1981, BAD BLOOD TUSKEGEE S; KATER M., 1983, NAZI PARTY; KATER MH, 1987, GER STUD REV, V10, P31, DOI 10.2307/1430442; Kater MH, 1989, DOCTORS HITLER; Katz J., 1972, EXPT HUMAN BEINGS; KATZ J, 1992, NAZI DOCTORS NUREMBE; Klee Ernst, 1990, DACHAU REV, V2, P46; Lederer S., 1994, CHILDREN RES SUBJECT; Lehner M., 1990, THESIS U VIENNA; Lifton R. J., 1986, NAZI DOCTORS MED KIL; MACILWAIN C, 1995, NATURE, V377, P374; MASOOD E, 1994, NATURE, V376, P107; MCINTYRE N, 1983, BRIT MED J, V287, P1919, DOI 10.1136/bmj.287.6409.1919; Mitscherlich A, 1949, DOCTORS INFAMY STORY; Muller-Hill B., 1988, MURDEROUS SCI; PAUL C, 1988, BMJ-BRIT MED J, V297, P533, DOI 10.1136/bmj.297.6647.533; Peiffer J, 1991, BRAIN PATHOL, V1, P125, DOI 10.1111/j.1750-3639.1991.tb00649.x; Pernkopf E., 1952, TOPOGRAPHISCHE ANATO, P271; PERNKOPF E, 1943, TOPOGRAPHISCHE ANATO; *PHIL I SCI INF, 1994, SCI CIT IND 1994  10; PLATZER W, 1989, PERNKOPF ANATOMY ATL, V2, P338; Proctor R. N., 1988, RACIAL HYGIENE; PROSS C, 1989, WERT MENSCHEN MED DT; Richardson E, 1990, FOUNDERS CHILD NEURO, P506; ROTHMAN DJ, 1987, NEW ENGL J MED, V317, P1195, DOI 10.1056/NEJM198711053171906; SEIDELMAN WE, 1989, NATURE, V337, P300, DOI 10.1038/337300a0; SEIDELMAN WE, 1989, HOLOCAUST GENOCIDE S, V4, P435, DOI 10.1093/hgs/4.4.435; SEIDELMAN WE, 1986, LANCET, V1, P1214; SEIDELMAN WE, 1988, MILBANK Q, V66, P221, DOI 10.2307/3350031; SHEVELL M, 1992, NEUROLOGY, V42, P2214, DOI 10.1212/WNL.42.11.2214; Taylor Telford, 1992, NAZI DOCTORS NUREMBE; Weindling P, 1989, HLTH RACE GERMAN POL; WHITNEY CR, 1993, NY TIMES        0116, P3; WILLIAMS DJ, 1988, J BIOCOMMUNICATION, P2; WISTRICH R, 1982, WHO WHO 3 REICH; 1933, JAMA-J AM MED ASSOC, V101, P722; 1978, SPIEGEL         0619, P84; 1935, JAMA-J AM MED ASSOC, V105, P1051; 1973, WORLD MED J, V21, P4; 1993, ZEIT            0122, P22; 1993, BUNDESARZTEKAMMER IN	55	54	54	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1996	313	7070					1463	1467		10.1136/bmj.313.7070.1463	http://dx.doi.org/10.1136/bmj.313.7070.1463			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	VX612	8973236	Green Published			2022-12-28	WOS:A1996VX61200036
J	Voytas, DF				Voytas, DF			Retroelements in genome organization	SCIENCE			English	Editorial Material							RETROTRANSPOSONS; ELEMENTS; PLANTS; GENES; DNA				Voytas, DF (corresponding author), IOWA STATE UNIV SCI & TECHNOL,DEPT ZOOL & GENET,AMES,IA 50011, USA.			Voytas, Daniel/0000-0002-4944-1224				BENNETZEN JL, 1993, TRENDS GENET, V9, P259, DOI 10.1016/0168-9525(93)90001-X; BENNETZEN JL, 1994, GENOME, V37, P565, DOI 10.1139/g94-081; CHALKER DL, 1992, GENE DEV, V6, P117, DOI 10.1101/gad.6.1.117; DEVINE SE, 1992, GENE DEV, V6, P620; FLAVELL AJ, 1992, NUCLEIC ACIDS RES, V20, P3639, DOI 10.1093/nar/20.14.3639; KONIECZNY A, 1991, GENETICS, V127, P801; Pelissier T, 1995, PLANT MOL BIOL, V29, P441, DOI 10.1007/BF00020976; ROTHNIE HM, 1991, NUCLEIC ACIDS RES, V19, P279, DOI 10.1093/nar/19.2.279; SanMiguel P, 1996, SCIENCE, V274, P765, DOI 10.1126/science.274.5288.765; VOYTAS DF, 1992, P NATL ACAD SCI USA, V89, P7124, DOI 10.1073/pnas.89.15.7124; WHITE SE, 1994, P NATL ACAD SCI USA, V91, P11792, DOI 10.1073/pnas.91.25.11792; Wright DA, 1996, GENETICS, V142, P569; ZOU S, 1992, GENE DEV, V6, P634	13	49	51	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					737	738		10.1126/science.274.5288.737	http://dx.doi.org/10.1126/science.274.5288.737			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8966554				2022-12-28	WOS:A1996VQ14500026
J	Reynolds, F; Crowhurst, JA				Reynolds, F; Crowhurst, JA			Opioids in labour - No analgesic effect	LANCET			English	Editorial Material							PAIN		QUEEN CHARLOTTES & CHELSEA HOSP,LONDON W6 0XG,ENGLAND	Imperial College London	Reynolds, F (corresponding author), ST THOMAS HOSP,DEPT ANAESTHET,LONDON SE1 7EH,ENGLAND.							Chamberlain G, 1993, PAIN ITS RELIEF CHIL; HOLDCROFT A, 1974, J OBSTET GYN BR COMM, V81, P603; MOORE J, 1993, EFFECTS BABY MATERNA, P148; MORGAN BM, 1982, LANCET, V2, P808; NORVELL KT, 1987, PAIN, V31, P77, DOI 10.1016/0304-3959(87)90008-X; Olofsson C, 1996, Int J Obstet Anesth, V5, P176, DOI 10.1016/S0959-289X(96)80028-8; Olofsson C, 1996, BRIT J OBSTET GYNAEC, V103, P968, DOI 10.1111/j.1471-0528.1996.tb09545.x; PAECH MJ, 1991, ANAESTH INTENS CARE, V19, P393, DOI 10.1177/0310057X9101900316; Ranta P, 1994, Int J Obstet Anesth, V3, P193, DOI 10.1016/0959-289X(94)90067-1; REYNOLDS F, 1989, BRIT MED J, V299, P751, DOI 10.1136/bmj.299.6702.751; WIENER PC, 1977, BRIT MED J, V2, P228, DOI 10.1136/bmj.2.6081.228	11	22	22	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					4	5		10.1016/S0140-6736(05)62156-3	http://dx.doi.org/10.1016/S0140-6736(05)62156-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988111				2022-12-28	WOS:A1997WA72500005
J	Cockerill, FR; MacDonald, KL; Thompson, RL; Roberson, F; Kohner, PC; BesserWiek, J; Manahan, JM; Musser, JM; Schlievert, PM; Talbot, J; Frankfort, B; Steckelberg, JM; Wilson, WR; Osterholm, MT; Abbott, JA; Badley, AD; Dale, JC; Dylla, BL; Holley, KE; Jacobsen, RA; Leavelle, DE; Osmon, DR; Uhl, JR; Vetter, EA; Anderson, EA; Clare, JG; Forfang, JC; Hedberg, CW; Korlath, JA; Rainbow, JI; Edmonson, L; Lovgren, M; Olstad, S				Cockerill, FR; MacDonald, KL; Thompson, RL; Roberson, F; Kohner, PC; BesserWiek, J; Manahan, JM; Musser, JM; Schlievert, PM; Talbot, J; Frankfort, B; Steckelberg, JM; Wilson, WR; Osterholm, MT; Abbott, JA; Badley, AD; Dale, JC; Dylla, BL; Holley, KE; Jacobsen, RA; Leavelle, DE; Osmon, DR; Uhl, JR; Vetter, EA; Anderson, EA; Clare, JG; Forfang, JC; Hedberg, CW; Korlath, JA; Rainbow, JI; Edmonson, L; Lovgren, M; Olstad, S			An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SHOCK-LIKE SYNDROME; GROUP-A STREPTOCOCCI; SCARLET FEVER TOXIN; MOLECULAR CHARACTERIZATION; EPIDEMIOLOGIC ANALYSIS; CHANGING EPIDEMIOLOGY; RHEUMATIC-FEVER; PYOGENES; INFECTIONS; BACTEREMIA	Objectives.-To determine if a common strain of group A streptococcus was responsible for an outbreak of invasive streptococcal disease in southeastern Minnesota and to determine whether this strain was prevalent among residents of this area during the outbreak who either had streptococcal pharyngitis or were asymptomatic streptococcal carriers. Design.-Pharyngeal culture survey and case-contact evaluation. Setting.-Three adjacent counties in southeastern Minnesota defined as the outbreak area. Outbreak period, January 1 through March 31, 1995. Patients.-Seven patients with invasive streptococcal infection, 1249 patients (adults and children) with sore throat who resided in the outbreak area, children from an elementary school located in 1 community where the majority of invasive cases occurred, and 896 students from 3 schools located in Minnesota counties outside the outbreak area. Measurements.-Pulsed-field gel electrophores is (DNA fingerprinting) of group A streptococcal isolates obtained from patients with invasive disease, throat swabs of patients with sore throat, and throat swabs of asymptomatic school-aged children. Results.-All patients with outbreak-associated invasive disease had group A streptococcal isolates that were indistinguishable by pulsed-field gel electrophoresis. Additional testing showed that these isolates carried significant virulence factors including pyrogenic exotoxin A and streptococcal superantigen. Five of these 7 patients with invasive disease had underlying medical conditions; 4 developed toxic shock syndrome and died (case fatality, 57%). The outbreak-associated group A streptococcal clone was found in 69 (26.5%) of the 260 patients with sore throat from whom group A streptococcus was isolated. The frequency of the outbreak done among pharyngeal carriers from the 3 schools outside the outbreak area was significantly less (range, 0%-10%) than in children from the school in the outbreak area (78%; relative risk, 29; 95% confidence interval, 11.1-78. 1; P<.001). Four of the 7 patients with outbreak-associated disease had contact with children who attended the school in the outbreak area, Conclusions.-A single clone of group A streptococcus was responsible for 7 cases of invasive streptococcal disease during an outbreak in Minnesota and for a significant number of pharyngitis cases that also occurred during the outbreak invasive disease occurred most frequently in persons with underlying medical conditions. This outbreak was also associated with increased carriage rates of the invasive streptococcal clone among community school-aged children, Cases of invasive group A streptococcal infection may therefore reflect the tip of the iceberg with regard to the burden of colonization of a specific invasive streptococcal clone in a community.	MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,DIV INFECT DIS,ROCHESTER,MN 55905; MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,MINNEAPOLIS,MN 55414; MINNESOTA DEPT HLTH,CLIN LAB SECT,MINNEAPOLIS,MN 55414; INTERSTATE CLIN & ZUMBROTA COMMUNITY HOSP,ZUMBROTA,MN 55992; BAYLOR COLL MED,DEPT PATHOL,SECT MOL PATHOBIOL,HOUSTON,TX 77030; UNIV MINNESOTA,DEPT MICROBIOL,MINNEAPOLIS,MN 55455; PROV LAB PUBL HLTH,NATL CTR STREPTOCOCCUS,EDMONTON,AB,CANADA; OLMSTED PUBL HLTH DEPT,ROCHESTER,MN	Mayo Clinic; Minnesota Department of Health (MHD); Minnesota Department of Health (MHD); Baylor College of Medicine; University of Minnesota System; University of Minnesota Twin Cities	Cockerill, FR (corresponding author), MAYO CLIN & MAYO FDN,DEPT LAB MED & PATHOL,DIV MICROBIOL,HILTON 4,ROCHESTER,MN 55905, USA.		badley, andrew d/O-9022-2014	Schlievert, Patrick/0000-0001-8314-9369	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL036611, R01HL036611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033119] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36611] Funding Source: Medline; NIAID NIH HHS [AI-33119] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUERBACH SB, 1992, ARCH INTERN MED, V152, P1017, DOI 10.1001/archinte.152.5.1017; BARTTER T, 1988, ARCH INTERN MED, V148, P1421, DOI 10.1001/archinte.148.6.1421; BISNO AL, 1991, NEW ENGL J MED, V325, P783, DOI 10.1056/NEJM199109123251106; CHOMARAT M, 1990, EUR J CLIN MICROBIOL, V9, P901, DOI 10.1007/BF01967508; CONE LA, 1987, NEW ENGL J MED, V317, P146, DOI 10.1056/NEJM198707163170305; Davies HD, 1996, NEW ENGL J MED, V335, P547, DOI 10.1056/NEJM199608223350803; DERMODY TS, 1995, CLIN INFECT DIS, V20, P1333; DRABICK JJ, 1989, NEW ENGL J MED, V321, P1545, DOI 10.1056/NEJM198911303212212; FRANCIS J, 1988, Q J MED, V68, P603; GAWORZEWSKA E, 1988, EPIDEMIOL INFECT, V100, P257, DOI 10.1017/S095026880006739X; GIVNER LB, 1991, J PEDIATR-US, V118, P341, DOI 10.1016/S0022-3476(05)82144-4; Griffith F, 1934, J HYG-CAMBRIDGE, V34, P542, DOI 10.1017/S0022172400043308; HANSMAN D, 1989, NEW ENGL J MED, V321, P1546; HARBAUGH MP, 1993, MOL MICROBIOL, V8, P981, DOI 10.1111/j.1365-2958.1993.tb01642.x; HAUSER AR, 1991, J CLIN MICROBIOL, V29, P1562, DOI 10.1128/JCM.29.8.1562-1567.1991; HENRICHSEN J, 1992, ZBL BAKT S, V22, P8; HOGE CW, 1993, JAMA-J AM MED ASSOC, V269, P384, DOI 10.1001/jama.269.3.384; JOHNSON DR, 1992, J INFECT DIS, V166, P374, DOI 10.1093/infdis/166.2.374; KAPUR V, 1993, MICROB PATHOGENESIS, V15, P327, DOI 10.1006/mpat.1993.1083; KISKA DL, 1995, 95 GEN M AM SOC MICR; Kline JB, 1996, INFECT IMMUN, V64, P861, DOI 10.1128/IAI.64.3.861-869.1996; MARTIN PR, 1990, SCAND J INFECT DIS, V22, P421, DOI 10.3109/00365549009027073; Maslow Joel N., 1993, P563; MAXTED WR, 1973, J MED MICROBIOL, V6, P83, DOI 10.1099/00222615-6-1-83; MIRANDA AG, 1991, J CLIN MICROBIOL, V29, P2752, DOI 10.1128/JCM.29.12.2752-2757.1991; MOSES AE, 1995, CLIN INFECT DIS, V20, P1393, DOI 10.1093/clinids/20.5.1393; MURRAY BE, 1990, J CLIN MICROBIOL, V28, P2059, DOI 10.1128/JCM.28.9.2059-2063.1990; MUSSER JM, 1993, J INFECT DIS, V167, P337, DOI 10.1093/infdis/167.2.337; MUSSER JM, 1991, P NATL ACAD SCI USA, V88, P2668, DOI 10.1073/pnas.88.7.2668; MUSSER JM, 1995, INFECT IMMUN, V63, P994, DOI 10.1128/IAI.63.3.994-1003.1995; MUSSER JM, 1992, J CLIN MICROBIOL, V30, P600, DOI 10.1128/JCM.30.3.600-603.1992; MUSSER JM, 1994, ARCH PATHOL LAB MED, V118, P128; NELSON K, 1991, J EXP MED, V174, P1271, DOI 10.1084/jem.174.5.1271; REDA KB, 1994, INFECT IMMUN, V62, P1867, DOI 10.1128/IAI.62.5.1867-1874.1994; ROTTA J, 1971, J EXP MED, V134, P1298, DOI 10.1084/jem.134.5.1298; SCHWARTZ B, 1990, LANCET, V336, P1167, DOI 10.1016/0140-6736(90)92777-F; STEVENS DL, 1995, EMERG INFECT DIS, V1, P69, DOI 10.3201/eid0103.950301; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; STEVENS DL, 1992, CLIN INFECT DIS, V14, P2, DOI 10.1093/clinids/14.1.2; STROMBERG A, 1991, J INFECT DIS, V164, P595, DOI 10.1093/infdis/164.3.595; TALKINGTON DF, 1993, INFECT IMMUN, V61, P3369, DOI 10.1128/IAI.61.8.3369-3374.1993; WHEELER MC, 1991, JAMA-J AM MED ASSOC, V266, P533, DOI 10.1001/jama.266.4.533; *WORK GROUP SEV ST, 1993, JAMA-J AM MED ASSOC, V269, P390	43	135	137	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1997	277	1					38	43		10.1001/jama.277.1.38	http://dx.doi.org/10.1001/jama.277.1.38			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ767	8980208				2022-12-28	WOS:A1997VZ76700027
J	Tu, JV; Naylor, CD; Kumar, D; DeBuono, BA; McNeil, BJ; Hannan, EL				Tu, JV; Naylor, CD; Kumar, D; DeBuono, BA; McNeil, BJ; Hannan, EL			Coronary artery bypass graft surgery in Ontario and New York State: Which rate is right?	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; UNITED-STATES; CARDIAC-SURGERY; CANADA; MORTALITY; OUTCOMES; CARE	Background: Previous studies have shown that the rate of coronary artery bypass graft (CABG) surgery is much higher in New York State than in Ontario. Objective: To compare the service context and clinical characteristics of patients having CABG surgery in New York and Ontario. Design: Retrospective analysis of data from cardiac: surgery registries in New York and Ontario. Patients: All 16 690 patients in New York and 5517 patients in Ontario who had isolated CABG surgery in 1993. Measurements: Clinical characteristics of patients having CABG surgery and rates of CABG surgery by coronary anatomy. Results: The overall age-adjusted rate of isolated CABG surgery was 1.79 times (95% CI, 1.74 to 1.85) greater in New York than in Ontario. Patients who had CABG surgery in New York were more likely to be elderly and female and to have recently had myocardial infarction (P < 0.001), whereas patients who had CABG surgery in Ontario were more likely to have had left ventricular dysfunction and severe coronary artery disease (two-vessel disease with proximal left anterior descending disease, three-vessel disease, or left main disease) (P < 0.001). The relative rate of CABG surgery for left main disease was 2.53 times (Ci, 2.35 to 2.73) greater in New York than in Ontario but was 8.97 times (CI, 8.01 to 10.06) greater for patients with limited coronary artery disease (one-vessel or two-vessel disease without proximal left anterior descending disease). Conclusions: The higher rates of CABG surgery in New York are associated with higher rates of CABG surgery among the elderly, women, and patients who recently had myocardial infarction. Potential underservicing in Ontario is suggested by a lower rate of CABG surgery for left main disease; however, the higher rate of CABG surgery in New York is also associated with a strikingly higher rate of surgery in patients with limited coronary disease. Such trade-offs highlight the difficulty of defining an optimal rate of CABG surgery.	SUNY ALBANY, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, RENSSELAER, NY 12144 USA; NEW YORK STATE DEPT HLTH, ALBANY, NY 12237 USA; HARVARD UNIV, SCH MED, DEPT HLTH CARE POLICY, BOSTON, MA 02115 USA; SUNNYBROOK HLTH SCI CTR, TORONTO, ON M4N 3M5, CANADA	State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; Harvard University; Harvard Medical School; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Tu, JV (corresponding author), INST CLIN EVALUAT SCI, G-106, 2075 BAYVIEW AVE, N YORK, ON M4N 3M5, CANADA.		Kalra, D/H-6661-2019	Kalra, D/0000-0001-5254-4067; Tu, Jack/0000-0003-0111-722X	AHRQ HHS [HS08464, HS08071, HS06503] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDERSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1661; ANDERSON GM, 1989, NEW ENGL J MED, V321, P1443, DOI 10.1056/NEJM198911233212105; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; GEORGE MV, 1994, 91520 STAT CAN; GRABOYS TB, 1987, JAMA-J AM MED ASSOC, V258, P1611, DOI 10.1001/jama.258.12.1611; GRUMBACH K, 1995, JAMA-J AM MED ASSOC, V274, P1282, DOI 10.1001/jama.274.16.1282; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; HANNAN EL, 1992, JAMA-J AM MED ASSOC, V268, P3092, DOI 10.1001/jama.268.21.3092; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; Hennekens C.H., 1987, EPIDEMIOLOGY MED; KATZ SJ, 1991, JAMA-J AM MED ASSOC, V266, P1108, DOI 10.1001/jama.266.8.1108; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MCCLELLAN M, 1994, JAMA-J AM MED ASSOC, V272, P859, DOI 10.1001/jama.272.11.859; MCGLYNN EA, 1994, JAMA-J AM MED ASSOC, V272, P934, DOI 10.1001/jama.272.12.934; NAYLOR CD, 1995, LANCET, V346, P1605, DOI 10.1016/S0140-6736(95)91934-1; NAYLOR CD, 1992, CAN MED ASSOC J, V146, P851; NAYLOR CD, 1991, HEALTH AFFAIR, V10, P110, DOI 10.1377/hlthaff.10.3.110; NAYLOR CD, 1994, ICES PRACTICES ATLAS, V1; *NY STAT DEP HLTH, 1993, SUMM REP ANN REP CAR; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; TU JV, 1995, CIRCULATION, V91, P677, DOI 10.1161/01.CIR.91.3.677; TU JV, 1996, IN PRESS CIRCULATION; US Census Bureau, 1994, STAT ABSTR US; WENNBERG J, 1986, NEW ENGL J MED, V314, P310, DOI 10.1056/NEJM198601303140509; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; ZARATE AO, 1994, INT MORTALITY CHARTB	28	70	70	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1997	126	1					13	19		10.7326/0003-4819-126-1-199701010-00002	http://dx.doi.org/10.7326/0003-4819-126-1-199701010-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA165	8992918				2022-12-28	WOS:A1997WA16500002
J	Ubel, PA; Goold, S				Ubel, PA; Goold, S			Recognizing bedside rationing: Clear cases and tough calls	ANNALS OF INTERNAL MEDICINE			English	Article							COST-CONTAINMENT; PHYSICIAN	Under increasing pressure to contain medical costs, physicians find themselves wondering whether it is ever proper to ration health care at the bedside. Opinion about this is divided, but one thing is clear: Whether physicians should ration at the bedside or not, they ought to be able to recognize when they are doing so. This paper describes three conditions that must be met for a physician's action to qualify as bedside rationing. The physician must 1) withhold, withdraw, or fail to recommend a service that, in the physician's best clinical judgment, is in the patient's best medical interests; 2) act primarily to promote the financial interests of someone other than the patient (including an organization, society at large, and the physician himself or herself); and 3) have control over the use of the beneficial service. This paper presents a series of cases that illustrate and elaborate on the importance of these three conditions. Physicians can use these conditions to identify instances of bedside rationing; leaders of the medical profession, ethicists, and policymakers can use them as a starting point for discussions about when, if ever, physicians should ration at the bedside.	UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV PENN, LEONARD DAVIS INST HLTH ECON, PHILADELPHIA, PA 19104 USA; VET AFFAIRS MED CTR, ANN ARBOR, MI USA	University of Michigan System; University of Michigan; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ubel, PA (corresponding author), UNIV PENN, DIV GEN INTERNAL MED,CTR BIOETH,SCH MED, VET AFFAIRS MED CTR,3401 MARKET ST, SUITE 320, PHILADELPHIA, PA 19104 USA.		Goold, Susan Dorr/N-6930-2014	Goold, Susan Dorr/0000-0002-0258-9774				ABRAMS FR, 1986, JAMA-J AM MED ASSOC, V256, P1784; ALDERMAN MH, 1992, JAMA-J AM MED ASSOC, V267, P2786, DOI 10.1001/jama.267.20.2786; ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; Anspach R., 1993, DECIDING WHO LIVES F; BARRY MJ, 1988, JAMA-J AM MED ASSOC, V259, P3010, DOI 10.1001/jama.259.20.3010; CASSELL EJ, 1981, JUSTICE HLTH CARE, P75; EDDY DM, 1992, JAMA-J AM MED ASSOC, V268, P2575, DOI 10.1001/jama.268.18.2575; GARLAND MJ, 1992, RATIONING AM MED CAR; GOOLD SD, 1995, HLTH CARE CRISIS SEA; GRUBBS NC, 1992, MAYO CLIN PROC, V67, P1163, DOI 10.1016/S0025-6196(12)61146-X; HALL MA, 1994, NEW YORK U LAW REV, V69, P693; HIATT HH, 1975, NEW ENGL J MED, V293, P235, DOI 10.1056/NEJM197507312930506; HOCHLA PKO, 1992, ARCH INTERN MED, V152, P1773, DOI 10.1001/archinte.152.9.1773; JAMES W, 1979, WILL TO BELIEVE; LIPSITCH M, 1995, NY TIMES        0912, pC1; MORREIM EH, 1989, ARCH INTERN MED, V149, P1012, DOI 10.1001/archinte.149.5.1012; MOSER M, 1993, CLEV CLIN J MED, V60, P27; PAUKER SG, 1981, J CHRON DIS, V34, P77, DOI 10.1016/0021-9681(81)90053-9; STEINBERG EP, 1992, NEW ENGL J MED, V326, P425, DOI 10.1056/NEJM199202133260701; SULMASY DP, 1992, ANN INTERN MED, V116, P920, DOI 10.7326/0003-4819-116-11-920; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; UBEL P, IN PRESS SOCIAL SCI; UBEL PA, 1995, ARCH INTERN MED, V155, P1837, DOI 10.1001/archinte.155.17.1837; UBEL PA, 1993, JAMA-J AM MED ASSOC, V270, P2469, DOI 10.1001/jama.270.20.2469; Ubel PA, 1996, ARCH INTERN MED, V156, P1262, DOI 10.1001/archinte.156.12.1262; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; WEKH HG, 1991, ANN INTERN MED, V115, P223; Wolf AMD, 1996, ARCH INTERN MED, V156, P1333, DOI 10.1001/archinte.156.12.1333	28	58	57	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1997	126	1					74	80		10.7326/0003-4819-126-1-199701010-00010	http://dx.doi.org/10.7326/0003-4819-126-1-199701010-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA165	8992926				2022-12-28	WOS:A1997WA16500010
J	Suri, C; Jones, PF; Patan, S; Bartunkova, S; Maisonpierre, PC; Davis, S; Sato, TN; Yancopoulos, GD				Suri, C; Jones, PF; Patan, S; Bartunkova, S; Maisonpierre, PC; Davis, S; Sato, TN; Yancopoulos, GD			Requisite role of Angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis	CELL			English	Article							ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE GENES; NEUREGULIN RECEPTOR; CARDIAC DEVELOPMENT; MOLECULAR-CLONING; VASCULAR SYSTEM; MICE LACKING; CELL LINEAGE; EXPRESSION; TEK	Vascular endothelial growth factor (VEGF), which acts via members of a family of endothelial-specific receptor tyrosine kinases, is the only factor that has been shown definitively to play a role in the formation of the embryonic vasculature. Only one other family of receptor tyrosine kinases, comprising TIE1 and TIE2, is largely endothelial cell specific. We have recently cloned a ligand for TIE2, termed Angiopoietin-1. Here we show that mice engineered to lack Angiopoietin-1 display angiogenic deficits reminiscent of those previously seen in mice lacking TIE2, demonstrating that Angiopoietin-1 is a primary physiologic ligand for TIE2 and that it has critical in vivo angiogenic actions that are distinct from VEGF and that are not reflected in the classic in vitro assays used to characterize VEGF. Angiopoietin-1 seems to play a crucial role in mediating reciprocal interactions between the endothelium and surrounding matrix and mesenchyme.	BETH ISRAEL HOSP,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215; MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02114	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Suri, C (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.							BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; Batard P, 1996, BLOOD, V87, P2212, DOI 10.1182/blood.V87.6.2212.bloodjournal8762212; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; DRAKE CJ, 1995, P NATL ACAD SCI USA, V92, P7657, DOI 10.1073/pnas.92.17.7657; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; FERRARA N, 1995, ANN NY ACAD SCI, V752, P246, DOI 10.1111/j.1749-6632.1995.tb17435.x; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hashiyama M, 1996, BLOOD, V87, P93; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; Patan S, 1996, MICROVASC RES, V51, P80, DOI 10.1006/mvre.1996.0009; Patan S, 1996, MICROVASC RES, V51, P260, DOI 10.1006/mvre.1996.0025; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W., 1991, DEV VASCULAR SYSTEM, P58; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; ZIEGLER SF, 1993, ONCOGENE, V8, P663	37	2229	2377	0	50	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1171	1180		10.1016/S0092-8674(00)81813-9	http://dx.doi.org/10.1016/S0092-8674(00)81813-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980224	Bronze			2022-12-28	WOS:A1996WA54100006
J	Jaster, JH; Malecha, MJ				Jaster, JH; Malecha, MJ			Cryptococcal meningitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Jaster, JH (corresponding author), UNIV TENNESSEE,MEMPHIS,TN 38163, USA.			Jaster, J. Howard/0000-0001-5406-9554					0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 26	1996	335	26					1962	1962		10.1056/NEJM199612263352605	http://dx.doi.org/10.1056/NEJM199612263352605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA160	8960476				2022-12-28	WOS:A1996WA16000005
J	Bone, RC				Bone, RC			Maumee: My Walden pond	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1996	276	24					1931	1931		10.1001/jama.276.24.1931	http://dx.doi.org/10.1001/jama.276.24.1931			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY689	8971049				2022-12-28	WOS:A1996VY68900001
J	Nath, I				Nath, I			Infectious diseases - Forward to the past	LANCET			English	Article											Nath, I (corresponding author), ALL INDIA INST MED SCI, DEPT BIOTECHNOL, NEW DELHI 110027, INDIA.							Binka FN, 1996, TROP MED INT HEALTH, V1, P147; Fine PEM, 1996, LANCET, V348, P17, DOI 10.1016/S0140-6736(96)02166-6; Mattner F, 1996, EUR J IMMUNOL, V26, P1553, DOI 10.1002/eji.1830260722; Nosten F, 1996, LANCET, V348, P701, DOI 10.1016/S0140-6736(96)04465-0; Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888	5	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	1996	348			2			SII11	SII11						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973489				2022-12-28	WOS:A1996WA46300011
J	Kroon, AA; vanAsten, WNJC; Stalenhoef, AFH				Kroon, AA; vanAsten, WNJC; Stalenhoef, AFH			Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease	ANNALS OF INTERNAL MEDICINE			English	Article						lipoprotein, LDL cholesterol; hypercholesterolemia; blood component removal; coronary arteriosclerosis; hydroxymethylglutaryl CoA reductases	INTIMA-MEDIA THICKNESS; CARDIOVASCULAR RISK-FACTORS; COLESTIPOL-NIACIN THERAPY; FAMILIAL HYPERCHOLESTEROLEMIA; LDL-APHERESIS; FEMORAL ATHEROSCLEROSIS; CAROTID ATHEROSCLEROSIS; HEART-DISEASE; REGRESSION; ASSOCIATIONS	Background: Apheresis of low-density lipoprotein (LDL) is an effective lipid-lowering treatment in hypercholesterolemic patients who have coronary artery disease and are refractory to drugs. More aggressive lipid-lowering therapy may further slow the progression of atherosclerosis. Objective: To compare the effect of LDL apheresis and simvastatin therapy with the effect of simvastatin therapy alone on the progression of peripheral vascular disease. Design: Open, randomized, single-center study. Setting: University hospital. Patients: 42 men with primary hypercholesterolemia (total cholesterol level > 8.0 mmol/L) and extensive coronary atherosclerosis. Intervention: Biweekly apheresis of LDL plus simvastatin, 40 mg/d (n = 21), or simvastatin, 40 mg/d (n = 21), for 2 years. Measurements: Lipid and lipoprotein levels, changes in hemodynamically significant stenoses in the aortotibial tract (measured by ankle:arm systolic blood pressure ratio combined with Doppler spectrum analysis of the femoral artery), and changes in the mean intima-media thickness of three carotid artery segments. Results: Mean baseline LDL cholesterol levels decreased from 7.8 to 3.0 mmol/L in the apheresis and simvastatin group and from 7.9 to 4.1 mmol/L in the simvastatin-only group; mean lipoprotein(a) levels decreased from 57.0 to 44.5 mg/dL (change, -19%) in the former group and increased from 38.4 to 44.5 mg/dL (change, 15%) in the latter group. In the apheresis group, the number of patients with hemodynamically significant stenoses in the aortotibial tract decreased from 9 to 7; in the simvastatin-only group, the number increased from 6 to 13 (P = 0.002). Mean intima-media thickness decreased by a mean +/- SD of 0.05 +/- 0.34 mm in the apheresis group and increased by 0.06 +/- 0.38 mm in the simvastatin-only group (P < 0.001). According to multiple regression analysis, changes in apolipoprotein B, total cholesterol, and lipoprotein(a) levels accounted for changes in the aortotibial tract (R(2) = 0.36); changes in lipoprotein(a) and apolipoprotein Al levels accounted for changes in the intima-media thickness of the carotid artery (R(2) = 0.49). Conclusions: Aggressive lipid lowering with simvastatin and LDL apheresis decreased the intima-media thickness of the carotid artery and prevented an increase in the number of hemodynamically significant stenoses in the lower limbs. Therapy with simvastatin alone did not prevent progression of carotid or aortotibial vascular disease.	UNIV NIJMEGEN HOSP, DEPT INTERNAL MED, NL-6500 HB NIJMEGEN, NETHERLANDS; UNIV NIJMEGEN HOSP, CLIN VASC LAB, NL-6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen			Stalenhoef, A.F.H./H-8094-2014					AGISHI T, 1993, ANGIOLOGY, V44, P222, DOI 10.1177/000331979304400308; APSTEIN CS, 1978, ATHEROSCLEROSIS, V31, P105, DOI 10.1016/0021-9150(78)90157-0; BERENSON GS, 1992, AM J CARDIOL, V70, P851, DOI 10.1016/0002-9149(92)90726-F; BLANKENHORN DH, 1993, CIRCULATION, V88, P20, DOI 10.1161/01.CIR.88.1.20; BLANKENHORN DH, 1991, CIRCULATION, V83, P438, DOI 10.1161/01.CIR.83.2.438; BOTS ML, 1994, ARTERIOSCLER THROMB, V14, P1885, DOI 10.1161/01.ATV.14.12.1885; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CRAVEN TE, 1990, CIRCULATION, V82, P1230, DOI 10.1161/01.CIR.82.4.1230; CROUSE JR, 1995, AM J CARDIOL, V75, P455, DOI 10.1016/S0002-9149(99)80580-3; DEMACKER PNM, 1980, CLIN CHEM, V26, P1775; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; FURBERG CD, 1994, J INTERN MED, V236, P575, DOI 10.1111/j.1365-2796.1994.tb00848.x; GORDON BR, 1992, AM J CARDIOL, V70, P1010, DOI 10.1016/0002-9149(92)90352-Y; Gordon Bruce R., 1994, Current Opinion in Lipidology, V5, P69, DOI 10.1097/00041433-199402000-00011; HEISS G, 1991, AM J EPIDEMIOL, V134, P250, DOI 10.1093/oxfordjournals.aje.a116078; HOMER D, 1991, MAYO CLIN PROC, V66, P259, DOI 10.1016/S0025-6196(12)61007-6; JURGENS G, 1989, LANCET, V1, P911; KARNEGIS JN, 1992, ATHEROSCLEROSIS, V92, P25, DOI 10.1016/0021-9150(92)90006-3; KELLER C, 1991, ATHEROSCLEROSIS, V86, P1, DOI 10.1016/0021-9150(91)90093-I; KNISEL W, 1993, J INTERN MED, V234, P479, DOI 10.1111/j.1365-2796.1993.tb00781.x; KOHLER TR, 1987, CIRCULATION, V76, P1074, DOI 10.1161/01.CIR.76.5.1074; KOIZUMI J, 1993, ATHEROSCLEROSIS, V100, P65, DOI 10.1016/0021-9150(93)90068-6; Kroon AA, 1996, CIRCULATION, V93, P1826, DOI 10.1161/01.CIR.93.10.1826; KROON AA, 1995, J INTERN MED, V238, P451, DOI 10.1111/j.1365-2796.1995.tb01223.x; KROON AA, 1996, LIPID LOWERING THERA, P193; LEGEMATE DA, 1991, ULTRASOUND MED BIOL, V17, P769, DOI 10.1016/0301-5629(91)90159-T; LOPESVIRELLA MFL, 1980, CLIN CHEM, V26, P1205; MABUCHI H, 1987, ATHEROSCLEROSIS, V68, P19, DOI 10.1016/0021-9150(87)90089-X; Mack Wendy J., 1993, Journal of the American College of Cardiology, V21, p166A; NEWMAN AB, 1993, CIRCULATION, V88, P837, DOI 10.1161/01.CIR.88.3.837; OLSSON AG, 1990, J INTERN MED, V227, P381, DOI 10.1111/j.1365-2796.1990.tb00176.x; PEDERSEN TR, 1994, LANCET, V344, P1383; PFOHL M, 1994, J LIPID RES, V35, P1946; PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399; RUBBA P, 1990, CIRCULATION, V81, P610, DOI 10.1161/01.CIR.81.2.610; SALONEN JT, 1994, J INTERN MED, V236, P561, DOI 10.1111/j.1365-2796.1994.tb00846.x; SALONEN R, 1994, ARTERIOSCLER THROMB, V14, P1631, DOI 10.1161/01.ATV.14.10.1631; SALONEN R, 1995, CIRCULATION, V92, P1758, DOI 10.1161/01.CIR.92.7.1758; SALONEN R, 1991, ULTRASOUND MED BIOL, V17, P225, DOI 10.1016/0301-5629(91)90043-V; SHARRETT AR, 1994, ARTERIOSCLER THROMB, V14, P1098, DOI 10.1161/01.ATV.14.7.1098; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SMITH GD, 1990, CIRCULATION, V82, P1925, DOI 10.1161/01.CIR.82.6.1925; STALENHOEF AFH, 1989, AM J MED A, V4, pS39; SUPERKO HR, 1994, CIRCULATION, V90, P1056, DOI 10.1161/01.CIR.90.2.1056; TATAMI R, 1992, ATHEROSCLEROSIS, V95, P1, DOI 10.1016/0021-9150(92)90170-L; THOMPSON GR, 1995, LANCET, V345, P811, DOI 10.1016/S0140-6736(95)92961-4; VANASTEN WNJC, 1991, SURGERY, V109, P633; WALLDIUS G, 1994, AM J CARDIOL, V74, P875, DOI 10.1016/0002-9149(94)90579-7; WENDELHAG I, 1993, ARTERIOSCLER THROMB, V13, P1404, DOI 10.1161/01.ATV.13.10.1404; Widmann M D, 1993, Ann Vasc Surg, V7, P446, DOI 10.1007/BF02002128; WIKSTRAND J, 1992, ARTERIOSCLER THROMB, V12, P114, DOI 10.1161/01.ATV.12.1.114; WONG ML, 1993, ARTERIOSCLER THROMB, V13, P482, DOI 10.1161/01.ATV.13.4.482; YAMAMOTO A, 1991, ATHEROSCLEROSIS, V89, P1, DOI 10.1016/0021-9150(91)90002-K; YAMAMOTO K, 1995, NUTR METAB CARDIOVAS, V5, P181	54	81	84	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1996	125	12					945	+		10.7326/0003-4819-125-12-199612150-00001	http://dx.doi.org/10.7326/0003-4819-125-12-199612150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX768	8967704	Green Submitted			2022-12-28	WOS:A1996VX76800004
J	Southall, D; Carballo, M				Southall, D; Carballo, M			Can children be protected from the effects of war?	BRITISH MEDICAL JOURNAL			English	Editorial Material									INT CTR MIGRAT & HLTH,GENEVA,SWITZERLAND									SOUTHALL D, 1995, INT CHILD HLTH, V6, P111	1	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1996	313	7070					1493	1493		10.1136/bmj.313.7070.1493	http://dx.doi.org/10.1136/bmj.313.7070.1493			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX612	8973277	Green Published			2022-12-28	WOS:A1996VX61200097
J	Krentz, AJ				Krentz, AJ			Fortnightly review - Insulin resistance	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEPENDENT DIABETES-MELLITUS; CORONARY HEART-DISEASE; ESSENTIAL-HYPERTENSION; GLUCOSE-TOLERANCE; RISK-FACTORS; TYPE-2; HYPERINSULINEMIA; MEN; PATHOGENESIS; NIDDM				Krentz, AJ (corresponding author), ROYAL S HANTS HOSP, DIABET RESOURCE CTR, SOUTHAMPTON SO14 0YG, HANTS, ENGLAND.		Krentz, Andrew/AAD-2493-2019					Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; [Anonymous], 1995, Diabetes, V44, P1249; Armstrong L, 1996, BRIT MED J, V312, P1601, DOI 10.1136/bmj.312.7046.1601; ARNIEL SA, 1986, NEW ENGL J MED, V315, P215; Bailey CJ, 1996, NEW ENGL J MED, V334, P574, DOI 10.1056/NEJM199602293340906; BANERJI MA, 1995, DIABETES, V44, P141, DOI 10.2337/diabetes.44.2.141; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARON AD, 1994, AM J PHYSIOL, V267, pE187, DOI 10.1152/ajpendo.1994.267.2.E187; BEATTY OL, 1993, BMJ-BRIT MED J, V307, P92, DOI 10.1136/bmj.307.6896.92; Bell PM, 1996, DIABETIC MED, V13, P504, DOI 10.1002/(SICI)1096-9136(199606)13:6<504::AID-DIA111>3.0.CO;2-P; BJORNTORP P, 1991, DIABETES CARE, V14, P1132, DOI 10.2337/diacare.14.12.1132; BUCHANAN TA, 1995, DIABETES REV, V3, P584; Cusi K, 1995, DIABETES REV, V3, P206; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; DINNEEN S, 1992, NEW ENGL J MED, V327, P707, DOI 10.1056/NEJM199209033271007; DURRINGTON PN, 1992, DIABETIC MED, V9, P597, DOI 10.1111/j.1464-5491.1992.tb01852.x; ELLIOTT WJ, 1995, DIABETES REV, V3, P477; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; Ferrannini E, 1996, DIABETES, V45, P947, DOI 10.2337/diabetes.45.7.947; FERRANNINI E, 1991, DIABETOLOGIA, V34, P416, DOI 10.1007/BF00403180; Fontbonne A, 1996, DIABETES CARE, V19, P920, DOI 10.2337/diacare.19.9.920; GERICH JE, 1991, DIABETOLOGIA, V34, P607, DOI 10.1007/BF00400282; GODSLAND IF, 1995, LANCET, V346, P100, DOI 10.1016/S0140-6736(95)92118-4; GROOP L, 1993, DIABETOLOGIA, V36, P642, DOI 10.1007/BF00404074; GROOP LC, 1993, DIABETOLOGIA, V36, P1326, DOI 10.1007/BF00400814; HARPER R, 1994, BRIT MED J, V309, P226, DOI 10.1136/bmj.309.6949.226; HOTHERNIELSEN O, 1990, DIABETOLOGIA, V33, P603, DOI 10.1007/BF00400204; JARRETT RJ, 1992, LANCET, V340, P469, DOI 10.1016/0140-6736(92)91781-3; KAHN CR, 1978, METABOLISM, V27, P1893; Kiechl S, 1996, BRIT MED J, V313, P1040; KRENTZ AJ, 1994, DRUG SAFETY, V11, P223, DOI 10.2165/00002018-199411040-00002; Krentz AJ, 1996, DIABETIC MED, V13, P30, DOI 10.1002/(SICI)1096-9136(199601)13:1<30::AID-DIA5>3.0.CO;2-I; Krook A, 1996, BAILLIERE CLIN ENDOC, V10, P97, DOI 10.1016/S0950-351X(96)80330-2; Krook A, 1996, LANCET, V347, P1586, DOI 10.1016/S0140-6736(96)91076-4; Kumar S, 1996, DIABETOLOGIA, V39, P701; LAWS A, 1993, BAILLIERE CLIN ENDOC, V7, P1063, DOI 10.1016/S0950-351X(05)80245-9; Mauriege P, 1996, LANCET, V348, P698, DOI 10.1016/S0140-6736(05)65601-2; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; Moller DE, 1996, DIABETES CARE, V19, P396, DOI 10.2337/diacare.19.4.396; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; NELSON RG, 1995, DIABETES, V44, P483; Nestler JE, 1996, NEW ENGL J MED, V335, P617, DOI 10.1056/NEJM199608293350902; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Ofei F, 1996, DIABETES, V45, P881, DOI 10.2337/diabetes.45.7.881; PARIS P, 1996, LANCET, V348, P358; Perseghin G, 1996, NEW ENGL J MED, V335, P1357, DOI 10.1056/NEJM199610313351804; Polonsky KS, 1996, NEW ENGL J MED, V334, P777, DOI 10.1056/NEJM199603213341207; RACHMAN J, 1995, DIABETIC MED, V12, P467, DOI 10.1111/j.1464-5491.1995.tb00526.x; RANDLE PJ, 1963, LANCET, V1, P785; Reaven GM, 1996, NEW ENGL J MED, V334, P374, DOI 10.1056/NEJM199602083340607; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RIMM EB, 1995, BRIT MED J, V310, P555, DOI 10.1136/bmj.310.6979.555; Savage PJ, 1996, ANN INTERN MED, V124, P123, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00008; SCHEEN AJ, 1994, DIABETES METAB REV, V10, P151, DOI 10.1002/dmr.5610100206; Seely B. Lynn, 1993, P187; Segal KR, 1996, DIABETES, V45, P988, DOI 10.2337/diabetes.45.7.988; SKARFORS ET, 1989, BRIT MED J, V298, P1147, DOI 10.1136/bmj.298.6681.1147; Smith Ulf, 1993, P327; Sorensen TI, 1996, BRIT MED J, V313, P953; Storlien LH, 1996, DIABETOLOGIA, V39, P621, DOI 10.1007/BF00418533; STOUT RW, 1990, DIABETES CARE, V13, P631, DOI 10.2337/diacare.13.6.631; STUMVOLL M, 1995, NEW ENGL J MED, V333, P550, DOI 10.1056/NEJM199508313330903; TEMPLE R, 1992, DIABETIC MED, V9, P503, DOI 10.1111/j.1464-5491.1992.tb01830.x; UNGER RH, 1985, DIABETOLOGIA, V28, P119; YKIJARVINEN H, 1995, DIABETOLOGIA, V38, P1378, DOI 10.1007/BF00400597; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105	67	57	59	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 30	1996	313	7069					1385	1389		10.1136/bmj.313.7069.1385	http://dx.doi.org/10.1136/bmj.313.7069.1385			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW685	8956710	Green Published			2022-12-28	WOS:A1996VW68500037
J	Farmer, RDT; Lawrenson, RA; Thompson, CR; Kennedy, JG; Hambleton, IR				Farmer, RDT; Lawrenson, RA; Thompson, CR; Kennedy, JG; Hambleton, IR			Population-based study of risk of venous thromboembolism associated with various oral contraceptives	LANCET			English	Article							PROGESTAGEN; WOMEN	Background Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens. However, confounding and bias in the design of these studies may have affected the findings. The aim of our study was to re-examine the association between risk of VTE and OC use with a different study design and analysis to avoid some of the bias and confounding of the earlier studies. Methods We used computer records of patients from 143 general practices in the UK. The study was based on the medical records of about 540000 women born between 1941 and 1981. All women who had a recorded diagnosis of deep-vein thrombosis, venous thrombosis not otherwise specified, or pulmonary embolus during the study period, and who had been treated with an anticoagulant were identified as potential cases of VTE. We did a cohort analysis to estimate and compare incidence of VTE in users of the main OC preparations, and a nested case-control study to calculate the odds ratios of VTE associated with use of different types of OC, after adjustment for potential confounding factors. In the case-control study, we matched cases to controls by exact year of birth, practice, and current use of OCs. We used a multiple logistic regression model that included body-mass index, number of cycles, change in type of OC prescribed within 3 months of the event, previous pregnancy, and concurrent disease. Findings 85 women met the inclusion criteria for VTE, two of whom were users of progestagen-onyy OCs. Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and five as venous thrombosis not otherwise specified. The crude rate of VTE per 10000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations. After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75). Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation OCs. Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol. With all second-generation OCs as the reference, the odds ratios for VTE were 3.49 (1.21-10.12) for desogestrel plus 20 g ethinyloestradiol and 1.18 (0.66-2.17) for the other third-generation progestagens. Interpretation The previously reported increase in odds ratio associated with third-generation OCs when compared with second-generation products is likely to have been the result of residual confounding by age. The increased odds ratio associated with products containing 20 mu g ethinyloestradiol and desogestrel compared with the 30 mu g product is biologically implausible, and is likely to be the result of preferential prescribing and, thus, confounding.			Farmer, RDT (corresponding author), UNIV LONDON,CHELSEA & WESTMINSTER HOSP,CHARING CROSS & WESTMINSTER MED SCH,LONDON SW10 9NH,ENGLAND.		Hambleton, Ian/AAP-3519-2020	Hambleton, Ian/0000-0002-5638-9794				ARRIGHI HM, 1994, EPIDEMIOLOGY, V5, P189, DOI 10.1097/00001648-199403000-00009; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; *COMM SAF MED, 1995, COMB OR CONTR THROMB; Farmer R. D. T., 1995, Journal of Obstetrics and Gynaecology (Abingdon), V15, P195, DOI 10.3109/01443619509015499; FORD BL, 1983, INCOMPLETE DATA SAMP, P185; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; HELMRICH SP, 1987, OBSTET GYNECOL, V69, P91; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; Lewis MA, 1996, CONTRACEPTION, V54, P5, DOI 10.1016/0010-7824(96)00112-6; Lidegaard O, 1996, CONTRACEPTION, V53, P135, DOI 10.1016/0010-7824(96)00035-2; Lis Y, 1993, PHARMACOEPIDEM DR S, V2, P51; MACRAE K, 1995, BRIT MED J, V311, P11; Sande IG, 1983, INCOMPLETE DATA SAMP, V3, P334; Spitzer WO, 1996, BRIT MED J, V312, P83; THOROGOOD M, 1992, INT J EPIDEMIOL, V21, P48, DOI 10.1093/ije/21.1.48; VESSEY M, 1986, BRIT MED J, V292, P302; WATT AH, 1995, LANCET, V346, P1430, DOI 10.1016/S0140-6736(95)92446-9; *WHO COLL STUD CAR, 1995, LANCET, V346, P1582; 1995, NATURE, V377, P663	19	288	289	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					83	88		10.1016/S0140-6736(96)07496-X	http://dx.doi.org/10.1016/S0140-6736(96)07496-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996419				2022-12-28	WOS:A1997WB80000010
J	Markram, H; Lubke, J; Frotscher, M; Sakmann, B				Markram, H; Lubke, J; Frotscher, M; Sakmann, B			Regulation of synaptic efficacy by coincidence of postsynaptic APs and EPSPs	SCIENCE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPUS; NEURONS	Activity-driven modifications in synaptic connections between neurons in the neocortex may occur during development and learning. In dual whole-cell voltage recordings from pyramidal neurons, the coincidence of postsynaptic action potentials (APs) and unitary excitatory postsynaptic potentials (EPSPs) was found to induce changes in EPSPs. Their average amplitudes were differentially up- or down-regulated, depending on the precise timing of postsynaptic APs relative to EPSPs. These observations suggest that APs propagating back into dendrites serve to modify single active synaptic connections, depending on the pattern of electrical activity in the pre- and postsynaptic neurons.	MAX PLANCK INST MED RES,ZELLPHYSIOL ABT,D-69120 HEIDELBERG,GERMANY; UNIV FREIBURG,INST ANAT,D-79104 FREIBURG,GERMANY	Max Planck Society; University of Freiburg			Lubke, Joachim/H-8762-2013	Lubke, Joachim/0000-0002-4086-3199				BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1995, SCIENCE, V269, P1730, DOI 10.1126/science.7569903; FOX K, 1995, NEURON, V15, P485, DOI 10.1016/0896-6273(95)90136-1; FRIEDLANDER MJ, 1990, J NEUROSCI, V10, P814; GUSTAFSSON B, 1987, J NEUROSCI, V7, P774; HEBB DO, 1949, ORG BEHAVIOR; Helmchen F, 1996, BIOPHYS J, V70, P1069, DOI 10.1016/S0006-3495(96)79653-4; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; Markram H, 1996, NATURE, V382, P807, DOI 10.1038/382807a0; MARKRAM H, 1995, J PHYSIOL-LONDON, V485, P1; MARKRAM H, IN PRESS J PHYSL; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; SCHILLER J, 1995, J PHYSIOL-LONDON, V487, P583, DOI 10.1113/jphysiol.1995.sp020902; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; STANTON PK, 1989, NATURE, V339, P215, DOI 10.1038/339215a0; Stricker C, 1996, J PHYSIOL-LONDON, V490, P443, DOI 10.1113/jphysiol.1996.sp021156; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; TALBOT MJ, 1996, J NEUROPHYSIOL, V70, P2120	19	2607	2670	4	151	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					213	215		10.1126/science.275.5297.213	http://dx.doi.org/10.1126/science.275.5297.213			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985014				2022-12-28	WOS:A1997WC02200038
J	Melbye, M; Wohlfahrt, J; Olsen, JH; Frisch, M; Westergaard, T; HelwegLarsen, K; Andersen, PK				Melbye, M; Wohlfahrt, J; Olsen, JH; Frisch, M; Westergaard, T; HelwegLarsen, K; Andersen, PK			Induced abortion and the risk of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REPRODUCTIVE FACTORS; YOUNG-WOMEN; PREGNANCY; SWEDISH	Background It has been hypothesized that an interrupted pregnancy might increase a woman's risk of breast cancer because breast cells could proliferate without the later protective effect of differentiation. Methods We established a population-based cohort with information on parity and vital status consisting of all Danish women born from April 1, 1935, through March 31, 1978. Through linkage with the National Registry of Induced Abortions, information on the number and dates of induced abortions among those women was combined with information on the gestational age of each aborted fetus. All new cases of breast cancer were identified through linkage with the Danish Cancer Registry. Results In the cohort of 1.5 million women (28.5 million person-years), we identified 370,715 induced abortions among 280,965 women (2.7 million person-years) and 10,246 women with breast cancer. After adjustment for known risk factors, induced abortion was not associated with an increased risk of breast cancer (relative risk, 1.00; 95 percent confidence interval, 0.94 to 1.06). No increases in risk were found in subgroups defined according to age at abortion, parity, time since abortion, or age at diagnosis of breast cancer. The relative risk of breast cancer increased with increasing gestational age of the fetus at the time of the most recent induced abortion: <7 weeks, 0.81 (95 percent confidence interval, 0.58 to 1.13); >12 weeks, 1.38 (1.00 to 1.90) (reference category, 9 to 10 weeks). Conclusions Induced abortions have no overall effect on the risk of breast cancer. (C) 1997, Massachusetts Medical Society.	DANISH CANC REGISTRY, COPENHAGEN, DENMARK; NATL BOARD HLTH, COPENHAGEN, DENMARK		Melbye, M (corresponding author), STATENS SERUM INST, DANISH EPIDEMIOL SCI CTR, DEPT EPIDEMIOL RES, 5 ARTILLERIVEJ, DK-2300 COPENHAGEN S, DENMARK.		Frisch, Morten/E-9206-2016	Frisch, Morten/0000-0002-3864-8860; Olsen, Jorgen Helge/0000-0001-9633-5662; melbye, mads/0000-0001-8264-6785				ADAMI HO, 1990, BRIT J CANCER, V62, P122, DOI 10.1038/bjc.1990.242; ALBREKTSEN G, 1995, BRIT J CANCER, V72, P480, DOI 10.1038/bjc.1995.359; ANDRIEU N, 1994, CANCER DETECT PREV, V18, P51; BERNSTEIN L, 1985, J NATL CANCER I, V74, P741; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; Brind J, 1996, J EPIDEMIOL COMMUN H, V50, P481, DOI 10.1136/jech.50.5.481; BRINTON LA, 1983, BRIT J CANCER, V47, P757, DOI 10.1038/bjc.1983.128; CALLE EE, 1995, CANCER CAUSE CONTROL, V6, P460, DOI 10.1007/BF00052187; DALING JR, 1994, JNCI-J NATL CANCER I, V86, P1584, DOI 10.1093/jnci/86.21.1584; EWERTZ M, 1988, BRIT J CANCER, V58, P99, DOI 10.1038/bjc.1988.172; HADJIMICHAEL OC, 1986, BRIT J CANCER, V53, P281, DOI 10.1038/bjc.1986.46; HARRIS BML, 1989, BMJ-BRIT MED J, V299, P1430, DOI 10.1136/bmj.299.6713.1430; HOWE HL, 1989, INT J EPIDEMIOL, V18, P300, DOI 10.1093/ije/18.2.300; KVALE G, 1987, AM J EPIDEMIOL, V126, P831, DOI 10.1093/oxfordjournals.aje.a114720; LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102; LINDEFORSHARRIS BM, 1991, AM J EPIDEMIOL, V134, P1003, DOI 10.1093/oxfordjournals.aje.a116173; LIPWORTH L, 1995, INT J CANCER, V61, P181, DOI 10.1002/ijc.2910610207; MICHELS KB, 1995, CANCER CAUSE CONTROL, V6, P75, DOI 10.1007/BF00051683; *NAT BOARD HLTH, 1993, VITALSTATISTIK, V1, P36; Newcomb RA, 1996, JAMA-J AM MED ASSOC, V275, P283, DOI 10.1001/jama.275.4.283; PARAZZINI F, 1991, INT J CANCER, V48, P816, DOI 10.1002/ijc.2910480605; PIKE MC, 1981, BRIT J CANCER, V43, P72, DOI 10.1038/bjc.1981.10; ROSENBERG L, 1993, EPIDEMIOL REV, V15, P133, DOI 10.1093/oxfordjournals.epirev.a036097; ROSENBERG L, 1994, J NATL CANCER I, V86, P1569, DOI 10.1093/jnci/86.21.1569; ROSENBERG L, 1988, AM J EPIDEMIOL, V127, P981, DOI 10.1093/oxfordjournals.aje.a114901; ROSENBERG L, 1994, AM J EPIDEMIOL, V140, P856; RUSSO J, 1980, AM J PATHOL, V100, P497; *SAS I, 1992, P229 SAS I; SELLERS TA, 1993, CANCER CAUSE CONTROL, V4, P21, DOI 10.1007/BF00051710; Storm H H, 1991, IARC Sci Publ, P220; Tavani A, 1996, INT J CANCER, V65, P401, DOI 10.1002/(SICI)1097-0215(19960208)65:4<401::AID-IJC1>3.0.CO;2-0	31	159	163	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1997	336	2					81	85		10.1056/NEJM199701093360201	http://dx.doi.org/10.1056/NEJM199701093360201			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC481	8988884				2022-12-28	WOS:A1997WC48100001
J	Zhang, N; Zhang, JP; Purcell, KJ; Cheng, Y; Howard, K				Zhang, N; Zhang, JP; Purcell, KJ; Cheng, Y; Howard, K			The Drosophila protein Wunen repels migrating germ cells	NATURE			English	Article							AXON MIGRATIONS; PHENOTYPES; RECEPTOR; ELEGANS	IN Drosophila, germ cells migrate in embryonic development from the lumen of the developing gut towards the overlying mesoderm, where they enter the gonads(1,2). The gene wunen is responsible for guiding the germ cells early in this process(3). Here we report that the protein Wunen has two properties that allow it to use repulsion to guide the germ cells. Wunen can transform a permissive cellular environment into a repulsive one, and is expressed in the gut in a pattern that guides germ cells towards the mesoderm. Wunen shows strong similarity to the enzyme type 2 phosphatidic acid phophatase (PAP2)(4), suggesting that it is involved in lipid metabolism.	ROCHE INST MOL BIOL, ROCHE RES CTR, NUTLEY, NJ 07110 USA; JACKSON LAB, BAR HARBOR, ME 04609 USA; MERCK SHARP & DOHME RES LABS, DEPT VIRUS & CELL BIOL, W POINT, PA 19486 USA; YALE UNIV, SCH MED, BOYER CTR MOL MED, DEPT CELL BIOL, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, BOYER CTR MOL MED, DEPT BIOL, NEW HAVEN, CT 06536 USA; UNIV NOTRE DAME, DEPT BIOL SCI, NOTRE DAME, IN 46556 USA; UCL, MOL CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND	Roche Holding; Jackson Laboratory; Merck & Company; Yale University; Yale University; University of Notre Dame; University of London; University College London								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROOKMAN JJ, 1992, DEVELOPMENT, V116, P1185; CALLAINI G, 1995, DEV BIOL, V170, P365, DOI 10.1006/dbio.1995.1222; COLAMARINO SA, 1995, CELL, V81, P6521; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; FAITH MJ, 1993, MICROBIOL REV, V57, P995; FAN, 1993, J BIOL CHEM, V121, P867; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; GRIEG S, 1995, CURR BIOL, V5, P1057; HART AC, 1993, NATURE, V361, P732, DOI 10.1038/361732a0; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; JAGLARZ MK, 1995, DEVELOPMENT, V121, P3495; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; KOBOYASHI S, 1996, NATURE, V380, P708; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Rabinowitz M, 1941, J MORPHOL, V69, P1, DOI 10.1002/jmor.1050690102; Sonnenblick BP, 1941, P NATL ACAD SCI USA, V27, P484, DOI 10.1073/pnas.27.10.484; TOROK T, 1993, GENETICS, V135, P71; Zhang N, 1996, GENETICS, V143, P1231	23	169	174	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 2	1997	385	6611					64	67		10.1038/385064a0	http://dx.doi.org/10.1038/385064a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985246				2022-12-28	WOS:A1997WA73100049
J	Freemantle, N; Drummond, M				Freemantle, N; Drummond, M			Should clinical trials with concurrent economic analyses be blinded?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION		UNIV YORK, DEPT HLTH SCI & CLIN EVALUAT, YORK YO1 5DD, N YORKSHIRE, ENGLAND	University of York - UK	Freemantle, N (corresponding author), UNIV YORK, CTR HLTH ECON, YORK YO1 5DD, N YORKSHIRE, ENGLAND.			Freemantle, Nick/0000-0001-5807-5740				Cook T.C., 1979, QUASIEXPERIMENTATION; Drummond M F, 1991, Int J Technol Assess Health Care, V7, P561; Freemantle N, 1996, BRIT MED J, V312, P1469, DOI 10.1136/bmj.312.7044.1469; FREEMANTLE N, 1995, BRIT MED J, V310, P955, DOI 10.1136/bmj.310.6985.955; Kramer, 1994, LISTENING PROZAC PSY; MARK DB, 1995, NEW ENGL J MED, V332, P1418, DOI 10.1056/NEJM199505253322106; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; Simon GE, 1996, JAMA-J AM MED ASSOC, V275, P1897, DOI 10.1001/jama.275.24.1897; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VANDEWERF F, 1995, JAMA-J AM MED ASSOC, V273, P1586, DOI 10.1001/jama.273.20.1586; 1992, MED LETT DRUGS THER, V34, P47	12	38	39	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1997	277	1					63	64		10.1001/jama.277.1.63	http://dx.doi.org/10.1001/jama.277.1.63			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ767	8980212				2022-12-28	WOS:A1997VZ76700031
J	McHugh, TJ; Blum, KI; Tsien, JZ; Tonegawa, S; Wilson, MA				McHugh, TJ; Blum, KI; Tsien, JZ; Tonegawa, S; Wilson, MA			Impaired hippocampal representation of space in CA1-specific NMDAR1 knockout mice	CELL			English	Article							LONG-TERM POTENTIATION; CALMODULIN KINASE-II; ASPARTATE RECEPTOR ANTAGONIST; SYNAPTIC PLASTICITY; MUTANT MICE; SELECTIVE IMPAIRMENT; FREQUENCY; BLOCKADE; MEMORY; RATS	To investigate the role of synaptic plasticity in the place-specific firing of the hippocampus, we have applied multiple electrode recording techniques to freely behaving mice with a CA1 pyramidal cell-specific knockout of the NMDAR1 gene. We have discovered that although the CA1 pyramidal cells of these mice retain place-related activity, there is a significant decrease in the spatial specificity of individual place fields. We have also found a striking deficit in the coordinated firing of pairs of neurons tuned to similar spatial locations. Pairs have uncorrelated firing even if their fields overlap. These results demonstrate that NMDA receptor-mediated synaptic plasticity is necessary for the proper representation of space in the CA1 region of the hippocampus.	MIT, CTR LEARNING & MEMORY, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	McHugh, TJ (corresponding author), MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.		McHugh, Thomas/M-6159-2019; McHugh, Thomas J/A-6693-2010	McHugh, Thomas/0000-0002-1243-5189; McHugh, Thomas J/0000-0002-1243-5189	NINDS NIH HHS [NS32925] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BUZSAKI G, 1986, BRAIN RES, V398, P242, DOI 10.1016/0006-8993(86)91483-6; BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; Chen C, 1997, ANNU REV NEUROSCI, V20, P157, DOI 10.1146/annurev.neuro.20.1.157; Chrobak JJ, 1996, J NEUROSCI, V16, P3056; DAVIS S, 1992, J NEUROSCI, V12, P21; EICHENBAUM H, 1988, BEHAV NEUROSCI, V102, P331, DOI 10.1037/0735-7044.102.3.331; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Hertz JA, 2018, INTRO THEORY NEURAL; HUERTA PT, 1993, NATURE, V364, P723, DOI 10.1038/364723a0; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; Kirkwood A, 1996, NATURE, V381, P526, DOI 10.1038/381526a0; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; MCNAUGHTON BL, 1983, J NEUROSCI METH, V8, P391, DOI 10.1016/0165-0270(83)90097-3; Miller KD, 1996, NEURON, V17, P371, DOI 10.1016/S0896-6273(00)80169-5; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; Paxinos G, 1995, RAT NERVOUS SYSTEM, V2nd; RANCK JB, 1973, EXP NEUROL, V41, P462, DOI 10.1016/0014-4886(73)90290-2; SAUCIER D, 1995, NATURE, V378, P186, DOI 10.1038/378186a0; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; STEVENS CF, 1994, CURR BIOL, V4, P687, DOI 10.1016/S0960-9822(00)00153-6; TURRIGIANO G, 1994, SCIENCE, V264, P974, DOI 10.1126/science.8178157; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; YLINEN A, 1995, J NEUROSCI, V15, P30; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	36	445	460	1	45	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 27	1996	87	7					1339	1349		10.1016/S0092-8674(00)81828-0	http://dx.doi.org/10.1016/S0092-8674(00)81828-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980239	Bronze			2022-12-28	WOS:A1996WA54100021
J	Loxterkamp, D				Loxterkamp, D			Hearing voices - How should doctors respond to their calling?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article																		BOWER AD, 1963, NEW ENGL J MED, V269, P667, DOI 10.1056/NEJM196309262691305; KAFKA FA, 1972, COMPLETE STORIES, P224; Stephens G G, 1995, J Am Board Fam Pract, V8, P250	3	12	12	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 26	1996	335	26					1991	1993		10.1056/NEJM199612263352611	http://dx.doi.org/10.1056/NEJM199612263352611			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA160	8960482				2022-12-28	WOS:A1996WA16000011
J	Newport, MJ; Huxley, CM; Huston, S; Hawrylowicz, CM; Oostra, BA; Williamson, R; Levin, M				Newport, MJ; Huxley, CM; Huston, S; Hawrylowicz, CM; Oostra, BA; Williamson, R; Levin, M			A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-MONOCYTES; TUBERCULOSIS INFECTION; MACROPHAGE; ACTIVATION; IDENTIFICATION; RESISTANCE; EXPRESSION; LYMPHOKINE; BINDING; MICE	Background Genetic differences in immune responses may affect susceptibility to mycobacterial infection, but no specific genes have been implicated in humans. We studied four children who had an unexplained genetic susceptibility to mycobacterial infection and who appeared to have inherited the same recessive mutation from a common ancestor. Methods We used microsatellite analysis, immunofluorescence studies, and sequence analysis to study the affected patients, unaffected family members, and normal controls. Results A genome search using microsatellite markers identified a region on chromosome 6q in which the affected children were ail homozygous for eight markers. The gene for interferon-gamma receptor 1 maps to this region. Immunofluorescence studies showed that the receptor was absent on leukocytes from the affected children. Sequence analysis of complementary DNA for the gene for interferon-gamma receptor 1 revealed a point mutation at nucleotide 395 that introduces a stop codon and results in a truncated protein that lacks the transmembrane and cytoplasmic domains. Conclusions Four children with severe mycobacterial infections had a mutation in the gene for interferon-gamma receptor 1 that leads to the absence of receptors on cell surfaces and a functional defect in the up-regulation of tumor necrosis factor a by macrophages in response to interferon-gamma. The interferon-gamma pathway is important in the response to intracellular pathogens such as mycobacteria. (C) 1996, Massachusetts Medical Society.	ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT PEDIAT,LONDON W2 1NY,ENGLAND; ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT BIOCHEM & MOL GENET,LONDON W2 1NY,ENGLAND; ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT IMMUNOL,LONDON W2 1NY,ENGLAND; ERASMUS UNIV ROTTERDAM,DEPT CLIN GENET,NL-3000 DR ROTTERDAM,NETHERLANDS	Imperial College London; Imperial College London; Imperial College London; Erasmus University Rotterdam			; Hawrylowicz, Catherine/Q-8483-2017	Katsanis, Sara/0000-0002-5044-8765; Levin, Michael/0000-0003-2767-6919; Newport, Melanie/0000-0002-8946-7525; Hawrylowicz, Catherine/0000-0002-2337-7463				AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BLACKWELL JM, 1989, RES IMMUNOL, V140, P767, DOI 10.1016/0923-2494(89)90029-1; Chan John, 1994, P389; COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621; COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243; DENIS M, 1991, CLIN EXP IMMUNOL, V84, P200, DOI 10.1111/j.1365-2249.1991.tb08149.x; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DSouza S, 1996, CLIN EXP IMMUNOL, V103, P35, DOI 10.1046/j.1365-2249.1996.00904.x; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FINE PEM, 1981, INT J LEPROSY, V49, P437; FLESCH IEA, 1990, INFECT IMMUN, V58, P2675, DOI 10.1128/IAI.58.8.2675-2677.1990; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HOLLAND SM, 1994, NEW ENGL J MED, V330, P1348, DOI 10.1056/NEJM199405123301904; HORSBURGH CR, 1989, AM REV RESPIR DIS, V139, P4, DOI 10.1164/ajrccm/139.1.4; HOUWEN RHJ, 1994, NAT GENET, V8, P380, DOI 10.1038/ng1294-380; Kallmann Franz J., 1943, AMER REV TUBERC, V47, P549; KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435; Klein N. J., 1994, Immunology and Infectious Diseases (Oxford), V4, P33; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; LEVIN M, 1995, LANCET, V345, P79, DOI 10.1016/S0140-6736(95)90059-4; LEWIS DB, 1990, PEDIATR INFECT DIS J, V9, P642; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; NEWPORT M, 1995, J MED GENET, V32, P904, DOI 10.1136/jmg.32.11.904; ORME IM, 1993, J IMMUNOL, V151, P518; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PFIZENMAIER K, 1988, J IMMUNOL, V141, P856; ROOK GAW, 1986, IMMUNOLOGY, V57, P159; SAMBROOK J, 1989, MOL CLONIG LAB MANUA, V2; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STRICKLAND RW, 1986, J IMMUNOL, V137, P1577; WALKER L, 1981, NATURE, V293, P69, DOI 10.1038/293069a0; WONG GHW, 1983, J IMMUNOL, V131, P788	37	964	995	1	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 26	1996	335	26					1941	1949		10.1056/NEJM199612263352602	http://dx.doi.org/10.1056/NEJM199612263352602			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA160	8960473				2022-12-28	WOS:A1996WA16000002
J	Carter, AJ				Carter, AJ			Narcosis and nightshade	BRITISH MEDICAL JOURNAL			English	Article								Although this year marks the 150th anniversary of the discovery of modern surgical anaesthesia, surgery itself has a much longer history. It is well known that extracts from the opium poppy, Papaver somniferum, were used to dull the pain of surgery during ancient times but less well known that extracts from plants with sedative powers often accompanied them, producing primitive anaesthesia. Most of these sedative plants were members of a large botanical family, the Solanaceae. This paper describes some of them and discusses the ways in which they were administered. It also explains why, during the middle ages, these primitive techniques went out of use but how none the less they provided Shakespeare with the inspiration for some of his greatest plays. When the active principal of the Solanaceae was identified as scopolamine, it came to play a part in 20th century anaesthesia. The combination of omnopon and scopolamine lives on as a premedication, and the presence of poppy heads and mandrake roots on the arms of today's Association of Anaesthetists serves to remind us of the speciality's links with its past.	N STAFFORDSHIRE HOSP,STOKE ON TRENT ST4 6QG,STAFFS,ENGLAND	Keele University; University Hospital of North Staffordshire NHS Trust								ATKINSON RS, 1993, LEES SYNOPSIS ANAEST, P92; BOCCACCIO G, 1993, LIT COMPANION MED, P295; BOWES JB, 1989, HIST ANAESTHESIA, P43; Dauriol M., 1847, LANCET, V1, P540; Dauriol M., 1847, J MED CHIRURGIE TOUL, V10, P178; DUNCUM B, 1947, DEV INHALATION ANAES, P375; ELLIS ES, 1946, ANCIENT ANODYNES, P137; GRIEVE M, 1931, MODERN HERBAL, P397; GUTHRIE D, 1945, HIST MED, P116; HUSEMANN T, 1900, DTSCH ZEIT F CHIR, V57, P516; KEYS TE, 1945, HIST SURG ANAESTHESI, P104; RICHARDSON BW, 1988, ASCLEPIAD, V5, P174; THOMPSON CJS, 1934, MYSTIC MANDRAKE, P100	13	19	19	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1630	1632		10.1136/bmj.313.7072.1630	http://dx.doi.org/10.1136/bmj.313.7072.1630			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991015	Green Published			2022-12-28	WOS:A1996VZ81100047
J	Smith, GD; Dorling, D				Smith, GD; Dorling, D			''I'm all right, John'': Voting patterns and mortality in England and Wales, 1981-92	BRITISH MEDICAL JOURNAL			English	Article							HEALTH; DEPRIVATION	Objective-To investigate the association between voting patterns, deprivation, and mortality across England and Wales. Design-Ecological study. Setting-All the electoral constituencies of England and Wales. Main outcome measures-Combined and sex specific standardised mortality ratios. Results-For the years surrounding the three elections of 1983, 1987, and 1992 overall standardised mortality ratios showed substantial negative correlations of -0.74 to -0.76 with Conservative voting and substantial positive correlations of 0.73 to 0.77 with Labour voting (all P<0.0001). Correlations were higher for male than female mortality. Conservative voting was strongly negatively correlated (r = -0.84) with the Townsend deprivation score, while Labour voting was positively correlated (r = 0.74) with this. Labour and Conservative voting explained more of the variance in mortality than did the Townsend score. In multiple regression analyses for the 1992 election Labour voting (P<0.0001), Conservative voting ((P<0.0001), the Townsend score (P = 0.016), and abstentions (P = 0.032) were all associated with mortality. Labour and Conservative voting explained 61% of the variance in mortality between constituencies; when Townsend score and abstentions were added this increased to 63%. Conclusions-Conservative and Labour voting are at least as strongly associated with mortality as is a standard deprivation index. Voting patterns may add information above that provided by indicators of material deprivation. People living in better circumstances and who have better health, who are least likely to require unemployment benefit and free school meals or to rely on a state pension in old age, and who are most able to opt out of state subsidised provision of transport, education, and the NHS, vote for the party that is most likely to dismantle the welfare state.	UNIV BRISTOL,DEPT GEOG,BRISTOL BS8 1SS,AVON,ENGLAND	University of Bristol	Smith, GD (corresponding author), UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL BS8 2PR,AVON,ENGLAND.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				BenShlomo Y, 1996, BRIT MED J, V312, P1013; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; Bentham G, 1995, J EPIDEMIOL COMMUN H, V49, pS57, DOI 10.1136/jech.49.Suppl_2.S57; Britton M, 1990, MORTALITY GEOGRAPHY; BRITTON M, 1990, MORTALITY GEOGRAPHY, P57; BRITTON M, 1990, MORTALITY GEOGRAPHY, P1; Carstairs V., 1991, DEPRIVATION HLTH SCO; Charlton J, 1996, Popul Trends, P17; DORLING D, IN PRESS CHANGING LI; DORLING D, 1996, PROGR PLANNING, V45, P67; EAMES M, 1993, BRIT MED J, V307, P1097, DOI 10.1136/bmj.307.6912.1097; ENGELS F, 1987, CONDITION WORKING CL; GOUGH I, 1994, INT J HEALTH SERV, V24, P715, DOI 10.2190/KHAM-M986-W67T-56B7; Kaplan GA, 1996, BRIT MED J, V312, P999; LENA HF, 1993, INT J HEALTH SERV, V23, P585, DOI 10.2190/EQUY-ACG8-X59F-AE99; MACINTYRE S, 1993, J SOC POLICY, V22, P213, DOI 10.1017/S0047279400019310; MACRAE K, 1994, BRIT MED J, V309, P1478, DOI 10.1136/bmj.309.6967.1478; MARTIN WJ, 1956, BRIT MED J, V1, P1523, DOI 10.1136/bmj.1.4982.1523; MCCARRON PG, 1994, BRIT MED J, V309, P1481, DOI 10.1136/bmj.309.6967.1481; MCLOONE P, 1994, BRIT MED J, V309, P1465, DOI 10.1136/bmj.309.6967.1465; PHILLIMORE P, 1994, BRIT MED J, V308, P1125, DOI 10.1136/bmj.308.6937.1125; PHILLIMORE P, 1994, HLTH INEQUALITY NO R; PHILO C, 1995, OFF MAP SOCIAL GEOGR; PINCHERL.G, 1969, BRIT J PREV SOC MED, V23, P72; POCOCK SJ, 1980, BMJ-BRIT MED J, V1, P1243; SIMPSON SN, 1994, J ROY STAT SOC A STA, V157, P313; SMITH GD, 1993, BRIT MED J, V307, P1085, DOI 10.1136/bmj.307.6912.1085; Smith GD, 1996, BRIT MED J, V312, P987; SMITH J, 1994, LABOURS LAST CHANCE; SPENCER N, 1982, USES ABUSES DEPRIVAT; Wilkinson R, 1996, UNHEALTHY SOC; Woolf B, 1947, BR J SOC MED, V1, P73	32	49	49	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1573	1577		10.1136/bmj.313.7072.1573	http://dx.doi.org/10.1136/bmj.313.7072.1573			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VZ811	8990989	Green Published			2022-12-28	WOS:A1996VZ81100010
J	Weidenschilling, SJ; Marzari, F				Weidenschilling, SJ; Marzari, F			Gravitational scattering as a possible origin for giant planets at small stellar distances	NATURE			English	Article							JUPITER; COMPANION; SYSTEMS; DISK	THE recent discoveries(1-4) of massive planetary companions orbiting several solar-type stars pose a conundrum, Conventional models(5,6) for the formation of giant planets (such as Jupiter and Saturn) place such objects at distances of several astronomical units from the parent star, whereas all but one of the new objects are on orbits well inside 1 AU; these planets must therefore have originated at larger distances and subsequently migrated inwards. One suggested migration mechanism invokes tidal interactions between the planet and the evolving circumstellar disk(7). Such a mechanism results in planets with small, essentially circular orbits, which appears to be the case for many of the new planets. But two of the objects have substantial orbital eccentricities, which are difficult to reconcile with a tidal-linkage model, Here we describe an alternative model for planetary migration that can account for these large orbital eccentricities, If a system of three or more giant planets form about a star, their orbits may become unstable as they gain mass by accreting gas from the circumstellar disk; subsequent gravitational encounters among these planets can eject one from the system while placing the others into highly eccentric orbits both closer and farther from the star.	UNIV PADUA,DIPARTIMENTO FIS,I-35131 PADUA,ITALY	University of Padua	Weidenschilling, SJ (corresponding author), PLANETARY SCI INST,SJI,620 N 6TH AVE,TUCSON,AZ 85705, USA.		Marzari, Francesco/X-2440-2019					Beckwith SVW, 1996, NATURE, V383, P139, DOI 10.1038/383139a0; BOSS A, 1995, NATURE, V379, P397; BOSS AP, 1995, SCIENCE, V267, P360, DOI 10.1126/science.267.5196.360; Butler RP, 1996, ASTROPHYS J, V464, pL153, DOI 10.1086/310102; Chambers JE, 1996, ICARUS, V119, P261, DOI 10.1006/icar.1996.0019; Cochran WD., 1996, B AM ASTRON SOC, V28, P1111; Everhart E., 1985, DYNAMICS COMETS THEI, P185; FARINELLA P, 1980, MOON PLANETS, V22, P25, DOI 10.1007/BF00896864; GLADMAN B, 1993, ICARUS, V106, P247, DOI 10.1006/icar.1993.1169; LATHAM DW, 1989, NATURE, V339, P38, DOI 10.1038/339038a0; Lin DNC, 1996, NATURE, V380, P606, DOI 10.1038/380606a0; LISSAUER JJ, 1987, ICARUS, V69, P249, DOI 10.1016/0019-1035(87)90104-7; Marcy GW, 1996, ASTROPHYS J, V464, pL147, DOI 10.1086/310096; POLLACK J, IN PRESS ICARUS; RASIO FA, IN PRESS SCIENCE; TAKEDA H, 1985, PROG THEOR PHYS, V74, P272, DOI 10.1143/PTP.74.272; WARD WR, 1988, ICARUS, V73, P330, DOI 10.1016/0019-1035(88)90103-0; WETHERILL GW, 1994, ASTROPHYS SPACE SCI, V212, P23, DOI 10.1007/BF00984505; WETHERILL GW, 1995, NATURE, V373, P470, DOI 10.1038/373470a0	20	366	368	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 19	1996	384	6610					619	621		10.1038/384619a0	http://dx.doi.org/10.1038/384619a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VZ296	8967949				2022-12-28	WOS:A1996VZ29600026
J	Yanovski, SZ; Dietz, WH; Goodwin, NJ; Hill, JO; PiSunyer, FX; Rolls, B; Stern, J; Weinsier, RL; Wilson, GT; Wing, RR; Hoofnagle, JH; Everhart, JE; Hubbard, VS				Yanovski, SZ; Dietz, WH; Goodwin, NJ; Hill, JO; PiSunyer, FX; Rolls, B; Stern, J; Weinsier, RL; Wilson, GT; Wing, RR; Hoofnagle, JH; Everhart, JE; Hubbard, VS			Long-term pharmacotherapy in the management of obesity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							FENFLURAMINE PLUS PHENTERMINE; CARDIOVASCULAR RISK-FACTORS; DOUBLE-BLIND TRIAL; WEIGHT CONTROL; CALORIC RESTRICTION; BODY-WEIGHT; FOLLOW-UP; DEXFENFLURAMINE TREATMENT; PULMONARY-HYPERTENSION; BEHAVIOR-MODIFICATION	Objectives.-To examine the rationale for long-term use of medications in the management of obesity, to provide an overview of published scientific information on their safety and efficacy, and to provide guidance to patients and practitioners regarding risks and benefits of treatment. Data Sources.-Original reports and reviews obtained through electronic database searches on anorexiant drugs supplemented by a manual search of bibliographies. Study Selection.-English-language articles that discussed the role of medications in the treatment of human obesity, and studies that evaluated their safety and efficacy for a minimum of 24 weeks. Data Extraction.-Studies were reviewed by experts in the fields of nutrition, obesity, and eating disorders to evaluate study design and the validity of authors' conclusions. Data Synthesis.-The long-term use of medications in the management of obesity is consistent with the current consensus that obesity responds poorly to short-term interventions. Net weight loss attributable to medication is modest, ranging from 2 to 10 kg, but patients taking active drug are more likely to lose 10% or more of initial body weight. Weight loss tends to reach a plateau by 6 months. Weight remains below baseline throughout treatment, although some studies show partial weight regain despite continued drug therapy. Most adverse effects are mild and self-limited, but rare serious outcomes have been reported. Conclusions.-Pharmacotherapy for obesity, when combined with appropriate behavioral approaches to change diet and physical activity, helps some obese patients lose weight and maintain weight loss for at least 1 year. There is little justification for the short-term use of anorexiant medications, but few studies have evaluated their safety and efficacy for more than 1 year. Until more data are available, pharmacotherapy cannot be recommended for routine use in obese individuals, although it may be helpful in carefully selected patients.	TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; HLTH WATCH INFORMAT & PROMOT SERV, NEW YORK, NY USA; UNIV COLORADO, DENVER, CO 80202 USA; COLUMBIA UNIV, ST LUKES ROOSEVELT HOSP CTR, NEW YORK, NY USA; PENN STATE UNIV, STATE COLL, PA 16804 USA; UNIV CALIF DAVIS, DAVIS, CA 95616 USA; UNIV ALABAMA, BIRMINGHAM, AL USA; RUTGERS STATE UNIV, PISCATAWAY, NJ USA; UNIV PITTSBURGH, SCH MED, PITTSBURGH, PA USA; NIDDK, DIV DIGEST DIS & NUTR, NIH, BETHESDA, MD USA	Tufts University; University of Colorado System; University of Colorado Denver; Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; University of California System; University of California Davis; University of Alabama System; University of Alabama Birmingham; Rutgers State University New Brunswick; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Rolls, Barbara J/AAE-3899-2019					Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; ABENHAIM L, 1995, FOOD DRUG ADM END ME, P142; [Anonymous], 1994, OBES RES, V2, P571; ASTRUP A, 1992, INT J OBESITY, V16, P269; ATANASSOFF PG, 1992, LANCET, V339, P436, DOI 10.1016/0140-6736(92)90129-Q; Atkinson RL, 1995, OBES RES, V3, pS497, DOI 10.1002/j.1550-8528.1995.tb00218.x; ATKINSON RL, 1994, AM J CLIN NUTR, V60, P153, DOI 10.1093/ajcn/60.2.153; BAUMGARTEN G, 1992, LANCET, V339, P359, DOI 10.1016/0140-6736(92)91676-Y; BERLIN I, 1993, EUR J CLIN PHARMACOL, V44, P601, DOI 10.1007/BF02440870; Blackburn G, 1992, WEIGHT CONTROL DIGES, V2, P121; BLACKBURN GL, 1984, POSTGRAD MED J, V60, P13; BLUNDELL JE, 1994, BIOMED PHARMACOTHER, V48, P119, DOI 10.1016/0753-3322(94)90100-7; BLUNDELL JE, 1987, INT J OBESITY, V11, P141; Bouchard C, 1996, OBES RES, V4, P77; BRAY GA, 1993, ANN INTERN MED, V119, P707, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00016; Bray GA, 1996, OBES RES, V4, P263, DOI 10.1002/j.1550-8528.1996.tb00544.x; BRAY GA, 1992, AM J CLIN NUTR, V55, P538; BREMER JM, 1994, INT J OBESITY, V18, P199; BRENOT F, 1993, BRIT HEART J, V70, P537; BROSS R, 1995, AM J CLIN NUTR, V61, P1020, DOI 10.1093/ajcn/61.5.1020; BROWNELL KD, 1991, BEHAV THER, V22, P153, DOI 10.1016/S0005-7894(05)80174-1; BRUNER D, 1995, FOOD DRUG ADM DRUG A, P17; *COMM DEV CRIT EV, 1995, WEIGH OPT CRIT EV WE, P4; *COMM NUTR, 1996, MASS MED SOC WHIT PA; CONNACHER AA, 1992, AM J CLIN NUTR, V55, P258; CONNOLLY VM, 1995, DIABETIC MED, V12, P416, DOI 10.1111/j.1464-5491.1995.tb00505.x; CONTRERA J, 1995, FOOD DRUG ADM END ME, P261; CRAIGHEAD LW, 1981, ARCH GEN PSYCHIAT, V38, P763; DALY PA, 1993, INT J OBESITY, V17, pS73; DARE GL, 1976, MED J AUSTRALIA, V2, P537, DOI 10.5694/j.1326-5377.1976.tb128210.x; Dietz W H, 1994, Obes Res, V2, P54; DOUGLAS JG, 1983, LANCET, V1, P384; Drent ML, 1995, OBES RES, V3, pS623, DOI 10.1002/j.1550-8528.1995.tb00236.x; Ellinwood Everett H., 1992, P1; ENZI G, 1988, CLIN NEUROPHARMACOL, V11, pS173; ENZI G, 1976, J INT MED RES, V4, P305, DOI 10.1177/030006057600400504; FAICH G, 1995, FOOD DRUG ADM END ME, P101; FINER N, 1992, INT J OBESITY, V16, pS25; FINER N, 1989, INT J OBESITY, V13, P91; FLETCHER SW, 1993, ANN INTERN MED, V119, P764, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00026; Goldstein D J, 1993, Obes Res, V1, P92; GOLDSTEIN DJ, 1994, INT J OBESITY, V18, P129; GOLDSTEIN DJ, 1992, INT J OBESITY, V16, P397; GOLDSTEIN DJ, 1994, AM J CLIN NUTR, V60, P647, DOI 10.1093/ajcn/60.5.647; Goldstein DJ, 1995, OBES RES, V3, pS481, DOI 10.1002/j.1550-8528.1995.tb00216.x; GUYGRAND B, 1989, LANCET, V2, P1142; GuyGrand B, 1995, OBES RES, V3, pS491, DOI 10.1002/j.1550-8528.1995.tb00217.x; GUYGRAND B, 1992, LANCET, V339, P360; GUYGRAND B, 1991, INT J OBES S2, V14, P48; HARTLEY GG, 1995, OBES RES S3, V3, pS380; HAWKE A, 1990, AUST NZ J SURG, V60, P755, DOI 10.1111/j.1445-2197.1990.tb07469.x; Hudson K D, 1977, J R Coll Gen Pract, V27, P497; Inoue S, 1995, OBES RES, V3, pS549, DOI 10.1002/j.1550-8528.1995.tb00226.x; KANDERS BS, 1992, TREATMENT SERIOUSLY, P213; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LAFERRERE B, 1989, BRAIN RES, V504, P258, DOI 10.1016/0006-8993(89)91365-6; LEVIN A, 1975, POSTGRAD MED J, V51, P186; LEVINE LR, 1989, INT J OBESITY, V13, P635; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; Marks SJ, 1996, OBES RES, V4, P1; MATHUSVLIEGEN EMH, 1993, NETH J MED, V43, P246; MCCANN U, 1994, J PHARMACOL EXP THER, V269, P792; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; McKay R H, 1973, Curr Med Res Opin, V1, P489, DOI 10.1185/03007997309111712; MCTAVISH D, 1992, DRUGS, V43, P713, DOI 10.2165/00003495-199243050-00007; MUNRO JF, 1968, BRIT MED J, V1, P352, DOI 10.1136/bmj.1.5588.352; NOBLE RE, 1990, CURR THER RES CLIN E, V47, P612; OCONNOR HT, 1995, INT J OBESITY, V19, P181; OKANE M, 1994, DIABETIC MED, V11, P105, DOI 10.1111/j.1464-5491.1994.tb00238.x; PASQUALI R, 1993, INT J OBESITY, V17, pS65; Pedrinola F, 1994, Obes Res, V2, P1; PFOHL M, 1994, INT J OBESITY, V18, P391; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; PISUNYER FX, 1993, ANN INTERN MED, V119, P722, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00019; PORIES WJ, 1995, ANN SURG, V222, P339, DOI 10.1097/00000658-199509000-00011; ROCHE N, 1992, LANCET, V339, P436; ROWLAND NE, 1986, APPETITE, V7, P71, DOI 10.1016/S0195-6663(86)80053-8; Ryan DH, 1995, OBES RES, V3, pS553, DOI 10.1002/j.1550-8528.1995.tb00227.x; SCALFI L, 1993, INT J OBESITY, V17, P91; SCHUSTER CR, 1986, PSYCHOPHARMACOL BULL, V22, P148; SENSI S, 1985, INT J CLIN PHARM RES, V5, P247; SILVERSTONE J T, 1965, Br J Clin Pract, V19, P395; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; SJOSTROM L, 1995, INT J OBESITY, V19, pS9; SPORER KA, 1995, DRUG SAFETY, V13, P94, DOI 10.2165/00002018-199513020-00004; STADEL B, 1995, FOOD DRUG ADM ENDOCR, P261; STEEL JM, 1973, PRACTITIONER, V211, P232; Stunkard A. J., 1984, EATING ITS DISORDERS, P157; STUNKARD AJ, 1981, J PSYCHOSOM RES, V25, P187, DOI 10.1016/0022-3999(81)90032-5; STUNKARD AJ, 1980, LANCET, V2, P1045; STUNKARD AJ, 1982, LIFE SCI, V30, P2043, DOI 10.1016/0024-3205(82)90445-3; TOORNVLIET AC, 1994, INT J OBESITY, V18, P650; TUCKER JA, 1991, INT J EAT DISORDER, V10, P689, DOI 10.1002/1098-108X(199111)10:6&lt;689::AID-EAT2260100607&gt;3.0.CO;2-6; *US DEP HHS, 1995, SEL PROV FED FOOD DR; VOELKER R, 1994, JAMA-J AM MED ASSOC, V272, P1087, DOI 10.1001/jama.272.14.1087; Wadden T A, 1995, Obes Res, V3, P549; WADDEN TA, 1993, ANN INTERN MED, V119, P688, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00012; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P615, DOI 10.1038/clpt.1992.73; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P581, DOI 10.1038/clpt.1992.68; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P586, DOI 10.1038/clpt.1992.69; WEINTRAUB M, 1984, ARCH INTERN MED, V144, P1143, DOI 10.1001/archinte.144.6.1143; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P642, DOI 10.1038/clpt.1992.76; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P608, DOI 10.1038/clpt.1992.72; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P634, DOI 10.1038/clpt.1992.75; WEINTRAUB M, 1989, MED CLIN N AM, V73, P237, DOI 10.1016/S0025-7125(16)30701-5; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P619, DOI 10.1038/clpt.1992.74; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P595, DOI 10.1038/clpt.1992.70; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P602, DOI 10.1038/clpt.1992.71; WEINTRAUB M, 1981, CLIN PHARMACOL THER, V30, P528, DOI 10.1038/clpt.1981.198; WILLIAMSON DF, 1995, AM J EPIDEMIOL, V141, P1128, DOI 10.1093/oxfordjournals.aje.a117386; WILSON GT, 1994, ADV BEHAV RES THER, V16, P31, DOI 10.1016/0146-6402(94)90002-7; WOLF AM, 1994, PHARMACOECONOMICS, V5, P34, DOI 10.2165/00019053-199400051-00007; 1995, OBES RES, V3, P473; [No title captured]	114	189	193	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1996	276	23					1907	1915						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX522	8968018				2022-12-28	WOS:A1996VX52200040
J	Farwell, B				Farwell, B			Health care in America: An intimate glimpse	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1996	125	12					1005	1006		10.7326/0003-4819-125-12-199612150-00014	http://dx.doi.org/10.7326/0003-4819-125-12-199612150-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX768	8967689				2022-12-28	WOS:A1996VX76800014
J	Leng, GC; Fowkes, FGR; Lee, AJ; Dunbar, J; Housley, E; Ruckley, CV				Leng, GC; Fowkes, FGR; Lee, AJ; Dunbar, J; Housley, E; Ruckley, CV			Use of ankle brachial pressure index to predict cardiovascular events and death: A cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PERIPHERAL ARTERIAL-DISEASE; RISK-FACTORS; CAROTID STENOSIS; HEART-DISEASE; ARM INDEX; MORTALITY; MEN; MORBIDITY; WOMEN	Objective-To determine whether a low ankle brachial pressure index is associated with an increased risk of cardiovascular events and death, and whether the prediction of such events could be improved by including this index. Design-Cohort study. Setting-11 practices in Edinburgh, Scotland. Subjects-1592 men and women aged 55-74 years selected at random from the age-sex registers of 11 general practices and followed up for 5 years. Main outcome measures-Incidence of fatal and non-fatal cardiovascular events and all cause mortality. Results-At baseline 90 (5.7%) of subjects had an ankle brachial pressure index less than or equal to 0.7, 288 (18.2%) had an index less than or equal to 0.9, and 566 (35.6%) less than or equal to 1.0. After five years subjects with an index less than or equal to 0.9 at baseline had an increased risk of non-fatal myocardial infarction (relative risk 1.38, 95% confidence interval 0.88 to 2.16), stroke (1.98, 1.05 to 3.77), cardiovascular death (1.85, 1.15 to 2.97), and all cause mortality (1.58, 1.14 to 2.18) after adjustment for age, sex, coronary disease, and diabetes at baseline. The ability to predict subsequent events was greatly increased by combining the index with other risk factors-for example, hypertensive smokers with normal cholesterol concentrations had a positive predictive value of 25.0%, increasing to 43.8% in subjects with a low index and decreasing to 15.6% in those with a normal index. Conclusion-The ankle brachial pressure index is a good predictor of subsequent cardiovascular events, and improves on predictions by conventional risk factors alone. It is simple and accurate and could be included in routine screening of cardiovascular status.	UNIV EDINBURGH, DEPT PUBL HLTH SCI, WOLFSON UNIT PREVENT PERIPHERAL VASC DIS, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND; ROYAL INFIRM EDINBURGH NHS TRUST, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND	University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh								CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; DORMANDY J, 1989, J CARDIOVASC SURG, V30, P50; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; FOWKES FGR, 1988, J EPIDEMIOL COMMUN H, V42, P128, DOI 10.1136/jech.42.2.128; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; KALLERO KS, 1981, J CHRON DIS, V34, P455, DOI 10.1016/0021-9681(81)90005-9; KANNEL WB, 1987, AM HEART J, V114, P213, DOI 10.1016/0002-8703(87)90964-1; KORNITZER M, 1995, ANGIOLOGY, V46, P211, DOI 10.1177/000331979504600304; KULLER LH, 1995, CIRCULATION, V92, P720, DOI 10.1161/01.CIR.92.4.720; NEWMAN AB, 1993, CIRCULATION, V88, P837, DOI 10.1161/01.CIR.88.3.837; OGREN M, 1995, BMJ-BRIT MED J, V310, P1294, DOI 10.1136/bmj.310.6990.1294; OGREN M, 1993, LANCET, V342, P1138, DOI 10.1016/0140-6736(93)92123-B; OURIEL K, 1982, SURGERY, V91, P686; Prineas R., 1982, MINNESOTA CODE MANUA; *REG GEN SCOTL, 1993, ANN REP; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; SLEIGHT P, 1991, AM HEART J, V121, P990, DOI 10.1016/0002-8703(91)90609-L; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; VOGT MT, 1993, JAMA-J AM MED ASSOC, V270, P465, DOI 10.1001/jama.270.4.465; VOGT MT, 1993, J AM GERIATR SOC, V41, P523, DOI 10.1111/j.1532-5415.1993.tb01889.x; WIDMER LK, 1986, P 14 WORLD C INT UN, P13; YAO ST, 1969, BRIT J SURG, V56, P676, DOI 10.1002/bjs.1800560910	23	397	409	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 7	1996	313	7070					1440	1444		10.1136/bmj.313.7070.1440	http://dx.doi.org/10.1136/bmj.313.7070.1440			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX612	8973232	Green Published			2022-12-28	WOS:A1996VX61200029
J	Sperling, RS; Shapiro, DE; Coombs, RW; Todd, JA; Herman, SA; McSherry, GD; OSullivan, MJ; VanDyke, RB; Jimenez, E; Rouzioux, C; Flynn, PM; Sullivan, JL; Spector, SA; Diaz, C; Rooney, J; Balsley, J; Gelber, RD; Connor, EM				Sperling, RS; Shapiro, DE; Coombs, RW; Todd, JA; Herman, SA; McSherry, GD; OSullivan, MJ; VanDyke, RB; Jimenez, E; Rouzioux, C; Flynn, PM; Sullivan, JL; Spector, SA; Diaz, C; Rooney, J; Balsley, J; Gelber, RD; Connor, EM			Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREGNANCY; PLASMA; HIV-1; AIDS; RNA	Background and Methods A placebo-controlled trial has shown that treatment with zidovudine reduces the rate at which human immunodeficiency virus type 1 (HIV-1) is transmitted from mother to infant. We present data from that trial showing the number of infected infants at 18 months of age and the relation between the maternal viral load, the risk of HIV-1 transmission, and the efficacy of zidovudine treatment. Viral cultures were obtained, and HIV-1 RNA was measured by two assays in samples of maternal blood obtained at study entry and at delivery. Results In 402 mother-infant pairs, the rate of transmission of HIV-1 was 7.6 percent (95 percent confidence interval, 4.3 to 12.3 percent) with zidovudine treatment and 22.6 percent (95 percent confidence interval, 17.0 to 29.0 percent) with placebo (P<0.001). In the placebo group, a large viral burden at entry or delivery or a positive culture was associated with an increased risk of transmission (the transmission rate was greater than 40 percent in the highest quartile of the RNA level). In both groups, transmission occurred at a wide range of maternal plasma HIV-1 RNA levels. Zidovudine reduced plasma RNA levels somewhat (median reduction, 0.24 log). Zidovudine was effective regardless of the HIV-1 RNA lever or the CD4+ count at entry. In the zidovudine group, however, after we adjusted for the base-line HIV-1 RNA level and CD4+ count, the reduction in viral RNA from base line to delivery was not significantly associated with the risk of transmission of HIV-1. Conclusions A high maternal plasma concentration of virus is a risk factor for the Transmission of HIV-1 from an untreated mother to her infant. The reduction in such transmission after zidovudine treatment is only partly explained by the reduction in plasma levels of viral RNA. To prevent HIV-1 transmission, initiating maternal treatment with zidovudine is recommended regardless of the plasma level of HIV-1 RNA or the CD4+ count. (C)1996, Massachusetts Medical Society.	CUNY MT SINAI SCH MED, DEPT OBSTET GYNECOL & REPROD SCI, NEW YORK, NY 10029 USA; HARVARD UNIV, SCH PUBL HLTH, STAT & DATA ANAL CTR, PEDIAT AIDS CLIN TRIALS GRP, BOSTON, MA 02115 USA; UNIV WASHINGTON, SCH MED, SEATTLE, WA USA; CHIRON CORP, EMERYVILLE, CA 94608 USA; ROCHE MOL SYST, BRANCHBURG, NJ USA; UNIV MED & DENT NEW JERSEY, NEW JERSEY MED SCH, DEPT PEDIAT, NEWARK, NJ 07103 USA; UNIV MIAMI, SCH MED, MIAMI, FL USA; TULANE UNIV, SCH MED, NEW ORLEANS, LA 70112 USA; SAN JUAN CITY HOSP, SAN JUAN, PR USA; HOP NECKER ENFANTS MALAD, SIDA, AGENCE NATL RECH, PARIS, FRANCE; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38105 USA; UNIV MASSACHUSETTS, WORCESTER, MA 01605 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Harvard T.H. Chan School of Public Health; University of Washington; University of Washington Seattle; Novartis; Roche Holding; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Miami; Tulane University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; St Jude Children's Research Hospital; University of Massachusetts System; University of Massachusetts Worcester			Flynn, Patricia M/N-8146-2018		NIAID NIH HHS [N 01 AI95030] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI095030] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BORKOWSKY W, 1994, J PEDIATR-US, V125, P345, DOI 10.1016/S0022-3476(05)83274-3; BOYER PJ, 1994, JAMA-J AM MED ASSOC, V271, P1925, DOI 10.1001/jama.271.24.1925; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599; *DIV AIDS, 1994, ACTG VIR MAN HIV LAB; Fang GW, 1995, P NATL ACAD SCI USA, V92, P12100, DOI 10.1073/pnas.92.26.12100; FISCUS SA, 1995, J INFECT DIS, V171, P305, DOI 10.1093/infdis/171.2.305; Fiscus Susan A., 1996, JAMA (Journal of the American Medical Association), V275, P1483, DOI 10.1001/jama.275.19.1483; FREEDMAN LS, 1992, STAT MED, V11, P167, DOI 10.1002/sim.4780110204; FRENKEL LM, 1995, CLIN INFECT DIS, V20, P1321, DOI 10.1093/clinids/20.5.1321; HOLLINGER FB, 1992, J CLIN MICROBIOL, V30, P1787, DOI 10.1128/JCM.30.7.1787-1794.1992; HOLODNIY M, 1995, J CLIN MICROBIOL, V33, P1562, DOI 10.1128/JCM.33.6.1562-1566.1995; MANTEL N, 1959, J NATL CANCER I, V22, P719; MAYAUX MJ, 1995, J ACQ IMMUN DEF SYND, V8, P188; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; TODD J, 1995, J ACQ IMMUN DEF SYND, V10, pS35; TSIATIS AA, 1995, J AM STAT ASSOC, V90, P27, DOI 10.2307/2291126; US Public Health Service, 1994, MMWR-MORBID MORTAL W, V43, P1; YENLIEBERMAN B, IN PRESS J CLIN MICR; ZAR JH, 1984, BIOSTAT ANAL, P113; 1995, MMWR-MORBID MORTAL W, V44, P929; 1994, MMWR-MORBID MORTAL W, V43, P1	23	603	622	1	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1996	335	22					1621	1629		10.1056/NEJM199611283352201	http://dx.doi.org/10.1056/NEJM199611283352201			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV936	8965861				2022-12-28	WOS:A1996VV93600001
J	Liou, JC; Malhotra, R				Liou, JC; Malhotra, R			Depletion of the outer asteroid belt	SCIENCE			English	Article							SOLAR-SYSTEM; NEPTUNE; ORIGIN; ORBIT	During the early history of the soar system, it is likely that the outer planets changed their distance from the sun, and hence, their influence on the asteroid belt evolved with time. The gravitational influence of Jupiter and Saturn on the orbital evolution of asteroids in the outer asteroid belt was calculated. The results show that the sweeping of mean motion resonances associated with planetary migration efficiently destabilizes orbits in the outer asteroid belt on a time scale of 10 million years. This mechanism provides an explanation for the observed depletion of asteroids in that region.	LUNAR & PLANETARY INST, HOUSTON, TX 77058 USA		Liou, JC (corresponding author), NASA, LYNDON B JOHNSON SPACE CTR, SN3, HOUSTON, TX 77058 USA.			Malhotra, Renu/0000-0002-1226-3305				BOWELL E, 1996, ASTEROID ORBITAL ELE; DERMOTT SF, 1983, NATURE, V301, P201, DOI 10.1038/301201a0; Duncan M, 1994, IAP ASTR M, P245; Everhart E., 1985, DYNAMICS COMETS THEI, P185; FERNANDEZ JA, 1984, ICARUS, V58, P109, DOI 10.1016/0019-1035(84)90101-5; Fernandez JA, 1996, PLANET SPACE SCI, V44, P431, DOI 10.1016/0032-0633(95)00142-5; Franklin FA, 1996, ASTRON J, V112, P1247, DOI 10.1086/118095; GLADMAN B, 1990, ASTRON J, V100, P1680, DOI 10.1086/115628; GREENBERG R, 1979, ASTEROIDS, P310; Harris K.R., UNPUB; Holman MJ, 1996, ASTRON J, V112, P1278, DOI 10.1086/118098; LECAR M, 1992, ICARUS, V96, P234, DOI 10.1016/0019-1035(92)90078-L; MALHOTRA R, 1993, NATURE, V365, P819, DOI 10.1038/365819a0; MALHOTRA R, 1995, ASTRON J, V110, P420, DOI 10.1086/117532; MALHOTRA R, 1994, CELEST MECH DYN ASTR, V60, P373, DOI 10.1007/BF00691903; Morbidelli A, 1996, ASTRON J, V111, P2453, DOI 10.1086/117979; NOBILI AM, 1989, ASTEROIDS, V2, P862; WISDOM J, 1987, ICARUS, V72, P241, DOI 10.1016/0019-1035(87)90175-8	18	46	46	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 17	1997	275	5298					375	377		10.1126/science.275.5298.375	http://dx.doi.org/10.1126/science.275.5298.375			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994031	Green Published			2022-12-28	WOS:A1997WC87300042
J	Damrauer, NH; Cerullo, G; Yeh, A; Boussie, TR; Shank, CV; McCusker, JK				Damrauer, NH; Cerullo, G; Yeh, A; Boussie, TR; Shank, CV; McCusker, JK			Femtosecond dynamics of excited-state evolution in [Ru(bpy)(3)](2+)	SCIENCE			English	Article							INTERLIGAND ELECTRON-TRANSFER; SOLVATION DYNAMICS; CHARGE SEPARATION; ARTIFICIAL PHOTOSYNTHESIS; RUTHENIUM(II) COMPLEXES; POLYPYRIDINE COMPLEXES; MOLECULAR-LEVEL; METAL DIMERS; SPECTROSCOPY; TRANSITION	Time-resolved absorption spectroscopy on the femtosecond time scale has been used to monitor the earliest events associated with excited-state relaxation in tris-(2,2'-bipyridine)ruthenium(II). The data reveal dynamics associated with the temporal evolution of the Franck-Condon state to the lowest energy excited state of this molecule. The process is essentially complete in similar to 300 femtoseconds after the initial excitation. This result is discussed with regard to reformulating long-held notions about excited-state relaxation, as well as its implication for the importance of non-equilibrium excited-state processes in understanding and designing molecular-based electron transfer, artificial photosynthetic, and photovoltaic assemblies in which compounds of this class are currently playing a key role.	UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV MAT SCI, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley			Cerullo, Giulio/F-6534-2011	Cerullo, Giulio/0000-0002-9534-2702				Adamson A. W., 1975, CONCEPTS INORGANIC P; ARRIVO SM, 1995, CHEM PHYS LETT, V235, P247, DOI 10.1016/0009-2614(95)00124-M; Balzani V., 1991, SUPRAMOLECULAR PHOTO; BESLER P, 1993, J AM CHEM SOC, V115, P4076; CHANG YJ, 1990, J PHYS CHEM-US, V94, P729, DOI 10.1021/j100365a041; COOLEY LF, 1990, J AM CHEM SOC, V112, P2612, DOI 10.1021/ja00163a022; CREUTZ C, 1980, J AM CHEM SOC, V102, P1309, DOI 10.1021/ja00524a014; DAMRAUER NH, UNPUB; DANIELSON E, 1987, J AM CHEM SOC, V109, P2519, DOI 10.1021/ja00242a050; DAUL C, 1994, INORG CHEM, V33, P3538, DOI 10.1021/ic00094a017; DEMAS JN, 1971, J AM CHEM SOC, V93, P1800; DOORN SK, 1993, J AM CHEM SOC, V115, P6398, DOI 10.1021/ja00067a065; DURRANT JR, 1996, ULTRAFAST PHENOMENA, V8, P140; EICHBERGER R, 1990, CHEM PHYS, V141, P159, DOI 10.1016/0301-0104(90)80027-U; Ferraudi G. J., 1988, ELEMENTS INORGANIC P; GRATZEL M, 1994, CURR SCI INDIA, V66, P706; GRATZEL M, 1994, RENEW ENERG, V5, P118, DOI 10.1016/0960-1481(94)90361-1; GUST D, 1991, TOP CURR CHEM, V159, P103; JAY C, 1993, MOL CRYST LIQ CRYS A, V234, P255, DOI 10.1080/10587259308042924; JOHNSON DG, 1993, J AM CHEM SOC, V115, P5692, DOI 10.1021/ja00066a039; JURIS A, 1988, COORDIN CHEM REV, V84, P85, DOI 10.1016/0010-8545(88)80032-8; Kalyanasundaram K., 1993, PHOTOSENSITIZATION P; KUMAR PV, 1995, J CHEM PHYS, V103, P3038, DOI 10.1063/1.470493; LARSON SL, 1995, J PHYS CHEM-US, V99, P6530, DOI 10.1021/j100017a038; LINDSAY E, 1993, INORG CHEM, V32, P3822, DOI 10.1021/ic00070a010; MALONE RA, 1991, J CHEM PHYS, V95, P8970, DOI 10.1063/1.461228; MARONCELLI M, 1991, J CHEM PHYS, V94, P2084, DOI 10.1063/1.459932; MCCUSKER JK, 1993, J AM CHEM SOC, V115, P298, DOI 10.1021/ja00054a043; MCLENDON G, 1989, PHOTOCHEMICAL ENERGY; MCMORROW D, 1991, J PHYS CHEM-US, V95, P10395, DOI 10.1021/j100178a029; MEYER TJ, 1994, INORG CHEM, V33, P3952, DOI 10.1021/ic00096a020; MEYER TJ, 1989, ACCOUNTS CHEM RES, V22, P163, DOI 10.1021/ar00161a001; *OPT SOC AM, 1996, ULTR PHEN C ED, V8; OREGAN B, 1991, NATURE, V353, P737, DOI 10.1038/353737a0; OWRUTSKY JC, 1995, J PHYS CHEM-US, V99, P4842, DOI 10.1021/j100013a064; PETEANU LA, 1993, P NATL ACAD SCI USA, V90, P11762, DOI 10.1073/pnas.90.24.11762; PETERSEN JD, 1994, COORDIN CHEM REV, V132, P15, DOI 10.1016/0010-8545(94)80018-9; Rehm JM, 1996, J PHYS CHEM-US, V100, P9577, DOI 10.1021/jp960155m; REID PJ, 1995, J PHYS CHEM-US, V99, P2609, DOI 10.1021/j100009a019; ROSENTHAL SJ, 1991, J CHEM PHYS, V95, P4715, DOI 10.1063/1.461742; Roundhill D. M., 1994, PHOTOCHEMISTRY PHOTO; SAUVAGE JP, 1994, CHEM REV, V94, P993, DOI 10.1021/cr00028a006; SCHOENLEIN RW, 1991, APPL PHYS LETT, V58, P801, DOI 10.1063/1.104494; SERPONE N, 1989, COORDIN CHEM REV, V93, P87, DOI 10.1016/0010-8545(89)80013-X; Shin YK, 1996, J PHYS CHEM-US, V100, P8157, DOI 10.1021/jp953395v; SONG XQ, 1993, J PHYS CHEM-US, V97, P3225, DOI 10.1021/j100115a026; SUTIN N, 1979, PHOTOCHEMISTRY, V80, P97; Sutin N, 1978, ADV CHEM SER, V168, P1; TOMINAGA K, 1993, J CHEM PHYS, V98, P1228, DOI 10.1063/1.464344; TRIBUTSCH H, 1995, SOL ENERG MAT SOL C, V38, P355, DOI 10.1016/0927-0248(95)00015-1; VICEK A, 1993, CHEMTRACTS INORG CHE, V5, P92; VICHOVA J, 1992, J AM CHEM SOC, V114, P10903, DOI 10.1021/ja00053a029; WILLNER I, 1991, TOP CURR CHEM, V159, P153; YABE T, 1990, J PHYS CHEM-US, V94, P7128, DOI 10.1021/j100381a034; Yersin H., 1987, PHOTOCHEMISTRY PHOTO; YONEMOTO EH, 1994, J AM CHEM SOC, V116, P10557, DOI 10.1021/ja00102a024	56	596	602	3	200	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 3	1997	275	5296					54	57		10.1126/science.275.5296.54	http://dx.doi.org/10.1126/science.275.5296.54			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974388				2022-12-28	WOS:A1997WA90300044
J	Shirakawa, T; Enomoto, T; Shimazu, S; Hopkin, JM				Shirakawa, T; Enomoto, T; Shimazu, S; Hopkin, JM			The inverse association between tuberculin responses and atopic disorder	SCIENCE			English	Article							SKIN-TEST REACTIVITY; ASTHMA; IMMUNITY; PREVALENCE; HYPERSENSITIVITY; INDUCTION; CHILDREN; CELLS	Human immune responses are heterogeneous and may involve antagonism between T helper (T-H) lymphocyte subsets and their cytokines. Atopy is characterized by immediate immunoglobulin E (IgE)-mediated hypersensitivity to agents such as dust mites and pollen, and it underlies the increasingly prevalent disorder asthma. Among Japanese schoolchildren, there was a strong inverse association between delayed hypersensitivity to Mycobacterium tuberculosis and atopy. Positive tuberculin responses predicted a lower incidence of asthma, lower serum IgE levels, and cytokine profiles biased toward T(H)1 type. Exposure and response to M. tuberculosis may, by modification of immune profiles, inhibit atopic disorder.	CHURCHILL HOSP, OSLER CHEST UNIT, LUNG RES LAB, OXFORD OX3 7LJ, ENGLAND; WAKAYAMA MED CTR, JAPANESE RED CROSS SOC, DEPT OTOLARYNGOL, WAKAYAMA, JAPAN; NATL WAKAYAMA HOSP, DEPT PEDIAT, WAKAYAMA, JAPAN	University of Oxford								Aebischer I, 1996, ADV IMMUNOL, V61, P341, DOI 10.1016/S0065-2776(08)60871-8; Baker RW, 1996, QJM-INT J MED, V89, P387; BRUCE IN, 1993, Q J MED, V86, P425; Burnet M., 1972, NATURAL HIST INFECT; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CARBALLIDO JM, 1992, EUR J IMMUNOL, V22, P1357, DOI 10.1002/eji.1830220605; COOPER AM, 1995, IMMUNOLOGY, V84, P423; DOLL R, 1992, AM J PUBLIC HEALTH, V82, P933, DOI 10.2105/AJPH.82.7.933; DONCKIER V, 1994, J IMMUNOL, V153, P2361; FEARONDT, 1996, SCIENCE, V270, P50; FINE PEM, 1994, LANCET, V344, P1245, DOI 10.1016/S0140-6736(94)90748-X; GALBRAITH NS, 1972, BMJ-BRIT MED J, V1, P647, DOI 10.1136/bmj.1.5801.647; GRANGE JM, 1996, Q J MED, V89, P387; Holt PG, 1996, TOXICOL LETT, V86, P205, DOI 10.1016/0378-4274(96)03692-2; Hopkin JM, 1995, PEDIAT ALLERG IMM-UK, V6, P139, DOI 10.1111/j.1399-3038.1995.tb00273.x; ISHIZAKA K, 1971, Clinical Allergy, V1, P9, DOI 10.1111/j.1365-2222.1971.tb02444.x; *JAP MIN HLTH WELF, 1995, TRENDS HLTH WELF JAP; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.immunol.11.1.129; LARSEN FS, 1993, MONOGR ALLERGY, V31, P9; MACKANESS GB, 1974, J EXP MED, V139, P1540, DOI 10.1084/jem.139.6.1540; MORRISONSMITH J, 1981, POSTGRAD MED J, V57, P774, DOI 10.1136/pgmj.57.674.774; OETTINGER T, 1995, INFECT IMMUN, V63, P4613, DOI 10.1128/IAI.63.12.4613-4618.1995; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; SHIRAKAWA T, 1993, ALLERGY, V48, P177, DOI 10.1111/j.1398-9995.1993.tb00710.x; SHIRAKAWA T, IN PRESS EUR J EPIDE; SPRINGETT VH, 1988, J EPIDEMIOL COMMUN H, V42, P370, DOI 10.1136/jech.42.4.370; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WAITE DA, 1980, CLIN ALLERGY, V10, P71, DOI 10.1111/j.1365-2222.1980.tb02082.x; Wichmann HE, 1996, CLIN EXP ALLERGY, V26, P621, DOI 10.1111/j.1365-2222.1996.tb00587.x; XU LX, 1994, INT IMMUNOL, V6, P515, DOI 10.1093/intimm/6.4.515; YOUMANS GP, 1975, AM REV RESPIR DIS, V111, P109	33	1057	1137	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 3	1997	275	5296					77	79		10.1126/science.275.5296.77	http://dx.doi.org/10.1126/science.275.5296.77			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974396				2022-12-28	WOS:A1997WA90300052
J	Bessho, F				Bessho, F			Where should neuroblastoma mass screening go?	LANCET			English	Editorial Material							JAPAN; AGE				Bessho, F (corresponding author), TOKYO UNIV HOSP,DEPT PAEDIAT,TOKYO 113,JAPAN.							Bessho F, 1996, INT J CANCER, V67, P520, DOI 10.1002/(SICI)1097-0215(19960807)67:4<520::AID-IJC10>3.0.CO;2-B; HANADA R, 1996, JPN J PEDIAT ONCOL, V33, P380; HAYASHI Y, 1995, J PEDIATR SURG, V30, P467, DOI 10.1016/0022-3468(95)90057-8; KANEKO Y, 1990, J CLIN ONCOL, V8, P2005, DOI 10.1200/JCO.1990.8.12.2005; NISHI M, 1992, AM J PEDIAT HEMATOL, V14, P327; NISHIHIRA H, 1996, JPN J PEDIAT ONCOL, V33, P379; YAMAMOTO K, 1995, J CLIN ONCOL, V13, P2033, DOI 10.1200/JCO.1995.13.8.2033	7	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1672	1672		10.1016/S0140-6736(05)65814-X	http://dx.doi.org/10.1016/S0140-6736(05)65814-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973422				2022-12-28	WOS:A1996VZ76600002
J	Bunker, JP; Stansfeld, S; Potter, J				Bunker, JP; Stansfeld, S; Potter, J			Freedom, responsibility, and health	BRITISH MEDICAL JOURNAL			English	Article							DISEASE	Freedom and responsibility, how much of each and how they sue balanced, have profound implications for our personal lives and for our work, The health of a population and its achievement in the workplace are enhanced when individuals have some freedom and some responsibility, but not too much of either, and when civil associations of individuals rather than individuals acting alone are the essential social units. The consistent association of social contacts with health and productivity provides strong support for the premise that intimate relationships are the focus around which people's lives revolve. Membership of a ''social network'' may be merely conforming to a reigning social norm, and this could mean having to pay an important price in the loss of creativity associated with individualism. But social conformity should not prevent individuals from going their own way, and it should be possible to combine the luxury of individuality with an active life in civic affairs. Less than complete freedom may fall short of existential utopia, but it may be best for our health and wellbeing.	UNIV LONDON UNIV COLL,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,LONDON WC1E 6BT,ENGLAND; TAVISTOCK CLIN,TAVISTOCK CTR,LONDON NW3 5BA,ENGLAND	University of London; University College London; UCL Medical School								AGUAYO R, 1991, DEMING MAN TAUGHT JA; Berkman LF, 1983, HLTH WAYS LIVING ALA; Berlin Isaiah, 2002, LIBERTY INCORPORATIN; Brunner E, 1996, LANCET, V347, P1008, DOI 10.1016/S0140-6736(96)90147-6; COHEN S, 1988, HEALTH PSYCHOL, V7, P269, DOI 10.1037/0278-6133.7.3.269; Dassbach Carl H., 1993, CRITICAL SOCIOLOGY, V20, P3; MARMOT MG, 1976, AM J EPIDEMIOL, V104, P225, DOI 10.1093/oxfordjournals.aje.a112296; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; Oakeshott M., 1975, HOBBES CIVIL ASS; Putnam R.D., 1994, MAKING DEMOCRACY WOR, DOI DOI 10.2307/206637; Riesman D, 1961, LONELY CROWD; Storr A., 1988, SOLITUDE RETURN SELF; Wolf Stewart, 1993, POWER CLAN INFLUENCE; WOMACK JP, 1990, MACHINE CHANGES WORL	14	4	4	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1582	1584		10.1136/bmj.313.7072.1582	http://dx.doi.org/10.1136/bmj.313.7072.1582			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8990992	Green Published			2022-12-28	WOS:A1996VZ81100013
J	Groves, T				Groves, T			SatelLife: Getting relevant information to the developing world	BRITISH MEDICAL JOURNAL			English	Article													Groves, Trish/A-9119-2009	Groves, Trish/0000-0001-7915-6419				GROVES T, 1996, BRIT MED J, V307, P1015; KALE R, 1994, BRIT MED J, V309, P939, DOI 10.1136/bmj.309.6959.939; Smith R, 1996, BRIT MED J, V313, P1062; 1996, ECONOMIST       0518, P19; 1996, SATELLIFE NEWS, V13, P3	5	21	21	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1606	1609		10.1136/bmj.313.7072.1606	http://dx.doi.org/10.1136/bmj.313.7072.1606			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991004	Green Published			2022-12-28	WOS:A1996VZ81100031
J	Kew, MC; Kassianides, C				Kew, MC; Kassianides, C			Hepatology - HGV: Hepatitis G virus or harmless G virus?	LANCET			English	Article											Kew, MC (corresponding author), UNIV WITWATERSRAND, DEPT MED, ZA-2193 JOHANNESBURG, SOUTH AFRICA.							Alter HJ, 1996, NEW ENGL J MED, V334, P1536, DOI 10.1056/NEJM199606063342310; Ellis AJ, 1996, GUT, V38, P454, DOI 10.1136/gut.38.3.454; Fiordalisi G, 1996, J INFECT DIS, V174, P181, DOI 10.1093/infdis/174.1.181; Lindor KD, 1996, GASTROENTEROLOGY, V110, P1515, DOI 10.1053/gast.1996.v110.pm8613058; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505	5	7	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	1996	348			2			SII10	SII10						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973488				2022-12-28	WOS:A1996WA46300010
J	Loefler, IJP				Loefler, IJP			Microbes, chemotherapy, evolution, and folly	LANCET			English	Article											Loefler, IJP (corresponding author), NAIROBI HOSP,ARGWINGS KODNEK RD,POB 47964,NAIROBI,KENYA.								0	24	25	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1703	1704		10.1016/S0140-6736(96)12006-7	http://dx.doi.org/10.1016/S0140-6736(96)12006-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973435				2022-12-28	WOS:A1996VZ76600015
J	Merkel, C; Marin, R; Enzo, E; Donada, C; Cavallarin, G; Torboli, P; Amodio, P; Sebastianelli, G; Sacerdoti, D; Felder, M; Mazzaro, C; Beltrame, P; Gatta, A; Bartoli, G; Borsato, L; Caruso, N; Cielo, R; DeVenuto, G; Dobrilla, G; Donadon, V; Spandri, P; Angeli, P; Bellumat, A; Brosolo, P; Caregaro, L; Cuppini, S; Sebastinelli, G; Susanna, S; Zanella, P; Merkel, C				Merkel, C; Marin, R; Enzo, E; Donada, C; Cavallarin, G; Torboli, P; Amodio, P; Sebastianelli, G; Sacerdoti, D; Felder, M; Mazzaro, C; Beltrame, P; Gatta, A; Bartoli, G; Borsato, L; Caruso, N; Cielo, R; DeVenuto, G; Dobrilla, G; Donadon, V; Spandri, P; Angeli, P; Bellumat, A; Brosolo, P; Caregaro, L; Cuppini, S; Sebastinelli, G; Susanna, S; Zanella, P; Merkel, C			Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis	LANCET			English	Article							ESOPHAGEAL-VARICES; PORTAL PRESSURE; PLUS ISOSORBIDE-5-MONONITRATE; HEMORRHAGE; PREVENTION; PROPRANOLOL; METAANALYSIS; HYPERTENSION; FAILURE; THERAPY	Background The risk of having a first cirrhosis-associated variceal bleed is lowered by about 50% by beta-blockers. Use of beta-blockers is currently recommended for patients with cirrhosis and oesophageal varices that are at risk of bleeding. We aimed to test the effectiveness of isosorbide mononitrate as an adjunct to the beta-blocker nadolol in the prophylaxis of first variceal bleeding in these patients. Methods We did a randomised multicentre study to compare the non-selective beta-blocker, nadolol, with nadolol plus isosorbide mononitrate in 146 relatively well (Child-Pugh score less than or equal to 11) patients who had oesophageal varices at risk of bleeding. Patients on nadolol alone received a single oral 40 mg daily dose. Every second day the dose was titrated to achieve 20-25% decrease in resting heart rate (maximum dose 160 mg daily). Patients receiving both drugs received nadolol as above then isosorbide mononitrate was added starting with 10 mg orally twice daily, which was increased to 20 mg unless hypotension or severe headache occurred. The main endpoint was the occurrence of variceal bleeding of any severity. Patients were followed up for up to 40 months. Findings During the study period 11 of 74 patients from the nadolol alone group and four of 72 from the nadalol plus isosorbide mononitrate group had variceal bleeding (log rank test p=0.03). Cumulative risk of variceal bleeding was 18% in the nadolol group and 7.5% in the combined treatment group (95% CI for difference 1-25%). Two patients in each group had a non-variceal bleed related to portal hypertension. 14 patients from the nadolol only group and eight from the combined treatment group died during the study period (log-rank test p=0.09). Four and eight patients, respectively, had to discontinue one of the drugs because of side-effects. Interpretation Nadolol plus isosorbide mononitrate is significantly more effective than nadolol alone in the primary prophylaxis of variceal bleeding in relatively well patients with cirrhosis, and has few side-effects.	PORDENONE GEN HOSP,PORDENONE,ITALY; DOLO GEN HOSP,DOLO,ITALY; ADRIA GEN HOSP,ADRIA,ITALY; BELLUNO GEN HOSP,BELLUNO,ITALY; TRENTO GEN HOSP,TRENT,ITALY; BOLZANO GEN HOSP,BOLZANO,ITALY; SCHIO GEN HOSP,SCHIO,ITALY; UDINE GEN HOSP,UDINE,ITALY; CHIOGGIA GEN HOSP,CHIOGGIA,ITALY	ULSS 3 Serenissima; Presidio Ospedaliero di Dolo; ULSS 5 Polesana; Ospedale di Adria; ULSS 1 Dolomiti; Ospedale di Belluno; Krankenhaus Bozen; University of Udine; University Hospital of Udine	Merkel, C (corresponding author), UNIV PADUA,DEPT CLIN MED,I-35126 PADUA,ITALY.		MERKEL, CARLO/B-6278-2013; Sacerdoti, David/G-3997-2012; Mazzaro, Cesare/P-7794-2019; Angeli, Paolo/A-9759-2015	MERKEL, CARLO/0000-0003-0185-4166; Sacerdoti, David/0000-0002-4933-7718; Mazzaro, Cesare/0000-0002-0305-6574; Amodio, Piero/0000-0002-2395-7599				ABSHAGEN U, 1981, EUR J CLIN PHARMACOL, V20, P269, DOI 10.1007/BF00618777; BEPPU K, 1981, GASTROINTEST ENDOSC, V27, P213, DOI 10.1016/S0016-5107(81)73224-3; BIDOGGIA H, 1987, CURR MED RES OPIN, V10, P601, DOI 10.1185/03007998709112414; BURROUGHS AK, 1986, HEPATOLOGY, V6, P1407, DOI 10.1002/hep.1840060631; DAMICO G, 1995, HEPATOLOGY, V22, P332, DOI 10.1002/hep.1840220145; FEU F, 1995, LANCET, V346, P1056, DOI 10.1016/S0140-6736(95)91740-3; GARCIAPAGAN JC, 1990, HEPATOLOGY, V11, P230, DOI 10.1002/hep.1840110212; GARCIAPAGAN JC, 1991, ANN INTERN MED, V114, P869, DOI 10.7326/0003-4819-114-10-869; GRAHAM DY, 1981, GASTROENTEROLOGY, V80, P800; GROSZMANN RJ, 1990, GASTROENTEROLOGY, V99, P1401, DOI 10.1016/0016-5085(90)91168-6; JAESCHKE R, 1990, AM J MED, V88, P279, DOI 10.1016/0002-9343(90)90154-6; MERKEL C, 1989, AM J GASTROENTEROL, V84, P717; MERKEL C, 1995, HEPATOLOGY, V22, P808, DOI 10.1016/0270-9139(95)90301-1; *N IT END CLUB STU, 1988, NEW ENGL J MED, V319, P983; PAGLIARO L, 1992, ANN INTERN MED, V117, P59, DOI 10.7326/0003-4819-117-1-59; POYNARD T, 1991, NEW ENGL J MED, V324, P1532, DOI 10.1056/NEJM199105303242202; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; SACERDOTI D, 1991, J HEPATOL, V12, P124, DOI 10.1016/0168-8278(91)90921-W; SCHLICHTING P, 1983, SCAND J GASTROENTERO, V18, P881, DOI 10.3109/00365528309182110; SMITH D, 1990, DRUG METAB DISPOS, V18, P429; THANDANI U, 1994, ANN INTERN MED, V120, P353; VOROBIOFF J, 1993, HEPATOLOGY, V18, P477, DOI 10.1016/0270-9139(93)90344-M	22	106	109	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1677	1681		10.1016/S0140-6736(96)05406-2	http://dx.doi.org/10.1016/S0140-6736(96)05406-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973428				2022-12-28	WOS:A1996VZ76600008
J	Murphy, K				Murphy, K			Recharging the batteries	BRITISH MEDICAL JOURNAL			English	Article											Murphy, K (corresponding author), UNIV MICHIGAN,MED CTR,ANN ARBOR,MI 48109, USA.							Brant WE, 1996, AM J ROENTGENOL, V166, P259, DOI 10.2214/ajr.166.2.8553927; MURPHY K, 1986, BRIT MED J, V293, P1649, DOI 10.1136/bmj.293.6562.1649; RABAN J, 1987, LOVE MONEY, P163	3	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1644	1646		10.1136/bmj.313.7072.1644	http://dx.doi.org/10.1136/bmj.313.7072.1644			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991018	Green Published			2022-12-28	WOS:A1996VZ81100054
J	deBruijn, SFTM; Stam, J; Kappelle, LJ				deBruijn, SFTM; Stam, J; Kappelle, LJ			Thunderclap headache as first symptom of cerebral venous sinus thrombosis	LANCET			English	Article							SUBARACHNOID HEMORRHAGE	Background Thunderclap headache raises the suspicion of subarachnoid haemorrhage, and it is not generally as a symptom of cerebral venous sinus thrombosis (CVST). We describe ten patients who presented with thunderclap headache mimicking subarachnoid haemorrhage, who appeared to have CVST. Methods Medical histories of 71 patients who had CVST between 1992 and 1996 were collected. 48 of these took part in a randomised trial of treatment for CVST. The diagnosis was confirmed by conventional angiography or magnetic resonance imaging and angiography in all patients. Findings In all ten patients who presented with thunderclap headache, characteristics of the headache and clinical signs and symptoms were clinically indistinguishable from those of subarachnoid haemorrhage. Computed tomography al admission was interpreted as normal in five patients (one with single-dose contrast), as subarachnoid haemorrhage in three, and as multiple intracranial haemorrhages in the remaining patients (one with single-dose contrast). Cerebrospinal fluid (CSF) analysis was done in six patients, and showed erythrocytes and bilirubin in one. CSF pressure was high in the only patient for whom it was measured. Interpretation The best initial investigation in patients with thunderclap headache is emergency computed tomography. If no abnormality is detected, lumbar puncture should be done after at least 12 h (to detect or exclude subarachnoid haemorrhage). CSF pressure should be measured. If the CSF pressure is high or if a headache of unknown origin persists, the diagnosis of CVST should be considered.	UNIV AMSTERDAM,ACAD MED CTR,DEPT NEUROL,NL-1100 DE AMSTERDAM,NETHERLANDS; UNIV UTRECHT,ACAD HOSP,DEPT NEUROL,NL-3508 TC UTRECHT,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University								ADAMS HP, 1980, JAMA-J AM MED ASSOC, V244, P794, DOI 10.1001/jama.244.8.794; Bousser M.-G., 1992, STROKE PATHOPHYSIOLO, P517; BOUSSER MG, 1985, STROKE, V16, P199, DOI 10.1161/01.STR.16.2.199; DAIF A, 1995, STROKE, V26, P1193, DOI 10.1161/01.STR.26.7.1193; DALESSIO DJ, 1994, NEUROLOGY, V44, P6; Einhaupl KM, 1990, CEREBRAL SINUS THROM, P149, DOI 10.1007/978- 1-4684-8199-0_14; SARNER M, 1967, J NEUROL NEUROSUR PS, V30, P67, DOI 10.1136/jnnp.30.1.67; VANDERWEE N, 1995, J NEUROL NEUROSUR PS, V58, P357, DOI 10.1136/jnnp.58.3.357; VERMEULEN M, 1990, J NEUROL NEUROSUR PS, V53, P365, DOI 10.1136/jnnp.53.5.365; WIJDICKS EFM, 1988, LANCET, V2, P68	10	176	180	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1623	1625		10.1016/S0140-6736(96)07294-7	http://dx.doi.org/10.1016/S0140-6736(96)07294-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8961993				2022-12-28	WOS:A1996VX87600012
J	Singh, N; Stempel, K				Singh, N; Stempel, K			Cholecystoduodenal fistula	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Singh, N (corresponding author), VET AFFAIRS MED CTR,PITTSBURGH,PA 15240, USA.								0	4	4	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1997	336	4					266	266		10.1056/NEJM199701233360406	http://dx.doi.org/10.1056/NEJM199701233360406			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE632	8995090				2022-12-28	WOS:A1997WE63200006
J	Pashitski, AE; Gurevich, A; Polyanskii, AA; Larbalestier, DC; Goyal, A; Specht, ED; Kroeger, DM; DeLuca, JA; Tkaczyk, JE				Pashitski, AE; Gurevich, A; Polyanskii, AA; Larbalestier, DC; Goyal, A; Specht, ED; Kroeger, DM; DeLuca, JA; Tkaczyk, JE			Reconstruction of current flow and imaging of current-limiting defects in polycrystalline superconducting films	SCIENCE			English	Article							HIGH-TEMPERATURE SUPERCONDUCTORS; MAGNETIC GRANULARITY; TRANSPORT CURRENTS; FLUX DISTRIBUTION; THIN-FILMS; YBA2CU3O7-DELTA; VORTICES; FIELD; OXIDE	Magneto-optical imaging was used to visualize the inhomogeneous penetration of magnetic flux into polycrystalline TlBa2Ca2Cu3Ox films with high critical current densities, to reconstruct the local two-dimensional supercurrent flow patterns and to correlate inhomogeneities in this flow with the local crystallographic misorientation. The films have almost perfect c-axis alignment and considerable local a- and b-axis texture because the grains lend to form colonies with only slightly misaligned a and b axes, Current flows freely over these low-angle grain boundaries but is strongly reduced at intermittent colony boundaries of high misorientation, The local (<10-micrometer scale) critical current density J(c) varies widely, being up to 10 times as great as the transport J(c) (scale of similar to 1 millimeter), which itself varies by a factor of about 5 in different sections of the film, The combined experiments show that the magnitude of the transport J(c) is largely determined by a few high-angle boundaries.	UNIV WISCONSIN, CTR APPL SUPERCONDUCT, MADISON, WI 53706 USA; OAK RIDGE NATL LAB, OAK RIDGE, TN 37831 USA; GE CO, SCHENECTADY, NY 12301 USA; RUSSIAN ACAD SCI, INST SOLID STATE PHYS, CHERNOGOLOVKA 142432, MOSCOW DIST, RUSSIA	University of Wisconsin System; University of Wisconsin Madison; United States Department of Energy (DOE); Oak Ridge National Laboratory; General Electric; Russian Academy of Sciences; Osipyan Institute of Solid State Physics RAS			Larbalestier, David/B-2277-2008; Gurevich, Alex/A-4327-2008; Specht, Eliot D/A-5654-2009	Larbalestier, David/0000-0001-7098-7208; Gurevich, Alex/0000-0003-0759-8941; Specht, Eliot D/0000-0002-3191-2163				BISHOP DJ, 1992, SCIENCE, V255, P165, DOI 10.1126/science.255.5041.165; BLATTER G, 1994, REV MOD PHYS, V66, P1125, DOI 10.1103/RevModPhys.66.1125; BRANDT EH, 1992, PHYS REV B, V46, P8628, DOI 10.1103/PhysRevB.46.8628; BRANDT EH, 1995, REP PROG PHYS, V58, P1465, DOI 10.1088/0034-4885/58/11/003; BRANDT EH, 1993, PHYS REV B, V48, P12893, DOI 10.1103/PhysRevB.48.12893; DAI HJ, 1994, SCIENCE, V265, P1552, DOI 10.1126/science.265.5178.1552; DELUCA JA, 1993, PHYSICA C, V205, P21, DOI 10.1016/0921-4534(93)90164-L; DIMOS D, 1990, PHYS REV B, V41, P4038, DOI 10.1103/PhysRevB.41.4038; DOROSINSKII LA, 1992, PHYSICA C, V203, P149, DOI 10.1016/0921-4534(92)90521-D; DURAN CA, 1992, NATURE, V357, P474, DOI 10.1038/357474a0; GRANT PD, 1994, PHYSICA C, V229, P289, DOI 10.1016/0921-4534(94)90509-6; Heinig NF, 1996, APPL PHYS LETT, V69, P577, DOI 10.1063/1.117758; IIJIMA Y, 1992, APPL PHYS LETT, V60, P769, DOI 10.1063/1.106514; KIM DH, 1991, PHYSICA C, V177, P431, DOI 10.1016/0921-4534(91)90500-X; Larbalestier D. C., 1996, Proceedings of the 10th Anniversary HTS Workshop on Physics, Materials and Applications, P41; Larbalestier DC, 1995, INST PHYS CONF SER, V148, P29; NAKAMURA N, 1992, APPL PHYS LETT, V61, P3044, DOI 10.1063/1.108004; Niculescu H, 1996, PHYSICA C, V261, P12, DOI 10.1016/0921-4534(96)00172-4; Parrell JA, 1996, SUPERCOND SCI TECH, V9, P393, DOI 10.1088/0953-2048/9/5/010; PASHITSKI AE, 1995, PHYSICA C, V246, P133, DOI 10.1016/0921-4534(95)00129-8; PASHITSKI AE, 1995, APPL PHYS LETT, V67, P2720, DOI 10.1063/1.114304; Polyanskii AA, 1996, PHYS REV B, V53, P8687, DOI 10.1103/PhysRevB.53.8687; ROTH BJ, 1989, J APPL PHYS, V65, P361, DOI 10.1063/1.342549; SCHUSTER T, 1992, J APPL PHYS, V72, P1479; SPECHT ED, 1995, PHYSICA C, V242, P164, DOI 10.1016/0921-4534(94)02382-4; SPECHT ED, 1994, PHYSICA C, V226, P76, DOI 10.1016/0921-4534(94)90480-4; TURCHINSKAYA M, 1993, PHYSICA C, V216, P205, DOI 10.1016/0921-4534(93)90655-A; WELP U, 1995, NATURE, V376, P44, DOI 10.1038/376044a0; WELP U, 1995, APPL PHYS LETT, V66, P1270, DOI 10.1063/1.113259; WU XD, 1995, APPL PHYS LETT, V67, P2397, DOI 10.1063/1.114559; XING W, 1994, J APPL PHYS, V76, P4244, DOI 10.1063/1.357308; ZELDOV E, 1994, PHYS REV B, V49, P9802, DOI 10.1103/PhysRevB.49.9802	32	82	82	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 17	1997	275	5298					367	369		10.1126/science.275.5298.367	http://dx.doi.org/10.1126/science.275.5298.367			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994028				2022-12-28	WOS:A1997WC87300039
J	Burke, RP; Wernovsky, G				Burke, RP; Wernovsky, G			Thoracoscopic clipping of patent ductus arteriosus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									CHILDRENS HOSP,PHILADELPHIA,PA 19104	University of Pennsylvania; Childrens Hospital of Philadelphia	Burke, RP (corresponding author), MIAMI CHILDRENS HOSP,MIAMI,FL 33155, USA.		Carvalho, Lidiane/P-8446-2019	Carvalho, Lidiane/0000-0002-2290-329X					0	9	9	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1997	336	3					185	185		10.1056/NEJM199701163360305	http://dx.doi.org/10.1056/NEJM199701163360305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC266	8988898				2022-12-28	WOS:A1997WC26600005
J	Troop, P				Troop, P			More resources, better survival?	LANCET			English	Editorial Material							CARDIOGENIC-SHOCK; TRIAL				Troop, P (corresponding author), NHS EXECUT ANGLIA & OXFORD,MILTON KEYNES MK14 6QP,BUCKS,ENGLAND.							HOCHMAN JS, 1995, CIRCULATION, V91, P873, DOI 10.1161/01.CIR.91.3.873; HOLMES DR, 1995, J AM COLL CARDIOL, V26, P668, DOI 10.1016/0735-1097(95)00215-P; VANDEWERF F, 1995, JAMA-J AM MED ASSOC, V273, P1586, DOI 10.1001/jama.273.20.1586	3	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					72	72		10.1016/S0140-6736(05)60879-3	http://dx.doi.org/10.1016/S0140-6736(05)60879-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996413				2022-12-28	WOS:A1997WB80000004
J	Schalm, SW				Schalm, SW			Clinical implications of lamivudine resistance by HBV	LANCET			English	Editorial Material							CHRONIC HEPATITIS-B; INFECTION; VIRUS				Schalm, SW (corresponding author), ERASMUS UNIV ROTTERDAM,ACAD HOSP ROTTERDAM DIJKZIGT,DEPT HEPATOGASTROENTEROL,NL-3015 GD ROTTERDAM,NETHERLANDS.							BENHAMOU Y, 1995, LANCET, V345, P396, DOI 10.1016/S0140-6736(95)90388-7; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; Ling R, 1996, HEPATOLOGY, V24, P711, DOI 10.1053/jhep.1996.v24.pm0008781347; MULLER R, 1994, J HEPATOL, V21, P1140, DOI 10.1016/S0168-8278(05)80632-4; NIEDERAU C, 1995, NEW ENGL J MED, V333, P1657; SCHALM SW, 1995, J HEPATOL, V22, P52; Tipples GA, 1996, HEPATOLOGY, V24, P714, DOI 10.1053/jhep.1996.v24.pm0008781348	7	29	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					3	4		10.1016/S0140-6736(05)62154-X	http://dx.doi.org/10.1016/S0140-6736(05)62154-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988109				2022-12-28	WOS:A1997WA72500003
J	Blum, U; Voshage, G; Lammer, J; Beyersdorf, F; Tollner, D; Kretschmer, G; Spillner, G; Polterauer, P; Nagel, G; Holzenbein, T; Thurnher, S; Langer, M				Blum, U; Voshage, G; Lammer, J; Beyersdorf, F; Tollner, D; Kretschmer, G; Spillner, G; Polterauer, P; Nagel, G; Holzenbein, T; Thurnher, S; Langer, M			Endoluminal stent-grafts for infrarenal abdominal aortic aneurysms	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; ENDOVASCULAR GRAFT; BIFURCATED GRAFT; PLACEMENT; FEASIBILITY; REPAIR; MANAGEMENT; MORTALITY	Background The treatment of aortic aneurysms with endovascular stents or stent-graft prostheses is receiving increasing attention as an alternative to major abdominal surgery. To define the clinical value of this technique, we prospectively studied the use of stent-graft endoprostheses made of nitinol and covered with polyester fabric for the treatment of infrarenal abdominal aortic aneurysms. Methods We treated a total of 154 patients at three academic hospitals. Twenty-one patients with aortic aneurysms not involving the aortic bifurcation received straight stent-grafts, and 133 patients with aortic aneurysms involving the bifurcation and the common iliac arteries received bifurcated stent-grafts. After a unilateral surgical arteriotomy, the endoprostheses were advanced through the femoral arteries and placed under fluoroscopic guidance. Computed tomography and intraarterial angiography were performed during an average follow-up of 12.5 months. Results The primary success rate, defined as complete exclusion of the abdominal aortic aneurysm from the circulation, was 86 percent in the group receiving straight grafts and 87 percent in the group receiving bifurcated grafts. In three patients the procedure had to be converted to an open surgical operation. Minor (n = 13) or major (n = 3) complications associated with the procedure (including 1 death) occurred in 10 percent of the patients. All patients had a postimplantation syndrome, with leukocytosis and elevated C-reactive protein levels. Conclusions Our results suggest that endovascular treatment of infrarenal abdominal aortic aneurysms is technically feasible and can effectively exclude abdominal aortic aneurysms from the circulation. With further refinement, endoluminal repair may emerge as an interventional strategy to treat infrarenal aortic aneurysms, especially in patients at high surgical risk. (C)1997, Massachusetts Medical Society.	HENRIETTENSTIFTUNG, DEPT RADIOL, HANNOVER, GERMANY; HENRIETTENSTIFTUNG, DEPT SURG, HANNOVER, GERMANY; UNIV HOSP, DEPT ANGIOG & INTERVENT RADIOL, VIENNA, AUSTRIA; UNIV HOSP, DEPT VASC SURG, VIENNA, AUSTRIA; UNIV HOSP FREIBURG, DEPT CARDIOVASC SURG, D-79106 FREIBURG, GERMANY	University Hospital Vienna; University Hospital Vienna; University of Freiburg	Blum, U (corresponding author), UNIV HOSP FREIBURG, DEPT DIAGNOST RADIOL, HUGSTETTER STR 55, D-79106 FREIBURG, GERMANY.		Beyersdorf, Friedhelm/AAK-3718-2020	Beyersdorf, Friedhelm/0000-0003-2975-2751				BALKO A, 1986, J SURG RES, V40, P305, DOI 10.1016/0022-4804(86)90191-5; Balm R, 1996, EUR J VASC ENDOVASC, V11, P214, DOI 10.1016/S1078-5884(96)80055-4; Becker G J, 1991, J Vasc Interv Radiol, V2, P225, DOI 10.1016/S1051-0443(91)72286-0; Blum U, 1996, RADIOLOGY, V198, P25, DOI 10.1148/radiology.198.1.8539389; Boudghene F, 1993, J Vasc Interv Radiol, V4, P497, DOI 10.1016/S1051-0443(93)71905-3; BROWN OW, 1981, ARCH SURG-CHICAGO, V116, P1484; Chuter T A, 1995, Cardiovasc Surg, V3, P121, DOI 10.1016/0967-2109(95)90884-8; CHUTER TAM, 1993, J VASC SURG, V18, P185, DOI 10.1016/0741-5214(93)90598-G; COLLIN J, 1988, LANCET, V2, P613; CRAGG AH, 1993, RADIOLOGY, V189, P775, DOI 10.1148/radiology.189.3.8234703; CREECH O, 1966, ANN SURG, V164, P935, DOI 10.1097/00000658-196612000-00001; DAKE MD, 1994, NEW ENGL J MED, V331, P1729, DOI 10.1056/NEJM199412293312601; DOTTER CT, 1969, INVEST RADIOL, V4, P329, DOI 10.1097/00004424-196909000-00008; DUBOST C, 1952, AMA ARCH SURG, V64, P405, DOI 10.1001/archsurg.1952.01260010419018; ERNST CB, 1993, NEW ENGL J MED, V328, P1167; GREENHALGH RM, 1990, BRIT MED J, V301, P136, DOI 10.1136/bmj.301.6744.136; HAGEN B, 1993, CARDIOVASC INTER RAD, V16, P339, DOI 10.1007/BF02603137; KATZ DJ, 1994, J VASC SURG, V19, P804, DOI 10.1016/S0741-5214(94)70005-2; KELLY TF, 1981, ANN SURG, V193, P686, DOI 10.1097/00000658-198106000-00003; LABORDE JC, 1992, RADIOLOGY, V184, P185, DOI 10.1148/radiology.184.1.1535160; LAWRENCE DD, 1987, RADIOLOGY, V163, P357, DOI 10.1148/radiology.163.2.2951767; May J, 1994, J Endovasc Surg, V1, P44; MAY J, 1995, EUR J VASC ENDOVASC, V10, P51, DOI 10.1016/S1078-5884(05)80198-4; MIRICH D, 1989, RADIOLOGY, V170, P1033, DOI 10.1148/radiology.170.3.2916054; MOORE WS, 1994, ANN SURG, V220, P331, DOI 10.1097/00000658-199409000-00009; Murphy KD, 1996, RADIOLOGY, V198, P473, DOI 10.1148/radiology.198.2.8596852; PALMAZ JC, 1986, SURGERY, V99, P199; Parodi J C, 1991, Ann Vasc Surg, V5, P491, DOI 10.1007/BF02015271; PARODI JC, 1995, J VASC SURG, V21, P549, DOI 10.1016/S0741-5214(95)70186-9; PIQUET P, 1994, J VASC SURG, V19, P698, DOI 10.1016/S0741-5214(94)70044-3; PORTER JM, 1995, J VASC SURG, V21, P995, DOI 10.1016/S0741-5214(95)70229-6; ROGER VL, 1989, J AM COLL CARDIOL, V14, P1245, DOI 10.1016/0735-1097(89)90423-3; RUIZ CE, 1995, CIRCULATION, V91, P2470, DOI 10.1161/01.CIR.91.9.2470; SCOTT RAP, 1991, BRIT J SURG, V78, P1122, DOI 10.1002/bjs.1800780929; SCOTT RAP, 1994, LANCET, V343, P413, DOI 10.1016/S0140-6736(94)91247-5; Volodos N L, 1991, Vasa Suppl, V33, P93; White G H, 1994, J Endovasc Surg, V1, P16; White GH, 1996, J VASC SURG, V23, P201, DOI 10.1016/S0741-5214(96)70264-1; YOSHIOKA T, 1988, AM J ROENTGENOL, V151, P673, DOI 10.2214/ajr.151.4.673; YUSUF SW, 1994, LANCET, V344, P650, DOI 10.1016/S0140-6736(94)92086-9	40	551	606	1	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1997	336	1					13	20		10.1056/NEJM199701023360103	http://dx.doi.org/10.1056/NEJM199701023360103			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA496	8970935				2022-12-28	WOS:A1997WA49600003
J	Davis, S; Aldrich, TH; Jones, PF; Acheson, A; Compton, DL; Jain, V; Ryan, TE; Bruno, J; Radziejewski, C; Maisonpierre, PC; Yancopoulos, GD				Davis, S; Aldrich, TH; Jones, PF; Acheson, A; Compton, DL; Jain, V; Ryan, TE; Bruno, J; Radziejewski, C; Maisonpierre, PC; Yancopoulos, GD			Isolation of Angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning	CELL			English	Article							ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE GENES; VASCULAR ENDOTHELIUM; MOLECULAR-CLONING; TEK; PROTEIN; FAMILY; CELLS; VASCULOGENESIS; ANGIOGENESIS	TIE2 is a receptor-like tyrosine kinase expressed almost exclusively in endothelial cells and early hemopoietic cells and required for the normal development of vascular structures during embryogenesis. We report the identification of a secreted ligand for TIE2, termed Angiopoietin-1, using a novel expression cloning technique that involves intracellular trapping and detection of the ligand in COS cells. The structure of Angiopoietin-1 differs from that of known angiogenic factors or other ligands for receptor tyrosine kinases. Although Angiopoietin-1 binds and induces the tyrosine phosphorylation of TIE2, it does not directly promote the growth of cultured endothelial cells. However, its expression in close proximity with developing blood vessels implicates Angiopoietin-1 in endothelial developmental processes.			Davis, S (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.							Batard P, 1996, BLOOD, V87, P2212, DOI 10.1182/blood.V87.6.2212.bloodjournal8762212; BURROWS FJ, 1994, PHARMACOL THERAPEUT, V64, P155, DOI 10.1016/0163-7258(94)90037-X; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; FERRARA N, 1995, ANN NY ACAD SCI, V752, P246, DOI 10.1111/j.1749-6632.1995.tb17435.x; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hashiyama M, 1996, BLOOD, V87, P93; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; KAIPAINEN A, 1994, CANCER RES, V54, P6571; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W., 1991, DEV VASCULAR SYSTEM, P58; Rodewald HR, 1996, ONCOGENE, V12, P397; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; ZIEGLER SF, 1993, ONCOGENE, V8, P663	37	1570	1741	0	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1161	1169		10.1016/S0092-8674(00)81812-7	http://dx.doi.org/10.1016/S0092-8674(00)81812-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980223	Bronze			2022-12-28	WOS:A1996WA54100005
J	Levin, M				Levin, M			Healing the children: Medical missions	LANCET			English	Article								In 1993, I started documenting medical missions organised by the American-based, non-profit organisation Healing the Children (HTC). With 14 chapters in 21 states, HTC has helped tens of thousands of children worldwide since it was founded in 1979. The organisation arranges specialised medical treatment and surgical care for children whose families cannot afford it or whose communities do not offer it. HTC relies entirely on volunteers. In 1995, the northeast chapter of HTC alone provided more than $7.5 million in services to about 2300 children. HTC also provides treatment and assistance to disadvantaged children in US communities, arranges special care in the USA for children from nearly 60 countries, and recruits organisations to provide supplies and refurbished equipment to hospitals in underdeveloped countries. In October, 1994, I travelled with an HTC team of over 50 medical personnel on a cardiac trip to Guatemala City. More recently, in April, 1996, I documented a team of Il who travelled to Cochabamba, Bolivia, to carry out soft tissue surgery.											0	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1712	1713		10.1016/S0140-6736(96)10118-5	http://dx.doi.org/10.1016/S0140-6736(96)10118-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8992174				2022-12-28	WOS:A1996VZ76600019
J	Fambrough, D; Goodman, CS				Fambrough, D; Goodman, CS			The Drosophila beaten path gene encodes a novel secreted protein that regulates defasciculation at motor axon choice points	CELL			English	Article							GROWTH CONE GUIDANCE; FASCICLIN-II; ADHESION MOLECULE; POLYSIALIC ACID; NEURONAL DEVELOPMENT; GRASSHOPPER EMBRYOS; EXPRESSION; NCAM; MOTONEURONS; OUTGROWTH	In the Drosophila embryo, at specific choice points along the major motor nerves, subsets of motor axons defasciculate and then steer into their muscle target regions. Here we describe the analysis of beaten path (beat), a gene required for the selective defasciculation of motor axons at these choice points. In beat mutant embryos, motor axons fail to defasciculate and bypass their targets. This phenotype is suppressed by mutations in FasII and conn, two genes encoding cell adhesion molecules expressed on motor axons, suggesting that beat provides an antiadhesive function. beat encodes a novel secreted protein that is expressed by motoneurons during outgrowth. Rescue and ectopic expression experiments support the model that Beat protein is secreted by motor axons where it functions to regulate their selective defasciculation at specific choice points.			Fambrough, D (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOL & CELL BIOL,BERKELEY,CA 94720, USA.							ASHBURNER M, 1990, GENETICS, V126, P679; BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BASTIANI MJ, 1984, J NEUROSCI, V4, P2311; BRAND AH, 1993, DEVELOPMENT, V118, P401; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; GREENINGLOH G, 1991, CELL, V67, P45; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MAHONE M, 1995, EMBO J, V14, P2043, DOI 10.1002/j.1460-2075.1995.tb07196.x; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; RAPER JA, 1984, J NEUROSCI, V4, P2329; RUTISHAUSER U, 1991, TRENDS NEUROSCI, V14, P528, DOI 10.1016/0166-2236(91)90006-G; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; TANG J, 1992, NEURON, V8, P1031, DOI 10.1016/0896-6273(92)90125-W; TANG JC, 1994, NEURON, V13, P405, DOI 10.1016/0896-6273(94)90356-5; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; XU Y, 1995, NEURAL BIOL SYSTEMS, P128; YANG PF, 1992, J CELL BIOL, V116, P1487, DOI 10.1083/jcb.116.6.1487; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	31	105	105	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1049	1058		10.1016/S0092-8674(00)81799-7	http://dx.doi.org/10.1016/S0092-8674(00)81799-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978609	Bronze			2022-12-28	WOS:A1996VY44700010
J	Scharenberg, AM; Kinet, JP				Scharenberg, AM; Kinet, JP			The emerging field of receptor-mediated inhibitory signaling: SHP or SHIP?	CELL			English	Review							ACTIVATION; DOMAIN		HARVARD UNIV,SCH MED,BOSTON,MA 02215	Harvard University; Harvard Medical School	Scharenberg, AM (corresponding author), BETH ISRAEL HOSP,DEPT PATHOL,LAB ALLERGY & IMMUNOL,BOSTON,MA 02215, USA.							AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; Ashman RF, 1996, J IMMUNOL, V157, P5; BINDSTADT BA, 1996, IN PRESS IMMUNITY; BJISTERBOSCH MK, 1985, J EXP MED, V162, P1825; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Chacko GW, 1996, J IMMUNOL, V157, P2234; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; KAUFMAN DS, 1995, P NATL ACAD SCI USA, V92, P6484, DOI 10.1073/pnas.92.14.6484; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MUTA T, 1994, NATURE, V369, P340, DOI 10.1038/369340a0; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	16	143	144	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					961	964		10.1016/S0092-8674(00)81790-0	http://dx.doi.org/10.1016/S0092-8674(00)81790-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978600	Bronze			2022-12-28	WOS:A1996VY44700001
J	Thompson, MS				Thompson, MS			Contraceptive implants: Long acting and provider dependent contraception raises concerns about freedom of choice	BMJ-BRITISH MEDICAL JOURNAL			English	Article								David Bromham's editorial on contraceptive implants ignores the wider issues to voice concern that trial by media could limit contraceptive choice by jeopardising research into new methods. However, it is more beneficial to the public for points of conflict to be debated openly. Furthermore, the impetus for research into new contraceptive technology is driven by profit and political motives and is only marginally affected by the media. Implanted contraceptives may increase the choice of contraceptive methods, but they put control of fertility increasingly into the hands of the medical profession. Herein lies their greatest problem: their potential to increase providers' control over clients) choice. There is the danger that certain groups of women may be targeted for their use: in the United States the coercive use of Norplant for mothers receiving welfare benefit has been suggested. Long acting contraceptives are a contraceptive of choice only when they are available without pressure, as part of a wider menu; when instant removal on request is guaranteed; and when there is an open and free flow of information and opinions between users, health professionals, and special interest groups.	UNIV DURHAM, DURHAM DH1 3HP, ENGLAND	Durham University								Bromham DR, 1996, BRIT MED J, V312, P1555, DOI 10.1136/bmj.312.7046.1555; COCKBURN A, 1994, NATION          0725, P116; DUNN CDR, 1993, SCRIPS 1993 REV FERT; FRASER IS, 1989, CONTRACEPTION SCI PR, P109; GARCIA G, 1992, WOMENS PERSPECTIVES, P29; Hardee K., 1994, International Family Planning Perspectives, V20, P59, DOI 10.2307/2133436; HARTMANN B, 1995, REPRODUCTIVE RIGHTS; MORSY S, 1993, NORPLANT HER SKIN, P89; ODLIND V, 1986, ACTA OBSTET GYN SCAN, P15; OLLILA E, 1993, NORPLANT SKIN, P47; WHELAN R, 1992, CHOICES CHILDBEARING; ZIMMERMAN M, 1990, STUD FAMILY PLANN, V21, P92, DOI 10.2307/1966670; 1993, CONTRACEPTIVE TECHNO, V14, P149	13	9	9	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 30	1996	313	7069					1393	1395		10.1136/bmj.313.7069.1393	http://dx.doi.org/10.1136/bmj.313.7069.1393			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VW685	8956712	Green Published			2022-12-28	WOS:A1996VW68500039
J	Manley, JL; Takagaki, Y				Manley, JL; Takagaki, Y			Molecular biology - The end of the message - Another link between yeast and mammals	SCIENCE			English	Editorial Material							PRE-MESSENGER-RNA; POLY(A) POLYMERASE; SACCHAROMYCES-CEREVISIAE; POLYADENYLATION; EXPRESSION; PROTEIN; SUPPRESSOR; CLEAVAGE; SUBUNIT				Manley, JL (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Manley, James/0000-0002-8341-1459				Chanfreau G, 1996, SCIENCE, V274, P1511, DOI 10.1126/science.274.5292.1511; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; Colgan DF, 1996, NATURE, V384, P282, DOI 10.1038/384282a0; GUNDERSON SI, 1994, CELL, V76, P531, DOI 10.1016/0092-8674(94)90116-3; GUO Z, IN PRESS TRENDS BIOC; Jenny A, 1996, SCIENCE, V274, P1514, DOI 10.1126/science.274.5292.1514; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; MITCHELSON A, 1993, GENE DEV, V7, P241, DOI 10.1101/gad.7.2.241; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; Stumpf G, 1996, SCIENCE, V274, P1517, DOI 10.1126/science.274.5292.1517; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x	18	41	42	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1481	1482		10.1126/science.274.5292.1481	http://dx.doi.org/10.1126/science.274.5292.1481			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8966619				2022-12-28	WOS:A1996VV77500032
J	Thomas, HC; Foster, GR; Sumiya, M; McIntosh, D; Jack, DL; Turner, MW; Summerfield, JA				Thomas, HC; Foster, GR; Sumiya, M; McIntosh, D; Jack, DL; Turner, MW; Summerfield, JA			Mutation of gene for mannose-binding protein associated with chronic hepatitis B viral infection	LANCET			English	Article							MANNAN; ACTIVATION; OPSONIN; ANTIGEN; ALLELE; LEVEL	Background Persistent infection with hepatitis B virus (HBV) affects 350 million people worldwide, and 20-40% of infected patients die of cirrhosis and liver cancer. Little is known about the host factors that determine the variable natural history. Studies have focused on the role of acquired rather than innate immunity. We have investigated the prevalence of mutations in the gene for mannose-binding protein (MBP), which have been associated with susceptibility to bacterial and fungal infections. Methods Mutations in the MBP gene were sought by sequence-specific oligonucleotide hybridisation, site-directed mutagenesis polymerase chain amplification, and direct sequencing in Caucasian and Asian patients with HBV infection, and in HBsAg-negative controls. Findings A mutation in codon 52 of the MBP gene was present in two (11%) of 19 Caucasian patients with acute hepatitis B and nine (27%) of 33 Caucasian patients with chronic hepatitis B, compared with four (4%) of 98 Caucasian controls (p=0.0004). By contrast, the prevalence of the mutation was similar in Asian patients with chronic hepatitis B and in Asian controls (one [5%] of 20 vs two [2%] of 117). Mutations in codon 54 and codon 57 were found in similar proportions of patients and controls. Interpretation These findings show in Caucasian, but not Asian, patients an association of the codon 52 mutation of the MBP gene with persistent HBV infection. They suggest an important role for this gene, or a gene in linkage disequilibrium with MBP, in determining outcome after HBV infection in adult but not neonatal life.	INST CHILD HLTH, IMMUNOBIOL UNIT, LONDON, ENGLAND	University of London; University College London	Thomas, HC (corresponding author), ST MARYS HOSP, IMPERIAL COLL,SCH MED,DEPT MED,LIVER UNIT, QEQM WING, LONDON W2 1PG, ENGLAND.		Thomas, Howard C/A-3152-2009	Foster, Graham/0000-0002-3704-386X				CARMAN WF, 1989, LANCET, V2, P588; GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; GERLICH W, 1993, VIRAL HEPATITIS, P93; HARTSHORN KL, 1993, J CLIN INVEST, V91, P1414, DOI 10.1172/JCI116345; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; Lipscombe RJ, 1996, EUR J HUM GENET, V4, P13; MADSEN HO, 1995, J IMMUNOL, V155, P3013; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; MALHOTRA R, 1993, BIOCHEM J, V293, P15, DOI 10.1042/bj2930015; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; MILICH DR, 1990, P NATL ACAD SCI USA, V87, P6599, DOI 10.1073/pnas.87.17.6599; MUNOZ L, 1989, THESIS U LONDON, P89; OHTA M, 1990, J BIOL CHEM, V265, P1980; SHERLOCK S, 1993, VIRAL HEPATITIS, P1; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8; SUPER M, 1990, CLIN EXP IMMUNOL, V79, P144; TAYLOR ME, 1989, BIOCHEM J, V262, P763, DOI 10.1042/bj2620763; THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604; WORDSWORTH BP, 1990, IMMUNOGENETICS, V32, P413	21	110	121	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	1996	348	9039					1417	1419		10.1016/S0140-6736(96)05409-8	http://dx.doi.org/10.1016/S0140-6736(96)05409-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8965590				2022-12-28	WOS:A1996VU98600013
J	Foreman, KE; Friborg, J; Kong, WP; Woffendin, C; Polverini, PJ; Nickoloff, BJ; Nabel, GJ				Foreman, KE; Friborg, J; Kong, WP; Woffendin, C; Polverini, PJ; Nickoloff, BJ; Nabel, GJ			Propagation of a human herpesvirus from AIDS-associated Kaposi's sarcoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; EPSTEIN-BARR-VIRUS; DNA-SEQUENCES; HIRT SUPERNATANT; HIV; INFECTION; EPIDEMIOLOGY; CELLS	Background Although unique DNA sequences related to gammaherpesviruses have been found in Kaposi's sarcoma lesions, it is uncertain whether this DNA encodes a virus that is able to reproduce. Methods We isolated and propagated a filterable agent whose DNA sequences were found to be identical to those of the Kaposi's sarcoma-associated herpesvirus (KSHV). We obtained early-passage spindle cells from skin lesions of patients with the acquired immunodeficiency syndrome (AIDS) who had Kaposi's sarcoma and cultured them with cells of the human embryonal-kidney epithelial-cell line 293. We characterized the virus according to its effects on cellular morphology and viral replication and its appearance on electron microscopy. Results KSHV was cytotoxic to 293 cells and was detected by the polymerase chain reaction (PCR) in infected cells but not uninfected ones. Cytotoxicity and positive PCR signals were consistently maintained with viral titers of 1 million per milliliter or higher for about 20 serial infections of 293 cells. The viral copy number was relatively low (1 to 10 copies per cell). Viral replication was confirmed by Southern blot analysis of DNA isolated from the enriched nuclear fraction of infected cells and by a semiquantitative PCR using dilutions of the lysates of infected cells to detect the 233-bp viral DNA fragment originally described in association with Kaposi's lesions. Electron microscopy revealed herpesvirus-like particles in about 1 percent of cells from infected cultures, as compared with none in cells from uninfected cultures. Conclusions A herpesvirus with DNA sequences identical to those of KSHV can be propagated from skin lesions of patients with AIDS-associated Kaposi's sarcoma. (C) 1997, Massachusetts Medical Society.	UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,MSRBI,DEPT INTERNAL MED & BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,DEPT ORAL PATHOL,ANN ARBOR,MI 48109; LOYOLA UNIV,MED CTR,DEPT PATHOL,CARDINAL BERNARDIN CANC CTR,SKIN DIS RES LABS,MAYWOOD,IL 60153	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Loyola University Chicago			Polverini, Peter/AAJ-8392-2020		NCI NIH HHS [CA70057, CA64416] Funding Source: Medline; NIAMS NIH HHS [AR40488] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064416, R01CA070057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; APOLLONI A, 1994, VIROLOGY, V202, P978, DOI 10.1006/viro.1994.1422; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, EUR J CANCER, V27, P1057, DOI 10.1016/0277-5379(91)90281-H; BERAL V, 1991, CANCER SURV, V10, P5; BERAL V, 1992, CANCER SURV, V12, pA225; Boshoff C, 1996, Lancet, V348, P138; Boshoff C, 1996, LANCET, V347, P338, DOI 10.1016/S0140-6736(96)90524-3; CAO M, 1989, J INVEST DERMATOL, V92, P391, DOI 10.1111/1523-1747.ep12277232; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; COEN DM, 1992, CURRENT PROTOCOLS MO, V2; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; EIZURU Y, 1984, J CLIN MICROBIOL, V20, P1012, DOI 10.1128/JCM.20.5.1012-1014.1984; Finesmith Tina H., 1994, International Journal of Dermatology, V33, P755, DOI 10.1111/j.1365-4362.1994.tb00983.x; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; HUANG TQ, 1993, ARCH DERMATOL, V129, P1622; HUANG YQ, 1993, ARCH DERMATOL, V129, P1291, DOI 10.1001/archderm.129.10.1291; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; JOACHIM HL, 1995, CANCER, V75, P1376; JONES K, 1995, J EXP MED, V182, P1213, DOI 10.1084/jem.182.5.1213; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; LEBBE C, 1995, LANCET, V345, P1180, DOI 10.1016/S0140-6736(95)91011-5; LENHOFF RJ, 1994, J VIROL, V68, P4565, DOI 10.1128/JVI.68.7.4565-4571.1994; LIN JC, 1995, LANCET, V346, P1601, DOI 10.1016/S0140-6736(95)91931-7; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; NAIDU YM, 1994, P NATL ACAD SCI USA, V91, P5281, DOI 10.1073/pnas.91.12.5281; PATER MM, 1976, VIROLOGY, V75, P481, DOI 10.1016/0042-6822(76)90046-5; RADY PL, 1995, LANCET, V345, P1339, DOI 10.1016/S0140-6736(95)92538-4; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; SAADU A, 1993, CLIN EXP IMMUNOL, V91, P50, DOI 10.1111/j.1365-2249.1993.tb03352.x; SAFAI B, 1985, ANN INTERN MED, V103, P744, DOI 10.7326/0003-4819-103-5-744; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; YANG J, 1994, J IMMUNOL, V152, P361	37	150	157	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1997	336	3					163	171		10.1056/NEJM199701163360302	http://dx.doi.org/10.1056/NEJM199701163360302			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC266	8988896				2022-12-28	WOS:A1997WC26600002
J	Petrie, J; Small, M; Connell, J				Petrie, J; Small, M; Connell, J			''Glitazones'', a prospect for non-insulin-dependent diabetes	LANCET			English	Editorial Material							EXPRESSION		W GLASGOW HOSP UNIV NHS TRUST,GLASGOW,LANARK,SCOTLAND	University of Glasgow	Petrie, J (corresponding author), UNIV GLASGOW,WESTERN INFIRM,DEPT MED & THERAPEUT,GLASGOW G11 6NT,LANARK,SCOTLAND.							Berger M, 1996, DIABETOLOGIA, V39, P873, DOI 10.1007/BF03035774; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; IBRAHIMI A, 1994, MOL PHARMACOL, V46, P1070; Iwamoto Y, 1996, DIABETIC MED, V13, P365, DOI 10.1002/(SICI)1096-9136(199604)13:4<365::AID-DIA19>3.0.CO;2-M; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; OSTREGA D, 1995, DIABETES, V44, P437, DOI 10.2337/diabetes.44.4.437; PETRIE JR, 1994, DRUGS, V47, P701, DOI 10.2165/00003495-199447050-00001; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; STEVENSON RW, 1990, DIABETES, V39, P1218, DOI 10.2337/diabetes.39.10.1218; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118	10	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					70	71		10.1016/S0140-6736(97)22002-7	http://dx.doi.org/10.1016/S0140-6736(97)22002-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996411				2022-12-28	WOS:A1997WB80000002
J	Keeling, MJ; Grenfell, BT				Keeling, MJ; Grenfell, BT			Disease extinction and community size: Modeling the persistence of measles	SCIENCE			English	Article							CHAOS; DYNAMICS; EPIDEMIC; COMPLEXITY; CHANCE	A basic issue in ecology is the relation between extinction and population size. One of the dearest manifestations of a population threshold for extinction is the critical community size below which infections like measles do not persist. The current generation of stochastic models overestimates the observed critical community size for measles, generating much less persistence of infection than is observed. The inclusion of a more biologically realistic model for the duration of infection produced a much closer fit to the actual critical community size and explains previously undescribed high-frequency oscillations in measles incidence.			Keeling, MJ (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, DOWNING ST, CAMBRIDGE CB2 3EJ, ENGLAND.		Keeling, Matt J/J-9280-2012	Keeling, Matt J/0000-0003-4639-4765	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON R M, 1991; Anderson R M, 1984, IMA J Math Appl Med Biol, V1, P233; ARON JL, 1984, J THEOR BIOL, V110, P665, DOI 10.1016/S0022-5193(84)80150-2; Bailey NT., 1975, MATH THEORY INFECT D; BAILEY NTJ, 1956, BIOMETRIKA, V43, P15; BARTLETT MS, 1960, J R STAT SOC SER A-G, V123, P37, DOI 10.2307/2343186; BARTLETT MS, 1957, J R STAT SOC SER A-G, V120, P48, DOI 10.2307/2342553; BLACK FL, 1966, J THEOR BIOL, V11, P207, DOI 10.1016/0022-5193(66)90161-5; BOLKER B, 1995, PHILOS T R SOC B, V348, P309, DOI 10.1098/rstb.1995.0070; BOLKER B, 1993, IMA J MATH APPL MED, V10, P83; BOLKER BM, 1993, P ROY SOC B-BIOL SCI, V251, P75, DOI 10.1098/rspb.1993.0011; Burnet M., 1972, NATURAL HIST INFECT; Cliff A., 1981, SPATIAL DIFFUSION HI; ENGBERT R, 1994, CHAOS SOLITON FRACT, V4, P1147, DOI 10.1016/0960-0779(94)90028-0; FERGUSON NM, 1996, PREPRINT; FINE PEM, 1982, INT J EPIDEMIOL, V11, P5, DOI 10.1093/ije/11.1.5; Grenfell B T, 1995, Stat Methods Med Res, V4, P160, DOI 10.1177/096228029500400205; GRENFELL BT, 1995, P ROY SOC B-BIOL SCI, V259, P97, DOI 10.1098/rspb.1995.0015; GRENFELL BT, 1992, J ROY STAT SOC B MET, V54, P383; GRENFELL BT, 1994, PHILOS T R SOC A, V348, P515, DOI 10.1098/rsta.1994.0108; GROSSMAN Z, 1980, THEOR POPUL BIOL, V18, P204, DOI 10.1016/0040-5809(80)90050-7; HOPPENSTEADT F, 1974, J FRANKLIN I, V297, P325, DOI 10.1016/0016-0032(74)90037-4; KEELING MJ, 1996, PREPRINT; Lloyd AL, 1996, J THEOR BIOL, V179, P1, DOI 10.1006/jtbi.1996.0042; MAY RM, 1984, MATH BIOSCI, V72, P83, DOI 10.1016/0025-5564(84)90063-4; MOLLISON D, 1984, NATURE, V310, P224, DOI 10.1038/310224a0; MOLLISON D, 1991, MATH BIOSCI, V107, P255, DOI 10.1016/0025-5564(91)90009-8; OLSEN LF, 1990, SCIENCE, V249, P499, DOI 10.1126/science.2382131; Schenzle D, 1984, IMA J Math Appl Med Biol, V1, P169; SIMPSON REH, 1952, LANCET, V263, P549; Soper HE, 1929, J R STAT SOC, V92, P34, DOI 10.2307/2341437	31	307	310	0	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 3	1997	275	5296					65	67		10.1126/science.275.5296.65	http://dx.doi.org/10.1126/science.275.5296.65			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974392				2022-12-28	WOS:A1997WA90300048
J	Raff, EC; Fackenthal, JD; Hutchens, JA; Hoyle, HD; Turner, FR				Raff, EC; Fackenthal, JD; Hutchens, JA; Hoyle, HD; Turner, FR			Microtubule architecture specified by a beta-tubulin isoform	SCIENCE			English	Article							DROSOPHILA-MELANOGASTER; GENE; EXPRESSION; ISOTYPE; SPERMATOGENESIS; NUCLEATION	In Drosophila melanogaster, a testis-specific beta-tublin (beta 2) is required for spermatogenesis. A sequence motif was identified in carboxyl termini of axonemal beta-tubulins in diverse taxa. As a test of whether orthologous beta-tubulins from different species are functionally equivalent, the moth Heliothis virescens beta 2 homolog was expressed in Drosophila testes. When coexpressed with beta 2, the moth isoform imposed the 16-protofilament structure characteristic of that found in the moth on the corresponding subset of Drosophila microtubules, which normally contain only 13-protofilament microtubules. Thus, the architecture of the microtubule cytoskeleton can be directed by a component beta-tubulin.	INDIANA UNIV,INDIANA MOL BIOL INST,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington	Raff, EC (corresponding author), INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405, USA.							BURNS RG, 1990, FEBS LETT, V27, P1; DAVIS MTB, 1988, INSECT BIOCHEM, V18, P389, DOI 10.1016/0020-1790(88)90054-6; Dettman RW, 1996, DEV BIOL, V177, P117, DOI 10.1006/dbio.1996.0150; DIAZ HB, 1990, J CELL BIOL, V111, P412; EVANS L, 1985, J CELL BIOL, V100, P1185, DOI 10.1083/jcb.100.4.1185; FACKENTHAL JD, 1993, DEV BIOL, V158, P213, DOI 10.1006/dbio.1993.1180; FACKENTHAL JD, 1995, GENETICS, V139, P267; FACKENTHAL JD, 1993, THESIS INDIANA U; GASCH A, 1988, MOL GEN GENET, V211, P8, DOI 10.1007/BF00338387; HOYLE HD, 1995, DEV GENET, V16, P148, DOI 10.1002/dvg.1020160208; HOYLE HD, 1990, J CELL BIOL, V111, P1009, DOI 10.1083/jcb.111.3.1009; HUTCHENS J, IN PRESS MOL BIOL CE; HYAMS JS, 1994, MICROTUBULES, P3; KIMBLE M, 1989, DEV BIOL, V131, P415, DOI 10.1016/S0012-1606(89)80014-4; KIMBLE M, 1990, GENETICS, V126, P991; LACHANCE LE, 1988, ANN ENTOMOL SOC AM, V81, P292, DOI 10.1093/aesa/81.2.292; MICHIELS F, 1987, CHROMOSOMA, V95, P387, DOI 10.1007/BF00333989; MOGENSEN MM, 1989, J CELL BIOL, V108, P1445, DOI 10.1083/jcb.108.4.1445; MOGENSEN MM, 1987, J CELL SCI, V88, P95; Pirrotta V, 1988, Biotechnology, V10, P437; Raff Elizabeth C., 1994, V13, P85; SAVAGE C, 1989, GENE DEV, V3, P870, DOI 10.1101/gad.3.6.870; SILFLOW CD, 1991, PROTOPLASMA, V164, P9, DOI 10.1007/BF01320810; Sogin Mitchell L., 1996, Microbiologia (Madrid), V12, P17; SULLIVAN KF, 1986, J BIOL CHEM, V261, P3317; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; Tates A.D., 1971, CYTODIFFERENTIATION	28	112	119	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					70	73		10.1126/science.275.5296.70	http://dx.doi.org/10.1126/science.275.5296.70			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974394				2022-12-28	WOS:A1997WA90300050
J	Heilbron, JL; Bynum, WF				Heilbron, JL; Bynum, WF			Eighteen-ninety-seven and all that	NATURE			English	Editorial Material									WELLCOME INST HIST MED,LONDON NW1 2BE,ENGLAND	University of London; University College London	Heilbron, JL (corresponding author), OFSLANG HOUSE,MILL ST,ISLIP OX5 2SZ,OXON,ENGLAND.							BOOLE G, MATH ANAL LOGIC; DIDEROT D, ENCYCLOPEDIE; HERSCHEL J, RESULTS OBSERVATIONS; HEVELIUS J, SELENOGRAPHIA; LIBAVIUS A, ALCHEMIA; LOUIS J, THEORIE FONCTIONS AN; MASCHERONI L, GEOMETRIA COMPASSO; Pascal B., 1647, EXPERIENCES NOUVELLE; PENOT GN, 1547, AQUAE NATURALIS VIRT; SMITH EC, 1947, NATURE, V159, P16, DOI 10.1038/159016a0; von Helmholtz Hermann L. F., 1847, ERHALTUNG KRAFT; 1992, NATURE, V355, P11	12	2	2	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1997	385	6611					13	16		10.1038/385013a0	http://dx.doi.org/10.1038/385013a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985238				2022-12-28	WOS:A1997WA73100017
J	Bito, H; Deisseroth, K; Tsien, RW				Bito, H; Deisseroth, K; Tsien, RW			CREB phosphorylation and dephosphorylation: A Ca2(+)- and stimulus duration-dependent switch for hippocampal gene expression	CELL			English	Article							PROTEIN-KINASE-IV; LONG-TERM-MEMORY; CAMP-RESPONSIVE ELEMENT; C-FOS TRANSCRIPTION; RAT-BRAIN; SOMATOSTATIN GENE; BINDING PROTEIN; MUTANT MICE; CALMODULIN; NEURONS	While changes in gene expression are critical for many brain functions, including long-term memory, little is known about the cellular processes that mediate stimulus-transcription coupling at central synapses. In studying the signaling pathways by which synaptic inputs control the phosphorylation state of cyclic AMP-responsive element binding protein (CREB) and determine expression of CRE-regulated genes, we found two important Ca2+/calmodulin (CaM)-regulated mechanisms in hippocampal neurons: a CaM kinase cascade involving nuclear CaMKIV and a calcineurin-dependent regulation of nuclear protein phosphatase 1 activity. Prolongation of the synaptic input on the time scale of minutes, in part by an activity-induced inactivation of calcineurin, greatly extends the period over which phospho-CREB levels are elevated, thus affecting induction of downstream genes.			Bito, H (corresponding author), STANFORD UNIV,BECKMAN CTR,SCH MED,DEPT MOL & CELLULAR PHYSIOL,STANFORD,CA 94305, USA.		Bito, Haruhiko/A-8635-2008	Bito, Haruhiko/0000-0001-6315-9594				ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Bennett PC, 1996, BRAIN RES, V730, P107; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; BROCKE L, 1995, J NEUROSCI, V15, P6797; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; CURRAN T, 1995, J NEUROBIOL, V26, P403, DOI 10.1002/neu.480260312; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; DEZAZZO J, 1995, TRENDS NEUROSCI, V18, P212, DOI 10.1016/0166-2236(95)93905-D; DUGAN LL, 1995, J NEUROSCI, V15, P6377; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; ITO T, 1994, ARCH BIOCHEM BIOPHYS, V312, P278, DOI 10.1006/abbi.1994.1310; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Klee C.B., 1988, CALMODULIN, P225; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; LIU FC, 1996, IN PRESS NEURON, V17; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUOKA N, 1995, NEUROSCIENCE, V66, P617, DOI 10.1016/0306-4522(94)00628-I; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MAYFORD M, 1995, CURR OPIN NEUROBIOL, V5, P141, DOI 10.1016/0959-4388(95)80019-0; Nagao M, 1995, MUTAT RES-FUND MOL M, V333, P173, DOI 10.1016/0027-5107(95)00143-3; NAKAMURA Y, 1995, NEUROSCIENCE, V68, P181, DOI 10.1016/0306-4522(95)00092-W; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; OUIMET CC, 1995, P NATL ACAD SCI USA, V92, P3396, DOI 10.1073/pnas.92.8.3396; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; PAYLOR R, 1994, BRAIN RES, V651, P275, DOI 10.1016/0006-8993(94)90707-2; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; SAKAGAMI H, 1993, MOL BRAIN RES, V19, P215, DOI 10.1016/0169-328X(93)90029-O; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; STEMMER PM, 1995, FEBS LETT, V374, P237, DOI 10.1016/0014-5793(95)01095-V; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; VALLEJO M, 1995, MOL CELL BIOL, V15, P415, DOI 10.1128/MCB.15.1.415; Wang XT, 1996, NATURE, V383, P434, DOI 10.1038/383434a0; XIE HJ, 1995, J IMMUNOL, V154, P1717; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; YOSHIDA K, 1995, J NEUROCHEM, V65, P1499; Zhang W, 1996, J EXP MED, V183, P413, DOI 10.1084/jem.183.2.413	73	943	963	0	47	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1203	1214		10.1016/S0092-8674(00)81816-4	http://dx.doi.org/10.1016/S0092-8674(00)81816-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980227	Bronze			2022-12-28	WOS:A1996WA54100009
J	Mizzen, CA; Yang, XJ; Kokubo, T; Brownell, JE; Bannister, AJ; OwenHughes, T; Workman, J; Wang, L; Berger, SL; Kouzarides, T; Nakatani, Y; Allis, CD				Mizzen, CA; Yang, XJ; Kokubo, T; Brownell, JE; Bannister, AJ; OwenHughes, T; Workman, J; Wang, L; Berger, SL; Kouzarides, T; Nakatani, Y; Allis, CD			The TAF(II)250 subunit of TFIID has histone acetyltransferase activity	CELL			English	Article							RNA-POLYMERASE-II; TATA-BOX-BINDING; TRANSCRIPTION FACTOR; NUCLEOSOMAL DNA; FACILITATED BINDING; ACETYLATION; CHROMATIN; GENE; ACTIVATION; INITIATION	The transcription initiation factor TFIID is a multimeric protein complex composed of TATA box-binding protein (TBP) and many TBP-associated factors (TAF(II)s). TAF(II)s are important cofactors that mediate activated transcription by providing interaction sites for distinct activators. Here, we present evidence that human TAF(II)250 and its homologs in Drosophila and yeast have histone acetyltransferase (HAT) activity in vitro. HAT activity maps to the central, most conserved portion of dTAF(II)230 and yTAF(II)130. The HAT activity of dTAF(II)230 resembles that of yeast and human GCN5 in that it is specific for histones H3 and H4 in vitro. Our findings suggest that targeted histone acetylation at specific promoters by TAF(II)250 may be involved in mechanisms by which TFIID gains access to transcriptionally repressed chromatin.	UNIV ROCHESTER, DEPT BIOL, ROCHESTER, NY 14627 USA; NICHHD, LAB MOL GROWTH REGULAT, NIH, BETHESDA, MD 20892 USA; UNIV CAMBRIDGE, WELLCOME CRC INST, CAMBRIDGE CB2 1QR, ENGLAND; PENN STATE UNIV, DEPT BIOCHEM & MOL BIOL, UNIVERSITY PK, PA 16802 USA; WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA; NARA INST SCI & TECHNOL, NARA 63001, JAPAN	University of Rochester; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Cambridge; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; The Wistar Institute; Nara Institute of Science & Technology				Owen-Hughes, Tom/0000-0002-0618-8185; Kouzarides, Tony/0000-0002-8918-4162; Berger, Shelley/0000-0001-5398-4400; Bannister, Andrew/0000-0002-6312-4436	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053512, R37GM053512] Funding Source: NIH RePORTER; NIGMS NIH HHS [NIH-GM53512] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANNUNZIATO AT, 1983, J BIOL CHEM, V258, P2675; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BAUER WR, 1994, J MOL BIOL, V236, P685, DOI 10.1006/jmbi.1994.1180; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Candau R, 1996, MOL CELL BIOL, V16, P593; CANDAU R, 1997, IN PRESS EMBO J; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; GODDE JS, 1995, NUCLEIC ACIDS RES, V23, P4557, DOI 10.1093/nar/23.22.4557; HAYASHIDA T, 1994, GENE, V141, P267; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; KINGSTON RE, 1994, CURR BIOL, V4, P325, DOI 10.1016/S0960-9822(00)00071-3; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LOIDL P, 1994, CHROMOSOMA, V103, P441; Lu L, 1996, J BIOL CHEM, V271, P18920, DOI 10.1074/jbc.271.31.18920; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Nakatani Y, 1996, J BIOL CHEM, V271, P6575, DOI 10.1074/jbc.271.12.6575; NISHIKAWA J, 1997, IN PRESS P NATL ACAD; NORTON VG, 1990, J BIOL CHEM, V265, P19848; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OLINS AL, 1976, NUCLEIC ACIDS RES, V3, P3271, DOI 10.1093/nar/3.12.3271; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; PRUZAN R, 1992, NUCLEIC ACIDS RES, V20, P5705, DOI 10.1093/nar/20.21.5705; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Roest HP, 1996, CELL, V86, P799, DOI 10.1016/S0092-8674(00)80154-3; Roth SY, 1996, TRENDS CELL BIOL, V6, P371, DOI 10.1016/0962-8924(96)20032-7; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; VETTESEDADEY M, 1994, MOL CELL BIOL, V14, P970, DOI 10.1128/MCB.14.2.970; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WANG L, 1997, IN PRESS MOL CELL BI; WEINZIERL RO, 1993, NATURE, V262, P511; WOLFFE AP, 1994, CURR OPIN GENET DEV, V4, P245, DOI 10.1016/S0959-437X(05)80051-6; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	70	618	628	0	17	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 27	1996	87	7					1261	1270		10.1016/S0092-8674(00)81821-8	http://dx.doi.org/10.1016/S0092-8674(00)81821-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980232	hybrid			2022-12-28	WOS:A1996WA54100014
J	Moss, AJ; Hall, WJ; Cannom, DS; Daubert, JP; Higgins, SL; Klein, H; Levine, JH; Saksena, S; Waldo, AL; Wilber, D; Brown, MW; Heo, M				Moss, AJ; Hall, WJ; Cannom, DS; Daubert, JP; Higgins, SL; Klein, H; Levine, JH; Saksena, S; Waldo, AL; Wilber, D; Brown, MW; Heo, M			Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIOVERTER-DEFIBRILLATOR; MYOCARDIAL-INFARCTION; ANTIARRHYTHMIC DRUGS; CARDIAC-ARREST; TACHYCARDIA; CLASSIFICATION; COMPLICATIONS; MORTALITY; TRIAL	Background Unsustained ventricular tachycardia in patients with previous myocardial infarction and left ventricular dysfunction is associated with a two-year mortality rate of about 30 percent. We studied. whether prophylactic therapy with an implanted cardioverter-defibrillator, as compared with conventional medical therapy, would improve survival in this high-risk group of patients. Methods Over the course of five years, 196 patients in New York Heart Association functional class I, II, or III with prior myocardial infarction; a left ventricular ejection fraction less than or equal to 0.35; a documented episode of asymptomatic unsustained ventricular tachycardia; and inducible, nonsuppressible ventricular tachyarrhythmia on electrophysiologic study were randomly assigned to receive an implanted defibrillator (n=95) or conventional medical therapy (n=101). We used a two-sided sequential design with death from any cause as the end point. Results The base-line characteristics of the two treatment groups were similar. During an average follow-up of 27 months, there were 15 deaths in the defibrillator group (11 from cardiac causes) and 39 deaths in the conventional-therapy group (27 from cardiac causes) (hazard ratio for overall mortality, 0.46; 95 percent confidence interval, 0.26 to 0.82; P=0.009). There was no evidence that amiodarone, beta-blockers, or any other antiarrhythmic therapy had a significant influence on the observed hazard ratio. Conclusions In patients with a prior myocardial infarction who are at high risk for ventricular tachyarrhythmia, prophylactic therapy with an implanted defibrillator leads to improved survival as compared with conventional medical therapy. (C) 1996, Massachusetts Medical Society.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOSTAT,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT COMMUNITY & PREVENT MED,ROCHESTER,NY 14642; GOOD SAMARITAN HOSP,LOS ANGELES,CA; SCRIPPS CLIN & HOSP,LA JOLLA,CA; UNIV HOSP,MAGDEBURG,GERMANY; ST FRANCIS HOSP,CTR HEART,ROSLYN,NY; EASTERN HEART INST,PASSAIC,NJ; CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,CLEVELAND,OH 44106; UNIV CHICAGO,CARDIOL UNIT,CHICAGO,IL 60637	University of Rochester; University of Rochester; Scripps Research Institute; University Hospital Magdeburg; Case Western Reserve University; University Hospitals of Cleveland; University of Chicago	Moss, AJ (corresponding author), UNIV ROCHESTER,MED CTR,SCH MED & DENT,DEPT MED,CARDIOL UNIT,HEART RES FOLLOW UP PROGRAM,BOX 653,ROCHESTER,NY 14642, USA.		Daubert, James P./ABC-1476-2021	Heo, Moonseong/0000-0001-7711-1209				ANDERSON KP, 1978, CIRCULATION, V57, P890, DOI 10.1161/01.CIR.57.5.890; [Anonymous], 1992, DESIGN ANAL SEQUENTI; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BIGGER JT, 1993, IMPLANTABLE CARDIOVE, P284; BRUNIER H, 1993, PET PLANNING EVALUAT; BUXTON AE, 1984, AM J CARDIOL, V53, P1275, DOI 10.1016/0002-9149(84)90078-X; COX DR, 1972, J R STAT SOC B, V34, P187; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; ECHT DS, 1985, CIRCULATION, V71, P289, DOI 10.1161/01.CIR.71.2.289; FOGOROS RN, 1989, PACE, V12, P1465, DOI 10.1111/j.1540-8159.1989.tb06151.x; GREENBERG H, 1987, AM J CARDIOL, V59, P1057, DOI 10.1016/0002-9149(87)90848-4; GREENE HL, 1994, AM HEART J, V127, P1171, DOI 10.1016/0002-8703(94)90106-6; HEALY B, 1989, NEW ENGL J MED, V320, P949, DOI 10.1056/NEJM198904063201432; HINKLE LE, 1982, CIRCULATION, V65, P457, DOI 10.1161/01.CIR.65.3.457; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELLY PA, 1988, J AM COLL CARDIOL, V11, P1278, DOI 10.1016/0735-1097(88)90292-6; LEHMANN MH, 1988, AM J CARDIOL, V62, P803, DOI 10.1016/0002-9149(88)91226-X; LEVINE JH, 1991, CIRCULATION, V84, P558, DOI 10.1161/01.CIR.84.2.558; MADIT Executive Committee Multicenter Automatic Defibrillator, 1991, PACE, V14, P920; MASON JW, 1993, NEW ENGL J MED, V329, P452, DOI 10.1056/NEJM199308123290702; MIROWSKI M, 1980, NEW ENGL J MED, V303, P322, DOI 10.1056/NEJM198008073030607; MORADY F, 1988, AM J CARDIOL, V61, P93, DOI 10.1016/0002-9149(88)91311-2; RUSKIN JN, 1983, NEW ENGL J MED, V309, P1302, DOI 10.1056/NEJM198311243092107; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201; SPIELMAN SR, 1985, J AM COLL CARDIOL, V6, P31, DOI 10.1016/S0735-1097(85)80248-5; *TASK FORC WORK GR, 1994, CIRCULATION, V89, P2892; WILBER DJ, 1990, CIRCULATION, V82, P350, DOI 10.1161/01.CIR.82.2.350; WINKLE RA, 1989, J AM COLL CARDIOL, V13, P1353, DOI 10.1016/0735-1097(89)90310-0	28	2898	2980	2	51	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 26	1996	335	26					1933	1940		10.1056/NEJM199612263352601	http://dx.doi.org/10.1056/NEJM199612263352601			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA160	8960472				2022-12-28	WOS:A1996WA16000001
J	Hawnaur, J; Isherwood, I				Hawnaur, J; Isherwood, I			Radiology - From electron to spin doctor	LANCET			English	Article											Hawnaur, J (corresponding author), UNIV MANCHESTER, SCH MED, DEPT DIAGNOST RADIOL, MANCHESTER M13 9PT, LANCS, ENGLAND.							Bahn MM, 1996, JMRI-J MAGN RESON IM, V6, P833, DOI 10.1002/jmri.1880060518; LeBihan D, 1996, J NEURORADIOLOGY, V23, P1; Mitchell DG, 1996, JMRI-J MAGN RESON IM, V6, P812, DOI 10.1002/jmri.1880060516; STRICKLAND N, 1996, IN PRESS BR J RADIOL; Szolar DH, 1996, J MAGN RESON IMAGING, V6, P78, DOI 10.1002/jmri.1880060117	5	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	1996	348			2			SII22	SII22						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973500				2022-12-28	WOS:A1996WA46300022
J	LaPorte, RE; Hibbitts, B				LaPorte, RE; Hibbitts, B			Rights, wrongs, and journals in the age of cyberspace - ''We all want to change the world''	BRITISH MEDICAL JOURNAL			English	Article							INTERNET		UNIV PITTSBURGH,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	LaPorte, RE (corresponding author), RANGOS RES CTR,DIABET RES CTR,PITTSBURGH,PA 15213, USA.							HELMAN T, 1995, BRIT MED J, V310, P1674, DOI 10.1136/bmj.310.6995.1674c; HIBBITTS BJ, 1996, U LAW REV, V71, P615; HIBBITTS BJ, IN PRESS AKRON LAW R; KASSIRER JP, 1995, NEW ENGL J MED, V332, P1709, DOI 10.1056/NEJM199506223322509; LAPORTE RE, 1995, BRIT MED J, V310, P1387, DOI 10.1136/bmj.310.6991.1387	5	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1609	1611		10.1136/bmj.313.7072.1609	http://dx.doi.org/10.1136/bmj.313.7072.1609			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991005	Green Published			2022-12-28	WOS:A1996VZ81100032
J	Metkus, AP; Trabulsy, PP; Schlobohm, RS; Hickey, MS				Metkus, AP; Trabulsy, PP; Schlobohm, RS; Hickey, MS			A firefighter with pancreatitis	LANCET			English	Article							CRITICALLY ILL PATIENTS; SEDATION; PROPOFOL		SAN FRANCISCO GEN HOSP,DEPT SURG,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center								BOYLE W A, 1990, Anesthesiology (Hagerstown), V73, pA245; CARRASCO G, 1993, CHEST, V103, P557, DOI 10.1378/chest.103.2.557; GOTTARDIS M, 1989, BRIT J ANAESTH, V62, P393, DOI 10.1093/bja/62.4.393; LESIURE GS, 1996, ANESTHESIOLOGY, V84, P224; LEVINE RL, 1994, CRIT CARE CLIN, V10, P709, DOI 10.1016/S0749-0704(18)30102-7	5	20	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1702	1702		10.1016/S0140-6736(96)06205-8	http://dx.doi.org/10.1016/S0140-6736(96)06205-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973434				2022-12-28	WOS:A1996VZ76600014
J	Freed, GL; Katz, SL; Clark, SJ				Freed, GL; Katz, SL; Clark, SJ			Safety of vaccinations - Miss America, the media, and public health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VACCINE INFORMATION PAMPHLETS; INFLAMMATORY BOWEL-DISEASE; MEASLES VACCINATION; PERTUSSIS-VACCINE; RUBELLA VACCINES; MEDICINE REPORT; RISK FACTOR; IMMUNIZATION; INSTITUTE; CAMPAIGN		UNIV N CAROLINA,DIV COMMUNITY PEDIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT HLTH POLICY & ADM,CHAPEL HILL,NC 27599; DUKE UNIV,MED CTR,DIV PEDIAT INFECT DIS,DURHAM,NC	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University	Freed, GL (corresponding author), UNIV N CAROLINA,CECIL G SHEPS CTR HLTH SERV RES,CB 7590,CHAPEL HILL,NC 27599, USA.		Clark, Stewart J/A-3462-2012	Clark, Stewart J/0000-0003-4792-7738				*AM AC PED, 1994, AAP NEWS         NOV, V10, P33; BARAFF LJ, 1988, PEDIATRICS, V81, P789; BAXTER T, 1995, LANCET, V345, P1363; BISHOP J, 1995, MED MEDIA CHANGING R, P23; BLANCHARD F, 1982, ASS PRESS       1202; BYERS RK, 1948, PEDIATRICS, V1, P437; CALMAN KC, 1995, LANCET, V345, P1362; *CDC, 1985, MMWR-MORBID MORTAL W, V34, P411; CHEEVERS J, 1995, LOS ANGELES TIM 1119, pB16; CLAYTON EW, 1990, J PEDIATR-US, V116, P508, DOI 10.1016/S0022-3476(05)81594-X; CUTTS FT, 1992, JAMA-J AM MED ASSOC, V267, P1952, DOI 10.1001/jama.267.14.1952; EVANS S, 1994, WASHINGTON POST 0923, pA3; FARRINGTON P, 1995, LANCET, V345, P1362, DOI 10.1016/S0140-6736(95)92559-7; FREED GL, 1993, MILBANK Q, V71, P65, DOI 10.2307/3350275; FULGINITI VA, 1992, PEDIATRICS, V89, P334; GOLDEN GS, 1990, J PEDIATR-US, V116, P854, DOI 10.1016/S0022-3476(05)80640-7; GOLDSMITH MF, 1992, JAMA-J AM MED ASSOC, V267, P2005; Gonzalez E R, 1982, JAMA, V248, P12, DOI 10.1001/jama.248.1.12; HILTS D, 1982, WASHINGTON POST 0428; HINMAN AR, 1986, AM J DIS CHILD, V140, P528, DOI 10.1001/archpedi.1986.02140200038022; HINMAN AR, 1984, PUBLIC HEALTH REP, V99, P255; HOWSON CP, 1992, PEDIATRICS, V89, P318; Howson CP, 1991, ADVERSE EFFECTS PERT; *I MED, 1994, ADV EV ASS CHILDH VA; *JOINT COMM VACC I, 1981, WHOOP COUGH, P170; KEANE V, 1993, CLIN PEDIATR, P2; KINNUNEN E, 1989, NEUROLOGY, V39, P1034, DOI 10.1212/WNL.39.8.1034; KITCH EW, 1994, VACCINES, P933; LIEU TA, 1994, ARCH PEDIAT ADOL MED, V148, P921, DOI 10.1001/archpedi.1994.02170090035004; MACDONALD TT, 1995, LANCET, V345, P1363; MANLEY H, 1985, GOOD HOUSEKEEPIN JUN, P220; MIHILL C, 1985, GUARDIAN        0428, P1; MIHILL C, 1995, GUARDIAN        0428, P8; MILLER D, 1995, LANCET, V345, P1363; MINOR PD, 1995, LANCET, V345, P1362; PATUREAU A, 1994, ATLANTA CONSTIT 0916, pA3; PETER G, 1994, 1994 RED BOOK REPORT, P7; RABINOVICH R, 1994, JAMA-J AM MED ASSOC, V271, P68, DOI 10.1001/jama.271.1.68; *REUT INF SERV, 1995, REUTERS EC NEWS 0428; Stuart-Harris C, 1979, Dev Biol Stand, V43, P75; Tarr Amy, 1985, NATL LAW        1104, P1; THOMPSON L, 1982, DTP VACCINE ROULETTE; THOMPSON NP, 1995, LANCET, V345, P1071, DOI 10.1016/S0140-6736(95)90816-1; TSAIRIS P, 1972, ARCH NEUROL-CHICAGO, V27, P109, DOI 10.1001/archneur.1972.00490140013004; UHARI M, 1989, LANCET, V2, P440; *US DHHS, 1995, PUB HLTH REP, V110, P373; *US PRESS INT, 1982, UN PRESS INT    0512; *WA BUS TRAD REP, 1993, VACCINE B        MAY, V3, P6; WALSH E, 1982, WASHINGTON POST 0630; 1994, ATLANTA CONSTIT 0924, pE5; 1994, NY TIMES        0919, pA12; 1994, NY TIMES        0918, pA38; 1984, NEWSWEEK        1224, V104, P34; 1994, NY TIMES        0926, pB9	54	58	58	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1996	276	23					1869	1872		10.1001/jama.276.23.1869	http://dx.doi.org/10.1001/jama.276.23.1869			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX522	8968002				2022-12-28	WOS:A1996VX52200016
J	Selbmann, HK				Selbmann, HK			Germany - Health care	LANCET			English	Article											Selbmann, HK (corresponding author), UNIV TUBINGEN,ABT MED DOKUMENTAT & DATENVERARBEITUNG,TUBINGEN,GERMANY.								0	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1631	1632		10.1016/S0140-6736(96)11073-4	http://dx.doi.org/10.1016/S0140-6736(96)11073-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8984307				2022-12-28	WOS:A1996VX87600015
J	Ryner, LC; Goodwin, SF; Castrillon, DH; Anand, A; Villella, A; Baker, BS; Hall, JC; Taylor, BJ; Wasserman, SA				Ryner, LC; Goodwin, SF; Castrillon, DH; Anand, A; Villella, A; Baker, BS; Hall, JC; Taylor, BJ; Wasserman, SA			Control of male sexual behavior and sexual orientation in Drosophila by the fruitless gene	CELL			English	Article							NERVOUS-SYSTEM; DNA-BINDING; MELANOGASTER; DIFFERENTIATION; MUSCLE; PROTEINS; METAMORPHOSIS; EXPRESSION; DOUBLESEX; COURTSHIP	Sexual orientation and courtship behavior in Drosophila are regulated by fruitless (fru), the first gene in a branch of the sex-determination hierarchy functioning specifically in the central nervous system (CNS). The phenotypes of new fru mutants encompass nearly all aspects of male sexual behavior. Alternative splicing of fru transcripts produces sex-specific proteins belonging to the BTB-ZF family of transcriptional regulators. The sex-specific fru products are produced in only about 500 of the 10(5) neurons that comprise the CNS. The properties of neurons expressing these fru products suggest that fru specifies the fates or activities of neurons that carry out higher order control functions to elicit and coordinate the activities comprising male courtship behavior.	BRANDEIS UNIV, DEPT BIOL, WALTHAM, MA 02254 USA; UNIV TEXAS, SW MED CTR, DEPT MOL BIOL & ONCOL, DALLAS, TX 75235 USA; OREGON STATE UNIV, DEPT ZOOL, CORVALLIS, OR 97331 USA	Brandeis University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Oregon State University	Ryner, LC (corresponding author), STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA.			Goodwin, Stephen/0000-0002-0552-4140	NIGMS NIH HHS [GM-21473] Funding Source: Medline; NINDS NIH HHS [NS-33352] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021473] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033352] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Banfi S, 1996, NAT GENET, V13, P167, DOI 10.1038/ng0696-167; BELOTE JM, 1987, P NATL ACAD SCI USA, V84, P8026, DOI 10.1073/pnas.84.22.8026; BREEDLOVE SM, 1994, ANNU REV PSYCHOL, V45, P389, DOI 10.1146/annurev.psych.45.1.389; BREEDLOVE SM, 1992, J NEUROSCI, V12, P4133; BURROWS M, 1992, TRENDS NEUROSCI, V15, P226, DOI 10.1016/0166-2236(92)90040-F; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; Burtis KC, 1993, CURR OPIN CELL BIOL, V5, P1006, DOI 10.1016/0955-0674(93)90085-5; CASTRILLON DH, 1993, GENETICS, V135, P489; Dauwalder B, 1996, P NATL ACAD SCI USA, V93, P9004, DOI 10.1073/pnas.93.17.9004; DIANTONIO A, 1993, J NEUROSCI, V13, P4924; EMERY IF, 1994, DEVELOPMENT, V120, P3275; GAILEY DA, 1991, DEVELOPMENT, V113, P879; GREENSPAN RJ, 1995, SCI AM, V272, P74; HALL JC, 1994, SCIENCE, V264, P1702, DOI 10.1126/science.8209251; HAMBLENCOYLE M, 1989, J NEUROGENET, V5, P229, DOI 10.3109/01677068909066210; HEISENBERG M, 1995, J NEUROSCI, V15, P1951, DOI 10.1523/JNEUROSCI.15-03-01951.1995; HEISENBERG M, 1994, CENTRAL BRAIN FUNCTI, P61; Hing ALY, 1996, J NEUROBIOL, V30, P454; HU S, 1995, NAT GENET, V11, P248, DOI 10.1038/ng1195-248; HU S, 1995, GENE DEV, V9, P2936, DOI 10.1101/gad.9.23.2936; Ito H, 1996, P NATL ACAD SCI USA, V93, P9687, DOI 10.1073/pnas.93.18.9687; KULKARNI SJ, 1987, GENETICS, V115, P461; LAWRENCE PA, 1986, CELL, V45, P505, DOI 10.1016/0092-8674(86)90282-5; LEVAY S, 1996, QUEER SCI; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MATSUO N, 1995, J BIOL CHEM, V270, P28216, DOI 10.1074/jbc.270.47.28216; MCKEOWN M, 1994, DEV GENET, V15, P201, DOI 10.1002/dvg.1020150302; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PERKINS A, 1995, HORM BEHAV, V29, P31, DOI 10.1006/hbeh.1995.1003; PIRROTTA V, 1986, DROSOPHILA PRACTICAL; READ D, 1992, MECH DEVELOP, V38, P183, DOI 10.1016/0925-4773(92)90052-L; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; RYNER LC, 1995, CELL, V81, P483, DOI 10.1016/0092-8674(95)90069-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Segade F, 1996, FEBS LETT, V387, P152, DOI 10.1016/0014-5793(96)00496-6; STOCKER RF, 1994, CELL TISSUE RES, V275, P3, DOI 10.1007/BF00305372; SWAAB DF, 1995, TRENDS NEUROSCI, V18, P264, DOI 10.1016/0166-2236(95)93913-I; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TAYLOR BJ, 1995, DEVELOPMENT, V121, P3079; TAYLOR BJ, 1994, DEV GENET, V15, P275, DOI 10.1002/dvg.1020150309; TAYLOR BJ, 1992, GENETICS, V132, P179; Villella A, 1996, GENETICS, V143, P331; VONKALM L, 1994, EMBO J, V13, P3505, DOI 10.1002/j.1460-2075.1994.tb06657.x; ZHANG SD, 1995, P NATL ACAD SCI USA, V92, P5525, DOI 10.1073/pnas.92.12.5525	46	390	397	3	73	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 13	1996	87	6					1079	1089		10.1016/S0092-8674(00)81802-4	http://dx.doi.org/10.1016/S0092-8674(00)81802-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978612	Bronze			2022-12-28	WOS:A1996VY44700013
J	Eaton, WA; Henry, ER; Hofrichter, J				Eaton, WA; Henry, ER; Hofrichter, J			Nanosecond crystallographic snapshots of protein structural changes	SCIENCE			English	Editorial Material							CARBON-MONOXIDE; HEME-PROTEINS; CONFORMATIONAL-CHANGES; MOLECULAR-DYNAMICS; SINGLE-CRYSTALS; LIGAND-BINDING; HEMOGLOBIN; MYOGLOBIN; SPECTROSCOPY; REACTIVITY				Eaton, WA (corresponding author), NIDDKD,CHEM PHYS LAB,NIH,BLDG 5,BETHESDA,MD 20892, USA.		Henry, Eric R/J-3414-2013	Henry, Eric R/0000-0002-5648-8696				AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; ANFINRUD PA, 1989, P NATL ACAD SCI USA, V86, P8387, DOI 10.1073/pnas.86.21.8387; CAMPBELL BF, 1987, SCIENCE, V238, P373, DOI 10.1126/science.3659921; DUDDELL DA, 1979, J CHEM SOC CHEM COMM, P75, DOI 10.1039/c39790000075; Eaton W A, 1981, Methods Enzymol, V76, P175; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; FRIEDMAN JM, 1985, SCIENCE, V228, P1273, DOI 10.1126/science.4001941; GREENE BI, 1978, P NATL ACAD SCI USA, V75, P5255, DOI 10.1073/pnas.75.11.5255; Hagen SJ, 1996, J PHYS CHEM-US, V100, P12008, DOI 10.1021/jp960219t; HAGEN SJ, 1996, SCIENCE, V104, P33695; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; HENRY ER, 1985, P NATL ACAD SCI USA, V82, P2034, DOI 10.1073/pnas.82.7.2034; HOFRICHTER J, 1983, P NATL ACAD SCI-BIOL, V80, P2235, DOI 10.1073/pnas.80.8.2235; HUANG XH, 1994, NAT STRUCT BIOL, V1, P226, DOI 10.1038/nsb0494-226; Johnson JB, 1996, BIOPHYS J, V71, P1563, DOI 10.1016/S0006-3495(96)79359-1; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LIM MH, 1993, P NATL ACAD SCI USA, V90, P5801, DOI 10.1073/pnas.90.12.5801; LYONS KB, 1982, HEMOGLOBIN OXYGEN BI, P333; MARTIN JL, 1983, P NATL ACAD SCI-BIOL, V80, P173, DOI 10.1073/pnas.80.1.173; Mozzarelli A, 1996, ANNU REV BIOPH BIOM, V25, P343; NG K, 1995, BIOCHEMISTRY-US, V34, P879, DOI 10.1021/bi00003a022; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P2888, DOI 10.1021/bi00062a021; SAWICKI CA, 1976, J BIOL CHEM, V251, P1533; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; SZABO A, 1978, P NATL ACAD SCI USA, V75, P2108, DOI 10.1073/pnas.75.5.2108; Tian WD, 1996, BIOCHEMISTRY-US, V35, P3487, DOI 10.1021/bi952474u; [No title captured]	31	11	11	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1631	1632		10.1126/science.274.5293.1631	http://dx.doi.org/10.1126/science.274.5293.1631			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8984630				2022-12-28	WOS:A1996VW71200038
J	Tobin, MJ; Luce, JM				Tobin, MJ; Luce, JM			Update in critical care medicine	ANNALS OF INTERNAL MEDICINE			English	Article									SAN FRANCISCO GEN HOSP, SAN FRANCISCO, CA 94110 USA	San Francisco General Hospital Medical Center	Tobin, MJ (corresponding author), LOYOLA UNIV, DIV PULM MED, 2160 1ST AVE, MAYWOOD, IL 60153 USA.							BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; ESTEBAN A, 1994, CHEST, V106, P1188, DOI 10.1378/chest.106.4.1188; PINGLETON SK, 1988, AM REV RESPIR DIS, V137, P1463, DOI 10.1164/ajrccm/137.6.1463	5	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1996	125	11					909	916		10.7326/0003-4819-125-11-199612010-00007	http://dx.doi.org/10.7326/0003-4819-125-11-199612010-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV541	8967672				2022-12-28	WOS:A1996VV54100007
J	Kirkman, J				Kirkman, J			Writing in English for an international readership - Confine yourself to forms of English that are easily understood	BRITISH MEDICAL JOURNAL			English	Article											Kirkman, J (corresponding author), JOHN KIRKMAN COMMUN CONSULTANCY,WITCHA COTTAGE,MARLBOROUGH SN8 2HQ,WILTS,ENGLAND.								0	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1996	313	7068					1321	1322						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV153	8983416				2022-12-28	WOS:A1996VV15300030
J	Vaara, M				Vaara, M			Lipid A: Target for antibacterial drugs	SCIENCE			English	Editorial Material							OUTER-MEMBRANE PERMEABILITY; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; RESISTANCE; BIOSYNTHESIS; ANTIBIOTICS; BACTERIA; MUTANT; AGENTS				Vaara, M (corresponding author), UNIV HELSINKI,DEPT BACTERIOL & IMMUNOL,HELSINKI 00014,FINLAND.		Vaara, Martti S/D-1698-2013					COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; Fernandes PB, 1996, ASM NEWS, V62, P21; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; GOLDMAN R, 1987, NATURE, V329, P162, DOI 10.1038/329162a0; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; HIRVAS L, 1991, EMBO J, V10, P1017, DOI 10.1002/j.1460-2075.1991.tb08036.x; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; Levy S B, 1994, Trends Microbiol, V2, P341, DOI 10.1016/0966-842X(94)90607-6; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RAETZ CRH, 1996, IN PRESS CELLULAR MO, V1; ROWLEY D, 1968, J BACTERIOL, V95, P1647, DOI 10.1128/JB.95.5.1647-1650.1968; SERVICE RF, 1995, SCIENCE, V270, P724, DOI 10.1126/science.270.5237.724; SPRATT BG, 1994, SCIENCE, V264, P388, DOI 10.1126/science.8153626; SWARTZ MN, 1994, P NATL ACAD SCI USA, V91, P2420, DOI 10.1073/pnas.91.7.2420; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; VAARA M, 1983, NATURE, V303, P526, DOI 10.1038/303526a0; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P2255, DOI 10.1128/AAC.37.11.2255; VAARA M, 1984, J IMMUNOL, V132, P2582; VUORIO R, 1992, ANTIMICROB AGENTS CH, V36, P826, DOI 10.1128/AAC.36.4.826	26	21	22	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 8	1996	274	5289					939	940		10.1126/science.274.5289.939	http://dx.doi.org/10.1126/science.274.5289.939			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VR792	8966574				2022-12-28	WOS:A1996VR79200035
J	Cote, RJ; Esrig, D; Groshen, S; Jones, PA; Skinner, DG				Cote, RJ; Esrig, D; Groshen, S; Jones, PA; Skinner, DG			p53 and treatment of bladder cancer	NATURE			English	Letter							ACCUMULATION				Cote, RJ (corresponding author), UNIV SO CALIF,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,1441 EASTLAKE AVE,LOS ANGELES,CA 90033, USA.							ESRIG D, 1993, AM J PATHOL, V143, P1389; ESRIG D, 1994, NEW ENGL J MED, V331, P1259, DOI 10.1056/NEJM199411103311903; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; PIKE MC, 1972, J ROY STAT SOC A STA, V135, P201; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; SKINNER DG, 1991, J UROLOGY, V145, P459, DOI 10.1016/S0022-5347(17)38368-4; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0	8	230	232	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1997	385	6612					123	124		10.1038/385123b0	http://dx.doi.org/10.1038/385123b0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WB728	8990112				2022-12-28	WOS:A1997WB72800034
J	Pich, EM; Pagliusi, SR; Tessari, M; TalabotAyer, D; vanHuijsduijnen, RH; Chiamulera, C				Pich, EM; Pagliusi, SR; Tessari, M; TalabotAyer, D; vanHuijsduijnen, RH; Chiamulera, C			Common neural substrates for the addictive properties of nicotine and cocaine	SCIENCE			English	Article							RAT NUCLEUS-ACCUMBENS; REINFORCEMENT; RECEPTORS; DOPAMINE; BRAIN; EXPRESSION; INJECTIONS; INDUCTION; PROTEINS; NEURONS	Regional brain activation was assessed by mapping of Fos-related protein expression in rats trained to self-administration of intravenous nicotine and cocaine. Both drugs produced specific overlapping patterns of activation in the shell and the core of the nucleus accumbens, medial prefrontal cortex, and medial caudate areas, but not in the amygdala. Thus, the reinforcing properties of cocaine and nicotine map on selected structures of the terminal fields of the mesocorticolimbic dopamine system, supporting the idea that common substrates for these addictive drugs exist.	GLAXO WELLCOME SPA,MED RES CTR,I-37100 VERONA,ITALY	GlaxoSmithKline	Pich, EM (corresponding author), GLAXO WELLCOME RES & DEV LTD,GENEVA BIOMED RES INST,CH-1228 GENEVA,SWITZERLAND.		van Huijsduijnen, Rob A.M. Hooft/B-3653-2009; Chiamulera, Cristiano/C-4917-2015	van Huijsduijnen, Rob A.M. Hooft/0000-0002-2261-9424; Chiamulera, Cristiano/0000-0001-5076-8518				BECKERANDRE M, 1992, EUR J BIOCHEM, V206, P401, DOI 10.1111/j.1432-1033.1992.tb16940.x; CAINE SB, 1994, J PHARMACOL EXP THER, V270, P209; CALABRESI P, 1989, BRIT J PHARMACOL, V98, P135, DOI 10.1111/j.1476-5381.1989.tb16873.x; CORRIGALL WA, 1992, PSYCHOPHARMACOLOGY, V107, P285, DOI 10.1007/BF02245149; CORRIGALL WA, 1989, PSYCHOPHARMACOLOGY, V99, P473, DOI 10.1007/BF00589894; DICHIARA G, 1995, DRUG ALCOHOL DEPEN, V38, P95, DOI 10.1016/0376-8716(95)01118-I; FISCHMAN MW, 1982, FED PROC, V41, P241; FLEMMER DD, 1989, PHARMACOL BIOCHEM BE, V34, P261, DOI 10.1016/0091-3057(89)90309-2; GOEDERS NE, 1983, SCIENCE, V221, P773, DOI 10.1126/science.6879176; HENNINGFIELD JE, 1983, PHARMACOL BIOCHEM BE, V19, P887, DOI 10.1016/0091-3057(83)90099-0; HOPE B, 1992, P NATL ACAD SCI USA, V89, P5764, DOI 10.1073/pnas.89.13.5764; HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2; JAFFE J H, 1979, National Institute on Drug Abuse Research Monograph, P4; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895; MORGANJI, 1991, ANN REV N EUROSCI, V14, P421; NISELL M, 1994, SYNAPSE, V16, P36, DOI 10.1002/syn.890160105; PANG Y, 1993, MOL BRAIN RES, V20, P162, DOI 10.1016/0169-328X(93)90122-6; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; REN T, 1992, BRAIN RES BULL, V29, P589, DOI 10.1016/0361-9230(92)90127-J; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; STOLERMAN IP, 1995, PSYCHOPHARMACOLOGY, V117, P2, DOI 10.1007/BF02245088; SWANSON LW, 1992, BRAIN BAMPS STRUCTUR; TESSARI M, 1995, PSYCHOPHARMACOLOGY, V121, P282, DOI 10.1007/BF02245640; YANG XM, 1992, PHARMACOL BIOCHEM BE, V41, P643, DOI 10.1016/0091-3057(92)90386-T; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291; ZOLI M, 1990, NEUROCHEM INT, V16, P383, DOI 10.1016/0197-0186(90)90002-B	27	271	274	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					83	86						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974398				2022-12-28	WOS:A1997WA90300054
J	Chen, SY; Yang, AG; Chen, JD; Kute, T; King, CR; Collier, J; Cong, YP; Yao, CP; Huang, XF				Chen, SY; Yang, AG; Chen, JD; Kute, T; King, CR; Collier, J; Cong, YP; Yao, CP; Huang, XF			Potent antitumour activity of a new class of tumour-specific killer cells	NATURE			English	Article							PSEUDOMONAS EXOTOXIN; PROTO-ONCOGENE; HUMAN-BREAST; ANTIBODY; EXPRESSION; CANCER; LYMPHOCYTES; MELANOMA; THERAPY; VECTORS	Two approaches to the antibody-directed targeting of toxic or cytolytic activity and augmentation of cellular immune responses have been explored For tumour immunotherapy, but so far success has been limited(1-3). Obstacles facing immunotherapy are the limited accessibility of antibodies or antibody conjugates to solid tumours and the difficulty in obtaining tumour-specific cytotoxic lymphocytes(4-7). Here we generate a new class of tumour-specific killer cells by genetically modifying lymphocytes to produce and secrete a targeted toxin against an oncoprotein overexpressed on breast and other tumour cells, The transduced lymphocytes were shown to have potent and selective cytotoxicity to tumours in culture and nude mouse models, The potent in vivo antitunour activity is probably a result of the migration of the lymphocytes to tumours as a targeted toxin carrier, and production and accumulation of the targeted toxins inside tumours as a producer. Our approach, which has features of both antibody-directed and cell-mediated immunotherapy, may have application in a gene therapy context.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,CTR COMPREHENS CANC,DEPT PATHOL,WINSTON SALEM,NC 27157; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,CTR COMPREHENS CANC,DEPT COMPARAT MED,WINSTON SALEM,NC 27157; GEORGETOWN UNIV,VINCENT T LOMBARDI CANC RES CTR,DEPT BIOCHEM,WASHINGTON,DC 20007; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Georgetown University; Harvard University; Harvard Medical School	Chen, SY (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,CTR COMPREHENS CANC,DEPT CANC BIOL,WINSTON SALEM,NC 27157, USA.							BATRA JK, 1992, P NATL ACAD SCI USA, V89, P5867, DOI 10.1073/pnas.89.13.5867; CHEN SY, 1995, GENE THER, V2, P116; CHEN SY, 1994, P NATL ACAD SCI USA, V91, P5932, DOI 10.1073/pnas.91.13.5932; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; CULVER K, 1991, P NATL ACAD SCI USA, V88, P3155, DOI 10.1073/pnas.88.8.3155; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; JOHNSON RA, 1982, APPLIED MULTIVARIATE, P226; KASPRZYK PG, 1992, CANCER RES, V52, P2771; King CR, 1996, SEMIN CANCER BIOL, V7, P79; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILLER AD, 1992, CURR TOP MICROBIOL, V158, P1; OSBORNE CK, 1985, CANCER RES, V45, P584; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; PEREZ P, 1985, NATURE, V316, P354, DOI 10.1038/316354a0; POTTER CRD, 1989, HISTOPATHOLOGY, V15, P351; PRESS MF, 1990, ONCOGENE, V5, P953; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; SHOCKLEY TR, 1992, CANCER RES, V52, P357; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; VITETTA ES, 1987, SCIENCE, V238, P1098, DOI 10.1126/science.3317828; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; YANG A, IN PRESS NATURE BIOT	27	61	79	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 2	1997	385	6611					78	80		10.1038/385078a0	http://dx.doi.org/10.1038/385078a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA731	8985250				2022-12-28	WOS:A1997WA73100053
J	Thompson, DC; Nunn, ME; Thompson, RS; Rivara, FP				Thompson, DC; Nunn, ME; Thompson, RS; Rivara, FP			Effectiveness of bicycle safety helmets in preventing serious facial injury	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FRACTURES	Objective.-To assess the effectiveness of helmets in preventing facial injuries. Design.-Case-control study between March 1, 1992, and August 31, 1994. Setting.-Seven Seattle, Wash, area hospitals including the regional trauma center and a large staff-model health maintenance organization. Patients.-Cases were patients with serious facial injury, ie, fractures or lacerations; controls were patients who had injuries other than facial. Minor facial injuries were excluded to avoid ascertainment bias in those seeking care for serious injuries to other areas. Results.-Serious facial injuries occurred to 700 (20.7%) patients. Helmets were used by 47% of cases and 57% of controls. After adjusting for age, sex, speed, and surface, we found that helmets reduced the risk of injury to the upper face (odds ratio [OR], 0.36; 95% confidence interval [CI], 0.26-0.49) and middle face (OR, 0.35; 95% CI, 0.24-0.50) but had no significant effect on serious injury to the lower face (OR, 0.88; 95% CI, 0.72-1.07). Conclusions.-Bicycle helmets offer substantial protection for the upper and mid face in addition to their known protection against head injuries. Helmets do not appear to offer any protection for the lower face.	UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT DENT PUBL HLTH SCI,SEATTLE,WA; GRP HLTH COOPERAT PUGET SOUND,DEPT PREVENT CARE,SEATTLE,WA 98121	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative	Thompson, DC (corresponding author), UNIV WASHINGTON,DEPT PEDIAT,HARBORVIEW INJURY PREVENT & RES CTR,325 9TH AVE,BOX 359960,SEATTLE,WA 98104, USA.							ATON CHC, 1996, MED J AUSTRALIA, V165, P249; BRESLOW NE, 1980, INT AGENCY RES CANC, V32, P190; Grimard G, 1995, Inj Prev, V1, P21, DOI 10.1136/ip.1.1.21; Henderson M, 1995, EFFECTIVENESS BICYCL; LINDQVIST C, 1986, INT J ORAL MAX SURG, V15, P12, DOI 10.1016/S0300-9785(86)80005-9; MYALL RWT, 1987, PEDIATRICS, V79, P639; Myall RWT, 1994, CONTROVERSIES ORAL M, V17, P191; Sosin DM, 1996, PEDIATRICS, V98, P868; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1471, DOI 10.2105/AJPH.80.12.1471; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; Thompson DC, 1996, EPIDEMIOLOGY SPORTS, P98; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101	12	99	102	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1996	276	24					1974	1975		10.1001/jama.276.24.1974	http://dx.doi.org/10.1001/jama.276.24.1974			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY689	8971067				2022-12-28	WOS:A1996VY68900030
J	Kapadia, CR; Spiro, H				Kapadia, CR; Spiro, H			Gastroenterology - Of oxides and onions	LANCET			English	Article											Kapadia, CR (corresponding author), YALE UNIV,SCH MED,333 CEDAR ST,NEW HAVEN,CT 06520, USA.							Atucha NM, 1996, GASTROENTEROLOGY, V111, P1627, DOI 10.1016/S0016-5085(96)70026-4; CONRYCANTILENA C, 1996, NEW ENGL J MED, V334, P1692; Dorant E, 1996, GASTROENTEROLOGY, V110, P12, DOI 10.1053/gast.1996.v110.pm8536847; Majeed AW, 1996, LANCET, V347, P989, DOI 10.1016/S0140-6736(96)90143-9; Singer II, 1996, GASTROENTEROLOGY, V111, P871, DOI 10.1016/S0016-5085(96)70055-0	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348			2			SII7	SII7						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973485				2022-12-28	WOS:A1996WA46300007
J	Kitson, AL				Kitson, AL			Does nursing have a future?	BRITISH MEDICAL JOURNAL			English	Article											Kitson, AL (corresponding author), ROYAL COLL NURSING UK,RCN INST,LONDON W1M 0AB,ENGLAND.		Kitson, Alison/AAW-6026-2021	Kitson, Alison/0000-0003-3053-8381				ABDEILAH RG, 1973, NEW DIRECTIONS PATIE; Abel-Smith Brian, 1960, HIST NURSING PROFESS; Aiken L., 1992, CHARTING NURSINGS FU; ALLPORT Gordon W., 1960, INDIVIDUAL HIS RELIG; AYDELOTTE MR, 1992, CHARTING NURSINGS FU; BLENDON RJ, 1988, JAMA-J AM MED ASSOC, V259, P3587, DOI 10.1001/jama.259.24.3587; Bradshaw A, 1994, LIGHTING LAMP; Campbell A., 2021, LOVE MAKERS; CRAWSHAW R, 1996, PHAROS           WIN; DOWLING S, 1995, BRIT MED J, V311, P309, DOI 10.1136/bmj.311.7000.309; DUBOS R, 1979, MIRAGE HLTH; DYSON R, 1990, CHANGING LABOUR UTIL; Frankl V. E., 1964, MANS SEARCH MEANING; FREIDSON E, 1975, PROFESSION MED; GRIFFITHS P, 1995, EVALUATING NURSING L; HALL J, 1996, ESSENTIAL PRACTICE P; HART PD, 1990, NATIONWIDE SURVEY AT; Henderson V., 1966, NATURE NURSING DEFIN; HENDERSON V, 1969, BASIC PRINCIPLES NUR; KESEY K, 1973, ONE FLEW OVER CUCKOO; KITSON A, 1985, ETHICAL ISSUES CARIN; LAWLER J, 1992, SCREENS NURSING SOMO; LYNAUGH J, 1992, CHARTING NURSINGS FU; Maslow A.H., 1954, MOTIVATION PERSONALI; MCKEOWN T, 1976, ROLE MED; NIGHTINGALE F, 1889, NOTES NURSING IT IS; *OFF TECHN ASS, 1986, STUD EFF NURS PRACT; Orem D., 1980, NURSING CONCEPTS PRA; Paterson J. G., 1976, HUMANISTIC NURSING R; Peplau H.E, 1952, INTERPERSONAL RELATI; RAFFERTY AM, 1993, NURSING ART SCI; RAFFERTY AM, 1995, POLITICAL LEADERSHIP; RICHARDSON G, 1995, FEWER DOCTORS MORE N; Roy C., 1976, INTRO NURSING ADAPTA; STOCKWELL F, 1972, UNPOPULAR PATIENT; Travelbee J., 1971, INTERPERSONAL ASPECT; TROTTERBETTS V, 1993, AM NURSE         JAN, P5; Vonnegut Kurt, 1968, WELCOME MONKEY HOUSE	38	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1647	1651		10.1136/bmj.313.7072.1647	http://dx.doi.org/10.1136/bmj.313.7072.1647			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991020	Green Published			2022-12-28	WOS:A1996VZ81100056
J	Tucker, KL; Mahnken, B; Wilson, PWF; Jacques, P; Selhub, J				Tucker, KL; Mahnken, B; Wilson, PWF; Jacques, P; Selhub, J			Folic acid fortification of the food supply - Potential benefits and risks for the elderly population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COBALAMIN DEFICIENCY; PERNICIOUS-ANEMIA; PLASMA HOMOCYSTEINE; FOLATE; HYPERHOMOCYSTEINEMIA; VITAMIN-B12; QUESTIONNAIRE; MACROCYTOSIS; PREVALENCE; DIAGNOSIS	Objective.-To estimate the potential benefits and risks of food folic acid fortification for an elderly population, Benefits are expected through the improvement of folate and homocysteine status, but there is also a risk of masking or precipitating clinical manifestations related to vitamin B-12 deficiency with increasing exposure to folic acid. Design.-Cross-sectional analysis, with projected change at various levels of folic acid fortification. Setting.-Participants in the Framingham Heart Study original cohort. Participants.-A total of 747 subjects aged 67 to 96 years who both completed usable food frequency questionnaires and had blood concentrations of B vitamins and homocysteine measured. Main Outcome Measures.-Projected blood folate and homocysteine concentrations and combined high folate intake and low plasma vitamin B-12 concentration. Results.-Percentages of this elderly population with folate intake below 400 mu g/d are projected to drop from 66% at baseline to 49% with 140 mu g of folate per 100 g of cereal-grain product, to 32% with 280 mu g, to 26% with 350 mu g, and to 11% with 700 mu g. Percentages with elevated homocysteine concentrations (>14 mu mol/L) are projected to drop from 26% at baseline to 21% with 140 mu g of folate per 100 g, to 17% with 280 mu g, to 16% with 350 mu g, and to 12% with 700 mu g. Without fortification, the prevalence of combined high folate intake (>1000 mu g/d) and low plasma vitamin B-12 concentration (<185 pmol/L [<250 pg/mL]) was 0.1%. This is projected to increase to 0.4% with folate fortification levels of 140 to 350 mu g/100 g and to 3.4% with 700 mu g. Conclusion.-The evidence suggests that, at the level of 140 mu g/100 g of cereal-grain product mandated by the Food and Drug Administration, the benefits of folate fortification, through projected decreases in homocysteine level and heart disease risk, greatly outweigh the expected risks, However, quantification of the actual risks associated with vitamin B-12 deficiency remains elusive. Before higher levels of folio acid fortification are implemented, further research is needed to better understand the clinical course of various forms of Vitamin B-12 deficiency, to measure the potential effect of high folate intake on this course, and to identify cost-effective approaches to the identification and treatment of all forms of vitamin B-12 deficiency.	NHLBI, FRAMINGHAM MASS HEART STUDY, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Tucker, KL (corresponding author), TUFTS UNIV, USDA, HUMAN NUTR RES CTR AGING, 711 WASHINGTON ST, BOSTON, MA 02111 USA.		Wilson, Peter W.F./J-2455-2016; Tucker, Katherine L/A-4545-2010	Tucker, Katherine/0000-0001-7640-662X	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN RH, 1990, AM J HEMATOL, V34, P90, DOI 10.1002/ajh.2830340204; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; BALDWIN JN, 1961, NEW ENGL J MED, V264, P1339, DOI 10.1056/NEJM196106292642604; BORCH K, 1984, SCAND J GASTROENTERO, V19, P154, DOI 10.1080/00365521.1984.12005702; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BRATTSTROM L, 1990, ATHEROSCLEROSIS, V81, P51, DOI 10.1016/0021-9150(90)90058-Q; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; CARMEL R, 1988, ARCH INTERN MED, V148, P1712, DOI 10.1001/archinte.148.8.1712; *CDCP, 1993, POSITION PAPER FOLIC; CHOSY JJ, 1962, AM J CLIN NUTR, V10, P349; CRANE NT, 1995, AM J PUBLIC HEALTH, V85, P660, DOI 10.2105/AJPH.85.5.660; DAWBER T. R., 1957, AMER JOUR PUBL HEALTH, V47, P4, DOI 10.2105/AJPH.47.4_Pt_2.4; DICKINSON CJ, 1995, QJM-INT J MED, V88, P357; ELLISON ABC, 1960, JAMA-J AM MED ASSOC, V173, P240, DOI 10.1001/jama.1960.03020210020006; FDA, 1993, FED REG         1014, V58, P53254; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANKEN DG, 1994, J INHERIT METAB DIS, V17, P159, DOI 10.1007/BF00735426; GLUECK CJ, 1995, AM J CARDIOL, V75, P132, DOI 10.1016/S0002-9149(00)80061-2; HEALTON EB, 1991, MEDICINE, V70, P229, DOI 10.1097/00005792-199107000-00001; HERBERT V, 1988, ARCH INTERN MED, V148, P1705, DOI 10.1001/archinte.148.8.1705; JACOBS DS, 1990, LAB TEST HDB; JACQUES PF, 1993, AM J CLIN NUTR, V57, P182, DOI 10.1093/ajcn/57.2.182; JOOSTEN E, 1993, AM J CLIN NUTR, V58, P468, DOI 10.1093/ajcn/58.4.468; LANDGREN F, 1995, J INTERN MED, V237, P381, DOI 10.1111/j.1365-2796.1995.tb01190.x; LEDERLE FA, 1991, JAMA-J AM MED ASSOC, V265, P94, DOI 10.1001/jama.265.1.94; LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; LINDENBAUM J, 1994, AM J CLIN NUTR, V60, P2, DOI 10.1093/ajcn/60.1.2; *MN NUTR DAT SYST, 1995, FOOD DAT VERS 9 NUTR; PEDERSEN AB, 1969, ACTA MED SCAND, V185, P449; ROMANO PS, 1995, AM J PUBLIC HEALTH, V85, P667, DOI 10.2105/AJPH.85.5.667; ROSS JF, 1948, BLOOD, V3, P68, DOI 10.1182/blood.V3.1.68.68; RUSSELL RM, 1992, AM J CLIN NUTR, V55, P1203; *SAS I INC, 1989, SAS STAT VERS 6 08; SAVAGE D, 1994, BRIT J HAEMATOL, V86, P844, DOI 10.1111/j.1365-2141.1994.tb04840.x; SAVAGE DG, 1995, BAILLIERE CLIN HAEM, V8, P657, DOI 10.1016/S0950-3536(05)80225-2; SCOTT JM, 1981, LANCET, V2, P337; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STABLER SP, 1990, BLOOD, V76, P871; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; TAMURA T, 1990, CLIN CHEM, V36, P1993; UBBINK JB, 1993, AM J CLIN NUTR, V57, P47, DOI 10.1093/ajcn/57.1.47; UBBINK JB, 1994, J NUTR, V124, P1927, DOI 10.1093/jn/124.10.1927; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; VANDENBERG M, 1994, J VASC SURG, V20, P933, DOI 10.1016/0741-5214(94)90230-5; WILLETT WC, 1987, J AM DIET ASSOC, V87, P43; 1996, FED REG         0305, V61, P8781	48	140	143	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1996	276	23					1879	1885		10.1001/jama.276.23.1879	http://dx.doi.org/10.1001/jama.276.23.1879			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX522	8968013				2022-12-28	WOS:A1996VX52200035
J	Nasmyth, K				Nasmyth, K			Viewpoint: Putting the cell cycle in order	SCIENCE			English	Editorial Material							SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; GENETIC-CONTROL; YEAST; DIVISION; MITOSIS; CHECKPOINTS; MATURATION; SPINDLE; EVENTS				Nasmyth, K (corresponding author), RES INST MOL PATHOL, DR BOHR GASSE 7, A-1030 VIENNA, AUSTRIA.			Nasmyth, Kim/0000-0001-7030-4403				DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HOWARD A, 1951, NATURE, V167, P599, DOI 10.1038/167599a0; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; JOHNSON RT, 1971, BIOL REV, V46, P97, DOI 10.1111/j.1469-185X.1971.tb01180.x; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; LOSICK R, 1993, SCIENCE, V262, P1227, DOI 10.1126/science.8235653; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MURRAY A, 1993, CELL CYCLE; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; NURSE P, 1980, GENETICS, V96, P627; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Stern Bodo, 1996, Trends in Genetics, V12, P345, DOI 10.1016/0168-9525(96)10036-6; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120	22	309	347	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 6	1996	274	5293					1643	1645		10.1126/science.274.5293.1643	http://dx.doi.org/10.1126/science.274.5293.1643			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8984634				2022-12-28	WOS:A1996VW71200043
J	AgueroRosenfeld, ME; Horowitz, HW; Wormser, GP; McKenna, DF; Nowakowski, J; Munoz, J; Dumler, JS				AgueroRosenfeld, ME; Horowitz, HW; Wormser, GP; McKenna, DF; Nowakowski, J; Munoz, J; Dumler, JS			Human granulocytic ehrlichiosis: A case series from a medical center in New York state	ANNALS OF INTERNAL MEDICINE			English	Article							UNITED-STATES	Background: Human granulocytic ehrlichiosis (HGE) is a newly described illness Objective: To describe the clinical and laboratory features of Design: Case series. Setting: Tertiary care facility in New York State. Patients: is adult patients with HGE. Measurements: Epidemiologic, clinical, and laboratory features; treatment; and outcome of patients with HGE. Results: Patients presented with such symptoms as fever (94%) and myalgia or arthralgia (78%). Thirteen patients (71%) recalled being bitten by a tick before onset of symptoms. Leukopenia or thrombocytopenia was seen in 82% of patients, and abnormal liver enzyme levels were seen in 81%. Results of polymerase chain reaction were positive in 9 of 12 patients (75%); morulae were seen in 3 of 12 patients (25%); and the agent that causes HGE was cultured from 2 patients. All but one patient (94%) developed antibodies to Ehrlichia equi. Five patients (28%) were briefly hospitalized, and none died. All patients were successfully treated with doxycycline. Conclusions: The illness associated with HGE in these patients from the northeastern United States was more mild than that originally described in reports of HGE in the midwestern United States.			AgueroRosenfeld, ME (corresponding author), WESTCHESTER CTY MED CTR, CLIN LABS, ROOM 1J-11A, VALHALLA, NY 10595 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043135, R01AR041508] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR41508, R01-AR43135] Funding Source: Medline; PHS HHS [U50/CCU210280] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bakken JS, 1996, JAMA-J AM MED ASSOC, V275, P199, DOI 10.1001/jama.275.3.199; BAKKEN JS, 1994, JAMA-J AM MED ASSOC, V272, P212, DOI 10.1001/jama.272.3.212; DUMLER JS, 1995, J CLIN MICROBIOL, V33, P1098, DOI 10.1128/JCM.33.5.1098-1103.1995; EDELMAN DC, 1996, MOL DIAGN, V1, P41; FISHBEIN DB, 1994, ANN INTERN MED, V120, P736, DOI 10.7326/0003-4819-120-9-199405010-00003; Goodman JL, 1996, NEW ENGL J MED, V334, P209, DOI 10.1056/NEJM199601253340401; HARDALO CJ, 1995, CLIN INFECT DIS, V21, P910, DOI 10.1093/clinids/21.4.910; Horowitz HW, 1996, NEUROLOGY, V46, P1026, DOI 10.1212/WNL.46.4.1026; Nadelman RB, 1996, AM J MED, V100, P502, DOI 10.1016/S0002-9343(95)99915-9; PETERSEN LR, 1989, J INFECT DIS, V159, P562, DOI 10.1093/infdis/159.3.562; TELFORD SR, 1995, ANN INTERN MED, V123, P277, DOI 10.7326/0003-4819-123-4-199508150-00006; Wormser GP, 1996, LANCET, V347, P981, DOI 10.1016/S0140-6736(96)91475-0; 1995, MMWR-MORBID MORTAL W, V44, P593	13	155	159	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1996	125	11					904	908		10.7326/0003-4819-125-11-199612010-00006	http://dx.doi.org/10.7326/0003-4819-125-11-199612010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV541	8967671				2022-12-28	WOS:A1996VV54100006
J	Start, RD; Brown, W; Bryant, RJ; Reed, MW; Cross, SS; Kent, G; Underwood, JCE				Start, RD; Brown, W; Bryant, RJ; Reed, MW; Cross, SS; Kent, G; Underwood, JCE			Ownership and uses of human tissue: Does the Nuffield bioethics report accord with opinion of surgical inpatients?	BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare opinion of surgical inpatients with the conclusions of the report of the Nuffield Council on Bioethics regarding the ownership and uses of human tissue. Design-Survey of results of questionnaires completed by patients. Setting-Large teaching hospital. Subjects-384 postoperative adult surgical patients. Results-There was strong support among patients for the use of tissues in medical education, research, and science with the exception of those tisssues which may transmit disease to others, Few patients (39; 10%) believed that they retained ownership of tissue removed at surgery, Most believed that the tissue belonged to the hospital (103; 27%), to nobody (103; 27%), or to the laboratory (77; 20%), Most patients had not been given any information about the possible uses of their tissues after removal. Conclusions-Surgical inpatients seem to endorse the conclusions of the Nuffield report regarding the ownership and uses of human tissue, The recommendations regarding patient information and consent procedures should be implemented at the earliest opportunity.	UNIV SHEFFIELD,SCH MED,DEPT PATHOL,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND; ROYAL HALLAMSHIRE HOSP,DEPT SURG,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND; UNIV SHEFFIELD,NO GEN HOSP,DEPT PSYCHIAT,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND	University of Sheffield; University of Sheffield; Northern General Hospital; University of Sheffield			Reed, Malcolm Walter/AAG-9219-2020; Bryant, Richard John/HGA-6778-2022	Reed, Malcolm Walter/0000-0001-7442-2132; Cross, Simon/0000-0003-2044-1754				Dickens B M, 1992, J Contemp Health Law Policy, V8, P73; *NHS MAN EX, 1990, GUID CONS EX TREATM; Nuffield Council on Bioethics, 1995, HUM TISS ETH LEG ISS	3	29	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1996	313	7069					1366	1368		10.1136/bmj.313.7069.1366	http://dx.doi.org/10.1136/bmj.313.7069.1366			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW685	8956702	Green Published			2022-12-28	WOS:A1996VW68500024
J	Castillo, J; Davalos, A; Noya, M				Castillo, J; Davalos, A; Noya, M			Progression of ischaemic stroke and excitotoxic aminoacids	LANCET			English	Article							FOCAL CEREBRAL-ISCHEMIA; GLUTAMATE; PROGNOSIS; RELEASE; INJURY	Background Mechanisms involved in progression of stroke are little understood. Studies in animals have shown an association between neuronal death mediated by excitatory aminoacids and deterioration in focal cerebral ischaemia. We looked for an association between concentrations of glutamate and glycine in plasma and cerebrospinal fluid (CSF) and early progression in a prospective study of 128 patients with acute ischaemic stroke. Methods Of 556 consecutive admissions to our emergency unit, 128 eligible patients with ischaemic stroke were included in our study. Blood and CSF samples were taken within the first 24 h from stroke onset when cerebral oedema had been excluded on a previous cranial computed tomography. Ischaemic stroke was judged to be in progression if the Canadian stroke scale score (1.5=maximum neurological deficit, 10=no deficit) fell by 1 or more points during the first 48 h after inclusion. Glutamate and glycine concentrations in plasma and CSF were measured by high-performance liquid chromatography. The effect of plasma and CSF glutamate concentrations on progression was analysed by logistic regression. Findings 43 (33.6%) patients had progressing ischaemic stroke. Concentrations of glutamate and glycine in plasma and CSF were higher in patients with progressing stroke than in those with stable cerebral infarcts (p<0.0001). There was a significant linear correlation between CSF and plasma concentrations of glutamate (r=0.79, p<0.001). The positive predictive value of a plasma glutamate concentration of more than 200 mu mol/L for progression of ischaemic stroke was 97% (95% CI 85-100). Glutamate concentrations of more than 200 mu mol/L in plasma and of more than 8.2 mu mol/L in CSF were independently and significantly associated with progression of neurological deficit (26.1 [6.9-98.6] and 40.9 [7.6-220], respectively). Interpretation Early neurological progression of acute ischaemic stroke is associated with high concentrations of glutamate in blood and CSF. Measurement of plasma glutamate may be useful for the early detection of those patients with acute stroke who will deteriorate during 48 h after onset.	HOSP DOCTOR JOSEP TRUETA, NEUROL SECT, GIRONA 17007, SPAIN; CLIN UNIV, HOSP GEN GALICIA, DEPT NEUROL, SANTIAGO DE COMPOSTELA, SPAIN	Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Complexo Hospitalario Universitario de Santiago de Compostela				Castillo, Jose/0000-0002-6685-3001				ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; ASPLUND K, 1992, CEREBROVASC DIS, V2, P317, DOI 10.1159/000109037; ASPLUND K, 1993, THROMBOLYTIC THERAPY, V2, P119; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BAKER CJ, 1995, NEUROSURGERY, V36, P994, DOI 10.1227/00006123-199505000-00016; BRITTON M, 1985, STROKE, V16, P629, DOI 10.1161/01.STR.16.4.629; BUTCHER SP, 1990, STROKE, V21, P1727, DOI 10.1161/01.STR.21.12.1727; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; CASTILLO J, 1994, CEREBROVASC DIS, V4, P66, DOI 10.1159/000108454; COTE R, 1986, STROKE, V17, P731, DOI 10.1161/01.STR.17.4.731; DAVALOS A, 1990, NEUROLOGY, V40, P1865, DOI 10.1212/WNL.40.12.1865; DAVALOS A, 1995, STROKE, V26, P2233, DOI 10.1161/01.STR.26.12.2233; DELZOPPO GJ, 1994, CEREBROVAS BRAIN MET, V6, P47; GAUTIER JC, 1985, STROKE, V16, P729, DOI 10.1161/01.STR.16.4.729; HOSSMANN KA, 1994, BRAIN PATHOL, V4, P23; HOSSMANN KA, 1994, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1994, P239; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; JORGENSEN HS, 1994, LANCET, V344, P156; KEMP JA, 1993, TRENDS PHARMACOL SCI, V14, P20, DOI 10.1016/0165-6147(93)90108-V; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MATSUMOTO K, 1993, J CEREBR BLOOD F MET, V13, P586, DOI 10.1038/jcbfm.1993.76; MYSEROS JS, 1995, NY ACAD SCI, V765, P262; OLLENSCHLAGER G, 1989, SCAND J CLIN LAB INV, V49, P773, DOI 10.3109/00365518909091556; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; ROBERT C, 1991, COMPUT BIOMED RES, V24, P514, DOI 10.1016/0010-4809(91)90037-W; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SAGE JI, 1984, STROKE, V15, P46, DOI 10.1161/01.STR.15.1.46; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; TAKAGI K, 1993, J CEREBR BLOOD F MET, V13, P575, DOI 10.1038/jcbfm.1993.75; TOMINAGA T, 1993, ALCOHOL ALCOHOLISM, V28, P103, DOI 10.1093/alcalc/28.Supplement_1A.103; TONI D, 1995, ARCH NEUROL-CHICAGO, V52, P670, DOI 10.1001/archneur.1995.00540310040014	32	279	291	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 11	1997	349	9045					79	83		10.1016/S0140-6736(96)04453-4	http://dx.doi.org/10.1016/S0140-6736(96)04453-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996418				2022-12-28	WOS:A1997WB80000009
J	Renn, J; Sauer, T; Stachel, J				Renn, J; Sauer, T; Stachel, J			The origin of gravitational lensing: A postscript to Einstein's 1936 Science paper	SCIENCE			English	Article								Gravitational lensing, now taken as an important astrophysical consequence of the general theory of relativity, was found even before this theory was formulated but was discarded as a speculative idea without any chance of empirical confirmation. Reconstruction of some of Einstein's research notes dating back to 1912 reveals that he explored the possibility of gravitational lensing 3 years before completing his general theory of relativity. On the basis of preliminary insights into this theory, Einstein had already derived the basic features of the tensing effect. When he finally published the very same results 24 years later, it was only in response to prodding by an amateur scientist.	BOSTON UNIV,DEPT PHYS,BOSTON,MA 02215	Boston University	Renn, J (corresponding author), MAX PLANCK INST HIST SCI,WILHELMSTR 44,D-10117 BERLIN,GERMANY.			Sauer, Tilman/0000-0002-0643-8236				BARNOTHY JM, 1989, GRAVITATIONAL LENSES, P23; Chwolson O., 1924, ASTR NACHRICHTEN, V221, P329, DOI [DOI 10.1002/(ISSN)1521-3994, 10.1002/asna.19242212003, DOI 10.1002/ASNA.19242212003]; EDDINGTON AS, 1920, TIME GRAVITATION, P133; Einstein A, 1911, ANN PHYS-BERLIN, V35, P898; Einstein A, 1936, Science, V84, P506, DOI 10.1126/science.84.2188.506; EINSTEIN A, 1936, COMMUNICATION   1218; KLEIN MJ, 1993, COLLECTED PAPERS A E, V3; POTTER RD, 1936, COMMUNICATION   0916; Schneider P., 1992, GRAVITATIONAL LENSES	9	44	45	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					184	186		10.1126/science.275.5297.184	http://dx.doi.org/10.1126/science.275.5297.184			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985006				2022-12-28	WOS:A1997WC02200029
J	Liu, S; Siegel, PZ; Brewer, RD; Mokdad, AH; Sleet, DA; Serdula, M				Liu, S; Siegel, PZ; Brewer, RD; Mokdad, AH; Sleet, DA; Serdula, M			Prevalence of alcohol-impaired driving - Results from a national self-reported survey of health behaviors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK FACTOR SURVEILLANCE	Objective.-To estimate how frequently adults in the United States drive while impaired by alcohol. Design.-Telephone survey. Setting-The 49 states (and the District of Columbia) that participated in the Behavioral Risk Factor Surveillance System (BRFSS) in 1993. Participants.-A total of 102 263 noninstitutionalized adults aged 18 years or older. Main Outcome Measures.-The percentage of respondents who reported alcohol-impaired driving; number of episodes of alcohol-impaired driving per 1 000 adult population; and total number of episodes of alcohol-impaired driving-each by age, sex, race, level of education, and state. Results.-Overall, 2.5% of adults reported an estimated 123 million episodes of alcohol-impaired driving in 1993, This corresponds to 655 episodes of alcohol-impaired driving for each 1000 adults (range among states per 1000 adults, 165-1550). Alcohol-impaired driving was most frequent among men aged 21 to 34 years (1739 episodes per 1 000 adults) and was nearly as frequent among men aged 18 to 20 years (1623 episodes per 1000 adults), despite legislation in all states that prohibited the sale of alcohol to persons younger than age 21 years in 1993. Conclusions.-Alcohol-impaired driving is common even among underage persons. Strict enforcement of laws that discourage alcohol-impaired driving is needed along with community and patient education to reduce the prevalence of alcohol-impaired driving and prevent injuries and deaths from alcohol-related motor vehicle crashes. Data From the BRFSS, an ongoing source of national and state-specific data on the number of episodes of alcohol-impaired driving, are potentially useful for monitoring trends and evaluating the effect of future efforts to reduce alcohol-impaired driving.	CTR DIS CONTROL & PREVENT,DIV UNINTENT INJURY PREVENT,NATL CTR INJURY PREVENT & CONTROL,ATLANTA,GA 30341; CTR DIS CONTROL,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,DIV NUTR & PHYS ACT,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,DIV ADULT & COMMUNITY HLTH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA			Liu, Simin/I-3689-2014; Liu, Simin/GSN-4159-2022	Liu, Simin/0000-0003-2098-3844; 				ANDA RF, 1986, JAMA-J AM MED ASSOC, V256, P3213, DOI 10.1001/jama.1986.03380230037007; Brewer R D, 1995, Arch Fam Med, V4, P499, DOI 10.1001/archfami.4.6.499; *BUR CENS, 1992, 1990 CENS POP HOUS S; CHERPITEL CJ, 1995, ANN EMERG MED, V26, P158, DOI 10.1016/S0196-0644(95)70146-X; *CTR DIS CONTR, 1992, US CHRON DIS DAT HDB; *CTR DIS CONTR PRE, 1993, MMWR MORB MORT WKLY, V43, P443; *CTR DIS CONTR PRE, 1993, MMWR MORB MORT WKLY, V42, P905; *CTR DIS CONTR PRE, 1995, MMWR MORB MORT WKLY, V44; *CTR DIS CONTR PRE, 1994, MMWR MORB MORT WKLY, V43, P759; *FED BUR INV, 1994, UN CRIM REP US 1993; FELL JC, 1989, HEALTH EDUC QUART, V16, P335, DOI 10.1177/109019818901600303; GENTILELLO LM, 1995, JAMA-J AM MED ASSOC, V274, P1043, DOI 10.1001/jama.274.13.1043; Gentry E M, 1985, Am J Prev Med, V1, P9; MAULL KI, 1984, JAMA-J AM MED ASSOC, V252, P1880, DOI 10.1001/jama.252.14.1880; *NAT CTR HLTH STAT, 1994, US DEPT HHS PUBL; *NAT HIGHW TRAFF S, 1995, TRAFF SAF FACTS 1994; *PUBL HLTH SERV, 1994, US DEPT HHS PUBL; REMINGTON PL, 1988, PUBLIC HEALTH REP, V103, P366; *RES TRIANGL I, 1989, SURV DAT AN SUDAAN V; Siegel P Z, 1991, MMWR CDC Surveill Summ, V40, P1; Siegel Paul Z, 1993, Morbidity and Mortality Weekly Report, V42, P23; SMITH PF, 1989, HEALTH EDUC QUART, V16, P345, DOI 10.1177/109019818901600304; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513	24	78	79	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 8	1997	277	2					122	125		10.1001/jama.277.2.122	http://dx.doi.org/10.1001/jama.277.2.122			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA650	8990336				2022-12-28	WOS:A1997WA65000031
J	Abulrahi, HA; Bohlega, EA; Fontaine, RE; AlSeghayer, SM; AlRuwais, AA				Abulrahi, HA; Bohlega, EA; Fontaine, RE; AlSeghayer, SM; AlRuwais, AA			Plasmodium falciparum malaria transmitted in hospital through heparin locks	LANCET			English	Article								Background After a community investigation had implicated hospital admission as a shared feature of a cluster of acute Plasmodium falciparum malaria (AFM) cases in Riyadh, Saudi Arabia, we began an in-hospital investigation to determine the method of transmission. Methods We investigated all AFM patients admitted to one paediatric hospital for any reason from December, 1991, to April, 1992. We classified AFM as locally acquired (LAFM) if during the month before AFM onset the patient had not visited a malarious area, and as hospital acquired (HAFM) if the LAFM patient had been admitted to hospital during that month. We compared exposures of HAFM cases with those of other patients sampled from the same wards. We observed nursing practices and investigated by anonymous questionnaire how nurses administered parenteral drugs. Findings Of 21 LAFM cases, 20 (95%) had a previous hospital admission (exposure admission) compared with 15 (25%) of 61 other patients (p<0.001; chi(2) test). During the exposure admission, all HAFM patients had occupied the same room as, or a room adjacent to, an AFM patient; 14 (23%) of 60 other patients occupied the same room or rooms adjacent to an AFM patient (p<0.001, chi(2)). 90% of HAFM patients received infusions through a heparin lock during the exposure admission, compared with 49% of 120 general patients (p<0.001, chi(2)). 10% of nurses admitted to using one syringe for more than one heparin lock and 50% filled syringes with enough heparin for three to ten heparin locks. Interpretation P falciparum was transmitted between patients when single syringes were used on heparin locks of sequential patients. This practice would easily transmit other blood-borne agents.	MINIST HLTH,SAUDI ARABIAN FIELD EPIDEMIOL TRAINING PROGRAM,RIYADH 11442,SAUDI ARABIA; MINIST HLTH,GEN DIRECTORATE INFECT & PARASIT DIS,MALARIA DEPT,RIYADH 11442,SAUDI ARABIA; CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,DIV INT HLTH,ATLANTA,GA	Ministry of Health - Saudi Arabia; Ministry of Health - Saudi Arabia; Centers for Disease Control & Prevention - USA								Dean A. G., 1990, EPI INFO VERSION 5 W; Fleiss JL, 1981, STAT METHODS RATES P; FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.1093/biomet/38.1-2.141; KEMPEN P M, 1989, Anesthesiology (Hagerstown), V71, pA948, DOI 10.1097/00000542-198909001-00948; LETTAU LA, 1991, INFECT CONT HOSP EP, V12, P111, DOI 10.1086/646297; NAVARRO P, 1987, Boletin de la Oficina Sanitaria Panamericana, V102, P476; ROSENBERG A D, 1989, Anesthesiology (Hagerstown), V71, pA949, DOI 10.1097/00000542-198909001-00949; 1990, MMWR-MORBID MORTAL W, V39, P426; 1990, MMWR-MORBID MORTAL W, V39, P433	9	51	53	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					23	25		10.1016/S0140-6736(96)03508-8	http://dx.doi.org/10.1016/S0140-6736(96)03508-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988119				2022-12-28	WOS:A1997WA72500013
J	daSilveira, CM; Salisbury, DM; deQuadros, CA				daSilveira, CM; Salisbury, DM; deQuadros, CA			Measles vaccination and Guillain-Barre syndrome	LANCET			English	Article								Background Guillain-Barre syndrome (GBS) has been associated with several infectious agents, and the possibility that the disorder may be caused by vaccination has been raised. We compared the numbers of cases of GBS observed immediately after mass measles vaccination campaigns with the numbers that would be expected from baseline rates, to assess whether there is a causal relation between measles vaccination and GBS. Methods We analysed data on 2296 cases of GBS reported to the Poliomyelitis Eradication Surveillance System of the Pan American Health Organization as cases of suspected poliomyelitis. These cases occurred among 73 million immunised children aged 9 months to 15 years in Argentina, Brazil, Chile, and Colombia, between January, 1990, and December, 1994. These children were targeted for mass measles vaccination compaigns (each lasting 1 month) in 1992 and 1993. The frequency of GBS cases observed during the Vaccination campaigns or the next 42 days (the latent period) was compared with that during the rest of the study period, with the assumption of a Poisson distribution. Findings The average annual incidence of GBS was 0.62 per 100 000 children aged 1-14 years. The number of cases that would be expected within any 72-day period would therefore be 92. The average observed number of cases during latent periods after measles vaccination was 97. The probability that 97 or more cases would occur during a period with an expected number of 92 was 0.31. Interpretation The average annual rates of GBS by age-group for the 5 years analysed were consistent with previous data; thus we are confident that the surveillance system is sufficiently sensitive. There was no statistically significant association between measles vaccination and GBS. If there is any causal relation, the number of GBS cases due to measles vaccination was so small that data from the vaccination of more than 70 million children were not sufficient to detect a rise in the number of observed GBS cases beyond the expected number.	DEPT HLTH,LONDON SE1 8UG,ENGLAND; PAN AMER HLTH ORG,WASHINGTON,DC	Pan American Health Organization								[Anonymous], 1978, Ann Neurol, V3, P565; ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707; Awong IE, 1996, ANN PHARMACOTHER, V30, P173, DOI 10.1177/106002809603000212; Cutts F, 1996, BRIT MED J, V312, P589; DEQUADROS CA, 1991, PEDIATR INFECT DIS J, V10, P222, DOI 10.1097/00006454-199103000-00011; deQuadros CA, 1996, JAMA-J AM MED ASSOC, V275, P224, DOI 10.1001/jama.275.3.224; Korinthenberg R, 1996, ARCH DIS CHILD, V74, P281, DOI 10.1136/adc.74.4.281; KOSKI CL, 1986, AM FAM PHYSICIAN, V34, P198; Lasky T, 1996, NEUROEPIDEMIOLOGY, V15, P57, DOI 10.1159/000109890; LILIENFELD AM, 1980, OBSERVATIONAL STUDIE, V2, P226; *MED CONTR AG, 1995, CURR PROB PHARMACOVI, V21, P9; *PAN AM HLTH ORG, 1988, 6 PAHO SPEC PROGR VA, P1; STRATTON KR, 1994, ADVERSE EVENTS ASS C, P34; STRATTON KR, 1994, ADVERSE EVENTS ASS C, P118	14	34	36	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					14	16						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988116				2022-12-28	WOS:A1997WA72500010
J	MorleyDavies, A; Cobbe, SM				MorleyDavies, A; Cobbe, SM			Cardiac pacing	LANCET			English	Article							SICK-SINUS SYNDROME; PERMANENT PACEMAKER IMPLANTATION; PROSPECTIVE RANDOMIZED TRIAL; SHORT ATRIOVENTRICULAR DELAY; DUAL-CHAMBER; EARLY COMPLICATIONS; HEART-FAILURE; AV BLOCK; SYNCOPE; ATRIAL				MorleyDavies, A (corresponding author), GLASGOW ROYAL INFIRM,DEPT CARDIOL,QUEEN ELIZABETH BLDG,GLASGOW G31 2ER,LANARK,SCOTLAND.							AGGARWAL RK, 1995, BRIT HEART J, V73, P571; Alagona P, 1996, CURR OPIN CARDIOL, V11, P9, DOI 10.1097/00001573-199601000-00003; ANDERSEN HR, 1994, LANCET, V344, P1523, DOI 10.1016/S0140-6736(94)90347-6; BAROLD SS, 1992, HEART DISEASE, P726; BERNSTEIN AD, 1987, PACE, V10, P794, DOI 10.1111/j.1540-8159.1987.tb06035.x; BOON NA, 1987, BRIT HEART J, V58, P34; Brecker SJD, 1996, EUR HEART J, V17, P819; CHARDACK WM, 1960, SURGERY, V48, P643; CHAUHAN A, 1994, PACE, V17, P2012, DOI 10.1111/j.1540-8159.1994.tb03791.x; CHOO MH, 1981, AM J CARDIOL, V48, P559, DOI 10.1016/0002-9149(81)90088-6; Connelly DT, 1996, PACE, V19, P261, DOI 10.1111/j.1540-8159.1996.tb03325.x; COWELL R, 1994, PACE, V17, P1980, DOI 10.1111/j.1540-8159.1994.tb03784.x; CUNNINGHAM AD, 1995, EUR J CLIN PACE ELEC, V5, P259; DEBELDER MA, 1992, BRIT MED J, V305, P861, DOI 10.1136/bmj.305.6858.861; FANANAPAZIR L, 1994, CIRCULATION, V90, P2731, DOI 10.1161/01.CIR.90.6.2731; FITZPATRICK A, 1992, BRIT MED J, V304, P365, DOI 10.1136/bmj.304.6823.365; FITZPATRICK A, 1989, LANCET, V1, P658, DOI 10.1016/S0140-6736(89)92155-7; FRIEDMAN RA, 1995, CIRCULATION, V92, P283, DOI 10.1161/01.CIR.92.3.283; FYKE FE, 1993, PACE, V16, P373, DOI 10.1111/j.1540-8159.1993.tb01596.x; GINKS W, 1979, BRIT HEART J, V41, P633; GOLD MR, 1995, J AM COLL CARDIOL, V26, P967, DOI 10.1016/0735-1097(95)00292-0; GOLDBERGER J, 1993, AM HEART J, V126, P488, DOI 10.1016/0002-8703(93)91083-Q; GRIFFITH MJ, 1994, BRIT HEART J, V71, P202; GRUBB BP, 1994, PACE, V17, P1434, DOI 10.1111/j.1540-8159.1994.tb02463.x; HELDMAN D, 1990, PACE, V13, P1742, DOI 10.1111/j.1540-8159.1990.tb06883.x; HELGUERA ME, 1994, PACE, V17, P56, DOI 10.1111/j.1540-8159.1994.tb01351.x; KAPPENBERGER LJ, 1994, AM HEART J, V127, P1022, DOI 10.1016/0002-8703(94)90081-7; KUBICA J, 1990, PACE, V13, P1737, DOI 10.1111/j.1540-8159.1990.tb06882.x; Kusumoto FM, 1996, NEW ENGL J MED, V334, P89, DOI 10.1056/NEJM199601113340206; LAU CP, 1992, PACE, V15, P1177, DOI 10.1111/j.1540-8159.1992.tb03121.x; Maron BJ, 1996, J AM COLL CARDIOL, V27, P431, DOI 10.1016/0735-1097(95)00463-7; MAZZETTI H, 1993, AM HEART J, V125, P831, DOI 10.1016/0002-8703(93)90178-C; MCCOMB JM, 1995, BRIT HEART J, V74, P9; MEYTES I, 1975, AM HEART J, V90, P426, DOI 10.1016/0002-8703(75)90421-4; MICHAELSSON M, 1995, CIRCULATION, V92, P442, DOI 10.1161/01.CIR.92.3.442; MOLINA JE, 1995, ANN THORAC SURG, V59, P686; MORLEY CA, 1984, INT J CARDIOL, V6, P287, DOI 10.1016/0167-5273(84)90188-8; MOUNSEY JP, 1994, BRIT HEART J, V72, P339; Nishimura RA, 1996, J AM COLL CARDIOL, V27, P421, DOI 10.1016/0735-1097(95)00445-9; OVSYSHCHER I, 1993, J AM COLL CARDIOL, V21, P761, DOI 10.1016/0735-1097(93)90110-M; PARSONNET V, 1989, J AM COLL CARDIOL, V13, P917, DOI 10.1016/0735-1097(89)90236-2; PETCH MC, 1993, BRIT MED J, V307, P215, DOI 10.1136/bmj.307.6898.215; PETERSEN M, 1994, BRIT HEART J, V71, P274; Rao V, 1995, CAN J CARDIOL, V11, P993; SCOTT CD, 1993, BRIT HEART J, V69, P399; SEINO Y, 1993, AM J CARDIOL, V72, P36, DOI 10.1016/0002-9149(93)90215-X; SHAW DB, 1980, BMJ-BRIT MED J, V280, P139, DOI 10.1136/bmj.280.6208.139; SRA JS, 1993, NEW ENGL J MED, V328, P1085, DOI 10.1056/NEJM199304153281504; SUTTON R, 1986, PACE, V9, P1110, DOI 10.1111/j.1540-8159.1986.tb06678.x; SUTTON R, 1990, PACE, V13, P1823, DOI 10.1111/j.1540-8159.1990.tb06897.x; THURGOOD JM, 1994, CIRCULATION, V90, P2342; TRAVILL CM, 1992, BRIT HEART J, V68, P163; *WORK PART BRIT PA, 1991, BRIT HEART J, V66, P185; 1991, J AM COLL CARDIOL, V18, P1; 1993, BRIT HEART J, V70, P592	55	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					41	46						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988130				2022-12-28	WOS:A1997WA72500045
J	Harjai, KJ; Licata, AA				Harjai, KJ; Licata, AA			Effects of amiodarone on thyroid function	ANNALS OF INTERNAL MEDICINE			English	Review							IODINE-INDUCED THYROTOXICOSIS; LOW-DOSE AMIODARONE; CONGESTIVE-HEART-FAILURE; INDUCED HYPOTHYROIDISM; POTASSIUM PERCHLORATE; ANTITHYROID ANTIBODIES; FOLLOW-UP; REVERSE TRIIODOTHYRONINE; VENTRICULAR ARRHYTHMIAS; ENHANCED SUSCEPTIBILITY	Purpose: To review the literature on the effects of amiodarone on thyroid physiology and management of amiodarone-induced thyroid disease. Data Sources: English-language articles identified through a MEDLINE search (for 1975 to 1995, using the terms amiodarone and thyroid) and selected cross-referenced articles. Study Selection: Articles on the effects of amiodarone on thyroid physiology and function tests and occurrence, recognition, and management of amiodarone-induced thyroid disease. Data Extraction: Data were manually extracted from selected studies and reports; emphasis was placed on information relevant to the practicing clinician. Data Synthesis: Amiodarone can have many effects on thyroid function test results, even in the absence of hyperthyroidism or hypothyroidism. It may cause an increase in serum levels of thyroxine, reverse triiodothyronine, and thyroid-stimulating hormone and a decrease in serum triiodothyronine levels. Thyrotoxicosis occurs in some patients and is related to several pathogenetic mechanisms. It often presents dramatically with obvious clinical manifestations and further changes in thyroid function test results. Medical options include therapy with thionamides, perchlorate, and prednisone. Radioactive iodine is of little use. Thyroidectomy is effective and is the only measure that consistently allows continued use of amiodarone. Unlike thyrotoxicosis, hypothyroidism is related to a persi stent Wolff-Chaikoff effect and often has a vague presentation. The goal of treatment of amiodarone-induced hypothyroidism is to bring serum thyroxine levels to the upper end of the normal range, as often seen in euthyroid patients who are receiving amiodarone. Conclusions: Thyroid dysfunction commonly occurs with amiodarone therapy. It may be difficult to recognize the dysfunction because of the many changes in thyroid function test results that occur in euthyroid patients who are receiving amiodarone. Effective strategies exist for the management of hyperthyroidism and hypothyroidism; these should be tailored to the needs of the individual patient.	CLEVELAND CLIN FDN, DEPT ENDOCRINOL, CLEVELAND, OH 44195 USA; ALTON OCHSNER MED FDN & OCHSNER CLIN, NEW ORLEANS, LA 70121 USA	Cleveland Clinic Foundation; Ochsner Health System								AANDERUD S, 1984, ENDOCRINOLOGY, V115, P1605, DOI 10.1210/endo-115-4-1605; ALBERT SG, 1987, J AM COLL CARDIOL, V9, P175, DOI 10.1016/S0735-1097(87)80098-0; ALINOVI A, 1985, J AM ACAD DERMATOL, V12, P563, DOI 10.1016/S0190-9622(85)70079-5; ALTHAUS B, 1988, SCHWEIZ MED WSCHR, V118, P1176; ALVES LE, 1985, ANN INTERN MED, V102, P412, DOI 10.7326/0003-4819-102-3-412_1; AMICO JA, 1984, ARCH INTERN MED, V144, P487, DOI 10.1001/archinte.144.3.487; ANASTASIOUNANA M, 1984, J ENDOCRINOL INVEST, V7, P405, DOI 10.1007/BF03351026; [Anonymous], 1987, LANCET, V2, P24; BAMBINI G, 1987, ARCH INTERN MED, V147, P1781, DOI 10.1001/archinte.147.10.1781; BARTALENA L, 1994, J CLIN ENDOCR METAB, V78, P423, DOI 10.1210/jc.78.2.423; BEKAERT J, 1979, COEUR MED INTERNE, V18, P241; BELFIORE A, 1984, J CLIN ENDOCR METAB, V59, P974, DOI 10.1210/jcem-59-5-974; BLOSSEY HC, 1988, WIEN MED WOCHENSCHR, V138, P444; BOROWSKI GD, 1985, AM J MED, V78, P443, DOI 10.1016/0002-9343(85)90336-5; BRAVERMAN LE, 1985, NUC COMPACT, V16, P380; BRAVERMAN LE, 1971, J CLIN ENDOCR METAB, V32, P515, DOI 10.1210/jcem-32-4-515; BRENNAN MD, 1987, SURGERY, V102, P1062; BROUSSOLLE C, 1989, J ENDOCRINOL INVEST, V12, P37; BURGER A, 1976, J CLIN INVEST, V58, P255, DOI 10.1172/JCI108466; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; CARNEY JA, 1975, AM J CLIN PATHOL, V64, P639; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; CHATTERJEE K, 1989, J AM COLL CARDIOL, V14, P1775, DOI 10.1016/0735-1097(89)90031-4; CHAZENBALK GD, 1984, ACTA PHYSIOL PHARM L, V34, P367; CHIOVATO L, 1994, ENDOCRINOLOGY, V134, P2277, DOI 10.1210/en.134.5.2277; CHOPRA IJ, 1979, ANN INTERN MED, V90, P905, DOI 10.7326/0003-4819-90-6-905; CLELAND JGF, 1987, BRIT HEART J, V57, P436; Collaborative Group for Amiodarone Evaluation, 1984, AM J CARDIOL, V53, P1564; DAMICO DJ, 1981, ARCH OPHTHALMOL-CHIC, V99, P257, DOI 10.1001/archopht.1981.03930010259007; DONAGHUE KC, 1985, MED J AUSTRALIA, V142, P594, DOI 10.5694/j.1326-5377.1985.tb113526.x; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; DUDOGNON P, 1979, REV NEUROL, V135, P527; FARWELL AP, 1990, JAMA-J AM MED ASSOC, V263, P1526, DOI 10.1001/jama.263.11.1526; FIGGE HL, 1990, J CLIN PHARMACOL, V30, P588, DOI 10.1002/j.1552-4604.1990.tb01861.x; FORESTI V, 1985, ANN INTERN MED, V103, P157, DOI 10.7326/0003-4819-103-1-157_2; FRADKIN JE, 1983, MEDICINE, V62, P1; FRANKLYN JA, 1985, CLIN ENDOCRINOL, V22, P257, DOI 10.1111/j.1365-2265.1985.tb03238.x; GORMAN CA, 1978, MAYO CLIN PROC, V53, P359; GOTZSCHE LBH, 1993, ACTA ENDOCRINOL-COP, V129, P337; Harjai KJ, 1996, PACE, V19, P1548, DOI 10.1111/j.1540-8159.1996.tb03179.x; HARRIS L, 1983, CIRCULATION, V67, P45, DOI 10.1161/01.CIR.67.1.45; HAWTHORNE GC, 1985, ARCH INTERN MED, V145, P1016, DOI 10.1001/archinte.145.6.1016; HEGER JJ, 1981, NEW ENGL J MED, V305, P539, DOI 10.1056/NEJM198109033051002; INGBAR SH, 1972, MAYO CLIN PROC, V47, P814; JAGGARAO NSV, 1982, POSTGRAD MED J, V58, P693, DOI 10.1136/pgmj.58.685.693; JOHNSON RS, 1961, BRIT MED J, V1, P1369, DOI 10.1136/bmj.1.5236.1369; JONCKHEER MH, 1978, CLIN ENDOCRINOL, V9, P27, DOI 10.1111/j.1365-2265.1978.tb03569.x; KANNAN R, 1984, ENDOCRINOLOGY, V115, P1710, DOI 10.1210/endo-115-5-1710; KEIDAR S, 1980, POSTGRAD MED J, V56, P356, DOI 10.1136/pgmj.56.655.356; LARSEN PR, 1982, NEW ENGL J MED, V306, P23; LEGER AF, 1983, J NUCL MED, V24, P582; LEGER AF, 1984, EUR J CLIN INVEST, V14, P449, DOI 10.1111/j.1365-2362.1984.tb01212.x; Leonard JL, 1986, THYROID HORMONE META, P189; MARCHLINSKI FE, 1982, ANN INTERN MED, V97, P839, DOI 10.7326/0003-4819-97-6-839; MARCUS FI, 1983, AM HEART J, V106, P924, DOI 10.1016/0002-8703(83)90017-0; MARCUS FI, 1981, AM HEART J, V101, P480, DOI 10.1016/0002-8703(81)90140-X; MARTINO E, 1986, CLIN ENDOCRINOL, V24, P627, DOI 10.1111/j.1365-2265.1986.tb01658.x; MARTINO E, 1986, J CLIN ENDOCR METAB, V63, P1233, DOI 10.1210/jcem-63-5-1233; MARTINO E, 1988, ACTA ENDOCRINOL-COP, V119, P167, DOI 10.1530/acta.0.1190167; MARTINO E, 1987, CLIN ENDOCRINOL, V26, P227, DOI 10.1111/j.1365-2265.1987.tb00781.x; MARTINO E, 1986, J ENDOCRINOL INVEST, V9, P201, DOI 10.1007/BF03348098; MARTINO E, 1987, HORM RES, V26, P158, DOI 10.1159/000180696; MARTINO E, 1984, ANN INTERN MED, V101, P28, DOI 10.7326/0003-4819-101-1-28; MARTINO E, 1994, ARCH INTERN MED, V154, P2722, DOI 10.1001/archinte.1994.00420230115013; MARTINO E, 1986, Italian Journal of Medicine, V2, P15; MATSUMURA LK, 1992, THYROID, V2, P279, DOI 10.1089/thy.1992.2.279; MCGREGOR AM, 1985, THYROID DISORDERS AS, P209; MEIER C, 1979, J NEUROL, V220, P231, DOI 10.1007/BF00314147; MEURISSE M, 1993, WORLD J SURG, V17, P622, DOI 10.1007/BF01659125; MONTEIRO E, 1986, BRIT MED J, V292, P227, DOI 10.1136/bmj.292.6515.227; MULLIGAN DC, 1993, SURGERY, V114, P1114; NADEMANEE K, 1989, PROG CARDIOVASC DIS, V31, P427, DOI 10.1016/0033-0620(89)90017-0; NADEMANEE K, 1982, CIRCULATION, V66, P200; NADEMANEE K, 1983, ANN INTERN MED, V98, P577, DOI 10.7326/0003-4819-98-5-577; NEWNHAM HH, 1988, AUST NZ J MED, V18, P37, DOI 10.1111/j.1445-5994.1988.tb02237.x; NICKLAS JM, 1991, AM HEART J, V122, P1016, DOI 10.1016/0002-8703(91)90466-U; PERRET G, 1992, J CARDIOVASC PHARM, V19, P473, DOI 10.1097/00005344-199204000-00001; PETER T, 1983, AM HEART J, V106, P943, DOI 10.1016/0002-8703(83)90020-0; PINCHERA A, 1986, FRONTIERS THYROIDOLO, P161; PLOMP TA, 1992, EUR J OBSTET GYN R B, V43, P201, DOI 10.1016/0028-2243(92)90174-W; POSNER J, 1984, ISRAEL J MED SCI, V20, P113; POUCELL S, 1984, GASTROENTEROLOGY, V86, P926; RABINOWE SL, 1986, AM J MED, V81, P53, DOI 10.1016/0002-9343(86)90181-6; RAEDER EA, 1985, AM HEART J, V109, P975, DOI 10.1016/0002-8703(85)90238-8; RAJATANAVIN R, 1984, AM J MED, V77, P378, DOI 10.1016/0002-9343(84)90726-5; RAKITA L, 1983, AM HEART J, V106, P906, DOI 10.1016/0002-8703(83)90015-7; RAO RH, 1986, J CLIN ENDOCR METAB, V62, P563, DOI 10.1210/jcem-62-3-563; REICHERT LJM, 1989, BRIT MED J, V298, P1547, DOI 10.1136/bmj.298.6687.1547; REIFFEL JA, 1994, CLIN CARDIOL, V17, P103, DOI 10.1002/clc.4960170303; RIGAS B, 1986, ANN INTERN MED, V104, P348, DOI 10.7326/0003-4819-104-3-348; ROSENBAUM MB, 1976, AM J CARDIOL, V38, P934, DOI 10.1016/0002-9149(76)90807-9; ROSENBAUM MB, 1983, AM HEART J, V106, P957, DOI 10.1016/0002-8703(83)90022-4; SAFRAN M, 1988, BRIT MED J, V297, P456, DOI 10.1136/bmj.297.6646.456; SALAMON E, 1989, CAN MED ASSOC J, V141, P1247; SANMARTI A, 1987, LANCET, V2, P865; SANMARTI A, 1984, AM HEART J, V108, P1262, DOI 10.1016/0002-8703(84)90751-8; SAVOIE JC, 1975, J CLIN ENDOCR METAB, V41, P685, DOI 10.1210/jcem-41-4-685; SELENKOW HA, 1965, ANN INTERN MED, V62, P714, DOI 10.7326/0003-4819-62-4-714; SHUKLA R, 1994, POSTGRAD MED J, V70, P492, DOI 10.1136/pgmj.70.825.492; SINGH BN, 1983, AM HEART J, V106, P788, DOI 10.1016/0002-8703(83)90002-9; SINGH BN, 1970, BRIT J PHARMACOL, V39, P657, DOI 10.1111/j.1476-5381.1970.tb09891.x; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201; SMYRK TC, 1987, AM J SURG PATHOL, V11, P197, DOI 10.1097/00000478-198703000-00004; SOGOL PB, 1983, ENDOCRINOLOGY, V113, P1464, DOI 10.1210/endo-113-4-1464; SOLOMON B, 1990, J CLIN ENDOCR METAB, V70, P1518, DOI 10.1210/jcem-70-6-1518; STAUBLI M, 1985, KLIN WOCHENSCHR, V63, P168, DOI 10.1007/BF01732171; TRIP MD, 1991, AM J MED, V91, P507, DOI 10.1016/0002-9343(91)90187-3; VANDAM EWCM, 1993, NETH J MED, V42, P21; WARTOFSKY L, 1982, ENDOCR REV, V3, P164, DOI 10.1210/edrv-3-2-164; WEISSEL M, 1987, J AM COLL CARDIOL, V10, P717, DOI 10.1016/S0735-1097(87)80218-8; WIDERHORN J, 1991, AM HEART J, V122, P1162, DOI 10.1016/0002-8703(91)90489-5; WIERSINGA WM, 1986, J CLIN ENDOCR METAB, V63, P485, DOI 10.1210/jcem-63-2-485; WIERSINGA WM, 1985, THYROID DISORDERS AS, P197; WIMPFHEIMER C, 1982, BRIT MED J, V284, P1835, DOI 10.1136/bmj.284.6332.1835-a; WOLFF J, 1948, J BIOL CHEM, V174, P555; WOLFF J, 1969, AM J MED, V47, P101, DOI 10.1016/0002-9343(69)90245-9; WOOLNER LB, 1957, J CLIN ENDOCR METAB, V17, P1202, DOI 10.1210/jcem-17-10-1202; YIN YL, 1992, J CARDIOVASC PHARM, V19, P541, DOI 10.1097/00005344-199204000-00010	118	214	234	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1997	126	1					63	73		10.7326/0003-4819-126-1-199701010-00009	http://dx.doi.org/10.7326/0003-4819-126-1-199701010-00009			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA165	8992925				2022-12-28	WOS:A1997WA16500009
J	King, AC; Oman, RF; Brassington, GS; Bliwise, DL; Haskell, WL				King, AC; Oman, RF; Brassington, GS; Bliwise, DL; Haskell, WL			Moderate-intensity exercise and self-rated quality of sleep in older adults - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICAL-ACTIVITY; INSOMNIA; MEN; HEALTH; INDEX; WOMEN	Objective.-To determine the effects of moderate-intensity exercise training on serf-rated (subjective) sleep quality among healthy, sedentary older adults reporting moderate sleep complaints, Design.-Randomized controlled trial of 16 weeks' duration, Setting.-General community, Participants.-Volunteer sample of 29 women and 14 men (of 67 eligible subjects) aged 50 to 76 years who were sedentary, free of cardiovascular disease, and reported moderate sleep complaints. No participant was withdrawn for adverse effects. Intervention.-Randomized to 16 weeks of community-based, moderate-intensity exercise training or to a wait-listed control condition, Exercise consisted primarily of four 30- to 40-minute endurance training sessions (low-impact aerobics; brisk walking) prescribed per week at 60% to 75% of heart rate reserve based on peak treadmill exercise heart rate. Main Outcome Measure.-Pittsburgh Sleep Quality index (PSQI). Results.-Compared with controls (C), subjects in the exercise training condition (E) showed significant improvement in the PSQI global steep score at 16 weeks (baseline and posttest values in mean [SD] for C=8.93 [3.1] and 8.8 [2.6]; baseline and posttest Values for E=8,7 [3.0] and 5.4 [2.8]; mean posttest difference between conditions=3.4; P<.001; 95% confidence interval, 1.9-5.4), as well as in the steep parameters of rated sleep quality, sleep-onset latency (baseline and posttest values for C=26.1 [20,0] and 23.8 [15.3]; for E=28.4 [20,2] and 14.6 [13.0]; net improvement=11.5 minutes), and sleep duration baseline and posttest scores for C=5.8 [1.1] and 6.0 [1,0]; for E=6.0 [1,1] and 6.8 [1.2]; net improvement=42 minutes) assessed via PSQI and sleep diaries (P=.05). Conclusions.-Older adults with moderate sleep complaints can improve self-rated sleep quality by initiating a regular moderate-intensity exercise program.	STANFORD UNIV,SCH MED,DIV CARDIOVASC MED,PALO ALTO,CA 94304; STANFORD UNIV,SCH MED,DEPT MED,STANFORD CTR RES DIS PREVENT,PALO ALTO,CA 94304; UNIV OKLAHOMA,COLL PUBL HLTH,DEPT HLTH PROMOT SCI,OKLAHOMA CITY,OK; EMORY UNIV,SCH MED,DEPT NEUROL,ATLANTA,GA 30322	Stanford University; Stanford University; University of Oklahoma System; University of Oklahoma Health Sciences Center; Emory University	King, AC (corresponding author), STANFORD UNIV,SCH MED,DEPT HLTH RES & POLICY,DIV EPIDEMIOL,730 WELCH RD,SUITE B,PALO ALTO,CA 94304, USA.		Winwood, Peter/A-6363-2008	King, Abby/0000-0002-7949-8811	NIA NIH HHS [AG-12358, AG-09991] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009991, R55AG012358, R01AG012358, R55AG009991] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALESSI CA, 1995, J AM GERIATR SOC, V43, P1098, DOI 10.1111/j.1532-5415.1995.tb07007.x; American College of Sports Medicine, 1986, GUID EX TEST PRESCR; [Anonymous], 1995, GUID EX TEST PRESCR; BANNERMAN C, 1988, POSTGRAD MED, V84, P265; BECK AT, 1974, PSYCHOL MEASUREMENTS, P151; BLIWISE DL, 1993, SLEEP, V16, P40, DOI 10.1093/sleep/16.1.40; BLUMENTHAL JA, 1991, JAMA-J AM MED ASSOC, V266, P2098, DOI 10.1001/jama.266.15.2098; BOOTZIN RR, 1981, BEHAV ASSESS, V3, P107; BUYSSE DJ, 1991, SLEEP, V14, P331; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; CARSKADON MA, 1976, AM J PSYCHIAT, V133, P1382; COATES TJ, 1982, J CONSULT CLIN PSYCH, V50, P345, DOI 10.1037/0022-006X.50.3.345; EFRON B, 1971, BIOMETRIKA, V58, P403, DOI 10.2307/2334377; GOSSARD D, 1986, AM J CARDIOL, V57, P446, DOI 10.1016/0002-9149(86)90770-8; HORNE JA, 1983, SLEEP, V6, P36, DOI 10.1093/sleep/6.1.36; KING AC, 1991, JAMA-J AM MED ASSOC, V266, P1535, DOI 10.1001/jama.266.11.1535; KING AC, 1993, HEALTH PSYCHOL, V12, P292, DOI 10.1037/0278-6133.12.4.292; KING AC, 1989, HEALTH PSYCHOL, V8, P305, DOI 10.1037/0278-6133.8.3.305; KRIPKE DF, 1979, ARCH GEN PSYCHIAT, V36, P103; Miles L. E., 1982, SLEEPING WAKING DISO, P383; MONK TH, 1991, J GERONTOL, V46, pM171, DOI 10.1093/geronj/46.5.M171; MORAN MG, 1988, AM J PSYCHIAT, V145, P1369; MORIN CM, 1988, J CONSULT CLIN PSYCH, V56, P748, DOI 10.1037/0022-006X.56.5.748; MUELLER JK, 1986, AM J CARDIOL, V57, P441, DOI 10.1016/0002-9149(86)90769-1; National Commission on Sleep Disorders Research, 1993, WAK AM NAT SLEEP AL, P1; O'Connor P J, 1995, Exerc Sport Sci Rev, V23, P105; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; PHILLIPS WT, 1995, J AGING PHYS ACTIV, V3, P261, DOI 10.1123/japa.3.3.261; PUDER R, 1983, BEHAV THER, V14, P424, DOI 10.1016/S0005-7894(83)80104-X; SPECTOR PC, 1985, SAS USERS GUIDE STAT, P433; STEVENSON JS, 1990, RES NURS HEALTH, V13, P209, DOI 10.1002/nur.4770130403; VITIELLO M, 1989, GERONTOLOGIST, V29, pA258; Vitiello M.V., 1994, SLEEP RES, V23, P149; Vitiello MV, 1994, SLEEP RES, V23, P148	34	420	424	2	95	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1997	277	1					32	37		10.1001/jama.277.1.32	http://dx.doi.org/10.1001/jama.277.1.32			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VZ767	8980207				2022-12-28	WOS:A1997VZ76700026
J	Tsien, JZ; Chen, DF; Gerber, D; Tom, C; Mercer, EH; Anderson, DJ; Mayford, M; Kandel, ER; Tonegawa, S				Tsien, JZ; Chen, DF; Gerber, D; Tom, C; Mercer, EH; Anderson, DJ; Mayford, M; Kandel, ER; Tonegawa, S			Subregion- and cell type-restricted gene knockout in mouse brain	CELL			English	Article							LONG-TERM POTENTIATION; II MUTANT MICE; RECEPTOR ANTAGONIST; KINASE; RECOMBINATION; NEURONS; SYSTEM; LTP	Using the phage P1-derived Cre/loxP recombination system, we have developed a method to create mice in which the deletion (knockout) of virtually any gene of interest is restricted to a subregion or a specific cell type in the brain such as the pyramidal cells of the hippocampal CA1 region. The Cre/loxP recombination-based gene deletion appears to require a certain level of Cre protein expression. The brain subregional restricted gene knockout should allow a more precise analysis of the impact of a gene mutation on animal behaviors.	CALTECH,DIV BIOL,HOWARD HUGHES MED INST,PASADENA,CA 91125; COLUMBIA UNIV,HOWARD HUGHES MED INST,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	California Institute of Technology; Howard Hughes Medical Institute; Columbia University; Howard Hughes Medical Institute	Tsien, JZ (corresponding author), MIT,CTR CANC RES,HOWARD HUGHES MED INST,CTR LEARNING & MEMORY,DEPT BIOL,CAMBRIDGE,MA 02139, USA.		Mercer, Eric H/AAX-6173-2021	Mercer, Eric H/0000-0002-6737-765X; Mayford, Mark/0000-0002-9001-5024	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925] Funding Source: NIH RePORTER; NINDS NIH HHS [NS32925] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGEVINE JAY B., 1965, EXP NEUROL SUPPL, V2, P1; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CAPECCHI MR, 1994, SCI AM, V270, P52, DOI 10.1038/scientificamerican0394-52; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DAVIS S, 1992, J NEUROSCI, V12, P21; ECCLES JC, 1953, PRINCIPLES NEUROPHYS; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GU M, 1994, SCIENCE, V265, P103; HEBB DO, 1949, ORG BEHAVIOR; HOGAN B, 1986, MANIPULATING MOUSE E; Joyner Alexandra L., 1994, Current Opinion in Neurobiology, V4, P37, DOI 10.1016/0959-4388(94)90029-9; KALDERON D, 1984, CELL, V39, P449; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; LASKO M, 1992, P NATL ACAD SCI USA, V89, P6232; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MAYFORD M, 1996, IN PRESS SCIENCE; MAYFORD M, 1996, IN PRESS P NATL ACAD; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; OBERDICK J, 1990, SCIENCE, V248, P223, DOI 10.1126/science.2109351; POKORNY J, 1981, BRAIN RES BULL, V7, P113, DOI 10.1016/0361-9230(81)90075-7; POKORNY J, 1981, BRAIN RES BULL, V7, P121, DOI 10.1016/0361-9230(81)90076-9; Sambrook J., 2002, MOL CLONING LAB MANU; Saucier D, 1996, BEHAV NEUROSCI, V110, P103, DOI 10.1037/0735-7044.110.1.103; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; STANFIELD BB, 1979, J COMP NEUROL, V185, P423, DOI 10.1002/cne.901850303; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; WEI JJ, 1991, I CHUAN HSUEH PAO, V18, P320; Zhang Y, 1996, NUCLEIC ACIDS RES, V24, P543, DOI 10.1093/nar/24.4.543	31	924	950	0	55	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 27	1996	87	7					1317	1326		10.1016/S0092-8674(00)81826-7	http://dx.doi.org/10.1016/S0092-8674(00)81826-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980237	hybrid			2022-12-28	WOS:A1996WA54100019
J	Adams, WL; Barry, KL; Fleming, MF				Adams, WL; Barry, KL; Fleming, MF			Screening for problem drinking in older primary care patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MIDDLE-AGED WOMEN; ALCOHOL-CONSUMPTION; CAGE QUESTIONNAIRE; BREAST-CANCER; ELDERLY PEOPLE; BLOOD-PRESSURE; UNITED-STATES; LONG-TERM; FOLLOW-UP; PREVALENCE	Objectives.-To describe potentially hazardous alcohol use among elderly patients in the primary care setting and to assess the widely used CAGE questionnaire (cut down, annoyed by criticism, guilty about drinking, eye-opener drinks) as a tool for detecting self-reported heavy and binge drinking among these patients. Design.-Cross-sectional study. Setting.-The offices of 88 primary care physicians at 21 sites in southeastern Wisconsin. Patients.-A total of 5065 consecutive consenting patients older than 60 years. Measures.-A previously validated self-administered questionnaire that included beverage-specific questions about the quantity and frequency of regular drinking in the last 3 months, the number of episodes of binge drinking (6 drinks per occasion), and the CAGE questionnaire. Results.-Fifteen percent of men and 12% of women regularly drank in excess of limits recommended by the National Institute of Alcohol Abuse and Alcoholism (>7 drinks per week for women and >14 drinks per week for men). Nine percent of men and 2% of women reported regularly consuming more than 21 drinks per week. When we administered the CAGE questionnaire, 9% of men and 3% of women screened positive for alcohol abuse within 3 months. The CAGE performed poorly in detecting heavy or binge drinkers; fewer than half were CAGE positive when the standard cutoff of 2 positive answers was used. Conclusions.-Alcohol consumption in excess of recommended limits is common among elderly outpatients. The CAGE questionnaire alone is insufficient to detect such drinking. Asking questions on the quantity and frequency of drinking in addition to administering the CAGE increases the number of problem drinkers detected.	MED COLL WISCONSIN,MILWAUKEE,WI 53226; UNIV WISCONSIN,MADISON,WI	Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Madison					NIAAA NIH HHS [R01 AA08512-02S1] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008512] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ADAMS WL, 1993, JAMA-J AM MED ASSOC, V270, P1222, DOI 10.1001/jama.270.10.1222; ADAMS WL, 1990, J AM GERIATR SOC, V38, P211, DOI 10.1111/j.1532-5415.1990.tb03493.x; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3; ANDA RF, 1988, JAMA-J AM MED ASSOC, V260, P2529, DOI 10.1001/jama.260.17.2529; BARNES GM, 1979, J AM GERIATR SOC, V27, P244, DOI 10.1111/j.1532-5415.1979.tb06125.x; BOHN MJ, 1995, J STUD ALCOHOL, V56, P423, DOI 10.15288/jsa.1995.56.423; BUCHSBAUM DG, 1991, ALCOHOL ALCOHOLISM, V26, P215, DOI 10.1093/oxfordjournals.alcalc.a045103; BUCHSBAUM DG, 1992, J AM GERIATR SOC, V40, P662, DOI 10.1111/j.1532-5415.1992.tb01956.x; BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; CRIQUI MH, 1981, HYPERTENSION, V3, P557, DOI 10.1161/01.HYP.3.5.557; DEITZ D, 1994, ALCOHOL HEALTH RES W, V18, P162; DUFOUR M, 1995, ANNU REV MED, V46, P123, DOI 10.1146/annurev.med.46.1.123; EKERDT DJ, 1989, J STUD ALCOHOL, V50, P347, DOI 10.15288/jsa.1989.50.347; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FELSON DT, 1988, AM J EPIDEMIOL, V128, P1102; FILLMORE KM, 1987, BRIT J ADDICT, V82, P77; FLEMING MF, 1991, ALCOHOL ALCOHOLISM, V26, P81; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GLYNN RJ, 1985, AM J PUBLIC HEALTH, V75, P1413, DOI 10.2105/AJPH.75.12.1413; GOODWIN JS, 1987, AM J PUBLIC HEALTH, V77, P173, DOI 10.2105/AJPH.77.2.173; HELZER JE, 1991, PSYCHIAT DISORDERS A, P81; HEMENWAY D, 1988, AM J PUBLIC HEALTH, V78, P1554, DOI 10.2105/AJPH.78.12.1554; HERNANDEZAVILA M, 1991, AM J CLIN NUTR, V54, P157, DOI 10.1093/ajcn/54.1.157; HOLBROOK TL, 1990, AM J EPIDEMIOL, V132, P902, DOI 10.1093/oxfordjournals.aje.a115733; ILIFFE S, 1991, AGE AGEING, V20, P120, DOI 10.1093/ageing/20.2.120; JONES TV, 1993, J GEN INTERN MED, V8, P674, DOI 10.1007/BF02598284; KAGAN A, 1981, CIRCULATION, V64, P27; KLATSKY AL, 1986, CIRCULATION, V73, P628, DOI 10.1161/01.CIR.73.4.628; KRISTENSON H, 1983, ALCOHOL CLIN EXP RES, V7, P203, DOI 10.1111/j.1530-0277.1983.tb05441.x; LONGNECKER MP, 1995, ALCOHOL, V12, P87, DOI 10.1016/0741-8329(94)00088-3; LONGNECKER MP, 1994, CANCER CAUSE CONTROL, V5, P73, DOI 10.1007/BF01830729; MACMAHON S, 1987, HYPERTENSION, V9, P111, DOI 10.1161/01.HYP.9.2.111; MAGRUDERHABIB K, 1986, HOSP COMMUNITY PSYCH, V37, P1251; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MYERS JK, 1984, ARCH GEN PSYCHIAT, V41, P959; *NAT RES COUNC, 1995, NUTR REQ LAB AN, P1; SCHATZKIN A, 1994, CANCER, V74, P1101, DOI 10.1002/1097-0142(19940801)74:3+<1101::AID-CNCR2820741519>3.0.CO;2-X; STEINWEG DL, 1993, AM J MED, V94, P520, DOI 10.1016/0002-9343(93)90088-7; STINSON FS, 1989, ALCOHOL HEALTH RES W, V13, P80; TEMPLE MT, 1989, BRIT J ADDICT, V84, P889; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P575; USDA and HHS, 1990, NUTR YOUR HLTH DIET; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; WERCH CE, 1989, INT J ADDICT, V24, P859, DOI 10.3109/10826088909047316; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902	45	161	162	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1996	276	24					1964	1967						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VY689	8971065				2022-12-28	WOS:A1996VY68900028
J	Farrell, L				Farrell, L			Seven deadly sins	BRITISH MEDICAL JOURNAL			English	Article														Wessely, Simon Charles/0000-0002-6743-9929				ANDERSON PB, 1993, ARCH SEX BEHAV, V22, P335, DOI 10.1007/BF01542122; Capps D., 1992, PASTORAL PSYCHOL, V40, P209; MARSHALL D, 1971, SEXUAL BEHAV MANGAIA; TOWNSEND JM, 1995, ARCH SEX BEHAV, V24, P173, DOI 10.1007/BF01541580; TOWNSEND JM, 1990, ARCH SEX BEHAV, V19, P149, DOI 10.1007/BF01542229	5	0	0	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1592	1592		10.1136/bmj.313.7072.1592	http://dx.doi.org/10.1136/bmj.313.7072.1592			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VZ811	8990995	Green Published			2022-12-28	WOS:A1996VZ81100018
J	Fuchs, CS				Fuchs, CS			Progress in rectal cancer	LANCET			English	Article							ADJUVANT THERAPY				Fuchs, CS (corresponding author), DANA FARBER CANC INST,DEPT MED ONCOL,BOSTON,MA 02115, USA.							ADAM IJ, 1994, LANCET, V344, P707, DOI 10.1016/S0140-6736(94)92206-3; DOUGLASS HO, 1990, NIH CONSENSUS STATE, P35; FUCHS CS, 1995, SEMIN ONCOL, V22, P472; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; *NIH CONS C, 1990, JAMA-J AM MED ASSOC, V264, P1444; OCONNELL M, 1994, NEW ENGL J MED, V331, P502, DOI 10.1056/NEJM199408253310803	6	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 14	1996	348	9042					1600	1600		10.1016/S0140-6736(05)65687-5	http://dx.doi.org/10.1016/S0140-6736(05)65687-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX876	8961983				2022-12-28	WOS:A1996VX87600002
J	Sutherland, D; Samakovlis, C; Krasnow, MA				Sutherland, D; Samakovlis, C; Krasnow, MA			Branchless encodes a Drosophila FGF homolog that controls tracheal cell migration and the pattern of branching	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; RECEPTOR HOMOLOG; MOUSE LUNG; BREATHLESS; MORPHOGENESIS; EXPRESSION; FIBROBLAST; TARGET	The molecular basis for patterning of complex organ structures like the lung and insect tracheal system is unknown. Here, we describe the Drosophila gene branchless (bnl) and demonstrate that it is a key determinant of the tracheal branching pattern. bnl is required for tracheal branching and is expressed dynamically in clusters of cells surrounding the developing tracheal system at each position where a new branch will form and grow out. Localized misexpression of bnl can direct branch formation and outgrowth to new positions. Generalized misexpression activates later programs of tracheal gene expression and branching, resulting in massive networks of branches. bnl encodes a homolog of mammalian fibroblast growth factors (FGFs) and appears to function as a ligand for the breathless receptor tyrosine kinase, an FGF receptor homolog expressed on developing tracheal cells. The results suggest that this FGF pathway specifies the tracheal branching pattern by guiding tracheal cell migration during primary branch formation and then activating later programs of finer branching at the ends of growing primary branches.			Sutherland, D (corresponding author), STANFORD UNIV,SCH MED,BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305, USA.							ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; AYRES MD, 1994, VIROLOGY, V202, P586, DOI 10.1006/viro.1994.1380; BRAND AH, 1993, DEVELOPMENT, V118, P401; DEVORE DL, 1995, CELL, V83, P611, DOI 10.1016/0092-8674(95)90101-9; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOSPODAROWICZ D, 1979, EXP EYE RES, V28, P501, DOI 10.1016/0014-4835(79)90038-1; Guillemin K, 1996, DEVELOPMENT, V122, P1353; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; KRATOCHWIL K, 1969, DEV BIOL, V20, P46, DOI 10.1016/0012-1606(69)90004-9; LEE T, IN PRESS GENES DEV; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Manning Gerards, 1993, P609; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MCFARLANE S, 1995, NEURON, V15, P1017, DOI 10.1016/0896-6273(95)90091-8; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MURPHY AM, 1995, DEVELOPMENT, V121, P2255; NOGAWA H, 1995, DEVELOPMENT, V121, P1015; ONEILL JW, 1994, BIOTECHNIQUES, V17, P874; PERRIMON N, 1991, DEV GENET, V12, P238, DOI 10.1002/dvg.1020120309; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; REICHMANFRIED M, 1995, MECH DEVELOP, V52, P265, DOI 10.1016/0925-4773(95)00407-R; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; Rudnick D, 1933, J EXP ZOOL, V66, P125, DOI 10.1002/jez.1400660106; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; Sambrook J., 2002, MOL CLONING LAB MANU; Simonet WS, 1995, P NATL ACAD SCI USA, V92, P12461, DOI 10.1073/pnas.92.26.12461; SPOONER BS, 1970, J EXP ZOOL, V175, P445, DOI 10.1002/jez.1401750404; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; TADERERA JV, 1967, DEV BIOL, V16, P489, DOI 10.1016/0012-1606(67)90061-9; TAUB M, 1990, P NATL ACAD SCI USA, V87, P4002, DOI 10.1073/pnas.87.10.4002; TERRANOVA VP, 1985, J CELL BIOL, V101, P2330, DOI 10.1083/jcb.101.6.2330; THOMAS KA, 1993, NEUROTROPHIC FACTORS, P285; Thompson D.W, 1917, GROWTH FORM; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	36	503	512	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1091	1101		10.1016/S0092-8674(00)81803-6	http://dx.doi.org/10.1016/S0092-8674(00)81803-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978613	Bronze			2022-12-28	WOS:A1996VY44700014
J	Barnouti, HN				Barnouti, HN			Letter from Iraq - Effect of sanctions on surgical practice	BRITISH MEDICAL JOURNAL			English	Article								The sanctions against Iraq have led health care to fall below minimally acceptable standards. Doctors must treat patients without adequate drugs, anaesthetics, or basic surgical supplies. The continuation of sanctions will lead to a further deterioration. No ethical, religious, or humane body should condone this.	AL MUSTANSYRIYA MED SCH,BAGHDAD,IRAQ										0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1996	313	7070					1474	1475		10.1136/bmj.313.7070.1474	http://dx.doi.org/10.1136/bmj.313.7070.1474			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX612	8973239	Green Published			2022-12-28	WOS:A1996VX61200039
J	Baum, HBA; Biller, BMK; Finkelstein, JS; Cannistraro, KB; Oppenheim, DS; Schoenfeld, AD; Michel, TH; Wittink, H; Klibanski, A				Baum, HBA; Biller, BMK; Finkelstein, JS; Cannistraro, KB; Oppenheim, DS; Schoenfeld, AD; Michel, TH; Wittink, H; Klibanski, A			Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency - A randomized, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						somatotropin; bone density; body composition; insulin-like growth factor I	X-RAY ABSORPTIOMETRY; CARDIOVASCULAR RISK-FACTORS; OSTEOBLAST-LIKE CELLS; MINERAL DENSITY; REPLACEMENT THERAPY; GH DEFICIENCY; FACTOR-I; METABOLISM; HEART; DISEASE	Background: Patients with adult-onset growth hormone deficiency have reduced bone density and increased fat mass. Growth hormone at high doses may decrease body fat in these patients, but the effects of growth hormone at more physiologic doses on bone density and body composition have not been convincingly shown. Objective: To determine whether long-term growth hormone therapy at a dose adjusted to maintain normal insulin-like growth factor 1 (IGF-1) levels has clinical effects in patients with adult-onset growth hormone deficiency. Design: Randomized, placebo-controlled study. Setting: Tertiary referral center. Patients: 32 men with adult-onset growth hormone deficiency. intervention: Growth hormone (initial daily dose. 10 mu g/kg of body weight) or placebo for 18 months. The growth hormone dose was reduced by 25% if IGF-1 levels were elevated. Measurements: Body composition and bone mineral density of the lumbar spine, femoral neck, and proximal radius were measured by dual energy x-ray absorptiometry at 6-month intervals. Markers of bone turnover were also measured during the first 12 months of the study. Results: Growth hormone therapy increased bone mineral density in the lumbar spine by a mean (+/- SD) of 5.1% +/- 4.1% and bone mineral density in the femoral neck by 2.4% +/- 3.5%. in the growth hormone group, significant increases were seen in the following markers of bone turnover: osteocalcin (4.4 +/- 3.6 mg/L to 7.2 +/- 4.6 mg/L) and urinary pyridinoline (39.0 +/- 19.8 nmol/mmol of creatinine to 55.7 +/- 25.5 nmol/mmol of creatinine) and deoxypyridinoline (8.4 +/- 7.1 nmol/mmol of creatinine to 14.9 +/- 9.4 nmol/mmol of creatinine). Percentage of body fat in the growth hormone group decreased (from 31.9% +/- 6.5% to 28.3% +/- 7.0%), and lean body mass increased (from 59.0 +/- 8.5 kg to 61.5 +/- 6.9 kg). These changes were significant compared with corresponding changes in the placebo group (P < 0.01 for all comparisons). Conclusions: Growth hormone administered to men with adult-onset growth hormone deficiency at a dose adjusted according to serum IGF-1 levels increases bone density and stimulates bone turnover, decreases body fat and increases lean mass, and is associated with a low incidence of side effects.	MASSACHUSETTS GEN HOSP, NEUROENDOCRINE UNIT, BOSTON, MA 02114 USA; MAINE MED CTR, PORTLAND, ME 04102 USA	Harvard University; Massachusetts General Hospital; Maine Medical Center			Finkelstein, Joel/M-6463-2019		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008783] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01066] Funding Source: Medline; NIDDK NIH HHS [DK08783] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMATO G, 1993, J CLIN ENDOCR METAB, V77, P1671, DOI 10.1210/jc.77.6.1671; BARNARD R, 1991, ENDOCRINOLOGY, V128, P1459, DOI 10.1210/endo-128-3-1459; Baum HBA, 1996, J CLIN ENDOCR METAB, V81, P84, DOI 10.1210/jc.81.1.84; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; BINGYOU RG, 1993, CALCIFIED TISSUE INT, V52, P183, DOI 10.1007/BF00298715; BINNERTS A, 1992, CLIN ENDOCRINOL, V37, P79, DOI 10.1111/j.1365-2265.1992.tb02287.x; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695, DOI 10.1152/jappl.1991.70.2.695; DEBOER H, 1992, J CLIN ENDOCR METAB, V75, P833, DOI 10.1210/jc.75.3.833; DEGERBLAD M, 1992, ACTA ENDOCRINOL-COP, V126, P387, DOI 10.1530/acta.0.1260387; ERNST M, 1988, BIOCHEM BIOPH RES CO, V151, P142, DOI 10.1016/0006-291X(88)90570-0; FINKELSTEIN JS, 1994, J CLIN ENDOCR METAB, V78, P724, DOI 10.1210/jc.78.3.724; GERTNER JM, 1979, J CLIN ENDOCR METAB, V49, P185, DOI 10.1210/jcem-49-2-185; HADDAWAY MJ, 1992, BRIT J RADIOL, V65, P213, DOI 10.1259/0007-1285-65-771-213; HAYWARD RP, 1987, Q J MED, V62, P41; HOFFMAN DM, 1995, J CLIN ENDOCR METAB, V80, P72, DOI 10.1210/jc.80.1.72; HOLMES SJ, 1994, J CLIN ENDOCR METAB, V78, P669, DOI 10.1210/jc.78.3.669; INZUCCHI SE, 1994, J CLIN ENDOCR METAB, V79, P691, DOI 10.1210/jc.79.3.691; LARCOS G, 1991, J NUCL MED, V32, P2101; LIE JT, 1980, AM HEART J, V100, P41, DOI 10.1016/0002-8703(80)90277-X; NASS R, 1995, J CLIN ENDOCR METAB, V80, P552, DOI 10.1210/jc.80.2.552; OHALLORAN DJ, 1993, J CLIN ENDOCR METAB, V76, P1344, DOI 10.1210/jc.76.5.1344; ROSEN T, 1993, CLIN ENDOCRINOL, V38, P63, DOI 10.1111/j.1365-2265.1993.tb00974.x; ROSEN T, 1993, ACTA ENDOCRINOL-COP, V129, P195, DOI 10.1530/acta.0.1290195; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; ROSEN T, 1994, ENDOCRINOL METAB, V1, P55; ROUBENOFF R, 1991, NUTR REV, V49, P163, DOI 10.1111/j.1753-4887.1991.tb03013.x; SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; VANDEWEGHE M, 1993, CLIN ENDOCRINOL, V39, P409, DOI 10.1111/j.1365-2265.1993.tb02387.x; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; WEAVER JU, 1995, J CLIN ENDOCR METAB, V80, P153, DOI 10.1210/jc.80.1.153; WHITEHEAD HM, 1992, CLIN ENDOCRINOL, V36, P45, DOI 10.1111/j.1365-2265.1992.tb02901.x	34	217	221	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1996	125	11					883	+		10.7326/0003-4819-125-11-199612010-00003	http://dx.doi.org/10.7326/0003-4819-125-11-199612010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV541	8967668				2022-12-28	WOS:A1996VV54100003
J	Urgert, R; Meyboom, S; Kuilman, M; Rexwinkel, H; Vissers, MN; Klerk, M; Katan, MB				Urgert, R; Meyboom, S; Kuilman, M; Rexwinkel, H; Vissers, MN; Klerk, M; Katan, MB			Comparison of effect of cafetiere and filtered coffee on serum concentrations of liver aminotransferases and lipids: Six month randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; GAMMA-GLUTAMYL-TRANSFERASE; CORONARY HEART-DISEASE; BOILED COFFEE; RAISING FACTOR; PAPER FILTER; FATTY-ACIDS; TROMSO; CONSUMPTION; POPULATION	Objective-To study the effects of prolonged intake of cafetiere coffee, which is rich in the diterpenes cafestol and kahweol, on serum aminotransferase and Lipid concentrations, Design-Randomised parallel controlled trial, Subjects-46 healthy men and women aged 19 to 69. Intervention-Consumption of five to six strong cups (0.9 litres) a day of either cafetiere (22 subjects) or filtered coffee (24 subjects) for 24 weeks. Main outcome measures-Mean changes in serum aminotransferase and lipid concentrations, Results-Cafetiere coffee raised alanine aminotransferase concentration by up to 80% above baseline values relative to filtered coffee, After 24 weeks the rise was still 45% (9 U/l (95% confidence interval 3 to 15 U/l), P = 0.007). Alanine aminotransferase concentration exceeded the upper limit of normal in eight of the 22 subjects drinking cafetiere coffee, being twice the upper limit of normal in three of them. Cafetiere coffee raised low density lipoprotein cholesterol concentrations by 9-14%. After 24 weeks the rise was 0.26 mmol/l (0.04 to 0.47 mmol/l) (P = 0.03) relative to filtered coffee. Triglyceride concentrations initially rose by 26% with cafetiere coffee but returned close to baseline values within six months, All increases were reversible after the intervention was stopped, Conclusions-Daily consumption of five to six cups of strong cafetiere coffee affects the integrity of liver cells as suggested by small increases in serum alanine aminotransferase concentration, The effect does not subside with prolonged intake, High intakes of coffee brews rich in cafestol and kahweol may thus be responsible for unexplained increases in this enzyme activity in apparently healthy subjects, Cafetiere coffee also raises low density lipoprotein cholesterol concentration and thus the risk of coronary heart disease.	AGR UNIV WAGENINGEN,DEPT HUMAN NUTR,NL-6703 HD WAGENINGEN,NETHERLANDS	Wageningen University & Research								AHOLA I, 1991, J INTERN MED, V230, P293, DOI 10.1111/j.1365-2796.1991.tb00447.x; ARO A, 1987, METABOLISM, V36, P1027, DOI 10.1016/0026-0495(87)90021-7; ARO A, 1990, ATHEROSCLEROSIS, V83, P257, DOI 10.1016/0021-9150(90)90171-E; BAK AAA, 1989, NEW ENGL J MED, V321, P1432, DOI 10.1056/NEJM198911233212103; BERGMEYER HU, 1978, CLIN CHEM, V24, P58; BONAA K, 1988, BRIT MED J, V297, P1103, DOI 10.1136/bmj.297.6656.1103; BOWERS GN, 1966, CLIN CHEM, V12, P70; CRIQUI MH, 1993, NEW ENGL J MED, V328, P1220, DOI 10.1056/NEJM199304293281702; FEUNEKES GIJ, 1993, AM J CLIN NUTR, V58, P489, DOI 10.1093/ajcn/58.4.489; FOSSATI P, 1982, CLIN CHEM, V28, P2077; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; HECKERS H, 1994, J INTERN MED, V235, P192, DOI 10.1111/j.1365-2796.1994.tb01058.x; La Vecchia Carlo, 1994, Annals of Epidemiology, V4, P480; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LINDAHL B, 1991, J INTERN MED, V230, P299, DOI 10.1111/j.1365-2796.1991.tb00448.x; *LIP RES CLIN PROG, 1984, JAMA-J AM MED ASSOC, V251, P365; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; NILSSEN O, 1990, AM J EPIDEMIOL, V132, P318, DOI 10.1093/oxfordjournals.aje.a115661; NILSSEN O, 1994, AM J EPIDEMIOL, V139, P787, DOI 10.1093/oxfordjournals.aje.a117075; PETERS A, 1991, QUAT C SCI INT CAF S, P97; PIETINEN P, 1990, INT J EPIDEMIOL, V19, P586, DOI 10.1093/ije/19.3.586; SIEDEL J, 1983, CLIN CHEM, V29, P1075; STENSVOLD I, 1989, J CLIN EPIDEMIOL, V42, P877, DOI 10.1016/0895-4356(89)90101-7; SZASZ G, 1969, CLIN CHEM, V15, P124; THELLE DS, 1983, NEW ENGL J MED, V308, P1454, DOI 10.1056/NEJM198306163082405; TVERDAL A, 1990, BRIT MED J, V300, P566, DOI 10.1136/bmj.300.6724.566; URGERT R, 1995, J AGR FOOD CHEM, V43, P2167, DOI 10.1021/jf00056a039; URGERT R, 1995, AM J CLIN NUTR, V61, P149, DOI 10.1093/ajcn/61.1.149; URGERT R, 1995, CIRCULATION, V92, P56; VANDUSSELDORP M, 1991, ARTERIOSCLER THROMB, V11, P586, DOI 10.1161/01.ATV.11.3.586; VANROOIJ J, 1995, AM J CLIN NUTR, V61, P1277, DOI 10.1093/ajcn/61.6.1277; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WEUSTENVANDERWOUW MPME, 1994, J LIPID RES, V35, P721; ZOCK PL, 1995, AM J CLIN NUTR, V61, P617, DOI 10.1093/ajcn/61.3.617	34	62	65	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1996	313	7069					1362	1366		10.1136/bmj.313.7069.1362	http://dx.doi.org/10.1136/bmj.313.7069.1362			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW685	8956701	Green Published			2022-12-28	WOS:A1996VW68500023
J	LopezIlasaca, M; Crespo, P; Pellici, PG; Gutkind, JS; Wetzker, R				LopezIlasaca, M; Crespo, P; Pellici, PG; Gutkind, JS; Wetzker, R			Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase gamma	SCIENCE			English	Article							DEPENDENT ACTIVATION; KINASE; COMPLEXES	The tyrosine kinase class of receptors induces mitogen-activated protein kinase (MAPK) activation through the sequential interaction of the signaling proteins Grb2, Sos, Ras, Raf, and MEK. Receptors coupled to heterotrimeric guanine triphosphate-binding protein (G protein) stimulate MAPK through G(beta gamma) subunits, but the subsequent intervening molecules are still poorly defined. Overexpression of phosphoinositide 3-kinase gamma (PI3K gamma) in COS-7 cells activated MAPK in a G(beta gamma)-dependent fashion, and expression of a catalytically inactive mutant of PI3K gamma abolished the stimulation of MAPK by G(beta gamma) or in response to stimulation of muscarinic (m2) G protein-coupled receptors. Signaling from PI3K gamma to MAPK appears to require a tyrosine kinase, Shc, Grb2, Sos, Ras, and Raf. These findings indicate that PI3K gamma mediates G(beta gamma)-dependent regulation of the MAPK signaling pathway.	NIDR,MOL SIGNALING UNIT,ORAL & PHARYNGEAL CANC BRANCH,NATL INST HLTH,BETHESDA,MD 20892; UNIV JENA,FAC MED,MAX PLANCK UNIT MOL CELL BIOL,D-07747 JENA,GERMANY; UNIV PERUGIA,MONTELUCE POLICLIN,MOL BIOL LAB,IST MED INTERNA & SCI ONCOL,I-20141 MILAN,ITALY	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Friedrich Schiller University of Jena; Max Planck Society; University of Perugia			Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Wetzker, Reinhard/AAD-8713-2019; Crespo, Piero/M-3273-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Crespo, Piero/0000-0003-2825-7783				Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; FERBY I, 1996, J BIOL CHEM, V271, P2799; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001; LOPEZILASACA M, UNPUB; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SALCINI AE, 1994, ONCOGENE, V9, P2827; SCHLEFFER B, 1996, J BIOL CHEM, V271, P10329; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Zhang SY, 1996, J BIOL CHEM, V271, P20208, DOI 10.1074/jbc.271.33.20208	22	616	626	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					394	397		10.1126/science.275.5298.394	http://dx.doi.org/10.1126/science.275.5298.394			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994038				2022-12-28	WOS:A1997WC87300049
J	Lemon, SM; Thomas, DL				Lemon, SM; Thomas, DL			Drug therapy - Vaccines to prevent viral hepatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							B SURFACE-ANTIGEN; C VIRUS-INFECTION; CONTROLLED CLINICAL-TRIAL; INDUCED ESCAPE MUTANT; LONG-TERM EFFICACY; A VIRUS; UNITED-STATES; NEUTRALIZING ANTIBODY; INACTIVATED VACCINE; ACTIVE IMMUNIZATION		JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV INFECT DIS, BALTIMORE, MD 21205 USA	Johns Hopkins University	Lemon, SM (corresponding author), UNIV N CAROLINA, DEPT MED, CB 7030, 547 BURNETT WOMACK, CHAPEL HILL, NC 27599 USA.				NIAID NIH HHS [U19-AI40035, R01-AI32599] Funding Source: Medline; NIDA NIH HHS [DA00232] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032599, U19AI040035] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; AMBROSCH F, 1994, J MED VIROL, V44, P452, DOI 10.1002/jmv.1890440426; ANDRE FE, 1990, PROG MED VIROL, V37, P72; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; ARMSTRONG ME, 1993, J HEPATOL, V18, pS20, DOI 10.1016/S0168-8278(05)80373-3; ASHER LVS, 1995, J MED VIROL, V47, P260, DOI 10.1002/jmv.1890470312; BEASLEY RP, 1977, AM J EPIDEMIOL, V105, P94, DOI 10.1093/oxfordjournals.aje.a112370; BEASLEY RP, 1981, LANCET, V2, P1129; BINN LN, 1984, J CLIN MICROBIOL, V20, P28, DOI 10.1128/JCM.20.1.28-33.1984; BINN LN, 1992, VACCINE, V10, pS102, DOI 10.1016/0264-410X(92)90558-2; BODSWORTH NJ, 1991, J INFECT DIS, V163, P1138, DOI 10.1093/infdis/163.5.1138; BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262; BURANS JP, 1994, CLIN INFECT DIS, V18, P100, DOI 10.1093/clinids/18.1.100; CARMAN WF, 1990, LANCET, V336, P325, DOI 10.1016/0140-6736(90)91874-A; Centres for Disease Control and Prevention, 1995, 56 CTR DIS CONTR PRE; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.iy.13.040195.000333; CHOO QL, 1994, P NATL ACAD SCI USA, V91, P1294, DOI 10.1073/pnas.91.4.1294; CLEMENS R, 1995, J INFECT DIS, V171, pS44, DOI 10.1093/infdis/171.Supplement_1.S44; CLEMENTS ML, 1994, J INFECT DIS, V170, P510, DOI 10.1093/infdis/170.3.510; COLLIER AC, 1988, ANN INTERN MED, V109, P101, DOI 10.7326/0003-4819-109-2-101; DAVIS HL, 1993, HUM MOL GENET, V2, P1847, DOI 10.1093/hmg/2.11.1847; DAVIS LG, 1989, LANCET, V1, P889; DECOCK KM, 1986, ANN INTERN MED, V105, P108, DOI 10.7326/0003-4819-105-1-108; DELEM AD, 1992, BIOLOGICALS, V20, P289, DOI 10.1016/S1045-1056(05)80049-1; DIENSTAG JL, 1982, ANN INTERN MED, V96, P575, DOI 10.7326/0003-4819-96-5-575; ELLERBECK EF, 1992, VACCINE, V10, P668, DOI 10.1016/0264-410X(92)90087-Z; FARCI P, 1994, P NATL ACAD SCI USA, V91, P7792, DOI 10.1073/pnas.91.16.7792; FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801; FORTUIN M, 1994, J INFECT DIS, V169, P1374, DOI 10.1093/infdis/169.6.1374; FRANCIS DP, 1982, ANN INTERN MED, V97, P362, DOI 10.7326/0003-4819-97-3-362; GARIN D, 1995, VACCINE, V13, P220, DOI 10.1016/0264-410X(95)93140-5; GOLDFARB J, 1994, PEDIATR INFECT DIS J, V13, P18, DOI 10.1097/00006454-199401000-00005; GREEN MS, 1993, J INFECT DIS, V168, P740, DOI 10.1093/infdis/168.3.740; Hadler S C, 1992, Curr Clin Top Infect Dis, V12, P282; HADLER SC, 1989, VACCINE, V7, P106, DOI 10.1016/0264-410X(89)90046-7; HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401; HADLER SC, 1986, REV INFECT DIS, V8, P548; HADLER SC, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P14; HOKE CH, 1995, J INFECT DIS, V171, pS53; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; HURWITZ ES, 1992, 32 INT C ANT AG CHEM; IINO S, 1992, VACCINE, V10, P323, DOI 10.1016/0264-410X(92)90371-P; INNIS BL, 1994, JAMA-J AM MED ASSOC, V271, P1328, DOI 10.1001/jama.271.17.1328; JILG W, 1989, J INFECT DIS, V160, P766, DOI 10.1093/infdis/160.5.766; KANE M, 1995, VACCINE, V13, pS47; KARAYIANNIS P, 1993, J MED VIROL, V41, P210, DOI 10.1002/jmv.1890410308; KOZIEL MJ, 1993, J IMMUNOL, V150, P2563; KOZIEL MJ, 1992, J IMMUNOL, V149, P3339; KRAWCZYNSKI K, 1993, HEPATOLOGY, V17, P932, DOI 10.1002/hep.1840170525; LAU JYN, 1993, LANCET, V342, P1335; LEMON SM, 1994, JAMA-J AM MED ASSOC, V271, P1363, DOI 10.1001/jama.271.17.1363; LEMON SM, 1992, REV MED VIROL, V2, P73, DOI 10.1002/rmv.1980020204; LEMON SM, 1993, SEMIN VIROL, V4, P285, DOI 10.1006/smvy.1993.1025; LEMON SM, 1985, NEW ENGL J MED, V313, P1059, DOI 10.1056/NEJM198510243131706; LEMON SM, 1992, VACCINE, V10, pS40, DOI 10.1016/0264-410X(92)90540-Z; LEMON SM, 1983, J INFECT DIS, V148, P1033, DOI 10.1093/infdis/148.6.1033; LEMON SM, 1994, INFECT AGENT DIS, V3, P38; LEWIS JA, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P94; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; LOUTAN L, 1994, LANCET, V343, P322, DOI 10.1016/S0140-6736(94)91162-2; MAO JS, 1989, J INFECT DIS, V159, P621, DOI 10.1093/infdis/159.4.621; MARION SA, 1994, AM J EPIDEMIOL, V140, P734, DOI 10.1093/oxfordjournals.aje.a117321; MCALEER WJ, 1984, NATURE, V307, P178, DOI 10.1038/307178a0; MCMAHON BJ, 1985, J INFECT DIS, V151, P599, DOI 10.1093/infdis/151.4.599; *MED EC, 1996, 1996 DRUG TOP RED BO; MIDTHUN K, 1991, J INFECT DIS, V163, P735, DOI 10.1093/infdis/163.4.735; MOULIAPELAT JP, 1994, VACCINE, V12, P499, DOI 10.1016/0264-410X(94)90306-9; MURPHY BL, 1974, INTERVIROLOGY, V3, P378, DOI 10.1159/000149775; NEWCOMER W, 1994, PEDIATR INFECT DIS J, V13, P640, DOI 10.1097/00006454-199407000-00011; OGRA PL, 1980, REV INFECT DIS, V2, P352; OHNUMA H, 1993, J VIROL, V67, P927, DOI 10.1128/JVI.67.2.927-932.1993; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; PING LH, 1992, J VIROL, V66, P2208, DOI 10.1128/JVI.66.4.2208-2216.1992; POL S, 1994, LANCET, V344, P342, DOI 10.1016/S0140-6736(94)91384-6; POOVORAWAN Y, 1994, J INFECT DIS, V169, P228, DOI 10.1093/infdis/169.1.228; PROVOST PJ, 1979, P SOC EXP BIOL MED, V160, P213, DOI 10.3181/00379727-160-40422; PURCELL RH, 1992, VACCINE, V10, pS148, DOI 10.1016/0264-410X(92)90572-2; REDFIELD RR, 1985, JAMA-J AM MED ASSOC, V254, P3203, DOI 10.1001/jama.254.22.3203; REHERMANN B, 1995, J EXP MED, V181, P1047, DOI 10.1084/jem.181.3.1047; RIZZETTO M, 1991, PROG CLIN BIOL RES, V364, P1; SCHODEL F, 1994, INFECT IMMUN, V62, P1669; SEEFF LB, 1987, NEW ENGL J MED, V316, P965, DOI 10.1056/NEJM198704163161601; SHAW FE, 1989, VACCINE, V7, P425, DOI 10.1016/0264-410X(89)90157-6; SHIMIZU YK, 1994, J VIROL, V68, P1494, DOI 10.1128/JVI.68.3.1494-1500.1994; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; SJOGREN MH, 1992, VACCINE, V10, pS135, DOI 10.1016/0264-410X(92)90568-5; *SMITHKL BEECH PHA, 1995, HAVR; STAPLETON JT, 1993, J VIROL, V67, P1080, DOI 10.1128/JVI.67.2.1080-1085.1993; STAPLETON JT, 1991, J INFECT DIS, V163, P7, DOI 10.1093/infdis/163.1.7; STAPLETON JT, 1985, GASTROENTEROLOGY, V89, P637, DOI 10.1016/0016-5085(85)90462-7; STEVENS CE, 1987, JAMA-J AM MED ASSOC, V257, P2612, DOI 10.1001/jama.257.19.2612; STRATTON KR, 1994, JAMA-J AM MED ASSOC, V271, P1602, DOI 10.1001/jama.271.20.1602; SZMUNESS W, 1975, ANN INTERN MED, V83, P489, DOI 10.7326/0003-4819-83-4-489; SZMUNESS W, 1982, NEW ENGL J MED, V307, P1481, DOI 10.1056/NEJM198212093072403; SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501; SZMUNESS W, 1981, HEPATOLOGY, V1, P377, DOI 10.1002/hep.1840010502; TAYLOR JM, 1992, ANNU REV MICROBIOL, V46, P253; THOMAS DL, 1994, J INFECT DIS, V169, P990, DOI 10.1093/infdis/169.5.990; TSAREV SA, 1994, P NATL ACAD SCI USA, V91, P10198, DOI 10.1073/pnas.91.21.10198; WATERS JA, 1992, J CLIN INVEST, V90, P2543, DOI 10.1172/JCI116148; WEBER DJ, 1985, JAMA-J AM MED ASSOC, V254, P3187, DOI 10.1001/jama.254.22.3187; WEINER A, 1995, P NATL ACAD SCI USA, V92, P2755, DOI 10.1073/pnas.92.7.2755; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702; WEST DJ, 1994, PEDIATR INFECT DIS J, V13, P745, DOI 10.1097/00006454-199408000-00015; WHITTLE HC, 1995, LANCET, V345, P1089, DOI 10.1016/S0140-6736(95)90822-6; WINTER AP, 1994, VACCINE, V12, P771, DOI 10.1016/0264-410X(94)90283-6; WOOD RC, 1993, JAMA-J AM MED ASSOC, V270, P2935, DOI 10.1001/jama.270.24.2935; XU ZY, 1995, J INFECT DIS, V171, P54, DOI 10.1093/infdis/171.1.54; XU ZY, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P700; 1996, MMWR-MORBID MORTAL W, V45, P145; 1982, MMWR-MORBID MORTAL W, V31, P317; IN PRESS MMWR MORB M	115	232	253	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 16	1997	336	3					196	204		10.1056/NEJM199701163360307	http://dx.doi.org/10.1056/NEJM199701163360307			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC266	8988900				2022-12-28	WOS:A1997WC26600007
J	Levine, JM				Levine, JM			Bullous pemphigoid	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Levine, JM (corresponding author), JEWISH HOME & HOSP AGED,BRONX,NY 10468, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1997	336	2					110	110		10.1056/NEJM199701093360206	http://dx.doi.org/10.1056/NEJM199701093360206			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC481	8988889				2022-12-28	WOS:A1997WC48100006
J	Lambiris, A; Greaves, MW				Lambiris, A; Greaves, MW			Dyspareunia and vulvodynia: Unrecognised manifestations of symptomatic dermographism	LANCET			English	Article											Lambiris, A (corresponding author), ST THOMAS HOSP,ST JOHNS INST DERMATOL,LONDON SE1 7EH,ENGLAND.							BREATHNACH SM, 1983, CLIN EXP DERMATOL, V8, P463, DOI 10.1111/j.1365-2230.1983.tb01814.x; GREAVES MW, 1995, NEW ENGL J MED, V332, P1767, DOI 10.1056/NEJM199506293322608; MCCALMAN J, 1992, ENVIRON PLANN C, V10, P423, DOI 10.1068/c100423; NEWCOMB RW, 1973, AM J MED, V54, P174, DOI 10.1016/0002-9343(73)90221-0; PERNICIARO C, 1993, ACTA DERM-VENEREOL, V73, P227	5	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					28	28		10.1016/S0140-6736(05)62159-9	http://dx.doi.org/10.1016/S0140-6736(05)62159-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988122				2022-12-28	WOS:A1997WA72500016
J	Owens, DK; Sanders, GD; Harris, RA; McDonald, KM; Heidenreich, PA; Dembitzer, AD; Hlatky, MA				Owens, DK; Sanders, GD; Harris, RA; McDonald, KM; Heidenreich, PA; Dembitzer, AD; Hlatky, MA			Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death	ANNALS OF INTERNAL MEDICINE			English	Article							CONGESTIVE-HEART-FAILURE; LOW-DOSE AMIODARONE; SUSTAINED VENTRICULAR-TACHYCARDIA; ACUTE MYOCARDIAL-INFARCTION; PLACEBO-CONTROLLED TRIAL; ANTIARRHYTHMIC THERAPY; TENTATIVE GUIDELINES; ECONOMIC EVALUATIONS; ARREST SURVIVORS; DRUG-THERAPY	Background: Implantable cardioverter defibrillators (ICDs) are remarkably effective in terminating ventricular arrhythmias, but they are expensive and the extent to which they extend life is unknown. The marginal cost-effectiveness of ICDs relative to amiodarone has not been clearly established. Objective: To compare the cost-effectiveness of a third-generation implantable ICD with that of empirical amiodarone treatment for preventing sudden cardiac death in patients at high or intermediate risk. Design: A Markov model was used to evaluate health and economic outcomes of patients who received an ICD, amiodarone, or a sequential regimen that reserved ICD for patients who had an arrhythmia during amiodarone treatment. Measurements: Life-years gained, quality-adjusted life-years gained, costs, and marginal cost-effectiveness. Results: For the base-case analysis, it was assumed that treatment with an ICD would reduce the total mortality rate by 20% to 40% at 1 year compared with amiodarone and that the ICD generator would be replaced every 4 years. In high-risk patients, if an ICD reduces total mortality by 20%, patients who receive an ICD live for 4.18 quality-adjusted life-years and have a lifetime expenditure of $88 400. Patients receiving amiodarone live for 3.68 quality-adjusted life-years and have a lifetime expenditure of $51 000. Marginal cost-effectiveness of an ICD relative to amiodarone is $74 400 per quality-adjusted life-year saved. If an ICD reduces mortality by 40%, the cost-effectiveness of ICD use is $37 300 per quality-adjusted life-year saved. Both choice of therapy (an ICD or amiodarone) and the cost-effectiveness ratio are sensitive to assumptions about quality of life. Conclusions: Use of an ICD will cost more than $50 000 per quality-adjusted life-year gained unless it reduces all-cause mortality by 30% or more relative to amiodarone. Current evidence does not definitively support or exclude a benefit of this magnitude, but ongoing randomized trials have sufficient statistical power to do so.	STANFORD UNIV, STANFORD, CA 94305 USA	Stanford University	Owens, DK (corresponding author), VET AFFAIRS PALO ALTO HLTH CARE SYST, SECT GEN INTERNAL MED 111A, 3801 MIRANDA AVE, PALO ALTO, CA 94304 USA.		Heidenreich, Paul/AAU-6864-2021	Heidenreich, Paul/0000-0001-7730-8490; Hlatky, Mark/0000-0003-4686-9441	AHRQ HHS [HS 08362] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AHERN TS, 1994, J AM COLL CARDIOL, V23, P1521; [Anonymous], 1993, Prog Cardiovasc Dis, V36, P97; [Anonymous], 1993, Am J Cardiol, V72, P280; [Anonymous], 1991, Pacing Clin Electrophysiol, V14, P920; BAKKER PFA, 1992, PACE, V15, P654, DOI 10.1111/j.1540-8159.1992.tb05158.x; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BETT JHN, 1989, EUR HEART J, V10, P685; BOCKER D, 1993, J AM COLL CARDIOL, V21, P1638; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; BUXTON AE, 1993, PROG CARDIOVASC DIS, V36, P215, DOI 10.1016/0033-0620(93)90015-6; CAIRNS JA, 1991, CIRCULATION, V84, P550, DOI 10.1161/01.CIR.84.2.550; CAMM AJ, 1993, AM J CARDIOL, V72, pF95, DOI 10.1016/0002-9149(93)90970-N; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; CONNOLLY SJ, 1992, AM J CARDIOL, V69, P959, DOI 10.1016/0002-9149(92)90801-5; CONNOLLY SJ, 1993, AM J CARDIOL, V72, pF103, DOI 10.1016/0002-9149(93)90972-F; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; EPSTEIN AE, 1995, AM J CARDIOL, V75, P470; Ferguson TB, 1996, J THORAC CARDIOV SUR, V111, P742, DOI 10.1016/S0022-5223(96)70334-3; FOGOROS RN, 1990, J AM COLL CARDIOL, V16, P381, DOI 10.1016/0735-1097(90)90590-L; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; GABRY MD, 1987, J AM COLL CARDIOL, V9, P1349, DOI 10.1016/S0735-1097(87)80477-1; GAFNI A, 1993, CAN MED ASSOC J, V148, P913; GILLUM RF, 1989, CIRCULATION, V79, P756, DOI 10.1161/01.CIR.79.4.756; GREENE HL, 1991, AM J CARDIOL, V67, P578; GREENE HL, 1994, AM HEART J, V127, P1171, DOI 10.1016/0002-8703(94)90106-6; HAMER AWF, 1989, J AM COLL CARDIOL, V14, P1768, DOI 10.1016/0735-1097(89)90030-2; HERRE JM, 1989, J AM COLL CARDIOL, V13, P442, DOI 10.1016/0735-1097(89)90525-1; HINE LK, 1989, JAMA-J AM MED ASSOC, V262, P3037, DOI 10.1001/jama.262.21.3037; KIM SG, 1995, AM J CARDIOL, V75, P1229, DOI 10.1016/S0002-9149(99)80768-1; KIM SG, 1993, AM J CARDIOL, V72, P1453, DOI 10.1016/0002-9149(93)90196-J; KIM SG, 1993, AM J CARDIOL, V72, P1263, DOI 10.1016/0002-9149(93)90294-M; KIM SG, 1993, AM J CARDIOL, V71, P1213, DOI 10.1016/0002-9149(93)90648-V; KLEMAN JM, 1994, CIRCULATION, V90, P2833, DOI 10.1161/01.CIR.90.6.2833; Kolar J A, 1990, J Cardiovasc Nurs, V4, P44; KORTE T, 1995, PACE, V18, P2053, DOI 10.1111/j.1540-8159.1995.tb03867.x; KUPERSMITH J, 1995, AM HEART J, V130, P507, DOI 10.1016/0002-8703(95)90359-3; KUPPERMANN M, 1990, CIRCULATION, V81, P91, DOI 10.1161/01.CIR.81.1.91; LARSEN GC, 1992, J AM COLL CARDIOL, V19, P1323, DOI 10.1016/0735-1097(92)90341-J; LAUPACIS A, 1993, CAN MED ASSOC J, V148, P927; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; LEHMANN MH, 1991, AM J CARDIOL, V68, P545; Lipscomb J., 1996, COST EFFECTIVENESS H, P214; LONGSTRETH WT, 1983, NEW ENGL J MED, V308, P1378, DOI 10.1056/NEJM198306093082302; MASON JW, 1987, NEW ENGL J MED, V316, P455; National Center for Health Statistics, 1993, MONTHLY VITAL STAT R, V41, P1; NAVARROLOPEZ F, 1993, AM J CARDIOL, V72, P1243, DOI 10.1016/0002-9149(93)90291-J; NAYLOR CD, 1993, CAN MED ASSOC J, V148, P921; NEWMAN D, 1992, AM J CARDIOL, V69, P899, DOI 10.1016/0002-9149(92)90789-2; NICKLAS JM, 1991, AM HEART J, V122, P1016, DOI 10.1016/0002-8703(91)90466-U; NUNAIN SO, 1995, CIRCULATION, V91, P2204, DOI 10.1161/01.CIR.91.8.2204; ODONOGHUE S, 1990, J AM COLL CARDIOL, V16, P1258, DOI 10.1016/0735-1097(90)90563-5; OWENS DK, 1990, MED INFORMATICS COMP, P70; PFISTERER ME, 1993, CIRCULATION, V87, P309, DOI 10.1161/01.CIR.87.2.309; PINSKI SL, 1995, ANN INTERN MED, V122, P770, DOI 10.7326/0003-4819-122-10-199505150-00007; PODRID PJ, 1995, ANN INTERN MED, V122, P689, DOI 10.7326/0003-4819-122-9-199505010-00008; POWELL AC, 1993, CIRCULATION, V88, P1083, DOI 10.1161/01.CIR.88.3.1083; RUSSELL LB, 1989, SCIENCE, V246, P892, DOI 10.1126/science.2510299; SAKSENA S, 1992, J AM COLL CARDIOL, V19, P490, DOI 10.1016/S0735-1097(10)80260-8; Sauve M J, 1996, Am J Crit Care, V5, P127; SAUVE MJ, 1995, HEART LUNG, V24, P133, DOI 10.1016/S0147-9563(05)80008-1; SAUVE MJ, 1994, CIRCULATION, V90, P379; SCHATZKIN A, 1984, AM HEART J, V107, P1300, DOI 10.1016/0002-8703(84)90302-8; SHANNON JA, 1991, MAYO CLIN PROC, V66, P1114, DOI 10.1016/S0025-6196(12)65790-5; SIEBELS J, 1994, AM HEART J, V127, P1139, DOI 10.1016/0002-8703(94)90101-5; SIEBELS J, 1993, AM J CARDIOL, V72, pF109, DOI 10.1016/0002-9149(93)90973-G; SIEBELS J, 1993, PACE, V16, P552, DOI 10.1111/j.1540-8159.1993.tb01624.x; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201; SINGH SN, 1993, AM J CARDIOL, V72, pF99, DOI 10.1016/0002-9149(93)90971-E; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Sox HC, 1988, MED DECISION MAKING; TCHOU PJ, 1988, ANN INTERN MED, V109, P529, DOI 10.7326/0003-4819-109-7-529; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; WEINBERG BA, 1993, AM HEART J, V125, P109, DOI 10.1016/0002-8703(93)90063-F; Wever EFD, 1996, CIRCULATION, V93, P489, DOI 10.1161/01.CIR.93.3.489; WEVER EFD, 1995, CIRCULATION, V91, P2195, DOI 10.1161/01.CIR.91.8.2195; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; ZIPES DP, 1995, CIRCULATION, V92, P59, DOI 10.1161/01.CIR.92.1.59; 1995, 1995 REDBOOK UPDATE	82	148	148	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1997	126	1					1	12		10.7326/0003-4819-126-1-199701010-00001	http://dx.doi.org/10.7326/0003-4819-126-1-199701010-00001			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA165	8992917				2022-12-28	WOS:A1997WA16500001
J	Baron, JH				Baron, JH			Why do medical students choose St Mary's Hospital Medical School?	BRITISH MEDICAL JOURNAL			English	Article							ADMISSION; AUDIT											MCMANUS IC, 1984, BRIT MED J, V289, P1201, DOI 10.1136/bmj.289.6453.1201; MCMANUS IC, 1993, MED EDUC, V27, P116, DOI 10.1111/j.1365-2923.1993.tb00241.x; MCMANUS IC, 1984, BRIT MED J, V289, P1288, DOI 10.1136/bmj.289.6454.1288; MCMANUS IC, 1984, BRIT MED J, V289, P1365, DOI 10.1136/bmj.289.6455.1365	4	3	3	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1646	1647		10.1136/bmj.313.7072.1646	http://dx.doi.org/10.1136/bmj.313.7072.1646			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991019	Green Published			2022-12-28	WOS:A1996VZ81100055
J	vonMuhlendahl, KE; Kromburg, S				vonMuhlendahl, KE; Kromburg, S			A clumsy 3-year-old who liked junk food	LANCET			English	Article											vonMuhlendahl, KE (corresponding author), KINDERHOSP,IBURGER STR 187,D-49082 OSNABRUCK,GERMANY.							MARX SJ, 1978, J CLIN ENDOCR METAB, V47, P1303, DOI 10.1210/jcem-47-6-1303; SUDA T, 1986, STEROID HORMONE RESI; TOMSON FN, 1978, J AM VET MED ASSOC, V173, P1103; TOMSON FN, 1980, NUTR SECONDARY HYPER, P59; TSUCHIYA Y, 1980, J CLIN ENDOCR METAB, V51, P685, DOI 10.1210/jcem-51-4-685	5	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348	9043					1705	1705						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973436				2022-12-28	WOS:A1996VZ76600016
J	Baumgartner, S; Littleton, JT; Broadie, K; Bhat, MA; Harbecke, R; Lengyel, JA; ChiquetEhrismann, R; Prokop, A; Bellen, HJ				Baumgartner, S; Littleton, JT; Broadie, K; Bhat, MA; Harbecke, R; Lengyel, JA; ChiquetEhrismann, R; Prokop, A; Bellen, HJ			A Drosophila neurexin is required for septate junction and blood-nerve barrier formation and function	CELL			English	Article							TUMOR-SUPPRESSOR PROTEIN; ALPHA-LATROTOXIN RECEPTOR; DISKS; TIGHT; HOMOLOG; ZO-1; SYNAPTOTAGMIN; CLONING; GENE; MELANOGASTER	Septate and tight junctions are thought to seal neighboring cells together and to function as barriers between epithelial cells. We have characterized a novel member of the neurexin family, Neurexin IV (NRX), which is localized to septate junctions (SJs) of epithelial and glial cells. NRX is a transmembrane protein with a cytoplasmic domain homologous to glycophorin C, a protein required for anchoring protein 4.1 in the red blood cell. Absence of NRX results in mislocalization of Coracle, a Drosophila protein 4.1 homolog, at SJs and causes dorsal closure defects similar to those observed in coracle mutants. nrx mutant embryos are paralyzed, and electrophysiological studies indicate that the rack of NRX in glial-glial SJs causes a breakdown of the blood-brain barrier. Electron microscopy demonstrates that nrx mutants lack the ladder-like intercellular septa characteristic of pleated SJs (pSJs). These studies identify NRX as the first transmembrane protein of SJ and demonstrate a requirement for NRX in the formation of septate-junction septa and intercellular barriers.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND; UNIV CALIF LOS ANGELES,DEPT MOL CELL & DEV BIOL,LOS ANGELES,CA 90095	Friedrich Miescher Institute for Biomedical Research; Baylor College of Medicine; Howard Hughes Medical Institute; University of Cambridge; University of California System; University of California Los Angeles			; BHAT, MANZOOR/S-9273-2018; Baumgartner, Stefan/A-5879-2011	Littleton, J. Troy/0000-0001-5576-2887; BHAT, MANZOOR/0000-0003-0989-1498; Bellen, Hugo/0000-0001-5992-5989; Prokop, Andreas/0000-0001-8482-3298; Baumgartner, Stefan/0000-0001-5320-8321	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009948] Funding Source: NIH RePORTER; NICHD NIH HHS [HD09948] Funding Source: Medline; Wellcome Trust Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome TrustEuropean Commission)		AULD VJ, 1995, CELL, V81, P757, DOI 10.1016/0092-8674(95)90537-5; BIEBER AJ, 1994, DROSOPHILA MELANOGAS, P683; Bock G., 1987, JUNCTIONAL COMPLEXES; BROADIE K, 1994, P NATL ACAD SCI USA, V91, P10727, DOI 10.1073/pnas.91.22.10727; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; BROADIE KS, 1993, J NEUROSCI, V13, P144; BRODY LC, 1995, GENOMICS, V25, P2328; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; FEHON RG, 1994, DEVELOPMENT, V120, P545; FRIEDMAN LS, 1995, GENOMICS, V25, P256, DOI 10.1016/0888-7543(95)80133-7; FRISTROM DK, 1982, J CELL BIOL, V94, P77, DOI 10.1083/jcb.94.1.77; Grawe F, 1996, DEVELOPMENT, V122, P951; Hata Y, 1996, J NEUROSCI, V16, P2488; HOOGWERF AM, 1988, GENETICS, V118, P665; HOYLE G, 1952, NATURE, V169, P281, DOI 10.1038/169281a0; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; JUANG JL, 1992, CELL TISSUE RES, V270, P95, DOI 10.1007/BF00381884; KIRKPATRICK C, 1995, CURR OPIN GENET DEV, V5, P56, DOI 10.1016/S0959-437X(95)90054-3; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; LANE LJ, 1980, ADV INSECT PHYSL, P35; LANE NJ, 1977, J CELL SCI, V26, P175; LANE NJ, 1991, FORM FUNCTION ZOOLOG, P87; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LOCKE M, 1965, J CELL BIOL, V25, P166, DOI 10.1083/jcb.25.1.166; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Lux S. E, 1995, BLOOD PRINCIPLES PRA; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; Prokop A, 1996, NEURON, V17, P617, DOI 10.1016/S0896-6273(00)80195-6; Prokop Andreas, 1993, P33; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; SEECOT RL, 1942, P NATL ACAD SCI USA, V69, P565; TEPASS U, 1994, DEV BIOL, V161, P563, DOI 10.1006/dbio.1994.1054; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1993, P NATL ACAD SCI USA, V90, P6410, DOI 10.1073/pnas.90.14.6410; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; Woods D F, 1993, J Cell Sci Suppl, V17, P171; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; 1994, NUCLEIC ACIDS RES, V22, P3456	48	333	335	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1059	1068		10.1016/S0092-8674(00)81800-0	http://dx.doi.org/10.1016/S0092-8674(00)81800-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978610	Bronze			2022-12-28	WOS:A1996VY44700011
J	Caprara, MG; Lehnert, V; Lambowitz, AM; Westhof, E				Caprara, MG; Lehnert, V; Lambowitz, AM; Westhof, E			A tyrosyl-tRNA synthetase recognizes a conserved tRNA-like structural motif in the group I intron catalytic core	CELL			English	Article							TRANSFER-RNA-SYNTHETASE; PROTEIN; MITOCHONDRIA; INVOLVEMENT; CEREVISIAE; REQUIRES; DOMAIN	The Neurospora crassa mitochondrial (mt) tyrosyl-tRNA synthetase (CYT-18 protein) functions in splicing group I introns, in addition to aminoacylating tRNA(Tyr). Here, we compared the CYT-18 binding sites in the N. crassa mt LSU and ND1 introns with that in N. crassa mt tRNA(Tyr) by constructing three-dimensional models based on chemical modification and RNA footprinting data. Remarkably, superimposition of the CYT-18 binding sites in the model structures revealed an extended three-dimensional overlap between the tRNA and the group I intron catalytic core. Our results provide insight into how an RNA-splicing factor can evolve from a cellular RNA-binding protein. Further, the structural similarities between group I introns and tRNAs are consistent with an evolutionary relationship and suggest a general mechanism for the evolution of complex catalytic RNAs.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210; CNRS,INST BIOL MOL & CELLULAIRE,F-67084 STRASBOURG,FRANCE	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Caprara, MG (corresponding author), OHIO STATE UNIV,DEPT MOL GENET,COLUMBUS,OH 43210, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037951, R37GM037951] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37951] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; BEDOUELLE H, 1993, BIOCHIMIE, V75, P1099, DOI 10.1016/0300-9084(93)90009-H; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRENNAN T, 1976, NUCLEIC ACIDS RES, V3, P3235, DOI 10.1093/nar/3.11.3235; BURKE JM, 1986, CELL, V45, P167, DOI 10.1016/0092-8674(86)90380-6; Caprara MG, 1996, J MOL BIOL, V257, P512, DOI 10.1006/jmbi.1996.0182; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CHERNIACK AD, 1990, CELL, V62, P745, DOI 10.1016/0092-8674(90)90119-Y; DERRICK WB, 1993, NUCLEIC ACIDS RES, V21, P4948, DOI 10.1093/nar/21.21.4948; DOCKBREGEON AC, 1989, J MOL BIOL, V206, P707, DOI 10.1016/0022-2836(89)90578-0; FELDEN B, 1994, J MOL BIOL, V235, P508, DOI 10.1006/jmbi.1994.1010; GAMPEL A, 1991, GENE DEV, V5, P1870, DOI 10.1101/gad.5.10.1870; GUO Q, 1982, GENE DEV, V6, P1537; HERBERT CJ, 1988, EMBO J, V7, P473, DOI 10.1002/j.1460-2075.1988.tb02835.x; JAEGER L, 1991, J MOL BIOL, V221, P1153, DOI 10.1016/0022-2836(91)90925-V; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAMPER U, 1992, MOL CELL BIOL, V12, P499; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; MASSIRE C, 1994, J MOL GRAPHICS, V12, P201, DOI 10.1016/0263-7855(94)80088-X; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; MOHR G, 1994, NATURE, V370, P147, DOI 10.1038/370147a0; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; Myers CA, 1996, J MOL BIOL, V262, P87, DOI 10.1006/jmbi.1996.0501; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; Saldanha R, 1996, J MOL BIOL, V261, P23, DOI 10.1006/jmbi.1996.0439; SALDANHA RJ, 1995, BIOCHEMISTRY-US, V34, P1275, DOI 10.1021/bi00004a022; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; SCHIMMEL P, 1995, CELL, V81, P983, DOI 10.1016/S0092-8674(05)80002-9; SHERMAN JM, 1992, NUCLEIC ACIDS RES, V20, P2847, DOI 10.1093/nar/20.11.2847; SIBLER AP, 1986, FEBS LETT, V194, P131, DOI 10.1016/0014-5793(86)80064-3; STEIN A, 1976, BIOCHEMISTRY-US, V15, P160, DOI 10.1021/bi00646a025; WESTHOF E, 1989, J MOL BIOL, V207, P417, DOI 10.1016/0022-2836(89)90264-7; Zarrinkar PP, 1996, NAT STRUCT BIOL, V3, P432, DOI 10.1038/nsb0596-432; ZARRINKAR PP, 1994, SCIENCE, V265, P918, DOI 10.1126/science.8052848	36	84	87	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1135	1145		10.1016/S0092-8674(00)81807-3	http://dx.doi.org/10.1016/S0092-8674(00)81807-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978617	Bronze			2022-12-28	WOS:A1996VY44700018
J	Goldman, D				Goldman, D			Human genetics - High anxiety	SCIENCE			English	Editorial Material							CHROMOSOME-18				Goldman, D (corresponding author), NIAAA,NEUROGENET LAB,NIH,ROCKVILLE,MD 20852, USA.		Goldman, David/F-9772-2010; Majid, Salma/AAT-2616-2020	Goldman, David/0000-0002-1724-5405; Majid, Salma/0000-0002-1724-5405				Benjamin J, 1996, NAT GENET, V12, P81, DOI 10.1038/ng0196-81; BERRETTINI WH, 1994, P NATL ACAD SCI USA, V91, P5918, DOI 10.1073/pnas.91.13.5918; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; CHILDS B, 1993, AM J HUM GENET, V52, P224; Cravchik A, 1996, J BIOL CHEM, V271, P26013, DOI 10.1074/jbc.271.42.26013; Ebstein RP, 1996, NAT GENET, V12, P78, DOI 10.1038/ng0196-78; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Malhotra AK, 1996, MOL PSYCHIATR, V1, P388; OKADA M, UNPUB; OZAKI N, IN PRESS MOL PSYCHOL; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; STINE OC, 1995, AM J HUM GENET, V57, P1384; STRAUB RE, 1995, NAT GENET, V11, P287, DOI 10.1038/ng1195-287; VANTOL HHM, 1992, NATURE, V358, P149	14	23	25	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1483	1483		10.1126/science.274.5292.1483	http://dx.doi.org/10.1126/science.274.5292.1483			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8966620				2022-12-28	WOS:A1996VV77500033
J	Folsch, UR; Nitsche, R; Ludtke, R; Hilgers, RA; Creutzfeldt, W				Folsch, UR; Nitsche, R; Ludtke, R; Hilgers, RA; Creutzfeldt, W			Early ERCP and papillotomy compared with conservative treatment for acute biliary pancreatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOSCOPIC SPHINCTEROTOMY; GALLSTONE PANCREATITIS; MANAGEMENT; COMPLICATIONS; ETIOLOGY; TRIAL	Background The role of early endoscopic retrograde cholangiopancreatography (ERCP) and papillotomy in the treatment of patients who have acute biliary pancreatitis without obstructive jaundice is uncertain. Methods We conducted a prospective, multicenter study in which 126 patients were randomly assigned to early ERCP (within 72 hours after the onset of symptoms) and endoscopic papillotomy for the removal of stones in the common bile duct, when appropriate, and 112 patients were assigned to conservative treatment. In the conservative-treatment group, ERCP was performed within three weeks if signs of biliary obstruction or sepsis developed. Overall mortality, mortality due to pancreatitis, and complications were compared in the two groups. Results Early ERCP was successful in 121 of the 126 patients in the invasive-treatment group. Endoscopic papillotomy was performed to remove bile-duct stones in 58 patients; stones were successfully extracted in 57. ERCP was performed in 22 of the 112 patients in the conservative-treatment group; papillotomy for stone removal was successful in 13 patients. Fourteen patients in the invasive-treatment group and 7 in the conservative-treatment group died within three months (P=0.10); 10 patients in the invasive-treatment group and 4 in the conservative-treatment group died from acute biliary pancreatitis (P=0.16). The overall rate of complications was similar in the two groups, but patients in the invasive-treatment group had more severe complications. Respiratory failure was more frequent in the invasive-treatment group, and jaundice was more frequent in the conservative-treatment group. Conclusions In patients with acute biliary pancreatitis but without obstructive jaundice, early ERCP and papillotomy were not beneficial. (C) 1997, Massachusetts Medical Society.	CHRISTIAN ALBRECHTS UNIV KIEL, DEPT MED, KIEL, GERMANY; UNIV GOTTINGEN, DEPT MED STAT, D-3400 GOTTINGEN, GERMANY; UNIV GOTTINGEN, DEPT MED, D-3400 GOTTINGEN, GERMANY	University of Kiel; University of Gottingen; University of Gottingen								ACOSTA JM, 1974, NEW ENGL J MED, V290, P484, DOI 10.1056/NEJM197402282900904; ACOSTA JM, 1980, SURGERY, V88, P118; [Anonymous], 1995, STAT MED, V14, P1659; ARMSTRONG CP, 1986, ANN SURG, V204, P59, DOI 10.1097/00000658-198607000-00008; BLACKSTONE MO, 1988, PANCREAS, V3, P340, DOI 10.1097/00006676-198805000-00016; BLAMEY SL, 1984, GUT, V25, P1340, DOI 10.1136/gut.25.12.1340; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; DONNER A, 1984, STAT MED, V3, P199, DOI 10.1002/sim.4780030302; DONNER A, 1990, STAT MED, V9, P1228; FAN ST, 1993, NEW ENGL J MED, V328, P228, DOI 10.1056/NEJM199301283280402; Freeman ML, 1996, NEW ENGL J MED, V335, P909, DOI 10.1056/NEJM199609263351301; GOODMAN AJ, 1985, GUT, V26, P125, DOI 10.1136/gut.26.2.125; KELLY TR, 1988, SURGERY, V104, P600; LANKISCH PG, 1989, DIGESTION, V44, P20, DOI 10.1159/000199888; LAWSON TL, 1983, RADIOL CLIN N AM, V21, P495; LEE SP, 1992, NEW ENGL J MED, V326, P589, DOI 10.1056/NEJM199202273260902; LEESE T, 1986, BRIT J SURG, V73, P988, DOI 10.1002/bjs.1800731214; LEESE T, 1985, BRIT J SURG, V72, P215, DOI 10.1002/bjs.1800720325; NEOPTOLEMOS JP, 1988, LANCET, V2, P979, DOI 10.1016/S0140-6736(88)90740-4; NOWAK A, 1995, GASTROENTEROLOGY, V108, pA380; SAFRANY L, 1980, DEUT MED WOCHENSCHR, V105, P115, DOI 10.1055/s-2008-1070617; STEER ML, 1986, EXOCRINE PANCREAS BI, P465; STONE HH, 1981, ANN SURG, V194, P305, DOI 10.1097/00000658-198109000-00008; TOOULI J, 1984, BRIT J SURG, V71, P251, DOI 10.1002/bjs.1800710402; Wald A, 1943, T AM MATH SOC, V54, P426, DOI 10.2307/1990256; WANG SS, 1988, PANCREAS, V3, P153, DOI 10.1097/00006676-198804000-00007; 1988, LANCET, V1, P915	27	421	442	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1997	336	4					237	242		10.1056/NEJM199701233360401	http://dx.doi.org/10.1056/NEJM199701233360401			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE632	8995085				2022-12-28	WOS:A1997WE63200001
J	Vadon, H; Sigmundsson, F				Vadon, H; Sigmundsson, F			Crustal deformation from 1992 to 1995 at the Mid-Atlantic Ridge, southwest Iceland, mapped by satellite radar interferometry	SCIENCE			English	Article							REYKJANES-PENINSULA; PLATE BOUNDARY; LANDERS EARTHQUAKE; STRESS; MOTION	Satellite radar interferometry observations of the Reykjanes Peninsula oblique rift in southwest Iceland show that the Reykjanes central volcano subsided at an average rate of up to 13 millimeters per year from 1992 to 1995 in response to use of its geothermal field. Interferograms spanning up to 3.12 years also include signatures of plate spreading and indicate that the plate boundary is locked at a depth of about 5 kilometers. Below that depth, the plate movements are accommodated by continuous ductile deformation, which is not fully balanced by inflow of magma from depth, causing subsidence of the plate boundary of about 6.5 millimeters per year.	UNIV ICELAND,NORD VOLCAN INST,IS-108 REYKJAVIK,ICELAND	University of Iceland	Vadon, H (corresponding author), CTR NATL ETUD SPATIALES,18 AVE EDOUARD BELIN,F-31055 TOULOUSE,FRANCE.		Sigmundsson, Freysteinn/F-7160-2015	Sigmundsson, Freysteinn/0000-0001-9052-4665				BJORNSSON G, 1991, 91016 NAT EN AUTH; BRANDSDOTTIR B, 1994, RH0394 U IC SCI I; DEMETS C, 1994, GEOPHYS RES LETT, V21, P2191, DOI 10.1029/94GL02118; EINARSSON P, 1991, TECTONOPHYSICS, V189, P261, DOI 10.1016/0040-1951(91)90501-I; Einarsson P., 1987, I HLUTARINS EDLI; EYSTEINSSON H, 1993, OS93029 NAT EN AUTH; FOULGER GR, 1992, NATURE, V358, P488, DOI 10.1038/358488a0; GOLDSTEIN RM, 1993, SCIENCE, V262, P1525, DOI 10.1126/science.262.5139.1525; GORDON RG, 1992, SCIENCE, V256, P333, DOI 10.1126/science.256.5055.333; Grant MA, 1982, GEOTHERMAL RESERVOIR; HALIDORSSON P, 1984, ESTIMATE EARTHQUAKE; KLEIN FW, 1977, J GEOPHYS RES, V82, P865, DOI 10.1029/JB082i005p00865; KLEIN FW, 1973, J GEOPHYS RES, V78, P5084, DOI 10.1029/JB078i023p05084; LISOWSKI M, 1991, J GEOPHYS RES-SOLID, V96, P8369, DOI 10.1029/91JB00199; MASSONNET D, 1995, GEOPHYS RES LETT, V22, P1537, DOI 10.1029/95GL00711; Massonnet D, 1996, NATURE, V382, P612, DOI 10.1038/382612a0; MASSONNET D, 1994, NATURE, V369, P227, DOI 10.1038/369227a0; Massonnet D, 1996, IEEE T GEOSCI REMOTE, V34, P489, DOI 10.1109/36.485126; MASSONNET D, 1993, NATURE, V364, P138, DOI 10.1038/364138a0; MCTIGUE DF, 1987, J GEOPHYS RES-SOLID, V92, P12931, DOI 10.1029/JB092iB12p12931; NIEMCZYK O, 1943, SPALTEN ISLAND; Saemundsson K., 1980, GEOLOGICAL MAP ICELA; SAVAGE JC, 1973, J GEOPHYS RES, V78, P832, DOI 10.1029/JB078i005p00832; SIGMUNDSSON F, 1995, J GEOPHYS RES-SOL EA, V100, P6235, DOI 10.1029/95JB00155; STURKELL E, 1994, GEOPHYS RES LETT, V21, P125, DOI 10.1029/93GL03421; TRYGGVASON E, 1968, J GEOPHYS RES, V73, P7039, DOI 10.1029/JB073i022p07039; Tryggvason E., 1974, GEODYNAMICS ICELAND, P241; Tryggvason E., 1982, CONTINENTAL OCEANIC, V8, P17, DOI [10.1029/GD008p0017, DOI 10.1029/GD008P0017]; TRYGGVASSON E, 1981, 8102 NORD VOLC I	31	58	59	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					193	197						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985009				2022-12-28	WOS:A1997WC02200032
J	Appleby, L				Appleby, L			Envy	BRITISH MEDICAL JOURNAL			English	Article											Appleby, L (corresponding author), WITHINGTON HOSP,MANCHESTER M20 8LR,LANCS,ENGLAND.								0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1592	1593		10.1136/bmj.313.7072.1592a	http://dx.doi.org/10.1136/bmj.313.7072.1592a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8990996	Green Published			2022-12-28	WOS:A1996VZ81100019
J	Garrow, J				Garrow, J			Gluttony	BRITISH MEDICAL JOURNAL			English	Article																		[Anonymous], PROVERBS; *BIBLE, PROVERBS, V23; *BIBLE, TITUS, V1; Crisp AH, 1995, P NUTR SOC, V54, P701, DOI 10.1079/PNS19950069; Garrow J. S., 1988, OBESITY RELATED DIS; GARROW JS, 1991, BRIT MED J, V303, P7704; HAMILTON BS, 1995, NAT MED, V1, P953, DOI 10.1038/nm0995-953; JENKINS DJA, 1994, AM J CLIN NUTR, V59, p706S, DOI 10.1093/ajcn/59.3.706S; JENKINS DJA, 1995, METABOLISM, V44, P549, DOI 10.1016/0026-0495(95)90066-7; RAVUSSIN E, 1995, METABOLISM, V44, P12, DOI 10.1016/0026-0495(95)90312-7	10	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1595	1596		10.1136/bmj.313.7072.1595	http://dx.doi.org/10.1136/bmj.313.7072.1595			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8990999	Green Published			2022-12-28	WOS:A1996VZ81100022
J	Orlander, PR; Nader, S				Orlander, PR; Nader, S			Endocrinology - Youthful hormones	LANCET			English	Article											Orlander, PR (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIV ENDOCRINOL,6431 FANNIN,SUITE 4200,HOUSTON,TX 77030, USA.							Amato G, 1996, CLIN ENDOCRINOL, V45, P27, DOI 10.1046/j.1365-2265.1996.00735.x; Copinschi G, 1996, J CLIN ENDOCR METAB, V81, P2776, DOI 10.1210/jc.81.8.2776; Fazio S, 1996, NEW ENGL J MED, V334, P809, DOI 10.1056/NEJM199603283341301; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; Johnson OL, 1996, NAT MED, V2, P795, DOI 10.1038/nm0796-795	5	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 21	1996	348			2			SII6	SII6						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973484				2022-12-28	WOS:A1996WA46300006
J	Rochon, PA; Gurwitz, JH				Rochon, PA; Gurwitz, JH			Geriatrics - The age of women	LANCET			English	Article									UNIV TORONTO, BAYCREST CTR GERIATR CARE, DEPT PREVENT MED & BIOSTAT, TORONTO, ON M6A 2E1, CANADA; UNIV MASSACHUSETTS, MED CTR, MEYERS PRIMARY CARE INST, WORCESTER, MA 01605 USA	University of Toronto; Baycrest; University of Massachusetts System; University of Massachusetts Worcester	Rochon, PA (corresponding author), UNIV TORONTO, BAYCREST CTR GERIATR CARE, DEPT MED, TORONTO, ON M6A 2E1, CANADA.		Rochon, Paula A/J-2918-2016	Rochon, Paula A/0000-0002-5973-4151				DargentMolina P, 1996, LANCET, V348, P145, DOI 10.1016/S0140-6736(96)01440-7; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Gurwitz JH, 1996, ANN INTERN MED, V124, P283, DOI 10.7326/0003-4819-124-3-199602010-00001; Krumholz HM, 1996, ANN INTERN MED, V124, P292, DOI 10.7326/0003-4819-124-3-199602010-00002; Relkin NR, 1996, LANCET, V347, P1091, DOI 10.1016/S0140-6736(96)90284-6	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	1996	348			2			SII8	SII8						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973486				2022-12-28	WOS:A1996WA46300008
J	Stahl, F				Stahl, F			Meiotic recombination in yeast: Coronation of the double-strand-break repair model	CELL			English	Review							SACCHAROMYCES-CEREVISIAE; MEIOSIS; DNA; IDENTIFICATION; MOLECULES				Stahl, F (corresponding author), UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403, USA.							ALANI E, 1994, GENETICS, V137, P19; COLLINS I, 1994, CELL, V76, P65, DOI 10.1016/0092-8674(94)90173-2; FAN QQ, 1995, MOL CELL BIOL, V15, P1679; Gilbertson LA, 1996, GENETICS, V144, P27; GOYON C, 1993, MOL CELL BIOL, V13, P373, DOI 10.1128/MCB.13.1.373; PORTER SE, 1993, GENETICS, V134, P5; RESNICK MA, 1976, J THEOR BIOL, V59, P97, DOI 10.1016/S0022-5193(76)80025-2; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8	10	76	78	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					965	968		10.1016/S0092-8674(00)81791-2	http://dx.doi.org/10.1016/S0092-8674(00)81791-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978601	Bronze			2022-12-28	WOS:A1996VY44700002
J	Hortobagyi, GN; Theriault, RL; Porter, L; Blayney, D; Lipton, A; Sinoff, C; Wheeler, H; Simeone, JF; Seaman, J; Knight, RD; Heffernan, M; Reitsma, DJ				Hortobagyi, GN; Theriault, RL; Porter, L; Blayney, D; Lipton, A; Sinoff, C; Wheeler, H; Simeone, JF; Seaman, J; Knight, RD; Heffernan, M; Reitsma, DJ			Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MITOMYCIN-C; PHASE-II; CHEMOTHERAPY; CARCINOMA; ONCOLOGY; 5-FLUOROURACIL; MITOXANTRONE; DOXORUBICIN; THERAPY; QUALITY	Background Bisphosphonates such as pamidronate disodium inhibit osteoclast-induced bone resorption associated with cancer that has metastasized to bone. Methods Women with stage IV breast cancer who were receiving cytotoxic chemotherapy and had at least one lytic bone lesion were given either placebo or pamidronate (90 mg) as a two-hour intravenous infusion monthly for 12 cycles. Skeletal complications, including pathologic fractures, the need for radiation to bone or bone surgery, spinal cord compression, and hypercalcemia (a serum calcium concentration above 12 mg per deciliter [3.0 mmol per liter] or elevated to any degree and requiring treatment), were assessed monthly. Bone pain, use of analgesic drugs, performance status, and quality of life were assessed throughout the trial. Results The efficacy of treatment was evaluated in 380 of 382 randomized patients, 185 receiving pamidronate and 195 receiving placebo. The median time to the occurrence of the first skeletal complication was greater in the pamidronate group than in the placebo group (13.1 vs. 7.0 months, P=0.005), and the proportion of patients in whom any skeletal complication occurred was lower (43 percent vs. 56 percent, P=0.008). There was significantly less increase in bone pain (P=0.046) and deterioration of performance status (P=0.027) in the pamidronate group than in the placebo group. Pamidronate was well tolerated. Conclusions Monthly infusions of pamidronate as a supplement to chemotherapy can protect against skeletal complications in women with stage IV breast cancer who have osteolytic bone metastases. (C) 1996, Massachusetts Medical Society.	ST THOMAS HOSP,ST THOMAS MED GRP,NASHVILLE,TN; ST VINCENT HOSP & MED CTR,LOS ANGELES,CA; MILTON S HERSHEY MED CTR,HERSHEY,PA; NE ONTARIO REG CANC CTR,SUDBURY,ON,CANADA; ROYAL N SHORE HOSP,DEPT CLIN ONCOL,ST LEONARDS,NSW 2065,AUSTRALIA; MASSACHUSETTS GEN HOSP,DEPT RADIOL,BOSTON,MA 02114; CIBA GEIGY PHARMACEUT CORP,SUMMIT,NJ	Saint Thomas Hospital; Saint Vincents Hospital Manhattan; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Royal North Shore Hospital; Harvard University; Massachusetts General Hospital	Hortobagyi, GN (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BREAST MED ONCOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.		Blayney, Douglas/AAK-2920-2020	Blayney, Douglas/0000-0002-7931-4533				BEARHRS OH, 1988, MANUAL STATING CANC; Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802; Burckhardt P, 1989, Recent Results Cancer Res, V116, P54; CARMOPEREIRA J, 1988, EUR J CANCER CLIN ON, V24, P473, DOI 10.1016/S0277-5379(98)90019-0; COLEMAN RE, 1993, CANCER TREAT REV, V19, P79, DOI 10.1016/0305-7372(93)90028-P; COLEMAN RE, 1985, CANCER TREAT REV, V12, P251, DOI 10.1016/0305-7372(85)90008-8; COLEMAN RE, 1988, BRIT J CANCER, V58, P621, DOI 10.1038/bjc.1988.272; *CRIT COMM NY HEAR, 1964, DIS HEART BLOOD VESS; DELENA M, 1988, TUMORI, V74, P57, DOI 10.1177/030089168807400110; DICOSTANZO F, 1986, CANCER, V57, P904; DODWELL DJ, 1990, MANAGEMENT BONE META, P76; Fleisch H, 1989, Recent Results Cancer Res, V116, P1; GLOVER D, 1994, CANCER, V74, P2949, DOI 10.1002/1097-0142(19941201)74:11<2949::AID-CNCR2820741110>3.0.CO;2-Q; HACKING A, 1991, OSTEOCLAST INHIBITIO, P45; HAYWARD JL, 1977, CANCER, V39, P1289, DOI 10.1002/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F; HENDERSON IC, 1989, J CLIN ONCOL, V7, P560, DOI 10.1200/JCO.1989.7.5.560; JOHNSTON AD, 1970, CLIN ORTHOPAEDICS, V73, P8; KELLIHAN MJ, 1992, ANN PHARMACOTHER, V26, P1262, DOI 10.1177/106002809202601015; MATTSSON W, 1982, CANCER, V49, P217, DOI 10.1002/1097-0142(19820115)49:2<217::AID-CNCR2820490203>3.0.CO;2-M; MORTON AR, 1988, BRIT MED J, V297, P772, DOI 10.1136/bmj.297.6651.772; MUSS HB, 1982, CANCER, V50, P2269, DOI 10.1002/1097-0142(19821201)50:11<2269::AID-CNCR2820501107>3.0.CO;2-L; PARVINEN LM, 1985, ACTA ONCOL, V24, P391, DOI 10.3109/02841868509134406; SPITZER WO, 1981, J CHRON DIS, V34, P585, DOI 10.1016/0021-9681(81)90058-8; TONG D, 1982, CANCER, V50, P893, DOI 10.1002/1097-0142(19820901)50:5<893::AID-CNCR2820500515>3.0.CO;2-Y; VANHOLTENVERZANTVOORT ATM, 1991, EUR J CANCER, V27, P544, DOI 10.1016/0277-5379(91)90212-V; VANHOLTENVERZANTVOORT ATM, 1993, J CLIN ONCOL, V11, P491, DOI 10.1200/JCO.1993.11.3.491; WHITEHOUSE JMA, 1985, J ROY SOC MED, V78, P18	27	779	796	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 12	1996	335	24					1785	1791		10.1056/NEJM199612123352401	http://dx.doi.org/10.1056/NEJM199612123352401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW683	8965890				2022-12-28	WOS:A1996VW68300001
J	Schambelan, M; Mulligan, K; Grunfeld, C; Daar, ES; LaMarca, A; Kotler, DP; Wang, J; Bozzette, SA; Breitmayer, JB; Hurley, A; Javaly, K; Pitt, J; Pang, M; Heald, AE; Shipp, KW; Pearce, D; Sova, K; Pate, P; Boswell, SL; Flynn, T; Polsky, B; Haverstick, L; Rothkopf, MM; Bliffen, DL; Rosenfeld, R; Pierson, RN; Winson, G; Tai, V; Bennison, WM; Kennedy, SM; Neu, TK; Robinson, CE; Schwalbert, RJ; LaMarca, D; Kuritzkes, DR; Ray, MG; Mellors, JW; Balser, BE; Balser, JP				Schambelan, M; Mulligan, K; Grunfeld, C; Daar, ES; LaMarca, A; Kotler, DP; Wang, J; Bozzette, SA; Breitmayer, JB; Hurley, A; Javaly, K; Pitt, J; Pang, M; Heald, AE; Shipp, KW; Pearce, D; Sova, K; Pate, P; Boswell, SL; Flynn, T; Polsky, B; Haverstick, L; Rothkopf, MM; Bliffen, DL; Rosenfeld, R; Pierson, RN; Winson, G; Tai, V; Bennison, WM; Kennedy, SM; Neu, TK; Robinson, CE; Schwalbert, RJ; LaMarca, D; Kuritzkes, DR; Ray, MG; Mellors, JW; Balser, BE; Balser, JP			Recombinant human growth hormone in patients with HIV-associated wasting - A randomized, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						somatotropin; human immunodeficiency virus infections; weight loss; weight gain; body composition	IMMUNODEFICIENCY-VIRUS INFECTION; X-RAY ABSORPTIOMETRY; BODY-COMPOSITION; DEFICIENT ADULTS; PARENTERAL-NUTRITION; MEGESTROL-ACETATE; AIDS; PROTEIN; MASS; RISK	Background: Body wasting, particularly loss of body cell mass, is an increasingly prevalent acquired immunodeficiency syndrome (AIDS)-defining condition and is an independent risk factor for death in patients infected with the human immunodeficiency virus (HIV). Treatment with growth hormone for 7 days resulted in weight gain and nitrogen retention, but the long-term effects of this treatment in patients with HIV-associated wasting are not known. Objective: To evaluate the long-term effect of treatment with growth hormone on weight, body composition, functional performance, and quality of life in patients with HIV-associated wasting. Design: Randomized, double-blind, placebo-controlled, multicenter trial. Setting: Outpatient university and community-based patient care facilities. Patients: 178 HIV-infected patients with a documented unintentional weight loss of at least 10% or weight less than 90% of the lower limit of ideal body weight. Intervention: Patients were randomly assigned to receive either recombinant human growth hormone, 0.1 mg/kg of body weight per day (average dosage, 6 mg/d) (n = 90) or placebo (n = 88) for 12 weeks. Measurements: Weight; body fat, lean body mass, and bone mineral content (measured by dual-energy x-ray absorptiometry); total body water (by deuterium oxide dilution); extracellular water (by sodium bromide dilution); work output (by treadmill exercise); quality of life; and safety of treatment. Results: Treatment with growth hormone resulted in a sustained and statistically significant increase in weight (mean increase +/- SD, 1.6 +/- 3.7 kg [P < 0.001]) and lean body mass (3.0 +/- 3.0 kg [P < 0.001]), accompanied by a decrease in body fat (-1.7 +/- 1.7 kg [P < 0.001]). In contrast, in patients receiving placebo, weight (increase, 0.1 +/- 3.1 kg), lean body mass (decrease, 0.1 +/- 2.0 kg), and body fat (decrease, 0.3 +/- 2.2 kg) did not change significantly from baseline. Differences between groups at week 12 were statistically significant (P = 0.011 for body weight and P < 0.001 for lean body mass and body fat). A greater increase in treadmill work output was noted in the group receiving growth hormone (increase, 99 +/- 293 kg . m/min) compared with the group receiving placebo (increase, 20 +/- 233 kg . m/min) (P = 0.039). Health status (quality of rife) scores did not differ between groups at baseline or after treatment. Days of disability and use of medical resources were the same for both groups. Treatment was well tolerated; no significant differences were seen between groups in clinical events, progression of AIDS, CD4(+) or CD8(+) cell counts, or viral burden. Conclusion: Treatment with growth hormone increases body weight, lean body mass, and treadmill work output and appears to be a safe and potentially effective therapy in patients with HIV-associated wasting.	DEPT VET AFFAIRS MED CTR, SAN FRANCISCO, CA USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; CEDARS SINAI MED CTR, LOS ANGELES, CA 90048 USA; THERAFIRST MED CTR, FT LAUDERDALE, FL USA; ST LUKES ROOSEVELT HOSP, NEW YORK, NY USA; COLUMBIA UNIV, NEW YORK, NY USA; DEPT VET AFFAIRS MED CTR, SAN DIEGO, CA USA; SERONO LABS, NORWELL, MA USA	University of California System; University of California San Francisco; Cedars Sinai Medical Center; Mount Sinai St. Luke's; Mount Sinai West; Columbia University	Schambelan, M (corresponding author), SAN FRANCISCO GEN HOSP, BLDG 100, ROOM 321, 1001 POTRERO AVE, SAN FRANCISCO, CA 94110 USA.				NIDDK NIH HHS [DK40990, DK45833, DK49448] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040990, R01DK049448, R01DK045833] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAL JE, 1995, J PAIN SYMPTOM MANAG, V10, P89, DOI 10.1016/0885-3924(94)00117-4; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; Berry SH, 1994, MEASURING PATIENT RE; BOZZETTE SA, 1994, MED CARE, V32, P716, DOI 10.1097/00005650-199407000-00005; BOZZETTE SA, 1995, JAMA-J AM MED ASSOC, V273, P295, DOI 10.1001/jama.273.4.295; Brooks G, 1984, EXERCISE PHYSL; BYRNE TA, 1993, ANN SURG, V218, P400, DOI 10.1097/00000658-199310000-00002; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695, DOI 10.1152/jappl.1991.70.2.695; CUNEO RC, 1991, J APPL PHYSIOL, V70, P688, DOI 10.1152/jappl.1991.70.2.688; EHRENPREIS ED, 1992, J ACQ IMMUN DEF SYND, V5, P1047; FRADKIN JE, 1993, JAMA-J AM MED ASSOC, V270, P2829, DOI 10.1001/jama.270.23.2829; GORE DC, 1991, ARCH SURG-CHICAGO, V126, P38; GUENTER P, 1993, J ACQ IMMUN DEF SYND, V6, P1130; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; HORBER FF, 1992, BRIT J RADIOL, V65, P895, DOI 10.1259/0007-1285-65-778-895; JORGENSEN JOL, 1989, LANCET, V1, P1221; KOTLER DP, 1991, AM J CLIN NUTR, V53, P149, DOI 10.1093/ajcn/53.1.149; KOTLER DP, 1990, JPEN-PARENTER ENTER, V14, P454, DOI 10.1177/0148607190014005454; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; KRENTZ AJ, 1993, J ACQ IMMUN DEF SYND, V6, P245; LAURENCE J, 1992, BLOOD, V79, P467; MANSON JM, 1988, ANN SURG, V208, P136, DOI 10.1097/00000658-198808000-00002; MAZESS RB, 1990, AM J CLIN NUTR, V51, P1106, DOI 10.1093/ajcn/51.6.1106; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Moore FD, 1963, BODY CELL MASS ITS S; MULLIGAN K, 1993, J CLIN ENDOCR METAB, V77, P956, DOI 10.1210/jc.77.4.956; OSTER MH, 1994, ANN INTERN MED, V121, P400, DOI 10.7326/0003-4819-121-6-199409150-00002; OTT M, 1995, J ACQ IMMUN DEF SYND, V9, P20; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; PALENICEK JP, 1995, J ACQ IMMUN DEF SYND, V10, P366; POVOLOTSKY J, 1992, PEDIATR AIDS HIV INF, V3, P108; RITZEN EM, 1993, HORM RES, V39, P99; ROSENFELD RG, 1986, J PEDIATR-US, V109, P428, DOI 10.1016/S0022-3476(86)80112-3; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; SCHOELLER DA, 1980, AM J CLIN NUTR, V33, P2686, DOI 10.1093/ajcn/33.12.2686; *SOC ACT ASS LIF I, 1980, 1979 BUILD STUD, P127; STRUWE M, 1993, ANN PHARMACOTHER, V27, P827, DOI 10.1177/106002809302700701; SUTTMANN U, 1995, J ACQ IMMUN DEF SYND, V8, P239, DOI 10.1097/00042560-199503010-00004; SVENDSEN OL, 1993, AM J CLIN NUTR, V57, P605, DOI 10.1093/ajcn/57.5.605; TUFFLI GA, 1995, J CLIN ENDOCR METAB, V80, P1416, DOI 10.1210/jc.80.4.1416; TURNER J, 1994, INT C AIDS, V10, P35; VONROENN JH, 1994, ANN INTERN MED, V121, P393, DOI 10.7326/0003-4819-121-6-199409150-00001; WARD HC, 1987, ANN SURG, V206, P56, DOI 10.1097/00000658-198707000-00009; WEISS PJ, 1993, NEW ENGL J MED, V329, P1962, DOI 10.1056/NEJM199312233292612; WONG WW, 1989, AM J CLIN NUTR, V50, P1290, DOI 10.1093/ajcn/50.6.1290; 1991, GUIDELINES EXERCISE	46	254	258	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1996	125	11					873	+		10.7326/0003-4819-125-11-199612010-00002	http://dx.doi.org/10.7326/0003-4819-125-11-199612010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV541	8967667				2022-12-28	WOS:A1996VV54100002
J	Asbury, D; Boggis, CRM; Sheals, D; Threlfall, AG; Woodman, CBJ				Asbury, D; Boggis, CRM; Sheals, D; Threlfall, AG; Woodman, CBJ			NHS breast screening programme: Is the high incidence of interval cancers inevitable?	BRITISH MEDICAL JOURNAL			English	Article									CHRISTIE HOSP NHS TRUST,CTR CANC EPIDEMIOL,MANCHESTER M20 4QL,LANCS,ENGLAND; WITHINGTON HOSP,MANCHESTER BREAST SCREENING SERV,MANCHESTER M20 0PT,LANCS,ENGLAND; ROYAL ALBERT EDWARD INFIRM,WIGAN BREAST SCREENING SERV,WIGAN WN1 2NN,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; University of Manchester								Day N, 1995, J Med Screen, V2, P180; FIELD S, 1995, BRIT MED J, V310, P203, DOI 10.1136/bmj.310.6974.203; FRISELL J, 1992, BREAST CANCER RES TR, V24, P11, DOI 10.1007/BF01832353; PEETERS PHM, 1989, BRIT J CANCER, V59, P929, DOI 10.1038/bjc.1989.196; WOODMAN CBJ, 1995, BRIT MED J, V310, P224, DOI 10.1136/bmj.310.6974.224	5	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1996	313	7069					1369	1370		10.1136/bmj.313.7069.1369	http://dx.doi.org/10.1136/bmj.313.7069.1369			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW685	8956704	Green Published			2022-12-28	WOS:A1996VW68500026
J	Harrison, R; Clayton, W; Wallace, P				Harrison, R; Clayton, W; Wallace, P			Can telemedicine be used to improve communication between primary and secondary care?	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS; CONSULTATION	Objective-To test feasibility and acceptability of teleconferencing routine outpatient consultations. Design-Exploratory trial of teleconferenced outpatient referrals of general practitioners. Setting-An inner city teaching hospital and surrounding general practices. Subjects-Six general practices linked to hospital outpatient clinics. Main outcome measures-Levels of participants' satisfaction measured with self administered questionnaires. Results-54 teleconsultations were performed in 10 different specialties. Few serious technical problems were encountered, and high levels of satisfaction with the consultations were reported by patients, hospital specialists, and general practitioners. Conclusions-Teleconferenced consultations for routine outpatient referrals with joint participation of general practitioner were feasible. These may have an important potential benefit for improving communication between primary and secondary care.			Harrison, R (corresponding author), UCL, SCH MED, ROYAL FREE HOSP, DEPT PRIMARY CARE & POPULAT SCI, LONDON NW3 2PF, ENGLAND.							*ADV GROUP HLTH TE, 1996, ASS EFF HLTH TECHN P; Allen A, 1995, Telemed J, V1, P41, DOI 10.1089/tmj.1.1995.1.41; BAILEY JJ, 1994, BRIT MED J, V308, P1083, DOI 10.1136/bmj.308.6936.1083; Brahams D, 1996, ROY S MED S, P54; COULTER A, 1992, REFERRALS MED OUTPAT, P97; *DEP HLTH, 1991, RES HLTH RES DEV STR; DWYER TF, 1973, AM J PSYCHIAT, V130, P865, DOI 10.1176/ajp.130.8.865; FRY J, 1988, BRIT MED J, V297, P337, DOI 10.1136/bmj.297.6644.337; HUBBLE JP, 1992, KANS MED, V93, P1212; LITTLEJOHNS PC, 1986, J ROY COLL GEN PRACT, V36, P313; MCLAREN P, 1995, BRIT MED J, V310, P1390, DOI 10.1136/bmj.310.6991.1390; Rinde Eivind Vvar Nordrum, 1993, World Health Forum, V14, P71; ROLAND M, 1992, J PUBLIC HEALTH MED, V14, P307; ROLAND M, 1992, HOSP REFERRALS, P108; VIERHOUT WPM, 1995, LANCET, V346, P990, DOI 10.1016/S0140-6736(95)91686-5	15	111	111	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 30	1996	313	7069					1377	1380		10.1136/bmj.313.7069.1377	http://dx.doi.org/10.1136/bmj.313.7069.1377			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW685	8956708	Green Published			2022-12-28	WOS:A1996VW68500030
J	Raine, R; Streetly, A; Daves, AM				Raine, R; Streetly, A; Daves, AM			Variation in local policies and guidelines for cholesterol management: National survey	BRITISH MEDICAL JOURNAL			English	Article									UNITED MED & DENT SCH,ST THOMAS HOSP,DEPT PUBL HLTH MED,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Raine, R (corresponding author), LAMBETH SOUTHWARK & LEWISHAM HLTH AUTHOR,DIRECTORATE PUBL HLTH & HLTH POLICY,LONDON SE1 7NT,ENGLAND.			Raine, Rosalind/0000-0003-0904-749X				[Anonymous], 1994, EFF HLTH CAR B; Pharoah PDP, 1996, BMJ-BRIT MED J, V312, P1443, DOI 10.1136/bmj.312.7044.1443; *U LEEDS, 1993, EFF HLTH CAR B, V6	3	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1996	313	7069					1368	1369		10.1136/bmj.313.7069.1368	http://dx.doi.org/10.1136/bmj.313.7069.1368			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW685	8956703	Green Published			2022-12-28	WOS:A1996VW68500025
J	Kushwaha, SS; Fallon, JT; Fuster, V				Kushwaha, SS; Fallon, JT; Fuster, V			Medical progress - Restrictive cardiomyopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CARCINOID HEART-DISEASE; IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; FAMILIAL AMYLOID POLYNEUROPATHY; PRIMARY SYSTEMIC AMYLOIDOSIS; CONSTRICTIVE PERICARDITIS; CARDIAC AMYLOIDOSIS; ENDOMYOCARDIAL BIOPSY; DOPPLER ECHOCARDIOGRAPHY; DIASTOLIC FUNCTION; RADIONUCLIDE ANGIOGRAPHY				Kushwaha, SS (corresponding author), CUNY, MT SINAI MED CTR, CARDIOVASC INST, BOX 1030, 1 GUSTAVE LEVY PL, NEW YORK, NY 10029 USA.		Fuster, Valentin/H-4319-2015	Fuster, Valentin/0000-0002-9043-9986; Fallon, John/0000-0002-7677-4868				ABELMANN WH, 1984, PROG CARDIOVASC DIS, V27, P73, DOI 10.1016/0033-0620(84)90020-3; ANGOMACHALELIS N, 1992, POSTGRAD MED J, V68, pS52; APPLETON CP, 1988, J AM COLL CARDIOL, V11, P757, DOI 10.1016/0735-1097(88)90208-2; ARBUSTINI E, 1995, AM HEART J, V130, P528, DOI 10.1016/0002-8703(95)90362-3; ARONEY C, 1988, AUST NZ J MED, V18, P877, DOI 10.1111/j.1445-5994.1988.tb01654.x; ARONEY CN, 1989, J AM COLL CARDIOL, V13, P1007, DOI 10.1016/0735-1097(89)90252-0; Backes R J, 1992, Cardiovasc Clin, V22, P105; BALAKRISHNAN KG, 1986, CARDIOLOGY, V73, P73, DOI 10.1159/000173987; Becker A E, 1988, Cardiovasc Clin, V19, P9; BENOTTI JR, 1980, CIRCULATION, V61, P1206, DOI 10.1161/01.CIR.61.6.1206; BERGER PB, 1994, MAYO CLIN PROC, V69, P162, DOI 10.1016/S0025-6196(12)61043-X; Billingham M E, 1985, Heart Vessels Suppl, V1, P278; BLAKE S, 1983, BRIT HEART J, V50, P273; Bolster Marcy B., 1994, Current Opinion in Rheumatology, V6, P642, DOI 10.1097/00002281-199411000-00016; BOOTH DR, 1995, CIRCULATION, V91, P962, DOI 10.1161/01.CIR.91.4.962; BOUCHARD A, 1989, AM J MED, V87, P160; BOUSTANY CW, 1991, ANN THORAC SURG, V51, P1007, DOI 10.1016/0003-4975(91)91034-S; Branea I, 1986, Med Interne, V24, P197; BROSIUS FC, 1981, AM J MED, V70, P519, DOI 10.1016/0002-9343(81)90574-X; BULOCK FA, 1995, BRIT HEART J, V73, P340; Buxbaum J, 1996, MT SINAI J MED, V63, P16; CAMERON J, 1987, AM HEART J, V113, P354, DOI 10.1016/0002-8703(87)90278-X; CETTA F, 1995, MAYO CLIN PROC, V70, P634, DOI 10.4065/70.7.634; CHEW C, 1975, AM J CARDIOL, V36, P438, DOI 10.1016/0002-9149(75)90891-7; CHEW CYC, 1977, BRIT HEART J, V39, P399; Child J S, 1988, Cardiol Clin, V6, P289; COOKE R, 1994, BRIT HEART J, V71, P561; CUETOGARCIA L, 1985, J AM COLL CARDIOL, V6, P737, DOI 10.1016/S0735-1097(85)80475-7; CUETOGARCIA L, 1984, MAYO CLIN PROC, V59, P589, DOI 10.1016/S0025-6196(12)62409-4; DAUBERT JP, 1993, AM J MED, V94, P335, DOI 10.1016/0002-9343(93)90066-X; DENG M, 1992, J HEART LUNG TRANSPL, V11, P139; DERVAN JP, 1991, CATHETER CARDIO DIAG, V22, P184, DOI 10.1002/ccd.1810220307; DUBREY S, 1995, AM J CARDIOL, V76, P739, DOI 10.1016/S0002-9149(99)80214-8; ERIKSSON A, 1983, ACTA PATH MICRO IM A, V91, P343; ERIKSSON P, 1986, ACTA ANAESTH SCAND, V30, P317, DOI 10.1111/j.1399-6576.1986.tb02422.x; FALK RH, 1984, J AM COLL CARDIOL, V3, P107, DOI 10.1016/S0735-1097(84)80436-2; FALK RH, 1983, AM J CARDIOL, V51, P826, DOI 10.1016/S0002-9149(83)80140-4; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; FAWZY ME, 1985, J AM COLL CARDIOL, V5, P983; FEIN FS, 1994, CARDIOVASC DRUG THER, V8, P65, DOI 10.1007/BF00877091; FELD S, 1992, ISRAEL J MED SCI, V28, P277; FIORI MG, 1994, CARDIOLOGY, V85, P145, DOI 10.1159/000176669; FITZPATRICK AP, 1990, BRIT HEART J, V63, P114; FOWLER NO, 1995, CLIN CARDIOL, V18, P341, DOI 10.1002/clc.4960180610; FURTH PA, 1985, AM J MED SCI, V290, P209, DOI 10.1097/00000441-198511000-00006; GALLO G, 1994, AM J PATHOL, V145, P526; GARRETT J, 1984, AM HEART J, V107, P394, DOI 10.1016/0002-8703(84)90394-6; GERTZ MA, 1991, BLOOD, V77, P257; GERTZ MA, 1992, MAYO CLIN PROC, V67, P428, DOI 10.1016/S0025-6196(12)60388-7; GERTZ MA, 1993, AM J HEMATOL, V44, P125, DOI 10.1002/ajh.2830440210; GERTZ MA, 1994, SEMIN ARTHRITIS RHEU, V24, P124, DOI 10.1016/S0049-0172(05)80006-X; GIBBONS WJ, 1991, CHEST, V100, P44, DOI 10.1378/chest.100.1.44; Gilbert E F, 1987, Am J Cardiovasc Pathol, V1, P189; GOMEZ GA, 1983, CANCER TREAT REP, V67, P1099; GOODWIN JF, 1992, POSTGRAD MED J, V68, pS3; GOTTDIENER JS, 1983, CIRCULATION, V67, P572, DOI 10.1161/01.CIR.67.3.572; GOTTDIENER JS, 1983, NEW ENGL J MED, V308, P569, DOI 10.1056/NEJM198303103081005; GUSTAVSSON A, 1994, AM J PATHOL, V144, P1301; HATLE LK, 1989, CIRCULATION, V79, P357, DOI 10.1161/01.CIR.79.2.357; HESSE A, 1993, BRIT HEART J, V70, P111; HILLSLEY RE, 1995, AM HEART J, V129, P199, DOI 10.1016/0002-8703(95)90062-4; HIROTA Y, 1990, AM HEART J, V120, P188, DOI 10.1016/0002-8703(90)90177-Y; HONGO M, 1989, J AM COLL CARDIOL, V13, P48, DOI 10.1016/0735-1097(89)90547-0; HOSENPUD JD, 1991, CIRCULATION, V84, P338; HOSHII Y, 1994, PATHOL INT, V44, P352; ISHIWATA S, 1993, JPN CIRC J, V57, P928, DOI 10.1253/jcj.57.928; IWAI K, 1994, SARCOIDOSIS, V11, P26; KATRITSIS D, 1991, J AM COLL CARDIOL, V18, P1230, DOI 10.1016/0735-1097(91)90540-P; KAVANAGH T, 1995, CAN J CARDIOL, V11, P136; KAWAMURA S, 1995, PATHOL INT, V45, P335, DOI 10.1111/j.1440-1827.1995.tb03466.x; KILLIAN DM, 1989, AM HEART J, V118, P563, DOI 10.1016/0002-8703(89)90273-1; KIM CH, 1984, AM J CARDIOL, V53, P1472, DOI 10.1016/S0002-9149(84)91473-5; KINOSHITA O, 1989, BRIT HEART J, V61, P198; KLEIN AL, 1991, CIRCULATION, V83, P808, DOI 10.1161/01.CIR.83.3.808; KLEIN AL, 1993, J AM COLL CARDIOL, V22, P1935, DOI 10.1016/0735-1097(93)90782-V; LEKAKIS J, 1992, AM HEART J, V124, P1630, DOI 10.1016/0002-8703(92)90085-A; LEWIS AB, 1992, AM HEART J, V123, P1589, DOI 10.1016/0002-8703(92)90814-C; LI XA, 1995, ARTERIOSCL THROM VAS, V15, P252, DOI 10.1161/01.ATV.15.2.252; LOOI LM, 1993, HUM PATHOL, V24, P602; LUNDIN L, 1991, PATHOL RES PRACT, V187, P73, DOI 10.1016/S0344-0338(11)81048-4; LUNDIN L, 1988, CIRCULATION, V77, P264, DOI 10.1161/01.CIR.77.2.264; MASON JW, 1977, CIRCULATION, V56, P889, DOI 10.1161/01.CIR.56.5.889; MASON JW, 1989, CIRCULATION, V79, P971, DOI 10.1161/01.CIR.79.5.971; MASUI T, 1992, RADIOLOGY, V182, P369, DOI 10.1148/radiology.182.2.1732952; MATSUI Y, 1976, ANN NY ACAD SCI, V278, P455, DOI 10.1111/j.1749-6632.1976.tb47058.x; MCDOUGALL NI, 1994, INT J CARDIOL, V47, P165, DOI 10.1016/0167-5273(94)90184-8; METRAS D, 1985, CIRCULATION, V72, P274; MORGAN JM, 1989, BRIT HEART J, V61, P29; MORTENSEN SA, 1986, BRIT HEART J, V55, P274; NAKATA T, 1995, J NUCL MED, V36, P1040; NAVARROLOPEZ F, 1980, CHEST, V78, P113, DOI 10.1378/chest.78.1.113; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; NIEDERAU C, 1994, BAILLIERE CLIN HAEM, V7, P881, DOI 10.1016/S0950-3536(05)80129-5; OKAYAMA K, 1995, CHEST, V107, P330, DOI 10.1378/chest.107.2.330; OLSEN EGJ, 1985, PROG CARDIOVASC DIS, V27, P241, DOI 10.1016/0033-0620(85)90008-8; OLSON LJ, 1987, NEW ENGL J MED, V317, P738, DOI 10.1056/NEJM198709173171205; OLSON LJ, 1984, AM J CARDIOL, V53, P980, DOI 10.1016/0002-9149(84)90551-4; ONI AA, 1992, J HEART LUNG TRANSPL, V11, P367; PELLIKKA PA, 1993, CIRCULATION, V87, P1188, DOI 10.1161/01.CIR.87.4.1188; PERRY A, 1995, ARCH PATHOL LAB MED, V119, P167; POLITI A, 1995, BRIT HEART J, V73, P486; RANLOV I, 1992, AM J MED, V93, P3, DOI 10.1016/0002-9343(92)90672-X; RATNER SJ, 1986, CHEST, V90, P528, DOI 10.1378/chest.90.4.528; RENTERIA VG, 1976, AM J CARDIOL, V38, P487, DOI 10.1016/0002-9149(76)90468-9; Richardson P, 1996, CIRCULATION, V93, P841, DOI 10.1161/01.CIR.93.5.841; ROBERTS WC, 1969, AM J MED, V46, P28, DOI 10.1016/0002-9343(69)90055-2; ROBERTS WC, 1968, AM J CARDIOL, V22, P85, DOI 10.1016/0002-9149(68)90250-6; ROBIOLIO PA, 1995, CIRCULATION, V92, P790, DOI 10.1161/01.CIR.92.4.790; SAEKI M, 1995, CIRCULATION, V91, P2497, DOI 10.1161/01.CIR.91.9.2497; SARAIVA MJM, 1992, AM J HUM GENET, V50, P1027; SARAIVA MJM, 1995, HUM MUTAT, V5, P191; SCHAFFER SW, 1992, AM J PHYSIOL, V262, pH1428; SCHOENFELD M H, 1990, Cardiology Clinics, V8, P663; SCHOENFELD MH, 1987, CIRCULATION, V75, P1012, DOI 10.1161/01.CIR.75.5.1012; SCHULTZHECTOR S, 1994, LAB INVEST, V71, P252; SCHULTZHECTOR S, 1992, RADIAT RES, V129, P281, DOI 10.2307/3578027; Schurle D R, 1984, J Kans Med Soc, V85, P49; SHAPER AG, 1968, BRIT HEART J, V30, P391; SHIBUYA T, 1992, INTERNAL MED, V31, P544, DOI 10.2169/internalmedicine.31.544; SIEGEL RJ, 1984, CIRCULATION, V70, P165, DOI 10.1161/01.CIR.70.2.165; Skinner M, 1996, AM J MED, V100, P290, DOI 10.1016/S0002-9343(97)89487-9; SMITH RRL, 1978, AM J MED, V65, P352, DOI 10.1016/0002-9343(78)90832-X; SMITH TJ, 1984, MAYO CLIN PROC, V59, P547, DOI 10.1016/S0025-6196(12)61493-1; STARK RM, 1977, AM J MED, V63, P653, DOI 10.1016/0002-9343(77)90211-X; TAI PC, 1987, LANCET, V1, P643; TAWARAHARA K, 1992, AM HEART J, V124, P1383, DOI 10.1016/0002-8703(92)90431-T; TYBERG TI, 1981, AM J CARDIOL, V47, P791, DOI 10.1016/0002-9149(81)90175-2; UYAMA E, 1992, ACTA NEUROL SCAND, V86, P407, DOI 10.1111/j.1600-0404.1992.tb05109.x; VAITKUS PT, 1991, AM HEART J, V122, P1431, DOI 10.1016/0002-8703(91)90587-8; VALANTINE H, 1987, BRIT HEART J, V57, P256; VALANTINE H A, 1987, Journal of Heart Transplantation, V6, P244; VIRMANI R, 1980, CHEST, V77, P423, DOI 10.1378/chest.77.3.423; WALTENBERGER J, 1993, AM J PATHOL, V142, P71; WILMSHURST PT, 1990, BRIT HEART J, V63, P323; WINTERS SL, 1991, J AM COLL CARDIOL, V18, P937, DOI 10.1016/0735-1097(91)90750-4; 1994, NEW ENGL J MED, V331, P460	136	243	255	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1997	336	4					267	276		10.1056/NEJM199701233360407	http://dx.doi.org/10.1056/NEJM199701233360407			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE632	8995091				2022-12-28	WOS:A1997WE63200007
J	Gershenfeld, NA; Chuang, IL				Gershenfeld, NA; Chuang, IL			Bulk spin-resonance quantum computation	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; LOGIC GATE; UNIVERSAL; COHERENCE; COMPUTERS	Quantum computation remains an enormously appealing but elusive goal. it is appealing because of its potential to perform superfast algorithms, such as finding prime factors in polynomial time, but also elusive because of the difficulty of simultaneously manipulating quantum degrees of freedom while preventing environmentally induced decoherence. A new approach to quantum computing is introduced based on the use of multiple-pulse resonance techniques to manipulate the small deviation from equilibrium of the density matrix of a macroscopic ensemble so that it appears to be the density matrix of a much lower dimensional pure state. A complete prescription for quantum computing is given for such a system.	UNIV CALIF SANTA BARBARA, INST THEORET PHYS, SANTA CLARA, CA 93106 USA	University of California System; University of California Santa Barbara	Gershenfeld, NA (corresponding author), MIT, MEDIA LAB, PHYS & MEDIA GRP, CAMBRIDGE, MA 02139 USA.			/0000-0001-7296-523X				Bandyopadhyay S, 1996, JPN J APPL PHYS 1, V35, P3350, DOI 10.1143/JJAP.35.3350; BARENCO A, 1995, PHYS REV A, V52, P3457, DOI 10.1103/PhysRevA.52.3457; BECKMAN D, 1996, QUANTPH9602016 LOS A; BLOCH F, 1946, PHYS REV, V70, P460, DOI 10.1103/PhysRev.70.460; CHUANG IL, 1995, PHYS REV A, V52, P3489, DOI 10.1103/PhysRevA.52.3489; CHUANG IL, 1995, SCIENCE, V270, P1633, DOI 10.1126/science.270.5242.1633; CHUPP TE, 1988, PHYS REV A, V38, P3998, DOI 10.1103/PhysRevA.38.3998; CIRAC JI, 1995, PHYS REV LETT, V74, P4091, DOI 10.1103/PhysRevLett.74.4091; CORY D, IN PRESS P NATL ACAD; DEUTSCH D, 1992, P ROY SOC LOND A MAT, V439, P553, DOI 10.1098/rspa.1992.0167; DIVINCENZO DP, 1995, PHYS REV A, V51, P1015, DOI 10.1103/PhysRevA.51.1015; DIVINCENZO DP, 1995, SCIENCE, V270, P255, DOI 10.1126/science.270.5234.255; DOMOKOS P, 1995, PHYS REV A, V52, P3554, DOI 10.1103/PhysRevA.52.3554; Ekert A, 1996, REV MOD PHYS, V68, P733, DOI 10.1103/RevModPhys.68.733; ERNST RR, 1994, PRINCIPLES NUCLEAR M; Hardy G.H., 2008, INTRO THEORY NUMBERS, V6th; KITAEV AY, 1995, QUANTPH9511026 LOS A; LLOYD S, 1995, SCI AM, V273, P140, DOI 10.1038/scientificamerican1095-140; LLOYD S, 1993, SCIENCE, V261, P1569, DOI 10.1126/science.261.5128.1569; LLOYD S, 1995, PHYS REV LETT, V75, P346, DOI 10.1103/PhysRevLett.75.346; MATEESCU G, 1993, 22D NMR DENSITY MATR; MORRIS GA, 1979, J AM CHEM SOC, V101, P760, DOI 10.1021/ja00497a058; SCHUMACHER B, 1995, PHYS REV A, V51, P2738, DOI 10.1103/PhysRevA.51.2738; Shor P. W., 1994, P 35 ANN S FDN COMP; SHOR PW, 1995, PHYS REV A, V52, pR2493, DOI 10.1103/PhysRevA.52.R2493; SHOR PW, IN PRESS SIAM J COMP; Simon D. R., 1994, Proceedings. 35th Annual Symposium on Foundations of Computer Science (Cat. No.94CH35717), P116, DOI 10.1109/SFCS.1994.365701; Steane AM, 1996, PHYS REV LETT, V77, P793, DOI 10.1103/PhysRevLett.77.793; TURCHETTE QA, 1995, PHYS REV LETT, V75, P4710, DOI 10.1103/PhysRevLett.75.4710; Wago K, 1996, J VAC SCI TECHNOL B, V14, P1197, DOI 10.1116/1.588513; WARREN WS, 1979, PHYS REV LETT, V43, P1791, DOI 10.1103/PhysRevLett.43.1791; ZHANG Y, 1995, MOL PHYS, V86, P347, DOI 10.1080/00268979509413617	35	1342	1412	0	111	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 17	1997	275	5298					350	356		10.1126/science.275.5298.350	http://dx.doi.org/10.1126/science.275.5298.350			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994025				2022-12-28	WOS:A1997WC87300036
J	Holmes, DR; Califf, RM; VandeWerf, F; Berger, PB; Bates, ER; Simoons, ML; White, HD; Thompson, TD; Topol, EJ				Holmes, DR; Califf, RM; VandeWerf, F; Berger, PB; Bates, ER; Simoons, ML; White, HD; Thompson, TD; Topol, EJ			Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: Results from the GUSTO trial	LANCET			English	Article							UNITED-STATES; ANGIOPLASTY THERAPY; MORTALITY; REPERFUSION; MANAGEMENT; REGISTRY; CANADA	Background Use of aggressive and invasive interventions is more common in the USA than in other countries. We have compared use of resources for patients with cardiogenic shock after myocardial infarction in the USA and in other countries, and assessed the association between use of resources and clinical outcomes. Methods We analysed data for patients with cardiogenic after myocardial infarction who were enrolled in the GUSTO-I trial (1891 treated in the USA, 1081 treated in other countries). Patients were randomly assigned combinations of streptokinase, heparin, and accelerated tissue-plasminogen activator (t-PA), then decisions about further interventions were left to the discretion of the attending physician. The interventions included in our analysis were: pulmonary-artery catheterisation, cardiac catheterisation, intravenous inotropic agents, ventilatory support, intra-aortic balloon counterpulsation (IABP), percutaneous transluminal coronary angioplasty (PTCA), and coronary bypass graft surgery (CABG). The primary outcome measure was death from any cause at 30 days of follow-up. Findings Patients who were treated in the USA were significantly younger than those treated elsewhere (median 68 [IQR 59-75] vs 70 [62-76], p<0.001), a smaller proportion had anterior infarction (49 vs 53%, p<0.001), and they had a shorter time to treatment (mean 3.1 vs 3.3 h, p<0.001). Aggressive diagnostic and therapeutic procedures were used more commonly in the USA than in the other countries: cardiac catheterisation (58 vs 23%); IABP (35 vs 7%); right-heart catheterisation (57 vs 22%); and ventilatory support (54 vs 38%). 483 (26%) of the patients treated in the USA underwent PTCA, compared with 82 (8%) patients in other countries. Patients who underwent revascularisation had better survival in all countries. Adjusted 30-day mortality was significantly lower among patients treated in the USA than among those treated elsewhere (50 vs 66%, p<0.001). The difference in mortality remained at 1 year-56% of patients treated in the USA died versus 70% of patients treated elsewhere (hazard ratio 0.69 [95% CI 0.63-0.75], p<0.001). Interpretation 30-day and 1-year mortality was significantly lower among patients treated in the USA than among those treated in other countries. This difference in mortality may be due to the greater use of invasive diagnostic and therapeutic interventions in the USA.	DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; UNIV ZIEKENHUIZEN LEUVEN, LOUVAIN, BELGIUM; UNIV MICHIGAN, MED CTR, DIV CARDIOL, ANN ARBOR, MI 48109 USA; ERASMUS UNIV ROTTERDAM, THORAXCTR, NL-3000 DR ROTTERDAM, NETHERLANDS; GREEN LANE HOSP, DEPT CARDIOL, AUCKLAND 3, NEW ZEALAND; DUKE CLIN RES INST, DURHAM, NC USA; CLEVELAND CLIN, DEPT CARDIOL, CLEVELAND, OH 44106 USA	Duke University; KU Leuven; University Hospital Leuven; University of Michigan System; University of Michigan; Erasmus University Rotterdam; Duke University; Cleveland Clinic Foundation	Holmes, DR (corresponding author), MAYO CLIN & MAYO FDN, 200 1ST ST SW, ROCHESTER, MN 55905 USA.			Topol, Eric/0000-0002-1478-4729				BARBASH GI, 1994, ARCH INTERN MED, V154, P2237, DOI 10.1001/archinte.154.19.2237; BARBASH GI, 1993, J AM COLL CARDIOL, V21, P281, DOI 10.1016/0735-1097(93)90664-M; GOLDBERG RJ, 1991, NEW ENGL J MED, V325, P1117, DOI 10.1056/NEJM199110173251601; HIBBARD MD, 1992, J AM COLL CARDIOL, V19, P639, DOI 10.1016/S0735-1097(10)80285-2; HOCHMAN JS, 1995, CIRCULATION, V91, P873, DOI 10.1161/01.CIR.91.3.873; HOLMES DR, 1995, J AM COLL CARDIOL, V26, P668, DOI 10.1016/0735-1097(95)00215-P; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; LEE L, 1991, J AM COLL CARDIOL, V17, P599, DOI 10.1016/S0735-1097(10)80171-8; LEE L, 1988, CIRCULATION, V1, P207; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; ONEILL WW, 1992, J AM COLL CARDIOL, V19, P915, DOI 10.1016/0735-1097(92)90270-W; PILOTE L, 1994, ARCH INTERN MED, V154, P1090, DOI 10.1001/archinte.154.10.1090; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VANDEWERF F, 1995, JAMA-J AM MED ASSOC, V273, P1586, DOI 10.1001/jama.273.20.1586	16	85	87	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 11	1997	349	9045					75	78		10.1016/S0140-6736(96)03031-0	http://dx.doi.org/10.1016/S0140-6736(96)03031-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996417	Green Submitted			2022-12-28	WOS:A1997WB80000008
J	OSullivan, JD; Allworth, AM; Paterson, DL; Snow, TM; Boots, R; Gleeson, LJ; Gould, AR; Hyatt, AD; Bradfield, J				OSullivan, JD; Allworth, AM; Paterson, DL; Snow, TM; Boots, R; Gleeson, LJ; Gould, AR; Hyatt, AD; Bradfield, J			Fatal encephalitis due to novel paramyxovirus transmitted from horses	LANCET			English	Article							MORBILLIVIRUS; HUMANS	Background In September, 1994, an outbreak of severe respiratory disease affected 18 horses, their trainer, and a stablehand in Queensland, Australia. Fourteen horses and one human being died. A novel virus was isolated from those affected and named equine morbillivirus (EMV). We report a case of encephalitis caused by this virus. Findings A 35-year-old man from Queensland had a brief aseptic meningitic illness in August, 1994, shortly after caring for two horses that died from EMV infection and then assisting at their necropsies. He then suffered severe encephalitis 13 months later, characterised by uncontrolled focal and generalised epileptic activity. Rising titres of neutralising antibodies to EMV in the patient's serum at the time of the second illness suggested an anamnestic response. Distinctive cortical changes were shown on magnetic resonance neuroimaging and histopathological examination of the brain at necropsy. Immunohistochemistry and electronmicroscopy of brain tissue revealed pathology characteristic of the earlier cases of EMV infection. PCR on cerebrospinal fluid taken during the second illness, brain tissue, and serum retained from the original illness resulted in an amplified product identical to that previously described from EMV. Interpretation The results of serology, PCR, electron-microscopy, and immunohistochemistry strongly suggest that EMV was the cause of this patient's encephalitis, and that exposure to the virus occurred 3 months before the fatal illness.	ROYAL BRISBANE HOSP,DEPT INFECT DIS,BRISBANE,QLD 4029,AUSTRALIA; ROYAL BRISBANE HOSP,DEPT NEUROL,BRISBANE,QLD 4029,AUSTRALIA; ROYAL BRISBANE HOSP,DEPT RADIOL,BRISBANE,QLD 4029,AUSTRALIA; ROYAL BRISBANE HOSP,DEPT INTENS CARE,BRISBANE,QLD 4029,AUSTRALIA; AUSTRALIAN ANIM HLTH LAB,GEELONG,VIC,AUSTRALIA	Royal Brisbane & Women's Hospital; Royal Brisbane & Women's Hospital; Royal Brisbane & Women's Hospital; Royal Brisbane & Women's Hospital; Commonwealth Scientific & Industrial Research Organisation (CSIRO)			O'Sullivan, John/C-6119-2013; Paterson, David L/A-9258-2010; Boots, Robert/K-1159-2013; Allworth, Anthony/G-3143-2011	Boots, Robert/0000-0002-2436-7654; Paterson, David/0000-0003-2079-4437				Gould AR, 1996, VIRUS RES, V43, P17, DOI 10.1016/0168-1702(96)01308-1; Hooper PT, 1996, AUST VET J, V74, P244, DOI 10.1111/j.1751-0813.1996.tb15414.x; MURRAY K, 1995, SCIENCE, V268, P94, DOI 10.1126/science.7701348; SELVEY LA, 1995, MED J AUSTRALIA, V162, P642, DOI 10.5694/j.1326-5377.1995.tb126050.x; Young PL, 1996, EMERG INFECT DIS, V2, P239, DOI 10.3201/eid0203.960315	5	232	244	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					93	95		10.1016/S0140-6736(96)06162-4	http://dx.doi.org/10.1016/S0140-6736(96)06162-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996421				2022-12-28	WOS:A1997WB80000012
J	Bell, SA; Schaller, M; Rocken, M				Bell, SA; Schaller, M; Rocken, M			Occlusive paromomycin for cutaneous leishmaniasis	LANCET			English	Article											Bell, SA (corresponding author), UNIV MUNICH,DEPT DERMATOL,D-80337 MUNICH,GERMANY.			Rocken, Martin/0000-0003-3795-7001				ELON J, 1992, J AM ACAD DERMATOL, V27, P227, DOI 10.1016/0190-9622(92)70175-F; ELON J, 1988, PARASITOL TODAY, V4, P76, DOI 10.1016/0169-4758(88)90200-1; KOFF AB, 1994, J AM ACAD DERMATOL, V31, P693, DOI 10.1016/S0190-9622(94)70229-2; ROCKEN M, 1995, DERMATOL VENEROL, P261	4	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					29	29		10.1016/S0140-6736(05)62161-7	http://dx.doi.org/10.1016/S0140-6736(05)62161-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988124				2022-12-28	WOS:A1997WA72500018
J	Bundey, S				Bundey, S			Few psychological consequences of presymptomatic testing for Huntington disease	LANCET			English	Editorial Material							DUTCH PROGRAM				Bundey, S (corresponding author), BIRMINGHAM WOMENS HOSP,CLIN GENET UNIT,BIRMINGHAM B15 2TG,W MIDLANDS,ENGLAND.							CODORI AM, 1994, AM J MED GENET, V54, P167, DOI 10.1002/ajmg.1320540303; *COMM INT HUNT ASS, 1994, J MED GENET, V31, P555; *HUNT DIS COLL RES, 1993, CELL, V72, P971; Lawson K, 1996, J MED GENET, V33, P856, DOI 10.1136/jmg.33.10.856; TIBBEN A, 1993, AM J MED GENET, V48, P103, DOI 10.1002/ajmg.1320480209; TIBBEN A, 1994, PSYCHOSOM MED, V56, P526, DOI 10.1097/00006842-199411000-00008	6	21	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					4	4		10.1016/S0140-6736(05)62155-1	http://dx.doi.org/10.1016/S0140-6736(05)62155-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988110				2022-12-28	WOS:A1997WA72500004
J	Wolffers, I				Wolffers, I			Culture, media, and HIV/AIDS in Asia	LANCET			English	Editorial Material							AIDS				Wolffers, I (corresponding author), VRIJE UNIV AMSTERDAM, FAC MED, SECT HLTH CARE DEV COUNTRIES, VAN DE BOECHORSTSTR 7, NL-1081 BT AMSTERDAM, NETHERLANDS.							Baker A. J., 1986, SOCIAL DIMENSIONS AI, P179; Clatts M C, 1989, Med Anthropol, V10, P105; DEBRUYN M, 1994, ALTERING IMAGE AIDS; FORD N, 1991, SOC SCI MED, V33, P405, DOI 10.1016/0277-9536(91)90321-3; Geertz Clifford, 1983, LOCAL KNOWLEDGE; Geertz Clifford, 1973, INTERPRETATION CULTU; HARRIS M, 1979, CULTURAL MATERIALISM; KEESING RM, 1987, CURR ANTHROPOL, V28, P161, DOI 10.1086/203508; KING D, 1990, WOMEN HEALTH, V16, P155, DOI 10.1300/J013v16n03_09; Lear D, 1990, INT Q COMMUN HLTH ED, V10, P253; Mann J., 1992, AIDS WORLD GLOBAL RE; NELKIN D, 1991, MILBANK Q, V69, P293, DOI 10.2307/3350206; Nelson KE, 1996, NEW ENGL J MED, V335, P297, DOI 10.1056/NEJM199608013350501; Osteria T, 1991, AIDS Educ Prev, V3, P133; PINS M, 1989, AIDS CARE, V1, P77; REID E, 1995, HIV AIDS GLOBAL INTE; SANDFORT T, 1992, 8 INT C AIDS AMST; Shilts Randy., 1987, BAND PLAYED; THANHDAM T, 1983, DEV CHANGE, V14, P533, DOI 10.1111/j.1467-7660.1983.tb00165.x; Weniger BG, 1996, NEW ENGL J MED, V335, P343, DOI 10.1056/NEJM199608013350510; Wolffers I, 1994, Ned Tijdschr Geneeskd, V138, P307; WOLFFERS I, 1995, HIV AIDS MASS MEDIA; WOLFFERS I, 1992, AIDS PRIMARY HLTH CA; WOLFFERS I, 1994, ALTERING IMAGE AIDS, P15	24	16	17	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 4	1997	349	9044					52	54		10.1016/S0140-6736(96)07032-8	http://dx.doi.org/10.1016/S0140-6736(96)07032-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WA725	8988132				2022-12-28	WOS:A1997WA72500047
J	Bingham, R; Dawson, JM; Shapiro, VD; Mendis, DA; Kellett, BJ				Bingham, R; Dawson, JM; Shapiro, VD; Mendis, DA; Kellett, BJ			Generation of X-rays from comet C/Hyakutake 1996 B2	SCIENCE			English	Article							PLASMA; HALLEY; GAS	The instability resulting from the relative motion of newly picked-up cometary photoions and the solar wind generates lower hybrid waves that are capable of accelerating electrons to the keV range of energies. These electrons may be responsible for the x-rays from comet C/Hyakutake 1996 B2 seen by the Rontgen X-ray Satellite. The inferred x-ray photon power depends on the electron energy, with keV electrons providing values of photon power two orders of magnitude greater than 100 eV electrons. These observations and in particular, spectral resolution of the x-rays, should provide more insight into the composition of the comet.	UNIV CALIF LOS ANGELES,DEPT PHYS,LOS ANGELES,CA 90024; UNIV CALIF SAN DIEGO,DEPT PHYS,LA JOLLA,CA 92092; UNIV CALIF SAN DIEGO,DEPT ELECT & COMP SCI,LA JOLLA,CA 92092	University of California System; University of California Los Angeles; University of California System; University of California San Diego; University of California System; University of California San Diego	Bingham, R (corresponding author), RUTHERFORD APPLETON LAB,DIDCOT OX11 0QX,OXON,ENGLAND.		Bingham, Robert/N-2042-2019	Bingham, Robert/0000-0002-9843-7635				CHAMBERLAIN JW, 1961, PHYSICS AURORA AIRGL; Chen F. F., 1984, INTRO PLASMA PHYSICS, V1, P240; DAWSON JM, 1981, FUSION, P465; GRINGAUZ KI, 1986, NATURE, V321, P282, DOI 10.1038/321282a0; HUDSON HS, 1981, PLANET SPACE SCI, V29, P1373, DOI 10.1016/0032-0633(81)90104-5; KLIMOV S, 1986, NATURE, V321, P292, DOI 10.1038/321292a0; KRANKOWSKY D, 1986, NATURE, V321, P326, DOI 10.1038/321326a0; Landau L., 1946, J PHYS USSR, V103, P25; Lisse CM, 1996, SCIENCE, V274, P205, DOI 10.1126/science.274.5285.205; MCBRIDE JB, 1972, PHYS FLUIDS, V157, P2367; MENDIS DA, 1985, PHYSICS COMETS FUNDA, V10; Mumma MJ, 1996, SCIENCE, V272, P1310, DOI 10.1126/science.272.5266.1310; POST DF, 1977, PPPL1352; Shapiro V.D., 1988, ASTROPHYS SPACE PHYS, V6, P425; Stix TH., 1992, WAVES PLASMAS; WALLIS MK, 1975, PLANET SPACE SCI, V23, P713, DOI 10.1016/0032-0633(75)90109-9	16	59	59	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					49	51		10.1126/science.275.5296.49	http://dx.doi.org/10.1126/science.275.5296.49			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974386				2022-12-28	WOS:A1997WA90300042
J	Guymon, CA; Hoggan, EN; Clark, NA; Rieker, TP; Walba, DM; Bowman, CN				Guymon, CA; Hoggan, EN; Clark, NA; Rieker, TP; Walba, DM; Bowman, CN			Effects of monomer structure on their organization and polymerization in a smectic liquid crystal	SCIENCE			English	Article							INSITU PHOTOPOLYMERIZATION; GELS; KINETICS	Photopolymerizable diacrylate monomers dissolved in fluid-layer smectic A and smectic C liquid crystal (LC) hosts exhibited significant spatial segregation and orientation that depend strongly on monomer structure. Small, flexible monomers such as 1,6-hexanediol diacrylate (HDDA) oriented parallel to the smectic layers and intercalated, whereas rod-shaped mesogen-like monomers such as 1,4-di-(4-(6-acryloyloxyhexyloxy)ben zoyloxy)-2-methylbenzene (C6M) oriented normal to the smectic layers and collected within them. Such spatial segregation caused by the smectic layering dramatically enhanced photopolymerization rates; for HDDA, termination rates were reduced, whereas for C6M, both the termination and propagation rates were increased. These polymerization precursor structures suggest novel materials-design paradigms for gel LCs and nanophase-separated polymer systems.	UNIV COLORADO,DEPT CHEM ENGN,BOULDER,CO 80309; UNIV COLORADO,DEPT PHYS,BOULDER,CO 80309; UNIV NEW MEXICO,CTR MICROENGINEERED MAT,DEPT CHEM & NUCL ENGN,ALBUQUERQUE,NM 87106; UNIV COLORADO,DEPT CHEM,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; University of New Mexico; University of Colorado System; University of Colorado Boulder			Bowman, Christopher N/B-1490-2008; Clark, Noel A/AAP-9116-2020; Clark, Noel A./E-9011-2010; Walba, David/F-7284-2013	Bowman, Christopher N/0000-0001-8458-7723; Clark, Noel A./0000-0001-9301-5540; 				ANSETH KS, 1995, MACROMOLECULES, V28, P2491, DOI 10.1021/ma00111a050; BOWMAN CN, 1994, POLYMER, V35, P3243; BROER DJ, 1989, MAKROMOL CHEM, V190, P19; BROER DJ, 1989, MAKROMOL CHEM, V190, P3201; DRZALC PS, 1995, LIQUID CRYSTAL DISPE; GUYMON CA, 1995, LIQ CRYST, V19, P719, DOI 10.1080/02678299508031091; GUYMON CA, UNPUB; HIKMET RAM, 1995, ADV MATER, V7, P300, DOI 10.1002/adma.19950070313; HIKMET RAM, 1995, PHYS REV E, V51, P5824, DOI 10.1103/PhysRevE.51.5824; HIKMET RAM, 1995, LIQ CRYST, V19, P65, DOI 10.1080/02678299508036721; HOYLE CE, 1995, MACROMOLECULES, V28, P1946, DOI 10.1021/ma00110a031; HOYLE CE, 1994, MACROMOLECULES, V27, P3790, DOI 10.1021/ma00092a018; HOYLE CE, 1994, MACROMOLECULES, V27, P6581, DOI 10.1021/ma00100a050; Jang W. G., 1996, Ferroelectrics, V180, P213, DOI 10.1080/00150199608223652; KITZEROW HS, 1994, LIQ CRYST, V16, P1, DOI 10.1080/02678299408036517; Lester G., 1993, Ferroelectrics, V148, P389, DOI 10.1080/00150199308019965; RIEKER TP, 1995, LIQ CRYST, V19, P497, DOI 10.1080/02678299508032011; WALBA DM, 1995, SCIENCE, V270, P250, DOI 10.1126/science.270.5234.250; WEISS RG, 1988, TETRAHEDRON, V44, P3413, DOI 10.1016/S0040-4020(01)85977-9; YANG DK, 1992, APPL PHYS LETT, V60, P3102, DOI 10.1063/1.106765	20	107	107	2	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					57	59		10.1126/science.275.5296.57	http://dx.doi.org/10.1126/science.275.5296.57			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974389				2022-12-28	WOS:A1997WA90300045
J	Schievink, WI				Schievink, WI			Medical progress - Intracranial aneurysms	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POLYCYSTIC KIDNEY-DISEASE; SPONTANEOUS SUBARACHNOID HEMORRHAGE; HONOLULU-HEART-PROGRAM; SACCULAR ANEURYSMS; CIGARETTE-SMOKING; MR-ANGIOGRAPHY; RISK-FACTORS; FOLLOW-UP; CONVENTIONAL ANGIOGRAPHY; INCIDENTAL ANEURYSMS				Schievink, WI (corresponding author), MAYO CLIN & MAYO FDN,DEPT NEUROL SURG,200 1ST ST SW,ROCHESTER,MN 55905, USA.							ADAMSON J, 1994, STROKE, V25, P963, DOI 10.1161/01.STR.25.5.963; ATKINSON JLD, 1989, J NEUROSURG, V70, P551, DOI 10.3171/jns.1989.70.4.0551; AUSTIN G, 1993, ANN CLIN LAB SCI, V23, P97; AUSTIN GM, 1989, NEUROSURGERY, V24, P722, DOI 10.1227/00006123-198905000-00011; BAILES JE, 1990, J NEUROSURG, V72, P559, DOI 10.3171/jns.1990.72.4.0559; BEGHI E, 1985, ARCH NEUROL-CHICAGO, V42, P1053, DOI 10.1001/archneur.1985.04060100035016; BONITA R, 1986, STROKE, V17, P831, DOI 10.1161/01.STR.17.5.831; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; BROMBERG JEC, 1995, BRIT MED J, V311, P288, DOI 10.1136/bmj.311.7000.288; Butler WE, 1996, NEUROSURGERY, V38, P506; CEDZICH C, 1990, J NEUROSURG, V72, P806, DOI 10.3171/jns.1990.72.5.0806; CHAMBERS WR, 1954, JAMA-J AM MED ASSOC, V155, P358, DOI 10.1001/jama.1954.73690220001007; CHAPMAN AB, 1992, NEW ENGL J MED, V327, P916, DOI 10.1056/NEJM199209243271303; CROWELL RM, 1995, SURG MANAGEMENT NEUR, P205; CURNES JT, 1993, AM J NEURORADIOL, V14, P971; Dandy WE, 1938, ANN SURG, V107, P654, DOI 10.1097/00000658-193805000-00003; DeBraekeleer M, 1996, ANN HUM GENET, V60, P99, DOI 10.1111/j.1469-1809.1996.tb01181.x; DION JE, 1987, STROKE, V18, P997, DOI 10.1161/01.STR.18.6.997; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; DRAKE CG, 1994, J NEUROSURG, V81, P656, DOI 10.3171/jns.1994.81.5.0656; Falk A, 1996, ROFO FORTSCHR RONTG, V164, P31, DOI 10.1055/s-2007-1015604; FOGELHOLM R, 1993, STROKE, V24, P1649, DOI 10.1161/01.STR.24.11.1649; FOX JL, 1983, INTRACRANIAL ANEURYS, V1, P19; Fujii Y, 1996, J NEUROSURG, V84, P35, DOI 10.3171/jns.1996.84.1.0035; GARFINKLE AM, 1992, J NEUROSURG, V76, P766, DOI 10.3171/jns.1992.76.5.0766; GRAF CJ, 1971, J NEUROSURG, V35, P438, DOI 10.3171/jns.1971.35.4.0438; GUGLIELMI G, 1991, J NEUROSURG, V75, P1, DOI 10.3171/jns.1991.75.1.0001; HILLMAN J, 1988, J NEUROSURG, V68, P901, DOI 10.3171/jns.1988.68.6.0901; Hope JKA, 1996, AM J NEURORADIOL, V17, P439; HUSTON J, 1994, AM J NEURORADIOL, V15, P1607; HUSTON J, 1993, J AM SOC NEPHROL, V3, P1871; INAGAWA T, 1990, SURG NEUROL, V34, P361, DOI 10.1016/0090-3019(90)90237-J; INAGAWA T, 1995, STROKE, V26, P761, DOI 10.1161/01.STR.26.5.761; INGALL TJ, 1989, STROKE, V20, P718, DOI 10.1161/01.STR.20.6.718; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; JUVELA S, 1993, STROKE, V24, P639, DOI 10.1161/01.STR.24.5.639; JUVELA S, 1993, J NEUROSURG, V79, P174, DOI 10.3171/jns.1993.79.2.0174; KASSELL NF, 1983, NEUROSURGERY, V13, P479, DOI 10.1227/00006123-198311000-00001; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; KING JT, 1994, J NEUROSURG, V81, P837, DOI 10.3171/jns.1994.81.6.0837; KNEKT P, 1991, J CLIN EPIDEMIOL, V44, P933, DOI 10.1016/0895-4356(91)90056-F; LEBLANC R, 1987, J NEUROSURG, V66, P35, DOI 10.3171/jns.1987.66.1.0035; LINDBERG M, 1992, BRIT J NEUROSURG, V6, P297, DOI 10.3109/02688699209023787; LONGSTRETH WT, 1992, STROKE, V23, P1242, DOI 10.1161/01.STR.23.9.1242; LONGSTRETH WT, 1993, NEUROLOGY, V43, P712, DOI 10.1212/WNL.43.4.712; LONGSTRETH WT, 1994, ANN INTERN MED, V121, P168, DOI 10.7326/0003-4819-121-3-199408010-00002; LOZANO AM, 1987, J NEUROSURG, V66, P522, DOI 10.3171/jns.1987.66.4.0522; MCCORMICK WF, 1965, J NEUROSURG, V22, P155, DOI 10.3171/jns.1965.22.2.0155; MCCORMICK WF, 1977, ARCH NEUROL-CHICAGO, V34, P285, DOI 10.1001/archneur.1977.00500170039006; McDougall CG, 1996, J NEUROSURG, V84, P393, DOI 10.3171/jns.1996.84.3.0393; MILLER CA, 1985, SURG NEUROL, V24, P173, DOI 10.1016/0090-3019(85)90181-8; MISRA BK, 1988, NEUROSURGERY, V23, P10, DOI 10.1227/00006123-198807000-00002; MOKRI B, 1994, SUNDTS OCCLUSIVE CER, P45; NICOLOSI A, 1986, J INFECT DIS, V154, P399, DOI 10.1093/infdis/154.3.399; NORRGARD O, 1987, NEUROSURGERY, V20, P236, DOI 10.1227/00006123-198702000-00006; NOWAK G, 1994, ACTA NEUROCHIR, V126, P33, DOI 10.1007/BF01476491; OGAWA T, 1995, AM J ROENTGENOL, V165, P1257, DOI 10.2214/ajr.165.5.7572514; OSTERGAARD JR, 1991, CEPHALALGIA, V11, P53, DOI 10.1046/j.1468-2982.1991.1101053.x; PAREKH HC, 1995, BRIT J NEUROSURG, V9, P695, DOI 10.1080/02688699550041025; PERTUISET B, 1989, ACTA NEUROCHIR, V100, P84, DOI 10.1007/BF01405281; PETITTI DB, 1978, LANCET, V2, P234; Petitti DB, 1996, NEW ENGL J MED, V335, P8, DOI 10.1056/NEJM199607043350102; PHILLIPS LH, 1980, NEUROLOGY, V30, P1034, DOI 10.1212/WNL.30.10.1034; PRZELOMSKI MM, 1986, NEUROLOGY, V36, P584, DOI 10.1212/WNL.36.4.584; RADHAKRISHNAN K, 1995, ANN NEUROL, V37, P67, DOI 10.1002/ana.410370113; RAPS EC, 1993, ARCH NEUROL-CHICAGO, V50, P265, DOI 10.1001/archneur.1993.00540030031010; RINNE J, 1994, NEUROSURGERY, V35, P803, DOI 10.1227/00006123-199411000-00001; RINNE JK, 1993, NEUROSURGERY, V33, P981; RONKAINEN A, 1995, RADIOLOGY, V195, P35, DOI 10.1148/radiology.195.1.7892491; RONKAINEN A, 1995, NEUROSURGERY, V37, P43, DOI 10.1227/00006123-199507000-00006; RONKAINEN A, 1993, NEUROSURGERY, V33, P787; RUGGIERI PM, 1994, RADIOLOGY, V191, P33, DOI 10.1148/radiology.191.1.8134594; SACCO RL, 1984, NEUROLOGY, V34, P847, DOI 10.1212/WNL.34.7.847; SCHIEVINK WI, 1994, STROKE, V25, P2028, DOI 10.1161/01.STR.25.10.2028; Schievink WI, 1996, J NEUROSURG, V84, P781, DOI 10.3171/jns.1996.84.5.0781; SCHIEVINK WI, 1994, LANCET, V343, P452, DOI 10.1016/S0140-6736(94)92693-X; SCHIEVINK WI, 1995, NEUROLOGY, V45, P871, DOI 10.1212/WNL.45.5.871; SCHIEVINK WI, 1995, J NEUROSURG, V83, P426, DOI 10.3171/jns.1995.83.3.0426; SCHIEVINK WI, 1994, STROKE, V25, P889, DOI 10.1161/01.STR.25.4.889; SCHIEVINK WI, 1988, SURG NEUROL, V29, P367, DOI 10.1016/0090-3019(88)90045-6; SCHIEVINK WI, 1989, SURG NEUROL, V32, P266, DOI 10.1016/0090-3019(89)90228-0; SCHIEVINK WI, 1995, J NEUROSURG, V82, P791, DOI 10.3171/jns.1995.82.5.0791; SCHIEVINK WI, 1991, NEUROSURGERY, V29, P434, DOI 10.1227/00006123-199109000-00017; SCHIEVINK WI, 1992, J NEUROSURG, V76, P1019, DOI 10.3171/jns.1992.76.6.1019; SCHWARTZ RB, 1994, RADIOLOGY, V192, P717, DOI 10.1148/radiology.192.3.8058939; SPETZLER RF, 1988, J NEUROSURG, V68, P868, DOI 10.3171/jns.1988.68.6.0868; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STEHBENS WE, 1983, INTRACRANIAL ANEURYS, V1, P272; StJean P, 1996, HUM HERED, V46, P92; SUNDT TM, 1990, SURG TECHNIQUES SACC; TAYLOR CL, 1995, J NEUROSURG, V83, P812, DOI 10.3171/jns.1995.83.5.0812; TEASDALE G, 1974, LANCET, V2, P81; TIDSWELL P, 1995, NEUROLOGY, V45, P875; TOFTDAHL DB, 1995, NEUROSURGERY, V37, P235, DOI 10.1227/00006123-199508000-00007; VANGIJN J, 1982, NEURORADIOLOGY, V23, P153, DOI 10.1007/BF00347559; VERMEULEN M, 1989, J NEUROL NEUROSUR PS, V52, P826, DOI 10.1136/jnnp.52.7.826; VESSEY MP, 1989, BMJ-BRIT MED J, V299, P1487, DOI 10.1136/bmj.299.6714.1487; Weir B, 1993, Clin Neurosurg, V40, P40; WIEBERS DO, 1992, NEW ENGL J MED, V327, P953, DOI 10.1056/NEJM199209243271310; WIEBERS DO, 1987, J NEUROSURG, V66, P23, DOI 10.3171/jns.1987.66.1.0023; WINN HR, 1983, J NEUROSURG, V59, P642, DOI 10.3171/jns.1983.59.4.0642; WINN HR, 1983, STROKE, V14, P121; *WORLD FED NEUR SU, 1988, J NEUROSURG, V68, P985; WYNN DR, 1990, NEUROLOGY, V40, P780, DOI 10.1212/WNL.40.5.780; YANO K, 1989, STROKE, V20, P1460, DOI 10.1161/01.STR.20.11.1460; YASARGIL MG, 1984, MICRONEUROSURGERY, V2; YOSHIDA S, 1986, Neuroepidemiology, V5, P61, DOI 10.1159/000110815; ZUBILLAGA AF, 1994, AM J NEURORADIOL, V15, P815	109	542	571	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 2	1997	336	1					28	40		10.1056/NEJM199701023360106	http://dx.doi.org/10.1056/NEJM199701023360106			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA496	8970938				2022-12-28	WOS:A1997WA49600006
J	Elmore, JG; Wells, CK; Howard, DH; Feinstein, AR				Elmore, JG; Wells, CK; Howard, DH; Feinstein, AR			The impact of clinical history on mammographic interpretations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEARCHING FILMS; RADIOGRAPHIC INTERPRETATION; CHEST RADIOGRAPHS; BREAST-CANCER; RADIOLOGY	Objective.-To determine whether mammographic interpretations are biased by the patient's clinical history. Design.-On 2 occasions, separated by a 5-month wash-out period, 10 radiologists read mammograms for the same 100 women, randomly divided into 2 groups of 50. For 1 group, the clinical history was supplied for the first reading and omitted (except for age) for the second reading. This sequence was reversed in the other group, In addition, 5 cases were shown a third time with a deliberately leading sham history, Patients.-Selected with stratified random sampling from 3 categories of diagnostic findings (64 had mammographic abnormalities) and from the definitive designation of breast cancer or no breast cancer (18 had breast cancer). Main Outcome Measures.-Radiologists' diagnostic accuracy and directional changes in interpretations and recommendations between the 2 readings. Results.-The direction suggested by the history led to small but consistent changes in the interpretations. Overall diagnostic accuracy was not altered, but recommendations were affected for appropriate further diagnostic workup: an alerting history leg, breast symptoms or family history of breast cancer) increased the number of workups recommended in patients without cancer (P=.01); and a nonalerting history led to fewer recommended workups in the cancer patients (P=.02), The direction of the sham histories led an average of 4 of the 10 radiologists to change previous diagnoses and an average of 1 radiologist to change a previous biopsy recommendation. Conclusions.-Knowledge of the clinical history may alter a radiologist's level of diagnostic suspicion without improving performance in either diagnosis or management recommendations.	UNIV WASHINGTON,SCH MED,DEPT EPIDEMIOL,SEATTLE,WA 98195; YALE UNIV,DEPT INTERNAL MED,NEW HAVEN,CT; YALE UNIV,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06520; CORNELL UNIV,MED CTR,NEW YORK HOSP,DEPT INTERNAL MED,NEW YORK,NY 10021	University of Washington; University of Washington Seattle; Yale University; Yale University; Cornell University; NewYork-Presbyterian Hospital	Elmore, JG (corresponding author), UNIV WASHINGTON,SCH MED,DEPT INTERNAL MED,ROOM BB527E HSB,BOX 356420,1959 NE PACIFIC ST,SEATTLE,WA 98195, USA.							BERBAUM KS, 1986, INVEST RADIOL, V21, P532, DOI 10.1097/00004424-198607000-00004; DOI K, 1992, SEMIN ULTRASOUND CT, V13, P140; DOUBILET P, 1981, AM J ROENTGENOL, V137, P1055, DOI 10.2214/ajr.137.5.1055; ELMORE JG, 1994, NEW ENGL J MED, V331, P1493, DOI 10.1056/NEJM199412013312206; Feinstein A.R., 1985, CLIN EPIDEMIOLOGY; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; KUNDEL HL, 1985, INVEST RADIOL, V20, P110; MATSUMOTO T, 1992, INVEST RADIOL, V27, P471, DOI 10.1097/00004424-199206000-00013; MCNEIL BJ, 1983, RADIOLOGY, V149, P75, DOI 10.1148/radiology.149.1.6611955; PARKER TW, 1982, INVEST RADIOL, V17, P152, DOI 10.1097/00004424-198203000-00007; POTCHEN EJ, 1979, INVEST RADIOL, V14, P404; RHEA JT, 1979, RADIOLOGY, V132, P277, DOI 10.1148/132.2.277; SCHREIBER MH, 1963, JAMA-J AM MED ASSOC, V185, P399, DOI 10.1001/jama.1963.03060050077027; SWENSSON RG, 1982, INVEST RADIOL, V17, P145, DOI 10.1097/00004424-198203000-00006; SWENSSON RG, 1977, RADIOLOGY, V123, P563, DOI 10.1148/123.3.563; SWENSSON RG, 1985, INVEST RADIOL, V20, P100, DOI 10.1097/00004424-198501000-00024; SWENSSON RG, 1979, S OPT CHEST RAD WASH; SWETS JA, 1985, INVEST RADIOL, V20, P115, DOI 10.1097/00004424-198501000-00027; SWETS JA, 1985, INVEST RADIOL, V20, P108, DOI 10.1097/00004424-198501000-00025; TABAR L, 1982, JAMA-J AM MED ASSOC, V247, P185, DOI 10.1001/jama.247.2.185	20	73	74	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1997	277	1					49	52		10.1001/jama.277.1.49	http://dx.doi.org/10.1001/jama.277.1.49			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ767	8980210				2022-12-28	WOS:A1997VZ76700029
J	Raghavan, D				Raghavan, D			Oncology - Are Voltaire and Rousseau now wrong?	LANCET			English	Article									SUNY BUFFALO, BUFFALO, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Raghavan, D (corresponding author), ROSWELL PK CANC INST, BUFFALO, NY USA.							Barnes MN, 1996, CLIN CANCER RES, V2, P1089; CREAVEN PJ, 1996, PRINCIPLES PRACTICE, P89; Gatzemeier U, 1996, EUR J CANCER, V32A, P243, DOI 10.1016/0959-8049(95)00444-0; Hochhauser D, 1996, J NATL CANCER I, V88, P1269, DOI 10.1093/jnci/88.18.1269; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	1996	348			2			SII17	SII17						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973495				2022-12-28	WOS:A1996WA46300017
J	Woods, WG; Tuchman, M; Robison, LL; Bernstein, M; Leclerc, JM; Brisson, LC; Brossard, J; Hill, G; Shuster, J; Luepker, R; Byrne, T; Weitzman, S; Bunin, G; Lemieux, B				Woods, WG; Tuchman, M; Robison, LL; Bernstein, M; Leclerc, JM; Brisson, LC; Brossard, J; Hill, G; Shuster, J; Luepker, R; Byrne, T; Weitzman, S; Bunin, G; Lemieux, B			A population-based study of the usefulness of screening for neuroblastoma	LANCET			English	Article							NEURO-BLASTOMA; CHILDREN; AGE; INFANTS; CANCER; JAPAN; MORTALITY; SURVIVAL; PROJECT; OLDER	Background Neuroblastoma has many characteristics which suggest that preclinical detection might improve outcome. The Quebec Neuroblastoma Screening Project was initiated to determine whether mass screening could reduce mortality in a large cohort of infants. As an early endpoint, we report whether screening could reduce the incidence of poor-prognosis neuroblastoma in children with advanced-stage disease over 1 year of age. Methods All 476 603 children born in the province of Quebec during the 5-year period of May 1, 1989, to April 30, 1994, were eligible for urinary assay of homovanillic acid and vanillylmandelic acid at 3 weeks and 6 months of age. Children with a positive screen were referred to one of four paediatric cancer centres in the province for uniform evaluation and treatment ii necessary. Standardised incidence ratios (SIRs) were calculated for neuroblastoma in the province and two similar population-based controls, the state of Minnesota and the province of Ontario, during the same period of time and with similar ascertainment procedures. Findings Compliance with screening in Quebec province was 91% at 3 weeks (n=425 816) and 74% at 6 months (n=349 706). Through July 31, 1995, with a follow-up of the birth cohort of 15-75 months, 118 cases of neuroblastoma were diagnosed, 43 detected preclinically by screening, 20 detected clinically before screening at 3 weeks of age. and 55 detected clinically after 3 weeks of age having normal screens (52) or never screened (3). Retrospective analysis of stored samples confirmed that 49 of 52 patients missed by screening had levels of catecholamine metabolites that were too low to be detected at 6 months or earlier. Based on US Surveillance, Epidemiology and End Results data, 54.5 cases of neuroblastoma would have been expected in Quebec province during the study period, for an SIR of 2.17 (95% CI 1.79-2.57, p<0.0001). For the two control groups, 43 and 80 cases of neuroblastoma were detected, respectively, compared with 37.9 and 85.4 expected, overall SIR 1.00 (not significant). SIRs for Quebec province by age at diagnosis in yearly intervals show a marked increased incidence under 1 year of age (SIR 2.85, 2.26-3.50), with no reduction in incidence in subsequent years. Limiting analysis to only patients diagnosed over 1 year of age with advanced-stage disease, 22 cases were detected in Quebec province versus 14.4 expected (SIR 1.52, 0.95-2.23). Data in the two control groups show no significant increase or decrease in any-stage disease in children under or over the age of 1 year, except for an increase in early-stage disease in Minnesota children over 1 year: 10 versus 38 expected (SIR 2.67, 1.27-4.58). Interpretation Screening for neuroblastoma increases the incidence in infants without decreasing the incidence of unfavourable advanced-stage disease in older children. it is unlikely that screening for neuroblastoma in infants will reduce mortality for this disease.	UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA; MONTREAL CHILDRENS HOSP, MONTREAL, PQ H3H 1P3, CANADA; HOP ST JUSTINE, MONTREAL, PQ H3T 1C5, CANADA; CHU LAVAL, Ste Foy, PQ, CANADA; CHU SHERBROOKE, SHERBROOKE, PQ J1H 5N4, CANADA; BUR CHRON DIS EPIDEMIOL, OTTAWA, ON, CANADA; UNIV FLORIDA, DEPT STAT, GAINESVILLE, FL 32611 USA; HOSP SICK CHILDREN, TORONTO, ON M5G 1X8, CANADA; CHILDRENS HOSP PHILADELPHIA, PHILADELPHIA, PA 19104 USA	University of Minnesota System; University of Minnesota Twin Cities; McGill University; Universite de Montreal; Laval University; University of Sherbrooke; State University System of Florida; University of Florida; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia			Shuster, Jonathan/ABB-5773-2021; Robison, Leslie/N-8122-2018	Shuster, Jonathan/0000-0001-9499-5616; 	NCI NIH HHS [CA 46907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDER A, 1991, MINN DEP HLTH DIS CO, V19, P33; BERNSTEIN ML, 1992, J CLIN ONCOL, V10, P323, DOI 10.1200/JCO.1992.10.2.323; BESSHO F, 1991, J PEDIATR-US, V119, P237, DOI 10.1016/S0022-3476(05)80733-4; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; BRODEUR GM, 1987, CANCER RES, V47, P4248; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; Campion P, 1991, Can Nurse, V87, P17; CARLSEN NLT, 1986, BRIT J CANCER, V54, P977, DOI 10.1038/bjc.1986.270; DRAPER GJ, 1994, CANCER SURV, V20, P493; ESTEVE J, 1995, BRIT J CANCER, V71, P1125, DOI 10.1038/bjc.1995.219; GREENBERG MC, 1994, REPORT PROVINCIAL PE; GURNEY JG, 1995, CANCER, V75, P2186, DOI 10.1002/1097-0142(19950415)75:8<2186::AID-CNCR2820750825>3.0.CO;2-F; KANEKO Y, 1990, J CLIN ONCOL, V8, P2005, DOI 10.1200/JCO.1990.8.12.2005; KRAMER S, 1983, J NATL CANCER I, V70, P49; KUSHNER BH, 1993, P AN M AM SOC CLIN, V12, P413; LEMIEUX B, 1987, ADV NEONATAL SCREENI, V2, P209; LEMIEUX B, 1989, EXCERPTA MED INT C S, V848, P401; MURPHY SB, 1991, LANCET, V337, P344, DOI 10.1016/0140-6736(91)90957-Q; NISHI M, 1987, CANCER, V60, P433, DOI 10.1002/1097-0142(19870801)60:3<433::AID-CNCR2820600326>3.0.CO;2-H; PARKER L, 1995, 4 INT S NEUR SCREEN, P32; PHILIP T, 1991, J CLIN ONCOL, V9, P1037, DOI 10.1200/JCO.1991.9.6.1037; SAWADA T, 1984, LANCET, V2, P271; STILLER CA, 1992, INT J CANCER, V52, P538, DOI 10.1002/ijc.2910520407; TUCHMAN M, 1990, PEDIATRICS, V86, P765; VANDENBROUCKE JP, 1982, AM J EPIDEMIOL, V115, P303, DOI 10.1093/oxfordjournals.aje.a113306; WOODS WG, 1992, PEDIATRICS, V89, P114; WOODS WG, 1992, SCREENING, V1, P273; YAMAMOTO K, 1995, J CLIN ONCOL, V13, P2033, DOI 10.1200/JCO.1995.13.8.2033; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C	29	168	170	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	1996	348	9043					1682	1687		10.1016/S0140-6736(96)06020-5	http://dx.doi.org/10.1016/S0140-6736(96)06020-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ766	8973429				2022-12-28	WOS:A1996VZ76600009
J	Brewer, TF; Heymann, SJ; Colditz, GA; Wilson, ME; Auerbach, K; Kane, D; Fineberg, HV				Brewer, TF; Heymann, SJ; Colditz, GA; Wilson, ME; Auerbach, K; Kane, D; Fineberg, HV			Evaluation of tuberculosis control policies using computer simulation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; DRUG-RESISTANT TUBERCULOSIS; HIV-INFECTED PATIENTS; UNITED-STATES; DECISION-ANALYSIS; EPIDEMIOLOGY; TRANSMISSION; MODEL; RISK	Objective.-To develop more effective methods to assess tuberculosis (TB) control strategies so we can meet national goals for the elimination of TB in the United States. Design.-Using a semi-Markov model that divided the US population into 3 age groups and 18 clinical states based on disease status and risk for TB and human immunodeficiency virus (HIV) infection, we measured the effects of 5 changes in TB policy, introduced singly and in combination: (1) increased coverage and (2) improved efficacy of preventive therapy, (3) increased coverage and (4) improved efficacy of treatment, and (5) introduction of BCG vaccination. Results.-A BCG Vaccination program that reached 10% of eligible children and 1% or eligible adults each year would produce a 17% reduction in cases and an 11% decline in deaths over 10 years. Preventive therapy programs among the general population would have little effect on the number of TB cases, but a program targeting HIV-infected patients would reduce HIV-associated TB cases and deaths 14% to 20%. A 10% improvement in the coverage and efficacy of both preventive therapy and treatment, coupled with the BCG vaccination program, would lead to a 47% decline in TB cases and a 50% decline in TB deaths relative to baseline over 10 years. Conclusions.-Improvements in treatment coverage or effectiveness alone are unlikely to reach established national goals for the elimination of TB. These goals can be achieved through a combination of improvements in current programs with targeted preventive therapy and BCG vaccination programs.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; HARVARD UNIV, SCH MED, DEPT HLTH CARE POLICY, BOSTON, MA 02115 USA; HARVARD UNIV, JOHN F KENNEDY SCH GOVT, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT POPULAT & INT HLTH, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, TECHNOL ASSESSMENT GRP, BOSTON, MA 02115 USA; MT AUBURN HOSP, DIV INFECT DIS, CAMBRIDGE, MA 02238 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Mount Auburn Hospital	Brewer, TF (corresponding author), BRIGHAM & WOMENS HOSP, CHANNING LAB, 181 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	AHRQ HHS [1 F32 HS00079] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BARRETTCONNOR E, 1981, PREV MED, V10, P69, DOI 10.1016/0091-7435(81)90007-4; BASS J, 1992, AM REV RESPIR DIS, V146, P1623; BELLIN E, 1994, JAMA-J AM MED ASSOC, V271, P708, DOI 10.1001/jama.271.9.708; BESNARD M, 1993, PEDIATR INFECT DIS J, V12, P993, DOI 10.1097/00006454-199312000-00006; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815; BLOWER SM, 1994, INT STAT REV, V62, P229, DOI 10.2307/1403510; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; BRAUN MM, 1993, JAMA-J AM MED ASSOC, V269, P2865, DOI 10.1001/jama.269.22.2865; BROWN RE, 1995, ARCH INTERN MED, V155, P1595, DOI 10.1001/archinte.155.15.1595; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; BURWEN D, 1993, P INT C AIDS JUN 6 1; BUSILLO CP, 1992, CHEST, V102, P797, DOI 10.1378/chest.102.3.797; Carter E J, 1992, R I Med, V75, P449; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; *CDCP, 1992, 7221 CDCP US DEP HLT; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P481; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P301; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P395; *CDCP, 1993, TUB STAT US 1991, P14; *CDCP, 1994, NAT HIV SER SUMM RES, P3; *CDCP, 1993, 7215 CDCP US DEP HLT; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P387; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; COMSTOCK GW, 1976, PUBLIC HEALTH REP, V91, P276; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; DUTT AK, 1984, AM J MED, V77, P233, DOI 10.1016/0002-9343(84)90697-1; *ENC BRIT, 1993, ENC BRIT, P741; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; GRAHAM NMH, 1993, ANN ALLERGY, V71, P421; GREENBERG PD, 1991, AM REV RESPIR DIS, V143, P490, DOI 10.1164/ajrccm/143.3.490; GUTMAN LT, 1994, PEDIATR INFECT DIS J, V13, P963, DOI 10.1097/00006454-199411000-00006; HAMBURG MA, 1992, NEW YORK STATE J MED, V92, P291; HART PD, 1977, BRIT MED J, V2, P293, DOI 10.1136/bmj.2.6082.293; HOBBY GL, 1974, AM REV RESPIR DIS, V110, P95; JAIN RK, 1989, COMPUT BIOMED RES, V22, P209, DOI 10.1016/0010-4809(89)90001-3; Karon J M, 1992, MMWR Recomm Rep, V41, P1; KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991; Lotte A, 1988, Bull Int Union Tuberc Lung Dis, V63, P47; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; MOULDING T, 1971, ANN INTERN MED, V74, P761, DOI 10.7326/0003-4819-74-5-761; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; RIEDER HL, 1991, CHEST, V100, P678, DOI 10.1378/chest.100.3.678; ROSE DN, 1992, J GEN INTERN MED, V7, P589, DOI 10.1007/BF02599196; ROSE DN, 1988, AM J PREV MED, V4, P102, DOI 10.1016/S0749-3797(18)31204-2; ROSE DN, 1986, JAMA-J AM MED ASSOC, V256, P2709, DOI 10.1001/jama.256.19.2709; Rouillon A, 1976, Adv Tuberc Res, V19, P64; SALOMON N, 1995, CLIN INFECT DIS, V21, P1245, DOI 10.1093/clinids/21.5.1245; SEAHOLM SK, 1988, INT J BIOMED COMPUT, V23, P97, DOI 10.1016/0020-7101(88)90067-0; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; Stokey E, 1978, PRIMER POLICY ANAL; TAYLOR WC, 1981, ANN INTERN MED, V94, P808, DOI 10.7326/0003-4819-94-6-808; *US BUR CENS, 1993, 1993 STAT ABSTR US; *US IMM NAT SERV S, 1994, IMM ADM COUNTR BIRTH; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; Wharton M, 1990, MMWR Recomm Rep, V39, P1; *WHO EXP PROGR IMM, 1993, INF SYST SUMM WHO AM; *WHO EXP PROGR IMM, 1993, INF SYST SUMM WHO W	69	36	36	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1996	276	23					1898	1903		10.1001/jama.276.23.1898	http://dx.doi.org/10.1001/jama.276.23.1898			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX522	8968016				2022-12-28	WOS:A1996VX52200038
J	Palermo, GD; Colombero, LT; Schattman, GL; Davis, OK; Rosenwaks, Z				Palermo, GD; Colombero, LT; Schattman, GL; Davis, OK; Rosenwaks, Z			Evolution of pregnancies and initial follow-up of newborns delivered after intracytoplasmic sperm injection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MALE-FACTOR INFERTILITY; CHROMOSOME-ABNORMALITIES; ASSISTED FERTILIZATION; SUBZONAL INSEMINATION; INVITRO FERTILIZATION; MATERNAL AGE; SPERMATOGENESIS; ABSENCE; RATES	Objective.-To analyze the in vivo development of embryos conceived after intracytoplasmic sperm injection (ICSI), as well as obstetric outcome, occurrence of chromosomal abnormalities, and rate of congenital malformations in neonates born as a result of this treatment. Design.-Retrospective study. Setting.-University-based in vitro fertilization (IVF) clinic. Patients.-A total of 751 couples in whom the male partners were presumed to be the cause of repeated failed IVF attempts or whose semen parameters were unacceptable for conventional IVF treatment. Interventions.-Analysis of pregnancies resulting from 987 ICSI cycles; pregnancy outcome data were obtained from the records of obstetrician-gynecologists and/or pediatricians. Main Outcome Measures.-Pregnancy rates, obstetric outcome, and frequency of chromosomal abnormalities and congenital malformations. Results.-The overall clinical pregnancy (fetal heartbeat) rate was 44.3%, with a resultant delivery rate per ICSI cycle of 38.7% (n=382). In 8 of 11 miscarriages for which cytogenetic data were available, an autosomal trisomy was found, and 7 additional pregnancies were terminated because of a chromosomal abnormality after prenatal diagnosis. There was an equal distribution of vaginal vs cesarean deliveries (n=192 and n=190, respectively). Of the 578 neonates resulting from treatment by ICSI, 15 (2.6%) presented with congenital abnormalities (9 major and 6 minor abnormalities). However, this frequency of malformations is lower than that observed in offspring born after standard IVF at our institution. Furthermore, when pregnancy outcome of ICSI vs IVF was analyzed in terms of semen origin, no differences were found in the frequency of miscarriages or in the rate of congenital malformations. Conclusions.-The evolution of pregnancies and occurrence of congenital malformations following treatment by ICSI were within the range observed with standard in vitro fertilization.			Palermo, GD (corresponding author), NEW YORK HOSP, CORNELL MED CTR, CTR REPROD MED & INFERTIL, DEPT OBSTET & GYNECOL, 505 E 70TH ST, NEW YORK, NY 10021 USA.							BIGGERS JD, 1981, NEW ENGL J MED, V304, P336, DOI 10.1056/NEJM198102053040607; BONDUELLE M, 1994, HUM REPROD, V9, P1765, DOI 10.1093/oxfordjournals.humrep.a138791; BONDUELLE M, 1994, HUM REPROD S4, V9, P38; BONDUELLE M, 1995, HUM REPROD UPDATE, V1, P3; COHEN J, 1992, J ASSIST REPROD GEN, V9, P197, DOI 10.1007/BF01203813; COHEN J, 1988, ANN NY ACAD SCI, V541, P1, DOI 10.1111/j.1749-6632.1988.tb22236.x; DEJONGE CJ, 1995, HUM REPROD, V10, P2518, DOI 10.1093/oxfordjournals.humrep.a135733; DOYLE PE, 1991, J EPIDEMIOL COMMUN H, V45, P43, DOI 10.1136/jech.45.1.43; GOVAERTS I, 1995, LANCET, V346, P1095; HARTZ SC, 1992, FERTIL STERIL, V57, P15; HASSOLD T, 1985, HUM GENET, V70, P11, DOI 10.1007/BF00389450; HOLMES LB, 1976, NEW ENGL J MED, V295, P204, DOI 10.1056/NEJM197607222950406; KOBAYASHI K, 1994, HUM MOL GENET, V3, P1965, DOI 10.1093/hmg/3.11.1965; LANCASTER PAL, 1987, LANCET, V2, P110; LIEBAERS I, 1995, LANCET, V346, P1095, DOI 10.1016/S0140-6736(95)91768-3; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; MUNNE S, 1995, FERTIL STERIL, V64, P382, DOI 10.1016/S0015-0282(16)57739-5; MUNNE S, 1995, HUM REPROD, V10, P1014, DOI 10.1093/oxfordjournals.humrep.a136027; *NEW YORK STAT DEP, 1990, CONG MALF REG ANN RE; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; PALERMO G, 1993, FERTIL STERIL, V59, P826; Palermo GD, 1996, HUM REPROD, V11, P172; Palermo GD, 1996, FERTIL STERIL, V65, P899; PALERMO GD, 1995, SEMIN REPROD ENDOCR, V13, P39, DOI 10.1055/s-2007-1016341; PALERMO GD, 1995, FERTIL STERIL, V63, P1231, DOI 10.1016/S0015-0282(16)57603-1; PATRIZIO P, 1993, HUM REPROD, V8, P215, DOI 10.1093/oxfordjournals.humrep.a138025; PATRIZIO P, 1995, HUM REPROD, V10, P2520, DOI 10.1093/oxfordjournals.humrep.a135734; SCHLESSELMAN JJ, 1979, AM J OBSTET GYNECOL, V135, P135; SCHOYSMAN R, 1994, J ANDROL, V15, pS10; SILBER SJ, 1994, HUM REPROD, V9, P1705, DOI 10.1093/oxfordjournals.humrep.a138778; SMITH DW, 1975, J PEDIATR-US, V87, P162, DOI 10.1016/S0022-3476(75)80111-9; Svendsen TO, 1996, FERTIL STERIL, V65, P561, DOI 10.1016/S0015-0282(16)58154-0; TESARIK J, 1995, LANCET, V346, P1096; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1055, DOI 10.1093/oxfordjournals.humrep.a138191; VELD PI, 1995, LANCET, V346, P773, DOI 10.1016/S0140-6736(95)91531-1; Warburton D, 1986, PERINATAL GENETICS D, P133; WISANTO A, 1995, HUM REPROD, V10, P2713, DOI 10.1093/oxfordjournals.humrep.a135773	37	129	131	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1996	276	23					1893	1897		10.1001/jama.276.23.1893	http://dx.doi.org/10.1001/jama.276.23.1893			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX522	8968015				2022-12-28	WOS:A1996VX52200037
J	Fine, MJ; Auble, TE; Yealy, DM; Hanusa, BH; Weissfeld, LA; Singer, DE; Coley, CM; Marrie, TJ; Kapoor, WN				Fine, MJ; Auble, TE; Yealy, DM; Hanusa, BH; Weissfeld, LA; Singer, DE; Coley, CM; Marrie, TJ; Kapoor, WN			A prediction rule to identify low-risk patients with community-acquired pneumonia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-TRACT INFECTIONS; REQUIRING HOSPITALIZATION; ANTIMICROBIAL THERAPY; MEDISGROUPS; MORTALITY; ADMISSION; ETIOLOGY; DECISION; STAY	Background There is considerable variability in rates of hospitalization of patients with community-acquired pneumonia, in part because of physicians' uncertainty in assessing the severity of illness at presentation. Methods From our analysis of data on 14,199 adult inpatients with community-acquired pneumonia, we derived a prediction rule that stratifies patients into five classes with respect to the risk of death within 30 days. The rule was validated with 1991 data on 38,039 inpatients and with data on 2287 inpatients and outpatients in the Pneumonia Patient Outcomes Research Team (PORT) cohort study. The prediction rule assigns points based on age and the presence of coexisting disease, abnormal physical findings (such as a respiratory rate of greater than or equal to 30 per minute or a temperature of greater than or equal to 40 degrees C), and abnormal laboratory findings (such as a pH <7.35, a blood urea nitrogen concentration greater than or equal to 30 mg per deciliter [11 mmol per liter] or a sodium concentration <130 mmol per liter) at presentation. Results There were no significant differences in mortality in each of the five risk classes among the three cohorts. Mortality ranged from 0.1 to 0.4 percent for class I patients (P=0.22), from 0.6 to 0.7 percent for class II (P=0.67), and from 0.9 to 2.8 percent for class III (P=0.12). Among the 1575 patients in the three lowest risk classes in the Pneumonia PORT cohort, there were only seven deaths, of which only four were pneumonia-related. The risk class was significantly associated with the risk of subsequent hospitalization among those treated as outpatients and with the use of intensive care and the number of days in the hospital among inpatients. Conclusions The prediction rule we describe accurately identifies the patients with community-acquired pneumonia who are at low risk for death and other adverse outcomes. This prediction rule may help physicians make more rational decisions about hospitalization for patients with pneumonia. (C) 1997, Massachusetts Medical Society.	UNIV PITTSBURGH,GRAD SCH PUBL HLTH,DEPT EMERGENCY MED,PITTSBURGH,PA; UNIV PITTSBURGH,GRAD SCH PUBL HLTH,DEPT BIOSTAT,PITTSBURGH,PA; MASSACHUSETTS GEN HOSP,MED SERV,GEN INTERNAL MED UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA; VICTORIA GEN HOSP,DEPT MED,DIV INFECT DIS,HALIFAX,NS B3H 2Y9,CANADA; DALHOUSIE UNIV,HALIFAX,NS,CANADA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Dalhousie University; University of Victoria; Dalhousie University					AHRQ HHS [R01HS-06468] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BARTLETT JG, 1995, NEW ENGL J MED, V333, P1618, DOI 10.1056/NEJM199512143332408; Breslow N, 1980, STATISTICAL METHODS, V32; BREWSTER AC, 1985, INQUIRY-J HEALTH CAR, V22, P377; Coley C. M., 1996, JGIM, V11, P45; Coley CM, 1996, ARCH INTERN MED, V156, P1565, DOI 10.1001/archinte.156.14.1565; COLLET D, 1994, MODELLING SURVIVAL D, P85; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; DANS PE, 1984, ARCH INTERN MED, V144, P1392, DOI 10.1001/archinte.144.7.1392; EHRENKRANZ NJ, 1992, INFECT CONT HOSP EP, V13, P21, DOI 10.2307/30146964; FARR BM, 1991, ANN INTERN MED, V115, P428, DOI 10.7326/0003-4819-115-6-428; FINE MJ, 1990, AM J MED, V89, P713, DOI 10.1016/0002-9343(90)90211-U; FINE MJ, 1990, AM J MED, V88, pN1; Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134; FINE MJ, 1995, J GEN INTERN MED, V10, P359, DOI 10.1007/BF02599830; FINE MJ, 1993, AM J MED, V94, P153, DOI 10.1016/0002-9343(93)90177-Q; FINE MJ, IN PRESS ARCH INTERN; GARIBALDI RA, 1985, AM J MED, V78, P32, DOI 10.1016/0002-9343(85)90361-4; GENTRY LO, 1992, AM REV RESPIR DIS, V145, P31, DOI 10.1164/ajrccm/145.1.31; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; IEZZONI LI, 1988, JAMA-J AM MED ASSOC, V260, P3159, DOI 10.1001/jama.260.21.3159; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P3611, DOI 10.1001/jama.260.24.3611; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KURASHI NY, 1992, THORAX, V47, P115, DOI 10.1136/thx.47.2.115; LAFORCE FM, 1985, AM J MED, V78, P52, DOI 10.1016/0002-9343(85)90364-X; Lave JR, 1996, J GEN INTERN MED, V11, P415, DOI 10.1007/BF02600189; MARRIE TJ, 1989, REV INFECT DIS, V11, P586; McCormick D., 1996, JGIM, V11, P80; MCMAHON LF, 1989, MED CARE, V27, P623, DOI 10.1097/00005650-198906000-00005; MCNEIL BJ, 1975, NEW ENGL J MED, V293, P211, DOI 10.1056/NEJM197507312930501; MOHER D, 1992, CAN MED ASSOC J, V146, P511; ORTQVIST A, 1990, EUR RESPIR J, V3, P1105; PALADINO JA, 1991, AM J MED, V91, P462, DOI 10.1016/0002-9343(91)90181-V; RAMIREZ JA, 1995, ARCH INTERN MED, V155, P1273, DOI 10.1001/archinte.155.12.1273; Roos N P, 1988, Health Care Financ Rev, V9, P53; SELKER HP, 1993, AM J CARDIOL, V71, P339, DOI 10.1016/0002-9149(93)90802-J; THOMAS JW, 1986, EVALUATION ALTERNATI, V1, P1; Wasson JH, 1996, JAMA-J AM MED ASSOC, V275, P641, DOI 10.1001/jama.275.8.641; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WEINGARTEN SR, 1994, CHEST, V105, P1109, DOI 10.1378/chest.105.4.1109; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WHO (World Health Organization), 1977, MAN INT STAT CLASS D; WYATT JC, 1995, BMJ-BRIT MED J, V311, P1539, DOI 10.1136/bmj.311.7019.1539; 1995, HLTH CARE FINANC REV, V16; 1987, Q J MED, V62, P195	44	3230	3394	2	83	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1997	336	4					243	250		10.1056/NEJM199701233360402	http://dx.doi.org/10.1056/NEJM199701233360402			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE632	8995086	Bronze			2022-12-28	WOS:A1997WE63200002
J	Dalton, CB; Austin, CC; Sobel, J; Hayes, PS; Bibb, WF; Graves, LM; Swaminathan, B; Proctor, ME; Griffin, PM				Dalton, CB; Austin, CC; Sobel, J; Hayes, PS; Bibb, WF; Graves, LM; Swaminathan, B; Proctor, ME; Griffin, PM			An outbreak of gastroenteritis and fever due to Listeria monocytogenes in milk	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MULTILOCUS ENZYME ELECTROPHORESIS; FIELD GEL-ELECTROPHORESIS; EPIDEMIC LISTERIOSIS; CHOCOLATE MILK; FOOD; INCUBATION; GROWTH; ADULTS	Background After an outbreak of gastroenteritis and fever among persons who attended a picnic in Illinois, chocolate milk served at the picnic was found to be contaminated with Listeria monocytogenes. Methods In investigating this outbreak, we interviewed the people who attended the picnic about what they ate and their symptoms. Surveillance for invasive listeriosis was initiated in the states that receive milk from the implicated dairy. Stool and milk samples were cultured for L. monocytogenes. Serum samples were tested for IgG antibody to listeriolysin O. Results Forty-five persons had symptoms that met the case definition for illness due to L. monocytogenes, and cultures of stool from 11 persons yielded the organism. Illness in the week after the picnic was associated with the consumption of chocolate milk. The most common symptoms were diarrhea (present in 79 percent of the cases) and fever (72 percent). Four persons were hospitalized. The median incubation period for infection was 20 hours (range, 9 to 32), and persons who became ill had elevated levels of antibody to listeriolysin O. Isolates from stool specimens from patients who became ill after the picnic, from sterile sites in three additional patients identified by surveillance, from the implicated chocolate milk, and from a tank drain at the dairy were all serotype 1/2b and were indistinguishable on multilocus enzyme electrophoresis, ribotyping, and DNA macrorestriction analysis. Conclusions L. monocytogenes is a cause of gastroenteritis with fever, and sporadic cases of invasive listeriosis may be due to unrecognized outbreaks caused by contaminated food. (C) 1997, Massachusetts Medical Society.	CTR DIS CONTROL & PREVENT,FOODBORNE & DIARRHEAL DIS BRANCH,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA; CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,EPIDEMIOL PROGRAM OFF,ATLANTA,GA; ILLINOIS DEPT PUBL HLTH,DIV INFECT DIS,SPRINGFIELD,IL 62761; WISCONSIN DEPT HLTH & SOCIAL SERV,BUR PUBL HLTH,MADISON,WI	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								*ASS OFF AN CHEM I, 1992, BACT AN MAN; BERCHE P, 1990, LANCET, V335, P624, DOI 10.1016/0140-6736(90)90411-W; BIBB WF, 1990, APPL ENVIRON MICROB, V56, P2133, DOI 10.1128/AEM.56.7.2133-2141.1990; BROSCH R, 1994, APPL ENVIRON MICROB, V60, P2584, DOI 10.1128/AEM.60.7.2584-2592.1994; BROSCH R, 1991, RES MICROBIOL, V142, P667, DOI 10.1016/0923-2508(91)90080-T; BULA CJ, 1995, CLIN INFECT DIS, V20, P66, DOI 10.1093/clinids/20.1.66; *CYT SOFTW CORP, 1995, STATX 3 WIND; DEAN AG, 1994, EPIINFO VERSION 6 02; DONNELLY CW, 1986, J FOOD PROTECT, V49, P994, DOI 10.4315/0362-028X-49.12.994; DONNELLY CW, 1986, J FOOD PROTECT, V49, P1002; FARBER JM, 1991, J CLIN MICROBIOL, V29, P2606, DOI 10.1128/JCM.29.11.2606-2608.1991; FARBER JM, 1991, MICROBIOL REV, V55, P476, DOI 10.1128/MMBR.55.3.476-511.1991; FARBER JM, 1991, MICROBIOL REV, V55, P752; FLEMING DW, 1985, NEW ENGL J MED, V312, P404, DOI 10.1056/NEJM198502143120704; Gholizadeh Y, 1996, J CLIN MICROBIOL, V34, P1391, DOI 10.1128/JCM.34.6.1391-1395.1996; GRAVES LM, 1994, J CLIN MICROBIOL, V32, P2936, DOI 10.1128/JCM.32.12.2936-2943.1994; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; MATAR GM, 1992, RES MICROBIOL, V143, P489, DOI 10.1016/0923-2508(92)90095-6; MCCLAIN D, 1988, J ASSOC OFF ANA CHEM, V71, P660; MIETTINEN A, 1990, J CLIN MICROBIOL, V28, P340, DOI 10.1128/JCM.28.2.340-343.1990; NIEMAN RE, 1980, REV INFECT DIS, V2, P207; PINNER RW, 1992, JAMA-J AM MED ASSOC, V267, P2046, DOI 10.1001/jama.267.15.2046; PROCTOR ME, 1995, APPL ENVIRON MICROB, V61, P3177, DOI 10.1128/AEM.61.8.3177-3179.1995; RIEDO FX, 1994, J INFECT DIS, V170, P693, DOI 10.1093/infdis/170.3.693; ROSENOW EM, 1987, J FOOD PROTECT, V50, P452, DOI 10.4315/0362-028X-50.6.452; SALAMINA G, 1993, 33 INT C ANT AG CHEM; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; SCHUCHAT A, 1991, CLIN MICROBIOL REV, V4, P169, DOI 10.1128/CMR.4.2.169-183.1991; SCHUCHAT A, 1991, CLIN MICROBIOL REV, V4, P396, DOI 10.1128/CMR.4.3.396-.1991; SCHWARTZ B, 1989, J INFECT DIS, V159, P680, DOI 10.1093/infdis/159.4.680; Seeliger H.P.R., 1979, METHOD MICROBIOL, V13, P31, DOI [10.1016/S0580-9517(08)70372-6, DOI 10.1016/S0580-9517(08)70372-6]; Vanderzant C, 1992, COMPENDIUM METHODS M; WEAVER RE, 1989, ISOLATION IDENTIFICA, P39; WELLS JG, 1983, J CLIN MICROBIOL, V18, P512, DOI 10.1128/JCM.18.3.512-520.1983	34	381	408	0	26	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 9	1997	336	2					100	105		10.1056/NEJM199701093360204	http://dx.doi.org/10.1056/NEJM199701093360204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC481	8988887				2022-12-28	WOS:A1997WC48100004
J	Cairns, BR; Lorch, Y; Li, Y; Zhang, MC; Lacomis, L; ErdjumentBromage, H; Tempst, P; Du, J; Laurent, B; Kornberg, RD				Cairns, BR; Lorch, Y; Li, Y; Zhang, MC; Lacomis, L; ErdjumentBromage, H; Tempst, P; Du, J; Laurent, B; Kornberg, RD			RSC, an essential, abundant chromatin-remodeling complex	CELL			English	Article							RNA-POLYMERASE-II; YEAST SWI/SNF COMPLEX; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; NUCLEOSOME DISRUPTION; MULTISUBUNIT COMPLEX; NUCLEAR-PROTEIN; PHO5 PROMOTER; GENE-PRODUCTS; HUMAN HOMOLOG	A novel 15-subunit complex with the capacity to remodel the structure of chromatin, termed RSC, has been isolated from S. cerevisiae on the basis of homology to the SWI/SNF complex. At least three RSC subunits are related to SWI/SNF polypeptides: Sth1p, Rsc6p, and Rsc8p are significantly similar to Swi2/Snf2p, Swp73p, and Swi3p, respectively, and were identified by mass spectrometric and sequence analysis of peptide fragments. Like SWI/SNF, RSC exhibits a DNA-dependent ATPase activity stimulated by both free and nucleosomal DNA and a capacity to perturb nucleosome structure. RSC is, however, at least 10-fold more abundant than SWI/SNF complex and is essential for mitotic growth. Contrary to a report for SWI/SNF complex, no association of RSC (nor of SWI/SNF complex) with RNA polymerase II holoenzyme was detected.	STANFORD UNIV, SCH MED, DEPT BIOL STRUCT, STANFORD, CA 94305 USA; MEM SLOAN KETTERING CANC CTR, PROGRAM MOL BIOL, NEW YORK, NY 10021 USA; SUNY HLTH SCI CTR, DEPT MICROBIOL & IMMUNOL, BROOKLYN, NY 11203 USA	Stanford University; Memorial Sloan Kettering Cancer Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center				Erdjument-Bromage, Hediye/0000-0003-0224-3594	NCI NIH HHS [5 P30 CA08748] Funding Source: Medline; NIGMS NIH HHS [GM36659] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; Cairns BR, 1996, GENE DEV, V10, P2131, DOI 10.1101/gad.10.17.2131; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; ESTRUCH F, 1990, MOL CELL BIOL, V10, P2544, DOI 10.1128/MCB.10.6.2544; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; GEROMANOS S, 1994, TECHNIQUES PROTEIN C, V5, P143; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HAPPEL AM, 1991, GENETICS, V128, P69; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; LORCH Y, 1992, GENE DEV, V6, P2282, DOI 10.1101/gad.6.12a.2282; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NEIGEBORN L, 1984, GENETICS, V108, P845; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SIKORSKI RS, 1989, GENETICS, V122, P19; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; TREICH I, 1995, MOL CELL BIOL, V15, P4240; TSUCHIYA E, 1992, EMBO J, V11, P4017, DOI 10.1002/j.1460-2075.1992.tb05495.x; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; WANG W, 1996, GENE DEV, V10, P2177; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3	55	572	594	0	19	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 27	1996	87	7					1249	1260		10.1016/S0092-8674(00)81820-6	http://dx.doi.org/10.1016/S0092-8674(00)81820-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WA541	8980231	Bronze			2022-12-28	WOS:A1996WA54100013
J	Clark, LC; Combs, GF; Turnbull, BW; Slate, EH; Chalker, DK; Chow, J; Davis, LS; Glover, RA; Graham, GF; Gross, EG; Krongrad, A; Lesher, JL; Park, HK; Sanders, BB; Smith, CL; Taylor, JR				Clark, LC; Combs, GF; Turnbull, BW; Slate, EH; Chalker, DK; Chow, J; Davis, LS; Glover, RA; Graham, GF; Gross, EG; Krongrad, A; Lesher, JL; Park, HK; Sanders, BB; Smith, CL; Taylor, JR			Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin a randomized controlled trial - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NUTRITION INTERVENTION TRIALS; PREDIAGNOSTIC SERUM SELENIUM; DISEASE-SPECIFIC MORTALITY; VITAMIN-E; GASTROINTESTINAL CANCER; SUBSEQUENT RISK; CLINICAL-TRIALS; BETA-CAROTENE; CHINA; MEN	Objective.-To determine whether a nutritional supplement of selenium will decrease the incidence of cancer. Design.-A multicenter, double-blind, randomized, placebo-controlled cancer prevention trial. Setting.-Seven dermatology clinics in the eastern United States. Patients. A total of 1312 patients (mean age, 63 years; range, 18-80 years) with a history of basal cell or squamous cell carcinomas of the skin were randomized from 1983 through 1991. Patients were treated for a mean (SD) of 4.5 (2.8) years and had a total follow-up of 6.4 (2.0) years. Interventions.-Oral administration of 200 mu g of selenium per day or placebo. Main Outcome Measures.-The primary end points for the trial were the incidences of basal and squamous cell carcinomas of the skin. The secondary end points, established in 1990, were all-cause mortality and total cancer mortality, total cancer incidence, and the incidences of lung, prostate, and colorectal cancers. Results.-After a total follow-up of 8271 person-years, selenium treatment did not significantly affect the incidence of basal cell or squamous cell skin cancer. There were 377 new cases of basal cell skin cancer among patients in the selenium group and 350 cases among the control group (relative risk [RR], 1.10; 95% confidence interval [CI], 0.95-1.28), and 218 new squamous cell skin cancers in the selenium group and 190 cases among the controls (RR, 1.14; 95% CI, 0.93-1.39). Analysis of secondary end points revealed that, compared with controls, patients treated with selenium had a nonsignificant reduction in all-cause mortality (108 deaths in the selenium group and 129 deaths in the control group [RR, 0.83; 95% CI, 0.63-1.08]) and significant reductions in total cancer mortality (29 deaths in the selenium treatment group and 57 deaths in controls [RR, 0.50; 95% CI, 0.31-0.80]), total cancer incidence (77 cancers in the selenium group and 119 in controls [RR, 0.63; 95% CI, 0.47-0.85]), and incidences of lung, colorectal, and prostate cancers. Primarily because of the apparent reductions in total cancer mortality and total cancer incidence in the selenium group, the blinded phase of the trial was stopped early. No cases of selenium toxicity occurred. Conclusions.-Selenium treatment did not protect against development of basal or squamous cell carcinomas of the skin. However, results from secondary end-point analyses support the hypothesis that supplemental selenium may reduce the incidence of, and mortality from, carcinomas of several sites. These effects of selenium require confirmation in an independent trial of appropriate design before new public health recommendations regarding selenium supplementation can be made.	CORNELL UNIV, DIV NUTR SCI, ITHACA, NY 14853 USA; CORNELL UNIV, CTR STAT, ITHACA, NY USA; GEORGIA DERMATOL & SKIN CANC CLIN, MACON, GA USA; COLUMBIA SKIN CLIN, COLUMBIA, SC USA; MED COLL GEORGIA, AUGUSTA, GA 30912 USA; WILSON DERMATOL CLIN, WILSON, NC USA; UNIV N CAROLINA, SCH MED, DIV DERMATOL, CHAPEL HILL, NC USA; UNIV CONNECTICUT, SCH MED, DIV DERMATOL, FARMINGTON, CT USA; UNIV MIAMI, VET ADM MED CTR, CORAL GABLES, FL 33124 USA; E CAROLINA UNIV, SCH MED, DEPT MED, DIV DERMATOL, GREENVILLE, NC USA; EASTERN DERMATOL, GREENVILLE, NC USA	Cornell University; Cornell University; University System of Georgia; Augusta University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Connecticut; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of North Carolina; East Carolina University	Clark, LC (corresponding author), UNIV ARIZONA, COLL MED, ARIZONA CANC CTR, 2504 E ELM ST, TUCSON, AZ 85716 USA.				NCI NIH HHS [R01-CA49764, R01-CA42334] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049764] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABULIBDEH H, 1990, BIOMETRICS, V46, P1017, DOI 10.2307/2532445; ALLAWAY WH, 1968, ARCH ENVIRON HEALTH, V16, P342, DOI 10.1080/00039896.1968.10665069; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; BURK RF, 1993, ANNU REV NUTR, V13, P65, DOI 10.1146/annurev.nu.13.070193.000433; Clark L C, 1984, Nutr Cancer, V6, P13, DOI 10.1080/01635588509513802; CLARK LC, 1991, ARCH ENVIRON HEALTH, V46, P37, DOI 10.1080/00039896.1991.9937427; CLARK LC, 1985, FED PROC, V44, P2584; CLARK LC, 1986, 3RD INT S SEL BIOL M, P1122; COATES RJ, 1988, AM J EPIDEMIOL, V128, P515, DOI 10.1093/oxfordjournals.aje.a114999; Combs G.F., 1986, ROLE SELENIUM NUTR; COMBS GF, 1994, RISK ASSESSMENT OF ESSENTIAL ELEMENTS, P167; COMBS GF, 1995, BIOCH MOL BIOL SELEN; COMSTOCK GW, 1992, AM J EPIDEMIOL, V135, P115, DOI 10.1093/oxfordjournals.aje.a116264; Cook RJ, 1996, J ROY STAT SOC A STA, V159, P93, DOI 10.2307/2983471; COX DR, 1989, J R STAT SOC B, V51, P305; El-Bayoumy K., 1991, PRACTICE ONCOLOGY, P1; FEX G, 1987, Nutrition and Cancer, V10, P221; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; Gailani MR, 1996, J NATL CANCER I, V88, P349, DOI 10.1093/jnci/88.6.349; GARLAND M, 1995, J NATL CANCER I, V87, P497, DOI 10.1093/jnci/87.7.497; GLATTRE E, 1989, INT J EPIDEMIOL, V18, P45, DOI 10.1093/ije/18.1.45; IP C, 1987, J AM COLL TOXICOL, V5, P7; IP C, 1987, CELLULAR MOL BIOL BR, P479; KNEKT P, 1990, J NATL CANCER I, V82, P864, DOI 10.1093/jnci/82.10.864; KNEKT P, 1988, INT J CANCER, V42, P846, DOI 10.1002/ijc.2910420609; KOK FJ, 1987, AM J EPIDEMIOL, V125, P12, DOI 10.1093/oxfordjournals.aje.a114493; LANFEAR J, 1994, CARCINOGENESIS, V15, P1387, DOI 10.1093/carcin/15.7.1387; LI JY, 1993, J NATL CANCER I, V85, P1492, DOI 10.1093/jnci/85.18.1492; LUO XL, 1994, COMMUN STAT-THEOR M, V23, P3417, DOI 10.1080/03610929408831455; MCSHANE LM, 1991, AM J CLIN NUTR, V53, P1354, DOI 10.1093/ajcn/53.6.1354; MENKES MS, 1986, NEW ENGL J MED, V315, P1250, DOI 10.1056/NEJM198611133152003; MILNER JA, 1985, FED PROC, V44, P2568; *NCI, 1992, CANC MORT PENT 1953; NELSON MA, 1994, CANCER LETT, V85, P23, DOI 10.1016/0304-3835(94)90234-8; NOMURA A, 1987, J NATL CANCER I, V79, P103; OLSON OE, 1975, J ASSOC OFF ANA CHEM, V58, P117; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; PELEG I, 1985, MED ONCOL TUMOR PHAR, V2, P157; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; POCOCK SJ, 1987, BIOMETRICS, V43, P487, DOI 10.2307/2531989; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RINGSTAD J, 1988, J CLIN PATHOL, V41, P454, DOI 10.1136/jcp.41.4.454; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; SALONEN JT, 1985, BMJ-BRIT MED J, V290, P417, DOI 10.1136/bmj.290.6466.417; SALONEN JT, 1984, AM J EPIDEMIOL, V120, P342, DOI 10.1093/oxfordjournals.aje.a113898; SCHOBER SE, 1987, AM J EPIDEMIOL, V126, P1033, DOI 10.1093/oxfordjournals.aje.a114742; SCHRAUZER GN, 1977, BIOINORG CHEM, V7, P23, DOI 10.1016/S0006-3061(00)80126-X; SCHRAUZER GN, 1971, EXPERIENTIA, V27, P1069, DOI 10.1007/BF02138885; Shamberger R J, 1971, CRC Crit Rev Clin Lab Sci, V2, P211, DOI 10.3109/10408367109151308; SHAMBERGER RJ, 1969, CAN MED ASSOC J, V100, P682; Tannock IF, 1996, J NATL CANCER I, V88, P206, DOI 10.1093/jnci/88.3-4.206; THOMPSON HJ, 1994, CARCINOGENESIS, V15, P183, DOI 10.1093/carcin/15.2.183; VANDENBRANDT PA, 1993, J NATL CANCER I, V85, P224; VIRTAMO J, 1987, CANCER, V60, P145, DOI 10.1002/1097-0142(19870715)60:2<145::AID-CNCR2820600203>3.0.CO;2-U; WILLETT WC, 1983, LANCET, V2, P130, DOI 10.1016/S0140-6736(83)90116-2; YANG G, 1989, J TRACE ELEM ELECT H, V3, P123	57	2309	2390	7	254	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1996	276	24					1957	1963		10.1001/jama.276.24.1957	http://dx.doi.org/10.1001/jama.276.24.1957			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY689	8971064				2022-12-28	WOS:A1996VY68900027
J	Callanan, V; OConnor, AF				Callanan, V; OConnor, AF			Otolaryngology - Making the deaf hear and the dumb speak	LANCET			English	Article											Callanan, V (corresponding author), UNITED MED & DENT SCH, ST THOMAS HOSP, DEPT OTOLARYNGOL HEAD & NECK SURG, LONDON SE1 7EH, ENGLAND.							deCarpentier JP, 1996, J LARYNGOL OTOL, V110, P37, DOI 10.1017/S0022215100132670; ElRefaie A, 1996, BRIT J AUDIOL, V30, P3, DOI 10.3109/03005369609077924; Koay B, 1996, CLIN OTOLARYNGOL, V21, P289, DOI 10.1111/j.1365-2273.1996.tb01071.x; Owen G, 1996, CLIN OTOLARYNGOL, V21, P54, DOI 10.1111/j.1365-2273.1996.tb01025.x; Wareing M, 1996, J LARYNGOL OTOL, V110, P232, DOI 10.1017/S0022215100133286	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	1996	348			2			SII19	SII19						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA463	8973497				2022-12-28	WOS:A1996WA46300019
J	Craddock, N; ODonovan, MC; Owen, MJ				Craddock, N; ODonovan, MC; Owen, MJ			Introducing Selfcite 2.0 - Career enhancing software	BRITISH MEDICAL JOURNAL			English	Article							BIPOLAR DISORDER				Craddock, N (corresponding author), UNIV WALES COLL CARDIFF,COLL MED,DEPT PSYCHOL MED,CARDIFF CF4 4XN,S GLAM,WALES.		O'Donovan, Michael C/P-7005-2018	O'Donovan, Michael C/0000-0001-7073-2379	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Craddock N, 1996, BRIT J PSYCHIAT, V169, P58, DOI 10.1192/bjp.169.1.58; Craddock N, 1996, BRIT MED BULL, V52, P434; CRADDOCK N, 1995, AM J HUM GENET, V57, P690; ODONOVAN MC, 1995, NAT GENET, V10, P380, DOI 10.1038/ng0895-380; ODONOVAN MC, IN PRESS PSYCHOL MED	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1659	1660		10.1136/bmj.313.7072.1659	http://dx.doi.org/10.1136/bmj.313.7072.1659			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991023	Green Published			2022-12-28	WOS:A1996VZ81100062
J	Butler, DK; Yasuda, LE; Yao, MC				Butler, DK; Yasuda, LE; Yao, MC			Induction of large DNA palindrome formation in yeast: Implications for gene amplification and genome stability in eukaryotes	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; INVERTED DUPLICATION; HAMSTER-CELLS; RIBOSOMAL DNA; TETRAHYMENA-PYRIFORMIS; RESISTANT LEISHMANIA; REPLICATION ORIGIN; CHROMOSOME LOSS; REPEATS; DELETION	Many amplified genes, including some oncogenes, are organized as large inverted repeats. How such giant palindromes are generated remains largely unknown. Recent studies of a palindrome in the ciliate Tetrahymena suggest a novel mechanism that requires chromosome breakage next to short inverted repeats. The prevalence of short inverted repeats in eukaryotic genomes raises the interesting possibility that this process may occur widely as a response to chromosome damage. Here we demonstrate that in Saccharomyces cerevisiae, large DNA palindromes are formed efficiently, probably by intramolecular recombination, when a double-strand break is introduced next to short inverted repeats. These results suggest a general mechanism for large palindromic DNA formation and reveal an important new source of genome instability resulting from chromosome breakage at selective sites.			Butler, DK (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98104, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013293] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01NIHGM26210] Funding Source: Medline; NIGMS NIH HHS [F32 GM1434, F32 GM13293] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEVERLEY SM, 1984, CELL, V38, P431, DOI 10.1016/0092-8674(84)90498-7; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BUTLER DK, 1995, MOL CELL BIOL, V15, P7117; CARROLL SM, 1987, MOL CELL BIOL, V7, P1740, DOI 10.1128/MCB.7.5.1740; CARROLL SM, 1988, MOL CELL BIOL, V8, P1525, DOI 10.1128/MCB.8.4.1525; COCKBURN AF, 1978, CHROMOSOMA, V70, P19, DOI 10.1007/BF00292212; DORSEY M, 1992, GENETICS, V132, P943; ENGBERG J, 1976, J MOL BIOL, V104, P455, DOI 10.1016/0022-2836(76)90281-3; Fan QC, 1996, MOL CELL BIOL, V16, P1267; FORD M, 1986, CELL, V45, P425, DOI 10.1016/0092-8674(86)90328-4; FORD M, 1985, P NATL ACAD SCI USA, V82, P3370, DOI 10.1073/pnas.82.10.3370; FRIED M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P143, DOI 10.1016/0167-4781(91)90095-4; Friedberg E.C., 1991, MOL CELLULAR BIOL TE, P147; Grondin K, 1996, MOL CELL BIOL, V16, P3587; HABER JE, 1995, BIOESSAYS, V17, P609, DOI 10.1002/bies.950170707; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; HYRIEN O, 1988, EMBO J, V7, P407, DOI 10.1002/j.1460-2075.1988.tb02828.x; KAFATOS FC, 1985, TRENDS GENET, V1, P301, DOI 10.1016/0168-9525(85)90119-2; KARRER KM, 1976, J MOL BIOL, V104, P421, DOI 10.1016/0022-2836(76)90280-1; KOSHLAND D, 1987, CELL, V48, P801, DOI 10.1016/0092-8674(87)90077-8; KRAMER KM, 1993, GENE DEV, V7, P2345, DOI 10.1101/gad.7.12a.2345; KUNES S, 1990, GENETICS, V124, P67; LEACH DRF, 1994, BIOESSAYS, V16, P893, DOI 10.1002/bies.950161207; MA C, 1988, MOL CELL BIOL, V8, P2316, DOI 10.1128/MCB.8.6.2316; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; NALBANTOGLU J, 1986, NUCLEIC ACIDS RES, V14, P8361, DOI 10.1093/nar/14.21.8361; OUELLETTE M, 1991, EMBO J, V10, P1009, DOI 10.1002/j.1460-2075.1991.tb08035.x; RAGHURAMAN MK, 1994, GENE DEV, V8, P554, DOI 10.1101/gad.8.5.554; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH KA, 1992, P NATL ACAD SCI USA, V89, P5427, DOI 10.1073/pnas.89.12.5427; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; VOGT VM, 1976, J MOL BIOL, V106, P567, DOI 10.1016/0022-2836(76)90252-7; WALTON JD, 1986, CELL, V46, P857, DOI 10.1016/0092-8674(86)90067-X; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WINDLE BE, 1992, MUTAT RES, V276, P199, DOI 10.1016/0165-1110(92)90009-X; YASUDA LF, 1991, CELL, V67, P505, DOI 10.1016/0092-8674(91)90525-4	39	69	70	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					1115	1122		10.1016/S0092-8674(00)81805-X	http://dx.doi.org/10.1016/S0092-8674(00)81805-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978615	Bronze			2022-12-28	WOS:A1996VY44700016
J	Eisen, JS				Eisen, JS			Zebrafish make a big splash	CELL			English	Review							BRACHYDANIO-RERIO; NEURAL CREST; FLOOR PLATE; CELL FATE; DROSOPHILA; GENE; MUTATIONS; EMBRYO; NOTOCHORD; POLARITY				Eisen, JS (corresponding author), UNIV OREGON,INST NEUROSCI,EUGENE,OR 97403, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD022486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023915] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22486] Funding Source: Medline; NINDS NIH HHS [NS23915] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abdelilah S, 1996, DEVELOPMENT, V123, P217; ALTABA ARI, 1990, TRENDS GENET, V6, P57; BAGNARA JT, 1979, SCIENCE, V203, P410, DOI 10.1126/science.760198; Baier H, 1996, DEVELOPMENT, V123, P415; BEKOFF A, 1992, J NEUROBIOL, V23, P1486, DOI 10.1002/neu.480231009; Brand M, 1996, DEVELOPMENT, V123, P129; Brand M, 1996, DEVELOPMENT, V123, P179; Campos-Ortega Jose A., 1993, P1091; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Chen JN, 1996, DEVELOPMENT, V123, P293; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; Currie PD, 1996, NATURE, V382, P452, DOI 10.1038/382452a0; DALE N, 1985, J PHYSIOL-LONDON, V363, P61, DOI 10.1113/jphysiol.1985.sp015695; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; DIETRICH WF, 1995, P NATL ACAD SCI USA, V92, P10849, DOI 10.1073/pnas.92.24.10849; Driever W, 1996, DEVELOPMENT, V123, P37; EISEN JS, 1993, DEV BIOL, V159, P50, DOI 10.1006/dbio.1993.1220; FELSENFELD AL, 1990, DEVELOPMENT, V108, P443; FurutaniSeiki M, 1996, DEVELOPMENT, V123, P229; Gaiano N, 1996, P NATL ACAD SCI USA, V93, P7777, DOI 10.1073/pnas.93.15.7777; GOODRICH ES, 1930, STUDIES STRUCTURE DE; Granato M, 1996, DEVELOPMENT, V123, P399; Haffter P, 1996, DEVELOPMENT, V123, P1; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; HAMMERSCHMIDT M, 1993, DEVELOPMENT, V119, P1107; Hammerschmidt M, 1996, DEVELOPMENT, V123, P95; Hammerschmidt M, 1996, DEVELOPMENT, V123, P143; Heisenberg CP, 1996, DEVELOPMENT, V123, P191; HENLON PD, 1996, DEV GENET, V18, P11; HO RK, 1990, NATURE, V348, P728, DOI 10.1038/348728a0; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; Jiang YJ, 1996, DEVELOPMENT, V123, P205; JOHNSON SL, 1995, GENETICS, V141, P1583; Kane DA, 1996, DEVELOPMENT, V123, P57; Kane DA, 1996, DEVELOPMENT, V123, P47; Karlstrom RO, 1996, DEVELOPMENT, V123, P461; Karlstrom RO, 1996, DEVELOPMENT, V123, P427; Kelsh RN, 1996, DEVELOPMENT, V123, P369; Kimmel CB, 1996, TRENDS GENET, V12, P329, DOI 10.1016/S0168-9525(96)80001-1; KIMMEL CB, 1989, NATURE, V337, P358, DOI 10.1038/337358a0; KIMMEL CB, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P203; Knapik EW, 1996, DEVELOPMENT, V123, P451; KRAUSS S, 1992, NATURE, V360, P87, DOI 10.1038/360087a0; LEE RKK, 1991, J COMP NEUROL, V304, P34; Malicki J, 1996, DEVELOPMENT, V123, P275; Malicki J, 1996, DEVELOPMENT, V123, P263; MARINI M, 1994, COMPUT MED IMAG GRAP, V18, P35, DOI 10.1016/0895-6111(94)90059-0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Melby AE, 1996, DEVELOPMENT, V122, P2225; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; MOENS CB, 1996, IN PRESS DEVELOPMENT; Muller M, 1996, DEVELOPMENT, V122, P2071; Mullins MC, 1996, DEVELOPMENT, V123, P81; Neuhauss SCF, 1996, DEVELOPMENT, V123, P357; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Odenthal J, 1996, DEVELOPMENT, V123, P391; Odenthal J, 1996, DEVELOPMENT, V123, P103; Pack M, 1996, DEVELOPMENT, V123, P321; PARODY TR, 1993, GENETICS, V135, P527; Piotrowski T, 1996, DEVELOPMENT, V123, P345; POSTLETHWAIT JH, 1994, SCIENCE, V264, P699, DOI 10.1126/science.8171321; RAIBLE DW, 1994, DEVELOPMENT, V120, P495; Ransom DG, 1996, DEVELOPMENT, V123, P311; Sagerstrom CG, 1996, DEVELOPMENT, V122, P1873; Schier AF, 1996, DEVELOPMENT, V123, P165; Schilling TF, 1996, DEVELOPMENT, V123, P329; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SOINICAKREZEL L, 1996, DEVELOPMENT, V123, P67; STAINER DYR, 1996, DEVELOPMENT, V123, P286; STAINIER DYR, 1995, DEVELOPMENT, V121, P3141; Stemple DL, 1996, DEVELOPMENT, V123, P117; STREISINGER G, 1981, NATURE, V291, P293, DOI 10.1038/291293a0; TALBOT WS, 1995, NATURE, V378, P150, DOI 10.1038/378150a0; Thorogood P, 1989, TRENDS NEUROSCI, V12, P38; Trowe T, 1996, DEVELOPMENT, V123, P439; vanEeden FJM, 1996, DEVELOPMENT, V123, P153; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; Weinstein BM, 1996, DEVELOPMENT, V123, P303; WESTERFIELD M, 1990, NEURON, V4, P867, DOI 10.1016/0896-6273(90)90139-7; Whitfield TT, 1996, DEVELOPMENT, V123, P241; Xu QL, 1995, DEVELOPMENT, V121, P4005; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	83	158	164	2	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 13	1996	87	6					969	977		10.1016/S0092-8674(00)81792-4	http://dx.doi.org/10.1016/S0092-8674(00)81792-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978602	Bronze			2022-12-28	WOS:A1996VY44700003
J	Ryan, K; Garrett, N; Mitchell, A; Gurdon, JB				Ryan, K; Garrett, N; Mitchell, A; Gurdon, JB			Eomesodermin, a key early gene in Xenopus mesoderm differentiation	CELL			English	Article							MAJOR DEVELOPMENTAL TRANSITION; MYOD EXPRESSION; BRACHYURY GENE; EARLY RESPONSE; VEGETAL CELLS; EARLY EMBRYOS; ACTIN GENES; INDUCTION; HOMOLOG; TRANSCRIPTION	Eomesodermin (Eomes) is a novel Xenopus T-domain gene. In normal development, it is expressed in mesodermal cells in a ventral-to-dorsal gradient of increasing concentration. It reaches its peak expression 1-2 hr before any other known panmesodermal gene. It is strongly inducible by normal vegetal cells and by mesoderm-inducing factors. Ectopic expression of Eomes in animal caps induces the transcription of nearly all mesodermal genes in a concentration-dependent way. Overexpression of Eomes dorsalizes ventral mesoderm, inducing gsc and changing cell fate to muscle and notochord. Blocking the function of Eomes causes gastrulation arrest and defective mesoderm-dependent gene activation. We propose that Eomes fulfills an essential function in initiating mesoderm differentiation and in determining mesodermal cell fate.			Ryan, K (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE CB2 1QR, ENGLAND.			GURDON, JOHN/0000-0002-5621-3799				ALTABA ARI, 1992, DEVELOPMENT, V116, P81; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BOLCE ME, 1993, DEV BIOL, V160, P413, DOI 10.1006/dbio.1993.1317; Bracket J., 1977, Current Topics Dev Biol, V11, P133, DOI 10.1016/S0070-2153(08)60745-0; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; BULFONE A, 1995, NEURON, V15, P63, DOI 10.1016/0896-6273(95)90065-9; CARNAC G, 1996, IN PRESS DEVELOPMENT; CASCIO S, 1987, DEVELOPMENT, V100, P297; CASCIO S, 1986, UCLA S MOL CELL BIOL, V51, P195; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; Conlon FL, 1996, DEVELOPMENT, V122, P2427; Culling C. F. A., 1963, HDB HISTOPATHOLOGICA; CUNLIFFE V, 1994, EMBO J, V13, P349, DOI 10.1002/j.1460-2075.1994.tb06268.x; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; DALE L, 1992, DEVELOPMENT, V115, P573; DAWID IB, 1994, J BIOL CHEM, V269, P6259; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GERHART JC, 1989, DEVELOPMENT S, V109, P37; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; GURDON JB, 1992, SEMIN DEV BIOL, V3, P255; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; Holland PWH, 1995, DEVELOPMENT, V121, P4283; HOPWOOD ND, 1991, DEVELOPMENT, V111, P551; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; ISAACS HV, 1994, EMBO J, V13, P4469, DOI 10.1002/j.1460-2075.1994.tb06769.x; ISAACS HV, 1992, DEVELOPMENT, V114, P711; JONES EA, 1987, DEVELOPMENT, V101, P557; KIMELMAN D, 1992, DEVELOPMENT, V116, P1; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KISPERT A, 1993, EMBO J, V12, P3211, DOI 10.1002/j.1460-2075.1993.tb05990.x; KRIEG PA, 1991, METHODS GENE TECHNOL, V1, P35; LEMAIRE P, 1993, CR ACAD SCI III-VIE, V316, P938; LEMAIRE P, 1994, DEVELOPMENT, V120, P1191; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop P.D., 1977, Current Topics Dev Biol, V11, P115, DOI 10.1016/S0070-2153(08)60744-9; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Pasteels J. J., 1964, Advances in Morphogenesis, V3, P363; RAO Y, 1994, GENE DEV, V8, P939, DOI 10.1101/gad.8.8.939; ReemKalma Y, 1995, P NATL ACAD SCI USA, V92, P12141, DOI 10.1073/pnas.92.26.12141; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1985, DIFFERENTIATION, V29, P109, DOI 10.1111/j.1432-0436.1985.tb00302.x; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; STENNARD F, 1996, IN PRESS DEVELOPMENT; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; WAKEFIELD L, 1983, EMBO J, V2, P1613, DOI 10.1002/j.1460-2075.1983.tb01632.x; WORMINGTON WM, 1983, DEV BIOL, V99, P248, DOI 10.1016/0012-1606(83)90273-7	69	212	217	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 13	1996	87	6					989	1000		10.1016/S0092-8674(00)81794-8	http://dx.doi.org/10.1016/S0092-8674(00)81794-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978604	Bronze			2022-12-28	WOS:A1996VY44700005
J	Boussard, E; Flahault, A; Vibert, JF; Valleron, AJ				Boussard, E; Flahault, A; Vibert, JF; Valleron, AJ			Sentiweb: French communicable disease surveillance on the world wide web	BMJ-BRITISH MEDICAL JOURNAL			English	Article											Boussard, E (corresponding author), INST FEDERAT ST ANTOINE RECH SANTE, INSERM, U444, 27 RUE CHALIGNY, F-75571 PARIS 12, FRANCE.							CARRAT F, 1992, AM J EPIDEMIOL, V135, P1293, DOI 10.1093/oxfordjournals.aje.a116236; GARNERIN P, 1992, ANN NY ACAD SCI, V670, P29, DOI 10.1111/j.1749-6632.1992.tb26072.x; Valleron A.-J., 1992, Morbidity and Mortality Weekly Report, V41, P101	3	33	33	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 30	1996	313	7069					1381	1382		10.1136/bmj.313.7069.1381	http://dx.doi.org/10.1136/bmj.313.7069.1381			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW685	8956709	Green Published			2022-12-28	WOS:A1996VW68500032
J	Loh, E; Sutton, MSJ; Wun, CCC; Rouleau, JL; Flaker, GC; Gottlieb, SS; Lamas, GA; Moye, LA; Goldhaber, SZ; Pfeffer, MA				Loh, E; Sutton, MSJ; Wun, CCC; Rouleau, JL; Flaker, GC; Gottlieb, SS; Lamas, GA; Moye, LA; Goldhaber, SZ; Pfeffer, MA			Ventricular dysfunction and the risk of stroke after myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TWO-DIMENSIONAL ECHOCARDIOGRAPHY; TERM FOLLOW-UP; DILATED CARDIOMYOPATHY; MURAL THROMBI; HEART-FAILURE; MORTALITY; PREVENTION; MANAGEMENT; CAPTOPRIL; EMBOLISM	Background In patients who have had a myocardial infarction, the long-term risk of stroke and its relation to the extent of left ventricular dysfunction have not been determined. We studied whether a reduced left ventricular ejection fraction is associated with an increased risk of stroke after myocardial infarction and whether other factors such as older age and therapy with anticoagulants, thrombolytic agents, or captopril affect long-term rates of stroke. Methods We performed an observational analysis of prospectively collected data on 2231 patients who had left ventricular dysfunction after acute myocardial infarction who were enrolled in the Survival and Ventricular Enlargement trial. The mean follow-up was 42 months. Risk factors for stroke were assessed by both univariate and multivariate Cox proportional-hazards analysis. Results Among these patients, 103 (4.6 percent) had fatal or nonfatal strokes during the study (rate of stroke per year of follow-up, 1.5 percent). The estimated five-year rate of stroke in all the patients was 8.1 percent. As compared with patients without stroke, patients with stroke were older (mean [+/-SD] age, 63+/-9 years vs. 59+/-11 years; P<0.001) and had lower ejection fractions (29+/-7 percent vs. 31+/-7 percent, P=0.01). Independent risk factors for stroke included a lower ejection fraction (for every decrease of 5 percentage points in the ejection fraction there was an 18 percent increase in the risk of stroke), older age, and the absence of aspirin or anticoagulant therapy. Patients with ejection fractions of less than or equal to 28 percent after myocardial infarction had a relative risk of stroke of 1.86, as compared with patients with ejection fractions of >35 percent (P=0.01). The use of thrombolytic agents and captopril had no significant effect on the risk of stroke. Conclusions During the five years after myocardial infarction, patients have a substantial risk of stroke. A decreased ejection fraction and older age are both independent predictors of an increased risk of stroke. Anticoagulant therapy appears to have a protective effect against stroke after myocardial infarction. (C) 1997, Massachusetts Medical Society.	UNIV TEXAS,HLTH SCI CTR,HOUSTON,TX; MONTREAL HEART INST,MONTREAL,PQ H1T 1C8,CANADA; UNIV MISSOURI HOSP & CLIN,COLUMBIA,MO; UNIV MARYLAND HOSP,BALTIMORE,MD 21201; MT SINAI MED CTR,MIAMI BEACH,FL 33140; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115	University of Texas System; University of Texas Health Science Center Houston; Universite de Montreal; University of Missouri System; University of Missouri Columbia; University System of Maryland; University of Maryland Baltimore; Mount Sinai Medical Center; Harvard University; Brigham & Women's Hospital	Loh, E (corresponding author), HOSP UNIV PENN,9 FOUNDERS PAVILION,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002514] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-02514] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, LANCET, V346, P1647; *ANT SEC PREV EV C, 1994, LANCET, V343, P499; ASINGER RW, 1981, NEW ENGL J MED, V305, P297, DOI 10.1056/NEJM198108063050601; BAKER DW, 1994, JAMA-J AM MED ASSOC, V272, P1614, DOI 10.1001/jama.272.20.1614; BEHAR S, 1991, AM J MED, V91, P45, DOI 10.1016/0002-9343(91)90072-6; CAIRNS JA, 1995, CHEST, V108, pS380, DOI 10.1378/chest.108.4_Supplement.380S; CIACCHERI M, 1989, BRIT HEART J, V62, P26; DOMENICUCCI S, 1987, CIRCULATION, V75, P737, DOI 10.1161/01.CIR.75.4.737; DRAPKIN A, 1972, J AMER MED ASSOC, V222, P541, DOI 10.1001/jama.222.5.541; DUNKMAN WB, 1993, CIRCULATION, V87, P94; FRIEDMAN MJ, 1982, AM J MED, V72, P894, DOI 10.1016/0002-9343(82)90848-8; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; HESS DC, 1993, NEUROL CLIN, V11, P399, DOI 10.1016/S0733-8619(18)30160-9; JOHANNESSEN KA, 1984, BRIT HEART J, V51, P533; KEATING EC, 1983, AM J MED, V74, P989, DOI 10.1016/0002-9343(83)90798-2; KOMRAD MS, 1984, NEUROLOGY, V34, P1403, DOI 10.1212/WNL.34.11.1403; KYRLE PA, 1985, THROMB HAEMOSTASIS, V54, P521; LAMAS GA, 1988, AM J CARDIOL, V62, P31, DOI 10.1016/0002-9149(88)91360-4; MAGGIONI A, 1991, BMJ-BRIT MED J, V302, P1428, DOI 10.1136/bmj.302.6790.1428; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; MARTIN R, 1993, J NEUROL NEUROSUR PS, V56, P760, DOI 10.1136/jnnp.56.7.760; *MED RES COUNC, 1969, BRIT MED J, V1, P335; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; Segal J P, 1978, Curr Probl Cardiol, V3, P1, DOI 10.1016/0146-2806(78)90026-9; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; STRATTON JR, 1988, CIRCULATION, V78, P1388, DOI 10.1161/01.CIR.78.6.1388; TANNE D, 1995, AM J CARDIOL, V76, P825, DOI 10.1016/S0002-9149(99)80236-7; THOMPSON PL, 1978, BRIT MED J, V2, P457, DOI 10.1136/bmj.2.6135.457; TURPIE AGG, 1989, NEW ENGL J MED, V320, P352, DOI 10.1056/NEJM198902093200604; VAITKUS PT, 1993, J AM COLL CARDIOL, V22, P1004, DOI 10.1016/0735-1097(93)90409-T; VISSER CA, 1984, CHEST, V86, P532, DOI 10.1378/chest.86.4.532; WEINREICH DJ, 1984, ANN INTERN MED, V100, P789, DOI 10.7326/0003-4819-100-6-789; 1973, JAMA-J AM MED ASSOC, V225, P724	34	419	430	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 23	1997	336	4					251	257		10.1056/NEJM199701233360403	http://dx.doi.org/10.1056/NEJM199701233360403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE632	8995087	Bronze			2022-12-28	WOS:A1997WE63200003
J	Hanski, I; Gyllenberg, M				Hanski, I; Gyllenberg, M			Uniting two general patterns in the distribution of species	SCIENCE			English	Article							METAPOPULATION DYNAMICS; REGIONAL DISTRIBUTION; AREA RELATIONSHIP; MODEL; ABUNDANCE; CORE; HYPOTHESIS; ARTIFACTS	Two patterns in the distribution of species have become firmly but independently established in ecology: the species-area curve, which describes how rapidly the number of species increases with area, and the positive relation between species' geographical distribution and average local abundance. There is no generally agreed explanation of either pattern, but for both the two main hypotheses are essentially the same: divergence of species along the ecological specialist-generalist continuum and colonization-extinction dynamics. A model is described that merges the two mechanisms, predicts both patterns, and thereby shows how the two general, but formerly disconnected, patterns are interrelated.	UNIV TURKU, DEPT MATH, FIN-20014 TURKU, FINLAND	University of Turku	Hanski, I (corresponding author), UNIV HELSINKI, DEPT SYSTEMAT & ECOL, POB 17, FIN-00014 HELSINKI, FINLAND.		Gyllenberg, Mats/D-1465-2013	Gyllenberg, Mats/0000-0002-0967-8454				Arrhenius O, 1921, J ECOL, V9, P95, DOI 10.2307/2255763; BROWN JH, 1984, AM NAT, V124, P255, DOI 10.1086/284267; BUYS MH, 1994, J VEG SCI, V5, P63, DOI 10.2307/3235638; Caswell Hal, 1993, P99; COLEMAN BD, 1981, MATH BIOSCI, V54, P191, DOI 10.1016/0025-5564(81)90086-9; CONNOR EF, 1979, AM NAT, V113, P791, DOI 10.1086/283438; Gaston K.J., 1994, RARITY, P1; GASTON KJ, 1990, OIKOS, V58, P329, DOI 10.2307/3545224; GASTON KJ, UNPUB; GILPIN ME, 1976, P NATL ACAD SCI USA, V73, P4130, DOI 10.1073/pnas.73.11.4130; Gleason HA, 1922, ECOLOGY, V3, P158, DOI 10.2307/1929150; GYLLENBERG M, 1992, THEOR POPUL BIOL, V42, P35, DOI 10.1016/0040-5809(92)90004-D; HANSKI I, 1994, J ANIM ECOL, V63, P151, DOI 10.2307/5591; HANSKI I, 1982, OIKOS, V38, P210, DOI 10.2307/3544021; HANSKI I, 1994, TRENDS ECOL EVOL, V9, P131, DOI 10.1016/0169-5347(94)90177-5; HANSKI I, 1991, OIKOS, V62, P88, DOI 10.2307/3545451; HANSKI I, 1993, AM NAT, V142, P17, DOI 10.1086/285527; Hanski Ilkka, 1993, P108; Harms W.B., 1990, P73; LAWTON JH, 1993, TRENDS ECOL EVOL, V8, P409, DOI 10.1016/0169-5347(93)90043-O; MAC ARTHUR ROBERT H., 1967; May R.M., 1975, P81; McIntosh Robert., 1985, BACKGROUND ECOLOGY C, DOI [10.1017/CBO9780511608537, DOI 10.1017/CBO9780511608537]; NEE S, 1991, OIKOS, V62, P83, DOI 10.2307/3545450; Nieminen M, 1996, OECOLOGIA, V108, P643, DOI 10.1007/BF00329038; PATTERSON B D, 1987, Conservation Biology, V1, P323, DOI 10.1111/j.1523-1739.1987.tb00052.x; PRESBERG B, 1992, HOSP COMMUNITY PSYCH, V43, P185; PRESTON FW, 1948, ECOLOGY, V29, P254, DOI 10.2307/1930989; PRESTON FW, 1960, ECOLOGY, V41, P611, DOI 10.2307/1931793; RICKLEFS RE, 1972, AM NAT, V106, P195, DOI 10.1086/282762; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; SCHOENER TW, 1976, 16TH P INT ORN C, P629; SUGIHARA G, 1980, AM NAT, V116, P770, DOI 10.1086/283669; Venier LA, 1996, OIKOS, V76, P564, DOI 10.2307/3546349; Williams CB, 1943, NATURE, V152, P264, DOI 10.1038/152264a0; WILLIAMS MR, 1995, ECOLOGY, V76, P2607, DOI 10.2307/2265831; WISSEL C, 1992, J BIOGEOGR, V19, P355, DOI 10.2307/2845563; WITKOWSKI Z, 1984, Bulletin of the Polish Academy of Sciences Biological Sciences, V32, P241	38	228	236	2	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 17	1997	275	5298					397	400		10.1126/science.275.5298.397	http://dx.doi.org/10.1126/science.275.5298.397			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	8994039				2022-12-28	WOS:A1997WC87300050
J	Kondo, T; Mori, T; Lebedeva, NV; Aoki, S; Ishiura, M; Golden, SS				Kondo, T; Mori, T; Lebedeva, NV; Aoki, S; Ishiura, M; Golden, SS			Circadian rhythms in rapidly dividing cyanobacteria	SCIENCE			English	Article							GENE-EXPRESSION; CLOCK; LUCIFERASE; REPORTER	The long-standing supposition that the biological clock cannot function in cells that divide more rapidly than the circadian cycle was investigated. During exponential growth in which the generation time was 10 hours, the profile of bioluminescence from a reporter strain of the cyanobacterium Synechococcus (species PCC 7942) matched a model based on the assumption that cells proliferate exponentially and the bioluminescence of each cell oscillates in a cosine fashion. Some messenger RNAs showed a circadian rhythm in abundance during continuous exponential growth with a doubling time of 5 to 6 hours. Thus, the cyanobacterial circadian clock functions in cells that divide three or more times during one circadian cycle.	VANDERBILT UNIV,DEPT BIOL,NASHVILLE,TN 37235; TEXAS A&M UNIV,DEPT BIOL,COLLEGE STN,TX 77843	Vanderbilt University; Texas A&M University System; Texas A&M University College Station	Kondo, T (corresponding author), NAGOYA UNIV,GRAD SCH SCI,DIV BIOL SCI,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN.							Bunning E, 1973, PHYSL CLOCK; BUSTOS SA, 1991, J BACTERIOL, V173, P7525, DOI 10.1128/jb.173.23.7525-7533.1991; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; Edmunds LN, 1988, CELLULAR MOL BASES B; Ehret C. F, 1970, pUnpaginated; Engelmann W., 1980, PHOTOCHEMICAL AND PHOTOBIOLOGICAL REVIEWS, V5, P49; ENSOR MH, 1996, CELL, V84, P677; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; KONDO T, 1994, J BACTERIOL, V176, P1881, DOI 10.1128/jb.176.7.1881-1885.1994; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; KONDO T, UNPUB; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; LIU Y, 1995, J BACTERIOL, V177, P2080, DOI 10.1128/jb.177.8.2080-2086.1995; LOROS J, 1995, SEMIN NEUROSCI, V7, P3, DOI 10.1016/1044-5765(95)90012-8; Mori T, 1996, P NATL ACAD SCI USA, V93, P10183, DOI 10.1073/pnas.93.19.10183; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; NJUS D, 1974, NATURE, V248, P116, DOI 10.1038/248116a0; SCHAEFER MR, 1989, J BACTERIOL, V171, P3973, DOI 10.1128/jb.171.7.3973-3981.1989; Sweeney BM., 1987, RHYTHMIC PHENOMENA P; Vetterling W.T., 1988, NUMERICAL RECIPES C; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	23	120	133	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					224	227		10.1126/science.275.5297.224	http://dx.doi.org/10.1126/science.275.5297.224			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8985018				2022-12-28	WOS:A1997WC02200042
J	Roelfsema, PR; Engel, AK; Konig, P; Singer, W				Roelfsema, PR; Engel, AK; Konig, P; Singer, W			Visuomotor integration is associated with zero time-lag synchronization among cortical areas	NATURE			English	Article							OSCILLATORY NEURONAL RESPONSES; CAT VISUAL-CORTEX; MOTOR CORTEX; MONKEY; POTENTIALS; MECHANISMS; COHERENCE; STRIATE	INFORMATION processing in the cerebral cortex invariably involves the activation of millions of neurons that are widely distributed over its various areas, These distributed activity patterns need to be integrated into coherent representational states, A candidate mechanism for the integration and coordination of neuronal activity between different brain regions is synchronization on a fine temporal scale(1-3). In the visual cortex, synchronization occurs selectively between the responses of neurons that represent related features(2-5) and that need to be integrated for the generation of coherent percepts; neurons in other areas of the cerebral cortex also synchronize their discharges(6-10). However, little is known about the patterns and the behavioural correlates of synchrony among widely separated cortical regions, Here we report that synchronization occurs between areas of the visual and parietal cortex, and between areas of the parietal and motor cortex, in the awake cat, When cats responded to a sudden change of a visual pattern, neuronal activity in cortical areas exhibited synchrony without time lags; this synchrony was particularly strong between areas subserving related functions, During reward and inter-trial episodes, zero-time-lag synchrony was lost and replaced by interactions exhibiting large and unsystematic time lags.	NETHERLANDS OPHTHALM RES INST,NL-1100 AC AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,DEPT MED PHYS,NL-1100 AC AMSTERDAM,NETHERLANDS; INST NEUROSCI,SAN DIEGO,CA 92121	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Amsterdam	Roelfsema, PR (corresponding author), MAX PLANCK INST BRAIN RES,DEUTSCHORDENSTR 46,D-60528 FRANKFURT,GERMANY.		König, Peter/ABB-2380-2020; anand, amit/A-7222-2009; Singer, Wolf/D-6874-2012; Engel, Andreas K./AAH-6384-2019; Engel, Andreas K/C-7781-2012; Roelfsema, Pieter/J-6903-2013	König, Peter/0000-0003-3654-5267; Engel, Andreas K./0000-0003-4899-8466; Engel, Andreas K/0000-0003-4899-8466; Roelfsema, Pieter/0000-0002-1625-0034				Abeles M., 1991, CORTICONICS; BOUYER JJ, 1981, ELECTROEN CLIN NEURO, V51, P244, DOI 10.1016/0013-4694(81)90138-3; BRESSLER SL, 1993, NATURE, V366, P153, DOI 10.1038/366153a0; BUCHWALD NA, 1964, NATURE, V201, P830, DOI 10.1038/201830a0; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL AK, 1992, TRENDS NEUROSCI, V15, P218, DOI 10.1016/0166-2236(92)90039-B; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P6048, DOI 10.1073/pnas.88.14.6048; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FRIEN A, 1994, NEUROREPORT, V5, P2273, DOI 10.1097/00001756-199411000-00017; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; JEANNEROD M, 1995, TRENDS NEUROSCI, V18, P314, DOI 10.1016/0166-2236(95)93921-J; KALASKA JF, 1992, SCIENCE, V255, P1517, DOI 10.1126/science.1549781; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; MITZDORF U, 1985, PHYSIOL REV, V65, P37, DOI 10.1152/physrev.1985.65.1.37; Munk MHJ, 1996, SCIENCE, V272, P271, DOI 10.1126/science.272.5259.271; Munk MHJ, 1995, J NEUROPHYSIOL, V74, P2401, DOI 10.1152/jn.1995.74.6.2401; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; NELSON JI, 1992, VISUAL NEUROSCI, V9, P21, DOI 10.1017/S0952523800006349; NIEOULLON A, 1976, BRAIN RES, V105, P405, DOI 10.1016/0006-8993(76)90590-4; Roelfsema PR, 1996, J COGNITIVE NEUROSCI, V8, P603, DOI 10.1162/jocn.1996.8.6.603; SANES JN, 1993, P NATL ACAD SCI USA, V90, P4470, DOI 10.1073/pnas.90.10.4470; SCANNELL JW, 1995, J NEUROSCI, V15, P1463; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; Steriade M, 1996, J NEUROSCI, V16, P392, DOI 10.1523/jneurosci.16-01-00392.1996; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; TUSA RJ, 1978, J COMP NEUROL, V177, P213, DOI 10.1002/cne.901770204; VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0	29	795	811	1	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 9	1997	385	6612					157	161		10.1038/385157a0	http://dx.doi.org/10.1038/385157a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WB728	8990118	Green Submitted			2022-12-28	WOS:A1997WB72800054
J	Skevas, A; Kastanioudakis, I; Bai, M; Kostoula, A				Skevas, A; Kastanioudakis, I; Bai, M; Kostoula, A			Old-world leishmaniasis of the auricle	LANCET			English	Article									UNIV IOANNINA,DEPT PATHOL,GR-45110 IOANNINA,GREECE; UNIV IOANNINA,DEPT MICROBIOL,GR-45110 IOANNINA,GREECE	University of Ioannina; University of Ioannina	Skevas, A (corresponding author), UNIV IOANNINA,DEPT OTOLARYNGOL,POB 1186,GR-45110 IOANNINA,GREECE.			Kastanioudakis, Ioannis/0000-0003-1853-9031				GREVELINK AS, 1996, J AM ACAD DERMATOL, V34, P257; GROGL M, 1992, AM J TROP MED HYG, V47, P117, DOI 10.4269/ajtmh.1992.47.117	2	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					28	29		10.1016/S0140-6736(05)62160-5	http://dx.doi.org/10.1016/S0140-6736(05)62160-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8988123				2022-12-28	WOS:A1997WA72500017
J	Sekiguchi, A; Tsukamoto, M; Ichinohe, M				Sekiguchi, A; Tsukamoto, M; Ichinohe, M			A free cyclotrigermenium cation with a 2 pi-electron system	SCIENCE			English	Article							SILICON DOUBLE-BOND; AB-INITIO IGLO; TRIETHYLSILYL CATIONS; MOLECULAR-STRUCTURE; SILYLIUM CATIONS; IONS; CHEMISTRY; CRYSTAL; ANALOGS; SEARCH	The reaction of tetrakis(tri-tert-butylsilyl)cyclotrigermene with trityl tetraphenylborate in benzene produces tris(tri-teri-butylsilyl)cyclotrigermenium tetraphenylborate [(tert-Bu(3)SiGe)(3)(+)BPh(4)(-)], which can be isolated as a yellow solid that is stable in the absence of air. The crystal structure of the cyclotrigermenium ion reveals a free germyl cation with a 2 pi-electron system. The three germanium atoms form an equilateral triangle similar to the carbon analog, the cyclopropenium ion.	TOHOKU UNIV,GRAD SCH SCI,AOBA KU,SENDAI,MIYAGI 98077,JAPAN	Tohoku University	Sekiguchi, A (corresponding author), UNIV TSUKUBA,DEPT CHEM,TSUKUBA,IBARAKI 305,JAPAN.							ALLEN FH, 1982, TETRAHEDRON, V38, P645, DOI 10.1016/0040-4020(82)80206-8; [Anonymous], 1971, PURE APPL CHEM; Arshadi M, 1996, J AM CHEM SOC, V118, P5120, DOI 10.1021/ja9542956; BRESLOW R, 1957, J AM CHEM SOC, V79, P5318, DOI 10.1021/ja01576a067; BRESLOW R, 1958, J AM CHEM SOC, V80, P5991, DOI 10.1021/ja01555a026; BROOK AG, 1981, J CHEM SOC CHEM COMM, P191, DOI 10.1039/c39810000191; BROOK AG, 1982, J AM CHEM SOC, V104, P5667, DOI 10.1021/ja00385a019; CORRIU RJP, 1974, J ORGANOMET CHEM, V74, P1, DOI 10.1016/S0022-328X(00)83756-0; JEMMIS ED, 1995, J AM CHEM SOC, V117, P11361, DOI 10.1021/ja00150a043; KIRA M, 1992, J AM CHEM SOC, V114, P6697, DOI 10.1021/ja00043a013; KU AT, 1972, J AM CHEM SOC, V94, P1688, DOI 10.1021/ja00760a043; LAMBERT JB, 1993, SCIENCE, V260, P1917, DOI 10.1126/science.260.5116.1917; LAMBERT JB, 1994, SCIENCE, V263, P984, DOI 10.1126/science.263.5149.984; LAMBERT JB, 1995, CHEM REV, V95, P1191, DOI 10.1021/cr00037a003; LAMBERT JB, IN PRESS ANGEW CHEM; LAMBERT JB, 1989, CHEM ORGANIC SILICON, pCH16; LI WK, 1992, THEOCHEM-J MOL STRUC, V89, P189; LI XW, 1995, J AM CHEM SOC, V117, P7578, DOI 10.1021/ja00133a045; MAERKER C, 1996, ORGANOSILICON CHEM M, V2; NAGASE S, 1993, PURE APPL CHEM, V65, P675, DOI 10.1351/pac199365040675; OLAH GA, 1994, SCIENCE, V263, P983; OLAH GA, 1992, J AM CHEM SOC, V114, P7737, DOI 10.1021/ja00046a020; OLAH GA, 1995, J AM CHEM SOC, V117, P8962, DOI 10.1021/ja00140a010; OLAH GA, 1995, B SOC CHIM FR, V132, P569; OLSSON L, 1995, J AM CHEM SOC, V117, P7460, DOI 10.1021/ja00133a019; OLSSON L, 1993, CHEM PHYS LETT, V215, P433, DOI 10.1016/0009-2614(93)85699-O; PAULING L, 1994, SCIENCE, V263, P983, DOI 10.1126/science.263.5149.983; Raabe G., 1989, CHEM ORGANIC SILICON; REED CA, 1993, SCIENCE, V262, P402, DOI 10.1126/science.262.5132.402; REED CA, 1994, SCIENCE, V263, P985, DOI 10.1126/science.263.5149.985; SCHLEYER PV, 1993, ANGEW CHEM INT EDIT, V32, P1471; SCHWARZ H, 1989, CHEM ORGANIC SILICON, pCH7; SEKIGUCHI A, 1995, J AM CHEM SOC, V117, P8025, DOI 10.1021/ja00135a025; SUNDARAL.M, 1966, J AM CHEM SOC, V88, P198, DOI 10.1021/ja00954a002; TSUMURAYA T, 1991, ANGEW CHEM INT EDIT, V30, P902, DOI 10.1002/anie.199109021; WEST R, 1987, ANGEW CHEM INT EDIT, V26, P1201, DOI 10.1002/anie.198712013; WEST R, 1981, SCIENCE, V214, P1343, DOI 10.1126/science.214.4527.1343; WONG MW, 1989, J AM CHEM SOC, V111, P6976, DOI 10.1021/ja00200a012; Xie YM, 1996, J AM CHEM SOC, V118, P10635, DOI 10.1021/ja9616701; XIE ZW, 1994, J CHEM SOC CHEM COMM, P2519, DOI 10.1039/c39940002519; XIE ZW, 1995, ORGANOMETALLICS, V14, P3933, DOI 10.1021/om00008a045; Xie ZW, 1996, J AM CHEM SOC, V118, P2922, DOI 10.1021/ja953211q	42	124	124	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					60	61		10.1126/science.275.5296.60	http://dx.doi.org/10.1126/science.275.5296.60			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8974390				2022-12-28	WOS:A1997WA90300046
J	Ronnemaa, T; Karonen, SL; Rissanen, A; Koskenvuo, M; Koivisto, VA				Ronnemaa, T; Karonen, SL; Rissanen, A; Koskenvuo, M; Koivisto, VA			Relation between plasma leptin levels and measures of body fat in identical twins discordant for obesity	ANNALS OF INTERNAL MEDICINE			English	Article							CARDIOVASCULAR-DISEASE; INSULIN SENSITIVITY; REGIONAL ADIPOSITY; GENE-PRODUCT; OB GENE; WEIGHT; TISSUE; MOUSE; RNA	Background: Plasma levels of leptin, the recently discovered satiety hormone, are associated with adiposity in humans. Objective: To determine whether genetic factors or body fat distribution affect the association between leptin levels and obesity. Participants: 23 healthy identical twin pairs (9 male pairs and 14 female pairs, 33 to 59 years of age) who were discordant for obesity (average weight difference, 18 kg). Measurements: Pasting plasma leptin levels were measured by radioimmunoassay. Distribution of abdominal fat into visceral and subcutaneous compartments was estimated by use of magnetic resonance imaging. Results: Plasma leptin levels were threefold higher in obese twins than in lean twins (mean +/- SD, 18.7 +/- 12.5 mu g/L compared with 6.4 +/- 4.8 mu g/L; P < 0.001); a similar difference was seen when the entire study group was divided according to sex. Compared with lean twins, plasma leptin levels were 3.7-fold higher in the obese twins who had visceral fat accumulation greater than the median and 2.1-fold higher in the obese twins who had visceral fat accumulation less than the median. The intrapair differences in leptin levels correlated with the corresponding differences in percentage of body fat in women (r = 0.73; P = 0.003) but not in men and correlated with differences in visceral fat area in men (r = 0.79; P = 0.019) and women (r = 0.73; P = 0.007). In multiple regression analyses that included intrapair differences in visceral fat area and total body fat, the association between differences in visceral fat area and leptin levels was significant in men (P = 0.029) but not in women. Conclusions: Plasma leptin levels are increased in obese persons, independent of genetic background. Visceral fat may be of special importance in the regulation of leptin levels, but it is probably less important in women than in men.	UNIV HELSINKI, CENT HOSP, DEPT CLIN CHEM, FIN-00290 HELSINKI, FINLAND; UNIV HELSINKI, CENT HOSP, DEPT PSYCHIAT, FIN-00180 HELSINKI, FINLAND; UNIV TURKU, DEPT PUBL HLTH, FIN-20520 TURKU, FINLAND; UNIV HELSINKI, CENT HOSP, DEPT MED, FIN-00290 HELSINKI, FINLAND	University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Turku; University of Helsinki; Helsinki University Central Hospital	Ronnemaa, T (corresponding author), UNIV TURKU, DEPT MED, RES & DEV CTR SOCIAL INSURANCE INST, KIINAMYLLYNKATU 4-8, FIN-20520 TURKU, FINLAND.							ABATE N, 1995, J CLIN INVEST, V96, P88, DOI 10.1172/JCI118083; Banks WA, 1996, PEPTIDES, V17, P305, DOI 10.1016/0196-9781(96)00025-3; Baumgartner R N, 1990, Exerc Sport Sci Rev, V18, P193; BJORNTORP P, 1990, ARTERIOSCLEROSIS, V10, P493, DOI 10.1161/01.ATV.10.4.493; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; CUSIN I, 1995, DIABETES, V44, P1467, DOI 10.2337/diabetes.44.12.1467; DESPRES JP, 1990, ARTERIOSCLEROSIS, V10, P497, DOI 10.1161/01.ATV.10.4.497; EVANS DJ, 1984, METABOLISM, V33, P68, DOI 10.1016/0026-0495(84)90164-1; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HEYMSFIELD SB, 1990, AM J CLIN NUTR, V52, P52, DOI 10.1093/ajcn/52.1.52; Kaprio J, 1978, Prog Clin Biol Res, V24 Pt B, P179; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; KISSEBAH AH, 1994, PHYSIOL REV, V74, P761, DOI 10.1152/physrev.1994.74.4.761; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; REED T, 1986, AM DERMATOGLYPH ASS, V5, P6; SARNA S, 1978, HUM HERED, V28, P241, DOI 10.1159/000152964; Siri WE., 1956, ADV BIOL MED PHYS, V4, P239, DOI DOI 10.1016/B978-1-4832-3110-5.50011-X; SMITH SM, 1955, ANN HUM GENET, V19, P273, DOI 10.1111/j.1469-1809.1955.tb01354.x; STATEN MA, 1989, INVEST RADIOL, V24, P345, DOI 10.1097/00004424-198905000-00002; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; WEIGLE DS, 1995, J CLIN INVEST, V96, P2065, DOI 10.1172/JCI118254; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	26	83	92	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1997	126	1					26	31		10.7326/0003-4819-126-1-199701010-00004	http://dx.doi.org/10.7326/0003-4819-126-1-199701010-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA165	8992920				2022-12-28	WOS:A1997WA16500004
J	Brennan, TA; Sox, CM; Burstin, HR				Brennan, TA; Sox, CM; Burstin, HR			Relation between negligent adverse events and the outcomes of medical-malpractice litigation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIABILITY; CLAIMS; RESOLUTION; STANDARD; CARE	Background We have previously shown that in New York State the initiation of malpractice suits correlates poorly with the actual occurrence of adverse events (injuries resulting from medical treatment) and negligence. There is little information on the outcome of such lawsuits, however. To assess the ability of malpractice litigation to make accurate determinations, we studied 51 malpractice suits to identify factors that predict payment to plaintiffs. Methods Among malpractice claims that we reviewed independently in an earlier study, we identified 51 litigated claims and followed them over a 10-year period to determine whether the malpractice insurer had closed the case. We obtained detailed summaries of the cases from the insurers and reviewed the litigation files if the outcome of a case differed from the outcome predicted in our original review. Results Of the 51 malpractice cases, 46 had been closed as of December 31, 1995. Among these cases, 10 of 24 that we originally identified as involving no adverse event were settled for the plaintiffs (mean payment, $28,760), as were 6 of 13 cases classified as involving adverse events but no negligence (mean payment, $98,192) and 5 of 9 cases in which adverse events due to negligence were found in our assess ment (mean payment, $66,944). Seven of eight claims involving permanent disability were settled for the plaintiffs (mean payment, $201,250). In a multivariate analysis, disability (permanent vs. temporary or none) was the only significant predictor of payment (P = 0.03). There was no association between the occurrence of an adverse event due to negligence (P = 0.32) or an adverse event of any type (P = 0.79) and payment. Conclusions Among the malpractice claims we studied, the severity of the patient's disability, not the occurrence of an adverse event or an adverse event due to negligence, was predictive of payment to the plaintiff. (C) 1996, Massachusetts Medical Society.			Brennan, TA (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.			Sox, Colin/0000-0002-0249-9656				BOVBJERG RR, 1995, MED MALPRACTICE PROB; Brennan T., 1996, NEW RULES REGULATION; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BURSTIN HR, 1993, JAMA-J AM MED ASSOC, V270, P1697, DOI 10.1001/jama.270.14.1697; CHENEY FW, 1989, JAMA-J AM MED ASSOC, V261, P1599, DOI 10.1001/jama.261.11.1599; DANZON PM, 1985, MED MALPRACTICE THEO; FARBER HS, 1994, J LEGAL STUD, V23, P777, DOI 10.1086/467945; FARBER HS, 1991, RAND J ECON, V22, P199, DOI 10.2307/2601017; Horwitz J, 1995, HEALTH AFFAIR, V14, P164, DOI 10.1377/hlthaff.14.4.164; KINNEY ED, 1995, J HEALTH POLIT POLIC, V20, P99, DOI 10.1215/03616878-20-1-99; LAWTHERS AG, 1992, J HEALTH POLIT POLIC, V17, P463, DOI 10.1215/03616878-17-3-463; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; PETERSEN SK, 1995, ANN INTERN MED, V122, P462, DOI 10.7326/0003-4819-122-6-199503150-00010; ROSENFIELD H, 1994, SILENT VIOLENCE SILE; SAS Institute, 1990, SAS STAT US GUID VER; SCHWARTZ GT, 1994, UCLA LAW REV, V42, P377; SLOAN FA, 1991, INSURING MED MALPRAC; Sloan Frank A., 1993, SUING MED MALPRACTIC; TARAGIN MI, 1992, ANN INTERN MED, V117, P780, DOI 10.7326/0003-4819-117-9-780; Weiler PC, 1993, MEASURE MALPRACTICE; WEILER PC, 1991, MED MALPR TRIAL; WHITE MJ, 1994, HEALTH AFFAIR, V13, P75, DOI 10.1377/hlthaff.13.4.75	22	269	274	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 26	1996	335	26					1963	1967		10.1056/NEJM199612263352606	http://dx.doi.org/10.1056/NEJM199612263352606			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WA160	8960477	Bronze			2022-12-28	WOS:A1996WA16000006
J	Berger, D				Berger, D			A fish induced pneumothorax: Dilemmas in the remote management of a sucking chest wound	BRITISH MEDICAL JOURNAL			English	Article																			0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1617	1618		10.1136/bmj.313.7072.1617	http://dx.doi.org/10.1136/bmj.313.7072.1617			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991009	Green Published			2022-12-28	WOS:A1996VZ81100040
J	Mumford, AD; Ashkan, K; Elborn, S				Mumford, AD; Ashkan, K; Elborn, S			Clinically significant pulmonary barotrauma after inflation of party balloons	BRITISH MEDICAL JOURNAL			English	Article									UNIV WALES HOSP,DEPT MED,CARDIFF CF4 4XN,S GLAM,WALES; BELFAST CITY HOSP,BELFAST BT9 7AB,ANTRIM,NORTH IRELAND	Cardiff University; Belfast City Hospital				elborn, joseph/0000-0002-2323-442X; mumford, andrew/0000-0002-5523-511X				Goldberg R E, 1987, J Thorac Imaging, V2, P88, DOI 10.1097/00005382-198707000-00012; JANZ MA, 1994, CLIN CHEST MED, V15, P75; MAUNDER RJ, 1984, ARCH INTERN MED, V144, P1447, DOI 10.1001/archinte.144.7.1447; PARKER JC, 1993, CRIT CARE MED, V21, P131, DOI 10.1097/00003246-199301000-00024; VARKEY B, 1973, AM REV RESPIR DIS, V108, P1396	5	14	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1619	1619		10.1136/bmj.313.7072.1619	http://dx.doi.org/10.1136/bmj.313.7072.1619			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991010	Green Published			2022-12-28	WOS:A1996VZ81100042
J	Pryce, AJ; Heatlie, HF; Chapman, SR				Pryce, AJ; Heatlie, HF; Chapman, SR			Buccaling under the pressure: Influence of secondary care establishments on the prescribing of glyceryl trinitrate buccal tablets in primary care	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; SUBLINGUAL NITROGLYCERIN; ANGINA-PECTORIS; WEIGHTINGS; ENGLAND; COSTS; AGE; SEX; PUS	Objective-To determine which characteristics were the best predictors of high rates of prescribing of glyceryl trinitrate buccal tablets. Design-Practice and patient characteristics from 197 practices were examined, and a multiple regression analysis was performed to examine which variables were important in predicting this prescribing. Setting-Former family health services authority (197 practices). Main outcome measure-Volume of prescribing of glyceryl trinitrate buccal tablets. Results-Four variables contributed significantly to a multiple regression model: the catchment area of the secondary care establishment; the number of partners in a practice; the level of practice deprivation; and whether the practice served an urban or a rural area. The model suggests that the most important variable was the catchment area of the secondary care establishment in which the practice was located. Conclusion-Although only the prescribing of short acting glyceryl trinitrate buccal tablets was studied, an impact of this size on primary care prescribing may have extensive implications for all drug expenditure in primary care.	UNIV KEELE,DEPT MED MANAGEMENT,KEELE ST5 5BG,STAFFS,ENGLAND	Keele University								ABRAMS J, 1983, ROYAL SOC MED INT C, V54, P13; *AUD COMM, 1994, 1 AUD COMM; BAKER R, 1995, BRIT J GEN PRACT, V45, P297; BRAY CL, 1991, EUR HEART J, V12, P16; EDWARDS C, 1991, INT J PHARM PRACTICE, V1, P73; HEALEY AT, 1994, HEALTH ECON, V3, P47, DOI 10.1002/hec.4730030107; LAHIRI A, 1989, American Journal of Noninvasive Cardiology, V3, P281; LLOYD DCEF, 1995, BRIT MED J, V311, P991; MCCARTHY M, 1992, BRIT J GEN PRACT, V42, P10; MORRIS R, 1991, J PUBLIC HEALTH MED, V13, P318; MORTONJONES TJ, 1993, BRIT MED J, V306, P1244, DOI 10.1136/bmj.306.6887.1244; *NHS EX, 1994, PURCH PRESCR; Office of Population Censuses and Surveys, 1995, MORB STAT GEN PRACT; REICHEK N, 1982, ADV PHARMACOTHERAPY, V1, P143; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; RYDEN L, 1987, EUR HEART J, V8, P995, DOI 10.1093/oxfordjournals.eurheartj.a062377; SCRIVENER G, 1995, BRIT MED J, V311, P163, DOI 10.1136/bmj.311.6998.163; STRICKLANDHODGE B, 1988, J ROY SOC MED, V81, P207, DOI 10.1177/014107688808100407; Townsend PP., 1988, HLTH DEPRIVATION INE; *WHO, 1991, GUID DDD; WILSON RPH, 1995, BRIT MED J, V311, P1347, DOI 10.1136/bmj.311.7016.1347	21	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1621	1624		10.1136/bmj.313.7072.1621	http://dx.doi.org/10.1136/bmj.313.7072.1621			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	8991012	Green Published			2022-12-28	WOS:A1996VZ81100044
J	Wright, DJM; Roberts, AP				Wright, DJM; Roberts, AP			Which doctors die first? Analysis of BMJ obituary columns	BRITISH MEDICAL JOURNAL			English	Article											Wright, DJM (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,LONDON W6 8RF,ENGLAND.							Balarajan R, 1995, Health Trends, V27, P114; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; NIEMI T, 1980, SCAND J SOC MED, V8, P39, DOI 10.1177/140349488000800106; *OFF POP CENC, 1955, MORT SER, P38	4	35	36	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1581	1582		10.1136/bmj.313.7072.1581	http://dx.doi.org/10.1136/bmj.313.7072.1581			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VZ811	8990991	Green Published			2022-12-28	WOS:A1996VZ81100012
J	Tighe, MJ; Kite, P; Fawley, WN; Thomas, D; McMahon, MJ				Tighe, MJ; Kite, P; Fawley, WN; Thomas, D; McMahon, MJ			An endoluminal brush to detect the infected central venous catheter in situ: A pitot study	BRITISH MEDICAL JOURNAL			English	Article							CULTURES		UNIV LEEDS,GEN INFIRM,NUTR SUPPORT SERV,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND; UNIV LEEDS,GEN INFIRM,DEPT SURG,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND; GEN INFIRM,DEPT MICROBIOL,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary; University of Leeds; Leeds General Infirmary; University of Leeds; Leeds General Infirmary								MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; MUGHAL MM, 1989, BRIT J SURG, V76, P15, DOI 10.1002/bjs.1800760107; PETTIGREW RA, 1985, BRIT J SURG, V72, P52, DOI 10.1002/bjs.1800720121; SHERERTZ RJ, 1990, J CLIN MICROBIOL, V28, P76, DOI 10.1128/JCM.28.1.76-82.1990	4	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1996	313	7071					1528	1529		10.1136/bmj.313.7071.1528	http://dx.doi.org/10.1136/bmj.313.7071.1528			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VY691	8978230	Green Published			2022-12-28	WOS:A1996VY69100023
J	Niu, W; Kim, Y; Tau, G; Heyduk, T; Ebright, RH				Niu, W; Kim, Y; Tau, G; Heyduk, T; Ebright, RH			Transcription activation at class II CAP-dependent promoters: Two interactions between CAP and RNA polymerase	CELL			English	Article							AMP RECEPTOR PROTEIN; ALANINE-SCANNING MUTAGENESIS; ESCHERICHIA-COLI-CRP; ALPHA-SUBUNIT; FUNCTIONAL SUBUNIT; GENE-ACTIVATION; CAMP-CRP; DNA; REGION; IDENTIFICATION	At Class II catabolite activator protein (CAP)-dependent promoters, CAP activates transcription from a DNA site overlapping the DNA site for RNA polymerase. We show that transcription activation at Class II CAP-dependent promoters requires not only the previously characterized interaction between an activating region of CAP and the RNA polymerase a subunit C-terminal domain, but also an interaction between a second, promoter-class-specific activating region of CAP and the RNA polymerase a subunit N-terminal domain. We further show that the two interactions affect different steps in transcription initiation. Transcription activation at Class II CAP-dependent promoters provides a paradigm for understanding how an activator can make multiple interactions with the transcription machinery, each interaction being responsible for a specific mechanistic consequence.	RUTGERS STATE UNIV, WAKSMAN INST, NEW BRUNSWICK, NJ 08855 USA; ST LOUIS UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, ST LOUIS, MO 63104 USA	Rutgers State University New Brunswick; Saint Louis University	Niu, W (corresponding author), RUTGERS STATE UNIV, DEPT CHEM, NEW BRUNSWICK, NJ 08855 USA.		Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140	NIGMS NIH HHS [R01 GM050514, GM41376, GM50514, R37 GM041376, R01 GM041376] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041376, R21GM050514, R01GM050514, R37GM041376] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATLUNG T, 1991, GENE, V107, P11, DOI 10.1016/0378-1119(91)90291-I; ATTEY A, 1994, NUCLEIC ACIDS RES, V22, P4375, DOI 10.1093/nar/22.21.4375; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; Belyaeva TA, 1996, NUCLEIC ACIDS RES, V24, P2243, DOI 10.1093/nar/24.12.2243; BLATTER E, 1994, PROTEIN EXPRES PURIF, V4, P503; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; Ebright YW, 1996, BIOCONJUGATE CHEM, V7, P380, DOI 10.1021/bc9600168; ESCHENLAUER AC, 1991, J BACTERIOL, V173, P5024, DOI 10.1128/jb.173.16.5024-5029.1991; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; HASAN N, 1994, GENE, V150, P51, DOI 10.1016/0378-1119(94)90856-7; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; IGARASHI K, 1991, P NATL ACAD SCI USA, V88, P8958, DOI 10.1073/pnas.88.20.8958; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; IRWIN N, 1987, P NATL ACAD SCI USA, V84, P8315, DOI 10.1073/pnas.84.23.8315; JIN RZ, 1995, J BIOL CHEM, V270, P19213, DOI 10.1074/jbc.270.33.19213; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; NIU W, 1994, J MOL BIOL, V243, P595, DOI 10.1016/0022-2836(94)90034-5; Parkinson G, 1996, J MOL BIOL, V260, P395, DOI 10.1006/jmbi.1996.0409; SABOURIN D, 1975, J BACTERIOL, V122, P338, DOI 10.1128/JB.122.1.338-340.1975; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; TANG H, 1994, GENE DEV, V8, P3058, DOI 10.1101/gad.8.24.3058; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; TANG H, 1996, IN PRESS METH ENZYMO; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WEST D, 1993, MOL MICROBIOL, V10, P789, DOI 10.1111/j.1365-2958.1993.tb00949.x; WILLIAMS R, 1991, NUCLEIC ACIDS RES, V19, P6705, DOI 10.1093/nar/19.24.6705; Williams RM, 1996, NUCLEIC ACIDS RES, V24, P1112, DOI 10.1093/nar/24.6.1112; ZHOU YH, 1994, J MOL BIOL, V243, P603, DOI 10.1016/0022-2836(94)90035-3; ZHOU YH, 1994, EMBO J, V13, P4549, DOI 10.1002/j.1460-2075.1994.tb06776.x; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081; ZHOU YH, 1993, CELL, V73, P375, DOI 10.1016/0092-8674(93)90236-J; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	41	228	236	0	8	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 13	1996	87	6					1123	1134		10.1016/S0092-8674(00)81806-1	http://dx.doi.org/10.1016/S0092-8674(00)81806-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VY447	8978616	Bronze, Green Accepted			2022-12-28	WOS:A1996VY44700017
J	Hobbs, M; Mayou, R; Harrison, B; Worlock, P				Hobbs, M; Mayou, R; Harrison, B; Worlock, P			A randomised controlled trial of psychological debriefing for victims of road traffic accidents	BRITISH MEDICAL JOURNAL			English	Article							STRESS-DISORDER		JOHN RADCLIFFE HOSP,OXFORD OX3 9DU,ENGLAND	University of Oxford	Hobbs, M (corresponding author), WARNEFORD HOSP,OXFORD OX3 7JX,ENGLAND.							BLANCHARD EB, 1995, BEHAV RES THER, V33, P529, DOI 10.1016/0005-7967(94)00079-Y; KOOPMAN C, 1995, J TRAUMA STRESS, V8, P29, DOI 10.1007/BF02105405; Malt U F, 1992, Psychiatr Med, V10, P117; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; RAPHAEL B, 1995, BRIT MED J, V310, P1479, DOI 10.1136/bmj.310.6993.1479	5	148	151	0	21	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1996	313	7070					1438	1439		10.1136/bmj.313.7070.1438	http://dx.doi.org/10.1136/bmj.313.7070.1438			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VX612	8973231	Green Published			2022-12-28	WOS:A1996VX61200027
J	Buetow, SA; Sibbald, B; Cantrill, JA; Halliwell, S				Buetow, SA; Sibbald, B; Cantrill, JA; Halliwell, S			Prevalence of potentially inappropriate long term prescribing in general practice in the United Kingdom, 1980-95: Systematic literature review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ELDERLY PATIENTS; CARE; PRACTITIONERS; HYPERTENSION; MANAGEMENT; AUDIT; APPROPRIATENESS; DIABETICS; SCOTLAND; CLINICS	Objective-To determine the prevalence of potentially inappropriate long term prescribing in general practice in the United Kingdom. Design-Review of 62 studies of the appropriateness of prescribing identified from seven electronic databases, from reference lists, and by hand searching of journals. A nominal group of 10 experts helped to define the appropriateness of prescribing. Setting-General practice in the United Kingdom. Main outcome measures-Prevalences of 19 indicators of inappropriate long term prescribing representing five dimensions: indication, choice of drug, drug administration, communication, and review. Results-Prevalences of potentially inappropriate prescribing varied by indicator and chronic condition, but drug dosages outside the therapeutic range consistently recorded the highest rates. The lowest rates were generally associated with indicators of the choice of the drug, except cost minimisation. Communication is studied less frequently than other dimensions of prescribing appropriateness. Conclusions-The evidence base to support allegations of widespread inappropriate prescribing in general practice is unsound. Although inappropriate prescribing has occurred, the scale of the problem is unknown because of limitations associated with selection of a standard, publication bias, and uncertainty about the context of prescribing decisions. Opportunities for cost savings and effectiveness gains are thus unclear. Indicators applicable to individual patients could yield evidence of prescribing appropriateness.	UNIV MANCHESTER, DEPT PHARM, MANCHESTER M13 9PL, LANCS, ENGLAND	University of Manchester	Buetow, SA (corresponding author), UNIV MANCHESTER, NATL PRIMARY CARE RES & DEV CTR, MANCHESTER M13 9PL, LANCS, ENGLAND.			Buetow, Stephen/0000-0002-9771-248X				ABELL C, 1990, PRACTITIONER, V234, P149; *AD COMM, 1994, PRESCR IMPR MOR VAR; BARBER N, 1995, BRIT MED J, V310, P923, DOI 10.1136/bmj.310.6984.923; *BRIT MED ASS ROYA, 1995, BRIT NAT FORM; BROOK RH, 1994, BRIT MED J, V308, P218, DOI 10.1136/bmj.308.6923.218; BRUCE SA, 1982, BRIT MED J, V284, P1235, DOI 10.1136/bmj.284.6324.1235; BURTON AJ, 1984, BRIT MED J, V288, P1650, DOI 10.1136/bmj.288.6431.1650-a; Cantrill JA, 2011, INT J PHARM PRACT, V4, P67, DOI DOI 10.1111/J.2042-7174.1996.TB00844.X; CHESOVER D, 1991, BRIT J GEN PRACT, V41, P282; DONOGHUE JM, 1994, POSTGRAD MED J, V70, pS23; DOWELL JS, 1995, BRIT MED J, V310, P505, DOI 10.1136/bmj.310.6978.505; DUKES G, 1990, EUR J CLIN PHARMACOL, V38, P315, DOI 10.1007/BF00315567; ECCLES M, 1991, BMJ-BRIT MED J, V302, P91, DOI 10.1136/bmj.302.6768.91; FAHEY T, 1994, BRIT J GEN PRACT, V44, P446; FORSTER DP, 1991, BRIT J GEN PRACT, V41, P67; FOTHERBY MD, 1992, BMJ-BRIT MED J, V305, P750, DOI 10.1136/bmj.305.6856.750; FRY J, 1995, REVIVING PRIMARY CAR; GILLEGHAN J, 1994, PRESCRIBER, V5, P13; GREGG I, 1983, BRIT MED J, V287, P57, DOI 10.1136/bmj.287.6384.57; GRIFFIN JP, 1990, FACTORS INFLUENCING, P5; HANLON JT, 1992, J CLIN EPIDEMIOL, V45, P1045, DOI 10.1016/0895-4356(92)90144-C; HAYES TM, 1984, BRIT MED J, V289, P728, DOI 10.1136/bmj.289.6447.728; HOLMES JK, 1992, IRISH MED J, V85, P154; HOPKINS DR, 1982, J ROY COLL GEN PRACT, V32, P758; KERR MP, 1994, BRIT J GEN PRACT, V44, P275; KOPERSKI M, 1992, BRIT J GEN PRACT, V42, P508; MATTHEWS K, 1993, EUR J CLIN PHARMACOL, V45, P205, DOI 10.1007/BF00315384; MCGAVOCK H, 1988, BRIT MED J, V296, P900, DOI 10.1136/bmj.296.6626.900; MCGHEE SM, 1994, BRIT J GEN PRACT, V44, P441; MULLAN E, 1994, FAM PRACT, V11, P267, DOI 10.1093/fampra/11.3.267; National Audit Office, 1993, REP PRESCR GEN MED P; OHANRAHAN M, 1982, IRISH MED J, V75, P102; PAYNE JN, 1993, BRIT MED J, V307, P1027, DOI 10.1136/bmj.307.6911.1027; PRINGLE M, 1993, BRIT MED J, V306, P630, DOI 10.1136/bmj.306.6878.630; SALINSKY JV, 1987, J ROY COLL GEN PRACT, V37, P202; SIBBALD B, 1996, FAM PRACT, V16, P345; SINGH BM, 1984, BRIT MED J, V289, P726, DOI 10.1136/bmj.289.6447.726; SMITH TDW, 1990, BMJ-BRIT MED J, V300, P74, DOI 10.1136/bmj.300.6717.74; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; TEELINGSMITH G, 1991, PATTERNS PRESCRIBING; Thomas S. H. L., 1995, British Journal of Clinical Pharmacology, V39, p97P; TSUI HH, 1987, PRACTITIONER, V231, P1153; TURNBRIDGE FKE, 1993, BR J GEN PRACT, V43, P291; WHITE PT, 1989, J ROY COLL GEN PRACT, V39, P182; WOOD DA, 1994, BRIT J GEN PRACT, V44, P62; YUDKIN JS, 1980, J EPIDEMIOL COMMUN H, V34, P277, DOI 10.1136/jech.34.4.277; 1985, BRIT MED J, V291, P254	47	36	36	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 30	1996	313	7069					1371	1374		10.1136/bmj.313.7069.1371	http://dx.doi.org/10.1136/bmj.313.7069.1371			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW685	8956706	Green Published			2022-12-28	WOS:A1996VW68500028
J	Miller, C				Miller, C			A chloride channel model?	SCIENCE			English	Editorial Material							QUATERNARY STRUCTURE; GLYCINE RECEPTOR; TRANSPORT				Miller, C (corresponding author), BRANDEIS UNIV,DEPT BIOCHEM,HOWARD HUGHES MED INST,WALTHAM,MA 02254, USA.							FABER HR, 1995, STRUCTURE, V3, P551, DOI 10.1016/S0969-2126(01)00189-7; Jentsch TJ, 1996, CURR OPIN NEUROBIOL, V6, P303, DOI 10.1016/S0959-4388(96)80112-7; LANGOSCH D, 1990, EUR J BIOCHEM, V194, P1, DOI 10.1111/j.1432-1033.1990.tb19419.x; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; NAYEEM N, 1994, J NEUROCHEM, V62, P815; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040	11	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 1	1996	274	5288					738	738		10.1126/science.274.5288.738	http://dx.doi.org/10.1126/science.274.5288.738			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VQ145	8966555				2022-12-28	WOS:A1996VQ14500027
